{"PMC7435501": [["CONFLICT OF INTERESTThe authors declare that there is no conflict of interest.AUTHOR CONTRIBUTIONSBeno\u00eet Bernar, assistant special\u2010isolation physician, was in charge of our patient and drafted this manuscript.", [["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 173, 180], ["no", "UNCERTAINTY", 54, 56]]], ["Gabriele Kropshofer and Roman Crazzolara, senior pediatric oncologists, were responsible for oncologic treatment.", [["oncologic treatment", "TREATMENT", 93, 112]]], ["Klaus Kapelari, active in medical crisis management in Tyrol and at the University Hospital of Innsbruck, provided Tyrolean epidemiologic data.", [["medical crisis management", "TREATMENT", 26, 51], ["active", "OBSERVATION_MODIFIER", 16, 22]]], ["Andrea Griesmacher is head of the Central Institute of Clinical Chemistry and Laboratory Medicine and supervised laboratory studies.", [["head", "ANATOMY", 22, 26], ["head", "ORGAN", 22, 26], ["supervised laboratory studies", "TEST", 102, 131]]], ["Thomas M\u00fcller, head of our department, and Sabine Scholl\u2010B\u00fcrgi, senior isolation\u2010ward physician, both bore ultimate clinical responsibility for treatment.", [["head", "ANATOMY", 15, 19], ["head", "ORGAN", 15, 19], ["treatment", "TREATMENT", 144, 153], ["head", "ANATOMY", 15, 19]]]], "5b65b3c98dde953330ad875e1ef7e7e729ee87bf": [["It draws in 3 million Muslims surging from all over the world which accounts for the largest gathering of people globally on an annual basis.IntroductionThe 2013 hajj season began from 13 October to 17 October 2013 (8) (9) (10) (11) (12) Dhu al-Hijjah).", [["people", "ORGANISM", 106, 112], ["people", "SPECIES", 106, 112], ["largest", "OBSERVATION_MODIFIER", 85, 92]]], ["The pilgrims perform their first circumambulations by walking seven times anticlockwise around the Kaaba.", [["their first circumambulations", "TREATMENT", 21, 50]]], ["When the sun sets, they leave Arafat and move to Muzdalifah, located between Arafat and Mina.", [["Arafat", "TREATMENT", 30, 36], ["Muzdalifah", "TREATMENT", 49, 59]]], ["For the completion of the umrah pilgrimage, which is called the lesser pilgrimage; it is different as it can be performed throughout the year, the pilgrims are not required to perform the brief stay at Arafat.IntroductionFor 1400 years, the mass gathering during hajj has been associated with the risk of communicable diseases, particularly respiratory infection.", [["respiratory", "ANATOMY", 341, 352], ["hajj", "CHEMICAL", 263, 267], ["communicable diseases", "DISEASE", 305, 326], ["respiratory infection", "DISEASE", 341, 362], ["the umrah pilgrimage", "TREATMENT", 22, 42], ["the mass", "PROBLEM", 237, 245], ["communicable diseases", "PROBLEM", 305, 326], ["respiratory infection", "PROBLEM", 341, 362], ["mass", "OBSERVATION", 241, 245], ["respiratory", "ANATOMY", 341, 352], ["infection", "OBSERVATION", 353, 362]]], ["1 Extended stays at hajj sites, physical exhaustion, extreme heat and crowded accommodation encourage disease transmission, especially those deriving from airborne agents.", [["physical exhaustion", "PROBLEM", 32, 51], ["extreme heat and crowded accommodation", "PROBLEM", 53, 91], ["disease transmission", "PROBLEM", 102, 122], ["airborne agents", "TREATMENT", 155, 170]]], ["2 Crowd densities during hajj are about up to seven people per square metre.", [["people", "SPECIES", 52, 58], ["Crowd", "OBSERVATION_MODIFIER", 2, 7], ["densities", "OBSERVATION", 8, 17]]], ["3 Respiratory tract infection during hajj continues to exert a burden on pilgrims.", [["Respiratory tract infection", "DISEASE", 2, 29], ["Respiratory tract infection", "PROBLEM", 2, 29], ["Respiratory tract", "ANATOMY", 2, 19], ["infection", "OBSERVATION", 20, 29]]], ["The respiratory problems account for 74% of all medical illnesses reported during hajj seasons.", [["respiratory", "ANATOMY", 4, 15], ["respiratory problems", "DISEASE", 4, 24], ["The respiratory problems", "PROBLEM", 0, 24], ["all medical illnesses", "PROBLEM", 44, 65], ["respiratory", "ANATOMY", 4, 15]]], ["4 Pneumonia being the leading reason for hospital admission in 39% of all patients.", [["Pneumonia", "DISEASE", 2, 11], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Pneumonia", "PROBLEM", 2, 11], ["Pneumonia", "OBSERVATION", 2, 11]]], ["5 A recent study involving Malaysian hajj pilgrims found that 90% of them had at least one respiratory symptom.", [["respiratory", "ANATOMY", 91, 102], ["A recent study", "TEST", 2, 16], ["one respiratory symptom", "PROBLEM", 87, 110], ["respiratory symptom", "OBSERVATION", 91, 110]]], ["6 Respiratory illness is a disease affecting the respiratory system and can be due to infection or non-infection.", [["respiratory system", "ANATOMY", 49, 67], ["Respiratory illness", "DISEASE", 2, 21], ["infection", "DISEASE", 86, 95], ["non-infection", "DISEASE", 99, 112], ["a disease affecting the respiratory system", "PROBLEM", 25, 67], ["infection", "PROBLEM", 86, 95], ["non-infection", "PROBLEM", 99, 112], ["Respiratory illness", "OBSERVATION", 2, 21], ["disease", "OBSERVATION", 27, 34], ["respiratory system", "ANATOMY", 49, 67], ["can be due to", "UNCERTAINTY", 72, 85], ["infection", "OBSERVATION", 86, 95]]], ["It is complex to define the syndromes of respiratory illness due to variation in the severity, duration and types of symptoms.", [["respiratory", "ANATOMY", 41, 52], ["respiratory illness", "DISEASE", 41, 60], ["the syndromes", "PROBLEM", 24, 37], ["respiratory illness", "PROBLEM", 41, 60], ["the severity", "PROBLEM", 81, 93], ["symptoms", "PROBLEM", 117, 125], ["respiratory illness", "OBSERVATION", 41, 60]]], ["7 The purpose of this study is to determine the prevalence of the respiratory illness among Malaysian hajj pilgrims in 2013, to describe its preventive measures and to determine the association between sociodemographic, previous experience of hajj/umrah, co-morbidity, smoking habits, vaccination and preventive measures with respiratory illness.", [["respiratory", "ANATOMY", 326, 337], ["respiratory illness", "DISEASE", 66, 85], ["respiratory illness", "DISEASE", 326, 345], ["this study", "TEST", 17, 27], ["the respiratory illness", "PROBLEM", 62, 85], ["co-morbidity", "PROBLEM", 255, 267], ["vaccination", "TREATMENT", 285, 296], ["preventive measures", "TREATMENT", 301, 320], ["respiratory illness", "PROBLEM", 326, 345], ["respiratory", "ANATOMY", 66, 77]]], ["Apart from those preventive measures, we also explored the association between good hand hygiene practice and respiratory illness/ILI.MethodsThis is a cross-sectional study involving all consented Malaysian hajj pilgrims in November, 2013.", [["hand", "ANATOMY", 84, 88], ["respiratory", "ANATOMY", 110, 121], ["respiratory illness", "DISEASE", 110, 129], ["ILI", "DISEASE", 130, 133], ["hand", "ORGANISM_SUBDIVISION", 84, 88], ["respiratory illness", "PROBLEM", 110, 129], ["ILI", "PROBLEM", 130, 133], ["a cross-sectional study", "TEST", 149, 172], ["respiratory", "ANATOMY", 110, 121]]], ["An expanded definition of respiratory illness was used for this study.", [["respiratory", "ANATOMY", 26, 37], ["respiratory illness", "DISEASE", 26, 45], ["respiratory illness", "PROBLEM", 26, 45], ["this study", "TEST", 59, 69], ["expanded", "OBSERVATION_MODIFIER", 3, 11], ["respiratory illness", "OBSERVATION", 26, 45]]], ["Respiratory illness was defined as when the person is having at least one of the respiratory symptoms (non-ILI) or ILI.", [["respiratory", "ANATOMY", 81, 92], ["Respiratory illness", "DISEASE", 0, 19], ["respiratory symptoms", "DISEASE", 81, 101], ["ILI", "DISEASE", 107, 110], ["ILI", "DISEASE", 115, 118], ["person", "SPECIES", 44, 50], ["Respiratory illness", "PROBLEM", 0, 19], ["the respiratory symptoms", "PROBLEM", 77, 101], ["ILI", "PROBLEM", 115, 118], ["illness", "OBSERVATION", 12, 19]]], ["With references to other studies and some limitations (mainly logistic problems), ILI is defined as the triad of cough, subjective fever and sore throat, those who did not fulfil the criteria of ILI were classified into a non-ILI group.", [["ILI", "DISEASE", 82, 85], ["cough", "DISEASE", 113, 118], ["fever", "DISEASE", 131, 136], ["sore throat", "DISEASE", 141, 152], ["ILI", "DISEASE", 195, 198], ["non-ILI", "CANCER", 222, 229], ["other studies", "TEST", 19, 32], ["ILI", "PROBLEM", 82, 85], ["cough", "PROBLEM", 113, 118], ["subjective fever", "PROBLEM", 120, 136], ["sore throat", "PROBLEM", 141, 152], ["ILI", "PROBLEM", 195, 198], ["cough", "OBSERVATION", 113, 118]]], ["[8] [9] [10] [11] Sample size was calculated based on two proportion formula.", [["[8] [9] [10] [11", "SIMPLE_CHEMICAL", 0, 16], ["Sample size", "TEST", 18, 29]]], ["The sample size according to potential associated factors, the largest sample size was given 780.", [["the largest sample size", "TEST", 59, 82], ["size", "OBSERVATION_MODIFIER", 11, 15], ["largest", "OBSERVATION_MODIFIER", 63, 70], ["size", "OBSERVATION_MODIFIER", 78, 82]]], ["After adding a possible non-respondent rate of 10%, the sample size for this study is 858.", [["this study", "TEST", 72, 82]]], ["The sample selection was based on convenient sampling due to logistic problems.", [["The sample selection", "TREATMENT", 0, 20], ["convenient sampling", "TEST", 34, 53], ["logistic problems", "PROBLEM", 61, 78]]], ["Pilgrims who were very ill and unable to independently respond to the proforma were excluded.MethodsData based on the social demographic, co-morbid illness, smoking habits, symptoms of respiratory illness, history of contact with respiratory ill patients, previous experience of hajj or umrah, the practice of preventive measures, influenza and pneumococcal vaccination and supplement intake against respiratory illness were obtained by a self-administered proforma.", [["respiratory", "ANATOMY", 185, 196], ["respiratory", "ANATOMY", 400, 411], ["co-morbid illness", "DISEASE", 138, 155], ["respiratory illness", "DISEASE", 185, 204], ["respiratory ill", "DISEASE", 230, 245], ["influenza", "DISEASE", 331, 340], ["respiratory illness", "DISEASE", 400, 419], ["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 246, 254], ["pneumococcal", "SPECIES", 345, 357], ["very ill", "PROBLEM", 18, 26], ["symptoms", "PROBLEM", 173, 181], ["respiratory illness", "PROBLEM", 185, 204], ["preventive measures", "TREATMENT", 310, 329], ["influenza", "PROBLEM", 331, 340], ["pneumococcal vaccination", "TREATMENT", 345, 369], ["respiratory illness", "PROBLEM", 400, 419]]], ["Good hand hygiene or optimal handwashing practices is defined as handwashing for 20 s at least five times per day by using water with soap or a hand sanitizer.", [["hand", "ANATOMY", 5, 9], ["hand", "ANATOMY", 144, 148], ["hand", "ORGANISM_SUBDIVISION", 5, 9], ["hand", "ORGANISM_SUBDIVISION", 144, 148], ["a hand sanitizer", "TREATMENT", 142, 158], ["hand", "ANATOMY", 5, 9], ["hygiene", "OBSERVATION", 10, 17]]], ["12, 13 In this study, we define good hand hygiene practice as those who frequently wash their hands using hand sanitizers indicated by Centres for Disease Control (CDC).", [["hand", "ANATOMY", 37, 41], ["hand", "ANATOMY", 106, 110], ["hand", "ORGANISM_SUBDIVISION", 37, 41], ["this study", "TEST", 10, 20], ["hand sanitizers", "TREATMENT", 106, 121]]], ["14 Those using water only, handkerchiefs or disposable tissues were considered as poor hand hygiene practices.MethodsHistory of contact with respiratory illness sufferers is defined as pilgrims who have direct contact or close contact (being within 6 feet (2 m) or within the room or care area for a prolonged period of time while not wearing recommended personal protective equipment.", [["tissues", "ANATOMY", 55, 62], ["hand", "ANATOMY", 87, 91], ["respiratory illness", "DISEASE", 141, 160], ["tissues", "TISSUE", 55, 62], ["hand", "ORGANISM_SUBDIVISION", 87, 91], ["handkerchiefs", "TREATMENT", 27, 40], ["disposable tissues", "PROBLEM", 44, 62], ["personal protective equipment", "TREATMENT", 355, 384]]], ["The proforma were given to participants in Malaysia before their departure and also at Makkah before departing for a brief stay at Arafat.", [["participants", "SPECIES", 27, 39]]], ["All respiratory symptoms that occurred 2 weeks after arrival in KSA were considered significant.MethodsThe Statistical Package for the Social Sciences (SPSS version 22.0) was exercised for data entry and statistical analysis.", [["respiratory", "ANATOMY", 4, 15], ["respiratory symptoms", "DISEASE", 4, 24], ["All respiratory symptoms", "PROBLEM", 0, 24], ["statistical analysis", "TEST", 204, 224], ["respiratory", "ANATOMY", 4, 15], ["symptoms", "OBSERVATION", 16, 24], ["significant", "OBSERVATION_MODIFIER", 84, 95]]], ["Descriptive statistics were applied to describe the prevalence, practice of deterrent measures and associated factors.", [["deterrent measures", "TREATMENT", 76, 94]]], ["The analysis of association between sociodemographic, previous experience of hajj or umrah, co-morbidity, smoking habits, vaccination and the practice of preventive measures with the respiratory illness were done using simple logistic regression and the variables with P value of <0.25 or variables with clinically significant values will be included further with multiple logistic regression analysis.", [["respiratory illness", "DISEASE", 183, 202], ["umrah", "PROBLEM", 85, 90], ["co-morbidity", "PROBLEM", 92, 104], ["vaccination", "TREATMENT", 122, 133], ["preventive measures", "TREATMENT", 154, 173], ["the respiratory illness", "PROBLEM", 179, 202], ["simple logistic regression", "TREATMENT", 219, 245], ["P value", "TEST", 269, 276], ["clinically significant values", "PROBLEM", 304, 333], ["multiple logistic regression analysis", "TEST", 364, 401]]], ["The risk estimation was carried out using the odds ratio (OR) and 95% confidence intervals (CI) and the P value of <0.05 were significant.", [["The risk estimation", "TEST", 0, 19], ["CI", "TEST", 92, 94], ["the P value", "TEST", 100, 111]]], ["Variable interaction and multi-collinearity followed by testing on a model assumption was performed before decisions made on the final model.", [["a model assumption", "TEST", 67, 85]]], ["For the final model, the P value of <0.05 were considered as significant.MethodsEthical approval was obtained from the USM Research and Ethics Committee before this study (Reference number:ResultsA total of 1200 proforma were distributed to the pilgrims, however, only 480 responded, only 40%.", [["the P value", "TEST", 21, 32], ["this study", "TEST", 160, 170]]], ["Out of 480 pilgrims who returned the proforma, 12 were excluded from the analysis as grossly incomplete.", [["the analysis", "TEST", 69, 81], ["grossly", "OBSERVATION_MODIFIER", 85, 92], ["incomplete", "OBSERVATION", 93, 103]]], ["The age for Malaysian Hajj pilgrims in this study ranged from 17 to 84 years old with a mean age of 52.52 (SD 10.15).", [["this study", "TEST", 39, 49]]], ["The males (56.2%) dominated the female pilgrims with an obvious male to female ratio of 1.3.ResultsMore than one-half of the pilgrims had at least one medical illness (60.0%).", [["pilgrims", "ORGANISM", 39, 47], ["pilgrims", "ORGANISM", 125, 133], ["The males", "TEST", 0, 9], ["female ratio", "TEST", 72, 84]]], ["Many of them had hypertension (26.5%), followed by diabetes mellitus (DM) (15.4%), allergic rhinitis (9.0%), bronchial asthma (5.6%) and others (3.6%).", [["bronchial", "ANATOMY", 109, 118], ["hypertension", "DISEASE", 17, 29], ["diabetes mellitus", "DISEASE", 51, 68], ["DM", "DISEASE", 70, 72], ["allergic rhinitis", "DISEASE", 83, 100], ["bronchial asthma", "DISEASE", 109, 125], ["hypertension", "PROBLEM", 17, 29], ["diabetes mellitus", "PROBLEM", 51, 68], ["DM)", "PROBLEM", 70, 73], ["allergic rhinitis", "PROBLEM", 83, 100], ["bronchial asthma", "PROBLEM", 109, 125], ["hypertension", "OBSERVATION", 17, 29], ["allergic rhinitis", "OBSERVATION", 83, 100], ["bronchial", "ANATOMY", 109, 118], ["asthma", "OBSERVATION", 119, 125]]], ["Some of the pilgrims still had smoked (12.2%) and 17.9% of them were obese ( Table 1) .ResultsThe prevalence of respiratory illness symptoms was 93.4% with a subset of 78.2% fulfil the criteria for ILI.", [["respiratory", "ANATOMY", 112, 123], ["respiratory illness", "DISEASE", 112, 131], ["ILI", "DISEASE", 198, 201], ["pilgrims", "ORGANISM", 12, 20], ["respiratory illness symptoms", "PROBLEM", 112, 140], ["ILI", "PROBLEM", 198, 201], ["obese", "OBSERVATION", 69, 74]]], ["Most of them had a respiratory illness of <2 weeks (77.8%).", [["respiratory", "ANATOMY", 19, 30], ["respiratory illness", "DISEASE", 19, 38], ["a respiratory illness", "PROBLEM", 17, 38], ["respiratory", "ANATOMY", 19, 30], ["illness", "OBSERVATION", 31, 38]]], ["Approximately 61.8% were administered antibiotics, only 2.1% of them were hospitalized.", [["antibiotics", "TREATMENT", 38, 49]]], ["One-half of them had a history of contact with respiratory illness sufferers (52.2%).", [["respiratory", "ANATOMY", 47, 58], ["respiratory illness", "DISEASE", 47, 66]]], ["They acquired the infection intensely at Arafat (81.2%) ( Table 2) .ResultsFor the practice of preventive measures, the total number of pilgrims that received influenza vaccinations was 305 (65.2%).", [["infection", "DISEASE", 18, 27], ["influenza", "DISEASE", 159, 168], ["the infection", "PROBLEM", 14, 27], ["Arafat", "TEST", 41, 47], ["preventive measures", "TREATMENT", 95, 114], ["influenza vaccinations", "TREATMENT", 159, 181], ["infection", "OBSERVATION", 18, 27]]], ["From those, 130 (27.8%) pilgrims had been immunized with influenza and pneumococcal vaccinations.", [["influenza", "DISEASE", 57, 66], ["pilgrims", "ORGANISM", 24, 32], ["pneumococcal", "SPECIES", 71, 83], ["influenza", "PROBLEM", 57, 66], ["pneumococcal vaccinations", "TREATMENT", 71, 96]]], ["A total of 82.9% of pilgrims wore face mask, i.e. surgical face masks, N95 face masks, dry towels, wet towels or veils as their face mask.", [["face", "ANATOMY", 34, 38], ["face", "ANATOMY", 59, 63], ["veils", "ANATOMY", 113, 118], ["face", "ANATOMY", 128, 132], ["pilgrims", "ORGANISM", 20, 28], ["pilgrims wore face mask", "TREATMENT", 20, 43], ["surgical face masks", "TREATMENT", 50, 69], ["N95 face masks", "TREATMENT", 71, 85], ["dry towels", "TREATMENT", 87, 97], ["wet towels", "TREATMENT", 99, 109], ["veils", "TREATMENT", 113, 118], ["their face mask", "TREATMENT", 122, 137], ["dry towels", "OBSERVATION", 87, 97]]], ["Only 31.8% of them practiced good hand hygiene.", [["hand", "ANATOMY", 34, 38], ["hand", "ORGANISM_SUBDIVISION", 34, 38]]], ["Nearly one-half of the respondents (44.4%) took vitamins as their food supplement (Table 3) .ResultsFactors associated with respiratory illness among Malaysian pilgrims using simple logistic regression analysis was shown in Table 4 .", [["respiratory", "ANATOMY", 124, 135], ["vitamins", "CHEMICAL", 48, 56], ["respiratory illness", "DISEASE", 124, 143], ["vitamins", "CHEMICAL", 48, 56], ["vitamins", "SIMPLE_CHEMICAL", 48, 56], ["vitamins", "TREATMENT", 48, 56], ["respiratory illness", "PROBLEM", 124, 143], ["simple logistic regression analysis", "TEST", 175, 210], ["respiratory illness", "OBSERVATION", 124, 143]]], ["All the supplements were seemed able to protect them from the illness, however they were not statistically significant (Table 4 ).", [["illness", "DISEASE", 62, 69]]], ["Malaysian hajj pilgrims with previous experience of hajj (OR 0.24; 95% CI 0.10-0.56) or umrah (OR 0.19; 95% CI 0.07-0.52) and those with good hand hygiene (OR 0.35; 95% CI 0.16-0.79) were significantly associated with lower risk of respiratory illness.", [["hand", "ANATOMY", 142, 146], ["respiratory", "ANATOMY", 232, 243], ["respiratory illness", "DISEASE", 232, 251], ["hand", "ORGANISM_SUBDIVISION", 142, 146], ["CI", "TEST", 71, 73], ["umrah", "TEST", 88, 93], ["CI", "TEST", 108, 110], ["CI", "TEST", 169, 171], ["respiratory illness", "PROBLEM", 232, 251], ["respiratory illness", "OBSERVATION", 232, 251]]], ["Otherwise, pilgrims having contact with those with respiratory illness (OR 3.01; 95% CI 1.35-6.68) were associated with higher risk ( Table 5 ).ResultsThe percentage of ILI was lower (38.9%) in those vaccinated with the influenza vaccine than those unvaccinated (61.1%).", [["respiratory", "ANATOMY", 51, 62], ["respiratory illness", "DISEASE", 51, 70], ["ILI", "DISEASE", 169, 172], ["respiratory illness", "PROBLEM", 51, 70], ["CI", "TEST", 85, 87], ["ILI", "TEST", 169, 172], ["the influenza vaccine", "TREATMENT", 216, 237]]], ["However, it was statistically not significant with a P value of 0.15 (Table 6 ).DiscussionThe prevalence of the respiratory illness varied by country of origin and by year based on the studies conducted over the past few years.", [["respiratory illness", "DISEASE", 112, 131], ["a P value", "TEST", 51, 60], ["the respiratory illness", "PROBLEM", 108, 131], ["the studies", "TEST", 181, 192], ["respiratory illness", "OBSERVATION", 112, 131]]], ["In our study, the prevalence of respiratory illness symptoms among Malaysian hajj pilgrims for the 2013 season was 93.4%, with a subset of 78.2% fulfilling the criteria for ILI.", [["respiratory", "ANATOMY", 32, 43], ["respiratory illness", "DISEASE", 32, 51], ["ILI", "DISEASE", 173, 176], ["our study", "TEST", 3, 12], ["respiratory illness symptoms", "PROBLEM", 32, 60], ["ILI", "PROBLEM", 173, 176], ["respiratory", "ANATOMY", 32, 43]]], ["The respiratory illness prevalence was consistent with French pilgrims during the same year (90.7%).", [["respiratory", "ANATOMY", 4, 15], ["respiratory illness", "DISEASE", 4, 23], ["The respiratory illness prevalence", "PROBLEM", 0, 34], ["respiratory", "ANATOMY", 4, 15], ["illness", "OBSERVATION", 16, 23], ["consistent with", "UNCERTAINTY", 39, 54]]], ["16 The results of our study are in parallel with previous studies, 97.0% and 90.0% for the 2009 Saudi Arabia hajj pilgrims and the 2007 Malaysian hajj pilgrims, respectively.", [["our study", "TEST", 18, 27], ["previous studies", "TEST", 49, 65]]], ["6, 17 In contradiction, the percentage was lower for the US pilgrims in 2009 who suffered from respiratory illness symptoms (41.3%).", [["respiratory", "ANATOMY", 95, 106], ["respiratory illness", "DISEASE", 95, 114], ["6, 17", "CHEMICAL", 0, 5], ["respiratory illness symptoms", "PROBLEM", 95, 123], ["respiratory", "ANATOMY", 95, 106]]], ["18 Crowdedness is a major risk factor for the transmission of respiratory illness.", [["respiratory", "ANATOMY", 62, 73], ["Crowdedness", "DISEASE", 3, 14], ["respiratory illness", "DISEASE", 62, 81], ["respiratory illness", "PROBLEM", 62, 81], ["respiratory illness", "OBSERVATION", 62, 81]]], ["These conditions contributed to almost one-half of the pilgrims (52.2%) having contact with people suffering from respiratory illness during hajj.", [["respiratory", "ANATOMY", 114, 125], ["respiratory illness", "DISEASE", 114, 133], ["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98], ["respiratory illness", "PROBLEM", 114, 133], ["respiratory illness", "OBSERVATION", 114, 133]]], ["They were at a significantly high risk of developing the respiratory illness by three times higher than those who do not have the contact (P value 0.01).", [["respiratory", "ANATOMY", 57, 68], ["respiratory illness", "DISEASE", 57, 76], ["the respiratory illness", "PROBLEM", 53, 76], ["respiratory", "ANATOMY", 57, 68], ["illness", "OBSERVATION", 69, 76]]], ["Practising contact avoidance during hajj is imperative as it can shorten the duration of respiratory illness.", [["respiratory", "ANATOMY", 89, 100], ["respiratory illness", "DISEASE", 89, 108], ["respiratory illness", "PROBLEM", 89, 108]]], ["18 Practicing social distancing and contact avoidance is effective in reducing the transmission of the respiratory symptoms during the 2009 US pilgrims and ILI symptoms in 2014 with the Indian pilgrims.", [["respiratory", "ANATOMY", 103, 114], ["respiratory symptoms", "DISEASE", 103, 123], ["ILI", "DISEASE", 156, 159], ["the respiratory symptoms", "PROBLEM", 99, 123], ["ILI symptoms", "PROBLEM", 156, 168], ["respiratory", "ANATOMY", 103, 114]]], ["18, 19 The majority of the respondents was inflicted with respiratory illness after a brief stay at Arafat (81.2%).", [["respiratory illness", "DISEASE", 58, 77], ["respiratory illness", "PROBLEM", 58, 77], ["Arafat", "TEST", 100, 106], ["majority", "OBSERVATION_MODIFIER", 11, 19]]], ["It may be correlated with the incubation period of the illness and the peak exposure of pilgrims whilst performing the hajj rituals.", [["illness", "DISEASE", 55, 62], ["the illness", "PROBLEM", 51, 62]]], ["Other studies estimated approximately one in three pilgrims will experience respiratory symptoms which usually occurred at the end or shortly after performing hajj rituals.", [["respiratory", "ANATOMY", 76, 87], ["respiratory symptoms", "DISEASE", 76, 96], ["Other studies", "TEST", 0, 13], ["respiratory symptoms", "PROBLEM", 76, 96]]], ["20 Influenza vaccination is one of the recommended vaccines for high risk pilgrims to reduce mortality and morbidity.", [["Influenza", "DISEASE", 3, 12], ["Influenza vaccination", "TREATMENT", 3, 24], ["vaccines", "TREATMENT", 51, 59], ["high risk pilgrims", "PROBLEM", 64, 82], ["morbidity", "PROBLEM", 107, 116]]], ["The vaccine uptake for influenza in our study is lower (65.2%) in contrast to Malaysian pilgrims in 2007 (72.8%) and Saudi Arabian pilgrims in 2009 (94.4%).", [["influenza", "DISEASE", 23, 32], ["The vaccine uptake", "TEST", 0, 18], ["influenza", "PROBLEM", 23, 32], ["our study", "TEST", 36, 45]]], ["6, 17 The percentage of vaccine uptake among the 2013 hajj pilgrims from other countries were as low as 31.8% for French pilgrims and 31.0% for pilgrims from Saudi Arabia, Qatar and Australia.", [["6, 17", "CHEMICAL", 0, 5], ["vaccine uptake", "PROBLEM", 24, 38], ["percentage", "OBSERVATION_MODIFIER", 10, 20]]], ["21, 22 Effective influenza vaccine remains debatable and cannot be proven if the study was conducted without virology confirmation.", [["influenza", "DISEASE", 17, 26], ["Effective influenza vaccine", "TREATMENT", 7, 34], ["the study", "TEST", 77, 86], ["virology confirmation", "TEST", 109, 130]]], ["Multiple factors such as mismatch between vaccine strains and circulating strains, inappropriate storage and the handling of the vaccine can reduce its effectiveness or waning of immunity in the population.", [["Multiple factors", "PROBLEM", 0, 16], ["mismatch between vaccine strains", "TREATMENT", 25, 57], ["circulating strains", "PROBLEM", 62, 81], ["inappropriate storage", "PROBLEM", 83, 104], ["the vaccine", "TREATMENT", 125, 136]]], ["One study systematically reviewed the available studies assessing the uptake and effectiveness of the influenza vaccine among pilgrims.", [["influenza", "DISEASE", 102, 111], ["One study", "TEST", 0, 9], ["the available studies", "TEST", 34, 55], ["the uptake", "PROBLEM", 66, 76], ["the influenza vaccine", "TREATMENT", 98, 119]]], ["The effectiveness of the influenza vaccine varied across studies, but was effective against laboratory-confirmed influenza with a P value of <0.001.", [["influenza", "DISEASE", 113, 122], ["the influenza vaccine", "TREATMENT", 21, 42], ["influenza", "PROBLEM", 113, 122], ["a P value", "TEST", 128, 137]]], ["23 In our study, the prevalence of ILI was not significantly associated with the status of the vaccination which was similar with pilgrims in Malaysia (2007), France (2006) and Iran (2006).", [["ILI", "DISEASE", 35, 38], ["our study", "TEST", 6, 15], ["ILI", "PROBLEM", 35, 38], ["ILI", "OBSERVATION", 35, 38]]], ["6, 24, 25 The vaccine was not associated with the reduction and number of acute respiratory symptoms nor any relation to the length of stay for Malaysian hajj pilgrims in 2007.", [["respiratory", "ANATOMY", 80, 91], ["The vaccine", "TREATMENT", 10, 21], ["acute respiratory symptoms", "PROBLEM", 74, 100], ["acute", "OBSERVATION_MODIFIER", 74, 79]]], ["26 The findings were not in accordance with the French pilgrims in 2013 in which the ILI symptoms were less frequently reported in the vaccinated group (34.1%) than unvaccinated group (61.5%) and was statistically significant (P value 0.009).", [["ILI", "DISEASE", 85, 88], ["the ILI symptoms", "PROBLEM", 81, 97], ["significant", "OBSERVATION_MODIFIER", 214, 225]]], ["21 In another study, they found that the influenza vaccine appeared to provide some protection in 'at risk' hajj pilgrims but not in the 'not at risk' group.", [["influenza", "DISEASE", 41, 50], ["another study", "TEST", 6, 19], ["the influenza vaccine", "TREATMENT", 37, 58]]], ["10 The influenza vaccines prevented clinic visits for ILI among Malaysian pilgrims in 2000 and Pakistani pilgrims in 1999.", [["influenza", "DISEASE", 7, 16], ["ILI", "DISEASE", 54, 57], ["The influenza vaccines", "TREATMENT", 3, 25], ["ILI", "PROBLEM", 54, 57]]], ["11, 27 The influenza vaccination is a protective factor for ILI more than for non-ILI, giving 70-77% protection for ILI and just 20% protection against the non-ILI group.", [["influenza", "DISEASE", 11, 20], ["ILI", "DISEASE", 60, 63], ["ILI", "DISEASE", 82, 85], ["ILI", "DISEASE", 116, 119], ["non-ILI", "CANCER", 156, 163], ["The influenza vaccination", "TREATMENT", 7, 32], ["ILI", "PROBLEM", 60, 63], ["ILI", "PROBLEM", 116, 119]]], ["11 One hundred and forty-nine of our respondents adopted good hand hygiene during hajj (31.8%).", [["hand", "ANATOMY", 62, 66], ["hand", "ORGANISM_SUBDIVISION", 62, 66]]], ["The results were similar to the French pilgrims in 2012 (46.3%) and the US hujjaj in 2009 (45.5%).", [["the US hujjaj", "TEST", 68, 81]]], ["18, 28 However, the adherence of French pilgrims towards hand sanitizer practices in 2009 was higher (77.4%) than in the 2012 hajj season.", [["hand", "ANATOMY", 57, 61], ["hand", "ORGANISM_SUBDIVISION", 57, 61]]], ["29 Effective hand hygiene practice in this study could significantly decrease the risk of respiratory illness by 60% than pilgrims who practiced poor hand hygiene.", [["hand", "ANATOMY", 13, 17], ["respiratory", "ANATOMY", 90, 101], ["hand", "ANATOMY", 150, 154], ["respiratory illness", "DISEASE", 90, 109], ["hand", "ORGANISM_SUBDIVISION", 13, 17], ["hand", "ORGANISM_SUBDIVISION", 150, 154], ["this study", "TEST", 38, 48], ["respiratory illness", "PROBLEM", 90, 109], ["respiratory", "ANATOMY", 90, 101], ["illness", "OBSERVATION", 102, 109]]], ["It was parallel with the US pilgrims in 2009 and the French pilgrims in 2012, as regularly washing hands and the use of hand sanitizers significantly causes less of the ILI symptoms.", [["hand", "ANATOMY", 120, 124], ["ILI", "DISEASE", 169, 172], ["hand", "ORGANISM_SUBDIVISION", 120, 124], ["hand sanitizers", "TREATMENT", 120, 135], ["the ILI symptoms", "PROBLEM", 165, 181]]], ["18, 28 A systematic review on hand-hygiene interventions, including education and the use of alcohol-based hand sanitizers towards respiratory illness indicated that some of the interventions were not efficacious against respiratory illnesses.", [["hand", "ANATOMY", 30, 34], ["hand", "ANATOMY", 107, 111], ["respiratory", "ANATOMY", 221, 232], ["alcohol", "CHEMICAL", 93, 100], ["respiratory illness", "DISEASE", 131, 150], ["respiratory illnesses", "DISEASE", 221, 242], ["alcohol", "CHEMICAL", 93, 100], ["hand", "ORGANISM_SUBDIVISION", 30, 34], ["alcohol", "SIMPLE_CHEMICAL", 93, 100], ["hand", "ORGANISM_SUBDIVISION", 107, 111], ["hand-hygiene interventions", "TREATMENT", 30, 56], ["education", "TREATMENT", 68, 77], ["respiratory illness", "PROBLEM", 131, 150], ["the interventions", "TREATMENT", 174, 191], ["respiratory illnesses", "PROBLEM", 221, 242]]], ["30 The consistent application of hand hygiene during critical points in the chain of transmission is likely to play a major role in shaping the relative effectiveness of hand-hygiene interventions in terms of disease outcome.DiscussionFace masks are able to limit the spread of microorganisms, mainly from the respiratory droplets.", [["hand", "ANATOMY", 33, 37], ["hand", "ANATOMY", 170, 174], ["respiratory droplets", "ANATOMY", 310, 330], ["hand", "ORGANISM_SUBDIVISION", 33, 37], ["hand", "ORGANISM_SUBDIVISION", 170, 174], ["hand hygiene", "TREATMENT", 33, 45], ["hygiene interventions", "TREATMENT", 175, 196], ["disease outcome", "PROBLEM", 209, 224], ["DiscussionFace masks", "TREATMENT", 225, 245], ["microorganisms", "PROBLEM", 278, 292], ["the respiratory droplets", "PROBLEM", 306, 330], ["respiratory droplets", "OBSERVATION", 310, 330]]], ["However, the CDC in USA found that the intermittent use of surgical-type masks was associated with more than a 2.5-fold greater risk of infection.", [["infection", "DISEASE", 136, 145], ["surgical-type masks", "TREATMENT", 59, 78], ["infection", "PROBLEM", 136, 145], ["intermittent", "OBSERVATION_MODIFIER", 39, 51], ["surgical", "OBSERVATION", 59, 67], ["infection", "OBSERVATION", 136, 145]]], ["Disposable face masks should be used once and replaced when they become moist and are to be disposed of properly.", [["Disposable face masks", "TREATMENT", 0, 21]]], ["Most of the Malaysian pilgrims admitted to wearing face masks during hajj (82.9%).", [["pilgrims", "ORGANISM", 22, 30], ["face masks", "TREATMENT", 51, 61]]], ["This finding was in accordance with other studies, 72.9% for Malaysian pilgrims in 2007 and 79.6% for French pilgrims in 2009.", [["other studies", "TEST", 36, 49]]], ["8, 29 The percentage was higher if compared with other countries in the 2009 hajj season; Saudi Arabia (56%) and USA (42%).", [["Saudi Arabia", "TEST", 90, 102], ["USA", "TEST", 113, 116], ["percentage", "OBSERVATION_MODIFIER", 10, 20], ["higher", "OBSERVATION_MODIFIER", 25, 31]]], ["17, 18 It has been revealed that face masks either offered no significant protection or were associated with a longer duration of sore throat and fever symptoms among hajj pilgrims.", [["sore throat", "DISEASE", 130, 141], ["fever", "DISEASE", 146, 151], ["face masks", "TREATMENT", 33, 43], ["sore throat", "PROBLEM", 130, 141], ["fever symptoms", "PROBLEM", 146, 160]]], ["25, 29, 31 A recent study illustrated that many pilgrims at the 2009 hajj may not have worn masks correctly (e.g. mistakenly positioning the top of the mask below the nose).", [["nose", "ANATOMY", 167, 171], ["nose", "ORGANISM_SUBDIVISION", 167, 171], ["A recent study", "TEST", 11, 25], ["nose", "ANATOMY", 167, 171]]], ["32 A recent review by Benkouiten et al. 33 in 2014 also mentioned that the effectiveness of the face mask in the prevention of the respiratory symptoms among hajj pilgrims revealed variable results.", [["respiratory", "ANATOMY", 131, 142], ["the face mask", "TREATMENT", 92, 105], ["the respiratory symptoms", "PROBLEM", 127, 151]]], ["Regular use of a face mask was the most essential practical protective factor in respiratory illness, using it for more than 8 h led to a substantial decrease in the incidence of ILI among Australian pilgrims in 2011.", [["respiratory", "ANATOMY", 81, 92], ["respiratory illness", "DISEASE", 81, 100], ["ILI", "DISEASE", 179, 182], ["a face mask", "TREATMENT", 15, 26], ["respiratory illness", "PROBLEM", 81, 100], ["ILI", "PROBLEM", 179, 182], ["respiratory illness", "OBSERVATION", 81, 100], ["substantial", "OBSERVATION_MODIFIER", 138, 149], ["decrease", "OBSERVATION_MODIFIER", 150, 158]]], ["34, 35 These masks were potentially effective at preventing respiratory virus acquisition by household contacts of infected people when worn by healthy people.", [["people", "ORGANISM", 124, 130], ["people", "ORGANISM", 152, 158], ["people", "SPECIES", 124, 130], ["people", "SPECIES", 152, 158], ["These masks", "TREATMENT", 7, 18], ["respiratory virus acquisition", "TREATMENT", 60, 89], ["respiratory virus", "OBSERVATION", 60, 77]]], ["36 Honey is one of the most promising natural substances that can combat or prevent respiratory illness.", [["respiratory", "ANATOMY", 84, 95], ["respiratory illness", "DISEASE", 84, 103], ["respiratory illness", "PROBLEM", 84, 103], ["one of the most", "OBSERVATION_MODIFIER", 12, 27]]], ["37 Approximately 22.9% of pilgrims consumed honey during hajj.", [["pilgrims", "ORGANISM", 26, 34]]], ["However, there was no other study to compare the prevalence of honey intake among hajj pilgrims except for one study to determine the effectiveness of honey in reducing respiratory symptoms.", [["respiratory", "ANATOMY", 169, 180], ["respiratory symptoms", "DISEASE", 169, 189], ["honey", "ORGANISM_SUBDIVISION", 63, 68], ["honey", "ORGANISM_SUBDIVISION", 151, 156], ["honey", "SPECIES", 63, 68], ["other study", "TEST", 22, 33], ["one study", "TEST", 107, 116], ["reducing respiratory symptoms", "PROBLEM", 160, 189]]], ["38 During the hajj, pilgrims undergo great physical and emotional strain.", [["great physical and emotional strain", "PROBLEM", 37, 72]]], ["However, every year is different and every person's experience is individually specific but they are able to prepare themselves as much as possible for the hajj challenges.", [["person", "SPECIES", 43, 49]]], ["The association of previous experiences during hajj or umrah with respiratory illness has not been studied before.", [["respiratory", "ANATOMY", 66, 77], ["respiratory illness", "DISEASE", 66, 85], ["respiratory illness", "PROBLEM", 66, 85], ["respiratory", "ANATOMY", 66, 77], ["illness", "OBSERVATION", 78, 85]]], ["Malaysian hajj pilgrims with previous experience of hajj or umrah were found to be significantly associated with lower risk of developing respiratory illness (P value of 0.001 for both).DiscussionFurther study needs to be conducted to explore the factors that contribute to the association of respiratory illness in those who have experienced performing hajj or umrah.", [["respiratory", "ANATOMY", 138, 149], ["respiratory", "ANATOMY", 293, 304], ["respiratory illness", "DISEASE", 138, 157], ["respiratory illness", "DISEASE", 293, 312], ["umrah", "PROBLEM", 60, 65], ["developing respiratory illness", "PROBLEM", 127, 157], ["P value", "TEST", 159, 166], ["DiscussionFurther study", "TEST", 186, 209], ["respiratory illness", "PROBLEM", 293, 312], ["respiratory", "ANATOMY", 138, 149], ["illness", "OBSERVATION", 150, 157]]], ["The limitations of this study include inadequate sample size and a poor response rate as it could affect the power of the study.", [["this study", "TEST", 19, 29], ["the study", "TEST", 118, 127], ["size", "OBSERVATION_MODIFIER", 56, 60]]], ["The small response rate could be due to a lack of commitment from the respondents following a very packed hajj ritual schedule.", [["a very packed hajj ritual schedule", "TREATMENT", 92, 126], ["small", "OBSERVATION_MODIFIER", 4, 9], ["response rate", "OBSERVATION", 10, 23]]], ["Shortage of staff to handle and follow-up the respondents in Makkah, further added to the problem.DiscussionIn conclusion, the prevalence of respiratory illness remains high among Malaysian hajj pilgrims despite having some practicing preventive measures.", [["respiratory", "ANATOMY", 141, 152], ["respiratory illness", "DISEASE", 141, 160], ["respiratory illness", "PROBLEM", 141, 160]]], ["All preventive measures including hand hygiene, wearing face masks and influenza vaccination must be practiced together to reduce the respiratory illness effectively.", [["hand", "ANATOMY", 34, 38], ["respiratory", "ANATOMY", 134, 145], ["respiratory illness", "DISEASE", 134, 153], ["hand", "ORGANISM_SUBDIVISION", 34, 38], ["All preventive measures", "TREATMENT", 0, 23], ["hand hygiene", "TREATMENT", 34, 46], ["wearing face masks", "TREATMENT", 48, 66], ["influenza vaccination", "TREATMENT", 71, 92], ["the respiratory illness", "PROBLEM", 130, 153], ["respiratory illness", "OBSERVATION", 134, 153]]], ["In our study, good hand hygiene practice was lower compared with other preventive measures; therefore, health authorities should find a way to overcome this problem.", [["hand", "ANATOMY", 19, 23], ["hand", "ORGANISM_SUBDIVISION", 19, 23], ["our study", "TEST", 3, 12]]], ["Further studies are required to develop a health education module to promote a comprehensive preventive measure for hajj pilgrims.", [["Further studies", "TEST", 0, 15], ["a health education module", "TREATMENT", 40, 65]]]], "4aa6c6d082407bee2de3cfdc3a8a11a229904fda": [["IntroductionAstrocytes were long considered secondary to neurons in central nervous system (CNS) function, and erroneously dismissed as \"brain glue\" (glia is the Greek term for glue).", [["neurons", "ANATOMY", 57, 64], ["central nervous system", "ANATOMY", 68, 90], ["CNS", "ANATOMY", 92, 95], ["brain", "ANATOMY", 137, 142], ["glia", "ANATOMY", 150, 154], ["neurons", "CELL", 57, 64], ["central nervous system", "ANATOMICAL_SYSTEM", 68, 90], ["CNS", "ANATOMICAL_SYSTEM", 92, 95], ["brain glue", "TISSUE", 137, 147], ["glia", "CELL_TYPE", 150, 154], ["IntroductionAstrocytes", "TEST", 0, 22], ["neurons in central nervous system", "PROBLEM", 57, 90], ["central", "ANATOMY_MODIFIER", 68, 75], ["nervous system", "ANATOMY", 76, 90]]], ["Research over the past two decades, however, has shown astrocytic roles extending to a range of brain functions far beyond basic physical and metabolic neuronal support (Sofroniew and Vinters, 2010) .", [["astrocytic", "ANATOMY", 55, 65], ["brain", "ANATOMY", 96, 101], ["neuronal", "ANATOMY", 152, 160], ["brain", "ORGAN", 96, 101], ["neuronal", "CELL", 152, 160], ["metabolic neuronal", "OBSERVATION", 142, 160]]], ["Astrocytic regulation of myelination was first hypothesised by M\u0171ller in 1904, who claimed that the demyelinating disease, Multiple Sclerosis (MS), was rooted in astrocytic dysfunction (M\u00fcller, 1904; Williams et al., 2007) .", [["astrocytic", "ANATOMY", 162, 172], ["demyelinating disease", "DISEASE", 100, 121], ["Multiple Sclerosis", "DISEASE", 123, 141], ["MS", "DISEASE", 143, 145], ["astrocytic dysfunction", "DISEASE", 162, 184], ["Astrocytic regulation of myelination", "PROBLEM", 0, 36], ["the demyelinating disease", "PROBLEM", 96, 121], ["Multiple Sclerosis (MS)", "PROBLEM", 123, 146], ["astrocytic dysfunction", "PROBLEM", 162, 184], ["demyelinating disease", "OBSERVATION", 100, 121], ["Multiple", "OBSERVATION_MODIFIER", 123, 131], ["Sclerosis", "OBSERVATION", 132, 141], ["astrocytic dysfunction", "OBSERVATION", 162, 184]]], ["Evidence has since continued to grow supporting the premise that astrocytes could be important in regulating myelination (Sofroniew and Vinters, 2010; Williams et al., 2007; Barnett and Linington, 2013; Moore et al., 2011) .IntroductionGlial fibrillary acidic protein (GFAP) has been used extensively in the study of astrocytes.", [["astrocytes", "ANATOMY", 65, 75], ["astrocytes", "ANATOMY", 317, 327], ["astrocytes", "CELL", 65, 75], ["Glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 236, 267], ["GFAP", "GENE_OR_GENE_PRODUCT", 269, 273], ["astrocytes", "CELL", 317, 327], ["astrocytes", "CELL_TYPE", 65, 75], ["Glial fibrillary acidic protein", "PROTEIN", 236, 267], ["GFAP", "PROTEIN", 269, 273], ["astrocytes", "CELL_TYPE", 317, 327], ["Glial fibrillary acidic protein", "TEST", 236, 267], ["GFAP", "TEST", 269, 273], ["astrocytes", "ANATOMY", 317, 327]]], ["Increased GFAP expression has been associated with astrocyte reactivity in CNS lesions and is a pathological hallmark of disease and/or injury.", [["astrocyte", "ANATOMY", 51, 60], ["CNS lesions", "ANATOMY", 75, 86], ["GFAP", "GENE_OR_GENE_PRODUCT", 10, 14], ["astrocyte", "CELL", 51, 60], ["CNS lesions", "PATHOLOGICAL_FORMATION", 75, 86], ["GFAP", "PROTEIN", 10, 14], ["Increased GFAP expression", "PROBLEM", 0, 25], ["astrocyte reactivity in CNS lesions", "PROBLEM", 51, 86], ["a pathological hallmark of disease", "PROBLEM", 94, 128], ["injury", "PROBLEM", 136, 142], ["associated with", "UNCERTAINTY", 35, 50], ["astrocyte reactivity", "OBSERVATION", 51, 71], ["CNS", "ANATOMY", 75, 78], ["lesions", "OBSERVATION", 79, 86], ["disease", "OBSERVATION", 121, 128], ["injury", "OBSERVATION", 136, 142]]], ["Fig. 1 illustrates astrocytes immunolabelled with GFAP and nestin, another marker thought to label reactive astrocytes (Kamphuis et al., 2012) .", [["astrocytes", "ANATOMY", 19, 29], ["astrocytes", "ANATOMY", 108, 118], ["astrocytes", "CELL", 19, 29], ["GFAP", "GENE_OR_GENE_PRODUCT", 50, 54], ["nestin", "GENE_OR_GENE_PRODUCT", 59, 65], ["astrocytes", "CELL", 108, 118], ["astrocytes", "CELL_TYPE", 19, 29], ["GFAP", "PROTEIN", 50, 54], ["nestin", "PROTEIN", 59, 65], ["reactive astrocytes", "CELL_TYPE", 99, 118], ["GFAP", "TEST", 50, 54], ["another marker", "TEST", 67, 81], ["reactive astrocytes", "OBSERVATION", 99, 118]]], ["In experimental allergic encephalomyelitis (EAE), a widely used animal model of MS, where demyelination is induced by myelin antigens, administered together with adjuvant that contains bacterial components (Traugott and Lebon, 1988; Tsukada et al., 1991; Villarroya et al., 1996) , GFAP expression was seen on more numerous and much larger astrocytic processes in chronic lesions compared to normal appearing white matter (Webster et al., 1985; Eng et al., 1971) .", [["astrocytic", "ANATOMY", 340, 350], ["lesions", "ANATOMY", 372, 379], ["white matter", "ANATOMY", 409, 421], ["allergic encephalomyelitis", "DISEASE", 16, 42], ["EAE", "DISEASE", 44, 47], ["MS", "DISEASE", 80, 82], ["demyelination", "DISEASE", 90, 103], ["myelin antigens", "GENE_OR_GENE_PRODUCT", 118, 133], ["GFAP", "GENE_OR_GENE_PRODUCT", 282, 286], ["lesions", "PATHOLOGICAL_FORMATION", 372, 379], ["myelin antigens", "PROTEIN", 118, 133], ["GFAP", "PROTEIN", 282, 286], ["experimental allergic encephalomyelitis", "PROBLEM", 3, 42], ["demyelination", "PROBLEM", 90, 103], ["myelin antigens", "PROBLEM", 118, 133], ["adjuvant", "TREATMENT", 162, 170], ["GFAP expression", "TEST", 282, 297], ["chronic lesions", "PROBLEM", 364, 379], ["allergic encephalomyelitis", "OBSERVATION", 16, 42], ["demyelination", "OBSERVATION", 90, 103], ["bacterial components", "OBSERVATION_MODIFIER", 185, 205], ["more numerous", "OBSERVATION_MODIFIER", 310, 323], ["much larger", "OBSERVATION_MODIFIER", 328, 339], ["astrocytic processes", "OBSERVATION", 340, 360], ["chronic", "OBSERVATION_MODIFIER", 364, 371], ["lesions", "OBSERVATION", 372, 379], ["white matter", "OBSERVATION_MODIFIER", 409, 421]]], ["Thus, the degree of GFAP immunoreactivity appears to reflect the level of reactive astrogliosis.", [["astrogliosis", "DISEASE", 83, 95], ["GFAP", "GENE_OR_GENE_PRODUCT", 20, 24], ["GFAP", "PROTEIN", 20, 24], ["GFAP immunoreactivity", "PROBLEM", 20, 41], ["reactive astrogliosis", "PROBLEM", 74, 95], ["GFAP immunoreactivity", "OBSERVATION", 20, 41], ["appears to reflect", "UNCERTAINTY", 42, 60], ["reactive", "OBSERVATION_MODIFIER", 74, 82], ["astrogliosis", "OBSERVATION", 83, 95]]], ["This was reviewed in detail by Sofroniew and Vinters (2010) , who described a continuum of phenotypic changes, that range from mild to severe, the latter resulting in glial scar formation (Sofroniew and Vinters, 2010; Nash et al., 2011a) .", [["glial scar", "ANATOMY", 167, 177], ["glial scar", "TISSUE", 167, 177], ["phenotypic changes", "PROBLEM", 91, 109], ["mild to severe", "PROBLEM", 127, 141], ["glial scar formation", "PROBLEM", 167, 187], ["phenotypic", "OBSERVATION", 91, 101], ["mild", "OBSERVATION_MODIFIER", 127, 131], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["glial", "ANATOMY", 167, 172], ["scar", "OBSERVATION", 173, 177]]], ["Attempts have also been made to define the astrocyte phenotype in more detail along this continuum (Liberto et al., 2004) .", [["astrocyte", "ANATOMY", 43, 52], ["astrocyte", "CELL", 43, 52], ["the astrocyte phenotype", "PROBLEM", 39, 62]]], ["It has been suggested that mild astrogliosis is associated with astrocyte \"activation\" and severe astrogliosis is associated with \"reactivity\", with the former promoting recovery of CNS function after injury and the latter walling off the injured area and preventing repair (Liberto et al., 2004) .", [["astrocyte", "ANATOMY", 64, 73], ["CNS", "ANATOMY", 182, 185], ["area", "ANATOMY", 247, 251], ["astrogliosis", "DISEASE", 32, 44], ["astrogliosis", "DISEASE", 98, 110], ["astrocyte", "CELL", 64, 73], ["CNS", "ANATOMICAL_SYSTEM", 182, 185], ["mild astrogliosis", "PROBLEM", 27, 44], ["astrocyte \"activation\"", "PROBLEM", 64, 86], ["severe astrogliosis", "PROBLEM", 91, 110], ["injury", "PROBLEM", 201, 207], ["repair", "TREATMENT", 267, 273], ["mild", "OBSERVATION_MODIFIER", 27, 31], ["astrogliosis", "OBSERVATION", 32, 44], ["associated with", "UNCERTAINTY", 48, 63], ["astrocyte \"", "OBSERVATION", 64, 75], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["astrogliosis", "OBSERVATION", 98, 110], ["CNS", "ANATOMY", 182, 185], ["injured", "OBSERVATION_MODIFIER", 239, 246], ["repair", "OBSERVATION", 267, 273]]], ["Although activated astrocytes have been associated with less detrimental effects on the CNS and reactive astrocytes as more damaging, it is clear that these properties are not all or nothing and reactive astrocytes can Fig. 1 .", [["astrocytes", "ANATOMY", 19, 29], ["CNS", "ANATOMY", 88, 91], ["astrocytes", "ANATOMY", 105, 115], ["astrocytes", "ANATOMY", 204, 214], ["astrocytes", "CELL", 19, 29], ["CNS", "ANATOMICAL_SYSTEM", 88, 91], ["astrocytes", "CELL", 105, 115], ["astrocytes", "CELL", 204, 214], ["activated astrocytes", "CELL_TYPE", 9, 29], ["reactive astrocytes", "CELL_TYPE", 96, 115], ["reactive astrocytes", "CELL_TYPE", 195, 214], ["activated astrocytes", "PROBLEM", 9, 29], ["the CNS and reactive astrocytes", "PROBLEM", 84, 115], ["CNS", "ANATOMY", 88, 91], ["reactive astrocytes", "OBSERVATION", 96, 115]]], ["Expression of astrocyte reactivity markers.", [["astrocyte", "ANATOMY", 14, 23], ["astrocyte", "CELL", 14, 23], ["astrocyte reactivity markers", "PROTEIN", 14, 42], ["astrocyte reactivity", "OBSERVATION", 14, 34]]], ["Rat neurosphere-derived astrocytes cultured on PLL-coated glass coverslips express the reactivity markers GFAP (green) and nestin (red).Fig.", [["neurosphere", "ANATOMY", 4, 15], ["astrocytes", "ANATOMY", 24, 34], ["PLL", "CHEMICAL", 47, 50], ["Rat neurosphere-derived astrocytes", "CELL", 0, 34], ["PLL", "SIMPLE_CHEMICAL", 47, 50], ["GFAP", "GENE_OR_GENE_PRODUCT", 106, 110], ["green)", "GENE_OR_GENE_PRODUCT", 112, 118], ["nestin", "GENE_OR_GENE_PRODUCT", 123, 129], ["Rat neurosphere-derived astrocytes", "CELL_LINE", 0, 34], ["reactivity markers", "PROTEIN", 87, 105], ["GFAP", "PROTEIN", 106, 110], ["nestin", "PROTEIN", 123, 129], ["red", "PROTEIN", 131, 134], ["Rat", "SPECIES", 0, 3], ["Rat neurosphere", "TEST", 0, 15], ["PLL-coated glass coverslips", "TREATMENT", 47, 74]]], ["2.Astrocytic effects on re/myelination can be classified into 4 main groups.", [["Astrocytic", "ANATOMY", 2, 12], ["Astrocytic effects", "PROBLEM", 2, 20]]], ["They contribute to re/myelination by: 1) Providing an energy source (lactate) and cholesterol for neurons.", [["neurons", "ANATOMY", 98, 105], ["lactate", "CHEMICAL", 69, 76], ["cholesterol", "CHEMICAL", 82, 93], ["lactate", "CHEMICAL", 69, 76], ["cholesterol", "CHEMICAL", 82, 93], ["lactate", "SIMPLE_CHEMICAL", 69, 76], ["cholesterol", "SIMPLE_CHEMICAL", 82, 93], ["neurons", "CELL", 98, 105], ["lactate", "TEST", 69, 76], ["neurons", "PROBLEM", 98, 105]]], ["Glucose taken up by endothelial cells lining the blood brain barrier is later transferred to astrocytes which transform it to glycogen, which can then be used to produce lactate.", [["endothelial cells", "ANATOMY", 20, 37], ["blood brain barrier", "ANATOMY", 49, 68], ["astrocytes", "ANATOMY", 93, 103], ["Glucose", "CHEMICAL", 0, 7], ["glycogen", "CHEMICAL", 126, 134], ["lactate", "CHEMICAL", 170, 177], ["Glucose", "CHEMICAL", 0, 7], ["lactate", "CHEMICAL", 170, 177], ["Glucose", "SIMPLE_CHEMICAL", 0, 7], ["endothelial cells", "CELL", 20, 37], ["blood brain barrier", "TISSUE", 49, 68], ["astrocytes", "CELL", 93, 103], ["glycogen", "SIMPLE_CHEMICAL", 126, 134], ["lactate", "SIMPLE_CHEMICAL", 170, 177], ["endothelial cells", "CELL_TYPE", 20, 37], ["astrocytes", "CELL_TYPE", 93, 103], ["Glucose", "TEST", 0, 7], ["lactate", "TEST", 170, 177]]], ["2) Playing a role in synaptic signal transmission by regulating the fluid, pH/ion (e.g. potassium, K + ), glio/neurotransmitter homeostasis and contributing to synapse modulation through secreted molecules, such as thrombospondins (THBSs) .", [["synaptic", "ANATOMY", 21, 29], ["fluid", "ANATOMY", 68, 73], ["synapse", "ANATOMY", 160, 167], ["potassium", "CHEMICAL", 88, 97], ["K", "CHEMICAL", 99, 100], ["potassium", "CHEMICAL", 88, 97], ["K +", "CHEMICAL", 99, 102], ["potassium", "SIMPLE_CHEMICAL", 88, 97], ["K +", "SIMPLE_CHEMICAL", 99, 102], ["thrombospondins", "GENE_OR_GENE_PRODUCT", 215, 230], ["THBSs", "GENE_OR_GENE_PRODUCT", 232, 237], ["secreted molecules", "PROTEIN", 187, 205], ["thrombospondins", "PROTEIN", 215, 230], ["THBSs", "PROTEIN", 232, 237], ["synaptic signal transmission", "TREATMENT", 21, 49], ["the fluid", "TEST", 64, 73], ["pH", "TEST", 75, 77], ["potassium", "TEST", 88, 97], ["K", "TEST", 99, 100], ["glio/neurotransmitter homeostasis", "PROBLEM", 106, 139], ["synapse modulation through secreted molecules", "PROBLEM", 160, 205]]], ["3) Affecting the survival, proliferation and maturation of oligodendrocytes by secreting growth factors, some of which are regulated by iron homeostasis provided by astrocytes.", [["oligodendrocytes", "ANATOMY", 59, 75], ["astrocytes", "ANATOMY", 165, 175], ["iron", "CHEMICAL", 136, 140], ["iron", "CHEMICAL", 136, 140], ["oligodendrocytes", "CELL", 59, 75], ["iron", "SIMPLE_CHEMICAL", 136, 140], ["astrocytes", "CELL", 165, 175], ["oligodendrocytes", "CELL_TYPE", 59, 75], ["growth factors", "PROTEIN", 89, 103], ["astrocytes", "CELL_TYPE", 165, 175], ["the survival", "PROBLEM", 13, 25], ["proliferation", "PROBLEM", 27, 40], ["maturation of oligodendrocytes", "PROBLEM", 45, 75], ["secreting growth factors", "PROBLEM", 79, 103], ["iron homeostasis", "TEST", 136, 152], ["survival", "OBSERVATION_MODIFIER", 17, 25], ["proliferation", "OBSERVATION_MODIFIER", 27, 40], ["oligodendrocytes", "OBSERVATION_MODIFIER", 59, 75], ["iron homeostasis", "OBSERVATION", 136, 152]]], ["Chemokines may also influence oligodendrocyte membrane ensheathment of axons.", [["oligodendrocyte membrane", "ANATOMY", 30, 54], ["axons", "ANATOMY", 71, 76], ["oligodendrocyte membrane", "CELLULAR_COMPONENT", 30, 54], ["axons", "CELLULAR_COMPONENT", 71, 76], ["Chemokines", "PROTEIN", 0, 10]]], ["4) Altering reactivity status through their release of chemokines/cytokines, which in turn affects the cross-talk between all neural cells including microglia. also be beneficial to CNS repair.", [["neural cells", "ANATOMY", 126, 138], ["microglia", "ANATOMY", 149, 158], ["CNS", "ANATOMY", 182, 185], ["neural cells", "CELL", 126, 138], ["microglia", "CELL", 149, 158], ["CNS", "ANATOMICAL_SYSTEM", 182, 185], ["chemokines", "PROTEIN", 55, 65], ["cytokines", "PROTEIN", 66, 75], ["neural cells", "CELL_TYPE", 126, 138], ["microglia", "CELL_TYPE", 149, 158], ["Altering reactivity status", "PROBLEM", 3, 29], ["chemokines/cytokines", "TREATMENT", 55, 75], ["CNS repair", "TREATMENT", 182, 192], ["neural cells", "ANATOMY", 126, 138], ["microglia", "ANATOMY", 149, 158], ["CNS", "ANATOMY", 182, 185], ["repair", "OBSERVATION", 186, 192]]], ["Interestingly, in studies using GFAP null mice, it was seen that animals had abnormal myelination, nonmyelinated axons in the optic nerve with an age related reduction in myelin thickness (Liedtke et al., 1996) .", [["axons", "ANATOMY", 113, 118], ["optic nerve", "ANATOMY", 126, 137], ["myelin", "ANATOMY", 171, 177], ["abnormal myelination", "DISEASE", 77, 97], ["reduction in myelin thickness", "DISEASE", 158, 187], ["GFAP", "GENE_OR_GENE_PRODUCT", 32, 36], ["nonmyelinated axons", "CELLULAR_COMPONENT", 99, 118], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 126, 137], ["myelin", "TISSUE", 171, 177], ["GFAP", "PROTEIN", 32, 36], ["mice", "SPECIES", 42, 46], ["abnormal myelination", "PROBLEM", 77, 97], ["nonmyelinated axons in the optic nerve", "PROBLEM", 99, 137], ["abnormal myelination", "OBSERVATION", 77, 97], ["axons", "ANATOMY_MODIFIER", 113, 118], ["optic nerve", "ANATOMY", 126, 137], ["reduction", "OBSERVATION_MODIFIER", 158, 167], ["myelin thickness", "OBSERVATION", 171, 187]]], ["Non-conservative mutations in the GFAP gene have also been linked to the white matter brain disorder, Alexander disease (Brenner et al., 2001; Li et al., 2002) .", [["white matter brain", "ANATOMY", 73, 91], ["white matter brain disorder", "DISEASE", 73, 100], ["Alexander disease", "DISEASE", 102, 119], ["GFAP", "GENE_OR_GENE_PRODUCT", 34, 38], ["brain", "ORGAN", 86, 91], ["GFAP gene", "DNA", 34, 43], ["Non-conservative mutations", "PROBLEM", 0, 26], ["the white matter brain disorder", "PROBLEM", 69, 100]]], ["Therefore, the evidence for direct or indirect astrocytic roles on re/myelination has been established both by in vitro and in vivo studies.Fig.", [["astrocytic", "ANATOMY", 47, 57], ["direct or indirect astrocytic roles", "PROBLEM", 28, 63], ["vivo studies", "TEST", 127, 139]]], ["2.Considering the limitations in the current treatments for demyelinating CNS diseases and injuries, it is crucial to identify other approaches to regulate myelination in search of novel strategies for repair.", [["CNS", "ANATOMY", 74, 77], ["demyelinating CNS diseases", "DISEASE", 60, 86], ["injuries", "DISEASE", 91, 99], ["CNS", "ANATOMICAL_SYSTEM", 74, 77], ["the current treatments", "TREATMENT", 33, 55], ["demyelinating CNS diseases", "PROBLEM", 60, 86], ["injuries", "PROBLEM", 91, 99], ["novel strategies", "TREATMENT", 181, 197], ["repair", "TREATMENT", 202, 208], ["demyelinating", "OBSERVATION_MODIFIER", 60, 73], ["CNS", "ANATOMY", 74, 77], ["diseases", "OBSERVATION", 78, 86]]], ["Astrocytes have been shown to promote myelination through their supportive roles on neuron survival and maintenance of neuronal activity, and their direct action on proliferation, differentiation and migration of oligodendrocytes (Fig. 2) .", [["Astrocytes", "ANATOMY", 0, 10], ["neuron", "ANATOMY", 84, 90], ["neuronal", "ANATOMY", 119, 127], ["oligodendrocytes", "ANATOMY", 213, 229], ["Astrocytes", "CELL", 0, 10], ["neuron", "CELL", 84, 90], ["neuronal", "CELL", 119, 127], ["oligodendrocytes", "CELL", 213, 229], ["Astrocytes", "CELL_TYPE", 0, 10], ["oligodendrocytes", "CELL_TYPE", 213, 229], ["Astrocytes", "PROBLEM", 0, 10], ["neuron survival", "TREATMENT", 84, 99], ["neuronal activity", "OBSERVATION", 119, 136]]], ["This review will focus on the interaction of astrocytes with neural cells to synergistically promote myelination.Role of cytokines and chemokinesIt is apparent that astrocytes can affect myelination under a range of normal and pathological conditions, but it is important to understand how this is regulated.", [["astrocytes", "ANATOMY", 45, 55], ["neural cells", "ANATOMY", 61, 73], ["astrocytes", "ANATOMY", 165, 175], ["astrocytes", "CELL", 45, 55], ["neural cells", "CELL", 61, 73], ["astrocytes", "CELL", 165, 175], ["astrocytes", "CELL_TYPE", 45, 55], ["neural cells", "CELL_TYPE", 61, 73], ["cytokines", "PROTEIN", 121, 130], ["chemokines", "PROTEIN", 135, 145], ["astrocytes", "CELL_TYPE", 165, 175], ["cytokines", "TREATMENT", 121, 130], ["chemokines", "TREATMENT", 135, 145], ["astrocytes", "OBSERVATION", 165, 175]]], ["Many molecules can trigger or even regulate astrogliosis, including large polypeptide growth factors and cytokines (John et al., 2003; Moore et al., 2011) , mediators of innate immunity such as lipopolysaccharide (LPS) and other Toll-like receptor ligands (Farina et al., 2007) , neurotransmitters (Bekar et al., 2008) , purines, reactive oxygen species, and molecules related to hypoxia and glucose deprivation (Swanson et al., 2004) .", [["astrogliosis", "DISEASE", 44, 56], ["lipopolysaccharide", "CHEMICAL", 194, 212], ["LPS", "CHEMICAL", 214, 217], ["purines", "CHEMICAL", 321, 328], ["oxygen", "CHEMICAL", 339, 345], ["hypoxia", "DISEASE", 380, 387], ["glucose", "CHEMICAL", 392, 399], ["purines", "CHEMICAL", 321, 328], ["oxygen", "CHEMICAL", 339, 345], ["glucose", "CHEMICAL", 392, 399], ["large polypeptide growth factors", "GENE_OR_GENE_PRODUCT", 68, 100], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 194, 212], ["LPS", "SIMPLE_CHEMICAL", 214, 217], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 229, 247], ["purines", "SIMPLE_CHEMICAL", 321, 328], ["reactive oxygen species", "SIMPLE_CHEMICAL", 330, 353], ["glucose", "SIMPLE_CHEMICAL", 392, 399], ["large polypeptide growth factors", "PROTEIN", 68, 100], ["cytokines", "PROTEIN", 105, 114], ["astrogliosis", "PROBLEM", 44, 56], ["large polypeptide growth factors", "PROBLEM", 68, 100], ["lipopolysaccharide (LPS", "TREATMENT", 194, 217], ["reactive oxygen species", "PROBLEM", 330, 353], ["hypoxia", "PROBLEM", 380, 387], ["glucose deprivation", "PROBLEM", 392, 411], ["astrogliosis", "OBSERVATION", 44, 56], ["large", "OBSERVATION_MODIFIER", 68, 73], ["reactive", "OBSERVATION", 330, 338], ["oxygen species", "OBSERVATION", 339, 353], ["hypoxia", "OBSERVATION", 380, 387]]], ["For the purpose of this review we will focus on cytokines and chemokines.", [["cytokines", "PROTEIN", 48, 57], ["chemokines", "PROTEIN", 62, 72], ["cytokines and chemokines", "TREATMENT", 48, 72]]], ["Although these compounds are primarily considered in the context of chemotaxis in immune cells, here we will highlight their roles on astrocyte activation and reactivity.", [["immune cells", "ANATOMY", 82, 94], ["astrocyte", "ANATOMY", 134, 143], ["immune cells", "CELL", 82, 94], ["astrocyte", "CELL", 134, 143], ["immune cells", "CELL_TYPE", 82, 94], ["chemotaxis in immune cells", "PROBLEM", 68, 94], ["chemotaxis", "OBSERVATION", 68, 78], ["immune cells", "OBSERVATION", 82, 94]]], ["These molecules can be produced in an autocrine or paracrine fashion by various cell types in the CNS including neurons, oligodendrocyte lineage cells, microglia, pericytes and endothelial cells.", [["cell", "ANATOMY", 80, 84], ["CNS", "ANATOMY", 98, 101], ["neurons", "ANATOMY", 112, 119], ["oligodendrocyte lineage cells", "ANATOMY", 121, 150], ["microglia", "ANATOMY", 152, 161], ["pericytes", "ANATOMY", 163, 172], ["endothelial cells", "ANATOMY", 177, 194], ["cell", "CELL", 80, 84], ["CNS", "ANATOMICAL_SYSTEM", 98, 101], ["neurons", "CELL", 112, 119], ["oligodendrocyte lineage cells", "CELL", 121, 150], ["microglia", "CELL", 152, 161], ["pericytes", "CELL", 163, 172], ["endothelial cells", "CELL", 177, 194], ["neurons", "CELL_TYPE", 112, 119], ["oligodendrocyte lineage cells", "CELL_TYPE", 121, 150], ["microglia", "CELL_TYPE", 152, 161], ["pericytes", "CELL_TYPE", 163, 172], ["endothelial cells", "CELL_TYPE", 177, 194], ["various cell types", "OBSERVATION", 72, 90], ["CNS", "ANATOMY", 98, 101], ["neurons", "ANATOMY", 112, 119], ["oligodendrocyte lineage cells", "OBSERVATION", 121, 150], ["endothelial cells", "OBSERVATION", 177, 194]]], ["Not only do these factors influence astrocyte phenotype but they also can affect a range of neural and immune cell types.Role of cytokines and chemokines2.2.", [["astrocyte", "ANATOMY", 36, 45], ["neural", "ANATOMY", 92, 98], ["immune cell", "ANATOMY", 103, 114], ["astrocyte", "CELL", 36, 45], ["neural", "CELL", 92, 98], ["immune cell", "CELL", 103, 114], ["neural and immune cell types", "CELL_TYPE", 92, 120], ["cytokines", "PROTEIN", 129, 138], ["chemokines", "PROTEIN", 143, 153], ["astrocyte phenotype", "PROBLEM", 36, 55], ["chemokines", "TEST", 143, 153], ["immune cell types", "OBSERVATION", 103, 120]]], ["Astrocyte activation (mild astrogliosis): a pro-reparative phenotype?Role of cytokines and chemokinesAstrocytes can be activated directly or indirectly.", [["Astrocyte", "ANATOMY", 0, 9], ["astrogliosis", "DISEASE", 27, 39], ["Astrocyte", "CELL", 0, 9], ["Astrocytes", "CELL", 101, 111], ["cytokines", "PROTEIN", 77, 86], ["chemokines", "PROTEIN", 91, 101], ["Astrocyte activation (mild astrogliosis)", "PROBLEM", 0, 40], ["a pro-reparative phenotype", "PROBLEM", 42, 68], ["cytokines and chemokinesAstrocytes", "TREATMENT", 77, 111], ["mild", "OBSERVATION_MODIFIER", 22, 26], ["astrogliosis", "OBSERVATION", 27, 39]]], ["For example, in response to injury, microglia become activated and release the cytokine interleukin 1\u03b2 (IL-1\u03b2, Herx et al., 2000) , which is an early injury signal (Auron, 1998) .", [["microglia", "ANATOMY", 36, 45], ["microglia", "CELL", 36, 45], ["interleukin 1\u03b2", "GENE_OR_GENE_PRODUCT", 88, 102], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 104, 109], ["microglia", "CELL_TYPE", 36, 45], ["cytokine", "PROTEIN", 79, 87], ["interleukin 1\u03b2", "PROTEIN", 88, 102], ["injury", "PROBLEM", 28, 34], ["the cytokine interleukin", "TEST", 75, 99], ["IL", "TEST", 104, 106], ["an early injury signal", "PROBLEM", 141, 163], ["injury", "OBSERVATION", 28, 34], ["early", "OBSERVATION_MODIFIER", 144, 149], ["injury", "OBSERVATION", 150, 156]]], ["The delay of astrocyte activation in mice lacking IL-1\u03b2, as well as in mice lacking IL-1 type 1 receptor suggests that microglial activation is necessary for astrocyte activation (Herx et al., 2000) .", [["astrocyte", "ANATOMY", 13, 22], ["microglial", "ANATOMY", 119, 129], ["astrocyte", "ANATOMY", 158, 167], ["astrocyte", "CELL", 13, 22], ["mice", "ORGANISM", 37, 41], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 50, 55], ["mice", "ORGANISM", 71, 75], ["IL-1 type 1 receptor", "GENE_OR_GENE_PRODUCT", 84, 104], ["microglial", "CELL", 119, 129], ["astrocyte", "CELL", 158, 167], ["IL-1\u03b2", "PROTEIN", 50, 55], ["IL-1 type 1 receptor", "PROTEIN", 84, 104], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 71, 75], ["astrocyte activation", "TREATMENT", 13, 33], ["mice lacking IL", "TREATMENT", 37, 52], ["mice lacking IL", "TREATMENT", 71, 86], ["microglial activation", "PROBLEM", 119, 140], ["astrocyte activation", "OBSERVATION", 13, 33]]], ["It has also been suggested that ciliary neurotrophic factor (CNTF; a member of the IL-6 family of cytokines)treated astrocytes in vitro had a phenotype that was more supportive of CNS repair and thus are, by definition, activated (Albrecht et al., 2002; .", [["astrocytes", "ANATOMY", 116, 126], ["CNS", "ANATOMY", 180, 183], ["ciliary neurotrophic factor", "GENE_OR_GENE_PRODUCT", 32, 59], ["CNTF", "GENE_OR_GENE_PRODUCT", 61, 65], ["IL-6", "GENE_OR_GENE_PRODUCT", 83, 87], ["astrocytes", "CELL", 116, 126], ["CNS", "ANATOMICAL_SYSTEM", 180, 183], ["ciliary neurotrophic factor", "PROTEIN", 32, 59], ["CNTF", "PROTEIN", 61, 65], ["IL-6 family", "PROTEIN", 83, 94], ["cytokines", "PROTEIN", 98, 107], ["astrocytes", "CELL_TYPE", 116, 126], ["ciliary neurotrophic factor (CNTF", "PROBLEM", 32, 65], ["the IL-6 family of cytokines)", "TREATMENT", 79, 108], ["CNS repair", "TREATMENT", 180, 190], ["CNS", "ANATOMY", 180, 183], ["repair", "OBSERVATION", 184, 190]]], ["Under CNTF treatment, astrocytes upregulate expression of classical reactivity markers such as GFAP, vimentin, and clusterin, show cellular and nuclear hypertrophy, and increase their proliferation rate (Winter et al., 1995; Levison et al., 1996; 1998; Hudgins and Levison, 1998) .", [["astrocytes", "ANATOMY", 22, 32], ["cellular", "ANATOMY", 131, 139], ["nuclear", "ANATOMY", 144, 151], ["hypertrophy", "DISEASE", 152, 163], ["CNTF", "GENE_OR_GENE_PRODUCT", 6, 10], ["astrocytes", "CELL", 22, 32], ["GFAP", "GENE_OR_GENE_PRODUCT", 95, 99], ["vimentin", "GENE_OR_GENE_PRODUCT", 101, 109], ["clusterin", "GENE_OR_GENE_PRODUCT", 115, 124], ["cellular", "CELL", 131, 139], ["nuclear", "CELLULAR_COMPONENT", 144, 151], ["CNTF", "PROTEIN", 6, 10], ["astrocytes", "CELL_TYPE", 22, 32], ["classical reactivity markers", "PROTEIN", 58, 86], ["GFAP", "PROTEIN", 95, 99], ["vimentin", "PROTEIN", 101, 109], ["clusterin", "PROTEIN", 115, 124], ["CNTF treatment", "TREATMENT", 6, 20], ["classical reactivity markers", "TEST", 58, 86], ["GFAP", "TEST", 95, 99], ["vimentin", "TEST", 101, 109], ["cellular and nuclear hypertrophy", "PROBLEM", 131, 163], ["nuclear hypertrophy", "OBSERVATION", 144, 163]]], ["There is a growing body of evidence for the promotion of neuronal survival by cytokine-activated astrocytes, potentially through secretion of various neurotrophic growth factors in the vicinity of neurons including nerve Fig. 3 .", [["neuronal", "ANATOMY", 57, 65], ["astrocytes", "ANATOMY", 97, 107], ["neurons", "ANATOMY", 197, 204], ["nerve", "ANATOMY", 215, 220], ["neuronal", "CELL", 57, 65], ["astrocytes", "CELL", 97, 107], ["neurotrophic growth factors", "GENE_OR_GENE_PRODUCT", 150, 177], ["neurons", "CELL", 197, 204], ["nerve Fig", "MULTI-TISSUE_STRUCTURE", 215, 224], ["cytokine", "PROTEIN", 78, 86], ["activated astrocytes", "CELL_TYPE", 87, 107], ["neurotrophic growth factors", "PROTEIN", 150, 177], ["cytokine-activated astrocytes", "PROBLEM", 78, 107], ["various neurotrophic growth factors", "PROBLEM", 142, 177], ["nerve Fig", "PROBLEM", 215, 224], ["evidence for", "UNCERTAINTY", 27, 39], ["neurotrophic growth", "OBSERVATION", 150, 169], ["neurons", "ANATOMY", 197, 204], ["nerve Fig", "OBSERVATION", 215, 224]]], ["Simplified schematic of the effects of cytokine-activated astrocytes on re/myelination.", [["astrocytes", "ANATOMY", 58, 68], ["astrocytes", "CELL", 58, 68], ["cytokine", "PROTEIN", 39, 47], ["activated astrocytes", "CELL_TYPE", 48, 68], ["activated astrocytes", "PROBLEM", 48, 68]]], ["Astrocytes can be influenced by various cytokines to change their reactivity status to one that falls within the continuum of phenotypes, namely more activated or reactive; both of which will secrete factors that can modulate myelination in a positive or negative way.", [["Astrocytes", "ANATOMY", 0, 10], ["Astrocytes", "CELL", 0, 10], ["Astrocytes", "CELL_TYPE", 0, 10], ["cytokines", "PROTEIN", 40, 49], ["Astrocytes", "PROBLEM", 0, 10], ["various cytokines", "PROBLEM", 32, 49], ["reactive", "OBSERVATION_MODIFIER", 163, 171]]], ["Astrocytes with more severe reactivity present increased GFAP expression, proliferation rate, and cellular hypertrophy with a more stellate morphology.", [["Astrocytes", "ANATOMY", 0, 10], ["cellular", "ANATOMY", 98, 106], ["stellate", "ANATOMY", 131, 139], ["hypertrophy", "DISEASE", 107, 118], ["Astrocytes", "CELL", 0, 10], ["GFAP", "GENE_OR_GENE_PRODUCT", 57, 61], ["cellular", "CELL", 98, 106], ["stellate", "TISSUE", 131, 139], ["Astrocytes", "CELL_TYPE", 0, 10], ["GFAP", "PROTEIN", 57, 61], ["Astrocytes", "TEST", 0, 10], ["more severe reactivity", "PROBLEM", 16, 38], ["increased GFAP expression", "PROBLEM", 47, 72], ["proliferation rate", "TEST", 74, 92], ["cellular hypertrophy", "PROBLEM", 98, 118], ["more severe", "OBSERVATION_MODIFIER", 16, 27], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["GFAP expression", "OBSERVATION", 57, 72], ["proliferation", "OBSERVATION_MODIFIER", 74, 87], ["rate", "OBSERVATION_MODIFIER", 88, 92], ["cellular hypertrophy", "OBSERVATION", 98, 118], ["more stellate", "OBSERVATION_MODIFIER", 126, 139], ["morphology", "OBSERVATION_MODIFIER", 140, 150]]], ["The milder \"activated\" astrocytes can secrete a range of factors including; neurotrophic factors, growth factors, and cytokines that will stimulate re/myelination by promoting neuronal survival, neurite outgrowth, neurogenesis, and/ or oligodendrocyte precursor cell (OPC) survival, proliferation, and/or maturation.", [["astrocytes", "ANATOMY", 23, 33], ["neuronal", "ANATOMY", 176, 184], ["neurite", "ANATOMY", 195, 202], ["oligodendrocyte precursor cell", "ANATOMY", 236, 266], ["OPC", "ANATOMY", 268, 271], ["astrocytes", "CELL", 23, 33], ["neurotrophic factors", "GENE_OR_GENE_PRODUCT", 76, 96], ["neuronal", "CELL", 176, 184], ["oligodendrocyte precursor cell", "CELL", 236, 266], ["OPC", "CELL", 268, 271], ["astrocytes", "CELL_TYPE", 23, 33], ["neurotrophic factors", "PROTEIN", 76, 96], ["growth factors", "PROTEIN", 98, 112], ["cytokines", "PROTEIN", 118, 127], ["The milder \"activated\" astrocytes", "PROBLEM", 0, 33], ["neurotrophic factors", "PROBLEM", 76, 96], ["growth factors", "PROBLEM", 98, 112], ["neurogenesis", "PROBLEM", 214, 226], ["oligodendrocyte precursor cell", "PROBLEM", 236, 266], ["milder", "OBSERVATION_MODIFIER", 4, 10]]], ["Conversely astrocytes that tend to have a more severe \"reactive\" phenotype, possibly induced by proinflammatory cytokines/CNS tissue damage, may secrete cytokines and chemokines that lead to myelin and oligodendrocyte damage in vitro, suppress remyelination, delay disease recovery in experimental autoimmune encephalomyelitis (EAE), and suppress myelination in myelinating embryonic rat mixed spinal cord cultures.", [["astrocytes", "ANATOMY", 11, 21], ["CNS tissue", "ANATOMY", 122, 132], ["myelin", "ANATOMY", 191, 197], ["oligodendrocyte", "ANATOMY", 202, 217], ["embryonic", "ANATOMY", 374, 383], ["spinal cord cultures", "ANATOMY", 394, 414], ["oligodendrocyte damage", "DISEASE", 202, 224], ["autoimmune encephalomyelitis", "DISEASE", 298, 326], ["EAE", "DISEASE", 328, 331], ["astrocytes", "CELL", 11, 21], ["CNS tissue", "TISSUE", 122, 132], ["myelin", "CELLULAR_COMPONENT", 191, 197], ["oligodendrocyte", "CELL", 202, 217], ["rat", "ORGANISM", 384, 387], ["spinal cord cultures", "CELL", 394, 414], ["astrocytes", "CELL_TYPE", 11, 21], ["proinflammatory cytokines", "PROTEIN", 96, 121], ["cytokines", "PROTEIN", 153, 162], ["chemokines", "PROTEIN", 167, 177], ["myelinating embryonic rat mixed spinal cord cultures", "CELL_LINE", 362, 414], ["rat", "SPECIES", 384, 387], ["a more severe \"reactive\" phenotype", "PROBLEM", 40, 74], ["proinflammatory cytokines", "PROBLEM", 96, 121], ["CNS tissue damage", "PROBLEM", 122, 139], ["secrete cytokines and chemokines", "PROBLEM", 145, 177], ["myelin", "PROBLEM", 191, 197], ["oligodendrocyte damage in vitro, suppress remyelination", "PROBLEM", 202, 257], ["delay disease recovery", "PROBLEM", 259, 281], ["experimental autoimmune encephalomyelitis", "PROBLEM", 285, 326], ["suppress myelination in myelinating embryonic rat mixed spinal cord cultures", "PROBLEM", 338, 414], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["reactive", "OBSERVATION_MODIFIER", 55, 63], ["\" phenotype", "OBSERVATION", 63, 74], ["possibly induced", "UNCERTAINTY", 76, 92], ["CNS tissue", "ANATOMY", 122, 132], ["autoimmune encephalomyelitis", "OBSERVATION", 298, 326], ["spinal cord", "ANATOMY", 394, 405]]], ["However, these reactive scar forming astrocytes can also protect CNS tissue by preventing immune cells from invading and exerting a pro-inflammatory response and have been shown to even ameliorate EAE. growth factor (NGF), brain-derived neurotrophic factor (BDNF), activity dependent neurotrophic factor (ADNF), hepatocyte growth factor (HGF), leukaemia inhibitory factor (LIF), fibroblast growth factor-2 (FGF-2) and CNTF (Schwartz and Nishiyama, 1994; Rudge et al., 1995; Uchida et al., 1998; Dreyfus et al., 1999; Messersmith et al., 2000; Albrecht et al., 2002; Fig. 3 ).", [["scar", "ANATOMY", 24, 28], ["astrocytes", "ANATOMY", 37, 47], ["CNS tissue", "ANATOMY", 65, 75], ["immune cells", "ANATOMY", 90, 102], ["EAE", "DISEASE", 197, 200], ["astrocytes", "CELL", 37, 47], ["CNS tissue", "TISSUE", 65, 75], ["immune cells", "CELL", 90, 102], ["growth factor", "GENE_OR_GENE_PRODUCT", 202, 215], ["NGF", "GENE_OR_GENE_PRODUCT", 217, 220], ["brain-derived neurotrophic factor", "GENE_OR_GENE_PRODUCT", 223, 256], ["BDNF", "GENE_OR_GENE_PRODUCT", 258, 262], ["activity dependent neurotrophic factor", "GENE_OR_GENE_PRODUCT", 265, 303], ["ADNF", "GENE_OR_GENE_PRODUCT", 305, 309], ["hepatocyte growth factor", "GENE_OR_GENE_PRODUCT", 312, 336], ["HGF", "GENE_OR_GENE_PRODUCT", 338, 341], ["leukaemia inhibitory factor", "GENE_OR_GENE_PRODUCT", 344, 371], ["LIF", "GENE_OR_GENE_PRODUCT", 373, 376], ["fibroblast growth factor-2", "GENE_OR_GENE_PRODUCT", 379, 405], ["FGF-2", "GENE_OR_GENE_PRODUCT", 407, 412], ["CNTF", "GENE_OR_GENE_PRODUCT", 418, 422], ["astrocytes", "CELL_TYPE", 37, 47], ["immune cells", "CELL_TYPE", 90, 102], ["growth factor", "PROTEIN", 202, 215], ["NGF", "PROTEIN", 217, 220], ["brain-derived neurotrophic factor", "PROTEIN", 223, 256], ["BDNF", "PROTEIN", 258, 262], ["neurotrophic factor", "PROTEIN", 284, 303], ["ADNF", "PROTEIN", 305, 309], ["hepatocyte growth factor", "PROTEIN", 312, 336], ["HGF", "PROTEIN", 338, 341], ["leukaemia inhibitory factor", "PROTEIN", 344, 371], ["LIF", "PROTEIN", 373, 376], ["fibroblast growth factor-2", "PROTEIN", 379, 405], ["FGF", "PROTEIN", 407, 410], ["CNTF", "PROTEIN", 418, 422], ["these reactive scar forming astrocytes", "PROBLEM", 9, 47], ["CNS tissue", "PROBLEM", 65, 75], ["immune cells", "PROBLEM", 90, 102], ["activity dependent neurotrophic factor (ADNF)", "PROBLEM", 265, 310], ["hepatocyte growth factor", "PROBLEM", 312, 336], ["leukaemia inhibitory factor", "PROBLEM", 344, 371], ["fibroblast growth factor", "TEST", 379, 403], ["FGF", "TEST", 407, 410], ["reactive", "OBSERVATION_MODIFIER", 15, 23], ["scar", "OBSERVATION", 24, 28], ["immune cells", "OBSERVATION", 90, 102], ["pro-inflammatory response", "OBSERVATION", 132, 157], ["brain", "ANATOMY", 223, 228], ["hepatocyte", "ANATOMY", 312, 322]]], ["Moreover, cultured spinal cord astrocytes, treated with CNTF, support the survival of a significantly greater number of ventral spinal motor neurons and promote neurite outgrowth better than unstimulated astrocytes (Albrecht et al., 2002) .", [["spinal cord astrocytes", "ANATOMY", 19, 41], ["ventral spinal motor neurons", "ANATOMY", 120, 148], ["neurite", "ANATOMY", 161, 168], ["astrocytes", "ANATOMY", 204, 214], ["spinal cord astrocytes", "CELL", 19, 41], ["CNTF", "GENE_OR_GENE_PRODUCT", 56, 60], ["ventral spinal motor neurons", "CELL", 120, 148], ["neurite", "CELL", 161, 168], ["astrocytes", "CELL", 204, 214], ["cultured spinal cord astrocytes", "CELL_LINE", 10, 41], ["CNTF", "PROTEIN", 56, 60], ["ventral spinal motor neurons", "CELL_TYPE", 120, 148], ["unstimulated astrocytes", "CELL_TYPE", 191, 214], ["cultured spinal cord astrocytes", "PROBLEM", 10, 41], ["CNTF", "TREATMENT", 56, 60], ["ventral spinal motor neurons", "PROBLEM", 120, 148], ["spinal cord", "ANATOMY", 19, 30], ["astrocytes", "ANATOMY", 31, 41], ["ventral", "ANATOMY_MODIFIER", 120, 127], ["spinal", "ANATOMY", 128, 134], ["motor neurons", "ANATOMY", 135, 148], ["neurite outgrowth", "OBSERVATION", 161, 178]]], ["Other researchers have shown that cytokine-activated astrocytes can promote neurogenesis, possibly by stimulating the differentiation of neural stem cells (NSCs) residing in the subventricular zone and the dentate gyrus in adult animals (Liberto et al., 2004) .", [["astrocytes", "ANATOMY", 53, 63], ["neural stem cells", "ANATOMY", 137, 154], ["NSCs", "ANATOMY", 156, 160], ["subventricular zone", "ANATOMY", 178, 197], ["dentate gyrus", "ANATOMY", 206, 219], ["astrocytes", "CELL", 53, 63], ["neural stem cells", "CELL", 137, 154], ["NSCs", "CELL", 156, 160], ["subventricular zone", "MULTI-TISSUE_STRUCTURE", 178, 197], ["dentate gyrus", "MULTI-TISSUE_STRUCTURE", 206, 219], ["cytokine", "PROTEIN", 34, 42], ["activated astrocytes", "CELL_TYPE", 43, 63], ["neural stem cells", "CELL_TYPE", 137, 154], ["NSCs", "CELL_TYPE", 156, 160], ["cytokine-activated astrocytes", "PROBLEM", 34, 63], ["neural stem cells", "OBSERVATION", 137, 154], ["subventricular", "ANATOMY_MODIFIER", 178, 192], ["zone", "ANATOMY_MODIFIER", 193, 197], ["dentate gyrus", "ANATOMY", 206, 219]]], ["Because these multipotent NSCs can migrate beyond their sites of origin and can later differentiate into oligodendrocytes, neurons and microglia, they have the potential to enhance recovery from CNS injury and disease.Role of cytokines and chemokinesImportantly, activated astrocytes have also shown positive effects on myelination.", [["NSCs", "ANATOMY", 26, 30], ["sites", "ANATOMY", 56, 61], ["oligodendrocytes", "ANATOMY", 105, 121], ["neurons", "ANATOMY", 123, 130], ["microglia", "ANATOMY", 135, 144], ["CNS", "ANATOMY", 195, 198], ["astrocytes", "ANATOMY", 273, 283], ["CNS injury", "DISEASE", 195, 205], ["NSCs", "CELL", 26, 30], ["oligodendrocytes", "CELL", 105, 121], ["neurons", "CELL", 123, 130], ["microglia", "CELL", 135, 144], ["CNS", "ANATOMICAL_SYSTEM", 195, 198], ["astrocytes", "CELL", 273, 283], ["NSCs", "CELL_TYPE", 26, 30], ["oligodendrocytes", "CELL_TYPE", 105, 121], ["neurons", "CELL_TYPE", 123, 130], ["microglia", "CELL_TYPE", 135, 144], ["cytokines", "PROTEIN", 226, 235], ["chemokines", "PROTEIN", 240, 250], ["activated astrocytes", "CELL_TYPE", 263, 283], ["these multipotent NSCs", "TREATMENT", 8, 30], ["CNS injury", "PROBLEM", 195, 205], ["disease", "PROBLEM", 210, 217], ["cytokines", "TREATMENT", 226, 235], ["chemokines", "TREATMENT", 240, 250], ["activated astrocytes", "TEST", 263, 283], ["positive effects on myelination", "PROBLEM", 300, 331], ["multipotent NSCs", "OBSERVATION", 14, 30], ["CNS", "ANATOMY", 195, 198], ["injury", "OBSERVATION", 199, 205]]], ["Our own investigations have shown that CNTF activated astrocytes can promote the percentage of myelinated fibres in CNS rat cultures (Nash et al., 2011b) .", [["astrocytes", "ANATOMY", 54, 64], ["myelinated fibres", "ANATOMY", 95, 112], ["CNS", "ANATOMY", 116, 119], ["CNTF", "GENE_OR_GENE_PRODUCT", 39, 43], ["astrocytes", "CELL", 54, 64], ["myelinated fibres", "TISSUE", 95, 112], ["rat", "ORGANISM", 120, 123], ["CNTF", "PROTEIN", 39, 43], ["astrocytes", "CELL_TYPE", 54, 64], ["myelinated fibres", "CELL_TYPE", 95, 112], ["CNS rat cultures", "CELL_LINE", 116, 132], ["rat", "SPECIES", 120, 123], ["Our own investigations", "TEST", 0, 22], ["CNTF activated astrocytes", "PROBLEM", 39, 64], ["myelinated fibres", "PROBLEM", 95, 112], ["CNS rat cultures", "TEST", 116, 132], ["myelinated fibres", "OBSERVATION", 95, 112], ["CNS", "ANATOMY", 116, 119]]], ["Further evidence of this has been shown in mice infected with the A-59 strain of the mouse hepatitis virus (MHV-A59), an animal model for MS (Jordan et al., 1989 , Messersmith et al., 2000 .", [["hepatitis virus", "DISEASE", 91, 106], ["MS", "DISEASE", 138, 140], ["mice", "ORGANISM", 43, 47], ["A-59 strain", "ORGANISM", 66, 77], ["mouse hepatitis virus", "ORGANISM", 85, 106], ["MHV-A59", "ORGANISM", 108, 115], ["mice", "SPECIES", 43, 47], ["mouse", "SPECIES", 85, 90], ["hepatitis virus", "SPECIES", 91, 106], ["mice", "SPECIES", 43, 47], ["A-59", "SPECIES", 66, 70], ["mouse hepatitis virus (MHV-A59", "SPECIES", 85, 115], ["the mouse hepatitis virus", "PROBLEM", 81, 106], ["hepatitis", "OBSERVATION", 91, 100]]], ["These animals have been shown to secrete increased levels of CNTF during the remyelination phase and CNTF mRNA is induced in the remyelinating regions in cells exhibiting astrocytic features (Albrecht et al., 2003) .", [["cells", "ANATOMY", 154, 159], ["astrocytic", "ANATOMY", 171, 181], ["CNTF", "GENE_OR_GENE_PRODUCT", 61, 65], ["CNTF", "GENE_OR_GENE_PRODUCT", 101, 105], ["cells", "CELL", 154, 159], ["CNTF", "PROTEIN", 61, 65], ["CNTF mRNA", "RNA", 101, 110], ["secrete increased levels of CNTF", "PROBLEM", 33, 65], ["the remyelination phase", "TEST", 73, 96], ["CNTF mRNA", "PROBLEM", 101, 110], ["astrocytic features", "PROBLEM", 171, 190], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["astrocytic features", "OBSERVATION", 171, 190]]], ["It is suggested that the increase in IL-1\u03b2 levels at early stages of CNS pathology stimulates the induction of CNTF mRNA and protein in astrocytes (St\u00f6ckli et al., 1991; Guthrie et al., 1997; Dallner et al., 2002; Liberto et al., 2004) , a phenomenon which appears to be important for remyelination (Herx et al., 2000) .", [["CNS", "ANATOMY", 69, 72], ["astrocytes", "ANATOMY", 136, 146], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 37, 42], ["CNS", "ANATOMICAL_SYSTEM", 69, 72], ["CNTF", "GENE_OR_GENE_PRODUCT", 111, 115], ["astrocytes", "CELL", 136, 146], ["IL-1\u03b2", "PROTEIN", 37, 42], ["CNTF mRNA", "RNA", 111, 120], ["astrocytes", "CELL_TYPE", 136, 146], ["the increase in IL", "TREATMENT", 21, 39], ["CNS pathology", "PROBLEM", 69, 82], ["CNTF mRNA", "TEST", 111, 120], ["a phenomenon", "PROBLEM", 238, 250], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["CNS", "ANATOMY", 69, 72]]], ["This could be due to FGF-2 signalling as CNTF treatment elevates astrocytic levels of Fgf-2 mRNA significantly, whereas, IL-1 \u03b2 shows no effect (Albrecht et al., 2003) .", [["FGF-2", "GENE_OR_GENE_PRODUCT", 21, 26], ["CNTF", "GENE_OR_GENE_PRODUCT", 41, 45], ["Fgf-2", "GENE_OR_GENE_PRODUCT", 86, 91], ["IL-1 \u03b2", "GENE_OR_GENE_PRODUCT", 121, 127], ["FGF", "PROTEIN", 21, 24], ["CNTF", "PROTEIN", 41, 45], ["Fgf-2 mRNA", "RNA", 86, 96], ["IL-1 \u03b2", "PROTEIN", 121, 127], ["FGF", "TEST", 21, 24], ["CNTF treatment", "TREATMENT", 41, 55], ["astrocytic levels", "TEST", 65, 82], ["Fgf", "TEST", 86, 89], ["no", "UNCERTAINTY", 134, 136]]], ["Since FGF-2 can enhance OPC proliferation (Albrecht et al., 2003) , it may produce more OPCs for subsequent myelination (Redwine et al., 1997; Messersmith et al., 2000) .", [["OPC", "ANATOMY", 24, 27], ["OPCs", "ANATOMY", 88, 92], ["FGF-2", "GENE_OR_GENE_PRODUCT", 6, 11], ["OPC", "CELL", 24, 27], ["OPCs", "CELL", 88, 92], ["FGF-2", "PROTEIN", 6, 11], ["OPCs", "CELL_TYPE", 88, 92], ["FGF", "TEST", 6, 9]]], ["Moreover, if the gp130 receptor, the ubiquitous signal transducer for CNTF and all IL-6 family members, is genetically removed from astrocytes, astrocyte survival was poor, there was a reduction in the development of astrogliosis, and larger areas of demyelination formed with a greater proinflammatory T cell response (Haroon et al., 2011) .Role of cytokines and chemokinesTherefore, CNTF seems to be an important cytokine involved in astrocyte reactivity and myelination.", [["astrocytes", "ANATOMY", 132, 142], ["astrocyte", "ANATOMY", 144, 153], ["T cell", "ANATOMY", 303, 309], ["astrocyte", "ANATOMY", 436, 445], ["astrogliosis", "DISEASE", 217, 229], ["demyelination", "DISEASE", 251, 264], ["gp130 receptor", "GENE_OR_GENE_PRODUCT", 17, 31], ["CNTF", "GENE_OR_GENE_PRODUCT", 70, 74], ["IL-6", "GENE_OR_GENE_PRODUCT", 83, 87], ["astrocytes", "CELL", 132, 142], ["astrocyte", "CELL", 144, 153], ["T cell", "CELL", 303, 309], ["CNTF", "GENE_OR_GENE_PRODUCT", 385, 389], ["astrocyte", "CELL", 436, 445], ["gp130 receptor", "PROTEIN", 17, 31], ["CNTF", "PROTEIN", 70, 74], ["IL-6 family members", "PROTEIN", 83, 102], ["astrocytes", "CELL_TYPE", 132, 142], ["cytokines", "PROTEIN", 350, 359], ["chemokines", "PROTEIN", 364, 374], ["CNTF", "PROTEIN", 385, 389], ["cytokine", "PROTEIN", 415, 423], ["a reduction", "PROBLEM", 183, 194], ["astrogliosis", "PROBLEM", 217, 229], ["demyelination", "PROBLEM", 251, 264], ["a greater proinflammatory T cell response", "PROBLEM", 277, 318], ["cytokines", "TREATMENT", 350, 359], ["chemokines", "TREATMENT", 364, 374], ["reduction", "OBSERVATION_MODIFIER", 185, 194], ["astrogliosis", "OBSERVATION", 217, 229], ["larger", "OBSERVATION_MODIFIER", 235, 241], ["areas", "OBSERVATION_MODIFIER", 242, 247], ["demyelination", "OBSERVATION", 251, 264], ["greater", "OBSERVATION_MODIFIER", 279, 286], ["proinflammatory T cell response", "OBSERVATION", 287, 318], ["seems to be", "UNCERTAINTY", 390, 401], ["astrocyte reactivity", "OBSERVATION", 436, 456]]], ["Interestingly, IL-1\u03b2 can also stimulate the astrocytic production of another IL-6 family cytokine, LIF, (Aloisi et al., 1994) , which has been shown to promote survival and differentiation of oligodendrocytes (Khan and De Vellis, 1994; Mayer et al., 1994; Bugga et al., 1998) .", [["oligodendrocytes", "ANATOMY", 192, 208], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 15, 20], ["IL-6", "GENE_OR_GENE_PRODUCT", 77, 81], ["LIF", "GENE_OR_GENE_PRODUCT", 99, 102], ["oligodendrocytes", "CELL", 192, 208], ["IL-1\u03b2", "PROTEIN", 15, 20], ["IL-6 family cytokine", "PROTEIN", 77, 97], ["LIF", "PROTEIN", 99, 102], ["oligodendrocytes", "CELL_TYPE", 192, 208]]], ["LIF also decreases disease severity when exogenously administered in both chronic and relapsing-remitting EAE mice (Aloisi et al., 1994; Butzkueven et al., 2002; Ishibashi et al., 2006) .", [["EAE", "DISEASE", 106, 109], ["LIF", "GENE_OR_GENE_PRODUCT", 0, 3], ["mice", "ORGANISM", 110, 114], ["LIF", "PROTEIN", 0, 3], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 110, 114], ["decreases disease severity", "PROBLEM", 9, 35], ["decreases", "OBSERVATION_MODIFIER", 9, 18], ["disease", "OBSERVATION", 19, 26], ["chronic", "OBSERVATION_MODIFIER", 74, 81]]], ["Positive effects of LIF on the survival and maturation of oligodendrocytes also provides evidence for the positive roles of LIF on myelination (Khan and De Vellis, 1994; Mayer et al., 1994; Bugga et al., 1998) .", [["oligodendrocytes", "ANATOMY", 58, 74], ["LIF", "GENE_OR_GENE_PRODUCT", 20, 23], ["oligodendrocytes", "CELL", 58, 74], ["LIF", "GENE_OR_GENE_PRODUCT", 124, 127], ["LIF", "PROTEIN", 20, 23], ["oligodendrocytes", "CELL_TYPE", 58, 74], ["LIF", "PROTEIN", 124, 127], ["the survival", "TREATMENT", 27, 39], ["maturation of oligodendrocytes", "PROBLEM", 44, 74], ["LIF", "OBSERVATION_MODIFIER", 20, 23]]], ["However, other pro-inflammatory cytokines such as tumour necrosis factoralpha (TNF-\u03b1) and interferon-gamma (IFN-\u03b3) have also been shown to potentiate reactive astrogliosis (Yong et al., 1991 John et al., 2003 as discussed below.Astrocyte reactivity (severe astrogliosis): an inhibitory phenotype?In contrast to their positive effects on myelination, astrocytes can also have a more detrimental effect on CNS repair via the secretion of chemokines/cytokines when in a more severe, reactive state (Fig. 3) .", [["Astrocyte", "ANATOMY", 228, 237], ["astrocytes", "ANATOMY", 350, 360], ["CNS", "ANATOMY", 404, 407], ["necrosis", "DISEASE", 57, 65], ["astrogliosis", "DISEASE", 159, 171], ["astrogliosis", "DISEASE", 257, 269], ["tumour necrosis factoralpha", "GENE_OR_GENE_PRODUCT", 50, 77], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 79, 84], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 90, 106], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 108, 113], ["Astrocyte", "CELL", 228, 237], ["astrocytes", "CELL", 350, 360], ["CNS", "ANATOMICAL_SYSTEM", 404, 407], ["pro-inflammatory cytokines", "PROTEIN", 15, 41], ["tumour necrosis factoralpha", "PROTEIN", 50, 77], ["TNF", "PROTEIN", 79, 82], ["\u03b1", "PROTEIN", 83, 84], ["interferon-gamma", "PROTEIN", 90, 106], ["IFN", "PROTEIN", 108, 111], ["astrocytes", "CELL_TYPE", 350, 360], ["chemokines", "PROTEIN", 436, 446], ["cytokines", "PROTEIN", 447, 456], ["other pro-inflammatory cytokines", "PROBLEM", 9, 41], ["tumour necrosis factoralpha", "PROBLEM", 50, 77], ["TNF", "TEST", 79, 82], ["interferon", "TREATMENT", 90, 100], ["reactive astrogliosis", "PROBLEM", 150, 171], ["Astrocyte reactivity (severe astrogliosis)", "PROBLEM", 228, 270], ["an inhibitory phenotype", "PROBLEM", 272, 295], ["CNS repair", "TREATMENT", 404, 414], ["chemokines/cytokines", "TREATMENT", 436, 456], ["a more severe, reactive state", "PROBLEM", 465, 494], ["pro-inflammatory cytokines", "OBSERVATION", 15, 41], ["tumour", "OBSERVATION_MODIFIER", 50, 56], ["necrosis", "OBSERVATION", 57, 65], ["gamma", "ANATOMY", 101, 106], ["reactive", "OBSERVATION_MODIFIER", 150, 158], ["astrogliosis", "OBSERVATION", 159, 171], ["severe", "OBSERVATION_MODIFIER", 250, 256], ["astrogliosis", "OBSERVATION", 257, 269], ["reactive", "OBSERVATION_MODIFIER", 480, 488]]], ["One such cytokine is TNF-\u03b1, which has been shown to induce myelin and oligodendrocyte damage in vitro (Selmaj and Raine, 1988) .", [["myelin", "ANATOMY", 59, 65], ["oligodendrocyte", "ANATOMY", 70, 85], ["oligodendrocyte damage", "DISEASE", 70, 92], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 21, 26], ["myelin", "CELLULAR_COMPONENT", 59, 65], ["oligodendrocyte", "CELL", 70, 85], ["cytokine", "PROTEIN", 9, 17], ["TNF", "PROTEIN", 21, 24], ["\u03b1", "PROTEIN", 25, 26], ["TNF", "TEST", 21, 24], ["myelin", "PROBLEM", 59, 65], ["oligodendrocyte damage", "PROBLEM", 70, 92], ["oligodendrocyte damage", "OBSERVATION", 70, 92]]], ["TNF-\u03b1 mRNA expression in MS plaques positively correlates with the extent of demyelination and has been shown to be present in microglia/macrophages and to a smaller percentage of astrocytes (Bitsch et al., 2000) .", [["MS plaques", "ANATOMY", 25, 35], ["microglia", "ANATOMY", 127, 136], ["macrophages", "ANATOMY", 137, 148], ["astrocytes", "ANATOMY", 180, 190], ["demyelination", "DISEASE", 77, 90], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["MS plaques", "PATHOLOGICAL_FORMATION", 25, 35], ["microglia", "CELL", 127, 136], ["macrophages", "CELL", 137, 148], ["astrocytes", "CELL", 180, 190], ["TNF-\u03b1 mRNA", "RNA", 0, 10], ["microglia", "CELL_TYPE", 127, 136], ["macrophages", "CELL_TYPE", 137, 148], ["astrocytes", "CELL_TYPE", 180, 190], ["TNF", "TEST", 0, 3], ["mRNA expression in MS plaques", "PROBLEM", 6, 35], ["demyelination", "PROBLEM", 77, 90], ["plaques", "OBSERVATION", 28, 35], ["demyelination", "OBSERVATION", 77, 90], ["macrophages", "ANATOMY", 137, 148], ["astrocytes", "ANATOMY", 180, 190]]], ["On the other hand, studies have shown TNF-\u03b1 expression is mainly associated with GFAP positive fibrous astrocytes in chronic active MS lesions at the lesion edge (Hofman et al., 1989) as well as foamy macrophages and endothelial cells (Selmaj et al., 1991) .", [["fibrous astrocytes", "ANATOMY", 95, 113], ["MS lesions", "ANATOMY", 132, 142], ["lesion edge", "ANATOMY", 150, 161], ["foamy macrophages", "ANATOMY", 195, 212], ["endothelial cells", "ANATOMY", 217, 234], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 38, 43], ["GFAP", "GENE_OR_GENE_PRODUCT", 81, 85], ["MS lesions", "PATHOLOGICAL_FORMATION", 132, 142], ["foamy macrophages", "CELL", 195, 212], ["endothelial cells", "CELL", 217, 234], ["TNF", "PROTEIN", 38, 41], ["\u03b1", "PROTEIN", 42, 43], ["GFAP positive fibrous astrocytes", "CELL_TYPE", 81, 113], ["foamy macrophages", "CELL_TYPE", 195, 212], ["endothelial cells", "CELL_TYPE", 217, 234], ["studies", "TEST", 19, 26], ["TNF", "TEST", 38, 41], ["GFAP positive fibrous astrocytes", "PROBLEM", 81, 113], ["chronic active MS lesions at the lesion edge", "PROBLEM", 117, 161], ["mainly associated with", "UNCERTAINTY", 58, 80], ["fibrous astrocytes", "OBSERVATION", 95, 113], ["chronic", "OBSERVATION_MODIFIER", 117, 124], ["active", "OBSERVATION_MODIFIER", 125, 131], ["MS", "OBSERVATION_MODIFIER", 132, 134], ["lesions", "OBSERVATION", 135, 142], ["lesion", "OBSERVATION_MODIFIER", 150, 156], ["edge", "OBSERVATION_MODIFIER", 157, 161], ["foamy macrophages", "OBSERVATION", 195, 212], ["endothelial cells", "OBSERVATION", 217, 234]]], ["However, the fact that astrocytes appear as the major or minor TNF-\u03b1 expressing cell types in MS lesions might be because astrocytes internalize the protein in a receptor-mediated manner (Ar\u00e1nguez et al., 1995; Kuhlmann et al., 2006) rather than producing it themselves as suggested by Hofman et al. (1989) and Bitsch et al. (2000) .", [["astrocytes", "ANATOMY", 23, 33], ["cell", "ANATOMY", 80, 84], ["MS lesions", "ANATOMY", 94, 104], ["astrocytes", "ANATOMY", 122, 132], ["astrocytes", "CELL", 23, 33], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 63, 68], ["cell", "CELL", 80, 84], ["MS lesions", "PATHOLOGICAL_FORMATION", 94, 104], ["astrocytes", "CELL", 122, 132], ["astrocytes", "CELL_TYPE", 23, 33], ["TNF", "PROTEIN", 63, 66], ["astrocytes", "CELL_TYPE", 122, 132], ["MS lesions", "PROBLEM", 94, 104], ["cell types", "OBSERVATION", 80, 90], ["lesions", "OBSERVATION", 97, 104]]], ["Moreover, it is possible that astrocytes require a longer period of time to become reactive upon injury and only produce TNF-\u03b1 first at the lesion edge of acute MS plaques and later both at the lesion edge and in the lesion centre of chronic active plaques (Selmaj et al., 1991) .", [["astrocytes", "ANATOMY", 30, 40], ["lesion edge", "ANATOMY", 140, 151], ["MS plaques", "ANATOMY", 161, 171], ["lesion edge", "ANATOMY", 194, 205], ["lesion centre", "ANATOMY", 217, 230], ["plaques", "ANATOMY", 249, 256], ["MS", "DISEASE", 161, 163], ["chronic active plaques", "DISEASE", 234, 256], ["astrocytes", "CELL", 30, 40], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 121, 126], ["lesion edge", "PATHOLOGICAL_FORMATION", 140, 151], ["MS plaques", "PATHOLOGICAL_FORMATION", 161, 171], ["lesion edge", "PATHOLOGICAL_FORMATION", 194, 205], ["plaques", "PATHOLOGICAL_FORMATION", 249, 256], ["astrocytes", "CELL_TYPE", 30, 40], ["TNF", "PROTEIN", 121, 124], ["\u03b1", "PROTEIN", 125, 126], ["injury", "PROBLEM", 97, 103], ["TNF", "TEST", 121, 124], ["acute MS plaques", "PROBLEM", 155, 171], ["chronic active plaques", "PROBLEM", 234, 256], ["reactive", "OBSERVATION_MODIFIER", 83, 91], ["lesion", "OBSERVATION", 140, 146], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["MS", "OBSERVATION_MODIFIER", 161, 163], ["plaques", "OBSERVATION", 164, 171], ["lesion", "OBSERVATION_MODIFIER", 194, 200], ["edge", "OBSERVATION_MODIFIER", 201, 205], ["lesion", "OBSERVATION", 217, 223], ["chronic", "OBSERVATION_MODIFIER", 234, 241], ["active", "OBSERVATION_MODIFIER", 242, 248], ["plaques", "OBSERVATION", 249, 256]]], ["In situ hybridisation for TNF-\u03b1 mRNA has been detected in GFAP-positive astrocytes in mice suffering from pneumococcal meningitis (Izadpanah et al., 2014) which also suggests that astrocytes can indeed produce TNF-\u03b1 in CNS pathologies.Astrocyte reactivity (severe astrogliosis): an inhibitory phenotype?Since TNF-\u03b1 effects the maturation of oligodendrocytes (Cammer and Zhang, 1999) , remyelination failure in the CNS lesions could be because TNF-\u03b1 prevents the in situ differentiation of oligodendrocytes.", [["GFAP-positive astrocytes", "ANATOMY", 58, 82], ["astrocytes", "ANATOMY", 180, 190], ["CNS", "ANATOMY", 219, 222], ["Astrocyte", "ANATOMY", 235, 244], ["oligodendrocytes", "ANATOMY", 341, 357], ["CNS lesions", "ANATOMY", 414, 425], ["oligodendrocytes", "ANATOMY", 489, 505], ["pneumococcal meningitis", "DISEASE", 106, 129], ["astrogliosis", "DISEASE", 264, 276], ["remyelination failure", "DISEASE", 385, 406], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 26, 31], ["GFAP", "GENE_OR_GENE_PRODUCT", 58, 62], ["mice", "ORGANISM", 86, 90], ["astrocytes", "CELL", 180, 190], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 210, 215], ["CNS", "ANATOMICAL_SYSTEM", 219, 222], ["Astrocyte", "CELL", 235, 244], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 309, 314], ["oligodendrocytes", "CELL", 341, 357], ["CNS lesions", "PATHOLOGICAL_FORMATION", 414, 425], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 443, 448], ["oligodendrocytes", "CELL", 489, 505], ["TNF-\u03b1 mRNA", "RNA", 26, 36], ["GFAP", "PROTEIN", 58, 62], ["positive astrocytes", "CELL_TYPE", 63, 82], ["astrocytes", "CELL_TYPE", 180, 190], ["TNF", "PROTEIN", 210, 213], ["TNF-\u03b1", "PROTEIN", 309, 314], ["oligodendrocytes", "CELL_TYPE", 341, 357], ["TNF-\u03b1", "PROTEIN", 443, 448], ["oligodendrocytes", "CELL_TYPE", 489, 505], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["pneumococcal", "SPECIES", 106, 118], ["TNF", "PROBLEM", 26, 29], ["GFAP", "TEST", 58, 62], ["pneumococcal meningitis", "PROBLEM", 106, 129], ["astrocytes", "PROBLEM", 180, 190], ["TNF", "TEST", 210, 213], ["CNS pathologies", "PROBLEM", 219, 234], ["Astrocyte reactivity (severe astrogliosis)", "PROBLEM", 235, 277], ["an inhibitory phenotype", "PROBLEM", 279, 302], ["TNF", "TEST", 309, 312], ["the maturation of oligodendrocytes", "PROBLEM", 323, 357], ["remyelination failure", "PROBLEM", 385, 406], ["the CNS lesions", "PROBLEM", 410, 425], ["TNF", "TEST", 443, 446], ["oligodendrocytes", "PROBLEM", 489, 505], ["positive astrocytes", "OBSERVATION", 63, 82], ["pneumococcal", "OBSERVATION_MODIFIER", 106, 118], ["meningitis", "OBSERVATION", 119, 129], ["CNS", "ANATOMY", 219, 222], ["pathologies", "OBSERVATION", 223, 234], ["severe", "OBSERVATION_MODIFIER", 257, 263], ["astrogliosis", "OBSERVATION", 264, 276], ["failure", "OBSERVATION", 399, 406], ["CNS", "ANATOMY", 414, 417], ["lesions", "OBSERVATION", 418, 425], ["oligodendrocytes", "OBSERVATION", 489, 505]]], ["Interestingly, direct cell contact between pre-oligodendrocytes (preOLs) and astrocytes has been shown to be a prerequisite for TNF to induce apoptosis in preOLs of rodent mixed glial cultures (Kim et al., 2011) .", [["cell", "ANATOMY", 22, 26], ["pre-oligodendrocytes", "ANATOMY", 43, 63], ["preOLs", "ANATOMY", 65, 71], ["astrocytes", "ANATOMY", 77, 87], ["preOLs", "ANATOMY", 155, 161], ["glial cultures", "ANATOMY", 178, 192], ["cell", "CELL", 22, 26], ["pre-oligodendrocytes", "GENE_OR_GENE_PRODUCT", 43, 63], ["preOLs", "GENE_OR_GENE_PRODUCT", 65, 71], ["astrocytes", "CELL", 77, 87], ["TNF", "GENE_OR_GENE_PRODUCT", 128, 131], ["glial cultures", "CELL", 178, 192], ["pre-oligodendrocytes", "CELL_TYPE", 43, 63], ["preOLs", "CELL_TYPE", 65, 71], ["astrocytes", "CELL_TYPE", 77, 87], ["TNF", "PROTEIN", 128, 131], ["preOLs", "CELL_TYPE", 155, 161], ["rodent mixed glial cultures", "CELL_LINE", 165, 192], ["astrocytes", "PROBLEM", 77, 87], ["TNF", "PROBLEM", 128, 131], ["apoptosis", "PROBLEM", 142, 151]]], ["Nevertheless, it is possible that TNF-\u03b1 increases production of PDGF in demyelinated spinal cord lesions of MHV-A59-injected mice (Redwine and Armstrong, 1998; Frost et al., 2003) as suggested by the increase of PDGF-\u03b2 transcription and PDGF-\u03b1\u03b2 protein levels in embryonic human astrocytes upon TNF-\u03b1 treatment (Silberstein et al., 1996) .", [["demyelinated spinal cord lesions", "ANATOMY", 72, 104], ["embryonic", "ANATOMY", 263, 272], ["astrocytes", "ANATOMY", 279, 289], ["TNF-\u03b1", "CHEMICAL", 295, 300], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 34, 39], ["PDGF", "GENE_OR_GENE_PRODUCT", 64, 68], ["spinal cord", "ORGAN", 85, 96], ["lesions", "PATHOLOGICAL_FORMATION", 97, 104], ["MHV-A59", "ORGANISM", 108, 115], ["mice", "ORGANISM", 125, 129], ["PDGF-\u03b2", "GENE_OR_GENE_PRODUCT", 212, 218], ["PDGF-\u03b1\u03b2", "GENE_OR_GENE_PRODUCT", 237, 244], ["human", "ORGANISM", 273, 278], ["astrocytes", "CELL", 279, 289], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 295, 300], ["TNF", "PROTEIN", 34, 37], ["PDGF", "PROTEIN", 64, 68], ["PDGF", "PROTEIN", 212, 216], ["PDGF", "PROTEIN", 237, 241], ["\u03b1\u03b2", "PROTEIN", 242, 244], ["embryonic human astrocytes", "CELL_TYPE", 263, 289], ["TNF", "PROTEIN", 295, 298], ["mice", "SPECIES", 125, 129], ["human", "SPECIES", 273, 278], ["human", "SPECIES", 273, 278], ["TNF", "TEST", 34, 37], ["PDGF in demyelinated spinal cord lesions", "PROBLEM", 64, 104], ["MHV", "TEST", 108, 111], ["PDGF-\u03b2 transcription", "TREATMENT", 212, 232], ["PDGF-\u03b1\u03b2 protein levels", "TEST", 237, 259], ["embryonic human astrocytes", "PROBLEM", 263, 289], ["TNF", "TEST", 295, 298], ["treatment", "TREATMENT", 301, 310], ["demyelinated", "OBSERVATION_MODIFIER", 72, 84], ["spinal cord", "ANATOMY", 85, 96], ["MHV", "ANATOMY", 108, 111]]], ["Therefore, astrocytes might have a positive role on remyelination both by producing TNF-\u03b1 and by secreting PDGF upon stimulation with TNF-\u03b1.", [["astrocytes", "ANATOMY", 11, 21], ["astrocytes", "CELL", 11, 21], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 84, 89], ["PDGF", "GENE_OR_GENE_PRODUCT", 107, 111], ["TNF-\u03b1.", "GENE_OR_GENE_PRODUCT", 134, 140], ["astrocytes", "CELL_TYPE", 11, 21], ["TNF", "PROTEIN", 84, 87], ["PDGF", "PROTEIN", 107, 111], ["TNF", "PROTEIN", 134, 137], ["remyelination", "PROBLEM", 52, 65], ["TNF", "TEST", 84, 87], ["TNF", "TEST", 134, 137]]], ["PDGF could in turn support the survival and enhance the proliferation of OPCs in demyelinating lesions (Woodruff et al., 2004; Vana et al., 2007) .", [["OPCs", "ANATOMY", 73, 77], ["demyelinating lesions", "ANATOMY", 81, 102], ["demyelinating lesions", "DISEASE", 81, 102], ["PDGF", "GENE_OR_GENE_PRODUCT", 0, 4], ["OPCs", "CELL", 73, 77], ["lesions", "PATHOLOGICAL_FORMATION", 95, 102], ["PDGF", "PROTEIN", 0, 4], ["OPCs", "CELL_TYPE", 73, 77], ["PDGF", "PROBLEM", 0, 4], ["demyelinating lesions", "PROBLEM", 81, 102], ["proliferation", "OBSERVATION_MODIFIER", 56, 69], ["demyelinating", "OBSERVATION_MODIFIER", 81, 94], ["lesions", "OBSERVATION", 95, 102]]], ["Consequently, it is yet difficult to conclude whether reactive astrocytes associated with increased TNF-\u03b1 levels in CNS lesions are predominantly stimulatory or inhibitory to remyelination.Astrocyte reactivity (severe astrogliosis): an inhibitory phenotype?IFN-\u03b3, another cytokine found in MS plaques, has been reported to not only activate astrocytes, but is also expressed by reactive astrocytes and by immune cells that astrocytes have stimulated (Pulver et al., 1987; Traugott and Lebon, 1988; Miljkovic et al., 2007; Hashioka et al., 2009; Ionescu et al., 2011) .", [["astrocytes", "ANATOMY", 63, 73], ["CNS lesions", "ANATOMY", 116, 127], ["Astrocyte", "ANATOMY", 189, 198], ["MS plaques", "ANATOMY", 290, 300], ["astrocytes", "ANATOMY", 341, 351], ["astrocytes", "ANATOMY", 387, 397], ["immune cells", "ANATOMY", 405, 417], ["astrocytes", "ANATOMY", 423, 433], ["astrogliosis", "DISEASE", 218, 230], ["astrocytes", "CELL", 63, 73], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 100, 105], ["CNS lesions", "PATHOLOGICAL_FORMATION", 116, 127], ["Astrocyte", "CELL", 189, 198], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 257, 262], ["astrocytes", "CELL", 341, 351], ["astrocytes", "CELL", 387, 397], ["immune cells", "CELL", 405, 417], ["astrocytes", "CELL", 423, 433], ["reactive astrocytes", "CELL_TYPE", 54, 73], ["TNF", "PROTEIN", 100, 103], ["IFN", "PROTEIN", 257, 260], ["\u03b3", "PROTEIN", 261, 262], ["cytokine", "PROTEIN", 272, 280], ["astrocytes", "CELL_TYPE", 341, 351], ["reactive astrocytes", "CELL_TYPE", 378, 397], ["immune cells", "CELL_TYPE", 405, 417], ["astrocytes", "CELL_TYPE", 423, 433], ["reactive astrocytes", "PROBLEM", 54, 73], ["increased TNF", "PROBLEM", 90, 103], ["CNS lesions", "PROBLEM", 116, 127], ["Astrocyte reactivity (severe astrogliosis)", "PROBLEM", 189, 231], ["an inhibitory phenotype", "PROBLEM", 233, 256], ["IFN", "TEST", 257, 260], ["MS plaques", "PROBLEM", 290, 300], ["reactive astrocytes", "PROBLEM", 378, 397], ["reactive", "OBSERVATION_MODIFIER", 54, 62], ["astrocytes", "OBSERVATION", 63, 73], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["TNF", "OBSERVATION_MODIFIER", 100, 103], ["CNS", "ANATOMY", 116, 119], ["lesions", "OBSERVATION", 120, 127], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["astrogliosis", "OBSERVATION", 218, 230], ["plaques", "OBSERVATION", 293, 300], ["astrocytes", "OBSERVATION", 341, 351], ["reactive astrocytes", "OBSERVATION", 378, 397]]], ["Similar to TNF-\u03b1, IFN-\u03b3 has been shown to suppress remyelination and to delay disease recovery in transgenic EAE mice, where IFN-\u03b3 expression by astrocytes was stimulated temporally in the recovery stage (Lin et al., 2006) .", [["astrocytes", "ANATOMY", 145, 155], ["EAE", "DISEASE", 109, 112], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 11, 16], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 18, 23], ["transgenic EAE mice", "ORGANISM", 98, 117], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 125, 130], ["astrocytes", "CELL", 145, 155], ["TNF", "PROTEIN", 11, 14], ["IFN-\u03b3", "PROTEIN", 18, 23], ["IFN", "PROTEIN", 125, 128], ["\u03b3", "PROTEIN", 129, 130], ["astrocytes", "CELL_TYPE", 145, 155], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["TNF", "TEST", 11, 14], ["IFN", "TEST", 18, 21], ["remyelination", "PROBLEM", 51, 64], ["delay disease recovery", "PROBLEM", 72, 94]]], ["Astrocyte-directed expression of IFN-\u03b3 in transgenic mice has also resulted in regional hypomyelination and selective disruption of brain histogenesis, which led to ataxia and shorter life span (LaFerla et al., 2000) .", [["Astrocyte", "ANATOMY", 0, 9], ["brain", "ANATOMY", 132, 137], ["ataxia", "DISEASE", 165, 171], ["Astrocyte", "CELL", 0, 9], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 33, 38], ["mice", "ORGANISM", 53, 57], ["brain", "ORGAN", 132, 137], ["IFN", "PROTEIN", 33, 36], ["\u03b3", "PROTEIN", 37, 38], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["Astrocyte", "TEST", 0, 9], ["IFN", "PROBLEM", 33, 36], ["regional hypomyelination", "PROBLEM", 79, 103], ["selective disruption of brain histogenesis", "PROBLEM", 108, 150], ["ataxia", "PROBLEM", 165, 171], ["regional hypomyelination", "OBSERVATION", 79, 103], ["selective", "OBSERVATION_MODIFIER", 108, 117], ["brain", "ANATOMY", 132, 137], ["histogenesis", "OBSERVATION", 138, 150]]], ["Furthermore, knocking down IFN-\u03b3 receptor expression in astrocytes three days before immunization suppressed EAE and demyelination by inhibiting inflammatory cell infiltration (Ding et al., 2015) .", [["astrocytes", "ANATOMY", 56, 66], ["inflammatory cell", "ANATOMY", 145, 162], ["EAE", "DISEASE", 109, 112], ["demyelination", "DISEASE", 117, 130], ["IFN-\u03b3 receptor", "GENE_OR_GENE_PRODUCT", 27, 41], ["astrocytes", "CELL", 56, 66], ["inflammatory cell", "CELL", 145, 162], ["IFN-\u03b3 receptor", "PROTEIN", 27, 41], ["astrocytes", "CELL_TYPE", 56, 66], ["knocking down IFN", "PROBLEM", 13, 30], ["receptor expression in astrocytes", "PROBLEM", 33, 66], ["immunization", "TREATMENT", 85, 97], ["EAE", "PROBLEM", 109, 112], ["demyelination", "PROBLEM", 117, 130], ["inflammatory cell infiltration", "PROBLEM", 145, 175], ["inflammatory cell infiltration", "OBSERVATION", 145, 175]]], ["These animals presented lower mean clinical scores even when the receptor silencing was initiated after disease onset or at disease peak (Ding et al., 2015) .", [["the receptor silencing", "TREATMENT", 61, 83], ["disease onset", "PROBLEM", 104, 117]]], ["Despite the abovementioned evidence suggesting inhibitory roles for reactive astrocytes on myelination, Hindinger et al. (2012) have proposed that IFN-\u03b3 signalling in astrocytes is indispensable for the alleviation of EAE since levels of demyelination and axonal loss are increased during acute EAE in mice with an astrocytic expression of a dominant negative allele for IFN-\u03b3 receptor.", [["astrocytes", "ANATOMY", 77, 87], ["astrocytes", "ANATOMY", 167, 177], ["axonal", "ANATOMY", 256, 262], ["EAE", "DISEASE", 218, 221], ["demyelination", "DISEASE", 238, 251], ["axonal loss", "DISEASE", 256, 267], ["EAE", "DISEASE", 295, 298], ["astrocytes", "CELL", 77, 87], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 147, 152], ["astrocytes", "CELL", 167, 177], ["axonal", "CELLULAR_COMPONENT", 256, 262], ["mice", "ORGANISM", 302, 306], ["IFN-\u03b3 receptor", "GENE_OR_GENE_PRODUCT", 371, 385], ["reactive astrocytes", "CELL_TYPE", 68, 87], ["IFN", "PROTEIN", 147, 150], ["\u03b3", "PROTEIN", 151, 152], ["astrocytes", "CELL_TYPE", 167, 177], ["dominant negative allele", "DNA", 342, 366], ["IFN-\u03b3 receptor", "PROTEIN", 371, 385], ["mice", "SPECIES", 302, 306], ["mice", "SPECIES", 302, 306], ["reactive astrocytes", "PROBLEM", 68, 87], ["signalling in astrocytes", "PROBLEM", 153, 177], ["the alleviation of EAE", "PROBLEM", 199, 221], ["demyelination", "PROBLEM", 238, 251], ["axonal loss", "PROBLEM", 256, 267], ["acute EAE", "PROBLEM", 289, 298], ["reactive astrocytes", "OBSERVATION", 68, 87], ["demyelination", "OBSERVATION", 238, 251], ["axonal loss", "OBSERVATION", 256, 267], ["increased", "OBSERVATION_MODIFIER", 272, 281]]], ["Nevertheless, their approach blocked IFN-\u03b3 signalling in astrocytes without decreasing the expression of IFN-\u03b3 receptor, which would lower the levels of IFN-\u03b3 available for immunoregulatory cells; whereas, Ding et al. (2015) have knocked down the expression of the receptor itself.", [["astrocytes", "ANATOMY", 57, 67], ["immunoregulatory cells", "ANATOMY", 173, 195], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 37, 42], ["astrocytes", "CELL", 57, 67], ["IFN-\u03b3 receptor", "GENE_OR_GENE_PRODUCT", 105, 119], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 153, 158], ["cells", "CELL", 190, 195], ["IFN", "PROTEIN", 37, 40], ["\u03b3", "PROTEIN", 41, 42], ["astrocytes", "CELL_TYPE", 57, 67], ["IFN-\u03b3 receptor", "PROTEIN", 105, 119], ["IFN", "PROTEIN", 153, 156], ["\u03b3", "PROTEIN", 157, 158], ["immunoregulatory cells", "CELL_TYPE", 173, 195], ["IFN", "TEST", 37, 40], ["signalling in astrocytes", "PROBLEM", 43, 67], ["IFN", "TEST", 105, 108], ["IFN", "TEST", 153, 156], ["immunoregulatory cells", "PROBLEM", 173, 195]]], ["Therefore, blocking or lowering IFN-\u03b3 signalling in astrocytes with a carefully planned strategy might provide new disease-modifying treatments that will limit demyelination.Astrocyte reactivity (severe astrogliosis): an inhibitory phenotype?Reactive astrocytes also secrete C-X-C motif chemokine 10 (CXCL10, Ransohoff et al., 1993) , particularly around active MS lesions (Omari et al., 2005; Carter et al., 2007) .", [["astrocytes", "ANATOMY", 52, 62], ["Astrocyte", "ANATOMY", 174, 183], ["astrocytes", "ANATOMY", 251, 261], ["MS lesions", "ANATOMY", 362, 372], ["demyelination", "DISEASE", 160, 173], ["astrogliosis", "DISEASE", 203, 215], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 32, 37], ["astrocytes", "CELL", 52, 62], ["Astrocyte", "CELL", 174, 183], ["astrocytes", "CELL", 251, 261], ["C-X-C motif chemokine 10", "GENE_OR_GENE_PRODUCT", 275, 299], ["CXCL10", "GENE_OR_GENE_PRODUCT", 301, 307], ["MS lesions", "CANCER", 362, 372], ["IFN", "PROTEIN", 32, 35], ["astrocytes", "CELL_TYPE", 52, 62], ["Reactive astrocytes", "CELL_TYPE", 242, 261], ["C-X-C motif chemokine 10", "PROTEIN", 275, 299], ["CXCL10", "PROTEIN", 301, 307], ["lowering IFN", "TREATMENT", 23, 35], ["signalling in astrocytes", "PROBLEM", 38, 62], ["a carefully planned strategy", "TREATMENT", 68, 96], ["new disease", "PROBLEM", 111, 122], ["modifying treatments", "TREATMENT", 123, 143], ["demyelination", "PROBLEM", 160, 173], ["Astrocyte reactivity (severe astrogliosis)", "PROBLEM", 174, 216], ["an inhibitory phenotype", "PROBLEM", 218, 241], ["Reactive astrocytes", "TEST", 242, 261], ["C", "TEST", 275, 276], ["motif chemokine", "TEST", 281, 296], ["CXCL10", "TEST", 301, 307], ["active MS lesions", "PROBLEM", 355, 372], ["severe", "OBSERVATION_MODIFIER", 196, 202], ["astrogliosis", "OBSERVATION", 203, 215], ["astrocytes", "OBSERVATION", 251, 261], ["lesions", "OBSERVATION", 365, 372]]], ["Cxcl10 mRNA expression increases significantly during peak disease and decreases during the recovery phases in animal models of MS (Godiska et al., 1995; Glabinski et al., 1997; Fife et al., 2001) .", [["MS", "DISEASE", 128, 130], ["Cxcl10", "GENE_OR_GENE_PRODUCT", 0, 6], ["Cxcl10 mRNA", "RNA", 0, 11], ["Cxcl10 mRNA expression", "TEST", 0, 22], ["peak disease", "PROBLEM", 54, 66], ["increases", "OBSERVATION_MODIFIER", 23, 32], ["significantly", "OBSERVATION_MODIFIER", 33, 46], ["peak disease", "OBSERVATION", 54, 66], ["decreases", "OBSERVATION_MODIFIER", 71, 80]]], ["A direct effect of CXCL10 on the inhibition of myelination was shown in dissociated rat spinal cord cells plated on astrocytes treated with CXCL10 and its neutralizing antibody.", [["spinal cord cells", "ANATOMY", 88, 105], ["astrocytes", "ANATOMY", 116, 126], ["CXCL10", "GENE_OR_GENE_PRODUCT", 19, 25], ["rat", "ORGANISM", 84, 87], ["spinal cord cells", "CELL", 88, 105], ["astrocytes", "CELL", 116, 126], ["CXCL10", "GENE_OR_GENE_PRODUCT", 140, 146], ["CXCL10", "PROTEIN", 19, 25], ["dissociated rat spinal cord cells", "CELL_LINE", 72, 105], ["astrocytes", "CELL_TYPE", 116, 126], ["CXCL10", "PROTEIN", 140, 146], ["neutralizing antibody", "PROTEIN", 155, 176], ["rat", "SPECIES", 84, 87], ["rat", "SPECIES", 84, 87], ["CXCL10", "TREATMENT", 19, 25], ["dissociated rat spinal cord cells", "PROBLEM", 72, 105], ["CXCL10", "TREATMENT", 140, 146], ["its neutralizing antibody", "TREATMENT", 151, 176], ["spinal cord", "ANATOMY", 88, 99]]], ["In these experiments CXCL10 identified by microarray analysis, was upregulated in an astrocyte phenotype that was inhibitory to CNS myelination in vitro.", [["astrocyte", "ANATOMY", 85, 94], ["CNS", "ANATOMY", 128, 131], ["CXCL10", "GENE_OR_GENE_PRODUCT", 21, 27], ["astrocyte", "CELL", 85, 94], ["CNS", "ANATOMICAL_SYSTEM", 128, 131], ["CXCL10", "PROTEIN", 21, 27], ["these experiments CXCL10", "TEST", 3, 27], ["microarray analysis", "TEST", 42, 61], ["an astrocyte phenotype", "PROBLEM", 82, 104], ["astrocyte phenotype", "OBSERVATION", 85, 104]]], ["Specifically, CXCL10 appeared to inhibit oligodendrocyte process extension (Nash et al., 2011b) .", [["oligodendrocyte", "ANATOMY", 41, 56], ["CXCL10", "GENE_OR_GENE_PRODUCT", 14, 20], ["oligodendrocyte", "CELL", 41, 56], ["CXCL10", "PROTEIN", 14, 20], ["CXCL10", "TEST", 14, 20], ["oligodendrocyte process extension", "PROBLEM", 41, 74], ["oligodendrocyte process", "OBSERVATION", 41, 64], ["Nash", "OBSERVATION_MODIFIER", 76, 80]]], ["Consequently, cytokines stand out as an important family of molecules to activate astrocytes and to initiate different forms of astrocyte reactivity that could be either beneficial or inhibitory for the CNS milieu in terms of re/myelination.Astrocyte reactivity (severe astrogliosis): an inhibitory phenotype?It should be noted that the secretion of such pro-inflammatory cytokines that can contribute to the lack of remyelination within MS plaques is not restricted to reactive astrocytes since other glial and inflammatory cell types will also secrete them.", [["astrocytes", "ANATOMY", 82, 92], ["astrocyte", "ANATOMY", 128, 137], ["CNS", "ANATOMY", 203, 206], ["Astrocyte", "ANATOMY", 241, 250], ["MS plaques", "ANATOMY", 438, 448], ["astrocytes", "ANATOMY", 479, 489], ["glial", "ANATOMY", 502, 507], ["cell", "ANATOMY", 525, 529], ["astrogliosis", "DISEASE", 270, 282], ["astrocytes", "CELL", 82, 92], ["astrocyte", "CELL", 128, 137], ["CNS", "ANATOMICAL_SYSTEM", 203, 206], ["Astrocyte", "CELL", 241, 250], ["astrocytes", "CELL", 479, 489], ["glial", "CELL", 502, 507], ["inflammatory cell", "CELL", 512, 529], ["cytokines", "PROTEIN", 14, 23], ["astrocytes", "CELL_TYPE", 82, 92], ["pro-inflammatory cytokines", "PROTEIN", 355, 381], ["reactive astrocytes", "CELL_TYPE", 470, 489], ["glial and inflammatory cell types", "CELL_TYPE", 502, 535], ["astrocyte reactivity", "PROBLEM", 128, 148], ["Astrocyte reactivity (severe astrogliosis)", "PROBLEM", 241, 283], ["an inhibitory phenotype", "PROBLEM", 285, 308], ["such pro-inflammatory cytokines", "PROBLEM", 350, 381], ["remyelination within MS plaques", "PROBLEM", 417, 448], ["reactive astrocytes", "PROBLEM", 470, 489], ["other glial and inflammatory cell types", "PROBLEM", 496, 535], ["severe", "OBSERVATION_MODIFIER", 263, 269], ["astrogliosis", "OBSERVATION", 270, 282], ["remyelination", "OBSERVATION", 417, 430], ["plaques", "OBSERVATION", 441, 448], ["reactive astrocytes", "OBSERVATION", 470, 489], ["inflammatory cell types", "OBSERVATION", 512, 535]]], ["Moreover, the up regulation of such cytokines by reactive astrocytes can also be protective for CNS injury.", [["astrocytes", "ANATOMY", 58, 68], ["CNS", "ANATOMY", 96, 99], ["astrocytes", "CELL", 58, 68], ["CNS", "ANATOMICAL_SYSTEM", 96, 99], ["cytokines", "PROTEIN", 36, 45], ["reactive astrocytes", "CELL_TYPE", 49, 68], ["such cytokines", "PROBLEM", 31, 45], ["reactive astrocytes", "PROBLEM", 49, 68], ["CNS injury", "PROBLEM", 96, 106], ["reactive astrocytes", "OBSERVATION", 49, 68], ["CNS", "ANATOMY", 96, 99], ["injury", "OBSERVATION", 100, 106]]], ["For example, the astrocytic scar can restrict leukocyte migration from within areas of damaged tissue into the otherwise healthy non damaged CNS tissue in close proximity to the scar protecting it from immune mediated damage (Faulkner et al., 2004; Okada et al., 2006; Herrmann et al., 2008; Voskuhl et al., 2009 ).Astrocytes provide energy and cholesterolA vital supportive role played by astrocytes following injury is the provision of an energy source, which is important if axons are to be myelinated.", [["astrocytic scar", "ANATOMY", 17, 32], ["leukocyte", "ANATOMY", 46, 55], ["tissue", "ANATOMY", 95, 101], ["CNS tissue", "ANATOMY", 141, 151], ["scar", "ANATOMY", 178, 182], ["Astrocytes", "ANATOMY", 315, 325], ["astrocytes", "ANATOMY", 390, 400], ["axons", "ANATOMY", 478, 483], ["cholesterol", "CHEMICAL", 345, 356], ["cholesterol", "CHEMICAL", 345, 356], ["astrocytic scar", "PATHOLOGICAL_FORMATION", 17, 32], ["leukocyte", "CELL", 46, 55], ["tissue", "TISSUE", 95, 101], ["CNS tissue", "TISSUE", 141, 151], ["scar", "PATHOLOGICAL_FORMATION", 178, 182], ["Astrocytes", "CELL", 315, 325], ["cholesterol", "SIMPLE_CHEMICAL", 345, 356], ["astrocytes", "CELL", 390, 400], ["axons", "CELLULAR_COMPONENT", 478, 483], ["Astrocytes", "CELL_TYPE", 315, 325], ["astrocytes", "CELL_TYPE", 390, 400], ["the astrocytic scar", "PROBLEM", 13, 32], ["leukocyte migration", "PROBLEM", 46, 65], ["damaged tissue", "PROBLEM", 87, 101], ["damaged CNS tissue", "PROBLEM", 133, 151], ["the scar", "PROBLEM", 174, 182], ["immune mediated damage", "PROBLEM", 202, 224], ["injury", "PROBLEM", 411, 417], ["astrocytic", "OBSERVATION_MODIFIER", 17, 27], ["scar", "OBSERVATION", 28, 32], ["leukocyte migration", "OBSERVATION", 46, 65], ["damaged tissue", "OBSERVATION", 87, 101], ["otherwise", "OBSERVATION_MODIFIER", 111, 120], ["healthy", "OBSERVATION_MODIFIER", 121, 128], ["non damaged", "OBSERVATION_MODIFIER", 129, 140], ["CNS tissue", "OBSERVATION", 141, 151], ["scar", "OBSERVATION", 178, 182]]], ["This energy is metabolized from glucose which enters the brain via the endothelial cells lining the blood brain barrier (BBB), which are in close contact with astrocytes.", [["brain", "ANATOMY", 57, 62], ["endothelial cells", "ANATOMY", 71, 88], ["blood brain barrier", "ANATOMY", 100, 119], ["BBB", "ANATOMY", 121, 124], ["astrocytes", "ANATOMY", 159, 169], ["glucose", "CHEMICAL", 32, 39], ["glucose", "CHEMICAL", 32, 39], ["glucose", "SIMPLE_CHEMICAL", 32, 39], ["brain", "ORGAN", 57, 62], ["endothelial cells", "CELL", 71, 88], ["blood brain barrier", "TISSUE", 100, 119], ["BBB", "MULTI-TISSUE_STRUCTURE", 121, 124], ["astrocytes", "CELL", 159, 169], ["endothelial cells", "CELL_TYPE", 71, 88], ["astrocytes", "CELL_TYPE", 159, 169], ["glucose", "TEST", 32, 39], ["brain", "ANATOMY", 57, 62], ["endothelial cells", "OBSERVATION", 71, 88], ["blood brain", "ANATOMY", 100, 111]]], ["Unlike endothelial cells, astrocytes biochemically transform glucose into glycogen, the principal source of stored energy in all cell types (Pellegri et al., 1996; Pfeiffer-Guglielmi et al., 2003) .", [["endothelial cells", "ANATOMY", 7, 24], ["astrocytes", "ANATOMY", 26, 36], ["cell", "ANATOMY", 129, 133], ["glucose", "CHEMICAL", 61, 68], ["glycogen", "CHEMICAL", 74, 82], ["glucose", "CHEMICAL", 61, 68], ["endothelial cells", "CELL", 7, 24], ["astrocytes", "CELL", 26, 36], ["glucose", "SIMPLE_CHEMICAL", 61, 68], ["glycogen", "SIMPLE_CHEMICAL", 74, 82], ["cell", "CELL", 129, 133], ["endothelial cells", "CELL_TYPE", 7, 24], ["astrocytes", "CELL_TYPE", 26, 36], ["Unlike endothelial cells", "PROBLEM", 0, 24], ["endothelial cells", "OBSERVATION", 7, 24], ["all cell", "OBSERVATION_MODIFIER", 125, 133]]], ["In addition, it has been suggested that astrocytes under low glucose concentrations can degrade stored glycogen into lactate which in turn increases extracellular lactate levels to provide energy for nearby axons when deprivation occurs after injury (Tekk\u00f6k et al., 2005) .", [["astrocytes", "ANATOMY", 40, 50], ["extracellular", "ANATOMY", 149, 162], ["axons", "ANATOMY", 207, 212], ["glucose", "CHEMICAL", 61, 68], ["glycogen", "CHEMICAL", 103, 111], ["lactate", "CHEMICAL", 117, 124], ["lactate", "CHEMICAL", 163, 170], ["glucose", "CHEMICAL", 61, 68], ["lactate", "CHEMICAL", 117, 124], ["lactate", "CHEMICAL", 163, 170], ["astrocytes", "CELL", 40, 50], ["glucose", "SIMPLE_CHEMICAL", 61, 68], ["glycogen", "SIMPLE_CHEMICAL", 103, 111], ["lactate", "SIMPLE_CHEMICAL", 117, 124], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 149, 162], ["lactate", "SIMPLE_CHEMICAL", 163, 170], ["axons", "MULTI-TISSUE_STRUCTURE", 207, 212], ["astrocytes", "CELL_TYPE", 40, 50], ["astrocytes under low glucose concentrations", "PROBLEM", 40, 83], ["glycogen into lactate", "TEST", 103, 124], ["extracellular lactate levels", "TEST", 149, 177], ["injury", "PROBLEM", 243, 249]]], ["The lactate derived from astroglial glycogen via glycolysis is transferred directly to the axon at the node of Ranvier (Hirrlinger and Nave, 2014) .", [["astroglial", "ANATOMY", 25, 35], ["axon", "ANATOMY", 91, 95], ["node", "ANATOMY", 103, 107], ["lactate", "CHEMICAL", 4, 11], ["glycogen", "CHEMICAL", 36, 44], ["lactate", "CHEMICAL", 4, 11], ["lactate", "SIMPLE_CHEMICAL", 4, 11], ["astroglial", "CELL", 25, 35], ["glycogen", "SIMPLE_CHEMICAL", 36, 44], ["axon", "CELLULAR_COMPONENT", 91, 95], ["The lactate", "TEST", 0, 11], ["node", "ANATOMY", 103, 107]]], ["The importance of lactate during demyelination is only just emerging.", [["lactate", "CHEMICAL", 18, 25], ["demyelination", "DISEASE", 33, 46], ["lactate", "CHEMICAL", 18, 25], ["lactate", "SIMPLE_CHEMICAL", 18, 25], ["lactate", "TEST", 18, 25], ["demyelination", "PROBLEM", 33, 46], ["demyelination", "OBSERVATION", 33, 46]]], ["Whether astrocytes maintain the energy levels of only axons as previously thought, or if this extends to oligodendrocytes as well, is an interesting concept.", [["astrocytes", "ANATOMY", 8, 18], ["axons", "ANATOMY", 54, 59], ["oligodendrocytes", "ANATOMY", 105, 121], ["astrocytes", "CELL", 8, 18], ["axons", "CELLULAR_COMPONENT", 54, 59], ["oligodendrocytes", "CELL", 105, 121], ["astrocytes", "CELL_TYPE", 8, 18], ["oligodendrocytes", "CELL_TYPE", 105, 121], ["the energy levels", "TEST", 28, 45], ["oligodendrocytes", "PROBLEM", 105, 121]]], ["Oligodendrocytes are known to consume lactate at higher levels than other CNS cells, therefore making them an important user of any lactate production.", [["Oligodendrocytes", "ANATOMY", 0, 16], ["CNS cells", "ANATOMY", 74, 83], ["lactate", "CHEMICAL", 38, 45], ["lactate", "CHEMICAL", 132, 139], ["lactate", "CHEMICAL", 38, 45], ["lactate", "CHEMICAL", 132, 139], ["Oligodendrocytes", "CELL", 0, 16], ["lactate", "SIMPLE_CHEMICAL", 38, 45], ["CNS cells", "CELL", 74, 83], ["lactate", "SIMPLE_CHEMICAL", 132, 139], ["Oligodendrocytes", "CELL_TYPE", 0, 16], ["CNS cells", "CELL_TYPE", 74, 83], ["lactate", "TEST", 38, 45], ["any lactate production", "PROBLEM", 128, 150], ["CNS cells", "ANATOMY", 74, 83]]], ["Furthermore, promotion of myelination via oligodendrocytes has been shown when endogenous lactate is applied (Rinholm and Bergersen, 2012) therefore at least some astrocytic lactate production may be targeted to myelinating oligodendrocytes (S\u00e1nchez-Abarca et al., 2001; Rinholm et al., 2011) .", [["oligodendrocytes", "ANATOMY", 42, 58], ["myelinating oligodendrocytes", "ANATOMY", 212, 240], ["lactate", "CHEMICAL", 90, 97], ["lactate", "CHEMICAL", 174, 181], ["lactate", "CHEMICAL", 90, 97], ["lactate", "CHEMICAL", 174, 181], ["oligodendrocytes", "CELL", 42, 58], ["lactate", "SIMPLE_CHEMICAL", 90, 97], ["lactate", "SIMPLE_CHEMICAL", 174, 181], ["oligodendrocytes", "CELL", 224, 240], ["oligodendrocytes", "CELL_TYPE", 42, 58], ["myelinating oligodendrocytes", "CELL_TYPE", 212, 240], ["myelination via oligodendrocytes", "PROBLEM", 26, 58], ["endogenous lactate", "TEST", 79, 97], ["some astrocytic lactate production", "PROBLEM", 158, 192]]], ["However, energy regulation in the CNS is more complex as recent evidence has shown that oligodendrocytes in turn can transfer glycolysis products such as lactate to axons via monocarboxylic acid transporters (MCT1, MCT2), which reside in internodal myelin and the axonal compartment (F\u00fcnfschilling et al., 2012) .Astrocytes provide energy and cholesterolCholesterol is essential to every cell in the body as it is an important component of cellular membranes.", [["CNS", "ANATOMY", 34, 37], ["oligodendrocytes", "ANATOMY", 88, 104], ["axons", "ANATOMY", 165, 170], ["internodal myelin", "ANATOMY", 238, 255], ["axonal compartment", "ANATOMY", 264, 282], ["Astrocytes", "ANATOMY", 313, 323], ["cell", "ANATOMY", 388, 392], ["body", "ANATOMY", 400, 404], ["cellular membranes", "ANATOMY", 440, 458], ["lactate", "CHEMICAL", 154, 161], ["monocarboxylic acid", "CHEMICAL", 175, 194], ["cholesterol", "CHEMICAL", 343, 354], ["Cholesterol", "CHEMICAL", 354, 365], ["lactate", "CHEMICAL", 154, 161], ["monocarboxylic acid", "CHEMICAL", 175, 194], ["cholesterol", "CHEMICAL", 343, 354], ["Cholesterol", "CHEMICAL", 354, 365], ["CNS", "ANATOMICAL_SYSTEM", 34, 37], ["oligodendrocytes", "CELL", 88, 104], ["lactate", "SIMPLE_CHEMICAL", 154, 161], ["axons", "CELLULAR_COMPONENT", 165, 170], ["monocarboxylic acid transporters", "GENE_OR_GENE_PRODUCT", 175, 207], ["MCT1", "GENE_OR_GENE_PRODUCT", 209, 213], ["MCT2", "GENE_OR_GENE_PRODUCT", 215, 219], ["internodal myelin", "CELLULAR_COMPONENT", 238, 255], ["axonal compartment", "CELLULAR_COMPONENT", 264, 282], ["Astrocytes", "CELL", 313, 323], ["cholesterol", "SIMPLE_CHEMICAL", 343, 354], ["Cholesterol", "SIMPLE_CHEMICAL", 354, 365], ["cell", "CELL", 388, 392], ["body", "ORGANISM_SUBDIVISION", 400, 404], ["cellular membranes", "CELLULAR_COMPONENT", 440, 458], ["oligodendrocytes", "CELL_TYPE", 88, 104], ["monocarboxylic acid transporters", "PROTEIN", 175, 207], ["MCT1", "PROTEIN", 209, 213], ["MCT2", "PROTEIN", 215, 219], ["Astrocytes", "CELL_TYPE", 313, 323], ["oligodendrocytes", "PROBLEM", 88, 104], ["glycolysis products", "TREATMENT", 126, 145], ["lactate", "TEST", 154, 161], ["monocarboxylic acid transporters", "TEST", 175, 207], ["cholesterol", "TEST", 343, 354], ["Cholesterol", "TEST", 354, 365], ["cellular membranes", "PROBLEM", 440, 458], ["energy regulation", "OBSERVATION", 9, 26], ["CNS", "ANATOMY", 34, 37], ["more complex", "OBSERVATION_MODIFIER", 41, 53], ["internodal myelin", "OBSERVATION", 238, 255], ["axonal compartment", "ANATOMY", 264, 282], ["every cell", "OBSERVATION_MODIFIER", 382, 392], ["body", "ANATOMY", 400, 404], ["cellular membranes", "OBSERVATION", 440, 458]]], ["In the CNS it is vital for normal brain development, is a precursor to many signalling molecules such as steroid hormones, and importantly, is a major structural component of myelin sheaths (Siegel et al., 1999) .", [["CNS", "ANATOMY", 7, 10], ["brain", "ANATOMY", 34, 39], ["myelin sheaths", "ANATOMY", 175, 189], ["steroid", "CHEMICAL", 105, 112], ["steroid", "CHEMICAL", 105, 112], ["CNS", "ANATOMICAL_SYSTEM", 7, 10], ["brain", "ORGAN", 34, 39], ["steroid hormones", "GENE_OR_GENE_PRODUCT", 105, 121], ["myelin sheaths", "CELLULAR_COMPONENT", 175, 189], ["signalling molecules", "PROTEIN", 76, 96], ["a precursor to many signalling molecules", "PROBLEM", 56, 96], ["steroid hormones", "PROBLEM", 105, 121], ["CNS", "ANATOMY", 7, 10], ["brain", "ANATOMY", 34, 39], ["myelin sheaths", "OBSERVATION", 175, 189]]], ["The BBB prevents the transport of either hepatic or dietary cholesterol, meaning that cholesterol must be derived by de novo synthesis within the CNS (Orth and Bellosta, 2012) .", [["hepatic", "ANATOMY", 41, 48], ["CNS", "ANATOMY", 146, 149], ["cholesterol", "CHEMICAL", 60, 71], ["cholesterol", "CHEMICAL", 86, 97], ["cholesterol", "CHEMICAL", 60, 71], ["cholesterol", "CHEMICAL", 86, 97], ["BBB", "MULTI-TISSUE_STRUCTURE", 4, 7], ["hepatic", "MULTI-TISSUE_STRUCTURE", 41, 48], ["cholesterol", "SIMPLE_CHEMICAL", 60, 71], ["cholesterol", "SIMPLE_CHEMICAL", 86, 97], ["CNS", "ANATOMICAL_SYSTEM", 146, 149], ["hepatic", "ANATOMY", 41, 48], ["CNS", "ANATOMY", 146, 149]]], ["Astrocytes are proposed to be one of the primary cellular sources of cholesterol (Pfrieger and Ungerer, 2011) and mediate its secretion by their expression of several apolipoproteins, molecules that bind cholesterol (Boyles et al., 1985; Lin et al., 1986; Xu et al., 2006; Kurumada et al., 2007) .", [["Astrocytes", "ANATOMY", 0, 10], ["cellular", "ANATOMY", 49, 57], ["cholesterol", "CHEMICAL", 69, 80], ["cholesterol", "CHEMICAL", 204, 215], ["cholesterol", "CHEMICAL", 69, 80], ["cholesterol", "CHEMICAL", 204, 215], ["Astrocytes", "CELL", 0, 10], ["cellular", "CELL", 49, 57], ["cholesterol", "SIMPLE_CHEMICAL", 69, 80], ["Pfrieger", "SIMPLE_CHEMICAL", 82, 90], ["apolipoproteins", "GENE_OR_GENE_PRODUCT", 167, 182], ["cholesterol", "SIMPLE_CHEMICAL", 204, 215], ["Astrocytes", "CELL_TYPE", 0, 10], ["apolipoproteins", "PROTEIN", 167, 182], ["Astrocytes", "PROBLEM", 0, 10]]], ["There is sufficient evidence to suggest that there is horizontal transfer of cholesterol (Boyles et al., 1985; Lin et al., 1986; Xu et al., 2006; Kurumada et al., 2007) with both astrocytes and oligodendrocytes producing cholesterol to maintain myelin sheath formation and neurons.", [["astrocytes", "ANATOMY", 179, 189], ["oligodendrocytes", "ANATOMY", 194, 210], ["myelin sheath", "ANATOMY", 245, 258], ["neurons", "ANATOMY", 273, 280], ["cholesterol", "CHEMICAL", 77, 88], ["cholesterol", "CHEMICAL", 221, 232], ["cholesterol", "CHEMICAL", 77, 88], ["cholesterol", "CHEMICAL", 221, 232], ["cholesterol", "SIMPLE_CHEMICAL", 77, 88], ["astrocytes", "CELL", 179, 189], ["oligodendrocytes", "CELL", 194, 210], ["cholesterol", "SIMPLE_CHEMICAL", 221, 232], ["myelin sheath", "CELLULAR_COMPONENT", 245, 258], ["neurons", "CELL", 273, 280], ["astrocytes", "CELL_TYPE", 179, 189], ["oligodendrocytes", "CELL_TYPE", 194, 210], ["sufficient evidence to suggest", "UNCERTAINTY", 9, 39], ["horizontal", "OBSERVATION_MODIFIER", 54, 64], ["both astrocytes", "ANATOMY", 174, 189], ["neurons", "ANATOMY", 273, 280]]], ["This transfer between cells is critically relevant to neurodegenerative diseases, since the availability of cholesterol is thought to be an essential rate limiting factor to myelin production (May et al., 2004; Liu et al., 2010) .", [["cells", "ANATOMY", 22, 27], ["myelin", "ANATOMY", 174, 180], ["neurodegenerative diseases", "DISEASE", 54, 80], ["cholesterol", "CHEMICAL", 108, 119], ["cholesterol", "CHEMICAL", 108, 119], ["cells", "CELL", 22, 27], ["cholesterol", "SIMPLE_CHEMICAL", 108, 119], ["myelin", "GENE_OR_GENE_PRODUCT", 174, 180], ["neurodegenerative diseases", "PROBLEM", 54, 80], ["neurodegenerative", "OBSERVATION_MODIFIER", 54, 71], ["diseases", "OBSERVATION", 72, 80]]], ["Therefore, in addition to their roles in providing energy to neurons, astrocytes also emerge as important cholesterol-suppliers in the CNS, which is vital for myelination.Astrocytes play a role in synaptic signal transmission and can modulate synapsesA further function of astrocytes is the removal of excitotoxic molecules from the extracellular space, thus supporting neuronal survival.", [["neurons", "ANATOMY", 61, 68], ["astrocytes", "ANATOMY", 70, 80], ["CNS", "ANATOMY", 135, 138], ["Astrocytes", "ANATOMY", 171, 181], ["synaptic", "ANATOMY", 197, 205], ["synapses", "ANATOMY", 243, 251], ["astrocytes", "ANATOMY", 273, 283], ["extracellular space", "ANATOMY", 333, 352], ["neuronal", "ANATOMY", 370, 378], ["cholesterol", "CHEMICAL", 106, 117], ["cholesterol", "CHEMICAL", 106, 117], ["neurons", "CELL", 61, 68], ["astrocytes", "CELL", 70, 80], ["cholesterol", "SIMPLE_CHEMICAL", 106, 117], ["CNS", "ANATOMICAL_SYSTEM", 135, 138], ["Astrocytes", "CELL", 171, 181], ["astrocytes", "CELL", 273, 283], ["extracellular space", "CELLULAR_COMPONENT", 333, 352], ["neuronal", "CELL", 370, 378], ["astrocytes", "CELL_TYPE", 70, 80], ["Astrocytes", "CELL_TYPE", 171, 181], ["astrocytes", "CELL_TYPE", 273, 283], ["excitotoxic molecules", "PROTEIN", 302, 323], ["synaptic signal transmission", "TREATMENT", 197, 225], ["modulate synapses", "PROBLEM", 234, 251], ["the removal of excitotoxic molecules", "TREATMENT", 287, 323], ["CNS", "ANATOMY", 135, 138], ["excitotoxic molecules", "OBSERVATION", 302, 323], ["extracellular space", "OBSERVATION", 333, 352], ["neuronal survival", "OBSERVATION", 370, 387]]], ["They can actively remove excitotoxic glutamate and convert it to glutamine by increasing their levels of glutamate transporters and glutamine synthetase (Faden et al., 1989; Eng et al., 1997; Krum et al., 2002) , thereby preventing neuronal cell death during brain pathology.", [["neuronal cell", "ANATOMY", 232, 245], ["brain", "ANATOMY", 259, 264], ["glutamate", "CHEMICAL", 37, 46], ["glutamine", "CHEMICAL", 65, 74], ["glutamate", "CHEMICAL", 105, 114], ["glutamine", "CHEMICAL", 132, 141], ["neuronal cell death", "DISEASE", 232, 251], ["glutamate", "CHEMICAL", 37, 46], ["glutamine", "CHEMICAL", 65, 74], ["glutamate", "CHEMICAL", 105, 114], ["glutamine", "CHEMICAL", 132, 141], ["glutamate", "SIMPLE_CHEMICAL", 37, 46], ["glutamine", "AMINO_ACID", 65, 74], ["glutamate", "SIMPLE_CHEMICAL", 105, 114], ["glutamine synthetase", "GENE_OR_GENE_PRODUCT", 132, 152], ["neuronal cell", "CELL", 232, 245], ["brain", "ORGAN", 259, 264], ["glutamine synthetase", "PROTEIN", 132, 152], ["excitotoxic glutamate", "TREATMENT", 25, 46], ["glutamine", "TREATMENT", 65, 74], ["glutamate transporters", "TREATMENT", 105, 127], ["glutamine synthetase", "TREATMENT", 132, 152], ["neuronal cell death", "PROBLEM", 232, 251], ["neuronal cell death", "OBSERVATION", 232, 251], ["brain", "ANATOMY", 259, 264], ["pathology", "OBSERVATION", 265, 274]]], ["Astrocytes can also release gliotransmitters such as glutamate, purine, GABA and D-serine into the synaptic cleft upon excitation by changes in neuronal synaptic activity and can thereby regulate neuronal excitability (Parpura et al., 1994; Bezzi et al., 1998; Mothet et al., 2000; Coco et al., 2003; Halassa et al., 2007) .", [["Astrocytes", "ANATOMY", 0, 10], ["synaptic cleft", "ANATOMY", 99, 113], ["neuronal synaptic", "ANATOMY", 144, 161], ["neuronal", "ANATOMY", 196, 204], ["glutamate", "CHEMICAL", 53, 62], ["purine", "CHEMICAL", 64, 70], ["GABA", "CHEMICAL", 72, 76], ["D-serine", "CHEMICAL", 81, 89], ["glutamate", "CHEMICAL", 53, 62], ["purine", "CHEMICAL", 64, 70], ["GABA", "CHEMICAL", 72, 76], ["D-serine", "CHEMICAL", 81, 89], ["Astrocytes", "CELL", 0, 10], ["glutamate", "SIMPLE_CHEMICAL", 53, 62], ["purine", "SIMPLE_CHEMICAL", 64, 70], ["GABA", "SIMPLE_CHEMICAL", 72, 76], ["D-serine", "SIMPLE_CHEMICAL", 81, 89], ["synaptic cleft", "CELLULAR_COMPONENT", 99, 113], ["neuronal synaptic", "CELLULAR_COMPONENT", 144, 161], ["neuronal", "CELL", 196, 204], ["Astrocytes", "CELL_TYPE", 0, 10], ["Astrocytes", "PROBLEM", 0, 10], ["glutamate, purine", "TREATMENT", 53, 70], ["GABA", "TREATMENT", 72, 76], ["D-serine", "TREATMENT", 81, 89]]], ["Neurotransmitter released from the neuronal synapse can reach adjacent astrocytes, stimulating increases in intracellular Ca 2+ concentrations, which then leads to the secretion of gliotransmitters (Porter and McCarthy, 1997) .", [["neuronal synapse", "ANATOMY", 35, 51], ["astrocytes", "ANATOMY", 71, 81], ["intracellular", "ANATOMY", 108, 121], ["Ca", "CHEMICAL", 122, 124], ["Ca 2+", "CHEMICAL", 122, 127], ["neuronal synapse", "CELLULAR_COMPONENT", 35, 51], ["astrocytes", "CELL", 71, 81], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 121], ["Ca 2+", "SIMPLE_CHEMICAL", 122, 127], ["astrocytes", "CELL_TYPE", 71, 81], ["adjacent astrocytes", "PROBLEM", 62, 81], ["intracellular Ca", "PROBLEM", 108, 124], ["astrocytes", "ANATOMY", 71, 81], ["increases", "OBSERVATION_MODIFIER", 95, 104]]], ["These regulatory molecules then can feedback to presynaptic nerve terminals to modulate synaptic neurotransmission (Araque et al., 1998) .", [["presynaptic nerve terminals", "ANATOMY", 48, 75], ["synaptic", "ANATOMY", 88, 96], ["nerve terminals", "MULTI-TISSUE_STRUCTURE", 60, 75], ["regulatory molecules", "PROTEIN", 6, 26], ["nerve", "ANATOMY", 60, 65]]], ["These observations have even given rise to the currently accepted 'tripartite synapse' hypothesis, where astrocytes form an active, integral regulatory component of the synapse (Araque et al., 1999; Halassa et al., 2007) .", [["astrocytes", "ANATOMY", 105, 115], ["synapse", "ANATOMY", 169, 176], ["astrocytes", "CELL", 105, 115], ["synapse", "CELLULAR_COMPONENT", 169, 176], ["astrocytes", "CELL_TYPE", 105, 115], ["active", "OBSERVATION_MODIFIER", 124, 130], ["component", "OBSERVATION_MODIFIER", 152, 161]]], ["Recently, electron microscopy has also shown microglia interacting with neuronal synapses (Tremblay et al., 2010) and playing a role in synapse maturation, synaptic remodelling, and synaptic activity (Ji et al., 2013) .", [["microglia", "ANATOMY", 45, 54], ["neuronal synapses", "ANATOMY", 72, 89], ["synapse", "ANATOMY", 136, 143], ["synaptic", "ANATOMY", 156, 164], ["synaptic", "ANATOMY", 182, 190], ["microglia", "CELL", 45, 54], ["neuronal", "CELL", 72, 80], ["synapse", "CELL", 136, 143], ["microglia", "CELL_TYPE", 45, 54], ["electron microscopy", "TEST", 10, 29], ["synaptic remodelling", "TREATMENT", 156, 176]]], ["Evidence has shown that microglia secrete immune factors that play an important role in synaptic connections and illustrates the complexity of cross-talk between neural cells and the immune system.", [["microglia", "ANATOMY", 24, 33], ["synaptic", "ANATOMY", 88, 96], ["neural cells", "ANATOMY", 162, 174], ["immune system", "ANATOMY", 183, 196], ["microglia", "CELL", 24, 33], ["immune factors", "GENE_OR_GENE_PRODUCT", 42, 56], ["neural cells", "CELL", 162, 174], ["immune system", "ANATOMICAL_SYSTEM", 183, 196], ["microglia", "CELL_TYPE", 24, 33], ["immune factors", "PROTEIN", 42, 56], ["neural cells", "CELL_TYPE", 162, 174], ["microglia secrete immune factors", "PROBLEM", 24, 56], ["neural cells", "ANATOMY", 162, 174]]], ["These researchers have suggested a change in name from tripartite synapse to the quad-partite synapse (Schafer et al., 2013; Wu et al., 2015) .Astrocytes play a role in synaptic signal transmission and can modulate synapsesIn addition to playing a role in synaptic signal transmission, astrocytes can also modulate synapses.", [["Astrocytes", "ANATOMY", 143, 153], ["synaptic", "ANATOMY", 169, 177], ["synaptic", "ANATOMY", 256, 264], ["astrocytes", "ANATOMY", 286, 296], ["synapses", "ANATOMY", 315, 323], ["Astrocytes", "CELL", 143, 153], ["astrocytes", "CELL", 286, 296], ["Astrocytes", "CELL_TYPE", 143, 153], ["astrocytes", "CELL_TYPE", 286, 296], ["a change in name", "PROBLEM", 33, 49], ["quad", "ANATOMY", 81, 85]]], ["It has been demonstrated that astrocytes secrete molecules such as thrombospondins that might be required for the formation, function and pruning of developing synapses (Ullian et al., 2001; Christopherson et al., 2005) .", [["astrocytes", "ANATOMY", 30, 40], ["synapses", "ANATOMY", 160, 168], ["astrocytes", "CELL", 30, 40], ["thrombospondins", "GENE_OR_GENE_PRODUCT", 67, 82], ["astrocytes", "CELL_TYPE", 30, 40], ["thrombospondins", "PROTEIN", 67, 82], ["astrocytes secrete molecules", "PROBLEM", 30, 58], ["thrombospondins", "PROBLEM", 67, 82], ["astrocytes", "OBSERVATION", 30, 40], ["secrete molecules", "OBSERVATION", 41, 58]]], ["Both presynaptic and postsynaptic activity in purified rat retinal ganglion cultures have been enhanced in the presence of astrocytes; and immunohistochemistry of rat brain cryosections from various developmental stages have shown that glial generation precedes the appearance of synapses (Ullian et al., 2001) .", [["presynaptic", "ANATOMY", 5, 16], ["retinal ganglion cultures", "ANATOMY", 59, 84], ["astrocytes", "ANATOMY", 123, 133], ["brain cryosections", "ANATOMY", 167, 185], ["glial", "ANATOMY", 236, 241], ["synapses", "ANATOMY", 280, 288], ["rat", "ORGANISM", 55, 58], ["retinal ganglion cultures", "CELL", 59, 84], ["astrocytes", "CELL", 123, 133], ["rat", "ORGANISM", 163, 166], ["brain cryosections", "MULTI-TISSUE_STRUCTURE", 167, 185], ["glial", "CELL", 236, 241], ["purified rat retinal ganglion cultures", "CELL_LINE", 46, 84], ["astrocytes", "CELL_TYPE", 123, 133], ["rat", "SPECIES", 55, 58], ["rat", "SPECIES", 163, 166], ["rat", "SPECIES", 163, 166], ["purified rat retinal ganglion cultures", "TEST", 46, 84], ["astrocytes", "PROBLEM", 123, 133], ["immunohistochemistry of rat brain cryosections", "TEST", 139, 185], ["various developmental stages", "PROBLEM", 191, 219], ["glial generation", "PROBLEM", 236, 252], ["postsynaptic activity", "OBSERVATION", 21, 42], ["ganglion", "ANATOMY", 67, 75], ["astrocytes", "ANATOMY", 123, 133], ["glial generation", "OBSERVATION", 236, 252]]], ["Astrocytes might also be functional in synaptic remodelling and pruning in healthy or diseased adult CNS (Barres, 2008) .", [["Astrocytes", "ANATOMY", 0, 10], ["synaptic", "ANATOMY", 39, 47], ["CNS", "ANATOMY", 101, 104], ["Astrocytes", "CELL", 0, 10], ["synaptic", "MULTI-TISSUE_STRUCTURE", 39, 47], ["CNS", "ANATOMICAL_SYSTEM", 101, 104], ["Astrocytes", "CELL_TYPE", 0, 10], ["Astrocytes", "PROBLEM", 0, 10], ["synaptic remodelling", "PROBLEM", 39, 59], ["might also be", "UNCERTAINTY", 11, 24], ["synaptic remodelling", "OBSERVATION", 39, 59], ["diseased", "OBSERVATION_MODIFIER", 86, 94]]], ["Because synaptic signal transmission can trigger astrocytes to secrete the cytokine LIF, which in turn increases the number of myelinated axons in dorsal root ganglion cultures co-cultured with oligodendrocytes (Ishibashi et al., 2006) , the support and maintenance of healthy signal transmission appears important for the regulation of myelination.Astrocytes play a role in synaptic signal transmission and can modulate synapsesFurthermore, astrocytes may contribute to synaptic transmission by supporting maintenance of the synaptic interstitial fluid by regulating ion, pH and transmitter homeostasis.", [["synaptic", "ANATOMY", 8, 16], ["astrocytes", "ANATOMY", 49, 59], ["myelinated axons", "ANATOMY", 127, 143], ["dorsal root ganglion cultures", "ANATOMY", 147, 176], ["oligodendrocytes", "ANATOMY", 194, 210], ["Astrocytes", "ANATOMY", 349, 359], ["synaptic", "ANATOMY", 375, 383], ["astrocytes", "ANATOMY", 442, 452], ["synaptic", "ANATOMY", 471, 479], ["synaptic interstitial fluid", "ANATOMY", 526, 553], ["astrocytes", "CELL", 49, 59], ["LIF", "GENE_OR_GENE_PRODUCT", 84, 87], ["myelinated axons", "CELLULAR_COMPONENT", 127, 143], ["dorsal root ganglion cultures", "CELL", 147, 176], ["oligodendrocytes", "CELL", 194, 210], ["Astrocytes", "CELL", 349, 359], ["astrocytes", "CELL", 442, 452], ["synaptic", "IMMATERIAL_ANATOMICAL_ENTITY", 526, 534], ["interstitial fluid", "IMMATERIAL_ANATOMICAL_ENTITY", 535, 553], ["astrocytes", "CELL_TYPE", 49, 59], ["cytokine", "PROTEIN", 75, 83], ["LIF", "PROTEIN", 84, 87], ["dorsal root ganglion cultures", "CELL_LINE", 147, 176], ["oligodendrocytes", "CELL_TYPE", 194, 210], ["Astrocytes", "CELL_TYPE", 349, 359], ["astrocytes", "CELL_TYPE", 442, 452], ["astrocytes", "PROBLEM", 49, 59], ["the cytokine LIF", "TREATMENT", 71, 87], ["dorsal root ganglion cultures", "TEST", 147, 176], ["the support", "TREATMENT", 238, 249], ["the synaptic interstitial fluid", "TREATMENT", 522, 553], ["myelinated axons", "ANATOMY", 127, 143], ["dorsal", "ANATOMY_MODIFIER", 147, 153], ["root ganglion", "ANATOMY", 154, 167], ["interstitial fluid", "OBSERVATION", 535, 553]]], ["Astrocyte processes contain transporters for potassium uptake and aquaporin 4 water channels (Nielsen et al., 1997; Rash et al., 1998; Amiry-Moghaddam et al., 2003; Solenov et al., 2004) , which maintain the transmitter homeostasis of the synaptic interstitial fluid (Steinh\u00e4user et al., 1994; Gundersen et al., 1996; Mennerick et al., 1996; Bergles and Jahr, 1997; Fujita et al., 1999) .", [["Astrocyte", "ANATOMY", 0, 9], ["synaptic interstitial fluid", "ANATOMY", 239, 266], ["potassium", "CHEMICAL", 45, 54], ["potassium", "CHEMICAL", 45, 54], ["Astrocyte", "CELL", 0, 9], ["potassium", "SIMPLE_CHEMICAL", 45, 54], ["aquaporin 4", "GENE_OR_GENE_PRODUCT", 66, 77], ["synaptic interstitial fluid", "TISSUE", 239, 266], ["potassium uptake", "TREATMENT", 45, 61], ["aquaporin 4 water channels", "TREATMENT", 66, 92], ["interstitial", "ANATOMY_MODIFIER", 248, 260], ["fluid", "OBSERVATION", 261, 266]]], ["Connexin channels and connexin proteins are important candidates which play a role in the regulation of neuronal activity and survival.", [["neuronal", "ANATOMY", 104, 112], ["Connexin", "GENE_OR_GENE_PRODUCT", 0, 8], ["connexin", "GENE_OR_GENE_PRODUCT", 22, 30], ["neuronal", "CELL", 104, 112], ["Connexin channels", "PROTEIN", 0, 17], ["connexin proteins", "PROTEIN", 22, 39], ["Connexin channels", "TREATMENT", 0, 17], ["connexin proteins", "TREATMENT", 22, 39]]], ["For example, astroglial connexins decrease neuronal excitability by removing extracellular potassium and glutamate; while also providing metabolic supply to neurons (Wallraff et al., 2006; Rouach et al., 2008; Froger et al. 2010; Pannasch et al., 2011) .", [["astroglial connexins", "ANATOMY", 13, 33], ["neuronal", "ANATOMY", 43, 51], ["extracellular", "ANATOMY", 77, 90], ["neurons", "ANATOMY", 157, 164], ["potassium", "CHEMICAL", 91, 100], ["glutamate", "CHEMICAL", 105, 114], ["potassium", "CHEMICAL", 91, 100], ["glutamate", "CHEMICAL", 105, 114], ["astroglial connexins", "GENE_OR_GENE_PRODUCT", 13, 33], ["neuronal", "CELL", 43, 51], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 90], ["potassium", "SIMPLE_CHEMICAL", 91, 100], ["glutamate", "SIMPLE_CHEMICAL", 105, 114], ["neurons", "CELL", 157, 164], ["astroglial connexins", "PROTEIN", 13, 33], ["astroglial connexins", "TREATMENT", 13, 33], ["extracellular potassium and glutamate", "TREATMENT", 77, 114]]], ["On the other hand, the elevation of connexin expression at lesion sites in CNS pathologies might also be associated with other, possibly protective, roles (Nagy et al., 1996; Koulakoff et al., 2008; Kuchibhotla et al., 2009; Mei et al., 2010; Karpuk et al., 2011) .", [["lesion sites", "ANATOMY", 59, 71], ["CNS", "ANATOMY", 75, 78], ["connexin", "GENE_OR_GENE_PRODUCT", 36, 44], ["lesion sites", "MULTI-TISSUE_STRUCTURE", 59, 71], ["CNS", "ANATOMICAL_SYSTEM", 75, 78], ["the elevation of connexin expression at lesion sites in CNS pathologies", "PROBLEM", 19, 90], ["elevation", "OBSERVATION_MODIFIER", 23, 32], ["CNS", "ANATOMY", 75, 78], ["pathologies", "OBSERVATION", 79, 90]]], ["Studies using connexin knockout animals allude to the importance of connexins in promoting communication between astrocytes and between astrocytes and oligodendrocytes on myelin integrity.", [["astrocytes", "ANATOMY", 113, 123], ["astrocytes", "ANATOMY", 136, 146], ["oligodendrocytes", "ANATOMY", 151, 167], ["myelin", "ANATOMY", 171, 177], ["connexin", "GENE_OR_GENE_PRODUCT", 14, 22], ["connexins", "GENE_OR_GENE_PRODUCT", 68, 77], ["astrocytes", "CELL", 113, 123], ["astrocytes", "CELL", 136, 146], ["oligodendrocytes", "CELL", 151, 167], ["myelin", "CELLULAR_COMPONENT", 171, 177], ["connexins", "PROTEIN", 68, 77], ["astrocytes", "CELL_TYPE", 113, 123], ["astrocytes", "CELL_TYPE", 136, 146], ["oligodendrocytes", "CELL_TYPE", 151, 167], ["Studies", "TEST", 0, 7], ["connexin knockout animals", "TREATMENT", 14, 39], ["connexins", "TREATMENT", 68, 77]]], ["Myelin damage has been observed in Cx47, Cx43/Cx30 and Cx30/Cx47 single/double knockout mice (Menichella et al., 2003; Odermatt et al., 2003; Lutz et al., 2009; Tress et al., 2012) .", [["Myelin", "ANATOMY", 0, 6], ["Myelin damage", "DISEASE", 0, 13], ["Myelin", "GENE_OR_GENE_PRODUCT", 0, 6], ["Cx47", "GENE_OR_GENE_PRODUCT", 35, 39], ["Cx43", "GENE_OR_GENE_PRODUCT", 41, 45], ["Cx30", "GENE_OR_GENE_PRODUCT", 46, 50], ["Cx30", "GENE_OR_GENE_PRODUCT", 55, 59], ["Cx47", "GENE_OR_GENE_PRODUCT", 60, 64], ["Cx47", "PROTEIN", 35, 39], ["Cx43", "PROTEIN", 41, 45], ["Cx30", "PROTEIN", 46, 50], ["Cx30", "PROTEIN", 55, 59], ["Cx47", "PROTEIN", 60, 64], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["Myelin damage", "PROBLEM", 0, 13], ["Cx30", "TEST", 55, 59]]], ["Interestingly, the level of oligodendrocyte gap junction connexins Cx47 and Cx32 were reduced both within and around lesions during early stages of inflammatory demyelination in EAE mice, (Traugott and Lebon, 1988; Tsukada et al., 1991; Villarroya et al., 1996; Meeuwsen et al., 2003) .", [["oligodendrocyte gap junction", "ANATOMY", 28, 56], ["lesions", "ANATOMY", 117, 124], ["demyelination", "DISEASE", 161, 174], ["EAE", "DISEASE", 178, 181], ["oligodendrocyte gap junction connexins Cx47", "GENE_OR_GENE_PRODUCT", 28, 71], ["Cx32", "GENE_OR_GENE_PRODUCT", 76, 80], ["lesions", "PATHOLOGICAL_FORMATION", 117, 124], ["mice", "ORGANISM", 182, 186], ["oligodendrocyte gap junction connexins", "PROTEIN", 28, 66], ["Cx47", "PROTEIN", 67, 71], ["Cx32", "PROTEIN", 76, 80], ["mice", "SPECIES", 182, 186], ["mice", "SPECIES", 182, 186], ["Cx32", "TEST", 76, 80], ["lesions", "PROBLEM", 117, 124], ["inflammatory demyelination", "PROBLEM", 148, 174], ["oligodendrocyte", "OBSERVATION", 28, 43], ["gap junction", "OBSERVATION", 44, 56], ["reduced", "OBSERVATION_MODIFIER", 86, 93], ["both", "OBSERVATION_MODIFIER", 94, 98], ["lesions", "OBSERVATION", 117, 124], ["early stages", "OBSERVATION_MODIFIER", 132, 144], ["inflammatory", "OBSERVATION_MODIFIER", 148, 160], ["demyelination", "OBSERVATION", 161, 174]]], ["These mice also presented decreased expression of Cx43, the major astrocytic partner of Cx47, when spinal cord sections were analysed immunohistochemically (Markoullis et al., 2012) .", [["spinal cord sections", "ANATOMY", 99, 119], ["mice", "ORGANISM", 6, 10], ["Cx43", "GENE_OR_GENE_PRODUCT", 50, 54], ["Cx47", "GENE_OR_GENE_PRODUCT", 88, 92], ["spinal cord sections", "MULTI-TISSUE_STRUCTURE", 99, 119], ["Cx43", "PROTEIN", 50, 54], ["Cx47", "PROTEIN", 88, 92], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["spinal cord sections", "TEST", 99, 119], ["decreased", "OBSERVATION_MODIFIER", 26, 35], ["spinal cord", "ANATOMY", 99, 110]]], ["Cx43 expression was increased at late EAE stages, where remyelination was observed, leading to the suggestion that astrocytic protein Cx43 might play an important role in recovery from neuroinflammation (Markoullis et al., 2012) .Astrocytic effects on oligodendrocyte precursor cell (OPC) survival, proliferation and maturationIn the 1980s advancements were made on the ability to grow purified cultures of glial cells, with Raff and colleagues in particular developing techniques to purify OPCs from the optic nerve, a tissue devoid of neuronal cell bodies (Raff et al., 1983) .", [["Astrocytic", "ANATOMY", 230, 240], ["oligodendrocyte precursor cell", "ANATOMY", 252, 282], ["OPC", "ANATOMY", 284, 287], ["cultures", "ANATOMY", 395, 403], ["glial cells", "ANATOMY", 407, 418], ["OPCs", "ANATOMY", 491, 495], ["optic nerve", "ANATOMY", 505, 516], ["tissue", "ANATOMY", 520, 526], ["neuronal cell bodies", "ANATOMY", 537, 557], ["EAE", "DISEASE", 38, 41], ["neuroinflammation", "DISEASE", 185, 202], ["Cx43", "GENE_OR_GENE_PRODUCT", 0, 4], ["Cx43", "GENE_OR_GENE_PRODUCT", 134, 138], ["oligodendrocyte precursor cell", "CELL", 252, 282], ["OPC", "CELL", 284, 287], ["glial cells", "CELL", 407, 418], ["OPCs", "CELL", 491, 495], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 505, 516], ["tissue", "TISSUE", 520, 526], ["neuronal cell bodies", "CELLULAR_COMPONENT", 537, 557], ["Cx43", "PROTEIN", 0, 4], ["astrocytic protein", "PROTEIN", 115, 133], ["Cx43", "PROTEIN", 134, 138], ["oligodendrocyte precursor cell", "CELL_TYPE", 252, 282], ["purified cultures", "CELL_LINE", 386, 403], ["glial cells", "CELL_TYPE", 407, 418], ["OPCs", "CELL_TYPE", 491, 495], ["Cx43 expression", "PROBLEM", 0, 15], ["remyelination", "PROBLEM", 56, 69], ["astrocytic protein Cx43", "PROBLEM", 115, 138], ["neuroinflammation", "PROBLEM", 185, 202], ["Astrocytic effects", "PROBLEM", 230, 248], ["oligodendrocyte precursor cell", "TREATMENT", 252, 282], ["proliferation", "PROBLEM", 299, 312], ["glial cells", "PROBLEM", 407, 418], ["Raff", "TREATMENT", 425, 429], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["late EAE", "OBSERVATION_MODIFIER", 33, 41], ["oligodendrocyte precursor cell", "OBSERVATION", 252, 282], ["glial cells", "OBSERVATION", 407, 418], ["optic nerve", "ANATOMY", 505, 516], ["neuronal cell bodies", "OBSERVATION", 537, 557]]], ["With the development of these culture techniques it was shown that astrocytes play important roles in OPC differentiation (Noble and Murray, 1984; Noble et al., 1988; Raff et al., 1988; Noble et al., 1989) and in the rate of oligodendrocyte axonal ensheathment (Watkins et al., 2008) .", [["astrocytes", "ANATOMY", 67, 77], ["OPC", "ANATOMY", 102, 105], ["oligodendrocyte axonal", "ANATOMY", 225, 247], ["astrocytes", "CELL", 67, 77], ["OPC", "CELL", 102, 105], ["oligodendrocyte", "CELL", 225, 240], ["astrocytes", "CELL_TYPE", 67, 77], ["these culture techniques", "TEST", 24, 48]]], ["Further in vitro studies, where conditioned medium collected from primary astrocyte monolayers was incubated with other neural cells, showed enhanced neuronal survival, proliferation of OPCs, and protection of oligodendrocytes from stress (Noble and Murray, 1984; Yoshida et al., 1995; Yamamuro et al., 2003; Zhu et al., 2006; Arai and Lo, 2010) .", [["astrocyte monolayers", "ANATOMY", 74, 94], ["neural cells", "ANATOMY", 120, 132], ["neuronal", "ANATOMY", 150, 158], ["OPCs", "ANATOMY", 186, 190], ["oligodendrocytes", "ANATOMY", 210, 226], ["astrocyte monolayers", "CELL", 74, 94], ["neural cells", "CELL", 120, 132], ["neuronal", "CELL", 150, 158], ["OPCs", "CELL", 186, 190], ["oligodendrocytes", "CELL", 210, 226], ["primary astrocyte monolayers", "CELL_LINE", 66, 94], ["neural cells", "CELL_TYPE", 120, 132], ["OPCs", "CELL_TYPE", 186, 190], ["oligodendrocytes", "CELL_TYPE", 210, 226], ["Further in vitro studies", "TEST", 0, 24], ["primary astrocyte monolayers", "TEST", 66, 94], ["other neural cells", "PROBLEM", 114, 132], ["enhanced neuronal survival", "PROBLEM", 141, 167], ["proliferation of OPCs", "PROBLEM", 169, 190], ["neural cells", "ANATOMY", 120, 132], ["neuronal survival", "OBSERVATION", 150, 167], ["Lo", "ANATOMY", 336, 338]]], ["It is likely that astrocytes support OPC survival and proliferation by providing soluble factors such as platelet derived growth factor (PDGF) and FGF-2 (B\u00f6gler et al., 1990; Ferrara et al., 1988; Pringle et al., 1989) .Astrocytic effects on oligodendrocyte precursor cell (OPC) survival, proliferation and maturationAstrocytes are important providers of secreted growth factors, for both neuronal and glial proliferation and survival.", [["astrocytes", "ANATOMY", 18, 28], ["OPC", "ANATOMY", 37, 40], ["Astrocytic", "ANATOMY", 220, 230], ["oligodendrocyte precursor cell", "ANATOMY", 242, 272], ["OPC", "ANATOMY", 274, 277], ["Astrocytes", "ANATOMY", 317, 327], ["neuronal", "ANATOMY", 389, 397], ["glial", "ANATOMY", 402, 407], ["astrocytes", "CELL", 18, 28], ["OPC", "CELL", 37, 40], ["platelet derived growth factor", "GENE_OR_GENE_PRODUCT", 105, 135], ["PDGF", "GENE_OR_GENE_PRODUCT", 137, 141], ["FGF-2", "GENE_OR_GENE_PRODUCT", 147, 152], ["oligodendrocyte precursor cell", "CELL", 242, 272], ["OPC", "CELL", 274, 277], ["Astrocytes", "CELL", 317, 327], ["neuronal", "CELL", 389, 397], ["glial", "CELL", 402, 407], ["astrocytes", "CELL_TYPE", 18, 28], ["soluble factors", "PROTEIN", 81, 96], ["platelet derived growth factor", "PROTEIN", 105, 135], ["PDGF", "PROTEIN", 137, 141], ["FGF", "PROTEIN", 147, 150], ["oligodendrocyte precursor cell", "CELL_TYPE", 242, 272], ["Astrocytes", "CELL_TYPE", 317, 327], ["secreted growth factors", "PROTEIN", 355, 378], ["platelet derived growth factor", "TEST", 105, 135], ["PDGF", "TEST", 137, 141], ["FGF", "TEST", 147, 150], ["Astrocytic effects", "PROBLEM", 220, 238], ["oligodendrocyte precursor cell", "TREATMENT", 242, 272], ["proliferation", "PROBLEM", 289, 302], ["secreted growth factors", "PROBLEM", 355, 378], ["is likely", "UNCERTAINTY", 3, 12], ["oligodendrocyte precursor cell", "OBSERVATION", 242, 272], ["glial proliferation", "OBSERVATION", 402, 421]]], ["For example, CNTF, although shown to be important in the activation of astrocytes, is constitutively expressed by white matter astrocytes, and is a key player in OPC survival and maturation in vitro and in vivo as discussed earlier (St\u00f6ckli et al., 1991; Dallner et al., 2002; Stankoff et al., 2002; Cao et al., 2010) .", [["astrocytes", "ANATOMY", 71, 81], ["white matter astrocytes", "ANATOMY", 114, 137], ["OPC", "ANATOMY", 162, 165], ["CNTF", "GENE_OR_GENE_PRODUCT", 13, 17], ["astrocytes", "CELL", 71, 81], ["astrocytes", "CELL", 127, 137], ["OPC", "CELL", 162, 165], ["CNTF", "PROTEIN", 13, 17], ["astrocytes", "CELL_TYPE", 71, 81], ["white matter astrocytes", "CELL_TYPE", 114, 137], ["CNTF", "TEST", 13, 17], ["white matter astrocytes", "PROBLEM", 114, 137]]], ["CNTF has also been reported to enhance the migration of subventricular zone-derived progenitors (Vernerey et al., 2013) , protect oligodendrocytes from apoptosis, and decrease myelin destruction in demyelinating pathological conditions (Linker et al., 2002) .", [["subventricular zone-derived progenitors", "ANATOMY", 56, 95], ["oligodendrocytes", "ANATOMY", 130, 146], ["myelin", "ANATOMY", 176, 182], ["CNTF", "CHEMICAL", 0, 4], ["myelin destruction", "DISEASE", 176, 194], ["CNTF", "GENE_OR_GENE_PRODUCT", 0, 4], ["subventricular zone-derived progenitors", "CELL", 56, 95], ["oligodendrocytes", "CELL", 130, 146], ["myelin", "GENE_OR_GENE_PRODUCT", 176, 182], ["CNTF", "PROTEIN", 0, 4], ["subventricular zone-derived progenitors", "CELL_TYPE", 56, 95], ["oligodendrocytes", "CELL_TYPE", 130, 146], ["oligodendrocytes", "PROBLEM", 130, 146], ["apoptosis", "PROBLEM", 152, 161], ["decrease myelin destruction in demyelinating pathological conditions", "PROBLEM", 167, 235], ["migration", "OBSERVATION_MODIFIER", 43, 52], ["subventricular zone", "OBSERVATION", 56, 75], ["apoptosis", "OBSERVATION_MODIFIER", 152, 161], ["decrease", "OBSERVATION_MODIFIER", 167, 175], ["myelin", "OBSERVATION_MODIFIER", 176, 182], ["destruction", "OBSERVATION_MODIFIER", 183, 194], ["demyelinating", "OBSERVATION_MODIFIER", 198, 211]]], ["In studies when CNTF was injected subcutaneously at the remyelination phase of cuprizoneinduced demyelination, an increase was seen in myelin oligodendrocyte glycoprotein (MOG) expression in the cerebral cortex (Salehi et al., 2013) .", [["subcutaneously", "ANATOMY", 34, 48], ["cerebral cortex", "ANATOMY", 195, 210], ["demyelination", "DISEASE", 96, 109], ["CNTF", "GENE_OR_GENE_PRODUCT", 16, 20], ["myelin oligodendrocyte glycoprotein", "GENE_OR_GENE_PRODUCT", 135, 170], ["MOG", "GENE_OR_GENE_PRODUCT", 172, 175], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 195, 210], ["CNTF", "PROTEIN", 16, 20], ["myelin oligodendrocyte glycoprotein", "PROTEIN", 135, 170], ["MOG", "PROTEIN", 172, 175], ["CNTF", "TREATMENT", 16, 20], ["cuprizoneinduced demyelination", "PROBLEM", 79, 109], ["an increase", "PROBLEM", 111, 122], ["myelin oligodendrocyte glycoprotein", "TREATMENT", 135, 170], ["demyelination", "OBSERVATION", 96, 109], ["increase", "OBSERVATION_MODIFIER", 114, 122], ["myelin oligodendrocyte", "OBSERVATION", 135, 157], ["cerebral cortex", "ANATOMY", 195, 210]]], ["Moreover, intraperitoneal injections of CNTF and intravenously transplanted mesenchymal stem cells that overexpress CNTF resulted in a reduced loss of neurons and disease severity, and increased neuronal functional recovery in EAE mice (Kuhlmann et al., 2006; Lu et al., 2009) .", [["intraperitoneal", "ANATOMY", 10, 25], ["mesenchymal stem cells", "ANATOMY", 76, 98], ["neurons", "ANATOMY", 151, 158], ["neuronal", "ANATOMY", 195, 203], ["loss of neurons", "DISEASE", 143, 158], ["EAE", "DISEASE", 227, 230], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 25], ["CNTF", "GENE_OR_GENE_PRODUCT", 40, 44], ["mesenchymal stem cells", "CELL", 76, 98], ["CNTF", "GENE_OR_GENE_PRODUCT", 116, 120], ["neurons", "CELL", 151, 158], ["neuronal", "CELL", 195, 203], ["mice", "ORGANISM", 231, 235], ["CNTF", "PROTEIN", 40, 44], ["intravenously transplanted mesenchymal stem cells", "CELL_LINE", 49, 98], ["CNTF", "PROTEIN", 116, 120], ["mice", "SPECIES", 231, 235], ["mice", "SPECIES", 231, 235], ["intraperitoneal injections of CNTF", "TREATMENT", 10, 44], ["intravenously transplanted mesenchymal stem cells", "TREATMENT", 49, 98], ["overexpress CNTF", "PROBLEM", 104, 120], ["a reduced loss of neurons", "PROBLEM", 133, 158], ["disease severity", "PROBLEM", 163, 179], ["intraperitoneal", "ANATOMY", 10, 25], ["mesenchymal stem cells", "OBSERVATION", 76, 98], ["reduced", "OBSERVATION_MODIFIER", 135, 142], ["neurons", "ANATOMY", 151, 158], ["increased", "OBSERVATION_MODIFIER", 185, 194], ["neuronal functional recovery", "OBSERVATION", 195, 223]]], ["However, in these experiments it is difficult to see if the effect is on the activation status of the astrocytes as discussed above, or the direct effect on the OPC.Astrocytic effects on oligodendrocyte precursor cell (OPC) survival, proliferation and maturationAstrocytes have also been shown to exhibit a crucial role in OPC remyelination via their iron exporter ferroportin (Fpn) in mice, where focal demyelination was induced by the injection of lysophosphatidylcholine (LPC) into their spinal cords (Schulz et al., 2012) .", [["astrocytes", "ANATOMY", 102, 112], ["Astrocytic", "ANATOMY", 165, 175], ["oligodendrocyte precursor cell", "ANATOMY", 187, 217], ["OPC", "ANATOMY", 219, 222], ["Astrocytes", "ANATOMY", 262, 272], ["OPC", "ANATOMY", 323, 326], ["spinal cords", "ANATOMY", 491, 503], ["focal demyelination", "DISEASE", 398, 417], ["lysophosphatidylcholine", "CHEMICAL", 450, 473], ["LPC", "CHEMICAL", 475, 478], ["iron", "CHEMICAL", 351, 355], ["lysophosphatidylcholine", "CHEMICAL", 450, 473], ["LPC", "CHEMICAL", 475, 478], ["astrocytes", "CELL", 102, 112], ["oligodendrocyte precursor cell", "CELL", 187, 217], ["OPC", "CELL", 219, 222], ["Astrocytes", "CELL", 262, 272], ["OPC", "CELL", 323, 326], ["iron", "SIMPLE_CHEMICAL", 351, 355], ["ferroportin", "GENE_OR_GENE_PRODUCT", 365, 376], ["Fpn", "GENE_OR_GENE_PRODUCT", 378, 381], ["mice", "ORGANISM", 386, 390], ["lysophosphatidylcholine", "SIMPLE_CHEMICAL", 450, 473], ["LPC", "SIMPLE_CHEMICAL", 475, 478], ["spinal cords", "TISSUE", 491, 503], ["astrocytes", "CELL_TYPE", 102, 112], ["iron exporter ferroportin", "PROTEIN", 351, 376], ["Fpn", "PROTEIN", 378, 381], ["mice", "SPECIES", 386, 390], ["mice", "SPECIES", 386, 390], ["the OPC", "TREATMENT", 157, 164], ["Astrocytic effects", "PROBLEM", 165, 183], ["oligodendrocyte precursor cell", "TREATMENT", 187, 217], ["proliferation", "PROBLEM", 234, 247], ["maturationAstrocytes", "PROBLEM", 252, 272], ["OPC remyelination", "TREATMENT", 323, 340], ["focal demyelination", "PROBLEM", 398, 417], ["lysophosphatidylcholine (LPC", "TREATMENT", 450, 478], ["oligodendrocyte precursor cell", "OBSERVATION", 187, 217], ["focal", "OBSERVATION_MODIFIER", 398, 403], ["demyelination", "OBSERVATION", 404, 417], ["spinal cords", "ANATOMY", 491, 503]]], ["In these astrocyte-specific Fpn KO mice, fewer remyelinating axons and a reduction in OPC proliferation were observed following LPC-induced demyelination compared to control animals.", [["remyelinating axons", "ANATOMY", 47, 66], ["OPC", "ANATOMY", 86, 89], ["LPC", "CHEMICAL", 128, 131], ["demyelination", "DISEASE", 140, 153], ["LPC", "CHEMICAL", 128, 131], ["Fpn", "GENE_OR_GENE_PRODUCT", 28, 31], ["KO mice", "ORGANISM", 32, 39], ["axons", "MULTI-TISSUE_STRUCTURE", 61, 66], ["OPC", "CELL", 86, 89], ["LPC", "SIMPLE_CHEMICAL", 128, 131], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["fewer remyelinating axons", "PROBLEM", 41, 66], ["a reduction in OPC proliferation", "PROBLEM", 71, 103], ["LPC", "TEST", 128, 131], ["induced demyelination", "PROBLEM", 132, 153], ["reduction", "OBSERVATION_MODIFIER", 73, 82], ["OPC proliferation", "OBSERVATION", 86, 103], ["demyelination", "OBSERVATION", 140, 153]]], ["This could either be due to direct effects on OPCs through limited iron supply or indirect effects via iron-deficient microglia, which expressed significantly lower levels of TNF-\u03b1 and IL-1\u03b2 when stimulated by LPS compared to control microglia (Schulz et al., 2012) .", [["OPCs", "ANATOMY", 46, 50], ["microglia", "ANATOMY", 118, 127], ["microglia", "ANATOMY", 234, 243], ["iron", "CHEMICAL", 67, 71], ["LPS", "CHEMICAL", 210, 213], ["iron", "CHEMICAL", 67, 71], ["OPCs", "CELL", 46, 50], ["iron", "SIMPLE_CHEMICAL", 67, 71], ["microglia", "CELL", 118, 127], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 175, 180], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 185, 190], ["LPS", "SIMPLE_CHEMICAL", 210, 213], ["microglia", "CELL", 234, 243], ["OPCs", "CELL_TYPE", 46, 50], ["iron-deficient microglia", "CELL_TYPE", 103, 127], ["TNF", "PROTEIN", 175, 178], ["IL-1\u03b2", "PROTEIN", 185, 190], ["microglia", "CELL_TYPE", 234, 243], ["direct effects on OPCs", "PROBLEM", 28, 50], ["limited iron supply", "TREATMENT", 59, 78], ["iron-deficient microglia", "PROBLEM", 103, 127], ["TNF", "TEST", 175, 178], ["IL", "TEST", 185, 187], ["iron-deficient microglia", "OBSERVATION", 103, 127]]], ["Because the expression of FGF-2 and insulin-like growth factor-1 (IGF-1) was significantly upregulated by IL-1\u03b2 and TNF-\u03b1, respectively, and the expression of transforming growth factor beta (TGF-\u03b2) was stimulated by IL-1\u03b2 in purified astrocyte cultures, it has been suggested that iron-deprivation in the milieu would lower the expression of IL-1\u03b2 and TNF-\u03b1 in microglia and thus lead to reduced growth factor expression in astrocytes, which would in turn render OPC proliferation and possibly differentiation (Schulz et al., 2012) .Future directions in astrocyte researchAs discussed throughout this review astrocytes can play important roles not just in myelination during development, but also in remyelination in adult tissue after CNS injury.", [["astrocyte cultures", "ANATOMY", 235, 253], ["microglia", "ANATOMY", 362, 371], ["astrocytes", "ANATOMY", 425, 435], ["OPC", "ANATOMY", 464, 467], ["astrocyte", "ANATOMY", 555, 564], ["astrocytes", "ANATOMY", 609, 619], ["adult tissue", "ANATOMY", 718, 730], ["CNS", "ANATOMY", 737, 740], ["FGF-2", "GENE_OR_GENE_PRODUCT", 26, 31], ["insulin-like growth factor-1", "GENE_OR_GENE_PRODUCT", 36, 64], ["IGF-1", "GENE_OR_GENE_PRODUCT", 66, 71], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 106, 111], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 116, 121], ["transforming growth factor beta", "GENE_OR_GENE_PRODUCT", 159, 190], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 192, 197], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 217, 222], ["astrocyte cultures", "CELL", 235, 253], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 343, 348], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 353, 358], ["microglia", "CELL", 362, 371], ["astrocytes", "CELL", 425, 435], ["OPC", "CELL", 464, 467], ["astrocyte", "CELL", 555, 564], ["astrocytes", "CELL", 609, 619], ["adult tissue", "TISSUE", 718, 730], ["CNS", "ANATOMICAL_SYSTEM", 737, 740], ["FGF-2", "PROTEIN", 26, 31], ["insulin-like growth factor-1", "PROTEIN", 36, 64], ["IGF", "PROTEIN", 66, 69], ["IL-1\u03b2", "PROTEIN", 106, 111], ["TNF", "PROTEIN", 116, 119], ["transforming growth factor beta", "PROTEIN", 159, 190], ["TGF-\u03b2", "PROTEIN", 192, 197], ["IL-1\u03b2", "PROTEIN", 217, 222], ["purified astrocyte cultures", "CELL_LINE", 226, 253], ["IL-1\u03b2", "PROTEIN", 343, 348], ["TNF-\u03b1", "PROTEIN", 353, 358], ["microglia", "CELL_TYPE", 362, 371], ["growth factor", "PROTEIN", 397, 410], ["astrocytes", "CELL_TYPE", 425, 435], ["astrocytes", "CELL_TYPE", 609, 619], ["FGF", "TEST", 26, 29], ["insulin", "TEST", 36, 43], ["growth factor", "TEST", 49, 62], ["IGF", "TEST", 66, 69], ["IL", "TEST", 106, 108], ["TNF", "TEST", 116, 119], ["transforming growth factor", "PROBLEM", 159, 185], ["TGF", "TEST", 192, 195], ["IL", "TEST", 217, 219], ["purified astrocyte cultures", "TEST", 226, 253], ["iron-deprivation in the milieu", "PROBLEM", 282, 312], ["IL", "TEST", 343, 345], ["TNF", "TEST", 353, 356], ["microglia", "PROBLEM", 362, 371], ["reduced growth factor expression in astrocytes", "PROBLEM", 389, 435], ["OPC proliferation", "PROBLEM", 464, 481], ["CNS injury", "PROBLEM", 737, 747], ["microglia", "ANATOMY", 362, 371], ["OPC proliferation", "OBSERVATION", 464, 481], ["possibly", "UNCERTAINTY", 486, 494], ["adult tissue", "OBSERVATION_MODIFIER", 718, 730], ["CNS", "ANATOMY", 737, 740], ["injury", "OBSERVATION", 741, 747]]], ["Their reparative roles might be related to their level of reactivity, so it is important to identify markers that can define these different astrocyte phenotypes although at present these are not easy to define.", [["astrocyte", "ANATOMY", 141, 150], ["astrocyte", "CELL", 141, 150], ["these different astrocyte phenotypes", "PROBLEM", 125, 161], ["might be related to", "UNCERTAINTY", 23, 42], ["astrocyte phenotypes", "OBSERVATION", 141, 161]]], ["One approach is to use microarrays.", [["microarrays", "TREATMENT", 23, 34]]], ["As described, Nash et al. (2011b) identified CXCL10 as inhibitory to myelination, but others using a lower-scale cDNA array that contained probes for cytokines, chemokines, growth factors and their receptors have identified other pro-inflammatory cytokines including TNF-\u03b1, IL-1\u03b2, or IFN-\u03b3 (Meeuwsen et al., 2003) .", [["CXCL10", "GENE_OR_GENE_PRODUCT", 45, 51], ["growth factors", "GENE_OR_GENE_PRODUCT", 173, 187], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 267, 272], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 274, 279], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 284, 289], ["CXCL10", "PROTEIN", 45, 51], ["cDNA array", "DNA", 113, 123], ["cytokines", "PROTEIN", 150, 159], ["chemokines", "PROTEIN", 161, 171], ["growth factors", "PROTEIN", 173, 187], ["pro-inflammatory cytokines", "PROTEIN", 230, 256], ["TNF", "PROTEIN", 267, 270], ["IL-1\u03b2", "PROTEIN", 274, 279], ["IFN", "PROTEIN", 284, 287], ["CXCL10", "TEST", 45, 51], ["a lower-scale cDNA array", "TREATMENT", 99, 123], ["cytokines", "PROBLEM", 150, 159], ["pro-inflammatory cytokines", "TEST", 230, 256], ["TNF", "TEST", 267, 270], ["IL", "TEST", 274, 276]]], ["Another large array was carried out on GFP-astrocytes purified at various time points after the onset of two models of disease, namely ischemic stroke (middle cerebral artery occlusion) and neuroinflammation induced by LPS injection (Zamanian et al., 2012) .", [["GFP-astrocytes", "ANATOMY", 39, 53], ["middle cerebral artery", "ANATOMY", 152, 174], ["ischemic stroke", "DISEASE", 135, 150], ["middle cerebral artery occlusion", "DISEASE", 152, 184], ["neuroinflammation", "DISEASE", 190, 207], ["LPS", "CHEMICAL", 219, 222], ["GFP", "GENE_OR_GENE_PRODUCT", 39, 42], ["astrocytes", "CELL", 43, 53], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 159, 174], ["LPS", "SIMPLE_CHEMICAL", 219, 222], ["GFP", "PROTEIN", 39, 42], ["astrocytes", "CELL_TYPE", 43, 53], ["Another large array", "PROBLEM", 0, 19], ["GFP", "TEST", 39, 42], ["disease", "PROBLEM", 119, 126], ["namely ischemic stroke", "PROBLEM", 128, 150], ["middle cerebral artery occlusion", "PROBLEM", 152, 184], ["neuroinflammation", "PROBLEM", 190, 207], ["LPS injection", "TREATMENT", 219, 232], ["large", "OBSERVATION_MODIFIER", 8, 13], ["disease", "OBSERVATION", 119, 126], ["ischemic", "OBSERVATION_MODIFIER", 135, 143], ["stroke", "OBSERVATION", 144, 150], ["middle cerebral artery", "ANATOMY", 152, 174], ["occlusion", "OBSERVATION", 175, 184]]], ["The resulting data suggested that astrocytes could present different mRNA expression profiles depending on the insult despite the presence of reactive gliosis in both types of CNS damage.", [["astrocytes", "ANATOMY", 34, 44], ["CNS", "ANATOMY", 176, 179], ["gliosis", "DISEASE", 151, 158], ["CNS damage", "DISEASE", 176, 186], ["astrocytes", "CELL", 34, 44], ["CNS", "ANATOMICAL_SYSTEM", 176, 179], ["astrocytes", "CELL_TYPE", 34, 44], ["The resulting data", "TEST", 0, 18], ["astrocytes", "PROBLEM", 34, 44], ["different mRNA expression profiles", "PROBLEM", 59, 93], ["the insult", "PROBLEM", 107, 117], ["reactive gliosis", "PROBLEM", 142, 158], ["CNS damage", "PROBLEM", 176, 186], ["reactive", "OBSERVATION_MODIFIER", 142, 150], ["gliosis", "OBSERVATION", 151, 158], ["both types", "OBSERVATION_MODIFIER", 162, 172], ["CNS", "ANATOMY", 176, 179], ["damage", "OBSERVATION", 180, 186]]], ["However, although there was upregulation of a core set of genes (lipocalin 2 and serpina3n), it was clear that changes in the astrocyte after injury are highly heterogeneous, and that changes in astrocyte activity may depend on the injury type.", [["astrocyte", "ANATOMY", 126, 135], ["astrocyte", "ANATOMY", 195, 204], ["lipocalin 2", "GENE_OR_GENE_PRODUCT", 65, 76], ["serpina3n", "GENE_OR_GENE_PRODUCT", 81, 90], ["astrocyte", "CELL", 126, 135], ["astrocyte", "CELL", 195, 204], ["lipocalin 2", "PROTEIN", 65, 76], ["serpina3n", "DNA", 81, 90], ["lipocalin", "TEST", 65, 74], ["injury", "PROBLEM", 142, 148], ["changes in astrocyte activity", "PROBLEM", 184, 213], ["the injury type", "PROBLEM", 228, 243], ["clear", "OBSERVATION", 100, 105], ["astrocyte", "ANATOMY", 126, 135], ["highly", "OBSERVATION_MODIFIER", 153, 159], ["heterogeneous", "OBSERVATION_MODIFIER", 160, 173], ["astrocyte activity", "OBSERVATION", 195, 213], ["injury", "OBSERVATION", 232, 238]]], ["Hopefully, more specific markers of \"good\" or \"bad\" astrocytes for CNS repair will be identified and allow more specific identification of how these astrocytes influence repair.Summary and conclusionsThere is abundant evidence to suggest that astrocytes contribute to re/myelination mainly by: 1) Providing the right conditions for neurons to myelinate by i) supplying neurons with energy and cholesterol, ii) removing excitotoxic molecules from the extracellular environment, and iii) regulating the fluid, ion, pH, and neuro/gliotransmitter homeostasis.Summary and conclusions2) Playing a role in the survival, proliferation, maturation and function of oligodendrocytes and the migration of OPCs into the lesioned areas in the CNS.Summary and conclusions3) Influencing microglia.", [["astrocytes", "ANATOMY", 52, 62], ["CNS", "ANATOMY", 67, 70], ["astrocytes", "ANATOMY", 149, 159], ["astrocytes", "ANATOMY", 243, 253], ["neurons", "ANATOMY", 332, 339], ["neurons", "ANATOMY", 369, 376], ["extracellular", "ANATOMY", 450, 463], ["fluid", "ANATOMY", 501, 506], ["oligodendrocytes", "ANATOMY", 655, 671], ["OPCs", "ANATOMY", 693, 697], ["CNS", "ANATOMY", 729, 732], ["microglia", "ANATOMY", 771, 780], ["cholesterol", "CHEMICAL", 393, 404], ["cholesterol", "CHEMICAL", 393, 404], ["astrocytes", "CELL", 52, 62], ["CNS", "ANATOMICAL_SYSTEM", 67, 70], ["astrocytes", "CELL", 149, 159], ["astrocytes", "CELL", 243, 253], ["neurons", "CELL", 332, 339], ["neurons", "CELL", 369, 376], ["cholesterol", "SIMPLE_CHEMICAL", 393, 404], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 450, 463], ["gliotransmitter", "SIMPLE_CHEMICAL", 527, 542], ["oligodendrocytes", "CELL", 655, 671], ["OPCs", "CELL", 693, 697], ["CNS", "ANATOMICAL_SYSTEM", 729, 732], ["microglia", "CELL", 771, 780], ["astrocytes", "CELL_TYPE", 52, 62], ["astrocytes", "CELL_TYPE", 149, 159], ["astrocytes", "CELL_TYPE", 243, 253], ["oligodendrocytes", "CELL_TYPE", 655, 671], ["OPCs", "CELL_TYPE", 693, 697], ["microglia", "CELL_TYPE", 771, 780], ["\"bad\" astrocytes", "PROBLEM", 46, 62], ["CNS repair", "TREATMENT", 67, 77], ["these astrocytes influence repair", "TREATMENT", 143, 176], ["astrocytes", "PROBLEM", 243, 253], ["excitotoxic molecules", "TREATMENT", 419, 440], ["neuro/gliotransmitter homeostasis", "TREATMENT", 521, 554], ["oligodendrocytes", "PROBLEM", 655, 671], ["Influencing microglia", "PROBLEM", 759, 780], ["abundant evidence to suggest", "UNCERTAINTY", 209, 237], ["fluid", "OBSERVATION", 501, 506], ["CNS", "ANATOMY", 729, 732], ["microglia", "OBSERVATION", 771, 780]]], ["The manner by which astrocytes affect myelination can often be seen to correlate with its level of reactivity.", [["astrocytes", "ANATOMY", 20, 30], ["astrocytes", "CELL", 20, 30], ["astrocytes", "CELL_TYPE", 20, 30]]], ["Astrocyte reactivity can be induced by the milieu of cytokines present after injury, which can be beneficial or inhibitory in re/myelination depending on the context and severity of the injury.", [["Astrocyte", "ANATOMY", 0, 9], ["Astrocyte", "CELL", 0, 9], ["cytokines", "PROTEIN", 53, 62], ["Astrocyte reactivity", "PROBLEM", 0, 20], ["injury", "PROBLEM", 77, 83], ["the injury", "PROBLEM", 182, 192], ["injury", "OBSERVATION", 186, 192]]], ["Due to the lack of gliosis-specific markers, there are currently no clear guidelines which allow different astrocytic reactivity phenotypes to be classified.", [["gliosis", "DISEASE", 19, 26], ["gliosis", "PROBLEM", 19, 26], ["different astrocytic reactivity phenotypes", "PROBLEM", 97, 139], ["gliosis", "OBSERVATION", 19, 26]]], ["However, if markers can be identified that classify the continuum of astrocyte phenotypes, it may aid in the design of new treatments targeting phenotypes that are more suited to regeneration and remyelination, and therefore benefit in the treatment of demyelinating diseases.", [["astrocyte", "ANATOMY", 69, 78], ["remyelination", "DISEASE", 196, 209], ["demyelinating diseases", "DISEASE", 253, 275], ["astrocyte", "CELL", 69, 78], ["astrocyte phenotypes", "PROBLEM", 69, 89], ["new treatments targeting phenotypes", "PROBLEM", 119, 154], ["remyelination", "PROBLEM", 196, 209], ["demyelinating diseases", "PROBLEM", 253, 275], ["astrocyte phenotypes", "OBSERVATION", 69, 89], ["demyelinating diseases", "OBSERVATION", 253, 275]]]], "4867e0d05f067189d610ca8e764d52dcc50a7b49": [["IntroductionHuman respiratory syncytial virus (RSV) is the leading viral cause of severe lower respiratory tract infections in infants and young children worldwide [1] .", [["lower respiratory tract", "ANATOMY", 89, 112], ["respiratory syncytial virus (RSV)", "DISEASE", 18, 51], ["lower respiratory tract infections", "DISEASE", 89, 123], ["IntroductionHuman respiratory syncytial virus", "ORGANISM", 0, 45], ["RSV", "ORGANISM", 47, 50], ["lower", "ORGANISM_SUBDIVISION", 89, 94], ["respiratory tract", "ORGANISM_SUBDIVISION", 95, 112], ["infants", "ORGANISM", 127, 134], ["children", "ORGANISM", 145, 153], ["respiratory syncytial virus (RSV", "SPECIES", 18, 50], ["infants", "SPECIES", 127, 134], ["children", "SPECIES", 145, 153], ["respiratory syncytial virus", "SPECIES", 18, 45], ["RSV", "SPECIES", 47, 50], ["IntroductionHuman respiratory syncytial virus", "PROBLEM", 0, 45], ["severe lower respiratory tract infections", "PROBLEM", 82, 123], ["syncytial virus", "OBSERVATION", 30, 45], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["lower", "ANATOMY_MODIFIER", 89, 94], ["respiratory tract", "ANATOMY", 95, 112], ["infections", "OBSERVATION", 113, 123]]], ["RSV-associated acute lower respiratory infection of children younger than 5 years of age causes~118,000 deaths worldwide annually [2] .", [["respiratory", "ANATOMY", 27, 38], ["RSV", "DISEASE", 0, 3], ["lower respiratory infection", "DISEASE", 21, 48], ["deaths", "DISEASE", 104, 110], ["RSV", "ORGANISM", 0, 3], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["acute lower respiratory infection", "PROBLEM", 15, 48], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["lower", "ANATOMY_MODIFIER", 21, 26], ["respiratory", "ANATOMY", 27, 38], ["infection", "OBSERVATION", 39, 48]]], ["So far, no licensed RSV vaccine or effective antiviral drug is available, although a number of vaccine and drug candidates are under development.", [["RSV", "ORGANISM", 20, 23], ["RSV", "SPECIES", 20, 23], ["licensed RSV vaccine", "TREATMENT", 11, 31], ["effective antiviral drug", "TREATMENT", 35, 59], ["vaccine", "TREATMENT", 95, 102], ["drug candidates", "TREATMENT", 107, 122], ["no", "UNCERTAINTY", 8, 10], ["RSV", "OBSERVATION", 20, 23]]], ["Understanding the fundamental mechanisms of virus-host interactions and identifying factors critical for RSV infection might lead to the development of new antiviral drugs.IntroductionRSV has a single stranded, non-segmented, negative sense RNA genome and belongs to the genus Orthopneumovirus of the family Pneumoviridae within the order Mononegavirales [3] .", [["RSV infection", "DISEASE", 105, 118], ["IntroductionRSV", "CHEMICAL", 172, 187], ["RSV", "ORGANISM", 105, 108], ["Orthopneumovirus", "GENE_OR_GENE_PRODUCT", 277, 293], ["IntroductionRSV", "DNA", 172, 187], ["non-segmented, negative sense RNA genome", "DNA", 211, 251], ["RSV", "SPECIES", 105, 108], ["virus", "PROBLEM", 44, 49], ["RSV infection", "PROBLEM", 105, 118], ["new antiviral drugs", "TREATMENT", 152, 171], ["new", "OBSERVATION_MODIFIER", 152, 155], ["antiviral drugs", "OBSERVATION", 156, 171]]], ["The genome is approximately 15.2 kb long and contains 10 genes that encode 11 proteins, namely (in 3' to 5' genomic order) the nonstructural proteins NS1 and NS2; nucleocapsid (N); phosphoprotein (P); matrix protein (M); small hydrophobic (SH), attachment (G), and fusion (F) glycoproteins; M2-1 and M2-2 proteins that are encoded by the two overlapping open reading frames in the M2 gene; and large polymerase protein (L) [4] .", [["NS1", "GENE_OR_GENE_PRODUCT", 150, 153], ["NS2", "GENE_OR_GENE_PRODUCT", 158, 161], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 163, 179], ["matrix protein", "GENE_OR_GENE_PRODUCT", 201, 215], ["G", "GENE_OR_GENE_PRODUCT", 257, 258], ["fusion (F) glycoproteins", "GENE_OR_GENE_PRODUCT", 265, 289], ["M2-1", "GENE_OR_GENE_PRODUCT", 291, 295], ["M2-2", "GENE_OR_GENE_PRODUCT", 300, 304], ["M2", "GENE_OR_GENE_PRODUCT", 381, 383], ["large polymerase protein (L)", "GENE_OR_GENE_PRODUCT", 394, 422], ["nonstructural proteins", "PROTEIN", 127, 149], ["NS1", "PROTEIN", 150, 153], ["NS2", "PROTEIN", 158, 161], ["nucleocapsid (N)", "PROTEIN", 163, 179], ["phosphoprotein (P)", "PROTEIN", 181, 199], ["matrix protein", "PROTEIN", 201, 215], ["M", "PROTEIN", 217, 218], ["small hydrophobic (SH), attachment (G), and fusion (F) glycoproteins", "PROTEIN", 221, 289], ["M2", "PROTEIN", 291, 293], ["1", "PROTEIN", 294, 295], ["M2", "PROTEIN", 300, 302], ["open reading frames", "DNA", 354, 373], ["M2 gene", "DNA", 381, 388], ["large polymerase protein", "PROTEIN", 394, 418], ["the nonstructural proteins NS1", "TEST", 123, 153], ["NS2", "TEST", 158, 161], ["nucleocapsid", "TEST", 163, 175], ["phosphoprotein (P); matrix protein (M", "TEST", 181, 218], ["small hydrophobic (SH)", "PROBLEM", 221, 243], ["attachment (G), and fusion (F)", "TEST", 245, 275], ["glycoproteins", "TEST", 276, 289], ["M2", "TEST", 291, 293], ["large polymerase protein", "TEST", 394, 418], ["genome", "OBSERVATION", 4, 10], ["approximately", "OBSERVATION_MODIFIER", 14, 27], ["15.2 kb", "OBSERVATION_MODIFIER", 28, 35], ["10 genes", "OBSERVATION_MODIFIER", 54, 62], ["small", "OBSERVATION_MODIFIER", 221, 226], ["hydrophobic", "OBSERVATION_MODIFIER", 227, 238], ["M2", "ANATOMY", 381, 383]]], ["The envelope glycoproteins G and F mediate viral attachment and fusion, for entry into the host cell, while SH forms ion channels whose role in infection remains unclear.", [["cell", "ANATOMY", 96, 100], ["infection", "DISEASE", 144, 153], ["G", "GENE_OR_GENE_PRODUCT", 27, 28], ["F", "GENE_OR_GENE_PRODUCT", 33, 34], ["host cell", "CELL", 91, 100], ["envelope glycoproteins G and F", "PROTEIN", 4, 34], ["SH", "PROTEIN", 108, 110], ["The envelope glycoproteins G and F mediate viral attachment and fusion", "TREATMENT", 0, 70], ["infection", "PROBLEM", 144, 153], ["viral attachment", "OBSERVATION", 43, 59], ["host cell", "OBSERVATION", 91, 100], ["infection", "OBSERVATION", 144, 153]]], ["SH and G are not essential for virus replication in immortalized cell lines [5] [6] [7] , but G is important for efficient replication in vivo [8] .IntroductionA number of host proteins and pathways have been suggested to play roles in RSV attachment and entry, but a detailed understanding remained elusive.", [["cell lines", "ANATOMY", 65, 75], ["G", "GENE_OR_GENE_PRODUCT", 7, 8], ["cell lines", "CELL", 65, 75], ["G", "GENE_OR_GENE_PRODUCT", 94, 95], ["RSV", "ORGANISM", 236, 239], ["immortalized cell lines", "CELL_LINE", 52, 75], ["host proteins", "PROTEIN", 172, 185], ["RSV", "SPECIES", 236, 239], ["virus replication", "TREATMENT", 31, 48], ["immortalized cell lines", "TREATMENT", 52, 75], ["cell lines", "OBSERVATION", 65, 75]]], ["For instance, it was shown that RSV utilizes lipid rafts in cholesterol-rich microdomains on the cell surface known as caveolae as a docking platform for entry [9] .", [["lipid rafts", "ANATOMY", 45, 56], ["cholesterol-rich microdomains", "ANATOMY", 60, 89], ["cell surface", "ANATOMY", 97, 109], ["caveolae", "ANATOMY", 119, 127], ["cholesterol", "CHEMICAL", 60, 71], ["cholesterol", "CHEMICAL", 60, 71], ["RSV", "ORGANISM", 32, 35], ["cholesterol", "SIMPLE_CHEMICAL", 60, 71], ["rich microdomains", "CELLULAR_COMPONENT", 72, 89], ["cell surface", "CELLULAR_COMPONENT", 97, 109], ["caveolae", "CELLULAR_COMPONENT", 119, 127], ["RSV", "SPECIES", 32, 35], ["RSV", "PROBLEM", 32, 35], ["lipid rafts in cholesterol", "TREATMENT", 45, 71], ["the cell surface", "TREATMENT", 93, 109]]], ["Cell surface glycosaminoglycans (GAGs) appear to be important in RSV attachment to immortalized cell lines [10] , but GAGs do not appear to be present on the apical surfaces of primary epithelial cells and so may not play an important role in vivo.", [["Cell surface", "ANATOMY", 0, 12], ["cell lines", "ANATOMY", 96, 106], ["apical surfaces", "ANATOMY", 158, 173], ["primary epithelial cells", "ANATOMY", 177, 201], ["Cell", "CELL", 0, 4], ["glycosaminoglycans", "GENE_OR_GENE_PRODUCT", 13, 31], ["GAGs", "GENE_OR_GENE_PRODUCT", 33, 37], ["RSV", "ORGANISM", 65, 68], ["cell lines", "CELL", 96, 106], ["GAGs", "GENE_OR_GENE_PRODUCT", 118, 122], ["apical surfaces", "CELLULAR_COMPONENT", 158, 173], ["epithelial cells", "CELL", 185, 201], ["immortalized cell lines", "CELL_LINE", 83, 106], ["primary epithelial cells", "CELL_TYPE", 177, 201], ["RSV", "SPECIES", 65, 68], ["Cell surface glycosaminoglycans (GAGs)", "TREATMENT", 0, 38], ["immortalized cell lines", "TREATMENT", 83, 106], ["GAGs", "PROBLEM", 118, 122], ["primary epithelial cells", "PROBLEM", 177, 201], ["cell lines", "OBSERVATION", 96, 106], ["apical", "ANATOMY_MODIFIER", 158, 164], ["primary epithelial cells", "OBSERVATION", 177, 201]]], ["The G protein contains a CX3C motif reported to mediate cell attachment by binding to the chemokine receptor CX3CR1 [11, 12] .", [["cell", "ANATOMY", 56, 60], ["G protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["CX3C", "GENE_OR_GENE_PRODUCT", 25, 29], ["cell", "CELL", 56, 60], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 109, 115], ["G protein", "PROTEIN", 4, 13], ["CX3C motif", "PROTEIN", 25, 35], ["chemokine receptor", "PROTEIN", 90, 108], ["CX3CR1", "PROTEIN", 109, 115], ["The G protein", "TREATMENT", 0, 13], ["a CX3C motif", "TREATMENT", 23, 35]]], ["Nucleolin also has been reported as a cellular receptor for RSV that is bound by the F protein [13] .", [["cellular", "ANATOMY", 38, 46], ["Nucleolin", "CHEMICAL", 0, 9], ["Nucleolin", "GENE_OR_GENE_PRODUCT", 0, 9], ["cellular", "CELL", 38, 46], ["RSV", "ORGANISM", 60, 63], ["Nucleolin", "PROTEIN", 0, 9], ["F protein", "PROTEIN", 85, 94], ["RSV", "SPECIES", 60, 63], ["Nucleolin", "TREATMENT", 0, 9], ["RSV", "PROBLEM", 60, 63]]], ["Epidermal growth factor receptor (EGFR) signaling has been postulated to play a role in triggering macropinocytic uptake of signaling occur in the caveolae and can be inhibited by cholesterol depletion.", [["macropinocytic", "ANATOMY", 99, 113], ["caveolae", "ANATOMY", 147, 155], ["cholesterol", "CHEMICAL", 180, 191], ["cholesterol", "CHEMICAL", 180, 191], ["Epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 0, 32], ["EGFR", "GENE_OR_GENE_PRODUCT", 34, 38], ["caveolae", "CELLULAR_COMPONENT", 147, 155], ["cholesterol", "SIMPLE_CHEMICAL", 180, 191], ["Epidermal growth factor receptor", "PROTEIN", 0, 32], ["EGFR", "PROTEIN", 34, 38], ["Epidermal growth factor receptor (EGFR) signaling", "PROBLEM", 0, 49], ["cholesterol depletion", "PROBLEM", 180, 201], ["caveolae", "ANATOMY", 147, 155], ["cholesterol depletion", "OBSERVATION", 180, 201]]], ["The cardiotonic steroid ouabain or the digitoxigenin derivative PST2238 inhibit RSV-triggered ATP1A1 activation, prevent RSV entry, and thus could serve as a target for antiviral drug development.Knockdown of ATP1A1 expression by siRNA transfectionWe performed a genome-wide high-throughput siRNA screen in which the expression of2 1,500 cellular genes was individually knocked down in human airway epithelial A549 cells by three individual siRNAs per gene, followed by infection with recombinant RSV expressing enhanced green fluorescent protein (RSV-GFP).", [["cellular", "ANATOMY", 338, 346], ["airway epithelial A549 cells", "ANATOMY", 392, 420], ["steroid", "CHEMICAL", 16, 23], ["ouabain", "CHEMICAL", 24, 31], ["digitoxigenin", "CHEMICAL", 39, 52], ["PST2238", "CHEMICAL", 64, 71], ["infection", "DISEASE", 470, 479], ["steroid", "CHEMICAL", 16, 23], ["ouabain", "CHEMICAL", 24, 31], ["digitoxigenin", "CHEMICAL", 39, 52], ["PST2238", "CHEMICAL", 64, 71], ["ouabain", "SIMPLE_CHEMICAL", 24, 31], ["digitoxigenin", "SIMPLE_CHEMICAL", 39, 52], ["PST2238", "SIMPLE_CHEMICAL", 64, 71], ["RSV", "ORGANISM", 80, 83], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 94, 100], ["RSV", "ORGANISM", 121, 124], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 209, 215], ["cellular", "CELL", 338, 346], ["human", "ORGANISM", 386, 391], ["airway epithelial A549 cells", "CELL", 392, 420], ["RSV", "ORGANISM", 497, 500], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 521, 546], ["RSV", "ORGANISM", 548, 551], ["GFP", "GENE_OR_GENE_PRODUCT", 552, 555], ["ATP1A1", "PROTEIN", 94, 100], ["ATP1A1", "PROTEIN", 209, 215], ["of2 1,500 cellular genes", "DNA", 328, 352], ["human airway epithelial A549 cells", "CELL_LINE", 386, 420], ["recombinant RSV expressing enhanced green fluorescent protein", "PROTEIN", 485, 546], ["RSV", "PROTEIN", 548, 551], ["GFP", "PROTEIN", 552, 555], ["human", "SPECIES", 386, 391], ["RSV", "SPECIES", 80, 83], ["RSV", "SPECIES", 121, 124], ["human", "SPECIES", 386, 391], ["RSV", "SPECIES", 497, 500], ["RSV", "SPECIES", 548, 551], ["The cardiotonic steroid ouabain", "TREATMENT", 0, 31], ["the digitoxigenin derivative", "TREATMENT", 35, 63], ["RSV", "PROBLEM", 80, 83], ["RSV entry", "PROBLEM", 121, 130], ["antiviral drug development", "TREATMENT", 169, 195], ["siRNA transfectionWe", "PROBLEM", 230, 250], ["a genome", "TEST", 261, 269], ["wide high-throughput siRNA screen", "PROBLEM", 270, 303], ["infection", "PROBLEM", 470, 479], ["airway", "ANATOMY", 392, 398], ["epithelial", "ANATOMY_MODIFIER", 399, 409], ["A549 cells", "OBSERVATION", 410, 420], ["infection", "OBSERVATION", 470, 479]]], ["Knockdowns that reduced GFP expression at 48 h post-infection (p.i.) with minimal effect on cell viability indicated a presumptive role for that protein in RSV replication.Knockdown of ATP1A1 expression by siRNA transfectionATP1A1 was among the genes with the strongest effect on RSV-GFP (S1 Table) which was confirmed with additional, different siRNAs.", [["cell", "ANATOMY", 92, 96], ["infection", "DISEASE", 52, 61], ["GFP", "GENE_OR_GENE_PRODUCT", 24, 27], ["cell", "CELL", 92, 96], ["RSV", "ORGANISM", 156, 159], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 185, 191], ["RSV", "ORGANISM", 280, 283], ["GFP", "GENE_OR_GENE_PRODUCT", 284, 287], ["S1 Table", "GENE_OR_GENE_PRODUCT", 289, 297], ["GFP", "PROTEIN", 24, 27], ["ATP1A1", "PROTEIN", 185, 191], ["siRNA transfectionATP1A1", "DNA", 206, 230], ["GFP", "PROTEIN", 284, 287], ["RSV", "SPECIES", 156, 159], ["RSV", "SPECIES", 280, 283], ["reduced GFP expression", "PROBLEM", 16, 38], ["infection", "PROBLEM", 52, 61], ["minimal effect on cell viability", "PROBLEM", 74, 106], ["RSV replication", "TREATMENT", 156, 171], ["ATP1A1 expression", "PROBLEM", 185, 202], ["siRNA transfectionATP1A1", "PROBLEM", 206, 230], ["RSV", "TEST", 280, 283], ["reduced", "OBSERVATION_MODIFIER", 16, 23], ["GFP expression", "OBSERVATION", 24, 38], ["infection", "OBSERVATION", 52, 61], ["minimal", "OBSERVATION_MODIFIER", 74, 81], ["cell viability", "OBSERVATION", 92, 106], ["RSV replication", "OBSERVATION", 156, 171], ["siRNA transfectionATP1A1", "OBSERVATION", 206, 230], ["different siRNAs", "OBSERVATION", 336, 352]]], ["Three siRNAs with the greatest effect on ATP1A1 expression and RSV infection were used for further experiments, and in addition two different scrambled siRNAs (Neg. siRNA 1 and 2) were included as negative controls.", [["RSV infection", "DISEASE", 63, 76], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 41, 47], ["RSV", "ORGANISM", 63, 66], ["ATP1A1", "PROTEIN", 41, 47], ["RSV", "SPECIES", 63, 66], ["Three siRNAs", "PROBLEM", 0, 12], ["ATP1A1 expression", "PROBLEM", 41, 58], ["RSV infection", "PROBLEM", 63, 76], ["siRNA", "TEST", 165, 170], ["siRNAs", "OBSERVATION", 6, 12], ["greatest", "OBSERVATION_MODIFIER", 22, 30], ["effect", "OBSERVATION_MODIFIER", 31, 37], ["RSV infection", "OBSERVATION", 63, 76]]], ["To confirm the efficiency of knockdown of ATP1A1 mRNA, A549 cells were transfected with this set of five siRNAs.", [["A549 cells", "ANATOMY", 55, 65], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 42, 48], ["A549 cells", "CELL", 55, 65], ["ATP1A1 mRNA", "RNA", 42, 53], ["A549 cells", "CELL_LINE", 55, 65], ["knockdown of ATP1A1 mRNA", "PROBLEM", 29, 53], ["A549 cells", "PROBLEM", 55, 65], ["A549 cells", "OBSERVATION", 55, 65]]], ["ATP1A1 mRNA level and the expression of ATP1A1 protein was quantified at different time points post transfection by TaqMan assay and Western blotting, respectively, and reported relative to Neg. siRNA1 at 48 h p.t.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 0, 6], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 40, 46], ["ATP1A1 mRNA", "RNA", 0, 11], ["ATP1A1 protein", "PROTEIN", 40, 54], ["siRNA1", "PROTEIN", 195, 201], ["ATP1A1 mRNA level", "TEST", 0, 17], ["ATP1A1 protein", "TEST", 40, 54], ["TaqMan assay", "TEST", 116, 128], ["Western blotting", "TEST", 133, 149]]], ["At 48 h post transfection (p.t.), the level of ATP1A1 mRNA was reduced to below 5% compared to Neg. siRNA 1 (Fig 1A) that resulted in a reduction of the ATP1A1 protein expression at 48 h p.t. to 39% (siRNA1 and 3) and 35% (siRNA2) (Fig 1C) and did not show any further reduction at 72 h p.t.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 47, 53], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 153, 159], ["ATP1A1 mRNA", "RNA", 47, 58], ["ATP1A1", "PROTEIN", 153, 159], ["siRNA2", "PROTEIN", 223, 229], ["the level of ATP1A1 mRNA", "TEST", 34, 58], ["siRNA", "TEST", 100, 105], ["the ATP1A1 protein expression", "TEST", 149, 178], ["siRNA1", "TEST", 200, 206]]], ["(S1 Fig) .Knockdown of ATP1A1 expression by siRNA transfectionThe transfected cells showed no visible cytotoxicity or morphological changes over the period of 72 h.", [["cells", "ANATOMY", 78, 83], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 23, 29], ["cells", "CELL", 78, 83], ["ATP1A1", "PROTEIN", 23, 29], ["transfected cells", "CELL_LINE", 66, 83], ["ATP1A1 expression", "TREATMENT", 23, 40], ["siRNA transfection", "TREATMENT", 44, 62], ["The transfected cells", "TEST", 62, 83], ["visible cytotoxicity", "PROBLEM", 94, 114], ["morphological changes", "PROBLEM", 118, 139], ["siRNA transfection", "OBSERVATION", 44, 62], ["transfected cells", "OBSERVATION", 66, 83], ["no", "UNCERTAINTY", 91, 93], ["visible", "OBSERVATION_MODIFIER", 94, 101], ["cytotoxicity", "OBSERVATION", 102, 114], ["morphological", "OBSERVATION_MODIFIER", 118, 131]]], ["For more sensitive evaluation, cellular ATP, which reflects cell viability, was measured in cell lysates at 72 h p.t.", [["cellular", "ANATOMY", 31, 39], ["cell", "ANATOMY", 60, 64], ["cell lysates", "ANATOMY", 92, 104], ["ATP", "CHEMICAL", 40, 43], ["ATP", "CHEMICAL", 40, 43], ["cellular", "CELL", 31, 39], ["ATP", "SIMPLE_CHEMICAL", 40, 43], ["cell", "CELL", 60, 64], ["cell lysates", "ORGANISM_SUBSTANCE", 92, 104], ["sensitive evaluation", "TEST", 9, 29], ["cellular ATP", "TEST", 31, 43], ["cell viability", "PROBLEM", 60, 74], ["cell viability", "OBSERVATION", 60, 74]]], ["The ATP1A1 siRNA knockdown showed only minimal reductions in cell viability (S1D Fig).ATP1A1 knockdown reduces RSV infectionA549 cells were transfected with the panel of siRNAs targeting ATP1A1, and 48 h later the cells were infected with RSV-GFP at an MOI of 1 plaque forming unit (PFU)/cell.", [["cell", "ANATOMY", 61, 65], ["A549 cells", "ANATOMY", 124, 134], ["cells", "ANATOMY", 214, 219], ["plaque", "ANATOMY", 262, 268], ["cell", "ANATOMY", 288, 292], ["RSV infection", "DISEASE", 111, 124], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 4, 10], ["cell", "CELL", 61, 65], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 86, 92], ["RSV", "ORGANISM", 111, 114], ["A549 cells", "CELL", 124, 134], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 187, 193], ["cells", "CELL", 214, 219], ["RSV", "ORGANISM", 239, 242], ["GFP", "GENE_OR_GENE_PRODUCT", 243, 246], ["cell", "CELL", 288, 292], ["ATP1A1", "PROTEIN", 4, 10], ["ATP1A1", "PROTEIN", 86, 92], ["A549 cells", "CELL_LINE", 124, 134], ["ATP1A1", "PROTEIN", 187, 193], ["RSV", "SPECIES", 111, 114], ["RSV", "SPECIES", 239, 242], ["The ATP1A1 siRNA knockdown", "TEST", 0, 26], ["minimal reductions in cell viability", "PROBLEM", 39, 75], ["ATP1A1 knockdown", "TREATMENT", 86, 102], ["RSV infectionA549 cells", "PROBLEM", 111, 134], ["the panel", "TEST", 157, 166], ["siRNAs", "TEST", 170, 176], ["ATP1A1", "TEST", 187, 193], ["RSV", "TEST", 239, 242], ["siRNA knockdown", "OBSERVATION", 11, 26], ["minimal", "OBSERVATION_MODIFIER", 39, 46], ["reductions", "OBSERVATION_MODIFIER", 47, 57], ["cell viability", "OBSERVATION", 61, 75], ["RSV infection", "OBSERVATION", 111, 124], ["A549 cells", "OBSERVATION", 124, 134]]], ["The efficiency of virus infection and replication were evaluated by GFP expression quantified by ELISA reader (Fig 2A) and flow cytometry (Fig 2C and 2D ).", [["infection", "DISEASE", 24, 33], ["GFP", "GENE_OR_GENE_PRODUCT", 68, 71], ["GFP", "PROTEIN", 68, 71], ["virus infection", "PROBLEM", 18, 33], ["flow cytometry", "TEST", 123, 137], ["efficiency", "OBSERVATION_MODIFIER", 4, 14], ["virus infection", "OBSERVATION", 18, 33]]], ["By ELISA reader, all three ATP1A1-specific siRNAs reduced the amount of GFP expression by about 50 to 75% compared to Neg. siRNA 1 (Fig 2A) .", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 27, 33], ["GFP", "GENE_OR_GENE_PRODUCT", 72, 75], ["ATP1A1", "PROTEIN", 27, 33], ["GFP", "PROTEIN", 72, 75], ["GFP expression", "TEST", 72, 86], ["siRNA", "TEST", 123, 128], ["amount", "OBSERVATION_MODIFIER", 62, 68], ["GFP expression", "OBSERVATION", 72, 86]]], ["This level of reduction was substantial given that the residual level of ATP1A1 expression remained 35% or greater, as was shown in Fig 1C.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 73, 79], ["ATP1A1", "PROTEIN", 73, 79], ["reduction", "TREATMENT", 14, 23], ["ATP1A1 expression", "TEST", 73, 90]]], ["We also investigated effects on infection with vesicular stomatitis virus expressing GFP (VSV-GFP).", [["infection", "DISEASE", 32, 41], ["vesicular stomatitis virus", "ORGANISM", 47, 73], ["GFP", "GENE_OR_GENE_PRODUCT", 85, 88], ["VSV", "ORGANISM", 90, 93], ["GFP", "GENE_OR_GENE_PRODUCT", 94, 97], ["GFP", "PROTEIN", 85, 88], ["VSV", "PROTEIN", 90, 93], ["GFP", "PROTEIN", 94, 97], ["vesicular stomatitis virus", "SPECIES", 47, 73], ["VSV", "SPECIES", 90, 93], ["infection", "PROBLEM", 32, 41], ["vesicular stomatitis virus", "PROBLEM", 47, 73], ["infection", "OBSERVATION", 32, 41], ["vesicular stomatitis", "OBSERVATION", 47, 67]]], ["ATP1A1 knockdown had no effect on GFP expression by VSV-GFP ( Fig 2B) .", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 0, 6], ["GFP", "GENE_OR_GENE_PRODUCT", 34, 37], ["VSV", "ORGANISM", 52, 55], ["GFP", "GENE_OR_GENE_PRODUCT", 56, 59], ["Fig 2B", "GENE_OR_GENE_PRODUCT", 62, 68], ["ATP1A1", "PROTEIN", 0, 6], ["GFP", "PROTEIN", 56, 59], ["ATP1A1 knockdown", "TEST", 0, 16], ["GFP expression", "TEST", 34, 48], ["VSV", "TEST", 52, 55], ["no", "UNCERTAINTY", 21, 23]]], ["This indicated that the reduction in GFP expression observed with RSV-GFP was specific to RSV, did not affect VSV, and was not due to some general effect on cellular functions.", [["cellular", "ANATOMY", 157, 165], ["GFP", "GENE_OR_GENE_PRODUCT", 37, 40], ["RSV", "ORGANISM", 66, 69], ["GFP", "GENE_OR_GENE_PRODUCT", 70, 73], ["RSV", "ORGANISM", 90, 93], ["VSV", "ORGANISM", 110, 113], ["cellular", "CELL", 157, 165], ["GFP", "PROTEIN", 37, 40], ["GFP", "PROTEIN", 70, 73], ["RSV", "SPECIES", 66, 69], ["RSV", "SPECIES", 90, 93], ["VSV", "SPECIES", 110, 113], ["the reduction in GFP expression", "PROBLEM", 20, 51], ["RSV", "PROBLEM", 66, 69], ["RSV", "PROBLEM", 90, 93], ["reduction", "OBSERVATION_MODIFIER", 24, 33], ["GFP expression", "OBSERVATION", 37, 51], ["cellular functions", "OBSERVATION", 157, 175]]], ["Analysis of cells infected with RSV-GFP (MOI = 1.0 PFU/cell) by flow cytometry 24 h p.i. showed that knockdown of ATP1A1 resulted in a broad reduction in GFP expression in the infected-cell population rather than a reduction in the number of GFP-expressing cells (Fig 2C and 2D) .ATP1A1 knockdown reduces RSV infectionThe effect of transfection with the panel of siRNAs on the production of progeny RSV-GFP were assessed 24 h p.i.", [["cells", "ANATOMY", 12, 17], ["cell", "ANATOMY", 55, 59], ["cell", "ANATOMY", 185, 189], ["cells", "ANATOMY", 257, 262], ["ATP1A1", "CHEMICAL", 114, 120], ["ATP1A1", "CHEMICAL", 280, 286], ["RSV infection", "DISEASE", 305, 318], ["cells", "CELL", 12, 17], ["RSV-GFP", "ORGANISM", 32, 39], ["cell", "CELL", 55, 59], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 114, 120], ["GFP", "GENE_OR_GENE_PRODUCT", 154, 157], ["-cell", "CELL", 184, 189], ["GFP", "GENE_OR_GENE_PRODUCT", 242, 245], ["cells", "CELL", 257, 262], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 280, 286], ["RSV", "ORGANISM", 305, 308], ["RSV", "ORGANISM", 399, 402], ["GFP", "GENE_OR_GENE_PRODUCT", 403, 406], ["ATP1A1", "PROTEIN", 114, 120], ["GFP", "PROTEIN", 154, 157], ["infected-cell population", "CELL_LINE", 176, 200], ["GFP", "PROTEIN", 242, 245], ["expressing cells", "CELL_TYPE", 246, 262], ["ATP1A1", "PROTEIN", 280, 286], ["GFP", "PROTEIN", 403, 406], ["RSV", "SPECIES", 32, 35], ["RSV", "SPECIES", 305, 308], ["RSV", "SPECIES", 399, 402], ["Analysis of cells", "TEST", 0, 17], ["RSV", "TEST", 32, 35], ["GFP", "TEST", 36, 39], ["MOI", "TEST", 41, 44], ["PFU/cell", "TEST", 51, 59], ["flow cytometry", "TEST", 64, 78], ["knockdown of ATP1A1", "PROBLEM", 101, 120], ["a broad reduction in GFP expression", "PROBLEM", 133, 168], ["the infected-cell population", "PROBLEM", 172, 200], ["a reduction", "PROBLEM", 213, 224], ["ATP1A1 knockdown", "TREATMENT", 280, 296], ["RSV infection", "PROBLEM", 305, 318], ["transfection", "TREATMENT", 332, 344], ["the panel", "TEST", 350, 359], ["broad", "OBSERVATION_MODIFIER", 135, 140], ["reduction", "OBSERVATION_MODIFIER", 141, 150], ["GFP expression", "OBSERVATION", 154, 168], ["infected", "OBSERVATION_MODIFIER", 176, 184], ["cell population", "OBSERVATION", 185, 200], ["reduction", "OBSERVATION_MODIFIER", 215, 224], ["expressing cells", "OBSERVATION", 246, 262], ["RSV", "OBSERVATION_MODIFIER", 305, 308], ["infection", "OBSERVATION", 309, 318], ["transfection", "OBSERVATION", 332, 344]]], ["The infected cells were collected by scraping, vortexed to release cell-associated virus, and pelleted by centrifugation.", [["cells", "ANATOMY", 13, 18], ["cell", "ANATOMY", 67, 71], ["cells", "CELL", 13, 18], ["cell", "CELL", 67, 71], ["infected cells", "CELL_TYPE", 4, 18], ["The infected cells", "PROBLEM", 0, 18], ["associated virus", "PROBLEM", 72, 88], ["infected cells", "OBSERVATION", 4, 18], ["virus", "OBSERVATION", 83, 88]]], ["Virus titers in the clarified supernatants were quantified by plaque titration on Vero cells (Fig 2E) .", [["supernatants", "ANATOMY", 30, 42], ["plaque", "ANATOMY", 62, 68], ["Vero cells", "ANATOMY", 82, 92], ["Virus", "ORGANISM", 0, 5], ["Vero cells", "CELL", 82, 92], ["Fig 2E", "CELL", 94, 100], ["Vero cells", "CELL_LINE", 82, 92], ["Virus titers", "TEST", 0, 12], ["Vero cells", "TREATMENT", 82, 92], ["plaque", "OBSERVATION", 62, 68], ["Vero cells", "OBSERVATION", 82, 92]]], ["This showed that, with ATP1A1 knockdown, RSV titers were reduced between 5-(siRNA3) and 42-fold (siRNA2) compared to Neg. siRNA 1, an effect that was even more dramatic than the reduction in GFP expression described above ( Fig 2E versus 2A and 2D ).", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 23, 29], ["RSV", "ORGANISM", 41, 44], ["GFP", "GENE_OR_GENE_PRODUCT", 191, 194], ["ATP1A1", "PROTEIN", 23, 29], ["siRNA2", "PROTEIN", 97, 103], ["GFP", "PROTEIN", 191, 194], ["RSV", "SPECIES", 41, 44], ["ATP1A1 knockdown", "TEST", 23, 39], ["RSV titers", "TEST", 41, 51], ["siRNA", "TEST", 122, 127], ["dramatic", "OBSERVATION_MODIFIER", 160, 168], ["GFP expression", "OBSERVATION", 191, 205]]], ["ATP1A1 siRNA 2 showed the strongest effect against both GFP expression and virus production.ATP1A1 forms clusters early during RSV infection independent of viral gene transcription or replicationA549 cells were infected with wt RSV (MOI = 5 PFU/cell), fixed at various times p.i., and subjected to immunofluorescence staining for ATP1A1 and RSV F protein.", [["A549 cells", "ANATOMY", 195, 205], ["cell", "ANATOMY", 245, 249], ["infection", "DISEASE", 131, 140], ["GFP", "GENE_OR_GENE_PRODUCT", 56, 59], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 92, 98], ["RSV", "ORGANISM", 127, 130], ["A549 cells", "CELL", 195, 205], ["RSV", "ORGANISM", 228, 231], ["cell", "CELL", 245, 249], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 330, 336], ["RSV F", "GENE_OR_GENE_PRODUCT", 341, 346], ["GFP", "PROTEIN", 56, 59], ["ATP1A1", "PROTEIN", 92, 98], ["A549 cells", "CELL_LINE", 195, 205], ["ATP1A1", "PROTEIN", 330, 336], ["RSV F protein", "PROTEIN", 341, 354], ["RSV", "SPECIES", 127, 130], ["RSV", "SPECIES", 228, 231], ["RSV", "SPECIES", 341, 344], ["ATP1A1 siRNA", "TEST", 0, 12], ["virus production", "PROBLEM", 75, 91], ["ATP1A1 forms clusters", "PROBLEM", 92, 113], ["RSV infection", "PROBLEM", 127, 140], ["viral gene transcription", "TREATMENT", 156, 180], ["replicationA549 cells", "PROBLEM", 184, 205], ["wt RSV", "TEST", 225, 231], ["MOI", "TEST", 233, 236], ["immunofluorescence staining", "TEST", 298, 325], ["ATP1A1", "TEST", 330, 336], ["GFP expression", "OBSERVATION", 56, 70], ["virus production", "OBSERVATION", 75, 91], ["clusters", "OBSERVATION_MODIFIER", 105, 113], ["RSV infection", "OBSERVATION", 127, 140], ["A549 cells", "OBSERVATION", 195, 205]]], ["In mock-treated cells, ATP1A1 was homogeneously distributed on the plasma membrane ( Fig 3A, top panel) .", [["cells", "ANATOMY", 16, 21], ["plasma membrane", "ANATOMY", 67, 82], ["cells", "CELL", 16, 21], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 23, 29], ["plasma membrane", "CELLULAR_COMPONENT", 67, 82], ["mock-treated cells", "CELL_LINE", 3, 21], ["ATP1A1", "PROTEIN", 23, 29], ["ATP1A1", "TREATMENT", 23, 29], ["the plasma membrane", "TEST", 63, 82], ["top panel", "TEST", 93, 102]]], ["Following infection with wt RSV, clusters of ATP1A1 were observed as early as 15 min p.i. ( Fig 3A, second panel), whereas these clusters were not evident in uninfected cells (Fig 3A, top panel).", [["cells", "ANATOMY", 169, 174], ["infection", "DISEASE", 10, 19], ["RSV", "ORGANISM", 28, 31], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 45, 51], ["cells", "CELL", 169, 174], ["ATP1A1", "PROTEIN", 45, 51], ["uninfected cells", "CELL_TYPE", 158, 174], ["RSV", "SPECIES", 28, 31], ["infection", "PROBLEM", 10, 19], ["wt RSV", "PROBLEM", 25, 31], ["ATP1A1", "TEST", 45, 51], ["second panel", "TEST", 100, 112], ["top panel", "TEST", 184, 193], ["infection", "OBSERVATION", 10, 19], ["not evident", "UNCERTAINTY", 143, 154], ["uninfected cells", "OBSERVATION", 158, 174]]], ["With time, the ATP1A1 clusters became more prominent and numerous, as shown for 30 min and 5 h p.i.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 15, 21], ["ATP1A1", "PROTEIN", 15, 21], ["more prominent", "OBSERVATION_MODIFIER", 38, 52]]], ["All shown timepoints are very early in the RSV replication cycle.", [["RSV", "ORGANISM", 43, 46], ["RSV", "SPECIES", 43, 46], ["RSV replication", "OBSERVATION", 43, 58]]], ["Some ATP1A1 clusters, but not all, partially co-localized with RSV F protein ( Fig 3A, indicated by arrows) .", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 5, 11], ["RSV F protein", "GENE_OR_GENE_PRODUCT", 63, 76], ["Fig 3A", "GENE_OR_GENE_PRODUCT", 79, 85], ["ATP1A1", "PROTEIN", 5, 11], ["RSV F protein", "PROTEIN", 63, 76], ["Fig 3A", "PROTEIN", 79, 85], ["RSV", "SPECIES", 63, 66], ["Some ATP1A1 clusters", "PROBLEM", 0, 20]]], ["The localization of clustered ATP1A1 in close proximity to RSV F became more noticeable at later time points such as 5 h p.i.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 30, 36], ["RSV", "ORGANISM", 59, 62], ["ATP1A1", "PROTEIN", 30, 36], ["RSV", "SPECIES", 59, 62], ["RSV", "OBSERVATION", 59, 62]]], ["(Fig 3A, bottom panel) .", [["bottom panel", "TEST", 9, 21]]], ["Localization of ATP1A1 clusters close to RSV N protein also could be observed (Fig 4 and S2 Fig) : co-localization with both F and N suggested that the RSV-specific staining most likely reflects enveloped virions (which had not yet fused).", [["virions", "ANATOMY", 205, 212], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 16, 22], ["RSV", "ORGANISM", 41, 44], ["RSV", "ORGANISM", 152, 155], ["ATP1A1", "PROTEIN", 16, 22], ["RSV N protein", "PROTEIN", 41, 54], ["F and N", "PROTEIN", 125, 132], ["RSV", "SPECIES", 41, 44], ["RSV", "SPECIES", 152, 155], ["ATP1A1 clusters", "PROBLEM", 16, 31], ["RSV N protein", "TEST", 41, 54], ["Fig", "TEST", 79, 82], ["the RSV", "TEST", 148, 155], ["enveloped virions", "PROBLEM", 195, 212], ["RSV", "OBSERVATION", 41, 44], ["RSV", "OBSERVATION", 152, 155], ["most likely reflects", "UNCERTAINTY", 174, 194], ["enveloped virions", "OBSERVATION", 195, 212]]], ["Similar clustering of ATP1A1 and RSV N protein also was observed for UV-inactivated RSV (S2 Fig), indicating that the staining largely involved pre-formed proteins from the incoming virus, and that clustering does not require transcription of the complete viral genome, viral RNA replication, or virus replication.ATP1A1 forms clusters early during RSV infection independent of viral gene transcription or replicationCross-sections ( Fig 3B) and a ZY-view movie (S1 Movie) of images of RSV-infected A549 cells 5 h p.i. indicate that the ATP1A1 clustering occurred at the cell surface and was localized close to the RSV virions.", [["Cross-sections", "ANATOMY", 417, 431], ["A549 cells", "ANATOMY", 499, 509], ["cell surface", "ANATOMY", 571, 583], ["RSV infection", "DISEASE", 349, 362], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 22, 28], ["RSV N", "GENE_OR_GENE_PRODUCT", 33, 38], ["RSV", "ORGANISM", 84, 87], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 314, 320], ["RSV", "ORGANISM", 349, 352], ["RSV", "ORGANISM", 486, 489], ["A549 cells", "CELL", 499, 509], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 537, 543], ["cell surface", "CELLULAR_COMPONENT", 571, 583], ["RSV", "ORGANISM", 615, 618], ["ATP1A1", "PROTEIN", 22, 28], ["RSV N protein", "PROTEIN", 33, 46], ["pre-formed proteins", "PROTEIN", 144, 163], ["viral genome", "DNA", 256, 268], ["ATP1A1", "PROTEIN", 314, 320], ["A549 cells", "CELL_LINE", 499, 509], ["ATP1A1", "PROTEIN", 537, 543], ["RSV", "SPECIES", 33, 36], ["RSV", "SPECIES", 84, 87], ["RSV", "SPECIES", 349, 352], ["RSV", "SPECIES", 486, 489], ["RSV", "SPECIES", 615, 618], ["ATP1A1", "TEST", 22, 28], ["RSV N protein", "TEST", 33, 46], ["UV", "PROBLEM", 69, 71], ["RSV", "PROBLEM", 84, 87], ["the staining", "PROBLEM", 114, 126], ["pre-formed proteins", "PROBLEM", 144, 163], ["the incoming virus", "PROBLEM", 169, 187], ["the complete viral genome", "TREATMENT", 243, 268], ["viral RNA replication", "TREATMENT", 270, 291], ["virus replication", "TREATMENT", 296, 313], ["ATP1A1 forms clusters", "PROBLEM", 314, 335], ["RSV infection", "PROBLEM", 349, 362], ["viral gene transcription", "TREATMENT", 378, 402], ["images", "TEST", 476, 482], ["RSV", "TEST", 486, 489], ["infected A549 cells", "PROBLEM", 490, 509], ["the ATP1A1 clustering", "PROBLEM", 533, 554], ["clusters", "OBSERVATION_MODIFIER", 327, 335], ["RSV infection", "OBSERVATION", 349, 362], ["RSV", "ANATOMY", 486, 489], ["A549 cells", "OBSERVATION", 499, 509], ["cell surface", "OBSERVATION", 571, 583], ["RSV virions", "OBSERVATION", 615, 626]]], ["Given the very early appearance of ATP1A1 clusters, independent of t.) and the ATP1A1 mRNA and protein levels were quantified.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 35, 41], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 79, 85], ["ATP1A1", "PROTEIN", 35, 41], ["ATP1A1 mRNA", "RNA", 79, 90], ["ATP1A1 clusters", "PROBLEM", 35, 50], ["the ATP1A1 mRNA", "TEST", 75, 90], ["protein levels", "TEST", 95, 109]]], ["(A) Relative quantification of ATP1A1 mRNA.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 31, 37], ["ATP1A1 mRNA", "RNA", 31, 42], ["ATP1A1 mRNA", "PROBLEM", 31, 42], ["ATP1A1 mRNA", "OBSERVATION", 31, 42]]], ["Total RNA was isolated, reverse transcribed, and quantified by an ATP1A1-specific TaqMan Assay.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 66, 72], ["ATP1A1", "PROTEIN", 66, 72], ["Total RNA", "TEST", 0, 9], ["an ATP1A1", "TEST", 63, 72]]], ["Values were normalized to 18S rRNA and expressed as mean values relative to Neg. siRNA 1 assigned the value of 1.0, with error bars indicating the standard deviation of three independent experiments with three replicate reactions each.", [["18S rRNA", "RNA", 26, 34], ["Values", "TEST", 0, 6], ["18S rRNA", "TEST", 26, 34], ["mean values", "TEST", 52, 63], ["siRNA", "TEST", 81, 86]]], ["(B) Western blot analysis of ATP1A1 expression.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 29, 35], ["ATP1A1", "PROTEIN", 29, 35], ["blot analysis", "TEST", 12, 25], ["ATP1A1 expression", "PROBLEM", 29, 46]]], ["Cells were lysed at 48 h p.t. and subjected to Western blotting with an anti-ATP1A1 rabbit monoclonal antibody (MAb) (ab76020) and a corresponding infrared dye 680RD-conjugated goat anti-rabbit secondary antibody.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["ab76020", "SIMPLE_CHEMICAL", 118, 125], ["680RD", "SIMPLE_CHEMICAL", 160, 165], ["anti-ATP1A1 rabbit monoclonal antibody", "PROTEIN", 72, 110], ["MAb", "PROTEIN", 112, 115], ["ab76020", "PROTEIN", 118, 125], ["infrared dye 680RD-conjugated goat anti-rabbit secondary antibody", "PROTEIN", 147, 212], ["rabbit", "SPECIES", 84, 90], ["goat", "SPECIES", 177, 181], ["anti-rabbit", "SPECIES", 182, 193], ["rabbit", "SPECIES", 84, 90], ["goat", "SPECIES", 177, 181], ["an anti-ATP1A1 rabbit monoclonal antibody", "TEST", 69, 110], ["a corresponding infrared dye", "TEST", 131, 159], ["conjugated goat anti-rabbit secondary antibody", "PROBLEM", 166, 212]]], ["Alpha-tubulin was used as a loading control and was detected by an anti-alpha-tubulin mouse MAb and an infrared dye 800CW-conjugated goat anti-mouse secondary antibody.", [["Alpha-tubulin", "CHEMICAL", 0, 13], ["Alpha-tubulin", "CHEMICAL", 0, 13], ["Alpha-tubulin", "SIMPLE_CHEMICAL", 0, 13], ["anti-alpha-tubulin", "GENE_OR_GENE_PRODUCT", 67, 85], ["mouse", "ORGANISM", 86, 91], ["Alpha-tubulin", "PROTEIN", 0, 13], ["anti-alpha-tubulin mouse MAb", "PROTEIN", 67, 95], ["infrared dye 800CW-conjugated goat anti-mouse secondary antibody", "PROTEIN", 103, 167], ["mouse", "SPECIES", 86, 91], ["goat", "SPECIES", 133, 137], ["anti-mouse", "SPECIES", 138, 148], ["mouse", "SPECIES", 86, 91], ["goat", "SPECIES", 133, 137], ["Alpha-tubulin", "TREATMENT", 0, 13], ["a loading control", "TREATMENT", 26, 43], ["an anti-alpha-tubulin mouse MAb", "TREATMENT", 64, 95], ["an infrared dye", "TEST", 100, 115], ["conjugated goat anti-mouse secondary antibody", "TREATMENT", 122, 167]]], ["A representative blot is shown.", [["A representative blot", "TEST", 0, 21], ["blot", "OBSERVATION", 17, 21]]], ["(C) Quantification of ATP1A1 Western blots.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 22, 28], ["ATP1A1", "PROTEIN", 22, 28]]], ["Western blot analyses of three independent experiments, as described in Part B, were quantified, normalized to alpha-tubulin, and reported relative to Neg. siRNA 1 assigned the value of 1.0, with error bars indicating the standard deviation.RSV G protein is required for ATP1A1 clusteringAs another means of exploring early events in RSV infection, we investigated whether RSV mutants bearing the deletion of the SH protein (dSH) or the combined deletion of SH and the , the cells were incubated for 17 h, and the GFP intensity of the total area of each well of A549 cells was quantified by scanning with an ELISA reader and is expressed relative to cells infected with the same virus for which the transfected siRNA was Neg. siRNA 1.", [["cells", "ANATOMY", 475, 480], ["A549 cells", "ANATOMY", 562, 572], ["cells", "ANATOMY", 650, 655], ["RSV infection", "DISEASE", 334, 347], ["alpha-tubulin", "GENE_OR_GENE_PRODUCT", 111, 124], ["RSV G", "GENE_OR_GENE_PRODUCT", 241, 246], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 271, 277], ["RSV", "ORGANISM", 334, 337], ["RSV", "ORGANISM", 373, 376], ["SH protein", "GENE_OR_GENE_PRODUCT", 413, 423], ["dSH", "GENE_OR_GENE_PRODUCT", 425, 428], ["cells", "CELL", 475, 480], ["GFP", "GENE_OR_GENE_PRODUCT", 514, 517], ["A549 cells", "CELL", 562, 572], ["cells", "CELL", 650, 655], ["alpha-tubulin", "PROTEIN", 111, 124], ["RSV G protein", "PROTEIN", 241, 254], ["ATP1A1", "PROTEIN", 271, 277], ["SH protein", "PROTEIN", 413, 423], ["dSH", "PROTEIN", 425, 428], ["A549 cells", "CELL_LINE", 562, 572], ["RSV", "SPECIES", 241, 244], ["RSV", "SPECIES", 334, 337], ["RSV", "SPECIES", 373, 376], ["alpha-tubulin", "TEST", 111, 124], ["siRNA", "TEST", 156, 161], ["RSV G protein", "TEST", 241, 254], ["ATP1A1 clustering", "PROBLEM", 271, 288], ["RSV infection", "PROBLEM", 334, 347], ["RSV mutants", "PROBLEM", 373, 384], ["the SH protein (dSH", "PROBLEM", 409, 428], ["the combined deletion of SH", "PROBLEM", 433, 460], ["the GFP intensity", "TEST", 510, 527], ["an ELISA", "TEST", 605, 613], ["the same virus", "PROBLEM", 670, 684], ["siRNA", "TREATMENT", 726, 731], ["standard deviation", "OBSERVATION", 222, 240], ["RSV", "ANATOMY", 334, 337], ["infection", "OBSERVATION", 338, 347], ["total", "OBSERVATION_MODIFIER", 535, 540], ["A549 cells", "OBSERVATION", 562, 572], ["transfected siRNA", "OBSERVATION", 699, 716]]], ["(C and D) Flow cytometry analysis of RSV-GFP expression.", [["RSV", "ORGANISM", 37, 40], ["GFP", "GENE_OR_GENE_PRODUCT", 41, 44], ["RSV", "SPECIES", 37, 40], ["C and D) Flow cytometry analysis", "TEST", 1, 33], ["RSV", "TEST", 37, 40], ["GFP expression", "OBSERVATION", 41, 55]]], ["Following infection with RSV-GFP, the cells were incubated for 24 h, and GFP expression of single, live, GFP + cells was quantified by flow cytometry, with cells from an untransfected, uninfected well included for reference.", [["cells", "ANATOMY", 38, 43], ["GFP + cells", "ANATOMY", 105, 116], ["cells", "ANATOMY", 156, 161], ["infection", "DISEASE", 10, 19], ["RSV", "ORGANISM", 25, 28], ["GFP", "GENE_OR_GENE_PRODUCT", 29, 32], ["cells", "CELL", 38, 43], ["GFP", "GENE_OR_GENE_PRODUCT", 73, 76], ["GFP", "GENE_OR_GENE_PRODUCT", 105, 108], ["cells", "CELL", 111, 116], ["cells", "CELL", 156, 161], ["GFP", "PROTEIN", 29, 32], ["GFP", "PROTEIN", 105, 108], ["RSV", "SPECIES", 25, 28], ["infection", "PROBLEM", 10, 19], ["RSV", "PROBLEM", 25, 28], ["GFP expression", "TEST", 73, 87], ["flow cytometry", "TEST", 135, 149], ["cells", "TEST", 156, 161], ["infection", "OBSERVATION", 10, 19], ["flow cytometry", "OBSERVATION", 135, 149]]], ["The plot (C) shows cell count versus GFP intensity, and the histogram (D) shows GFP MFI relative to cells infected with the same virus for which the transfected siRNA was Neg. siRNA 1.", [["cell", "ANATOMY", 19, 23], ["cells", "ANATOMY", 100, 105], ["cell", "CELL", 19, 23], ["GFP", "GENE_OR_GENE_PRODUCT", 37, 40], ["GFP MFI", "GENE_OR_GENE_PRODUCT", 80, 87], ["cells", "CELL", 100, 105], ["GFP MFI", "PROTEIN", 80, 87], ["The plot (C", "TEST", 0, 11], ["cell count", "TEST", 19, 29], ["GFP intensity", "TEST", 37, 50], ["the histogram (D)", "TEST", 56, 73], ["GFP MFI", "PROBLEM", 80, 87], ["cells infected", "PROBLEM", 100, 114], ["the same virus", "PROBLEM", 120, 134], ["the transfected siRNA", "PROBLEM", 145, 166], ["siRNA", "TREATMENT", 176, 181], ["cell count", "OBSERVATION", 19, 29], ["transfected siRNA", "OBSERVATION", 149, 166]]], ["(E) Titer of progeny RSV-GFP.", [["RSV", "ORGANISM", 21, 24], ["GFP", "GENE_OR_GENE_PRODUCT", 25, 28], ["GFP", "PROTEIN", 25, 28], ["RSV", "SPECIES", 21, 24]]], ["Following infection with RSV-GFP (MOI = 1 PFU/cell), the cells were incubated for 24 h, and the cells and media were harvested together (Materials and Methods) and the yield of RSV-GFP was determined by plaque titration on Vero cells.", [["cell", "ANATOMY", 46, 50], ["cells", "ANATOMY", 57, 62], ["cells", "ANATOMY", 96, 101], ["plaque", "ANATOMY", 203, 209], ["Vero cells", "ANATOMY", 223, 233], ["infection", "DISEASE", 10, 19], ["RSV", "ORGANISM", 25, 28], ["GFP", "GENE_OR_GENE_PRODUCT", 29, 32], ["cell", "CELL", 46, 50], ["cells", "CELL", 57, 62], ["cells", "CELL", 96, 101], ["RSV", "ORGANISM", 177, 180], ["GFP", "GENE_OR_GENE_PRODUCT", 181, 184], ["Vero cells", "CELL", 223, 233], ["GFP", "PROTEIN", 181, 184], ["Vero cells", "CELL_LINE", 223, 233], ["RSV", "SPECIES", 25, 28], ["RSV", "SPECIES", 177, 180], ["infection", "PROBLEM", 10, 19], ["RSV", "TEST", 25, 28], ["MOI", "TEST", 34, 37], ["the cells", "PROBLEM", 53, 62], ["RSV", "PROBLEM", 177, 180], ["GFP", "TEST", 181, 184], ["Vero cells", "TREATMENT", 223, 233], ["infection", "OBSERVATION", 10, 19], ["plaque", "OBSERVATION", 203, 209], ["Vero cells", "OBSERVATION", 223, 233]]], ["All data in A-D are derived from at least three independent experiments and shown as mean values with error bars indicating the standard deviation.", [["A-D", "GENE_OR_GENE_PRODUCT", 12, 15], ["All data", "TEST", 0, 8], ["standard deviation", "OBSERVATION", 128, 146]]], ["The statistical significance of difference was determined by one-way analysis of variance with Dunnett's multiple comparison post-test and p-values are shown for each comparison.RSV G protein is required for ATP1A1 clusteringhttps://doi.org/10.1371/journal.ppat.1007963.g002 attachment G glycoprotein (dSH/dG) retained the ability to trigger the clustering of ATP1A1 (deletion of RSV F could not be investigated because it abrogates infectivity).", [["RSV G", "GENE_OR_GENE_PRODUCT", 178, 183], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 208, 214], ["G glycoprotein", "GENE_OR_GENE_PRODUCT", 286, 300], ["dSH", "GENE_OR_GENE_PRODUCT", 302, 305], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 360, 366], ["RSV F", "GENE_OR_GENE_PRODUCT", 380, 385], ["RSV G protein", "PROTEIN", 178, 191], ["ATP1A1", "PROTEIN", 208, 214], ["G glycoprotein", "PROTEIN", 286, 300], ["dSH", "PROTEIN", 302, 305], ["dG", "PROTEIN", 306, 308], ["ATP1A1", "PROTEIN", 360, 366], ["RSV F", "PROTEIN", 380, 385], ["RSV", "SPECIES", 178, 181], ["RSV", "SPECIES", 380, 383], ["p-values", "TEST", 139, 147], ["RSV G protein", "TEST", 178, 191], ["G glycoprotein (dSH/dG)", "TREATMENT", 286, 309], ["ATP1A1 (deletion of RSV F", "TREATMENT", 360, 385]]], ["A549 cells were infected with wt RSV, RSV dSH, or RSV dSH/dG (MOI = 10 PFU/cell) and incubated for 5 h.", [["A549 cells", "ANATOMY", 0, 10], ["cell", "ANATOMY", 75, 79], ["dG", "CHEMICAL", 58, 60], ["A549 cells", "CELL", 0, 10], ["RSV", "ORGANISM", 33, 36], ["RSV", "ORGANISM", 38, 41], ["RSV", "ORGANISM", 50, 53], ["cell", "CELL", 75, 79], ["A549 cells", "CELL_LINE", 0, 10], ["RSV", "SPECIES", 33, 36], ["RSV", "SPECIES", 38, 41], ["RSV", "SPECIES", 50, 53], ["A549 cells", "PROBLEM", 0, 10], ["wt RSV", "PROBLEM", 30, 36], ["RSV dSH", "PROBLEM", 38, 45], ["RSV dSH", "PROBLEM", 50, 57], ["MOI", "TEST", 62, 65]]], ["Cells were fixed, permeabilized and immunostained with antibodies specific to ATP1A1 (green) and RSV N (red) (Fig 4) .", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 78, 84], ["RSV", "ORGANISM", 97, 100], ["antibodies", "PROTEIN", 55, 65], ["ATP1A1", "PROTEIN", 78, 84], ["RSV", "SPECIES", 97, 100], ["antibodies", "TEST", 55, 65], ["ATP1A1", "TEST", 78, 84], ["RSV", "ANATOMY", 97, 100]]], ["Wt RSV was included as a reference and showed increased cluster formation compared to Fig 3, which may have been due to the increased MOI of 10 PFU/cell compared to 5 PFU/cell.", [["cell", "ANATOMY", 148, 152], ["cell", "ANATOMY", 171, 175], ["RSV", "ORGANISM", 3, 6], ["cell", "CELL", 148, 152], ["cell", "CELL", 171, 175], ["RSV", "SPECIES", 3, 6], ["Wt RSV", "TEST", 0, 6], ["increased cluster formation", "PROBLEM", 46, 73], ["the increased MOI", "PROBLEM", 120, 137], ["RSV", "OBSERVATION", 3, 6], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["cluster formation", "OBSERVATION", 56, 73]]], ["The RSV dSH virus induced clustering that was very similar to that with wt RSV, indicating that deletion of the SH protein seemed to have no effect on ATP1A1 clustering.", [["RSV dSH virus", "ORGANISM", 4, 17], ["RSV", "ORGANISM", 75, 78], ["SH", "GENE_OR_GENE_PRODUCT", 112, 114], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 151, 157], ["SH protein", "PROTEIN", 112, 122], ["ATP1A1", "PROTEIN", 151, 157], ["RSV dSH virus", "SPECIES", 4, 17], ["RSV", "SPECIES", 75, 78], ["The RSV dSH virus", "PROBLEM", 0, 17], ["wt RSV", "PROBLEM", 72, 78], ["deletion of the SH protein", "PROBLEM", 96, 122], ["ATP1A1 clustering", "PROBLEM", 151, 168], ["RSV", "ANATOMY", 4, 7], ["dSH virus", "OBSERVATION", 8, 17]]], ["On the other hand, the dSH/dG virus did not induce any ATP1A1 clustering, and the viral particles, stained for RSV N in red, were reduced in amount and were much more dispersed as compared to wt RSV and the dSH virus.", [["dG", "CHEMICAL", 27, 29], ["dSH/dG virus", "ORGANISM", 23, 35], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 55, 61], ["RSV", "ORGANISM", 111, 114], ["RSV", "ORGANISM", 195, 198], ["dSH virus", "ORGANISM", 207, 216], ["ATP1A1", "PROTEIN", 55, 61], ["RSV", "SPECIES", 111, 114], ["RSV", "SPECIES", 195, 198], ["dSH virus", "SPECIES", 207, 216], ["the dSH/dG virus", "PROBLEM", 19, 35], ["any ATP1A1 clustering", "PROBLEM", 51, 72], ["the viral particles", "PROBLEM", 78, 97], ["RSV N in red", "PROBLEM", 111, 123], ["the dSH virus", "PROBLEM", 203, 216], ["viral particles", "OBSERVATION", 82, 97], ["reduced", "OBSERVATION_MODIFIER", 130, 137], ["amount", "OBSERVATION_MODIFIER", 141, 147]]], ["The lack of ATP1A1 cluster formation with the dSH/dG virus suggested that RSV G protein is involved in triggering ATP1A1 clustering.Ouabain and PST2238 inhibit RSV infectionThe clustering of ATP1A1 in response to RSV exposure suggested that its signaling function might play a role in RSV infection.", [["Ouabain", "CHEMICAL", 132, 139], ["PST2238", "CHEMICAL", 144, 151], ["RSV infection", "DISEASE", 160, 173], ["RSV infection", "DISEASE", 285, 298], ["Ouabain", "CHEMICAL", 132, 139], ["PST2238", "CHEMICAL", 144, 151], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 12, 18], ["dSH/dG virus", "ORGANISM", 46, 58], ["RSV G", "GENE_OR_GENE_PRODUCT", 74, 79], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 114, 120], ["Ouabain", "SIMPLE_CHEMICAL", 132, 139], ["PST2238", "SIMPLE_CHEMICAL", 144, 151], ["RSV", "ORGANISM", 160, 163], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 191, 197], ["RSV", "ORGANISM", 213, 216], ["RSV", "ORGANISM", 285, 288], ["ATP1A1", "PROTEIN", 12, 18], ["dSH", "PROTEIN", 46, 49], ["RSV G protein", "PROTEIN", 74, 87], ["ATP1A1", "PROTEIN", 114, 120], ["ATP1A1", "PROTEIN", 191, 197], ["RSV", "SPECIES", 74, 77], ["RSV", "SPECIES", 160, 163], ["RSV", "SPECIES", 213, 216], ["RSV", "SPECIES", 285, 288], ["ATP1A1 cluster formation", "PROBLEM", 12, 36], ["the dSH/dG virus", "PROBLEM", 42, 58], ["RSV G protein", "PROBLEM", 74, 87], ["Ouabain", "TREATMENT", 132, 139], ["RSV infection", "PROBLEM", 160, 173], ["RSV exposure", "PROBLEM", 213, 225], ["RSV infection", "PROBLEM", 285, 298], ["RSV", "OBSERVATION_MODIFIER", 160, 163], ["infection", "OBSERVATION", 164, 173], ["RSV exposure", "OBSERVATION", 213, 225], ["RSV", "OBSERVATION_MODIFIER", 285, 288], ["infection", "OBSERVATION", 289, 298]]], ["For example, ATP1A1 signaling cascades can result in the induction of endocytosis including clathrin-mediated or caveolin-mediated endocytosis, or macropinocytosis, which could be involved in RSV entry.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 13, 19], ["clathrin", "GENE_OR_GENE_PRODUCT", 92, 100], ["caveolin", "GENE_OR_GENE_PRODUCT", 113, 121], ["RSV", "ORGANISM", 192, 195], ["ATP1A1", "PROTEIN", 13, 19], ["clathrin", "PROTEIN", 92, 100], ["caveolin", "PROTEIN", 113, 121], ["RSV", "SPECIES", 192, 195], ["ATP1A1 signaling cascades", "PROBLEM", 13, 38], ["endocytosis", "PROBLEM", 70, 81], ["clathrin", "PROBLEM", 92, 100], ["caveolin-mediated endocytosis", "PROBLEM", 113, 142], ["macropinocytosis", "PROBLEM", 147, 163], ["endocytosis", "OBSERVATION", 131, 142], ["RSV entry", "OBSERVATION", 192, 201]]], ["The only known agonists for ATP1A1 signaling are CTS such as ouabain, which activate non-receptor tyrosine kinase Srcmediated signaling pathways [29] .", [["CTS", "DISEASE", 49, 52], ["ouabain", "CHEMICAL", 61, 68], ["tyrosine", "CHEMICAL", 98, 106], ["ouabain", "CHEMICAL", 61, 68], ["tyrosine", "CHEMICAL", 98, 106], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 28, 34], ["ouabain", "SIMPLE_CHEMICAL", 61, 68], ["non-receptor tyrosine kinase", "GENE_OR_GENE_PRODUCT", 85, 113], ["ATP1A1", "PROTEIN", 28, 34], ["non-receptor tyrosine kinase", "PROTEIN", 85, 113], ["ATP1A1 signaling", "PROBLEM", 28, 44], ["CTS", "TEST", 49, 52], ["ouabain", "TEST", 61, 68], ["non-receptor tyrosine kinase", "TEST", 85, 113], ["signaling pathways", "TEST", 126, 144]]], ["The synthetic digitoxigenin derivative PST2238 is a competitive inhibitor of ouabain that inhibits ouabain binding and signaling [37] .", [["digitoxigenin", "CHEMICAL", 14, 27], ["PST2238", "CHEMICAL", 39, 46], ["ouabain", "CHEMICAL", 77, 84], ["ouabain", "CHEMICAL", 99, 106], ["digitoxigenin", "CHEMICAL", 14, 27], ["PST2238", "CHEMICAL", 39, 46], ["ouabain", "CHEMICAL", 77, 84], ["ouabain", "CHEMICAL", 99, 106], ["digitoxigenin derivative", "SIMPLE_CHEMICAL", 14, 38], ["PST2238", "SIMPLE_CHEMICAL", 39, 46], ["ouabain", "SIMPLE_CHEMICAL", 77, 84], ["ouabain", "SIMPLE_CHEMICAL", 99, 106], ["The synthetic digitoxigenin derivative", "TREATMENT", 0, 38], ["a competitive inhibitor of ouabain", "TREATMENT", 50, 84], ["ouabain binding", "PROBLEM", 99, 114]]], ["Therefore, we tested ouabain and PST2238 for their effects on RSV infection.Ouabain and PST2238 inhibit RSV infectionSerial dilutions of ouabain and PST2238 were evaluated for cytotoxicity on A549 cells (S3C and S3D Fig) , and we selected concentrations for ouabain (25 nM) and PST2238 (20 \u03bcM) that had less than 20% reduction in cell viability 24 h post treatment, which was the longest treatment period for these studies.", [["A549 cells", "ANATOMY", 192, 202], ["cell", "ANATOMY", 330, 334], ["ouabain", "CHEMICAL", 21, 28], ["PST2238", "CHEMICAL", 33, 40], ["RSV infection", "DISEASE", 62, 75], ["Ouabain", "CHEMICAL", 76, 83], ["PST2238", "CHEMICAL", 88, 95], ["ouabain", "CHEMICAL", 137, 144], ["PST2238", "CHEMICAL", 149, 156], ["ouabain", "CHEMICAL", 258, 265], ["PST2238", "CHEMICAL", 278, 285], ["ouabain", "CHEMICAL", 21, 28], ["PST2238", "CHEMICAL", 33, 40], ["Ouabain", "CHEMICAL", 76, 83], ["PST2238", "CHEMICAL", 88, 95], ["ouabain", "CHEMICAL", 137, 144], ["PST2238", "CHEMICAL", 149, 156], ["ouabain", "CHEMICAL", 258, 265], ["PST2238", "CHEMICAL", 278, 285], ["ouabain", "SIMPLE_CHEMICAL", 21, 28], ["PST2238", "SIMPLE_CHEMICAL", 33, 40], ["RSV", "ORGANISM", 62, 65], ["Ouabain", "SIMPLE_CHEMICAL", 76, 83], ["PST2238", "SIMPLE_CHEMICAL", 88, 95], ["RSV", "ORGANISM", 104, 107], ["ouabain", "SIMPLE_CHEMICAL", 137, 144], ["PST2238", "SIMPLE_CHEMICAL", 149, 156], ["A549 cells", "CELL", 192, 202], ["S3C", "CELL", 204, 207], ["S3D Fig", "CELL", 212, 219], ["ouabain", "SIMPLE_CHEMICAL", 258, 265], ["PST2238", "SIMPLE_CHEMICAL", 278, 285], ["cell", "CELL", 330, 334], ["A549 cells", "CELL_LINE", 192, 202], ["RSV", "SPECIES", 62, 65], ["RSV", "SPECIES", 104, 107], ["ouabain", "TREATMENT", 21, 28], ["PST2238", "TREATMENT", 33, 40], ["RSV infection", "PROBLEM", 62, 75], ["Ouabain", "TEST", 76, 83], ["PST2238", "TEST", 88, 95], ["RSV infectionSerial dilutions of ouabain", "PROBLEM", 104, 144], ["PST2238", "TEST", 149, 156], ["cytotoxicity", "PROBLEM", 176, 188], ["A549 cells", "TEST", 192, 202], ["S3C", "TEST", 204, 207], ["ouabain", "TEST", 258, 265], ["PST2238", "TEST", 278, 285], ["treatment", "TREATMENT", 355, 364], ["these studies", "TEST", 409, 422], ["RSV", "ANATOMY", 62, 65], ["infection", "OBSERVATION", 66, 75], ["A549 cells", "OBSERVATION", 192, 202], ["cell viability", "OBSERVATION", 330, 344]]], ["The effects of ouabain and PST2238 on ATP1A1 and EGFR expression were analyzed by immunofluorescence microscopy (Fig 5A) using antibodies specific for ATP1A1 and EGFR.", [["ouabain", "CHEMICAL", 15, 22], ["PST2238", "CHEMICAL", 27, 34], ["ouabain", "CHEMICAL", 15, 22], ["PST2238", "CHEMICAL", 27, 34], ["ouabain", "SIMPLE_CHEMICAL", 15, 22], ["PST2238", "SIMPLE_CHEMICAL", 27, 34], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 38, 44], ["EGFR", "GENE_OR_GENE_PRODUCT", 49, 53], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 151, 157], ["EGFR", "GENE_OR_GENE_PRODUCT", 162, 166], ["ATP1A1", "PROTEIN", 38, 44], ["EGFR", "PROTEIN", 49, 53], ["ATP1A1", "PROTEIN", 151, 157], ["EGFR", "PROTEIN", 162, 166], ["ouabain", "TEST", 15, 22], ["PST2238", "TEST", 27, 34], ["ATP1A1", "TEST", 38, 44], ["EGFR expression", "TEST", 49, 64], ["immunofluorescence microscopy", "TEST", 82, 111], ["antibodies", "TEST", 127, 137], ["ATP1A1", "TEST", 151, 157], ["EGFR", "TEST", 162, 166]]], ["EGFR was evaluated in addition to ATP1A1 because it previously was shown to be important for RSV entry [14] and is closely associated with the ATP1A1 signalosome [31, 32] .", [["EGFR", "GENE_OR_GENE_PRODUCT", 0, 4], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 34, 40], ["RSV", "ORGANISM", 93, 96], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 143, 149], ["EGFR", "PROTEIN", 0, 4], ["ATP1A1", "PROTEIN", 34, 40], ["ATP1A1 signalosome", "PROTEIN", 143, 161], ["RSV", "SPECIES", 93, 96], ["EGFR", "TEST", 0, 4], ["ATP1A1", "TREATMENT", 34, 40]]], ["In mock-treated cells, ATP1A1 and EGFR had homogeneous membrane distributions ( Fig 5A, left column) .", [["cells", "ANATOMY", 16, 21], ["membrane", "ANATOMY", 55, 63], ["cells", "CELL", 16, 21], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 23, 29], ["EGFR", "GENE_OR_GENE_PRODUCT", 34, 38], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["mock-treated cells", "CELL_LINE", 3, 21], ["ATP1A1", "PROTEIN", 23, 29], ["EGFR", "PROTEIN", 34, 38], ["ATP1A1", "TEST", 23, 29], ["EGFR", "TEST", 34, 38], ["homogeneous membrane distributions", "PROBLEM", 43, 77], ["homogeneous", "OBSERVATION_MODIFIER", 43, 54], ["membrane distributions", "OBSERVATION", 55, 77], ["left", "ANATOMY_MODIFIER", 88, 92], ["column", "ANATOMY", 93, 99]]], ["After 24 h treatment with ouabain, the ATP1A1 level was greatly reduced (Fig 5A, middle column, top panel)-presumably due to the removal of cellsurface Na + ,K + -ATPase by clathrin-mediated endocytosis induced by ATP1A1 signaling [35, 36] -while EGFR expression and localization appeared unchanged ( Fig 5A, RSV G is required for ATP1A1 clustering.", [["ouabain", "CHEMICAL", 26, 33], ["Na", "CHEMICAL", 152, 154], ["K", "CHEMICAL", 158, 159], ["ouabain", "CHEMICAL", 26, 33], ["Na +", "CHEMICAL", 152, 156], ["K +", "CHEMICAL", 158, 161], ["ouabain", "SIMPLE_CHEMICAL", 26, 33], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 39, 45], ["cellsurface Na + ,K + -ATPase", "GENE_OR_GENE_PRODUCT", 140, 169], ["clathrin", "GENE_OR_GENE_PRODUCT", 173, 181], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 247, 251], ["RSV G", "GENE_OR_GENE_PRODUCT", 309, 314], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 331, 337], ["ATP1A1", "PROTEIN", 39, 45], ["cellsurface Na + ,K + -ATPase", "PROTEIN", 140, 169], ["clathrin", "PROTEIN", 173, 181], ["ATP1A1", "PROTEIN", 214, 220], ["EGFR", "PROTEIN", 247, 251], ["RSV G", "PROTEIN", 309, 314], ["ATP1A1", "PROTEIN", 331, 337], ["RSV", "SPECIES", 309, 312], ["ouabain", "TREATMENT", 26, 33], ["the ATP1A1 level", "TEST", 35, 51], ["greatly reduced", "PROBLEM", 56, 71], ["Fig 5A", "TEST", 73, 79], ["middle column", "TEST", 81, 94], ["top panel", "TEST", 96, 105], ["cellsurface", "TEST", 140, 151], ["Na", "TEST", 152, 154], ["K", "TEST", 158, 159], ["clathrin", "TEST", 173, 181], ["ATP1A1 signaling", "TEST", 214, 230], ["EGFR expression", "TEST", 247, 262], ["RSV G", "TREATMENT", 309, 314], ["ATP1A1 clustering", "PROBLEM", 331, 348], ["unchanged", "OBSERVATION_MODIFIER", 289, 298]]], ["A549 cells were inoculated with wt RSV, rgRSV-dSH or rgRSV-dSH/dG (MOI = 10 PFU/cell) and incubated for 5 h.", [["A549 cells", "ANATOMY", 0, 10], ["cell", "ANATOMY", 80, 84], ["rgRSV-dSH/dG", "CHEMICAL", 53, 65], ["A549 cells", "CELL", 0, 10], ["RSV", "ORGANISM", 35, 38], ["rgRSV-dSH", "SIMPLE_CHEMICAL", 40, 49], ["rgRSV", "ORGANISM", 53, 58], ["dG", "SIMPLE_CHEMICAL", 63, 65], ["cell", "CELL", 80, 84], ["A549 cells", "CELL_LINE", 0, 10], ["RSV", "SPECIES", 35, 38], ["A549 cells", "TEST", 0, 10], ["wt", "TEST", 32, 34], ["RSV", "TEST", 35, 38], ["rgRSV", "TEST", 40, 45], ["dSH", "PROBLEM", 46, 49], ["rgRSV", "TEST", 53, 58], ["dSH", "PROBLEM", 59, 62], ["dG", "PROBLEM", 63, 65], ["MOI", "TEST", 67, 70]]], ["Cells were fixed with 4% PFA and subjected to immunofluorescence staining, as described for Fig 3.", [["Cells", "ANATOMY", 0, 5], ["PFA", "CHEMICAL", 25, 28], ["Cells", "CELL", 0, 5], ["PFA", "SIMPLE_CHEMICAL", 25, 28], ["Cells", "TEST", 0, 5], ["4% PFA", "TREATMENT", 22, 28], ["immunofluorescence staining", "TEST", 46, 73]]], ["ATP1A1 (green) was detected by an anti-ATP1A1 rabbit MAb (ab76020) and AF568-conjugated donkey anti-rabbit secondary antibody.", [["AF568", "CHEMICAL", 71, 76], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 0, 6], ["ab76020", "SIMPLE_CHEMICAL", 58, 65], ["AF568", "SIMPLE_CHEMICAL", 71, 76], ["ATP1A1", "PROTEIN", 0, 6], ["anti-ATP1A1 rabbit MAb", "PROTEIN", 34, 56], ["ab76020", "PROTEIN", 58, 65], ["AF568", "PROTEIN", 71, 76], ["conjugated donkey anti-rabbit secondary antibody", "PROTEIN", 77, 125], ["rabbit", "SPECIES", 46, 52], ["donkey", "SPECIES", 88, 94], ["anti-rabbit", "SPECIES", 95, 106], ["rabbit", "SPECIES", 46, 52], ["donkey", "SPECIES", 88, 94], ["an anti-ATP1A1 rabbit MAb", "TEST", 31, 56], ["AF568", "TEST", 71, 76]]], ["RSV N (red) was detected by an anti-RSV N mouse MAb (ab94806) and an AF647-conjugated donkey anti-mouse secondary antibody.", [["RSV", "ORGANISM", 0, 3], ["mouse", "ORGANISM", 42, 47], ["AF647", "SIMPLE_CHEMICAL", 69, 74], ["anti-RSV N mouse MAb", "PROTEIN", 31, 51], ["ab94806", "PROTEIN", 53, 60], ["AF647", "PROTEIN", 69, 74], ["conjugated donkey anti-mouse secondary antibody", "PROTEIN", 75, 122], ["mouse", "SPECIES", 42, 47], ["donkey", "SPECIES", 86, 92], ["anti-mouse", "SPECIES", 93, 103], ["RSV", "SPECIES", 0, 3], ["mouse", "SPECIES", 42, 47], ["donkey", "SPECIES", 86, 92], ["an anti-RSV N mouse MAb", "TREATMENT", 28, 51], ["an AF647", "TEST", 66, 74]]], ["The cell nuclei were stained with DAPI (blue).", [["cell nuclei", "ANATOMY", 4, 15], ["DAPI", "CHEMICAL", 34, 38], ["cell nuclei", "CELL", 4, 15], ["DAPI", "SIMPLE_CHEMICAL", 34, 38], ["cell nuclei", "OBSERVATION", 4, 15]]], ["Images (z-stacks) were acquired on a Leica SP8 confocal microscope, with a 63x objective (NA 1.4) and a zoom of 3.0.", [["NA", "TEST", 90, 92], ["a zoom", "TEST", 102, 108]]], ["Scale bar 10 \u03bcm.Ouabain and PST2238 inhibit RSV infectionhttps://doi.org/10.1371/journal.ppat.1007963.g004 ATP1A1 signaling is required for macropinocytic entry of RSV Uninfected A549 cells were treated for 24 h with either 25 nM ouabain or 20 \u03bcM PST2238 and subjected to an immunofluorescence staining.", [["macropinocytic", "ANATOMY", 140, 154], ["A549 cells", "ANATOMY", 179, 189], ["Ouabain", "CHEMICAL", 16, 23], ["PST2238", "CHEMICAL", 28, 35], ["infectionhttps://doi.org/10.1371/journal.ppat.1007963.g004", "CHEMICAL", 48, 106], ["ouabain", "CHEMICAL", 230, 237], ["PST2238", "CHEMICAL", 247, 254], ["Ouabain", "CHEMICAL", 16, 23], ["PST2238", "CHEMICAL", 28, 35], ["ouabain", "CHEMICAL", 230, 237], ["PST2238", "CHEMICAL", 247, 254], ["Ouabain", "SIMPLE_CHEMICAL", 16, 23], ["PST2238", "SIMPLE_CHEMICAL", 28, 35], ["RSV", "ORGANISM", 44, 47], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 107, 113], ["RSV", "ORGANISM", 164, 167], ["A549 cells", "CELL", 179, 189], ["ouabain", "SIMPLE_CHEMICAL", 230, 237], ["PST2238", "SIMPLE_CHEMICAL", 247, 254], ["ATP1A1", "PROTEIN", 107, 113], ["A549 cells", "CELL_LINE", 179, 189], ["RSV", "SPECIES", 44, 47], ["RSV", "SPECIES", 164, 167], ["Ouabain", "TEST", 16, 23], ["RSV", "PROBLEM", 44, 47], ["an immunofluorescence staining", "PROBLEM", 272, 302], ["RSV", "OBSERVATION", 44, 47], ["A549 cells", "OBSERVATION", 179, 189]]], ["ATP1A1 (green) was detected by an anti-ATP1A1 rabbit MAb (ab76020) and an AF488-conjugated donkey anti-rabbit secondary antibody.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 0, 6], ["AF488", "SIMPLE_CHEMICAL", 74, 79], ["ATP1A1", "PROTEIN", 0, 6], ["anti-ATP1A1 rabbit MAb", "PROTEIN", 34, 56], ["ab76020", "PROTEIN", 58, 65], ["AF488", "PROTEIN", 74, 79], ["conjugated donkey anti-rabbit secondary antibody", "PROTEIN", 80, 128], ["rabbit", "SPECIES", 46, 52], ["donkey", "SPECIES", 91, 97], ["anti-rabbit", "SPECIES", 98, 109], ["rabbit", "SPECIES", 46, 52], ["anti-rabbit", "SPECIES", 98, 109], ["an anti-ATP1A1 rabbit MAb", "TEST", 31, 56], ["an AF488", "TEST", 71, 79]]], ["EGFR (red) was detected by an anti-EGFR rat MAb (ab231) and an AF647-conjugated goat anti-rat secondary antibody.", [["AF647", "CHEMICAL", 63, 68], ["EGFR", "GENE_OR_GENE_PRODUCT", 0, 4], ["rat", "ORGANISM", 40, 43], ["ab231", "GENE_OR_GENE_PRODUCT", 49, 54], ["AF647", "SIMPLE_CHEMICAL", 63, 68], ["EGFR", "PROTEIN", 0, 4], ["anti-EGFR rat MAb", "PROTEIN", 30, 47], ["ab231", "PROTEIN", 49, 54], ["AF647", "PROTEIN", 63, 68], ["goat anti-rat secondary antibody", "PROTEIN", 80, 112], ["rat", "SPECIES", 40, 43], ["goat", "SPECIES", 80, 84], ["rat", "SPECIES", 40, 43], ["goat", "SPECIES", 80, 84], ["EGFR", "TEST", 0, 4], ["an anti-EGFR rat MAb", "TEST", 27, 47], ["an AF647", "TEST", 60, 68]]], ["The cell nuclei were stained with DAPI (blue).", [["cell nuclei", "ANATOMY", 4, 15], ["DAPI", "CHEMICAL", 34, 38], ["cell nuclei", "CELL", 4, 15], ["DAPI", "SIMPLE_CHEMICAL", 34, 38], ["cell nuclei", "OBSERVATION", 4, 15]]], ["RSV infection was evaluated by (i) GFP expression 17 h p.i.", [["RSV infection", "DISEASE", 0, 13], ["RSV", "ORGANISM", 0, 3], ["GFP", "GENE_OR_GENE_PRODUCT", 35, 38], ["RSV", "SPECIES", 0, 3], ["RSV infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13]]], ["(Fig 5B) , and (ii) the yield of progeny RSV harvested 24 h p.i., quantified by plaque assay on Vero cells (Fig 5C) .", [["plaque", "ANATOMY", 80, 86], ["Vero cells", "ANATOMY", 96, 106], ["RSV", "ORGANISM", 41, 44], ["Vero cells", "CELL", 96, 106], ["Vero cells", "CELL_LINE", 96, 106], ["RSV", "SPECIES", 41, 44], ["progeny RSV harvested", "TREATMENT", 33, 54], ["Vero cells (Fig 5C", "TREATMENT", 96, 114], ["RSV harvested", "OBSERVATION", 41, 54], ["plaque", "OBSERVATION", 80, 86]]], ["Both methods correlated well, and demonstrated a reduction in RSV replication for both compounds that was greater than that achieved with the ATP1A1-specific siR-NAs (Fig 2) .", [["RSV", "ORGANISM", 62, 65], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 142, 148], ["siR-NAs", "GENE_OR_GENE_PRODUCT", 158, 165], ["ATP1A1", "PROTEIN", 142, 148], ["siR", "PROTEIN", 158, 161], ["RSV", "SPECIES", 62, 65], ["a reduction in RSV replication", "TREATMENT", 47, 77], ["the ATP1A1", "TEST", 138, 148], ["reduction", "OBSERVATION_MODIFIER", 49, 58], ["RSV replication", "OBSERVATION", 62, 77]]], ["Ouabain had the strongest effect: it reduced viral GFP expression by 96% and virus yield by almost 3.0 log 10 compared to infected cells that did not receive the drug, and the corresponding reductions observed with PST2238 were 89% (GFP reduction) and 2.0 log 10 (reduction in viral yield).Ouabain and PST2238 inhibit RSV infectionTo investigate the stage of RSV infection that is inhibited by the compounds, a \"time of addition\" experiment was performed.", [["cells", "ANATOMY", 131, 136], ["Ouabain", "CHEMICAL", 0, 7], ["PST2238", "CHEMICAL", 215, 222], ["Ouabain", "CHEMICAL", 290, 297], ["PST2238", "CHEMICAL", 302, 309], ["RSV infection", "DISEASE", 359, 372], ["Ouabain", "CHEMICAL", 0, 7], ["PST2238", "CHEMICAL", 215, 222], ["Ouabain", "CHEMICAL", 290, 297], ["PST2238", "CHEMICAL", 302, 309], ["Ouabain", "SIMPLE_CHEMICAL", 0, 7], ["GFP", "GENE_OR_GENE_PRODUCT", 51, 54], ["cells", "CELL", 131, 136], ["PST2238", "SIMPLE_CHEMICAL", 215, 222], ["GFP", "GENE_OR_GENE_PRODUCT", 233, 236], ["Ouabain", "SIMPLE_CHEMICAL", 290, 297], ["PST2238", "SIMPLE_CHEMICAL", 302, 309], ["RSV", "ORGANISM", 318, 321], ["RSV", "ORGANISM", 359, 362], ["infected cells", "CELL_TYPE", 122, 136], ["RSV", "SPECIES", 318, 321], ["RSV", "SPECIES", 359, 362], ["Ouabain", "TREATMENT", 0, 7], ["virus yield", "TEST", 77, 88], ["infected cells", "PROBLEM", 122, 136], ["PST2238", "TEST", 215, 222], ["GFP reduction", "TEST", 233, 246], ["Ouabain", "TREATMENT", 290, 297], ["RSV infectionTo", "PROBLEM", 318, 333], ["RSV infection", "PROBLEM", 359, 372], ["RSV", "OBSERVATION", 318, 321], ["RSV", "OBSERVATION_MODIFIER", 359, 362], ["infection", "OBSERVATION", 363, 372]]], ["A549 cells were infected with RSV-GFP (MOI = 3 PFU/ cell), and at different times p.i. ouabain (Fig 5D and 5E ) or PST2238 (Fig 5F and 5G ) was added.", [["A549 cells", "ANATOMY", 0, 10], ["cell", "ANATOMY", 52, 56], ["ouabain", "CHEMICAL", 87, 94], ["PST2238", "CHEMICAL", 115, 122], ["ouabain", "CHEMICAL", 87, 94], ["PST2238", "CHEMICAL", 115, 122], ["A549 cells", "CELL", 0, 10], ["RSV", "ORGANISM", 30, 33], ["GFP", "GENE_OR_GENE_PRODUCT", 34, 37], ["cell", "CELL", 52, 56], ["ouabain", "SIMPLE_CHEMICAL", 87, 94], ["PST2238", "SIMPLE_CHEMICAL", 115, 122], ["A549 cells", "CELL_LINE", 0, 10], ["RSV", "SPECIES", 30, 33], ["A549 cells", "PROBLEM", 0, 10], ["RSV", "TEST", 30, 33], ["MOI", "TEST", 39, 42], ["PST2238 (Fig 5F", "TREATMENT", 115, 130]]], ["Cells were incubated for a total of 24 h p.i. and the viral GFP expression intensity of single, live cells was analyzed by flow cytometry.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 101, 106], ["Cells", "CELL", 0, 5], ["GFP", "GENE_OR_GENE_PRODUCT", 60, 63], ["cells", "CELL", 101, 106], ["the viral GFP", "TEST", 50, 63], ["flow cytometry", "TEST", 123, 137]]], ["For both compounds, the strongest inhibitory effect was observed when the inhibitor was added simultaneously with RSV-GFP at 0 h, resulting in 85% and 66% reduction of GFP expression by ouabain and PST2238, respectively ( Fig 5D-5G ).", [["ouabain", "CHEMICAL", 186, 193], ["PST2238", "CHEMICAL", 198, 205], ["ouabain", "CHEMICAL", 186, 193], ["PST2238", "CHEMICAL", 198, 205], ["RSV", "ORGANISM", 114, 117], ["GFP", "GENE_OR_GENE_PRODUCT", 118, 121], ["GFP", "GENE_OR_GENE_PRODUCT", 168, 171], ["ouabain", "SIMPLE_CHEMICAL", 186, 193], ["PST2238", "SIMPLE_CHEMICAL", 198, 205], ["GFP", "PROTEIN", 118, 121], ["GFP", "PROTEIN", 168, 171], ["RSV", "SPECIES", 114, 117], ["the inhibitor", "TREATMENT", 70, 83], ["RSV", "TEST", 114, 117], ["ouabain", "TEST", 186, 193], ["PST2238", "TEST", 198, 205]]], ["The inhibition of infection continued to diminish and was almost completely lost when the drugs were added at 10 h p.i.", [["infection", "DISEASE", 18, 27], ["infection", "PROBLEM", 18, 27], ["the drugs", "TREATMENT", 86, 95], ["infection", "OBSERVATION", 18, 27], ["diminish", "OBSERVATION_MODIFIER", 41, 49]]], ["These results suggest a role for ATP1A1 early in infection, such as uptake and entry.Ouabain and PST2238 inhibit RSV infectionWe also investigated whether PST2238 treatment had any effect on the clustering of ATP1A1 that was noted above in response to RSV.", [["infection", "DISEASE", 49, 58], ["Ouabain", "CHEMICAL", 85, 92], ["PST2238", "CHEMICAL", 97, 104], ["PST2238", "CHEMICAL", 155, 162], ["Ouabain", "CHEMICAL", 85, 92], ["PST2238", "CHEMICAL", 97, 104], ["PST2238", "CHEMICAL", 155, 162], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 33, 39], ["Ouabain", "SIMPLE_CHEMICAL", 85, 92], ["PST2238", "SIMPLE_CHEMICAL", 97, 104], ["RSV", "ORGANISM", 113, 116], ["PST2238", "SIMPLE_CHEMICAL", 155, 162], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 209, 215], ["RSV", "ORGANISM", 252, 255], ["ATP1A1", "PROTEIN", 33, 39], ["ATP1A1", "PROTEIN", 209, 215], ["RSV", "SPECIES", 113, 116], ["RSV", "SPECIES", 252, 255], ["ATP1A1", "PROBLEM", 33, 39], ["infection", "PROBLEM", 49, 58], ["Ouabain", "TREATMENT", 85, 92], ["RSV infectionWe", "PROBLEM", 113, 128], ["PST2238 treatment", "TREATMENT", 155, 172], ["the clustering of ATP1A1", "PROBLEM", 191, 215], ["RSV", "PROBLEM", 252, 255], ["infection", "OBSERVATION", 49, 58], ["RSV", "OBSERVATION", 113, 116]]], ["A549 cells were pretreated with PST2238 as described above and visualized by confocal microscopy.", [["A549 cells", "ANATOMY", 0, 10], ["PST2238", "CHEMICAL", 32, 39], ["PST2238", "CHEMICAL", 32, 39], ["A549 cells", "CELL", 0, 10], ["PST2238", "SIMPLE_CHEMICAL", 32, 39], ["A549 cells", "CELL_LINE", 0, 10], ["A549 cells", "PROBLEM", 0, 10], ["confocal microscopy", "TEST", 77, 96]]], ["PST2238 treatment had no apparent effect on ATP1A1 clustering.", [["PST2238", "CHEMICAL", 0, 7], ["PST2238", "CHEMICAL", 0, 7], ["PST2238", "SIMPLE_CHEMICAL", 0, 7], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 44, 50], ["ATP1A1", "PROTEIN", 44, 50], ["treatment", "TREATMENT", 8, 17], ["ATP1A1 clustering", "PROBLEM", 44, 61], ["no apparent", "UNCERTAINTY", 22, 33]]], ["This indicates that clustering of ATP1A1 did not depend on signaling from ATP1A1 and occurs prior to the step blocked by PST2238.Src-kinase activity is required for RSV entryWe next investigated the downstream signaling pathways of ATP1A1 that might be involved in ATP1A1-dependent RSV entry.", [["PST2238", "CHEMICAL", 121, 128], ["PST2238", "CHEMICAL", 121, 128], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 34, 40], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 74, 80], ["PST2238", "SIMPLE_CHEMICAL", 121, 128], ["Src", "GENE_OR_GENE_PRODUCT", 129, 132], ["RSV", "ORGANISM", 165, 168], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 232, 238], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 265, 271], ["RSV", "ORGANISM", 282, 285], ["ATP1A1", "PROTEIN", 34, 40], ["ATP1A1", "PROTEIN", 74, 80], ["Src", "PROTEIN", 129, 132], ["ATP1A1", "PROTEIN", 232, 238], ["ATP1A1", "PROTEIN", 265, 271], ["RSV", "SPECIES", 165, 168], ["RSV", "SPECIES", 282, 285], ["clustering of ATP1A1", "PROBLEM", 20, 40], ["ATP1A1", "TEST", 74, 80], ["Src", "TEST", 129, 132], ["dependent", "OBSERVATION_MODIFIER", 272, 281], ["RSV entry", "OBSERVATION", 282, 291]]], ["Binding of ouabain to ATP1A1 activates the c-Src-kinase that transactivates EGFR signaling [17] .", [["ouabain", "CHEMICAL", 11, 18], ["ouabain", "CHEMICAL", 11, 18], ["ouabain", "SIMPLE_CHEMICAL", 11, 18], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 22, 28], ["c-Src", "GENE_OR_GENE_PRODUCT", 43, 48], ["EGFR", "GENE_OR_GENE_PRODUCT", 76, 80], ["ATP1A1", "PROTEIN", 22, 28], ["c-Src-kinase", "PROTEIN", 43, 55], ["EGFR", "PROTEIN", 76, 80], ["ATP1A1", "TEST", 22, 28], ["the c-Src", "TEST", 39, 48], ["EGFR signaling", "TEST", 76, 90]]], ["Therefore, we investigated whether c-Src activity is needed for RSV infection, which was done using two Src-kinase inhibitors PP2 and Src-Inhibitior I (SrcI-I).", [["RSV infection", "DISEASE", 64, 77], ["PP2", "CHEMICAL", 126, 129], ["c-Src", "GENE_OR_GENE_PRODUCT", 35, 40], ["RSV", "ORGANISM", 64, 67], ["Src-", "GENE_OR_GENE_PRODUCT", 104, 108], ["PP2", "SIMPLE_CHEMICAL", 126, 129], ["Src-Inhibitior I", "GENE_OR_GENE_PRODUCT", 134, 150], ["SrcI-I", "GENE_OR_GENE_PRODUCT", 152, 158], ["Src", "PROTEIN", 37, 40], ["Src", "PROTEIN", 134, 137], ["Inhibitior I", "PROTEIN", 138, 150], ["SrcI-I", "PROTEIN", 152, 158], ["RSV", "SPECIES", 64, 67], ["c-Src activity", "PROBLEM", 35, 49], ["RSV infection", "PROBLEM", 64, 77], ["two Src-kinase inhibitors", "TREATMENT", 100, 125], ["PP2", "TEST", 126, 129], ["Src", "TEST", 134, 137]]], ["A549 cells were pre-treated with these inhibitors separately or together for 5 h, using concentrations that preliminary studies showed were non-cytotoxic (S4 Fig) , followed by infection with RSV-GFP (MOI = 1 PFU/cell) in the continued presence of inhibitors.", [["A549 cells", "ANATOMY", 0, 10], ["cell", "ANATOMY", 213, 217], ["infection", "DISEASE", 177, 186], ["A549 cells", "CELL", 0, 10], ["RSV", "ORGANISM", 192, 195], ["GFP", "GENE_OR_GENE_PRODUCT", 196, 199], ["cell", "CELL", 213, 217], ["A549 cells", "CELL_LINE", 0, 10], ["RSV", "SPECIES", 192, 195], ["A549 cells", "PROBLEM", 0, 10], ["these inhibitors", "TREATMENT", 33, 49], ["preliminary studies", "TEST", 108, 127], ["non-cytotoxic (S4 Fig", "PROBLEM", 140, 161], ["infection", "PROBLEM", 177, 186], ["RSV", "TEST", 192, 195], ["MOI", "TEST", 201, 204], ["inhibitors", "TREATMENT", 248, 258], ["infection", "OBSERVATION", 177, 186]]], ["The efficiency of RSV infection was evaluated by (i) GFP expression at 17 h p.i. for all treatments (Fig 6A) , and (ii) RSV titration at 24 h p.i. for cells that had been treated with both inhibitors (SrcI-I+PP2) ( Fig 6B) .", [["cells", "ANATOMY", 151, 156], ["RSV infection", "DISEASE", 18, 31], ["PP2", "CHEMICAL", 208, 211], ["RSV", "ORGANISM", 18, 21], ["GFP", "GENE_OR_GENE_PRODUCT", 53, 56], ["RSV", "ORGANISM", 120, 123], ["cells", "CELL", 151, 156], ["SrcI-I+PP2", "GENE_OR_GENE_PRODUCT", 201, 211], ["GFP", "PROTEIN", 53, 56], ["RSV", "SPECIES", 18, 21], ["RSV", "SPECIES", 120, 123], ["RSV infection", "PROBLEM", 18, 31], ["all treatments", "TREATMENT", 85, 99], ["RSV titration", "TREATMENT", 120, 133], ["cells", "PROBLEM", 151, 156], ["both inhibitors", "TREATMENT", 184, 199], ["SrcI", "TEST", 201, 205], ["efficiency", "OBSERVATION_MODIFIER", 4, 14], ["RSV", "OBSERVATION_MODIFIER", 18, 21], ["infection", "OBSERVATION", 22, 31]]], ["Each Src-inhibitor showed a modest but significant (p < 0.0001) reduction in GFP intensity of 23% (SrcI-I) and 33% (PP2) relative to mock-treated infected cells.", [["cells", "ANATOMY", 155, 160], ["GFP", "GENE_OR_GENE_PRODUCT", 77, 80], ["SrcI-I", "GENE_OR_GENE_PRODUCT", 99, 105], ["PP2", "SIMPLE_CHEMICAL", 116, 119], ["cells", "CELL", 155, 160], ["mock-treated infected cells", "CELL_LINE", 133, 160], ["Each Src-inhibitor", "TEST", 0, 18], ["GFP intensity", "TEST", 77, 90], ["SrcI", "TEST", 99, 103], ["PP2", "TEST", 116, 119], ["mock", "TEST", 133, 137], ["infected cells", "PROBLEM", 146, 160], ["modest", "OBSERVATION_MODIFIER", 28, 34], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["infected cells", "OBSERVATION", 146, 160]]], ["When added together, the inhibitory effect increased to 45% reduction compared to mocktreated infected cells.", [["cells", "ANATOMY", 103, 108], ["cells", "CELL", 103, 108], ["mocktreated infected cells", "CELL_LINE", 82, 108], ["mocktreated infected cells", "PROBLEM", 82, 108], ["infected cells", "OBSERVATION", 94, 108]]], ["The RSV titer (PFU) for the combined Src-inhibitor treatment showed a 2-fold, significant (two-tailed, unpaired t-test, p = 0.0014) reduction compared to mocktreated infected cells.", [["cells", "ANATOMY", 175, 180], ["Src-inhibitor", "CHEMICAL", 37, 50], ["RSV", "ORGANISM", 4, 7], ["cells", "CELL", 175, 180], ["mocktreated infected cells", "CELL_TYPE", 154, 180], ["RSV", "SPECIES", 4, 7], ["The RSV titer", "TEST", 0, 13], ["the combined Src-inhibitor treatment", "TREATMENT", 24, 60], ["reduction", "TREATMENT", 132, 141], ["mocktreated infected cells", "PROBLEM", 154, 180], ["infected cells", "OBSERVATION", 166, 180]]], ["These data confirmed that Src-kinase activity contributes to RSV infection.EGFR knockdown reduces RSV infectionNext, we investigated whether EGFR, a downstream signaling partner of Src-kinase, made a contribution to RSV infection.", [["RSV infection", "DISEASE", 61, 74], ["RSV infection", "DISEASE", 216, 229], ["Src", "GENE_OR_GENE_PRODUCT", 26, 29], ["RSV", "ORGANISM", 61, 64], ["EGFR", "GENE_OR_GENE_PRODUCT", 75, 79], ["RSV", "ORGANISM", 98, 101], ["EGFR", "GENE_OR_GENE_PRODUCT", 141, 145], ["Src-kinase", "GENE_OR_GENE_PRODUCT", 181, 191], ["RSV", "ORGANISM", 216, 219], ["Src", "PROTEIN", 26, 29], ["EGFR", "PROTEIN", 75, 79], ["EGFR", "PROTEIN", 141, 145], ["Src-kinase", "PROTEIN", 181, 191], ["RSV", "SPECIES", 61, 64], ["RSV", "SPECIES", 98, 101], ["RSV", "SPECIES", 216, 219], ["These data", "TEST", 0, 10], ["Src-kinase activity", "PROBLEM", 26, 45], ["RSV infection", "PROBLEM", 61, 74], ["EGFR knockdown", "PROBLEM", 75, 89], ["RSV infectionNext", "PROBLEM", 98, 115], ["EGFR", "TEST", 141, 145], ["Src-kinase", "PROBLEM", 181, 191], ["RSV infection", "PROBLEM", 216, 229], ["RSV infection", "OBSERVATION", 61, 74], ["RSV infectionNext", "OBSERVATION", 98, 115], ["RSV", "OBSERVATION_MODIFIER", 216, 219], ["infection", "OBSERVATION", 220, 229]]], ["We identified an EGFR-specific siRNA that reduced EGFR expression in A549 cells to 15% at the protein level compared to Neg.", [["A549 cells", "ANATOMY", 69, 79], ["EGFR", "GENE_OR_GENE_PRODUCT", 17, 21], ["EGFR", "GENE_OR_GENE_PRODUCT", 50, 54], ["A549 cells", "CELL", 69, 79], ["EGFR", "PROTEIN", 17, 21], ["EGFR", "PROTEIN", 50, 54], ["A549 cells", "CELL_LINE", 69, 79], ["an EGFR", "TEST", 14, 21], ["reduced EGFR expression in A549 cells", "PROBLEM", 42, 79], ["the protein level", "TEST", 90, 107], ["EGFR", "OBSERVATION", 17, 21], ["A549 cells", "OBSERVATION", 69, 79]]], ["EGFR knockdown cells were infected with RSV-GFP and infection was evaluated by viral GFP intensity quantified by ELISA reader 17 h p.i.", [["cells", "ANATOMY", 15, 20], ["infection", "DISEASE", 52, 61], ["EGFR", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 15, 20], ["RSV", "ORGANISM", 40, 43], ["GFP", "GENE_OR_GENE_PRODUCT", 44, 47], ["GFP", "GENE_OR_GENE_PRODUCT", 85, 88], ["EGFR", "PROTEIN", 0, 4], ["RSV", "SPECIES", 40, 43], ["EGFR knockdown cells", "PROBLEM", 0, 20], ["RSV", "PROBLEM", 40, 43], ["GFP", "PROBLEM", 44, 47], ["infection", "PROBLEM", 52, 61], ["knockdown cells", "OBSERVATION", 5, 20], ["infection", "OBSERVATION", 52, 61]]], ["(Fig 7B) and by plaque titration 24 h p.i. on Vero cells (Fig 7C) .", [["plaque", "ANATOMY", 16, 22], ["Vero cells", "ANATOMY", 46, 56], ["Vero cells", "CELL", 46, 56], ["Vero cells", "CELL_LINE", 46, 56], ["plaque titration", "TREATMENT", 16, 32], ["Vero cells", "TREATMENT", 46, 56]]], ["EGFR knockdown resulted in a nearly 50% reduction in viral GFP expression ( Fig 7B) as compared to Neg. siRNA 1 (p = 0.0001).", [["EGFR", "GENE_OR_GENE_PRODUCT", 0, 4], ["GFP", "GENE_OR_GENE_PRODUCT", 59, 62], ["EGFR", "PROTEIN", 0, 4], ["EGFR knockdown", "TEST", 0, 14], ["viral GFP expression", "PROBLEM", 53, 73], ["siRNA", "TEST", 104, 109], ["viral GFP expression", "OBSERVATION", 53, 73]]], ["There also was a 38% reduction in RSV titer compared to Neg. siRNA 2 (p = 0.0015) or mock-transfected cells (p = 0.0001) ( Fig 7C) .", [["cells", "ANATOMY", 102, 107], ["RSV", "ORGANISM", 34, 37], ["cells", "CELL", 102, 107], ["mock-transfected cells", "CELL_LINE", 85, 107], ["RSV", "SPECIES", 34, 37], ["a 38% reduction in RSV titer", "PROBLEM", 15, 43], ["siRNA", "TEST", 61, 66], ["mock-transfected cells", "TEST", 85, 107], ["RSV", "OBSERVATION", 34, 37]]], ["There was a modest but consistent reduction in PFU titer for Neg. siRNA1 for unknown reason and hence the reduction in titer for EGFR siRNA treated cells was not significantly lower compared to this particular control siRNA (ns, p = 0.9891), but as noted above the reduction in GFP expression was highly significant.", [["cells", "ANATOMY", 148, 153], ["EGFR", "GENE_OR_GENE_PRODUCT", 129, 133], ["cells", "CELL", 148, 153], ["GFP", "GENE_OR_GENE_PRODUCT", 278, 281], ["siRNA1", "PROTEIN", 66, 72], ["EGFR siRNA treated cells", "CELL_LINE", 129, 153], ["GFP", "PROTEIN", 278, 281], ["PFU titer", "TEST", 47, 56], ["siRNA1", "PROBLEM", 66, 72], ["the reduction in titer", "TREATMENT", 102, 124], ["EGFR siRNA treated cells", "PROBLEM", 129, 153], ["ns", "TEST", 225, 227], ["GFP expression", "TEST", 278, 292], ["modest", "OBSERVATION_MODIFIER", 12, 18], ["reduction", "OBSERVATION_MODIFIER", 34, 43], ["PFU titer", "OBSERVATION", 47, 56], ["reduction", "OBSERVATION_MODIFIER", 265, 274], ["GFP expression", "OBSERVATION", 278, 292], ["significant", "OBSERVATION_MODIFIER", 304, 315]]], ["None of the siRNAs had an effect on cell viability ( Fig 7D) .", [["cell", "ANATOMY", 36, 40], ["cell", "CELL", 36, 40], ["the siRNAs", "PROBLEM", 8, 18], ["siRNAs", "OBSERVATION", 12, 18], ["cell viability", "OBSERVATION", 36, 50]]], ["Taken together, these data confirm that EGFR plays a role in RSV infection.EGFR Tyrosine 845 is phosphorylated in response to RSV infection and is ATP1A1 dependentWe next investigated EGFR phosphorylation during RSV infection.", [["RSV infection", "DISEASE", 61, 74], ["Tyrosine 845", "CHEMICAL", 80, 92], ["RSV infection", "DISEASE", 126, 139], ["RSV infection", "DISEASE", 212, 225], ["Tyrosine", "CHEMICAL", 80, 88], ["EGFR", "GENE_OR_GENE_PRODUCT", 40, 44], ["RSV", "ORGANISM", 61, 64], ["EGFR Tyrosine 845", "GENE_OR_GENE_PRODUCT", 75, 92], ["RSV", "ORGANISM", 126, 129], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 147, 153], ["EGFR", "GENE_OR_GENE_PRODUCT", 184, 188], ["RSV", "ORGANISM", 212, 215], ["EGFR", "PROTEIN", 40, 44], ["EGFR", "PROTEIN", 75, 79], ["ATP1A1", "PROTEIN", 147, 153], ["EGFR", "PROTEIN", 184, 188], ["RSV", "SPECIES", 61, 64], ["RSV", "SPECIES", 126, 129], ["RSV", "SPECIES", 212, 215], ["these data", "TEST", 16, 26], ["RSV infection", "PROBLEM", 61, 74], ["EGFR Tyrosine", "TEST", 75, 88], ["phosphorylated", "PROBLEM", 96, 110], ["RSV infection", "PROBLEM", 126, 139], ["ATP1A1 dependentWe", "PROBLEM", 147, 165], ["EGFR phosphorylation", "PROBLEM", 184, 204], ["RSV infection", "PROBLEM", 212, 225], ["RSV", "OBSERVATION_MODIFIER", 61, 64], ["infection", "OBSERVATION", 65, 74], ["RSV infection", "OBSERVATION", 126, 139], ["RSV infection", "OBSERVATION", 212, 225]]], ["Effect of EGFR knockdown on RSV infection.", [["RSV infection", "DISEASE", 28, 41], ["EGFR", "GENE_OR_GENE_PRODUCT", 10, 14], ["RSV", "ORGANISM", 28, 31], ["EGFR", "PROTEIN", 10, 14], ["RSV", "SPECIES", 28, 31], ["EGFR knockdown", "PROBLEM", 10, 24], ["RSV infection", "PROBLEM", 28, 41], ["EGFR knockdown", "OBSERVATION", 10, 24], ["RSV infection", "OBSERVATION", 28, 41]]], ["(A) ATP1A1 and EGFR expression in A549 cells transfected with siRNAs targeting ATP1A1 or EGFR.A549 cells were transfected with ATP1A1 siRNA 2, EGFR siRNA, or Neg. siRNA 1 or 2, incubated for 48 h, and subjected to immunofluorescence staining for ATP1A1 (green) and EGFR (red) as described for Fig 4A.", [["A549 cells", "ANATOMY", 34, 44], ["A549 cells", "ANATOMY", 94, 104], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 4, 10], ["EGFR", "GENE_OR_GENE_PRODUCT", 15, 19], ["A549 cells", "CELL", 34, 44], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 79, 85], ["EGFR", "GENE_OR_GENE_PRODUCT", 89, 93], ["A549 cells", "CELL", 94, 104], ["EGFR", "GENE_OR_GENE_PRODUCT", 143, 147], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 246, 252], ["EGFR", "GENE_OR_GENE_PRODUCT", 265, 269], ["ATP1A1", "PROTEIN", 4, 10], ["EGFR", "PROTEIN", 15, 19], ["A549 cells", "CELL_LINE", 34, 44], ["ATP1A1", "PROTEIN", 79, 85], ["EGFR", "PROTEIN", 89, 93], ["A549 cells", "CELL_LINE", 94, 104], ["ATP1A1", "PROTEIN", 246, 252], ["EGFR", "PROTEIN", 265, 269], ["red", "PROTEIN", 271, 274], ["A) ATP1A1", "TEST", 1, 10], ["EGFR expression in A549 cells", "PROBLEM", 15, 44], ["siRNAs targeting ATP1A1", "TREATMENT", 62, 85], ["EGFR", "TEST", 89, 93], ["A549 cells", "TEST", 94, 104], ["ATP1A1 siRNA", "TEST", 127, 139], ["EGFR siRNA", "TEST", 143, 153], ["siRNA", "TEST", 163, 168], ["immunofluorescence staining", "TEST", 214, 241], ["ATP1A1", "TEST", 246, 252], ["EGFR", "TEST", 265, 269], ["A549 cells", "OBSERVATION", 34, 44]]], ["Images (z-stacks) were acquired on a Leica SP5 confocal microscope with 63x objective NA 1.4 and 2.0x zoom.", [["63x objective NA 1.4 and 2.0x zoom", "DNA", 72, 106], ["objective NA", "TEST", 76, 88]]], ["(B and C) EGFR knockdown reduces RSV infection and virion production.", [["RSV infection", "DISEASE", 33, 46], ["EGFR", "GENE_OR_GENE_PRODUCT", 10, 14], ["RSV", "ORGANISM", 33, 36], ["EGFR", "PROTEIN", 10, 14], ["RSV", "SPECIES", 33, 36], ["B and C) EGFR knockdown", "TREATMENT", 1, 24], ["RSV infection", "PROBLEM", 33, 46], ["virion production", "PROBLEM", 51, 68], ["RSV infection", "OBSERVATION", 33, 46], ["virion production", "OBSERVATION", 51, 68]]], ["A549 cells were transfected with an EGFR-specific siRNA or Neg. siRNA 1 or 2, and 48 h later were infected with RSV-GFP (MOI = 1 PFU/cell).", [["A549 cells", "ANATOMY", 0, 10], ["cell", "ANATOMY", 133, 137], ["A549 cells", "CELL", 0, 10], ["EGFR", "GENE_OR_GENE_PRODUCT", 36, 40], ["RSV", "ORGANISM", 112, 115], ["GFP", "GENE_OR_GENE_PRODUCT", 116, 119], ["cell", "CELL", 133, 137], ["A549 cells", "CELL_LINE", 0, 10], ["EGFR", "PROTEIN", 36, 40], ["RSV", "SPECIES", 112, 115], ["A549 cells", "PROBLEM", 0, 10], ["an EGFR", "TEST", 33, 40], ["specific siRNA", "TEST", 41, 55], ["siRNA", "TEST", 64, 69], ["RSV", "TEST", 112, 115], ["MOI", "TEST", 121, 124]]], ["Infection was quantified by (B) GFP signal of the total well, scanned by ELISA reader at 17 h p.i., and RSV production was assessed by (C) plaque titration on Vero cells 24 h p.i.", [["plaque", "ANATOMY", 139, 145], ["Vero cells", "ANATOMY", 159, 169], ["GFP", "GENE_OR_GENE_PRODUCT", 32, 35], ["RSV", "ORGANISM", 104, 107], ["Vero cells", "CELL", 159, 169], ["Vero cells", "CELL_LINE", 159, 169], ["RSV", "SPECIES", 104, 107], ["Infection", "PROBLEM", 0, 9], ["RSV production", "PROBLEM", 104, 118]]], ["(D) Cell viability.", [["Cell", "ANATOMY", 4, 8], ["Cell", "CELL", 4, 8], ["Cell viability", "OBSERVATION", 4, 18]]], ["An ATP-based cell viability assay (CellTiter-Glo) was performed 72 h p.t. to evaluate the viability of the transfected cells.", [["cell", "ANATOMY", 13, 17], ["cells", "ANATOMY", 119, 124], ["ATP", "CHEMICAL", 3, 6], ["ATP", "CHEMICAL", 3, 6], ["ATP", "SIMPLE_CHEMICAL", 3, 6], ["cell", "CELL", 13, 17], ["cells", "CELL", 119, 124], ["transfected cells", "CELL_LINE", 107, 124], ["An ATP", "TEST", 0, 6], ["based cell viability assay", "TEST", 7, 33], ["cell", "OBSERVATION", 13, 17], ["viability assay", "OBSERVATION", 18, 33], ["transfected cells", "OBSERVATION", 107, 124]]], ["Cells were lysed, the ATP concentration was determined by luciferase activity relative to mocktransfected cells, as a measure of viability. or were pretreated with ouabain, PST2238, or the Src-inhibitors SrcI-1+PP2.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 106, 111], ["ATP", "CHEMICAL", 22, 25], ["ouabain", "CHEMICAL", 164, 171], ["PST2238", "CHEMICAL", 173, 180], ["PP2", "CHEMICAL", 211, 214], ["ATP", "CHEMICAL", 22, 25], ["ouabain", "CHEMICAL", 164, 171], ["PST2238", "CHEMICAL", 173, 180], ["SrcI-1", "CHEMICAL", 204, 210], ["PP2", "CHEMICAL", 211, 214], ["Cells", "CELL", 0, 5], ["ATP", "SIMPLE_CHEMICAL", 22, 25], ["luciferase", "GENE_OR_GENE_PRODUCT", 58, 68], ["cells", "CELL", 106, 111], ["ouabain", "SIMPLE_CHEMICAL", 164, 171], ["PST2238", "SIMPLE_CHEMICAL", 173, 180], ["SrcI-1", "GENE_OR_GENE_PRODUCT", 204, 210], ["PP2", "SIMPLE_CHEMICAL", 211, 214], ["luciferase", "PROTEIN", 58, 68], ["mocktransfected cells", "CELL_LINE", 90, 111], ["Cells", "TEST", 0, 5], ["the ATP concentration", "TEST", 18, 39], ["mocktransfected cells", "TREATMENT", 90, 111], ["ouabain", "TREATMENT", 164, 171], ["PST2238", "TEST", 173, 180], ["the Src-inhibitors SrcI", "TEST", 185, 208], ["PP2", "PROBLEM", 211, 214]]], ["The cells were then infected with RSV (MOI = 5 PFU/cell) and lysates were prepared following 5 h of incubation.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 51, 55], ["lysates", "ANATOMY", 61, 68], ["cells", "CELL", 4, 9], ["RSV", "ORGANISM", 34, 37], ["cell", "CELL", 51, 55], ["lysates", "ORGANISM_SUBSTANCE", 61, 68], ["RSV", "SPECIES", 34, 37], ["RSV", "PROBLEM", 34, 37], ["MOI", "TEST", 39, 42], ["lysates", "TREATMENT", 61, 68], ["incubation", "TREATMENT", 100, 110]]], ["The lysates were analyzed using an EGFR phosphorylation array to identify the EGFR sites that were phosphorylated during infection.Fig 7.", [["lysates", "ANATOMY", 4, 11], ["infection", "DISEASE", 121, 130], ["lysates", "ORGANISM_SUBSTANCE", 4, 11], ["EGFR", "GENE_OR_GENE_PRODUCT", 35, 39], ["EGFR", "GENE_OR_GENE_PRODUCT", 78, 82], ["EGFR", "PROTEIN", 35, 39], ["EGFR sites", "DNA", 78, 88], ["The lysates", "TREATMENT", 0, 11], ["an EGFR phosphorylation array", "TEST", 32, 61], ["the EGFR sites", "PROBLEM", 74, 88], ["phosphorylated during infection", "PROBLEM", 99, 130], ["infection", "OBSERVATION", 121, 130]]], ["Effect of EGFR knockdown on RSV infection.", [["RSV infection", "DISEASE", 28, 41], ["EGFR", "GENE_OR_GENE_PRODUCT", 10, 14], ["RSV", "ORGANISM", 28, 31], ["EGFR", "PROTEIN", 10, 14], ["RSV", "SPECIES", 28, 31], ["EGFR knockdown", "PROBLEM", 10, 24], ["RSV infection", "PROBLEM", 28, 41], ["EGFR knockdown", "OBSERVATION", 10, 24], ["RSV infection", "OBSERVATION", 28, 41]]], ["(A) ATP1A1 and EGFR expression in A549 cells transfected with siRNAs targeting ATP1A1 or EGFR.EGFR in RSV-infected A549 cells was phosphorylated at Tyr845, which was not detected for uninfected cells (Fig 8 and S6A Fig) , whereas both samples showed nearly equivalent 5 \u03bcM] for 5 h pre-inoculation).", [["A549 cells", "ANATOMY", 34, 44], ["A549 cells", "ANATOMY", 115, 125], ["cells", "ANATOMY", 194, 199], ["samples", "ANATOMY", 235, 242], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 4, 10], ["EGFR", "GENE_OR_GENE_PRODUCT", 15, 19], ["A549 cells", "CELL", 34, 44], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 79, 85], ["EGFR", "GENE_OR_GENE_PRODUCT", 89, 93], ["EGFR", "GENE_OR_GENE_PRODUCT", 94, 98], ["RSV", "ORGANISM", 102, 105], ["A549 cells", "CELL", 115, 125], ["Tyr845", "GENE_OR_GENE_PRODUCT", 148, 154], ["cells", "CELL", 194, 199], ["ATP1A1", "PROTEIN", 4, 10], ["EGFR", "PROTEIN", 15, 19], ["A549 cells", "CELL_LINE", 34, 44], ["ATP1A1", "PROTEIN", 79, 85], ["EGFR", "PROTEIN", 89, 93], ["EGFR", "PROTEIN", 94, 98], ["RSV-infected A549 cells", "CELL_LINE", 102, 125], ["Tyr845", "PROTEIN", 148, 154], ["uninfected cells", "CELL_TYPE", 183, 199], ["RSV", "SPECIES", 102, 105], ["A) ATP1A1", "TEST", 1, 10], ["EGFR expression in A549 cells", "PROBLEM", 15, 44], ["siRNAs targeting ATP1A1", "TREATMENT", 62, 85], ["EGFR", "TEST", 89, 93], ["EGFR", "TEST", 94, 98], ["RSV", "TEST", 102, 105], ["infected A549 cells", "PROBLEM", 106, 125], ["phosphorylated", "PROBLEM", 130, 144], ["uninfected cells", "PROBLEM", 183, 199], ["Fig", "TEST", 201, 204], ["A549 cells", "OBSERVATION", 34, 44], ["RSV", "ANATOMY", 102, 105], ["infected", "OBSERVATION_MODIFIER", 106, 114], ["A549 cells", "OBSERVATION", 115, 125]]], ["Coincident with these treatments, the cells were serum starved for 16 h, and then were inoculated with wt RSV (MOI = 5 PFU/cell) and incubated for 5 h.", [["cells", "ANATOMY", 38, 43], ["serum", "ANATOMY", 49, 54], ["cell", "ANATOMY", 123, 127], ["cells", "CELL", 38, 43], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["RSV", "ORGANISM", 106, 109], ["cell", "CELL", 123, 127], ["RSV", "SPECIES", 106, 109], ["these treatments", "TREATMENT", 16, 32], ["wt RSV", "TEST", 103, 109], ["MOI", "TEST", 111, 114]]], ["The cells were lysed and lysates were incubated with a phospho-specific EGFR antibody array, followed by detection of bound EGFR with a biotinylated pan (i.e., universal) EGFR antibody, followed by incubation with horse radish peroxidase-conjugated streptavidin, and visualization with X-ray film (RayBiotech, Inc.).", [["cells", "ANATOMY", 4, 9], ["lysates", "ANATOMY", 25, 32], ["cells", "CELL", 4, 9], ["lysates", "ORGANISM_SUBSTANCE", 25, 32], ["EGFR", "GENE_OR_GENE_PRODUCT", 72, 76], ["EGFR", "GENE_OR_GENE_PRODUCT", 124, 128], ["EGFR", "GENE_OR_GENE_PRODUCT", 171, 175], ["horse", "ORGANISM", 214, 219], ["radish peroxidase", "SIMPLE_CHEMICAL", 220, 237], ["conjugated streptavidin", "SIMPLE_CHEMICAL", 238, 261], ["phospho-specific EGFR antibody", "PROTEIN", 55, 85], ["EGFR", "PROTEIN", 124, 128], ["biotinylated pan", "PROTEIN", 136, 152], ["EGFR antibody", "PROTEIN", 171, 184], ["horse radish peroxidase", "PROTEIN", 214, 237], ["conjugated streptavidin", "PROTEIN", 238, 261], ["horse", "SPECIES", 214, 219], ["radish", "SPECIES", 220, 226], ["horse radish", "SPECIES", 214, 226], ["lysates", "TEST", 25, 32], ["a phospho-specific EGFR antibody array", "TEST", 53, 91], ["bound EGFR", "PROBLEM", 118, 128], ["a biotinylated pan", "TREATMENT", 134, 152], ["universal) EGFR antibody", "TEST", 160, 184], ["horse radish peroxidase", "TREATMENT", 214, 237], ["conjugated streptavidin", "TREATMENT", 238, 261], ["visualization with X-ray film", "TEST", 267, 296]]], ["(A) X-ray film showing representative array spots of pTyr845 EGFR and its corresponding pan EGFR for each treatment.", [["pTyr845 EGFR", "GENE_OR_GENE_PRODUCT", 53, 65], ["EGFR", "GENE_OR_GENE_PRODUCT", 92, 96], ["pTyr845 EGFR", "PROTEIN", 53, 65], ["EGFR", "PROTEIN", 92, 96], ["A) X-ray film", "TEST", 1, 14], ["pTyr845 EGFR", "TREATMENT", 53, 65], ["its corresponding pan EGFR", "TREATMENT", 70, 96], ["each treatment", "TREATMENT", 101, 115]]], ["(B-D) Quantification of EGFR Tyr845 phosphorylation. pTyr845 EGFR signals of three independent experiments with two technical replicates each were quantified by scanning and normalized to the signal of the internal array positive controls and pan EGFR.", [["(B-D", "CHEMICAL", 0, 4], ["B-D", "GENE_OR_GENE_PRODUCT", 1, 4], ["EGFR", "GENE_OR_GENE_PRODUCT", 24, 28], ["pTyr845", "GENE_OR_GENE_PRODUCT", 53, 60], ["EGFR", "GENE_OR_GENE_PRODUCT", 61, 65], ["EGFR", "GENE_OR_GENE_PRODUCT", 247, 251], ["EGFR", "PROTEIN", 24, 28], ["EGFR", "PROTEIN", 61, 65], ["EGFR", "PROTEIN", 247, 251], ["EGFR Tyr845 phosphorylation", "TREATMENT", 24, 51], ["EGFR signals", "TEST", 61, 73], ["scanning", "TEST", 161, 169], ["pan EGFR", "TEST", 243, 251]]], ["(B) shows the siRNA knockdown samples reported relative to Neg. siRNA 1-transfected, RSV-infected samples, and (C) shows the chemical-treated samples reported relative to mock-treated, RSV-infected samples.", [["samples", "ANATOMY", 30, 37], ["samples", "ANATOMY", 98, 105], ["samples", "ANATOMY", 142, 149], ["samples", "ANATOMY", 198, 205], ["RSV-infected", "DISEASE", 185, 197], ["RSV", "ORGANISM", 85, 88], ["samples", "CANCER", 98, 105], ["RSV", "ORGANISM", 185, 188], ["samples", "CANCER", 198, 205], ["RSV", "SPECIES", 85, 88], ["RSV", "SPECIES", 185, 188], ["the siRNA knockdown samples", "PROBLEM", 10, 37], ["siRNA", "TEST", 64, 69], ["RSV", "PROBLEM", 85, 88], ["infected samples", "TEST", 89, 105], ["mock", "TEST", 171, 175], ["RSV", "PROBLEM", 185, 188], ["infected samples", "PROBLEM", 189, 205], ["siRNA knockdown", "OBSERVATION", 14, 29], ["infected", "OBSERVATION", 89, 97], ["infected", "OBSERVATION", 189, 197]]], ["(D) As control, PST2238 or Ouabain pretreated A549 cells were stimulated with EGF (100 ng/ml) for 45 min and the pTyr845 EGFR signal was quantified.", [["A549 cells", "ANATOMY", 46, 56], ["PST2238", "CHEMICAL", 16, 23], ["Ouabain", "CHEMICAL", 27, 34], ["EGF", "CHEMICAL", 78, 81], ["PST2238", "CHEMICAL", 16, 23], ["Ouabain", "CHEMICAL", 27, 34], ["PST2238", "SIMPLE_CHEMICAL", 16, 23], ["Ouabain", "SIMPLE_CHEMICAL", 27, 34], ["A549 cells", "CELL", 46, 56], ["EGF", "GENE_OR_GENE_PRODUCT", 78, 81], ["pTyr845", "GENE_OR_GENE_PRODUCT", 113, 120], ["EGFR", "GENE_OR_GENE_PRODUCT", 121, 125], ["A549 cells", "CELL_LINE", 46, 56], ["pTyr845", "PROTEIN", 113, 120], ["EGFR", "PROTEIN", 121, 125], ["Ouabain pretreated A549 cells", "TREATMENT", 27, 56], ["EGF", "TEST", 78, 81], ["the pTyr845 EGFR signal", "TEST", 109, 132]]], ["The statistical significance of the differences were determined by one-way analysis of variance with Dunnett multiple-comparison test and the p-values are indicated for each comparison.Fig 7.", [["comparison test", "TEST", 118, 133], ["the p-values", "TEST", 138, 150]]], ["Effect of EGFR knockdown on RSV infection.", [["RSV infection", "DISEASE", 28, 41], ["EGFR", "GENE_OR_GENE_PRODUCT", 10, 14], ["RSV", "ORGANISM", 28, 31], ["EGFR", "PROTEIN", 10, 14], ["RSV", "SPECIES", 28, 31], ["EGFR knockdown", "PROBLEM", 10, 24], ["RSV infection", "PROBLEM", 28, 41], ["EGFR knockdown", "OBSERVATION", 10, 24], ["RSV infection", "OBSERVATION", 28, 41]]], ["(A) ATP1A1 and EGFR expression in A549 cells transfected with siRNAs targeting ATP1A1 or EGFR.https://doi.org/10.1371/journal.ppat.1007963.g008 phosphorylation of ErbB2 (another member of the human EGFR family) at Thr686 and Ser1113 (S6 Fig).", [["A549 cells", "ANATOMY", 34, 44], ["Thr", "CHEMICAL", 214, 217], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 4, 10], ["EGFR", "GENE_OR_GENE_PRODUCT", 15, 19], ["A549 cells", "CELL", 34, 44], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 79, 85], ["EGFR.https://doi.org/10.1371/journal.ppat.1007963.g008", "GENE_OR_GENE_PRODUCT", 89, 143], ["ErbB2", "GENE_OR_GENE_PRODUCT", 163, 168], ["human", "ORGANISM", 192, 197], ["EGFR", "GENE_OR_GENE_PRODUCT", 198, 202], ["Thr686", "AMINO_ACID", 214, 220], ["Ser1113", "AMINO_ACID", 225, 232], ["ATP1A1", "PROTEIN", 4, 10], ["EGFR", "PROTEIN", 15, 19], ["A549 cells", "CELL_LINE", 34, 44], ["ATP1A1", "PROTEIN", 79, 85], ["ErbB2", "PROTEIN", 163, 168], ["human EGFR family", "PROTEIN", 192, 209], ["Thr686", "PROTEIN", 214, 220], ["Ser1113", "PROTEIN", 225, 232], ["S6 Fig", "PROTEIN", 234, 240], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 192, 197], ["A) ATP1A1", "TEST", 1, 10], ["EGFR expression in A549 cells", "PROBLEM", 15, 44], ["siRNAs targeting ATP1A1", "TREATMENT", 62, 85], ["A549 cells", "OBSERVATION", 34, 44]]], ["The level of pTyr845 in RSV-infected cells was significantly (p < 0.0001) reduced in the ATP1A1 siRNA knockdown cells, to an average of 35% (siRNA1), 22% (siRNA2), and 33% (siRNA3) relative to Neg. siRNA1 ( Fig 8B) .", [["cells", "ANATOMY", 37, 42], ["cells", "ANATOMY", 112, 117], ["pTyr845", "GENE_OR_GENE_PRODUCT", 13, 20], ["RSV", "ORGANISM", 24, 27], ["cells", "CELL", 37, 42], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 89, 95], ["cells", "CELL", 112, 117], ["pTyr845", "PROTEIN", 13, 20], ["RSV-infected cells", "CELL_TYPE", 24, 42], ["ATP1A1 siRNA knockdown cells", "CELL_LINE", 89, 117], ["siRNA1", "PROTEIN", 141, 147], ["siRNA2", "PROTEIN", 155, 161], ["siRNA3", "PROTEIN", 173, 179], ["siRNA1", "PROTEIN", 198, 204], ["RSV", "SPECIES", 24, 27], ["The level", "TEST", 0, 9], ["RSV", "TEST", 24, 27], ["infected cells", "PROBLEM", 28, 42], ["the ATP1A1 siRNA knockdown cells", "PROBLEM", 85, 117], ["siRNA1", "TEST", 141, 147], ["siRNA2", "TEST", 155, 161], ["siRNA3", "TEST", 173, 179], ["siRNA1", "TEST", 198, 204], ["infected cells", "OBSERVATION", 28, 42], ["siRNA knockdown cells", "OBSERVATION", 96, 117]]], ["The phosphorylation of Tyr845 in RSV-infected cells was similar to Neg. siRNA1.", [["cells", "ANATOMY", 46, 51], ["Tyr845", "GENE_OR_GENE_PRODUCT", 23, 29], ["RSV", "ORGANISM", 33, 36], ["cells", "CELL", 46, 51], ["Neg. siRNA1", "GENE_OR_GENE_PRODUCT", 67, 78], ["Tyr845", "PROTEIN", 23, 29], ["RSV-infected cells", "CELL_LINE", 33, 51], ["Neg. siRNA1", "PROTEIN", 67, 78], ["RSV", "SPECIES", 33, 36], ["The phosphorylation", "TEST", 0, 19], ["RSV", "PROBLEM", 33, 36], ["infected cells", "PROBLEM", 37, 51], ["infected cells", "OBSERVATION", 37, 51]]], ["While it was slightly reduced for Neg. siRNA2, the difference was not significant (p = 0.3651) compared to Neg. siRNA1.", [["Neg. siRNA1", "GENE_OR_GENE_PRODUCT", 107, 118], ["siRNA2", "PROTEIN", 39, 45], ["siRNA1", "PROTEIN", 112, 118], ["not", "UNCERTAINTY", 66, 69], ["significant", "OBSERVATION_MODIFIER", 70, 81]]], ["Consistent with the ATP1A1 knockdown, a significant reduction in Tyr845 phosphorylation also was observed when the cells were pre-treated with ouabain, PST2238, or Src-kinase inhibitors (SrcI-I +PP2) prior to infection with RSV ( Fig 8C) .", [["cells", "ANATOMY", 115, 120], ["ouabain", "CHEMICAL", 143, 150], ["PST2238", "CHEMICAL", 152, 159], ["SrcI-I", "CHEMICAL", 187, 193], ["PP2", "CHEMICAL", 195, 198], ["infection", "DISEASE", 209, 218], ["Tyr845", "CHEMICAL", 65, 71], ["ouabain", "CHEMICAL", 143, 150], ["PST2238", "CHEMICAL", 152, 159], ["PP2", "CHEMICAL", 195, 198], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 20, 26], ["Tyr845", "GENE_OR_GENE_PRODUCT", 65, 71], ["cells", "CELL", 115, 120], ["ouabain", "SIMPLE_CHEMICAL", 143, 150], ["PST2238", "SIMPLE_CHEMICAL", 152, 159], ["Src-kinase inhibitors", "SIMPLE_CHEMICAL", 164, 185], ["SrcI-I", "GENE_OR_GENE_PRODUCT", 187, 193], ["PP2", "SIMPLE_CHEMICAL", 195, 198], ["RSV", "ORGANISM", 224, 227], ["ATP1A1", "PROTEIN", 20, 26], ["Tyr845", "PROTEIN", 65, 71], ["Src", "PROTEIN", 164, 167], ["PP2", "PROTEIN", 195, 198], ["RSV", "SPECIES", 224, 227], ["the ATP1A1 knockdown", "TREATMENT", 16, 36], ["a significant reduction", "PROBLEM", 38, 61], ["Tyr845 phosphorylation", "PROBLEM", 65, 87], ["ouabain", "TEST", 143, 150], ["PST2238", "TEST", 152, 159], ["Src", "TEST", 164, 167], ["kinase inhibitors", "TEST", 168, 185], ["SrcI", "TEST", 187, 191], ["PP2", "PROBLEM", 195, 198], ["infection", "PROBLEM", 209, 218], ["RSV ( Fig 8C", "TREATMENT", 224, 236], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["reduction", "OBSERVATION_MODIFIER", 52, 61], ["infection", "OBSERVATION", 209, 218]]], ["For ouabain-and PST2238-treated cells, the level of pTyr845 was reduced to 27% and 26%, respectively, compared to mock-treated RSV-infected cells; the reduction was similar to that observed for ATP1A1 knockdown.", [["cells", "ANATOMY", 32, 37], ["cells", "ANATOMY", 140, 145], ["ouabain", "CHEMICAL", 4, 11], ["PST2238", "CHEMICAL", 16, 23], ["RSV-infected", "DISEASE", 127, 139], ["ouabain", "CHEMICAL", 4, 11], ["PST2238", "CHEMICAL", 16, 23], ["ouabain", "SIMPLE_CHEMICAL", 4, 11], ["PST2238", "SIMPLE_CHEMICAL", 16, 23], ["cells", "CELL", 32, 37], ["pTyr845", "GENE_OR_GENE_PRODUCT", 52, 59], ["RSV", "ORGANISM", 127, 130], ["cells", "CELL", 140, 145], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 194, 200], ["PST2238-treated cells", "CELL_LINE", 16, 37], ["pTyr845", "PROTEIN", 52, 59], ["mock-treated RSV-infected cells", "CELL_LINE", 114, 145], ["ATP1A1", "PROTEIN", 194, 200], ["RSV", "SPECIES", 127, 130], ["ouabain", "TEST", 4, 11], ["PST2238", "TEST", 16, 23], ["the level", "TEST", 39, 48], ["mock", "TEST", 114, 118], ["RSV", "PROBLEM", 127, 130], ["infected cells", "PROBLEM", 131, 145], ["the reduction", "TREATMENT", 147, 160], ["ATP1A1 knockdown", "TREATMENT", 194, 210], ["infected cells", "OBSERVATION", 131, 145]]], ["To confirm a lack of a direct inhibitory effect of Ouabain or PST2238 on EGFR, A549 cells were pre-treated with PST2238 or Ouabain and stimulated with EGF for 45 min.", [["A549 cells", "ANATOMY", 79, 89], ["Ouabain", "CHEMICAL", 51, 58], ["PST2238", "CHEMICAL", 62, 69], ["PST2238", "CHEMICAL", 112, 119], ["Ouabain", "CHEMICAL", 123, 130], ["Ouabain", "CHEMICAL", 51, 58], ["PST2238", "CHEMICAL", 62, 69], ["PST2238", "CHEMICAL", 112, 119], ["Ouabain", "CHEMICAL", 123, 130], ["Ouabain", "SIMPLE_CHEMICAL", 51, 58], ["PST2238", "SIMPLE_CHEMICAL", 62, 69], ["EGFR", "GENE_OR_GENE_PRODUCT", 73, 77], ["A549 cells", "CELL", 79, 89], ["PST2238", "SIMPLE_CHEMICAL", 112, 119], ["Ouabain", "SIMPLE_CHEMICAL", 123, 130], ["EGF", "GENE_OR_GENE_PRODUCT", 151, 154], ["EGFR", "PROTEIN", 73, 77], ["A549 cells", "CELL_LINE", 79, 89], ["EGF", "PROTEIN", 151, 154], ["Ouabain", "TREATMENT", 51, 58], ["EGFR", "TEST", 73, 77], ["A549 cells", "TREATMENT", 79, 89], ["Ouabain", "TREATMENT", 123, 130]]], ["The EGF-induced phosphorylation of pTyr845 indeed was not affected by the compounds as compared to mocktreated cells (Fig 8D) .", [["cells", "ANATOMY", 111, 116], ["EGF", "GENE_OR_GENE_PRODUCT", 4, 7], ["pTyr845", "GENE_OR_GENE_PRODUCT", 35, 42], ["cells", "CELL", 111, 116], ["EGF", "PROTEIN", 4, 7], ["pTyr845", "PROTEIN", 35, 42], ["mocktreated cells", "CELL_LINE", 99, 116], ["The EGF", "TEST", 0, 7]]], ["The Src-kinase inhibitors (SrcI-I+PP2) reduced phosphorylation at Tyr845 to 12% compared to mock-treated infected cells ( Fig 8C) .", [["cells", "ANATOMY", 114, 119], ["PP2", "CHEMICAL", 34, 37], ["PP2", "CHEMICAL", 34, 37], ["Src-kinase", "GENE_OR_GENE_PRODUCT", 4, 14], ["SrcI-I+PP2", "GENE_OR_GENE_PRODUCT", 27, 37], ["Tyr845", "AMINO_ACID", 66, 72], ["cells", "CELL", 114, 119], ["PP2", "PROTEIN", 34, 37], ["mock-treated infected cells", "CELL_LINE", 92, 119], ["The Src-kinase inhibitors", "TEST", 0, 25], ["SrcI", "TEST", 27, 31], ["PP2", "TEST", 34, 37], ["reduced phosphorylation", "PROBLEM", 39, 62], ["mock", "TEST", 92, 96], ["infected cells", "PROBLEM", 105, 119]]], ["Thus, phosphorylation at EGFR Tyr845 could be reduced either by decreasing ATP1A1 expression or by ATP1A1-or Src-specific inhibitors.", [["EGFR Tyr845", "GENE_OR_GENE_PRODUCT", 25, 36], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 75, 81], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 99, 105], ["EGFR Tyr845", "PROTEIN", 25, 36], ["ATP1A1", "PROTEIN", 75, 81], ["ATP1A1", "PROTEIN", 99, 105], ["phosphorylation at EGFR", "TREATMENT", 6, 29], ["ATP1A1", "TEST", 99, 105], ["Src-specific inhibitors", "TREATMENT", 109, 132]]], ["This suggested that EGFR pTyr845 is ATP1A1-dependent and that Srckinase serves as a signaling effector to transactivate EGFR by Tyr845 phosphorylation.Macropinocytosis is induced by RSV and is mediated by ATP1A1EGFR signaling is known to cause actin rearrangement, membrane ruffling, and activation of endocytosis and macropinocytosis [31, 33, 34] .", [["membrane", "ANATOMY", 265, 273], ["Macropinocytosis", "DISEASE", 151, 167], ["EGFR", "GENE_OR_GENE_PRODUCT", 20, 24], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 36, 42], ["Srckinase", "GENE_OR_GENE_PRODUCT", 62, 71], ["EGFR", "GENE_OR_GENE_PRODUCT", 120, 124], ["Tyr845", "GENE_OR_GENE_PRODUCT", 128, 134], ["RSV", "ORGANISM", 182, 185], ["ATP1A1EGFR", "GENE_OR_GENE_PRODUCT", 205, 215], ["actin", "GENE_OR_GENE_PRODUCT", 244, 249], ["membrane", "CELLULAR_COMPONENT", 265, 273], ["EGFR", "PROTEIN", 20, 24], ["pTyr845", "PROTEIN", 25, 32], ["ATP1A1", "PROTEIN", 36, 42], ["Srckinase", "PROTEIN", 62, 71], ["EGFR", "PROTEIN", 120, 124], ["Tyr845", "PROTEIN", 128, 134], ["ATP1A1EGFR", "PROTEIN", 205, 215], ["actin", "PROTEIN", 244, 249], ["RSV", "SPECIES", 182, 185], ["EGFR", "TEST", 20, 24], ["ATP1A1-dependent", "PROBLEM", 36, 52], ["Macropinocytosis", "PROBLEM", 151, 167], ["RSV", "PROBLEM", 182, 185], ["actin rearrangement", "PROBLEM", 244, 263], ["membrane ruffling", "PROBLEM", 265, 282], ["activation of endocytosis", "PROBLEM", 288, 313], ["macropinocytosis", "PROBLEM", 318, 334], ["EGFR", "OBSERVATION", 20, 24], ["RSV", "OBSERVATION", 182, 185], ["known to cause", "UNCERTAINTY", 229, 243], ["actin rearrangement", "OBSERVATION", 244, 263], ["membrane ruffling", "OBSERVATION", 265, 282]]], ["Macropinocytosis is a nonspecific, fluidic uptake at the cell surface that initiates through actin rearrangement and membrane ruffling that give rise to large vesicles called macropinosomes.", [["cell surface", "ANATOMY", 57, 69], ["membrane", "ANATOMY", 117, 125], ["vesicles", "ANATOMY", 159, 167], ["macropinosomes", "ANATOMY", 175, 189], ["Macropinocytosis", "DISEASE", 0, 16], ["cell surface", "CELLULAR_COMPONENT", 57, 69], ["actin", "GENE_OR_GENE_PRODUCT", 93, 98], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["vesicles", "CELLULAR_COMPONENT", 159, 167], ["macropinosomes", "CELLULAR_COMPONENT", 175, 189], ["actin", "PROTEIN", 93, 98], ["Macropinocytosis", "PROBLEM", 0, 16], ["a nonspecific, fluidic uptake at the cell surface", "PROBLEM", 20, 69], ["membrane ruffling", "PROBLEM", 117, 134], ["large vesicles called macropinosomes", "PROBLEM", 153, 189], ["nonspecific", "OBSERVATION_MODIFIER", 22, 33], ["fluidic uptake", "OBSERVATION", 35, 49], ["cell surface", "OBSERVATION", 57, 69], ["actin rearrangement", "OBSERVATION", 93, 112], ["membrane ruffling", "OBSERVATION", 117, 134], ["large", "OBSERVATION_MODIFIER", 153, 158], ["vesicles", "OBSERVATION", 159, 167]]], ["Limited prior evidence suggested macropinocytosis as a route of RSV uptake [14, 16] .", [["RSV", "ORGANISM", 64, 67], ["RSV", "SPECIES", 64, 67], ["macropinocytosis", "PROBLEM", 33, 49], ["RSV uptake", "PROBLEM", 64, 74], ["macropinocytosis", "OBSERVATION", 33, 49]]], ["In the present study, A549 cells were infected with wt RSV (MOI = 5 PFU/cell) in the presence of dextran (10,000 MW) conjugated to fluorescent dye (Alexa Fluor [AF] 568) as a fluidic uptake marker.", [["A549 cells", "ANATOMY", 22, 32], ["cell", "ANATOMY", 72, 76], ["dextran", "CHEMICAL", 97, 104], ["Alexa Fluor [AF] 568", "CHEMICAL", 148, 168], ["A549 cells", "CELL", 22, 32], ["RSV", "ORGANISM", 55, 58], ["cell", "CELL", 72, 76], ["dextran", "SIMPLE_CHEMICAL", 97, 104], ["fluorescent dye", "SIMPLE_CHEMICAL", 131, 146], ["Alexa Fluor", "SIMPLE_CHEMICAL", 148, 159], ["AF] 568", "SIMPLE_CHEMICAL", 161, 168], ["A549 cells", "CELL_LINE", 22, 32], ["RSV", "SPECIES", 55, 58], ["A549 cells", "PROBLEM", 22, 32], ["wt RSV", "TEST", 52, 58], ["MOI", "TEST", 60, 63], ["dextran", "TREATMENT", 97, 104], ["a fluidic uptake marker", "TEST", 173, 196], ["A549 cells", "OBSERVATION", 22, 32]]], ["At different time points p.i., cells were washed and fixed, nuclei were counterstained with DAPI, and the uptake of dextran was analyzed by fluorescence confocal microscopy.", [["cells", "ANATOMY", 31, 36], ["nuclei", "ANATOMY", 60, 66], ["dextran", "CHEMICAL", 116, 123], ["DAPI", "CHEMICAL", 92, 96], ["cells", "CELL", 31, 36], ["nuclei", "CELLULAR_COMPONENT", 60, 66], ["DAPI", "SIMPLE_CHEMICAL", 92, 96], ["dextran", "SIMPLE_CHEMICAL", 116, 123], ["DAPI", "TREATMENT", 92, 96], ["dextran", "TREATMENT", 116, 123], ["fluorescence confocal microscopy", "TEST", 140, 172]]], ["Cells that had been mock-infected were found to contain dextran-positive vesicles that were small, round, and homogeneous in size with an average volume of~0.5 \u03bcm 3 (Fig 9A, top panel) , reflecting the basal level of dextran uptake.", [["Cells", "ANATOMY", 0, 5], ["vesicles", "ANATOMY", 73, 81], ["dextran", "CHEMICAL", 56, 63], ["dextran", "CHEMICAL", 217, 224], ["Cells", "CELL", 0, 5], ["dextran", "SIMPLE_CHEMICAL", 56, 63], ["dextran", "SIMPLE_CHEMICAL", 217, 224], ["infected", "PROBLEM", 25, 33], ["dextran", "TEST", 56, 63], ["an average volume", "TEST", 135, 152], ["Fig 9A", "TEST", 166, 172], ["top panel", "TEST", 174, 183], ["dextran uptake", "PROBLEM", 217, 231], ["positive vesicles", "OBSERVATION", 64, 81], ["small", "OBSERVATION_MODIFIER", 92, 97], ["round", "OBSERVATION_MODIFIER", 99, 104], ["homogeneous", "OBSERVATION_MODIFIER", 110, 121], ["size", "OBSERVATION_MODIFIER", 125, 129], ["average", "OBSERVATION_MODIFIER", 138, 145], ["volume", "OBSERVATION_MODIFIER", 146, 152], ["basal", "ANATOMY_MODIFIER", 202, 207], ["dextran uptake", "OBSERVATION", 217, 231]]], ["This phenotype changed dramatically by 5 h after infection with wt RSV (Fig 9A, bottom panel) .", [["infection", "DISEASE", 49, 58], ["RSV", "ORGANISM", 67, 70], ["RSV", "SPECIES", 67, 70], ["infection", "PROBLEM", 49, 58], ["wt RSV", "TEST", 64, 70], ["bottom panel", "TEST", 80, 92]]], ["The dextran-positive vesicles were much bigger (average volume of~5.7 \u03bcm 3 ) and irregular in shape, as is typical of macropinosomes.", [["vesicles", "ANATOMY", 21, 29], ["dextran", "CHEMICAL", 4, 11], ["dextran", "SIMPLE_CHEMICAL", 4, 11], ["macropinosomes", "GENE_OR_GENE_PRODUCT", 118, 132], ["macropinosomes", "PROTEIN", 118, 132], ["The dextran", "TREATMENT", 0, 11], ["volume", "TEST", 56, 62], ["irregular in shape", "PROBLEM", 81, 99], ["positive vesicles", "OBSERVATION", 12, 29], ["much", "OBSERVATION_MODIFIER", 35, 39], ["bigger", "OBSERVATION_MODIFIER", 40, 46], ["average", "OBSERVATION_MODIFIER", 48, 55], ["volume", "OBSERVATION_MODIFIER", 56, 62], ["5.7 \u03bcm", "OBSERVATION_MODIFIER", 66, 72], ["irregular", "OBSERVATION_MODIFIER", 81, 90], ["shape", "OBSERVATION_MODIFIER", 94, 99], ["macropinosomes", "OBSERVATION", 118, 132]]], ["The induction of large dextran-positive vesicles also was visible at earlier time points and could be detected as early as 30 min p.i. and became more prominent at 1 h p.i.", [["vesicles", "ANATOMY", 40, 48], ["dextran", "CHEMICAL", 23, 30], ["dextran", "GENE_OR_GENE_PRODUCT", 23, 30], ["large dextran", "TREATMENT", 17, 30], ["positive vesicles", "PROBLEM", 31, 48], ["large", "OBSERVATION_MODIFIER", 17, 22], ["positive vesicles", "OBSERVATION", 31, 48], ["more prominent", "OBSERVATION_MODIFIER", 146, 160]]], ["This showed that RSV infection induces macropinocytosis.Macropinocytosis is induced by RSV and is mediated by ATP1A1Next, A549 cells were infected with RSV in the presence of dextran-AF568 (cyan), and at 5 h p.i. were co-stained for ATP1A1 (AF488; green) and RSV N (marker of RSV virions; AF647; red) and visualized by fluorescence confocal microscopy.", [["A549 cells", "ANATOMY", 122, 132], ["RSV infection", "DISEASE", 17, 30], ["Macropinocytosis", "DISEASE", 56, 72], ["dextran-AF568", "CHEMICAL", 175, 188], ["RSV", "ORGANISM", 17, 20], ["RSV", "ORGANISM", 87, 90], ["ATP1A1Next", "GENE_OR_GENE_PRODUCT", 110, 120], ["A549 cells", "CELL", 122, 132], ["RSV", "ORGANISM", 152, 155], ["dextran-AF568", "SIMPLE_CHEMICAL", 175, 188], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 233, 239], ["AF488; green)", "GENE_OR_GENE_PRODUCT", 241, 254], ["RSV", "ORGANISM", 259, 262], ["RSV", "ORGANISM", 276, 279], ["ATP1A1Next", "PROTEIN", 110, 120], ["A549 cells", "CELL_LINE", 122, 132], ["ATP1A1", "PROTEIN", 233, 239], ["RSV N", "PROTEIN", 259, 264], ["RSV", "SPECIES", 17, 20], ["RSV", "SPECIES", 87, 90], ["RSV", "SPECIES", 152, 155], ["RSV", "SPECIES", 259, 262], ["RSV", "SPECIES", 276, 279], ["RSV infection", "PROBLEM", 17, 30], ["macropinocytosis", "PROBLEM", 39, 55], ["Macropinocytosis", "PROBLEM", 56, 72], ["RSV", "PROBLEM", 87, 90], ["A549 cells", "PROBLEM", 122, 132], ["RSV", "PROBLEM", 152, 155], ["dextran", "TREATMENT", 175, 182], ["ATP1A1", "TEST", 233, 239], ["AF488", "TEST", 241, 246], ["RSV N (marker of RSV virions", "PROBLEM", 259, 287], ["fluorescence confocal microscopy", "TEST", 319, 351], ["RSV", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 21, 30], ["macropinocytosis", "OBSERVATION_MODIFIER", 39, 55], ["RSV", "OBSERVATION", 87, 90], ["RSV virions", "OBSERVATION", 276, 287]]], ["As previously noted, 5 h p.i. is very early in RSV infection, and the N protein that is detected would be mainly from the input virus particles, as was shown earlier with UV-inactivated virus.", [["RSV infection", "DISEASE", 47, 60], ["RSV", "ORGANISM", 47, 50], ["N protein", "PROTEIN", 70, 79], ["RSV", "SPECIES", 47, 50], ["RSV infection", "PROBLEM", 47, 60], ["the N protein", "TEST", 66, 79], ["the input virus particles", "PROBLEM", 118, 143], ["UV-inactivated virus", "PROBLEM", 171, 191], ["RSV", "OBSERVATION_MODIFIER", 47, 50], ["infection", "OBSERVATION", 51, 60]]], ["Clusters of ATP1A1 were observed co-localized with RSV N protein in the dextran-positive macropinosomes (Fig 9B, indicated by arrows), indicating that RSV was indeed taken up by macropinocytosis.", [["macropinosomes", "ANATOMY", 89, 103], ["dextran", "CHEMICAL", 72, 79], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 12, 18], ["dextran", "SIMPLE_CHEMICAL", 72, 79], ["RSV", "ORGANISM", 151, 154], ["ATP1A1", "PROTEIN", 12, 18], ["RSV N protein", "PROTEIN", 51, 64], ["dextran-positive macropinosomes", "PROTEIN", 72, 103], ["RSV", "SPECIES", 51, 54], ["RSV", "SPECIES", 151, 154], ["ATP1A1", "TEST", 12, 18], ["RSV N protein", "TEST", 51, 64], ["the dextran", "TEST", 68, 79], ["Fig 9B", "TEST", 105, 111], ["RSV", "PROBLEM", 151, 154], ["macropinocytosis", "PROBLEM", 178, 194], ["RSV", "OBSERVATION", 151, 154]]], ["Co-staining for RSV F and N was also performed and showed that both proteins were co-localized in the dextran-positive macropinosomes (Fig 9C) .", [["dextran", "CHEMICAL", 102, 109], ["RSV", "ORGANISM", 16, 19], ["dextran", "SIMPLE_CHEMICAL", 102, 109], ["dextran-positive macropinosomes", "PROTEIN", 102, 133], ["RSV", "SPECIES", 16, 19], ["RSV F and N", "TEST", 16, 27], ["both proteins", "PROBLEM", 63, 76], ["the dextran", "TREATMENT", 98, 109]]], ["The presence of RSV F suggests that the RSV detected in the macropinosomes was enveloped, indicating that fusion and release of RSV induces and is taken up by ATP1A1-dependent macropinocytosis, which can be blocked by ouabain or PST2238.", [["macropinosomes", "ANATOMY", 60, 74], ["ouabain", "CHEMICAL", 218, 225], ["PST2238", "CHEMICAL", 229, 236], ["ouabain", "CHEMICAL", 218, 225], ["PST2238", "CHEMICAL", 229, 236], ["RSV", "ORGANISM", 16, 19], ["RSV", "ORGANISM", 40, 43], ["macropinosomes", "GENE_OR_GENE_PRODUCT", 60, 74], ["RSV", "ORGANISM", 128, 131], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 159, 165], ["ouabain", "SIMPLE_CHEMICAL", 218, 225], ["PST2238", "SIMPLE_CHEMICAL", 229, 236], ["ATP1A1", "PROTEIN", 159, 165], ["RSV", "SPECIES", 16, 19], ["RSV", "SPECIES", 40, 43], ["RSV", "SPECIES", 128, 131], ["RSV F", "PROBLEM", 16, 21], ["the RSV", "PROBLEM", 36, 43], ["fusion", "PROBLEM", 106, 112], ["RSV", "PROBLEM", 128, 131], ["dependent macropinocytosis", "PROBLEM", 166, 192], ["RSV", "OBSERVATION", 16, 19], ["RSV", "OBSERVATION", 40, 43], ["fusion", "OBSERVATION", 106, 112], ["RSV", "OBSERVATION", 128, 131], ["macropinocytosis", "OBSERVATION", 176, 192]]], ["Macropinocytosis was assayed by monitoring the uptake of dextran (10,000 MW) conjugated to AF568 (dextran-AF568).", [["dextran", "CHEMICAL", 57, 64], ["AF568", "CHEMICAL", 91, 96], ["dextran-AF568", "CHEMICAL", 98, 111], ["AF568", "CHEMICAL", 91, 96], ["dextran", "SIMPLE_CHEMICAL", 57, 64], ["AF568", "SIMPLE_CHEMICAL", 91, 96], ["dextran-AF568", "SIMPLE_CHEMICAL", 98, 111], ["Macropinocytosis", "PROBLEM", 0, 16], ["dextran", "TREATMENT", 57, 64], ["dextran", "TEST", 98, 105]]], ["All incubations with dextran-AF568 were preceded by serum-starvation for 16 h.", [["serum", "ANATOMY", 52, 57], ["dextran-AF568", "CHEMICAL", 21, 34], ["dextran-AF568", "SIMPLE_CHEMICAL", 21, 34], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["dextran", "TREATMENT", 21, 28]]], ["(A) RSV induces macropinocytosis.", [["RSV", "ORGANISM", 4, 7], ["RSV", "SPECIES", 4, 7], ["macropinocytosis", "PROBLEM", 16, 32], ["RSV", "OBSERVATION", 4, 7], ["macropinocytosis", "OBSERVATION", 16, 32]]], ["A549 cells were mock-infected or infected with wt RSV (MOI = 5 PFU/cell) in medium containing dextran-AF568 (cyan).", [["A549 cells", "ANATOMY", 0, 10], ["cell", "ANATOMY", 67, 71], ["dextran-AF568", "CHEMICAL", 94, 107], ["A549 cells", "CELL", 0, 10], ["RSV", "ORGANISM", 50, 53], ["cell", "CELL", 67, 71], ["dextran-AF568", "SIMPLE_CHEMICAL", 94, 107], ["A549 cells", "CELL_LINE", 0, 10], ["RSV", "SPECIES", 50, 53], ["A549 cells", "PROBLEM", 0, 10], ["mock", "TEST", 16, 20], ["infected", "PROBLEM", 21, 29], ["infected", "PROBLEM", 33, 41], ["wt RSV", "TEST", 47, 53], ["MOI", "TEST", 55, 58], ["dextran", "TREATMENT", 94, 101]]], ["At 5 h p. i., cells were fixed with 4% PFA and nuclei counterstained with DAPI (blue), and imaged on a Leica SP5 confocal microscope with a 40x Objective NA 1.3 and 2.0x zoom.", [["cells", "ANATOMY", 14, 19], ["nuclei", "ANATOMY", 47, 53], ["PFA", "CHEMICAL", 39, 42], ["DAPI", "CHEMICAL", 74, 78], ["cells", "CELL", 14, 19], ["PFA", "SIMPLE_CHEMICAL", 39, 42], ["nuclei", "ORGANISM_SUBSTANCE", 47, 53], ["DAPI", "SIMPLE_CHEMICAL", 74, 78], ["Objective NA", "TEST", 144, 156]]], ["(B) Co-localization of ATP1A1, RSV N, and dextran-AF568 in RSV-infected A549 cells.", [["A549 cells", "ANATOMY", 72, 82], ["dextran-AF568", "CHEMICAL", 42, 55], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 23, 29], ["RSV", "ORGANISM", 31, 34], ["dextran-AF568", "SIMPLE_CHEMICAL", 42, 55], ["RSV", "ORGANISM", 59, 62], ["A549 cells", "CELL", 72, 82], ["ATP1A1", "PROTEIN", 23, 29], ["RSV-infected A549 cells", "CELL_LINE", 59, 82], ["RSV", "SPECIES", 31, 34], ["RSV", "SPECIES", 59, 62], ["ATP1A1", "TEST", 23, 29], ["RSV N", "TEST", 31, 36], ["dextran", "TEST", 42, 49], ["RSV", "PROBLEM", 59, 62], ["infected A549 cells", "PROBLEM", 63, 82], ["RSV", "ANATOMY", 59, 62], ["infected", "OBSERVATION_MODIFIER", 63, 71], ["A549 cells", "OBSERVATION", 72, 82]]], ["Cells were infected with RSV in the presence of dextran-AF568 as described above, incubated for 5 h, fixed with 4% PFA, permeabilized with 0.1% Triton X-100, subjected to immunofluorescence staining with an anti-ATP1A1 rabbit MAb (ab76020) and an anti-RSV-N mouse MAb (ab94806), followed by AF488-conjugated goat anti-rabbit and AF647-conjugated goat anti-mouse secondary nucleocapsid presumably occurs subsequently in the internal vesicles rather than at the plasma membrane.Macropinocytosis is induced by RSV and is mediated by ATP1A1To examine the role of ATP1A1 in this putative uptake mechanism, ATP1A1 expression was knocked down with siRNA, or the cells were treated with ouabain or PST2238 as previously described.", [["Cells", "ANATOMY", 0, 5], ["internal vesicles", "ANATOMY", 423, 440], ["plasma membrane", "ANATOMY", 460, 475], ["cells", "ANATOMY", 655, 660], ["dextran-AF568", "CHEMICAL", 48, 61], ["Triton X-100", "CHEMICAL", 144, 156], ["AF488", "CHEMICAL", 291, 296], ["AF647", "CHEMICAL", 329, 334], ["Macropinocytosis", "DISEASE", 476, 492], ["ouabain", "CHEMICAL", 679, 686], ["PST2238", "CHEMICAL", 690, 697], ["PFA", "CHEMICAL", 115, 118], ["ouabain", "CHEMICAL", 679, 686], ["PST2238", "CHEMICAL", 690, 697], ["Cells", "CELL", 0, 5], ["RSV", "ORGANISM", 25, 28], ["dextran-AF568", "SIMPLE_CHEMICAL", 48, 61], ["PFA", "SIMPLE_CHEMICAL", 115, 118], ["Triton X-100", "SIMPLE_CHEMICAL", 144, 156], ["rabbit", "ORGANISM", 219, 225], ["MAb", "GENE_OR_GENE_PRODUCT", 226, 229], ["ab76020", "GENE_OR_GENE_PRODUCT", 231, 238], ["RSV", "ORGANISM", 252, 255], ["mouse", "ORGANISM", 258, 263], ["ab94806", "ORGANISM", 269, 276], ["AF488", "SIMPLE_CHEMICAL", 291, 296], ["goat", "ORGANISM", 308, 312], ["anti-rabbit", "GENE_OR_GENE_PRODUCT", 313, 324], ["AF647", "GENE_OR_GENE_PRODUCT", 329, 334], ["goat", "ORGANISM", 346, 350], ["vesicles", "CELLULAR_COMPONENT", 432, 440], ["plasma membrane", "CELLULAR_COMPONENT", 460, 475], ["RSV", "ORGANISM", 507, 510], ["ATP1A1To", "GENE_OR_GENE_PRODUCT", 530, 538], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 559, 565], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 601, 607], ["cells", "CELL", 655, 660], ["ouabain", "SIMPLE_CHEMICAL", 679, 686], ["PST2238", "SIMPLE_CHEMICAL", 690, 697], ["anti-ATP1A1 rabbit MAb", "PROTEIN", 207, 229], ["ab76020", "PROTEIN", 231, 238], ["anti-RSV-N mouse MAb", "PROTEIN", 247, 267], ["ab94806", "PROTEIN", 269, 276], ["AF488", "PROTEIN", 291, 296], ["conjugated goat anti-rabbit and AF647-conjugated goat anti-mouse secondary nucleocapsid", "PROTEIN", 297, 384], ["ATP1A1To", "PROTEIN", 530, 538], ["ATP1A1", "PROTEIN", 559, 565], ["ATP1A1", "PROTEIN", 601, 607], ["rabbit", "SPECIES", 219, 225], ["mouse", "SPECIES", 258, 263], ["goat", "SPECIES", 308, 312], ["anti-rabbit", "SPECIES", 313, 324], ["goat", "SPECIES", 346, 350], ["anti-mouse", "SPECIES", 351, 361], ["RSV", "SPECIES", 25, 28], ["rabbit", "SPECIES", 219, 225], ["RSV", "SPECIES", 252, 255], ["mouse", "SPECIES", 258, 263], ["goat", "SPECIES", 308, 312], ["goat", "SPECIES", 346, 350], ["RSV", "SPECIES", 507, 510], ["RSV", "PROBLEM", 25, 28], ["dextran", "TREATMENT", 48, 55], ["immunofluorescence staining", "TEST", 171, 198], ["an anti-ATP1A1 rabbit MAb", "TREATMENT", 204, 229], ["an anti-RSV", "TEST", 244, 255], ["N mouse MAb", "TREATMENT", 256, 267], ["AF488", "TEST", 291, 296], ["conjugated goat anti-rabbit", "TREATMENT", 297, 324], ["AF647-conjugated goat anti-mouse", "TREATMENT", 329, 361], ["nucleocapsid", "PROBLEM", 372, 384], ["Macropinocytosis", "PROBLEM", 476, 492], ["RSV", "PROBLEM", 507, 510], ["siRNA", "TREATMENT", 641, 646], ["ouabain", "TREATMENT", 679, 686], ["internal vesicles", "ANATOMY", 423, 440], ["plasma membrane", "ANATOMY", 460, 475], ["RSV", "OBSERVATION", 507, 510]]], ["Next, these cells were infected with RSV (MOI = 5 PFU/cell) in the presence of dextran-AF568, followed by fluorescence confocal microscopy.", [["cells", "ANATOMY", 12, 17], ["cell", "ANATOMY", 54, 58], ["dextran-AF568", "CHEMICAL", 79, 92], ["cells", "CELL", 12, 17], ["RSV", "ORGANISM", 37, 40], ["cell", "CELL", 54, 58], ["dextran-AF568", "SIMPLE_CHEMICAL", 79, 92], ["RSV", "SPECIES", 37, 40], ["RSV", "PROBLEM", 37, 40], ["MOI", "TEST", 42, 45], ["dextran", "TREATMENT", 79, 86], ["fluorescence confocal microscopy", "TEST", 106, 138]]], ["Multiple random Z-stack images were acquired by confocal microscopy, and dextran-positive vesicles were analyzed by Imaris imaging software to determine the total fluorescence intensity per vesicle.", [["vesicles", "ANATOMY", 90, 98], ["vesicle", "ANATOMY", 190, 197], ["dextran", "CHEMICAL", 73, 80], ["dextran", "SIMPLE_CHEMICAL", 73, 80], ["vesicle", "CELLULAR_COMPONENT", 190, 197], ["Multiple random Z-stack images", "TEST", 0, 30], ["confocal microscopy", "TEST", 48, 67], ["dextran", "TREATMENT", 73, 80], ["Imaris imaging software", "TEST", 116, 139], ["vesicle", "ANATOMY", 190, 197]]], ["Vesicles smaller than 1.0 \u03bcm 3 were excluded to omit the basal level of dextran uptake and to focus on the large vesicles that are typical for macropinosomes.", [["Vesicles", "ANATOMY", 0, 8], ["vesicles", "ANATOMY", 113, 121], ["dextran", "CHEMICAL", 72, 79], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8], ["dextran", "SIMPLE_CHEMICAL", 72, 79], ["vesicles", "CELLULAR_COMPONENT", 113, 121], ["Vesicles", "TEST", 0, 8], ["dextran uptake", "PROBLEM", 72, 86], ["macropinosomes", "PROBLEM", 143, 157], ["smaller", "OBSERVATION_MODIFIER", 9, 16], ["basal", "ANATOMY_MODIFIER", 57, 62], ["dextran uptake", "OBSERVATION", 72, 86], ["large", "OBSERVATION_MODIFIER", 107, 112], ["vesicles", "OBSERVATION", 113, 121], ["typical for", "UNCERTAINTY", 131, 142], ["macropinosomes", "OBSERVATION", 143, 157]]], ["The total intensity of dextran vesicles larger than 1.0 \u03bcm 3 was determined per field, normalized to the number of nuclei and expressed relative to Neg. siRNA1-transfected cells (Fig 9D) .", [["nuclei", "ANATOMY", 115, 121], ["cells", "ANATOMY", 172, 177], ["dextran", "CHEMICAL", 23, 30], ["dextran vesicles", "SIMPLE_CHEMICAL", 23, 39], ["nuclei", "CELLULAR_COMPONENT", 115, 121], ["siRNA1", "GENE_OR_GENE_PRODUCT", 153, 159], ["cells", "CELL", 172, 177], ["Fig 9D", "CELL", 179, 185], ["siRNA1", "PROTEIN", 153, 159], ["transfected cells", "CELL_LINE", 160, 177], ["dextran vesicles", "TREATMENT", 23, 39], ["siRNA1", "TEST", 153, 159], ["total", "OBSERVATION_MODIFIER", 4, 9], ["intensity", "OBSERVATION_MODIFIER", 10, 19], ["dextran vesicles", "OBSERVATION", 23, 39], ["larger", "OBSERVATION_MODIFIER", 40, 46]]], ["This showed that dextran uptake was increased 4-fold in RSV-infected as compared to uninfected-cells, which had both been transfected with Neg. siRNA1 (Fig 9D) , confirming the visual observation of increased dextran-AF568 uptake (Fig 9A) .", [["cells", "ANATOMY", 95, 100], ["dextran", "CHEMICAL", 17, 24], ["RSV-infected", "DISEASE", 56, 68], ["dextran", "CHEMICAL", 209, 216], ["dextran", "SIMPLE_CHEMICAL", 17, 24], ["RSV", "ORGANISM", 56, 59], ["cells", "CELL", 95, 100], ["dextran-AF568", "SIMPLE_CHEMICAL", 209, 222], ["uninfected-cells", "CELL_TYPE", 84, 100], ["Neg. siRNA1", "PROTEIN", 139, 150], ["AF568", "PROTEIN", 217, 222], ["RSV", "SPECIES", 56, 59], ["dextran uptake", "PROBLEM", 17, 31], ["RSV", "PROBLEM", 56, 59], ["the visual observation", "TEST", 173, 195], ["increased dextran", "TREATMENT", 199, 216], ["dextran uptake", "OBSERVATION", 17, 31], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["RSV", "ANATOMY", 56, 59], ["infected", "OBSERVATION", 60, 68]]], ["On the other hand, knockdown of ATP1A1 caused a significant (p = 0.0003) reduction of 33% compared to Neg. siRNA1 (Fig 9D) .", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 32, 38], ["ATP1A1", "PROTEIN", 32, 38], ["siRNA1", "PROTEIN", 107, 113], ["reduction", "TEST", 73, 82], ["significant", "OBSERVATION_MODIFIER", 48, 59]]], ["Ouabain and PST2238 caused an even-greater reduction in RSV-induced macropinosomes, to less than 50% compared to mock-treated, RSV-infected cells (Fig 9E) .", [["macropinosomes", "ANATOMY", 68, 82], ["cells", "ANATOMY", 140, 145], ["Ouabain", "CHEMICAL", 0, 7], ["PST2238", "CHEMICAL", 12, 19], ["RSV-infected", "DISEASE", 127, 139], ["Ouabain", "CHEMICAL", 0, 7], ["PST2238", "CHEMICAL", 12, 19], ["Ouabain", "SIMPLE_CHEMICAL", 0, 7], ["PST2238", "SIMPLE_CHEMICAL", 12, 19], ["RSV", "ORGANISM", 56, 59], ["macropinosomes", "PATHOLOGICAL_FORMATION", 68, 82], ["RSV", "ORGANISM", 127, 130], ["cells", "CELL", 140, 145], ["Fig 9E", "CELL", 147, 153], ["mock-treated, RSV-infected cells", "CELL_LINE", 113, 145], ["RSV", "SPECIES", 56, 59], ["RSV", "SPECIES", 127, 130], ["Ouabain", "TEST", 0, 7], ["RSV", "PROBLEM", 56, 59], ["induced macropinosomes", "PROBLEM", 60, 82], ["mock", "TEST", 113, 117], ["RSV", "PROBLEM", 127, 130], ["RSV", "OBSERVATION", 56, 59], ["infected cells", "OBSERVATION", 131, 145]]], ["Since RSV G was suggested to be important for triggering ATP1A1 activation, based on the loss of clustering observed with the dSH/ dG mutant as described previously in Fig 4, we also quantified macropinosomes in cells infected with wt RSV or the dSH/dG RSV mutant.", [["cells", "ANATOMY", 212, 217], ["dG", "CHEMICAL", 250, 252], ["RSV", "ORGANISM", 6, 9], ["G", "GENE_OR_GENE_PRODUCT", 10, 11], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 57, 63], ["dSH", "GENE_OR_GENE_PRODUCT", 126, 129], ["macropinosomes", "GENE_OR_GENE_PRODUCT", 194, 208], ["cells", "CELL", 212, 217], ["wt RSV", "ORGANISM", 232, 238], ["dSH/dG RSV mutant", "ORGANISM", 246, 263], ["ATP1A1", "PROTEIN", 57, 63], ["dSH", "PROTEIN", 126, 129], ["macropinosomes", "PROTEIN", 194, 208], ["RSV", "SPECIES", 6, 9], ["RSV", "SPECIES", 235, 238], ["RSV", "SPECIES", 253, 256], ["RSV", "PROBLEM", 6, 9], ["ATP1A1 activation", "TREATMENT", 57, 74], ["the dSH/ dG mutant", "PROBLEM", 122, 140], ["wt RSV", "PROBLEM", 232, 238], ["RSV", "OBSERVATION", 6, 9], ["RSV mutant", "OBSERVATION", 253, 263]]], ["This showed that macropinosome formation indeed was significantly (p = 0.0039) reduced for the dSH/dG virus as compared to wt RSV (Fig 9F) , consistent with a role for the G protein in activating the pathway leading to macropinosome formation.Macropinocytosis is induced by RSV and is mediated by ATP1A1Signaling from ATP1A1 also can induce clathrin-mediated endocytosis [17, 26] , and this endocytic pathway has been controversially suggested to be involved in RSV uptake [15] .", [["macropinosome", "ANATOMY", 17, 30], ["macropinosome", "ANATOMY", 219, 232], ["dG", "CHEMICAL", 99, 101], ["Macropinocytosis", "DISEASE", 243, 259], ["macropinosome", "SIMPLE_CHEMICAL", 17, 30], ["dSH/dG virus", "ORGANISM", 95, 107], ["RSV", "ORGANISM", 126, 129], ["Fig 9F", "ORGANISM", 131, 137], ["G protein", "GENE_OR_GENE_PRODUCT", 172, 181], ["macropinosome", "GENE_OR_GENE_PRODUCT", 219, 232], ["RSV", "ORGANISM", 274, 277], ["ATP1A1Signaling", "GENE_OR_GENE_PRODUCT", 297, 312], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 318, 324], ["clathrin", "GENE_OR_GENE_PRODUCT", 341, 349], ["RSV", "ORGANISM", 462, 465], ["G protein", "PROTEIN", 172, 181], ["ATP1A1Signaling", "PROTEIN", 297, 312], ["ATP1A1", "PROTEIN", 318, 324], ["clathrin", "PROTEIN", 341, 349], ["RSV", "SPECIES", 126, 129], ["RSV", "SPECIES", 274, 277], ["RSV", "SPECIES", 462, 465], ["macropinosome formation", "PROBLEM", 17, 40], ["the dSH/dG virus", "PROBLEM", 91, 107], ["wt RSV", "TEST", 123, 129], ["the G protein", "TREATMENT", 168, 181], ["macropinosome formation", "PROBLEM", 219, 242], ["Macropinocytosis", "PROBLEM", 243, 259], ["RSV", "PROBLEM", 274, 277], ["mediated endocytosis", "PROBLEM", 350, 370], ["RSV uptake", "PROBLEM", 462, 472], ["dG virus", "OBSERVATION", 99, 107], ["macropinosome formation", "OBSERVATION", 219, 242], ["RSV", "OBSERVATION", 274, 277]]], ["However, preliminary studies in our hands using an inhibitor of clathrin-mediated endocytosis (e.g., chlorpromazine) did not detect effects on RSV infection at non-cytotoxic concentrations (S8 Fig), and this was not pursued further.Cholesterol is required for RSV uptake and signalingATP1A1-Src-EGFR signaling characteristically is associated with caveolae [17, [26] [27] [28] .", [["caveolae", "ANATOMY", 348, 356], ["chlorpromazine", "CHEMICAL", 101, 115], ["RSV infection", "DISEASE", 143, 156], ["Cholesterol", "CHEMICAL", 232, 243], ["chlorpromazine", "CHEMICAL", 101, 115], ["Cholesterol", "CHEMICAL", 232, 243], ["clathrin", "GENE_OR_GENE_PRODUCT", 64, 72], ["chlorpromazine", "SIMPLE_CHEMICAL", 101, 115], ["RSV", "ORGANISM", 143, 146], ["Cholesterol", "SIMPLE_CHEMICAL", 232, 243], ["RSV", "ORGANISM", 260, 263], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 284, 290], ["Src", "GENE_OR_GENE_PRODUCT", 291, 294], ["EGFR", "GENE_OR_GENE_PRODUCT", 295, 299], ["caveolae [17, [26] [27] [28]", "SIMPLE_CHEMICAL", 348, 376], ["clathrin", "PROTEIN", 64, 72], ["ATP1A1", "PROTEIN", 284, 290], ["Src", "PROTEIN", 291, 294], ["EGFR", "PROTEIN", 295, 299], ["RSV", "SPECIES", 143, 146], ["RSV", "SPECIES", 260, 263], ["preliminary studies", "TEST", 9, 28], ["an inhibitor of clathrin-mediated endocytosis", "TREATMENT", 48, 93], ["chlorpromazine", "TREATMENT", 101, 115], ["RSV infection", "PROBLEM", 143, 156], ["Cholesterol", "TEST", 232, 243], ["RSV uptake", "PROBLEM", 260, 270], ["signalingATP1A1", "TEST", 275, 290], ["caveolae", "TEST", 348, 356], ["RSV", "OBSERVATION", 143, 146]]], ["The structural integrity of caveolae depends on the presence of cholesterol, and cholesterol-depletion disrupts caveolae from the plasma membrane [39, 40] .", [["caveolae", "ANATOMY", 28, 36], ["caveolae", "ANATOMY", 112, 120], ["plasma membrane", "ANATOMY", 130, 145], ["cholesterol", "CHEMICAL", 64, 75], ["cholesterol", "CHEMICAL", 81, 92], ["cholesterol", "CHEMICAL", 64, 75], ["cholesterol", "CHEMICAL", 81, 92], ["caveolae", "CELLULAR_COMPONENT", 28, 36], ["cholesterol", "SIMPLE_CHEMICAL", 64, 75], ["cholesterol", "SIMPLE_CHEMICAL", 81, 92], ["caveolae", "CELLULAR_COMPONENT", 112, 120], ["plasma membrane", "CELLULAR_COMPONENT", 130, 145], ["cholesterol", "TEST", 64, 75], ["cholesterol-depletion", "PROBLEM", 81, 102], ["the plasma membrane", "TEST", 126, 145], ["structural", "OBSERVATION_MODIFIER", 4, 14], ["integrity", "OBSERVATION_MODIFIER", 15, 24], ["caveolae", "OBSERVATION", 28, 36]]], ["We therefore evaluated the impact of depleting cholesterol in A549 cells prior to RSV infection, which was done using methylbeta-cyclodextrin (MBCD) and Mevinolin, individually or in combination at non-cytotoxic antibodies.", [["A549 cells", "ANATOMY", 62, 72], ["cholesterol", "CHEMICAL", 47, 58], ["RSV infection", "DISEASE", 82, 95], ["methylbeta-cyclodextrin", "CHEMICAL", 118, 141], ["MBCD", "CHEMICAL", 143, 147], ["Mevinolin", "CHEMICAL", 153, 162], ["cholesterol", "CHEMICAL", 47, 58], ["methylbeta-cyclodextrin", "CHEMICAL", 118, 141], ["MBCD", "CHEMICAL", 143, 147], ["Mevinolin", "CHEMICAL", 153, 162], ["cholesterol", "SIMPLE_CHEMICAL", 47, 58], ["A549 cells", "CELL", 62, 72], ["RSV", "ORGANISM", 82, 85], ["methylbeta-cyclodextrin", "SIMPLE_CHEMICAL", 118, 141], ["MBCD", "SIMPLE_CHEMICAL", 143, 147], ["Mevinolin", "SIMPLE_CHEMICAL", 153, 162], ["A549 cells", "CELL_LINE", 62, 72], ["non-cytotoxic antibodies", "PROTEIN", 198, 222], ["RSV", "SPECIES", 82, 85], ["depleting cholesterol in A549 cells", "PROBLEM", 37, 72], ["RSV infection", "PROBLEM", 82, 95], ["methylbeta-cyclodextrin (MBCD)", "TREATMENT", 118, 148], ["Mevinolin", "TREATMENT", 153, 162], ["depleting cholesterol", "OBSERVATION", 37, 58], ["A549 cells", "OBSERVATION", 62, 72], ["RSV infection", "OBSERVATION", 82, 95]]], ["Z-stacks were acquired on Leica SP8 confocal microscope with 63x objective, NA 1.4 and 3.0x zoom.", [["NA", "CHEMICAL", 76, 78], ["Z-stacks", "TEST", 0, 8], ["NA", "TEST", 76, 78]]], ["Arrows indicate co-localization of ATP1A1 (green) and RSV N (red) in dextran-AF568-positive (cyan) vesicles.", [["cyan) vesicles", "ANATOMY", 93, 107], ["dextran", "CHEMICAL", 69, 76], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 35, 41], ["green)", "GENE_OR_GENE_PRODUCT", 43, 49], ["RSV N (red)", "GENE_OR_GENE_PRODUCT", 54, 65], ["dextran-AF568", "SIMPLE_CHEMICAL", 69, 82], ["ATP1A1", "PROTEIN", 35, 41], ["RSV N", "PROTEIN", 54, 59], ["AF568", "PROTEIN", 77, 82], ["RSV", "SPECIES", 54, 57], ["ATP1A1", "TEST", 35, 41], ["RSV N", "TEST", 54, 59], ["dextran", "TEST", 69, 76], ["vesicles", "ANATOMY", 99, 107]]], ["(C) Co-localization of RSV F and RSV N with dextran-AF568 in RSV-infected A549 cells.", [["A549 cells", "ANATOMY", 74, 84], ["dextran-AF568", "CHEMICAL", 44, 57], ["RSV", "ORGANISM", 23, 26], ["F", "GENE_OR_GENE_PRODUCT", 27, 28], ["RSV", "ORGANISM", 33, 36], ["dextran-AF568", "SIMPLE_CHEMICAL", 44, 57], ["RSV", "ORGANISM", 61, 64], ["A549 cells", "CELL", 74, 84], ["RSV-infected A549 cells", "CELL_LINE", 61, 84], ["RSV", "SPECIES", 23, 26], ["RSV", "SPECIES", 33, 36], ["RSV", "SPECIES", 61, 64], ["RSV F", "TEST", 23, 28], ["dextran", "TREATMENT", 44, 51], ["RSV", "PROBLEM", 61, 64], ["infected A549 cells", "PROBLEM", 65, 84], ["RSV", "ANATOMY", 23, 26], ["RSV", "ANATOMY", 61, 64], ["infected", "OBSERVATION_MODIFIER", 65, 73], ["A549 cells", "OBSERVATION", 74, 84]]], ["Cells were infected with RSV in the presence of dextran-AF568, incubated for 5 h, fixed, and permeabilized as described in B. The cells were then subjected to immunostaining: RSV F was detected with AF488-conjugated anti-RSV F MAb #1129 [72] , and RSV N was detected with an allophycocyanin (APC)-conjugated anti-RSV N MAb (NB100-64752APC, Novus Biologicals, LLC).", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 130, 135], ["dextran-AF568", "CHEMICAL", 48, 61], ["AF488", "CHEMICAL", 199, 204], ["NB100-64752APC", "CHEMICAL", 324, 338], ["AF488", "CHEMICAL", 199, 204], ["APC", "CHEMICAL", 292, 295], ["Cells", "CELL", 0, 5], ["RSV", "ORGANISM", 25, 28], ["dextran-AF568", "SIMPLE_CHEMICAL", 48, 61], ["cells", "CELL", 130, 135], ["RSV", "ORGANISM", 175, 178], ["AF488", "SIMPLE_CHEMICAL", 199, 204], ["RSV", "ORGANISM", 221, 224], ["RSV", "ORGANISM", 248, 251], ["allophycocyanin", "GENE_OR_GENE_PRODUCT", 275, 290], ["APC", "GENE_OR_GENE_PRODUCT", 292, 295], ["RSV", "ORGANISM", 313, 316], ["NB100-64752APC", "SIMPLE_CHEMICAL", 324, 338], ["LLC", "CANCER", 359, 362], ["AF488", "PROTEIN", 199, 204], ["APC", "PROTEIN", 292, 295], ["RSV N MAb", "PROTEIN", 313, 322], ["RSV", "SPECIES", 25, 28], ["RSV", "SPECIES", 175, 178], ["RSV", "SPECIES", 221, 224], ["RSV", "SPECIES", 248, 251], ["RSV", "SPECIES", 313, 316], ["RSV", "PROBLEM", 25, 28], ["dextran", "TREATMENT", 48, 55], ["RSV F", "TEST", 175, 180], ["AF488", "TEST", 199, 204], ["RSV N", "PROBLEM", 248, 253], ["an allophycocyanin", "TREATMENT", 272, 290], ["APC", "TEST", 292, 295], ["conjugated anti-RSV N MAb", "TREATMENT", 297, 322], ["NB100", "TEST", 324, 329], ["LLC", "ANATOMY", 359, 362]]], ["Image acquisition and analysis were performed as described above for B. Arrows indicate RSV F (green) and RSV N (red) in dextran-AF568-positive (cyan) vesicles.", [["vesicles", "ANATOMY", 151, 159], ["dextran", "CHEMICAL", 121, 128], ["RSV", "ORGANISM", 88, 91], ["RSV", "ORGANISM", 106, 109], ["dextran-AF568", "SIMPLE_CHEMICAL", 121, 134], ["RSV", "SPECIES", 88, 91], ["RSV", "SPECIES", 106, 109], ["Image acquisition", "TEST", 0, 17], ["analysis", "TEST", 22, 30], ["B. Arrows", "TEST", 69, 78], ["RSV F", "TEST", 88, 93], ["RSV N", "TEST", 106, 111], ["dextran", "TEST", 121, 128], ["vesicles", "ANATOMY", 151, 159]]], ["All scale bars are 10 \u03bcm.", [["10 \u03bcm", "OBSERVATION_MODIFIER", 19, 24]]], ["(D-F) Quantification of dextran-AF568 uptake during RSV infection.", [["dextran-AF568", "CHEMICAL", 24, 37], ["RSV infection", "DISEASE", 52, 65], ["D-F", "SIMPLE_CHEMICAL", 1, 4], ["dextran-AF568", "SIMPLE_CHEMICAL", 24, 37], ["RSV", "ORGANISM", 52, 55], ["RSV", "SPECIES", 52, 55], ["dextran", "TREATMENT", 24, 31], ["AF568 uptake", "PROBLEM", 32, 44], ["RSV infection", "PROBLEM", 52, 65], ["RSV infection", "OBSERVATION", 52, 65]]], ["(D) A549 cells were transfected with ATP1A1 siRNA2 or Neg. siRNA 1, incubated for 48 h p.t., and inoculated with wt RSV in dextran-AF568-containing medium, or (E) A549 cells were pre-treated with ouabain or PST2238 for 16 h and inoculated with wt RSV in dextran-AF568-containing medium, or (F) A549 cells were infected with wt RSV or rgRSV dSH/dG in dextran-AF568-containing medium.", [["A549 cells", "ANATOMY", 4, 14], ["A549 cells", "ANATOMY", 163, 173], ["A549 cells", "ANATOMY", 294, 304], ["dextran-AF568", "CHEMICAL", 123, 136], ["ouabain", "CHEMICAL", 196, 203], ["PST2238", "CHEMICAL", 207, 214], ["dextran-AF568", "CHEMICAL", 254, 267], ["rgRSV dSH/dG", "CHEMICAL", 334, 346], ["dextran-AF568", "CHEMICAL", 350, 363], ["ouabain", "CHEMICAL", 196, 203], ["PST2238", "CHEMICAL", 207, 214], ["D) A549 cells", "CELL", 1, 14], ["RSV", "ORGANISM", 116, 119], ["dextran-AF568", "SIMPLE_CHEMICAL", 123, 136], ["A549 cells", "CELL", 163, 173], ["ouabain", "SIMPLE_CHEMICAL", 196, 203], ["PST2238", "SIMPLE_CHEMICAL", 207, 214], ["RSV", "ORGANISM", 247, 250], ["dextran-AF568", "SIMPLE_CHEMICAL", 254, 267], ["A549 cells", "CELL", 294, 304], ["RSV", "ORGANISM", 327, 330], ["rgRSV", "ORGANISM", 334, 339], ["dSH/dG", "SIMPLE_CHEMICAL", 340, 346], ["dextran-AF568", "SIMPLE_CHEMICAL", 350, 363], ["A549 cells", "CELL_LINE", 4, 14], ["ATP1A1 siRNA2", "DNA", 37, 50], ["Neg. siRNA 1", "DNA", 54, 66], ["A549 cells", "CELL_LINE", 163, 173], ["A549 cells", "CELL_LINE", 294, 304], ["RSV", "SPECIES", 116, 119], ["RSV", "SPECIES", 247, 250], ["RSV", "SPECIES", 327, 330], ["rgRSV", "SPECIES", 334, 339], ["A549 cells", "PROBLEM", 4, 14], ["ATP1A1 siRNA2", "TREATMENT", 37, 50], ["siRNA", "TEST", 59, 64], ["dextran", "TREATMENT", 123, 130], ["ouabain", "TREATMENT", 196, 203], ["wt RSV", "TEST", 244, 250], ["dextran", "TEST", 254, 261], ["A549 cells", "PROBLEM", 294, 304], ["wt RSV", "PROBLEM", 324, 330], ["dG in dextran", "TREATMENT", 344, 357]]], ["For all treatments (D-F) cells were fixed 5 h p.i., counterstained with DAPI and z-stacks were acquired on a Leica SP8 confocal microscope with 63x objective NA 1.4, 1.0x zoom.", [["D-F) cells", "ANATOMY", 20, 30], ["DAPI", "CHEMICAL", 72, 76], ["D-F) cells", "CELL", 20, 30], ["DAPI", "SIMPLE_CHEMICAL", 72, 76], ["all treatments (D-F) cells", "TREATMENT", 4, 30], ["objective NA", "TEST", 148, 160]]], ["For each treatment, the uptake of dextran-AF568 in vesicles greater than 1.0 \u03bcm 3 was quantified as described in detail in the Materials and Methods section.", [["vesicles", "ANATOMY", 51, 59], ["dextran-AF568", "CHEMICAL", 34, 47], ["dextran-AF568", "SIMPLE_CHEMICAL", 34, 47], ["vesicles", "CELLULAR_COMPONENT", 51, 59], ["each treatment", "TREATMENT", 4, 18], ["dextran", "TREATMENT", 34, 41], ["Methods section", "TREATMENT", 141, 156]]], ["Mean values are reported relative to RSV-infected cells transfected with Neg. siRNA 1 (D), or mock-treated infected cells (E), or wt RSV-infected cells (F).", [["cells", "ANATOMY", 50, 55], ["cells", "ANATOMY", 116, 121], ["cells", "ANATOMY", 146, 151], ["RSV", "ORGANISM", 37, 40], ["cells", "CELL", 50, 55], ["cells", "CELL", 116, 121], ["E", "CELL", 123, 124], ["RSV", "ORGANISM", 133, 136], ["cells", "CELL", 146, 151], ["F", "CELL", 153, 154], ["RSV-infected cells", "CELL_LINE", 37, 55], ["mock-treated infected cells", "CELL_LINE", 94, 121], ["infected cells", "CELL_TYPE", 137, 151], ["RSV", "SPECIES", 37, 40], ["RSV", "SPECIES", 133, 136], ["Mean values", "TEST", 0, 11], ["RSV", "TEST", 37, 40], ["infected cells", "PROBLEM", 41, 55], ["siRNA", "TEST", 78, 83], ["infected cells", "PROBLEM", 107, 121], ["wt RSV", "PROBLEM", 130, 136], ["infected cells", "OBSERVATION", 41, 55], ["infected cells", "OBSERVATION", 137, 151]]], ["Error bars indicate the standard deviation of at least three independent experiments.", [["standard deviation", "OBSERVATION", 24, 42]]], ["P-values are shown for each comparison.", [["P", "DNA", 0, 1], ["P-values", "TEST", 0, 8]]], ["First, we infected cholesterol-depleted A549 cells with RSV-GFP and found that GFP expression at 17 h p.i. was reduced to approximately 50% with each of the depletions, compared to control infected cells (Fig 10A) .", [["A549 cells", "ANATOMY", 40, 50], ["cells", "ANATOMY", 198, 203], ["cholesterol", "CHEMICAL", 19, 30], ["cholesterol", "CHEMICAL", 19, 30], ["cholesterol", "SIMPLE_CHEMICAL", 19, 30], ["A549 cells", "CELL", 40, 50], ["RSV", "ORGANISM", 56, 59], ["GFP", "GENE_OR_GENE_PRODUCT", 60, 63], ["GFP", "GENE_OR_GENE_PRODUCT", 79, 82], ["cells", "CELL", 198, 203], ["A549 cells", "CELL_LINE", 40, 50], ["GFP", "PROTEIN", 60, 63], ["GFP", "PROTEIN", 79, 82], ["control infected cells", "CELL_TYPE", 181, 203], ["RSV", "SPECIES", 56, 59], ["RSV-GFP", "TEST", 56, 63], ["GFP expression", "TEST", 79, 93], ["the depletions", "PROBLEM", 153, 167], ["infected", "OBSERVATION", 10, 18], ["A549 cells", "OBSERVATION", 40, 50], ["depletions", "OBSERVATION", 157, 167]]], ["Next, we quantified the level of RSV-induced macropinocytosis in cholesterol-depleted cells by dextran-AF568 uptake into large vesicles.", [["cells", "ANATOMY", 86, 91], ["vesicles", "ANATOMY", 127, 135], ["cholesterol", "CHEMICAL", 65, 76], ["dextran-AF568", "CHEMICAL", 95, 108], ["cholesterol", "CHEMICAL", 65, 76], ["RSV", "ORGANISM", 33, 36], ["cholesterol", "SIMPLE_CHEMICAL", 65, 76], ["cells", "CELL", 86, 91], ["dextran-AF568", "SIMPLE_CHEMICAL", 95, 108], ["vesicles", "CELLULAR_COMPONENT", 127, 135], ["cholesterol-depleted cells", "CELL_TYPE", 65, 91], ["RSV", "SPECIES", 33, 36], ["RSV", "PROBLEM", 33, 36], ["macropinocytosis", "PROBLEM", 45, 61], ["cholesterol", "TEST", 65, 76], ["dextran", "TEST", 95, 102], ["large vesicles", "PROBLEM", 121, 135], ["RSV", "OBSERVATION", 33, 36], ["macropinocytosis", "OBSERVATION", 45, 61], ["depleted cells", "OBSERVATION", 77, 91], ["large vesicles", "ANATOMY", 121, 135]]], ["In RSVinfected cells, dextran uptake was reduced by each of the cholesterol-depletion treatments, with the most significant (p < 0.0001) reduction of 59% observed for the combined MBCD-Mevinolin treatment (Fig 10B) .", [["RSVinfected cells", "ANATOMY", 3, 20], ["dextran", "CHEMICAL", 22, 29], ["cholesterol", "CHEMICAL", 64, 75], ["MBCD-Mevinolin", "CHEMICAL", 180, 194], ["cholesterol", "CHEMICAL", 64, 75], ["Mevinolin", "CHEMICAL", 185, 194], ["RSVinfected cells", "CELL", 3, 20], ["dextran", "SIMPLE_CHEMICAL", 22, 29], ["cholesterol", "SIMPLE_CHEMICAL", 64, 75], ["MBCD-Mevinolin", "SIMPLE_CHEMICAL", 180, 194], ["RSVinfected cells", "CELL_LINE", 3, 20], ["dextran uptake", "PROBLEM", 22, 36], ["the cholesterol-depletion treatments", "TREATMENT", 60, 96], ["the combined MBCD", "PROBLEM", 167, 184], ["Mevinolin treatment", "TREATMENT", 185, 204], ["RSVinfected cells", "OBSERVATION", 3, 20], ["dextran uptake", "OBSERVATION", 22, 36]]], ["The phosphorylation of EGFR Tyr845 also was determined in RSV-infected cells pretreated with MBCD + Mevinolin.", [["cells", "ANATOMY", 71, 76], ["RSV-infected", "DISEASE", 58, 70], ["MBCD", "CHEMICAL", 93, 97], ["Mevinolin", "CHEMICAL", 100, 109], ["MBCD", "CHEMICAL", 93, 97], ["Mevinolin", "CHEMICAL", 100, 109], ["EGFR", "GENE_OR_GENE_PRODUCT", 23, 27], ["RSV", "ORGANISM", 58, 61], ["cells", "CELL", 71, 76], ["MBCD + Mevinolin", "SIMPLE_CHEMICAL", 93, 109], ["EGFR Tyr845", "PROTEIN", 23, 34], ["RSV-infected cells", "CELL_LINE", 58, 76], ["RSV", "SPECIES", 58, 61], ["EGFR", "TEST", 23, 27], ["RSV", "PROBLEM", 58, 61], ["infected cells", "PROBLEM", 62, 76], ["MBCD", "TREATMENT", 93, 97], ["Mevinolin", "TREATMENT", 100, 109], ["infected cells", "OBSERVATION", 62, 76]]], ["A modest but significant (two tailed t-test, p = 0.0163) reduction in pTyr845 was observed (Fig 10C) .", [["pTyr845", "GENE_OR_GENE_PRODUCT", 70, 77], ["pTyr845", "PROTEIN", 70, 77], ["tailed t-test", "TEST", 30, 43], ["p", "TEST", 45, 46], ["modest", "OBSERVATION_MODIFIER", 2, 8], ["significant", "OBSERVATION_MODIFIER", 13, 24]]], ["These results show that cholesterol depletion results in reduced EGFR transactivation, reduced macropinocytosis, and reduced RSV infection, consistent with caveolae as the site of ATP1A1 signaling.Validation of findings in primary human small airway epithelial cells and differentiated human airway epithelial air-liquid interface (HAE-ALI) culturesAll experiments described above were performed with the human airway epithelial A549 cell line.", [["caveolae", "ANATOMY", 156, 164], ["small airway epithelial cells", "ANATOMY", 237, 266], ["airway epithelial air-liquid interface", "ANATOMY", 292, 330], ["airway epithelial A549 cell line", "ANATOMY", 411, 443], ["cholesterol", "CHEMICAL", 24, 35], ["RSV infection", "DISEASE", 125, 138], ["ALI", "DISEASE", 336, 339], ["cholesterol", "CHEMICAL", 24, 35], ["cholesterol", "SIMPLE_CHEMICAL", 24, 35], ["EGFR", "GENE_OR_GENE_PRODUCT", 65, 69], ["RSV", "ORGANISM", 125, 128], ["caveolae", "CELLULAR_COMPONENT", 156, 164], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 180, 186], ["human", "ORGANISM", 231, 236], ["small airway epithelial cells", "CELL", 237, 266], ["human", "ORGANISM", 286, 291], ["airway epithelial", "TISSUE", 292, 309], ["human", "ORGANISM", 405, 410], ["airway epithelial A549 cell line", "CELL", 411, 443], ["EGFR", "PROTEIN", 65, 69], ["ATP1A1", "PROTEIN", 180, 186], ["primary human small airway epithelial cells", "CELL_TYPE", 223, 266], ["differentiated human airway epithelial air-liquid interface (HAE-ALI) cultures", "CELL_LINE", 271, 349], ["human airway epithelial A549 cell line", "CELL_LINE", 405, 443], ["human", "SPECIES", 231, 236], ["human", "SPECIES", 286, 291], ["human", "SPECIES", 405, 410], ["RSV", "SPECIES", 125, 128], ["human", "SPECIES", 231, 236], ["human", "SPECIES", 286, 291], ["human", "SPECIES", 405, 410], ["cholesterol depletion", "PROBLEM", 24, 45], ["reduced EGFR transactivation", "PROBLEM", 57, 85], ["reduced macropinocytosis", "PROBLEM", 87, 111], ["reduced RSV infection", "PROBLEM", 117, 138], ["ATP1A1 signaling", "PROBLEM", 180, 196], ["primary human small airway epithelial cells", "PROBLEM", 223, 266], ["differentiated human airway epithelial air-liquid interface", "PROBLEM", 271, 330], ["cultures", "TEST", 341, 349], ["the human airway epithelial A549 cell line", "TREATMENT", 401, 443], ["cholesterol depletion", "OBSERVATION", 24, 45], ["reduced", "OBSERVATION_MODIFIER", 57, 64], ["EGFR transactivation", "OBSERVATION", 65, 85], ["reduced", "OBSERVATION_MODIFIER", 87, 94], ["macropinocytosis", "OBSERVATION", 95, 111], ["reduced", "OBSERVATION_MODIFIER", 117, 124], ["RSV infection", "OBSERVATION", 125, 138], ["consistent with", "UNCERTAINTY", 140, 155], ["small", "OBSERVATION_MODIFIER", 237, 242], ["airway epithelial cells", "OBSERVATION", 243, 266], ["airway epithelial", "OBSERVATION", 292, 309], ["air-liquid interface", "OBSERVATION", 310, 330], ["airway", "ANATOMY", 411, 417], ["epithelial", "ANATOMY_MODIFIER", 418, 428], ["A549 cell line", "OBSERVATION", 429, 443]]], ["We sought to confirm some of the major findings using primary human small airway epithelial cells (HSAEC) from a 16-year old healthy male donor.", [["small airway epithelial cells", "ANATOMY", 68, 97], ["HSAEC", "ANATOMY", 99, 104], ["human", "ORGANISM", 62, 67], ["small airway epithelial cells", "CELL", 68, 97], ["HSAEC", "CELL", 99, 104], ["primary human small airway epithelial cells", "CELL_TYPE", 54, 97], ["HSAEC", "CELL_TYPE", 99, 104], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["primary human small airway epithelial cells", "PROBLEM", 54, 97], ["small", "OBSERVATION_MODIFIER", 68, 73], ["airway epithelial cells", "OBSERVATION", 74, 97]]], ["SiRNA transfection knocked down the expression of ATP1A1 protein to 25-30% compared to Neg. siRNA 1 (Fig 11A) , which was somewhat more than the reduction to 35-39% observed for A549 cells.", [["A549 cells", "ANATOMY", 178, 188], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 50, 56], ["A549 cells", "CELL", 178, 188], ["SiRNA", "PROTEIN", 0, 5], ["ATP1A1 protein", "PROTEIN", 50, 64], ["A549 cells", "CELL_LINE", 178, 188], ["SiRNA transfection", "TEST", 0, 18], ["ATP1A1 protein", "TEST", 50, 64], ["siRNA", "TEST", 92, 97], ["A549 cells", "PROBLEM", 178, 188]]], ["Following the same protocols as for A549 cells, we found that (i) knockdown of ATP1A1 reduced the expression of RSV-GFP to 29-42% of the negative control (Fig 11B) , similar to what was observed with A549 cells (Fig 2A) . (ii) Phosphorylation of EGFR Tyr845 was also significantly (p = 0.0038) reduced in ATP1A1-knockdown (siRNA2) HSAEC (Fig 11C) , similar to what was seen in A549 cells (Fig 8) . (iii) The inhibitory effects of ouabain and PST2238 on the expression of RSV-GFP were even stronger in HSAEC than in A549 cells (Fig 11D) .", [["A549 cells", "ANATOMY", 36, 46], ["A549 cells", "ANATOMY", 200, 210], ["A549 cells", "ANATOMY", 377, 387], ["HSAEC", "ANATOMY", 501, 506], ["A549 cells", "ANATOMY", 515, 525], ["ouabain", "CHEMICAL", 430, 437], ["PST2238", "CHEMICAL", 442, 449], ["ouabain", "CHEMICAL", 430, 437], ["PST2238", "CHEMICAL", 442, 449], ["A549 cells", "CELL", 36, 46], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 79, 85], ["RSV", "ORGANISM", 112, 115], ["GFP", "GENE_OR_GENE_PRODUCT", 116, 119], ["A549 cells", "CELL", 200, 210], ["Fig 2A", "CELL", 212, 218], ["EGFR", "GENE_OR_GENE_PRODUCT", 246, 250], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 305, 311], ["A549 cells", "CELL", 377, 387], ["ouabain", "SIMPLE_CHEMICAL", 430, 437], ["PST2238", "SIMPLE_CHEMICAL", 442, 449], ["RSV", "ORGANISM", 471, 474], ["GFP", "GENE_OR_GENE_PRODUCT", 475, 478], ["HSAEC", "CELL", 501, 506], ["A549 cells", "CELL", 515, 525], ["Fig 11D", "CELL", 527, 534], ["A549 cells", "CELL_LINE", 36, 46], ["ATP1A1", "PROTEIN", 79, 85], ["GFP", "PROTEIN", 116, 119], ["A549 cells", "CELL_LINE", 200, 210], ["EGFR Tyr845", "PROTEIN", 246, 257], ["ATP1A1", "PROTEIN", 305, 311], ["siRNA2", "PROTEIN", 323, 329], ["A549 cells", "CELL_LINE", 377, 387], ["GFP", "PROTEIN", 475, 478], ["HSAEC", "CELL_TYPE", 501, 506], ["A549 cells", "CELL_LINE", 515, 525], ["RSV", "SPECIES", 112, 115], ["RSV", "SPECIES", 471, 474], ["A549 cells", "PROBLEM", 36, 46], ["ATP1A1", "TEST", 79, 85], ["RSV", "TEST", 112, 115], ["GFP", "TEST", 116, 119], ["EGFR", "TEST", 246, 250], ["ATP1A1", "TEST", 305, 311], ["HSAEC", "TEST", 331, 336], ["ouabain", "TREATMENT", 430, 437], ["RSV-GFP", "TEST", 471, 478], ["A549 cells", "OBSERVATION", 200, 210]]], ["IC 50 titrations of the compounds on HSAEC for RSV-GFP expression showed that the values were lower (i.e., more effective inhibition) in HSAEC than A549 cells by 4.9-fold for ouabain (S3A Fig) and 8.2-fold for PST2238 (S3B Fig). (iv) RSV-induced ATP1A1 clustering and colocalization of ATP1A1 and RSV N also was observed in HSAEC (Fig 11E) , similar to A549 cells (Fig 3) .Validation of findings in primary human small airway epithelial cells and differentiated human airway epithelial air-liquid interface (HAE-ALI) culturesIn addition, we used HAE-ALI cultures, a model of primary, differentiated, polarized mucociliary airway epithelium, to investigate the localization of ATP1A1 and to confirm the phenomenon of RSV-induced ATP1A1 clustering.", [["HSAEC", "ANATOMY", 137, 142], ["A549 cells", "ANATOMY", 148, 158], ["HSAEC", "ANATOMY", 324, 329], ["A549 cells", "ANATOMY", 353, 363], ["small airway epithelial cells", "ANATOMY", 413, 442], ["airway epithelial air-liquid interface", "ANATOMY", 468, 506], ["mucociliary airway epithelium", "ANATOMY", 610, 639], ["ouabain", "CHEMICAL", 175, 182], ["ALI", "DISEASE", 512, 515], ["HAE", "DISEASE", 546, 549], ["ALI", "DISEASE", 550, 553], ["ouabain", "CHEMICAL", 175, 182], ["PST2238", "CHEMICAL", 210, 217], ["HSAEC", "SIMPLE_CHEMICAL", 37, 42], ["RSV", "ORGANISM", 47, 50], ["GFP", "GENE_OR_GENE_PRODUCT", 51, 54], ["HSAEC", "CELL", 137, 142], ["A549 cells", "CELL", 148, 158], ["ouabain", "SIMPLE_CHEMICAL", 175, 182], ["RSV", "ORGANISM", 234, 237], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 246, 252], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 286, 292], ["RSV", "ORGANISM", 297, 300], ["A549 cells", "CELL", 353, 363], ["Fig 3", "CELL", 365, 370], ["human", "ORGANISM", 407, 412], ["small airway epithelial cells", "CELL", 413, 442], ["human", "ORGANISM", 462, 467], ["airway epithelial", "TISSUE", 468, 485], ["HAE-ALI cultures", "CELL", 546, 562], ["mucociliary airway epithelium", "TISSUE", 610, 639], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 676, 682], ["RSV", "ORGANISM", 716, 719], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 728, 734], ["GFP", "PROTEIN", 51, 54], ["HSAEC", "CELL_TYPE", 137, 142], ["A549 cells", "CELL_LINE", 148, 158], ["PST2238", "PROTEIN", 210, 217], ["ATP1A1", "PROTEIN", 246, 252], ["ATP1A1", "PROTEIN", 286, 292], ["RSV N", "PROTEIN", 297, 302], ["HSAEC", "CELL_LINE", 324, 329], ["A549 cells", "CELL_LINE", 353, 363], ["primary human small airway epithelial cells", "CELL_TYPE", 399, 442], ["differentiated human airway epithelial air-liquid interface (HAE-ALI) cultures", "CELL_LINE", 447, 525], ["ALI cultures", "CELL_LINE", 550, 562], ["ATP1A1", "PROTEIN", 676, 682], ["ATP1A1", "PROTEIN", 728, 734], ["human", "SPECIES", 407, 412], ["human", "SPECIES", 462, 467], ["RSV", "SPECIES", 47, 50], ["RSV", "SPECIES", 234, 237], ["RSV", "SPECIES", 297, 300], ["human", "SPECIES", 407, 412], ["human", "SPECIES", 462, 467], ["RSV", "SPECIES", 716, 719], ["RSV-GFP expression", "TEST", 47, 65], ["the values", "TEST", 78, 88], ["A549 cells", "TEST", 148, 158], ["ouabain (S3A Fig", "TEST", 175, 191], ["PST2238", "TEST", 210, 217], ["RSV", "PROBLEM", 234, 237], ["ATP1A1 clustering", "PROBLEM", 246, 263], ["ATP1A1", "TEST", 286, 292], ["RSV N", "PROBLEM", 297, 302], ["primary human small airway epithelial cells", "PROBLEM", 399, 442], ["differentiated human airway epithelial air-liquid interface", "PROBLEM", 447, 506], ["cultures", "TEST", 517, 525], ["HAE", "TEST", 546, 549], ["ALI cultures", "TEST", 550, 562], ["polarized mucociliary airway epithelium", "PROBLEM", 600, 639], ["ATP1A1", "TEST", 676, 682], ["RSV", "PROBLEM", 716, 719], ["ATP1A1 clustering", "PROBLEM", 728, 745], ["A549 cells", "OBSERVATION", 353, 363], ["small", "OBSERVATION_MODIFIER", 413, 418], ["airway epithelial cells", "OBSERVATION", 419, 442], ["airway epithelial", "OBSERVATION", 468, 485], ["air-liquid interface", "OBSERVATION", 486, 506], ["mucociliary airway epithelium", "OBSERVATION", 610, 639], ["RSV", "OBSERVATION", 716, 719]]], ["Cells were infected with wt RSV (10 6 PFU/ transwell), incubated for 1h or 5 h, fixed with PFA, permeabilized with TritonX-100, and immunostained for RSV F (red) and ATP1A1 (green), as described for A549 cells in Fig 3.", [["Cells", "ANATOMY", 0, 5], ["A549 cells", "ANATOMY", 199, 209], ["TritonX-100", "CHEMICAL", 115, 126], ["PFA", "CHEMICAL", 91, 94], ["Cells", "CELL", 0, 5], ["RSV", "ORGANISM", 28, 31], ["PFA", "SIMPLE_CHEMICAL", 91, 94], ["TritonX-100", "SIMPLE_CHEMICAL", 115, 126], ["RSV F (red)", "GENE_OR_GENE_PRODUCT", 150, 161], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 166, 172], ["A549 cells", "CELL", 199, 209], ["Fig 3", "CELL", 213, 218], ["ATP1A1", "PROTEIN", 166, 172], ["A549 cells", "CELL_LINE", 199, 209], ["RSV", "SPECIES", 28, 31], ["RSV", "SPECIES", 150, 153], ["wt RSV", "TEST", 25, 31], ["PFA", "TEST", 91, 94], ["TritonX", "TEST", 115, 122], ["RSV F", "PROBLEM", 150, 155], ["ATP1A1", "TEST", 166, 172], ["A549 cells", "OBSERVATION", 199, 209]]], ["The apical surface was demarcated by staining for F-actin (cyan) since it is abundant beneath the apical membrane and provides a close estimation of the apical surface location.", [["apical surface", "ANATOMY", 4, 18], ["apical membrane", "ANATOMY", 98, 113], ["apical surface", "ANATOMY", 153, 167], ["apical surface", "CELLULAR_COMPONENT", 4, 18], ["F-actin", "GENE_OR_GENE_PRODUCT", 50, 57], ["apical membrane", "CELLULAR_COMPONENT", 98, 113], ["apical surface", "CELLULAR_COMPONENT", 153, 167], ["F-actin", "PROTEIN", 50, 57], ["F-actin (cyan", "TREATMENT", 50, 63], ["apical", "ANATOMY_MODIFIER", 4, 10], ["surface", "OBSERVATION_MODIFIER", 11, 18], ["demarcated", "OBSERVATION_MODIFIER", 23, 33], ["abundant", "OBSERVATION_MODIFIER", 77, 85], ["apical", "ANATOMY_MODIFIER", 98, 104], ["membrane", "ANATOMY_MODIFIER", 105, 113], ["apical", "ANATOMY_MODIFIER", 153, 159], ["surface", "OBSERVATION_MODIFIER", 160, 167]]], ["To visualize ATP1A1 location, three-dimensional sections are shown without ( Fig 12A) and with (Fig 12B) F-actin staining.", [["sections", "ANATOMY", 48, 56], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 13, 19], ["F-actin", "GENE_OR_GENE_PRODUCT", 105, 112], ["ATP1A1", "PROTEIN", 13, 19], ["F-actin", "PROTEIN", 105, 112], ["F-actin staining", "PROBLEM", 105, 121], ["F-actin staining", "OBSERVATION", 105, 121]]], ["In mock treated cells, ATP1A1 was predominantly present in the basolateral surfaces of cells with relatively smaller amounts present on the apical surface in a spotted distribution, (Fig 12, left panel) .", [["cells", "ANATOMY", 16, 21], ["basolateral surfaces", "ANATOMY", 63, 83], ["cells", "ANATOMY", 87, 92], ["apical surface", "ANATOMY", 140, 154], ["cells", "CELL", 16, 21], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 23, 29], ["basolateral surfaces", "CELLULAR_COMPONENT", 63, 83], ["cells", "CELL", 87, 92], ["apical surface", "CELLULAR_COMPONENT", 140, 154], ["mock treated cells", "CELL_LINE", 3, 21], ["ATP1A1", "PROTEIN", 23, 29], ["ATP1A1", "TREATMENT", 23, 29], ["Fig", "TEST", 183, 186], ["left panel", "TEST", 191, 201], ["basolateral", "ANATOMY_MODIFIER", 63, 74], ["surfaces", "ANATOMY_MODIFIER", 75, 83], ["cells", "ANATOMY", 87, 92], ["relatively", "OBSERVATION_MODIFIER", 98, 108], ["smaller", "OBSERVATION_MODIFIER", 109, 116], ["amounts", "OBSERVATION_MODIFIER", 117, 124], ["apical", "ANATOMY_MODIFIER", 140, 146], ["surface", "ANATOMY_MODIFIER", 147, 154], ["spotted distribution", "OBSERVATION", 160, 180]]], ["Upon infection with RSV, ATP1A1 clusters were visible as early as 1 h p.i.", [["infection", "DISEASE", 5, 14], ["RSV", "ORGANISM", 20, 23], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 25, 31], ["ATP1A1", "PROTEIN", 25, 31], ["RSV", "SPECIES", 20, 23], ["infection", "PROBLEM", 5, 14], ["RSV", "PROBLEM", 20, 23], ["ATP1A1 clusters", "TREATMENT", 25, 40], ["infection", "OBSERVATION", 5, 14], ["RSV", "OBSERVATION", 20, 23]]], ["(Fig 12A and 12B, middle panel) , which became more noticeable and larger at 5 h p. i.", [["Fig", "TEST", 1, 4], ["middle panel", "TEST", 18, 30], ["larger", "OBSERVATION_MODIFIER", 67, 73]]], ["(Fig 12A and 12B right panel) .", [["Fig", "TEST", 1, 4], ["12B right panel", "TEST", 13, 28]]], ["The apical ATP1A1 seemed to increase in amount over time following infection, suggesting its recruitment to the apical surface.", [["apical", "ANATOMY", 4, 10], ["apical surface", "ANATOMY", 112, 126], ["infection", "DISEASE", 67, 76], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 11, 17], ["apical surface", "CELLULAR_COMPONENT", 112, 126], ["apical ATP1A1", "PROTEIN", 4, 17], ["The apical ATP1A1", "PROBLEM", 0, 17], ["infection", "PROBLEM", 67, 76], ["apical", "ANATOMY_MODIFIER", 4, 10], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["amount", "OBSERVATION_MODIFIER", 40, 46], ["infection", "OBSERVATION", 67, 76], ["recruitment", "OBSERVATION_MODIFIER", 93, 104], ["apical", "ANATOMY_MODIFIER", 112, 118], ["surface", "ANATOMY_MODIFIER", 119, 126]]], ["The ATP1A1 clusters were mostly visible in close proximity to RSV F. These observations were similar to those in A549 cells (Fig 3) , confirming that RSV-induced ATP1A1 clustering could be reproducibly demonstrated in two different primary cell systems.DiscussionIn the present study, we investigated the host proteins involved in RSV infection using a genome-wide high-throughput siRNA screen in human airway A549 cells infected with a recombinant RSV that expresses GFP.", [["A549 cells", "ANATOMY", 113, 123], ["cell", "ANATOMY", 240, 244], ["airway A549 cells", "ANATOMY", 403, 420], ["RSV infection", "DISEASE", 331, 344], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 4, 10], ["RSV", "ORGANISM", 62, 65], ["A549 cells", "CELL", 113, 123], ["Fig 3", "CELL", 125, 130], ["RSV", "ORGANISM", 150, 153], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 162, 168], ["cell", "CELL", 240, 244], ["RSV", "ORGANISM", 331, 334], ["human", "ORGANISM", 397, 402], ["airway A549 cells", "CELL", 403, 420], ["RSV", "ORGANISM", 449, 452], ["GFP", "GENE_OR_GENE_PRODUCT", 468, 471], ["ATP1A1 clusters", "DNA", 4, 19], ["A549 cells", "CELL_LINE", 113, 123], ["ATP1A1", "PROTEIN", 162, 168], ["human airway A549 cells", "CELL_LINE", 397, 420], ["GFP", "PROTEIN", 468, 471], ["human", "SPECIES", 397, 402], ["RSV", "SPECIES", 62, 65], ["RSV", "SPECIES", 150, 153], ["RSV", "SPECIES", 331, 334], ["human", "SPECIES", 397, 402], ["RSV", "SPECIES", 449, 452], ["The ATP1A1 clusters", "TEST", 0, 19], ["RSV", "PROBLEM", 150, 153], ["ATP1A1 clustering", "PROBLEM", 162, 179], ["the present study", "TEST", 266, 283], ["the host proteins", "PROBLEM", 301, 318], ["RSV infection", "PROBLEM", 331, 344], ["a genome", "TEST", 351, 359], ["human airway A549 cells", "PROBLEM", 397, 420], ["a recombinant RSV", "PROBLEM", 435, 452], ["RSV", "OBSERVATION", 150, 153], ["primary cell systems", "OBSERVATION", 232, 252], ["RSV infection", "OBSERVATION", 331, 344], ["airway", "ANATOMY", 403, 409], ["A549 cells", "OBSERVATION", 410, 420]]], ["Knockdown of the cellular ATP1A1 protein provided one of the greatest reductions in GFP expression with minimal effects on cell viability.", [["cellular", "ANATOMY", 17, 25], ["cell", "ANATOMY", 123, 127], ["cellular", "CELL", 17, 25], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 26, 32], ["GFP", "GENE_OR_GENE_PRODUCT", 84, 87], ["cell", "CELL", 123, 127], ["cellular ATP1A1 protein", "PROTEIN", 17, 40], ["GFP", "PROTEIN", 84, 87], ["the cellular ATP1A1 protein", "TEST", 13, 40], ["cell viability", "PROBLEM", 123, 137], ["greatest", "OBSERVATION_MODIFIER", 61, 69], ["reductions", "OBSERVATION_MODIFIER", 70, 80], ["GFP expression", "OBSERVATION", 84, 98], ["minimal", "OBSERVATION_MODIFIER", 104, 111], ["cell viability", "OBSERVATION", 123, 137]]], ["ATP1A1 is the major subunit of Na + ,K + -ATPase, a transmembrane complex that is an ATPase, an ion channel, and also is involved in signal transduction [17] .", [["Na", "CHEMICAL", 31, 33], ["K", "CHEMICAL", 37, 38], ["Na +", "CHEMICAL", 31, 35], ["K +", "CHEMICAL", 37, 40], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 0, 6], ["Na + ,K + -ATPase", "GENE_OR_GENE_PRODUCT", 31, 48], ["transmembrane", "CELLULAR_COMPONENT", 52, 65], ["ATPase", "GENE_OR_GENE_PRODUCT", 85, 91], ["ATP1A1", "PROTEIN", 0, 6], ["Na + ,K + -ATPase", "PROTEIN", 31, 48], ["transmembrane complex", "PROTEIN", 52, 73], ["ATPase", "PROTEIN", 85, 91], ["ion channel", "PROTEIN", 96, 107], ["Na", "TEST", 31, 33], ["K", "TEST", 37, 38], ["a transmembrane complex", "PROBLEM", 50, 73], ["ion channel", "OBSERVATION_MODIFIER", 96, 107]]], ["In this study, we provided evidence that ATP1A1-in particular its signal transduction function-is needed for efficient RSV infection.DiscussionWe Fig 1B.", [["RSV infection", "DISEASE", 119, 132], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 41, 47], ["RSV", "ORGANISM", 119, 122], ["ATP1A1", "PROTEIN", 41, 47], ["RSV", "SPECIES", 119, 122], ["this study", "TEST", 3, 13], ["ATP1A1", "TEST", 41, 47], ["efficient RSV infection", "PROBLEM", 109, 132], ["infection", "OBSERVATION", 123, 132]]], ["(B) Efficiency of RSV infection in HSAEC cells following knockdown of ATP1A1 expression using Davis, RRID: MMRRC_011687-UCD).", [["HSAEC cells", "ANATOMY", 35, 46], ["RSV infection", "DISEASE", 18, 31], ["RSV", "ORGANISM", 18, 21], ["HSAEC cells", "CELL", 35, 46], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 70, 76], ["HSAEC cells", "CELL_LINE", 35, 46], ["ATP1A1", "PROTEIN", 70, 76], ["RSV", "SPECIES", 18, 21], ["RSV infection in HSAEC cells", "PROBLEM", 18, 46], ["RSV infection", "OBSERVATION", 18, 31]]], ["It was necessary to use the heterozygous ATP1A1 +/genotype because the homozygous ATP1A1 -/knock-out is lethal at the preweaning stage.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 41, 47], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 82, 88], ["ATP1A1", "PROTEIN", 41, 47], ["ATP1A1", "DNA", 82, 88], ["the heterozygous ATP1A1", "TEST", 24, 47], ["the homozygous ATP1A1", "TEST", 67, 88], ["lethal", "PROBLEM", 104, 110]]], ["No significant difference in the virus load was observed between ATP1A1 +/mice and their wildtype litter mates.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 65, 71], ["mice", "ORGANISM", 74, 78], ["ATP1A1", "PROTEIN", 65, 71], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 74, 78], ["significant difference", "PROBLEM", 3, 25], ["the virus load", "TEST", 29, 43], ["ATP1A1", "TEST", 65, 71], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION_MODIFIER", 15, 25], ["virus load", "OBSERVATION", 33, 43]]], ["This was not surprising, given the modest reduction in ATP1A1 expression (reduced only by 30-35% compared to wt litter mates), which presumably was not sufficient to reduce the efficiency of RSV infection.DiscussionTwo ATP1A1-binding drugs, ouabain and PST2238, were found to inhibit RSV infection.", [["RSV infection", "DISEASE", 191, 204], ["ouabain", "CHEMICAL", 241, 248], ["PST2238", "CHEMICAL", 253, 260], ["RSV infection", "DISEASE", 284, 297], ["ouabain", "CHEMICAL", 241, 248], ["PST2238", "CHEMICAL", 253, 260], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 55, 61], ["RSV", "ORGANISM", 191, 194], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 219, 225], ["ouabain", "SIMPLE_CHEMICAL", 241, 248], ["PST2238", "SIMPLE_CHEMICAL", 253, 260], ["RSV", "ORGANISM", 284, 287], ["ATP1A1", "PROTEIN", 55, 61], ["ATP1A1", "PROTEIN", 219, 225], ["RSV", "SPECIES", 191, 194], ["RSV", "SPECIES", 284, 287], ["the modest reduction in ATP1A1 expression", "PROBLEM", 31, 72], ["RSV infection", "PROBLEM", 191, 204], ["ouabain", "TREATMENT", 241, 248], ["PST2238", "TEST", 253, 260], ["RSV infection", "PROBLEM", 284, 297], ["modest", "OBSERVATION_MODIFIER", 35, 41], ["reduction", "OBSERVATION_MODIFIER", 42, 51], ["reduced", "OBSERVATION_MODIFIER", 74, 81], ["RSV infection", "OBSERVATION", 191, 204], ["RSV", "OBSERVATION_MODIFIER", 284, 287], ["infection", "OBSERVATION", 288, 297]]], ["Inhibition of RSV infection with ouabain was achieved at sub-nanomolar concentrations that initiate ATP1A1 signaling cascades [17, 26] but are not inhibitory for its ATPase and ion channel functions and do not alter the cytosolic Na + and K + levels [41] .", [["cytosolic", "ANATOMY", 220, 229], ["RSV infection", "DISEASE", 14, 27], ["ouabain", "CHEMICAL", 33, 40], ["Na", "CHEMICAL", 230, 232], ["K", "CHEMICAL", 239, 240], ["ouabain", "CHEMICAL", 33, 40], ["Na +", "CHEMICAL", 230, 234], ["K +", "CHEMICAL", 239, 242], ["RSV", "ORGANISM", 14, 17], ["ouabain", "SIMPLE_CHEMICAL", 33, 40], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 100, 106], ["ATPase", "GENE_OR_GENE_PRODUCT", 166, 172], ["Na +", "SIMPLE_CHEMICAL", 230, 234], ["K +", "SIMPLE_CHEMICAL", 239, 242], ["ATP1A1", "PROTEIN", 100, 106], ["ATPase", "PROTEIN", 166, 172], ["RSV", "SPECIES", 14, 17], ["RSV infection", "PROBLEM", 14, 27], ["ouabain", "TREATMENT", 33, 40], ["sub-nanomolar concentrations", "TREATMENT", 57, 85], ["ion channel functions", "TEST", 177, 198], ["the cytosolic Na", "TEST", 216, 232], ["K + levels", "TEST", 239, 249], ["RSV infection", "OBSERVATION", 14, 27]]], ["While incubation with ouabain depletes Na + ,K + -ATPase over time from the plasma membrane, it is unlikely that this depletion was the sole mechanism for the inhibition of RSV infection, because the antiviral effect of ouabain was evident even when added simultaneously with the virus inoculum.", [["plasma membrane", "ANATOMY", 76, 91], ["ouabain", "CHEMICAL", 22, 29], ["Na", "CHEMICAL", 39, 41], ["K", "CHEMICAL", 45, 46], ["RSV infection", "DISEASE", 173, 186], ["ouabain", "CHEMICAL", 220, 227], ["ouabain", "CHEMICAL", 22, 29], ["Na +", "CHEMICAL", 39, 43], ["K +", "CHEMICAL", 45, 48], ["ouabain", "CHEMICAL", 220, 227], ["ouabain", "SIMPLE_CHEMICAL", 22, 29], ["Na + ,K + -ATPase", "GENE_OR_GENE_PRODUCT", 39, 56], ["plasma membrane", "CELLULAR_COMPONENT", 76, 91], ["RSV", "ORGANISM", 173, 176], ["ouabain", "SIMPLE_CHEMICAL", 220, 227], ["Na + ,K + -ATPase", "PROTEIN", 39, 56], ["RSV", "SPECIES", 173, 176], ["ouabain depletes", "TEST", 22, 38], ["Na", "TEST", 39, 41], ["K", "TEST", 45, 46], ["the plasma membrane", "TEST", 72, 91], ["this depletion", "PROBLEM", 113, 127], ["RSV infection", "PROBLEM", 173, 186], ["the antiviral effect of ouabain", "TREATMENT", 196, 227], ["the virus inoculum", "PROBLEM", 276, 294], ["plasma membrane", "ANATOMY", 76, 91], ["unlikely", "UNCERTAINTY", 99, 107], ["RSV", "OBSERVATION_MODIFIER", 173, 176], ["infection", "OBSERVATION", 177, 186], ["virus inoculum", "OBSERVATION", 280, 294]]], ["We speculate that the mechanism of inhibition by shorter-term treatment with ouabain involves the indicated siRNAs, assayed by GFP quantification by ELISA reader, as in Fig 2A.", [["ouabain", "CHEMICAL", 77, 84], ["ouabain", "CHEMICAL", 77, 84], ["ouabain", "SIMPLE_CHEMICAL", 77, 84], ["GFP", "GENE_OR_GENE_PRODUCT", 127, 130], ["shorter-term treatment", "TREATMENT", 49, 71], ["ouabain", "TREATMENT", 77, 84], ["siRNAs", "PROBLEM", 108, 114]]], ["(C) EGFR Tyr845 phosphorylation in HSAEC cells following knockdown of ATP1A1 expression using ATP1A1 siRNA 2, as in Fig 8. competition with RSV for ATP1A1 signaling, as is discussed later.", [["HSAEC cells", "ANATOMY", 35, 46], ["EGFR", "GENE_OR_GENE_PRODUCT", 4, 8], ["HSAEC cells", "CELL", 35, 46], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 70, 76], ["RSV", "ORGANISM", 140, 143], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 148, 154], ["EGFR", "PROTEIN", 4, 8], ["HSAEC cells", "CELL_LINE", 35, 46], ["ATP1A1", "PROTEIN", 70, 76], ["ATP1A1", "PROTEIN", 148, 154], ["RSV", "SPECIES", 140, 143], ["EGFR", "TEST", 4, 8], ["phosphorylation in HSAEC cells", "TREATMENT", 16, 46], ["ATP1A1 expression", "TREATMENT", 70, 87], ["ATP1A1 siRNA", "TREATMENT", 94, 106], ["RSV", "PROBLEM", 140, 143], ["ATP1A1 signaling", "PROBLEM", 148, 164]]], ["Treatment with PST2238 also reduced the efficiency of RSV infection.", [["PST2238", "CHEMICAL", 15, 22], ["RSV infection", "DISEASE", 54, 67], ["PST2238", "CHEMICAL", 15, 22], ["PST2238", "SIMPLE_CHEMICAL", 15, 22], ["RSV", "ORGANISM", 54, 57], ["RSV", "SPECIES", 54, 57], ["Treatment", "TREATMENT", 0, 9], ["PST2238", "TREATMENT", 15, 22], ["RSV infection", "PROBLEM", 54, 67], ["efficiency", "OBSERVATION_MODIFIER", 40, 50], ["RSV infection", "OBSERVATION", 54, 67]]], ["PST2238 is a competitive inhibitor of ouabain that shares a common binding site on the extracellular domain of ATP1A1.", [["extracellular", "ANATOMY", 87, 100], ["PST2238", "CHEMICAL", 0, 7], ["ouabain", "CHEMICAL", 38, 45], ["PST2238", "CHEMICAL", 0, 7], ["ouabain", "CHEMICAL", 38, 45], ["PST2238", "SIMPLE_CHEMICAL", 0, 7], ["ouabain", "SIMPLE_CHEMICAL", 38, 45], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 87, 100], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 111, 117], ["extracellular domain", "PROTEIN", 87, 107], ["ATP1A1", "PROTEIN", 111, 117], ["a competitive inhibitor of ouabain", "TREATMENT", 11, 45], ["a common binding site", "PROBLEM", 58, 79]]], ["PST2238 does not induce signaling and indeed blocks ATP1A1 signaling in response to ouabain or RSV.", [["PST2238", "CHEMICAL", 0, 7], ["ouabain", "CHEMICAL", 84, 91], ["PST2238", "CHEMICAL", 0, 7], ["ouabain", "CHEMICAL", 84, 91], ["PST2238", "SIMPLE_CHEMICAL", 0, 7], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 52, 58], ["ouabain", "SIMPLE_CHEMICAL", 84, 91], ["RSV", "ORGANISM", 95, 98], ["ATP1A1", "PROTEIN", 52, 58], ["RSV", "SPECIES", 95, 98], ["RSV", "PROBLEM", 95, 98]]], ["Both of these ATP1A1-binding drugs implicated ATP1A1-and in particular ATP1A1 signaling-as being important for efficient RSV infection.", [["RSV infection", "DISEASE", 121, 134], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 14, 20], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 46, 52], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 71, 77], ["RSV", "ORGANISM", 121, 124], ["ATP1A1", "PROTEIN", 14, 20], ["ATP1A1", "PROTEIN", 46, 52], ["ATP1A1", "PROTEIN", 71, 77], ["RSV", "SPECIES", 121, 124], ["these ATP1A1-binding drugs", "TREATMENT", 8, 34], ["ATP1A1", "TEST", 46, 52], ["efficient RSV infection", "PROBLEM", 111, 134], ["infection", "OBSERVATION", 125, 134]]], ["Time-of-addition experiments indicated that the inhibitory effects of ouabain and PST2238 occurred very early during infection.DiscussionWe observed a striking phenomenon in which ATP1A1 formed clusters in the plasma membrane within 15 minutes following infection with RSV.", [["plasma membrane", "ANATOMY", 210, 225], ["ouabain", "CHEMICAL", 70, 77], ["PST2238", "CHEMICAL", 82, 89], ["infection", "DISEASE", 117, 126], ["infection", "DISEASE", 254, 263], ["ouabain", "CHEMICAL", 70, 77], ["PST2238", "CHEMICAL", 82, 89], ["ouabain", "SIMPLE_CHEMICAL", 70, 77], ["PST2238", "SIMPLE_CHEMICAL", 82, 89], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 180, 186], ["plasma membrane", "CELLULAR_COMPONENT", 210, 225], ["RSV", "ORGANISM", 269, 272], ["ATP1A1", "PROTEIN", 180, 186], ["RSV", "SPECIES", 269, 272], ["ouabain", "TREATMENT", 70, 77], ["infection", "PROBLEM", 117, 126], ["a striking phenomenon", "PROBLEM", 149, 170], ["infection", "PROBLEM", 254, 263], ["RSV", "PROBLEM", 269, 272], ["infection", "OBSERVATION", 117, 126], ["plasma membrane", "ANATOMY", 210, 225], ["infection", "OBSERVATION", 254, 263]]], ["This clustering was not affected by treatment with PST2238, indicating that clustering does not depend on ATP1A1 signaling.", [["PST2238", "CHEMICAL", 51, 58], ["PST2238", "CHEMICAL", 51, 58], ["PST2238", "SIMPLE_CHEMICAL", 51, 58], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 106, 112], ["ATP1A1", "PROTEIN", 106, 112], ["ATP1A1 signaling", "PROBLEM", 106, 122]]], ["Clustering of ATP1A1 occurred with equal efficiency with UV-inactivated RSV, and thus was independent of transcription of the complete genome, viral RNA replication, and virus replication.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 14, 20], ["RSV", "ORGANISM", 72, 75], ["ATP1A1", "PROTEIN", 14, 20], ["RSV", "SPECIES", 72, 75], ["Clustering of ATP1A1", "PROBLEM", 0, 20], ["UV", "TREATMENT", 57, 59], ["inactivated RSV", "PROBLEM", 60, 75], ["the complete genome", "TREATMENT", 122, 141], ["viral RNA replication", "TREATMENT", 143, 164], ["virus replication", "TREATMENT", 170, 187], ["equal efficiency", "OBSERVATION_MODIFIER", 35, 51], ["RSV", "OBSERVATION", 72, 75]]], ["This clustering was reminiscent of the behavior of signaling receptors following ligand binding, and suggested there might be a physical interaction between the virions and the cell surface that triggers ATP1A1 clustering.", [["virions", "ANATOMY", 161, 168], ["cell surface", "ANATOMY", 177, 189], ["virions", "CELLULAR_COMPONENT", 161, 168], ["cell surface", "CELLULAR_COMPONENT", 177, 189], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 204, 210], ["signaling receptors", "PROTEIN", 51, 70], ["ATP1A1", "PROTEIN", 204, 210], ["a physical interaction between the virions", "PROBLEM", 126, 168], ["ATP1A1 clustering", "PROBLEM", 204, 221]]], ["Interaction of this sort could be imagined as part of viral attachment or part of a cellular response to RSV virions.", [["cellular", "ANATOMY", 84, 92], ["cellular", "CELL", 84, 92], ["RSV", "ORGANISM", 105, 108], ["RSV", "SPECIES", 105, 108], ["viral attachment", "PROBLEM", 54, 70], ["RSV virions", "PROBLEM", 105, 116], ["RSV virions", "OBSERVATION", 105, 116]]], ["However, we were unable to detect binding between ATP1A1 and any of the RSV surface glycoproteins (G, F or SH) by various co-immunoprecipitation techniques.", [["surface", "ANATOMY", 76, 83], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 50, 56], ["RSV surface glycoproteins", "GENE_OR_GENE_PRODUCT", 72, 97], ["G, F", "GENE_OR_GENE_PRODUCT", 99, 103], ["ATP1A1", "PROTEIN", 50, 56], ["RSV surface glycoproteins", "PROTEIN", 72, 97], ["G, F or SH", "PROTEIN", 99, 109], ["RSV", "SPECIES", 72, 75], ["ATP1A1", "TEST", 50, 56]]], ["For example, we investigated possible binding using the human lung epithelial cell line H1299 ATP1A1-YFP (kindly provided by Uri Alon, Weizmann Institute of Science, Rehovot, Israel [42, 43] ) that chromosomally expressed ATP1A1 genetically fused to yellow fluorescent protein (YFP) tag.", [["lung epithelial cell line H1299 ATP1A1-YFP", "ANATOMY", 62, 104], ["human", "ORGANISM", 56, 61], ["lung epithelial cell line H1299 ATP1A1-YFP", "CELL", 62, 104], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 222, 228], ["yellow fluorescent protein", "GENE_OR_GENE_PRODUCT", 250, 276], ["YFP", "GENE_OR_GENE_PRODUCT", 278, 281], ["human lung epithelial cell line H1299 ATP1A1", "CELL_LINE", 56, 100], ["YFP", "PROTEIN", 101, 104], ["ATP1A1", "PROTEIN", 222, 228], ["yellow fluorescent protein (YFP) tag", "PROTEIN", 250, 286], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["the human lung epithelial cell line", "TEST", 52, 87], ["ATP1A1", "TEST", 94, 100], ["yellow fluorescent protein", "TEST", 250, 276], ["lung", "ANATOMY", 62, 66], ["epithelial cell line", "OBSERVATION", 67, 87]]], ["These cells were infected with RSV, incubated for 1h and lysed, and co-immunoprecipitation was performed with YFP-specific antibodies followed by Western blotting with antibodies to RSV proteins.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["RSV", "ORGANISM", 31, 34], ["YFP", "GENE_OR_GENE_PRODUCT", 110, 113], ["RSV", "ORGANISM", 182, 185], ["YFP", "PROTEIN", 110, 113], ["specific antibodies", "PROTEIN", 114, 133], ["antibodies", "PROTEIN", 168, 178], ["RSV proteins", "PROTEIN", 182, 194], ["RSV", "SPECIES", 31, 34], ["RSV", "SPECIES", 182, 185], ["RSV", "PROBLEM", 31, 34], ["co-immunoprecipitation", "TEST", 68, 90], ["YFP", "TEST", 110, 113], ["specific antibodies", "TEST", 114, 133], ["RSV proteins", "PROBLEM", 182, 194]]], ["However, there was no evidence of pull-down of RSV proteins.", [["RSV", "ORGANISM", 47, 50], ["RSV proteins", "PROTEIN", 47, 59], ["RSV", "SPECIES", 47, 50], ["pull", "TEST", 34, 38], ["RSV proteins", "PROBLEM", 47, 59], ["no evidence of", "UNCERTAINTY", 19, 33], ["pull", "OBSERVATION", 34, 38], ["RSV proteins", "OBSERVATION", 47, 59]]], ["We also performed comparable co-precipitation experiments in which, prior to lysis, cells were treated with the permeable, reversible crosslinker dithiobis (succinimidyl propionate) [44] .", [["cells", "ANATOMY", 84, 89], ["crosslinker", "CHEMICAL", 134, 145], ["dithiobis (succinimidyl propionate", "CHEMICAL", 146, 180], ["dithiobis (succinimidyl propionate)", "CHEMICAL", 146, 181], ["cells", "CELL", 84, 89], ["dithiobis (succinimidyl propionate", "SIMPLE_CHEMICAL", 146, 180], ["lysis", "TREATMENT", 77, 82], ["the permeable, reversible crosslinker dithiobis (succinimidyl propionate)", "TREATMENT", 108, 181], ["reversible", "OBSERVATION_MODIFIER", 123, 133], ["crosslinker dithiobis", "OBSERVATION", 134, 155]]], ["We also incubated RSV virions with ATP1A1 immobilized on beads.", [["RSV", "ORGANISM", 18, 21], ["ATP1A1", "SIMPLE_CHEMICAL", 35, 41], ["ATP1A1", "PROTEIN", 35, 41], ["RSV", "SPECIES", 18, 21], ["RSV virions", "TREATMENT", 18, 29], ["ATP1A1 immobilized on beads", "TREATMENT", 35, 62], ["RSV virions", "OBSERVATION", 18, 29]]], ["However, there was no evidence of binding between ATP1A1 and RSV proteins in these experiments.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 50, 56], ["RSV", "ORGANISM", 61, 64], ["ATP1A1", "PROTEIN", 50, 56], ["RSV proteins", "PROTEIN", 61, 73], ["RSV", "SPECIES", 61, 64], ["binding between ATP1A1 and RSV proteins", "PROBLEM", 34, 73], ["no evidence of", "UNCERTAINTY", 19, 33], ["RSV proteins", "OBSERVATION", 61, 73]]], ["We also performed a cell-based binding assay [45] , using A549 cells that had been siRNA-transfected to knock down ATP1A1.", [["cell", "ANATOMY", 20, 24], ["A549 cells", "ANATOMY", 58, 68], ["cell", "CELL", 20, 24], ["A549 cells", "CELL", 58, 68], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 115, 121], ["A549 cells", "CELL_LINE", 58, 68], ["ATP1A1", "PROTEIN", 115, 121], ["a cell-based binding assay", "TEST", 18, 44], ["A549 cells", "TREATMENT", 58, 68], ["siRNA", "TEST", 83, 88], ["siRNA", "OBSERVATION", 83, 88]]], ["Specifically, the cells were transfected with ATP1A1 siRNA, incubated for 48 h, detached, and incubated on ice with RSV for 30 min, after which the cells were extensively washed and incubated with a pool of RSV Fspecific monoclonal antibodies to detect possible bound virus.", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 148, 153], ["cells", "CELL", 18, 23], ["RSV", "ORGANISM", 116, 119], ["cells", "CELL", 148, 153], ["RSV", "ORGANISM", 207, 210], ["RSV Fspecific monoclonal antibodies", "PROTEIN", 207, 242], ["RSV", "SPECIES", 116, 119], ["RSV", "SPECIES", 207, 210], ["ATP1A1 siRNA", "TREATMENT", 46, 58], ["RSV", "TREATMENT", 116, 119], ["RSV Fspecific monoclonal antibodies", "TEST", 207, 242], ["bound virus", "PROBLEM", 262, 273], ["possible", "UNCERTAINTY", 253, 261], ["bound virus", "OBSERVATION", 262, 273]]], ["ATP1A1 knockdown did not result in an appreciable reduction in RSV binding, and thus we did not detect any contribution of ATP1A1 to RSV attachment.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 0, 6], ["RSV", "ORGANISM", 63, 66], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 123, 129], ["RSV", "ORGANISM", 133, 136], ["ATP1A1", "PROTEIN", 0, 6], ["ATP1A1", "PROTEIN", 123, 129], ["RSV", "SPECIES", 63, 66], ["RSV", "SPECIES", 133, 136], ["ATP1A1 knockdown", "TEST", 0, 16], ["an appreciable reduction in RSV binding", "PROBLEM", 35, 74], ["ATP1A1 to RSV attachment", "PROBLEM", 123, 147], ["appreciable", "OBSERVATION_MODIFIER", 38, 49], ["reduction", "OBSERVATION", 50, 59], ["RSV binding", "OBSERVATION", 63, 74], ["RSV", "OBSERVATION", 133, 136]]], ["Treatment of the cells with heparinase I prior to RSV exposure to remove cell surface GAGs, which was done to eliminate GAG-mediated RSV attachment, also did not reveal any contribution of ATP1A1 to RSV attachment.", [["cells", "ANATOMY", 17, 22], ["cell surface", "ANATOMY", 73, 85], ["cells", "CELL", 17, 22], ["heparinase I", "GENE_OR_GENE_PRODUCT", 28, 40], ["RSV", "ORGANISM", 50, 53], ["cell", "CELL", 73, 77], ["GAGs", "GENE_OR_GENE_PRODUCT", 86, 90], ["GAG", "SIMPLE_CHEMICAL", 120, 123], ["RSV", "ORGANISM", 133, 136], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 189, 195], ["RSV", "ORGANISM", 199, 202], ["heparinase I", "PROTEIN", 28, 40], ["ATP1A1", "PROTEIN", 189, 195], ["RSV", "SPECIES", 50, 53], ["RSV", "SPECIES", 133, 136], ["RSV", "SPECIES", 199, 202], ["the cells", "PROBLEM", 13, 22], ["heparinase I", "TREATMENT", 28, 40], ["RSV exposure", "PROBLEM", 50, 62], ["cell surface GAGs", "TEST", 73, 90], ["GAG-mediated RSV attachment", "PROBLEM", 120, 147], ["ATP1A1 to RSV attachment", "PROBLEM", 189, 213], ["RSV attachment", "OBSERVATION", 199, 213]]], ["Therefore, there was no evidence of stable binding of any RSV surface protein to ATP1A1.DiscussionIt may be that an interaction between ATP1A1 and one or more RSV proteins occurs but is insufficiently stable to be detected by these methods.", [["surface", "ANATOMY", 62, 69], ["RSV", "ORGANISM", 58, 61], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 81, 87], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 136, 142], ["RSV", "ORGANISM", 159, 162], ["RSV surface protein", "PROTEIN", 58, 77], ["ATP1A1", "PROTEIN", 81, 87], ["ATP1A1", "PROTEIN", 136, 142], ["RSV proteins", "PROTEIN", 159, 171], ["RSV", "SPECIES", 58, 61], ["RSV", "SPECIES", 159, 162], ["any RSV surface protein", "PROBLEM", 54, 77], ["ATP1A1", "TEST", 81, 87], ["an interaction between ATP1A1", "PROBLEM", 113, 142], ["more RSV proteins", "PROBLEM", 154, 171], ["no evidence of", "UNCERTAINTY", 21, 35], ["stable", "OBSERVATION", 36, 42]]], ["Using RSV deletion mutants, we did demonstrate that the RSV G protein is required to trigger ATP1A1 clustering.", [["RSV", "ORGANISM", 6, 9], ["RSV G", "GENE_OR_GENE_PRODUCT", 56, 61], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 93, 99], ["RSV deletion mutants", "DNA", 6, 26], ["RSV G protein", "PROTEIN", 56, 69], ["ATP1A1", "PROTEIN", 93, 99], ["RSV", "SPECIES", 6, 9], ["RSV", "SPECIES", 56, 59], ["RSV deletion mutants", "PROBLEM", 6, 26], ["the RSV G protein", "TEST", 52, 69]]], ["This implies that an initial virus attachment event involving G is needed to initiate ATP1A1 clustering.", [["G", "GENE_OR_GENE_PRODUCT", 62, 63], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 86, 92], ["ATP1A1", "PROTEIN", 86, 92], ["an initial virus attachment event", "PROBLEM", 18, 51]]], ["That initial attachment event might involve a direct interaction between RSV G and ATP1A1, although there is as yet no evidence of this, as already noted.", [["RSV G", "GENE_OR_GENE_PRODUCT", 73, 78], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 83, 89], ["RSV G", "PROTEIN", 73, 78], ["RSV", "SPECIES", 73, 76], ["a direct interaction between RSV G and ATP1A1", "PROBLEM", 44, 89], ["no evidence of", "UNCERTAINTY", 116, 130]]], ["It perhaps is more likely that RSV attachment is an earlier event involving other cellular structures, and that attachment induces ATP1A1 signaling through some as-yet unknown intermediate step.", [["cellular structures", "ANATOMY", 82, 101], ["RSV", "ORGANISM", 31, 34], ["cellular structures", "TISSUE", 82, 101], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 131, 137], ["ATP1A1", "PROTEIN", 131, 137], ["RSV", "SPECIES", 31, 34], ["RSV attachment", "PROBLEM", 31, 45], ["is more likely", "UNCERTAINTY", 11, 25], ["RSV", "OBSERVATION", 31, 34], ["cellular structures", "OBSERVATION", 82, 101]]], ["Clustering of signaling receptors in general can increase ligand binding and signal transduction [46] by reducing the effective dissociation rate through enhancing rebinding within the receptor cluster [47] .", [["signaling receptors", "PROTEIN", 14, 33], ["signaling receptors", "PROBLEM", 14, 33], ["signal transduction", "TEST", 77, 96], ["the effective dissociation rate", "PROBLEM", 114, 145], ["signaling receptors", "OBSERVATION", 14, 33]]], ["Therefore, clustering of ATP1A1 may be beneficial for RSV infection by enhancing the ATP1A1-mediated signaling that is required for viral uptake.DiscussionWe hypothesized that RSV utilizes ATP1A1 signaling for uptake into the cell by endocytosis.", [["cell", "ANATOMY", 226, 230], ["RSV infection", "DISEASE", 54, 67], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 25, 31], ["RSV", "ORGANISM", 54, 57], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 85, 91], ["RSV", "ORGANISM", 176, 179], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 189, 195], ["cell", "CELL", 226, 230], ["ATP1A1", "PROTEIN", 25, 31], ["ATP1A1", "PROTEIN", 85, 91], ["ATP1A1", "PROTEIN", 189, 195], ["RSV", "SPECIES", 54, 57], ["RSV", "SPECIES", 176, 179], ["ATP1A1", "TREATMENT", 25, 31], ["RSV infection", "PROBLEM", 54, 67], ["the ATP1A1", "TEST", 81, 91], ["viral uptake", "PROBLEM", 132, 144], ["RSV", "PROBLEM", 176, 179], ["infection", "OBSERVATION", 58, 67], ["RSV", "OBSERVATION", 176, 179], ["endocytosis", "OBSERVATION", 234, 245]]], ["This potentially could involve any of the various pathways including clathrin-or caveolinmediated endocytosis or macropinocytosis.", [["clathrin", "GENE_OR_GENE_PRODUCT", 69, 77], ["clathrin", "PROTEIN", 69, 77], ["clathrin", "PROBLEM", 69, 77], ["caveolinmediated endocytosis", "PROBLEM", 81, 109], ["macropinocytosis", "PROBLEM", 113, 129], ["macropinocytosis", "OBSERVATION", 113, 129]]], ["We showed that RSV infection indeed induces and requires ATP1A1 signaling, and confirmed that Src-kinase activity was required for efficient RSV infection.", [["RSV infection", "DISEASE", 15, 28], ["RSV infection", "DISEASE", 141, 154], ["RSV", "ORGANISM", 15, 18], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 57, 63], ["Src", "GENE_OR_GENE_PRODUCT", 94, 97], ["RSV", "ORGANISM", 141, 144], ["ATP1A1", "PROTEIN", 57, 63], ["Src", "PROTEIN", 94, 97], ["RSV", "SPECIES", 15, 18], ["RSV", "SPECIES", 141, 144], ["RSV infection", "PROBLEM", 15, 28], ["Src-kinase activity", "PROBLEM", 94, 113], ["efficient RSV infection", "PROBLEM", 131, 154], ["RSV", "OBSERVATION_MODIFIER", 15, 18], ["infection", "OBSERVATION", 19, 28], ["RSV", "OBSERVATION_MODIFIER", 141, 144], ["infection", "OBSERVATION", 145, 154]]], ["We also confirmed that EGFR is essential for efficient RSV infection, as previously shown [14] , but is not sufficient alone and requires the upstream activation of ATP1A1 and c-Src for efficient RSV infection.DiscussionATP1A1 signaling in response to ouabain results in clathrin-mediated endocytosis and the uptake and destruction of Na + ,K + -ATPase [35, 36] .", [["RSV infection", "DISEASE", 55, 68], ["RSV infection", "DISEASE", 196, 209], ["ouabain", "CHEMICAL", 252, 259], ["Na", "CHEMICAL", 335, 337], ["K", "CHEMICAL", 341, 342], ["ouabain", "CHEMICAL", 252, 259], ["Na +", "CHEMICAL", 335, 339], ["K +", "CHEMICAL", 341, 344], ["EGFR", "GENE_OR_GENE_PRODUCT", 23, 27], ["RSV", "ORGANISM", 55, 58], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 165, 171], ["c-Src", "GENE_OR_GENE_PRODUCT", 176, 181], ["RSV", "ORGANISM", 196, 199], ["DiscussionATP1A1", "GENE_OR_GENE_PRODUCT", 210, 226], ["ouabain", "SIMPLE_CHEMICAL", 252, 259], ["clathrin", "GENE_OR_GENE_PRODUCT", 271, 279], ["Na + ,K + -ATPase", "GENE_OR_GENE_PRODUCT", 335, 352], ["EGFR", "PROTEIN", 23, 27], ["ATP1A1", "PROTEIN", 165, 171], ["c", "PROTEIN", 176, 177], ["Src", "PROTEIN", 178, 181], ["DiscussionATP1A1", "PROTEIN", 210, 226], ["clathrin", "PROTEIN", 271, 279], ["Na + ,K + -ATPase", "PROTEIN", 335, 352], ["RSV", "SPECIES", 55, 58], ["RSV", "SPECIES", 196, 199], ["EGFR", "TEST", 23, 27], ["efficient RSV infection", "PROBLEM", 45, 68], ["ATP1A1", "TEST", 165, 171], ["c-Src", "TREATMENT", 176, 181], ["efficient RSV infection", "PROBLEM", 186, 209], ["ouabain", "TEST", 252, 259], ["mediated endocytosis", "PROBLEM", 280, 300], ["the uptake", "PROBLEM", 305, 315], ["Na", "TEST", 335, 337], ["K", "TEST", 341, 342], ["EGFR", "OBSERVATION", 23, 27], ["essential for", "UNCERTAINTY", 31, 44], ["RSV", "OBSERVATION_MODIFIER", 55, 58], ["infection", "OBSERVATION", 59, 68], ["RSV infection", "OBSERVATION", 196, 209]]], ["Clathrin-mediated endocytosis also has been controversially suggested to be involved in the uptake of RSV [15] .", [["Clathrin", "GENE_OR_GENE_PRODUCT", 0, 8], ["RSV", "ORGANISM", 102, 105], ["Clathrin", "PROTEIN", 0, 8], ["RSV", "SPECIES", 102, 105], ["the uptake of RSV", "PROBLEM", 88, 105]]], ["In preliminary experiments, inhibitors of clathrin-mediated endocytosis did not affect RSV infection.", [["RSV infection", "DISEASE", 87, 100], ["clathrin", "GENE_OR_GENE_PRODUCT", 42, 50], ["RSV", "ORGANISM", 87, 90], ["clathrin", "PROTEIN", 42, 50], ["RSV", "SPECIES", 87, 90], ["inhibitors of clathrin", "TREATMENT", 28, 50], ["mediated endocytosis", "PROBLEM", 51, 71], ["RSV infection", "PROBLEM", 87, 100], ["infection", "OBSERVATION", 91, 100]]], ["However, we found that RSV infection induced a high level of macropinocytosis, and that these macropinosomes contained a high content of RSV virions.", [["RSV infection", "DISEASE", 23, 36], ["RSV", "ORGANISM", 23, 26], ["RSV", "ORGANISM", 137, 140], ["RSV", "SPECIES", 23, 26], ["RSV", "SPECIES", 137, 140], ["RSV infection", "PROBLEM", 23, 36], ["a high level of macropinocytosis", "PROBLEM", 45, 77], ["these macropinosomes", "PROBLEM", 88, 108], ["RSV virions", "PROBLEM", 137, 148], ["RSV", "OBSERVATION_MODIFIER", 23, 26], ["infection", "OBSERVATION", 27, 36], ["macropinocytosis", "OBSERVATION", 61, 77], ["high content", "OBSERVATION", 121, 133], ["RSV virions", "OBSERVATION", 137, 148]]], ["Previous studies also have suggested a role for macropinocytosis in RSV uptake [14, 16] .", [["RSV", "ORGANISM", 68, 71], ["RSV", "SPECIES", 68, 71], ["Previous studies", "TEST", 0, 16], ["macropinocytosis in RSV uptake", "PROBLEM", 48, 78]]], ["Macropinocytosis also can be induced through components of the ATP1A1 signaling pathway.", [["Macropinocytosis", "DISEASE", 0, 16], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 63, 69], ["ATP1A1", "PROTEIN", 63, 69], ["Macropinocytosis", "PROBLEM", 0, 16]]], ["For example, it has been described that phosphorylation of EGFR Tyr845 by c-Src, in an EGF-independent manner, can lead to the induction of macropinocytosis [31, 32] , Src-kinase activity plays an important role during macropinosome formation and trafficking [48] , and can synergistically enhance macropinocytic induction [49] .DiscussionTypical macropinosomes are formed as a result of extensive, nonspecific fluidic uptake at the plasma membrane (reviewed in [25, 33, 49] ) that engulf fluid and solid cargo from outside of the cell into cytoplasmic vesicles.", [["macropinosome", "ANATOMY", 219, 232], ["plasma membrane", "ANATOMY", 433, 448], ["fluid", "ANATOMY", 489, 494], ["cell", "ANATOMY", 531, 535], ["cytoplasmic vesicles", "ANATOMY", 541, 561], ["EGFR Tyr845", "GENE_OR_GENE_PRODUCT", 59, 70], ["c-Src", "GENE_OR_GENE_PRODUCT", 74, 79], ["EGF", "GENE_OR_GENE_PRODUCT", 87, 90], ["Src-kinase", "GENE_OR_GENE_PRODUCT", 168, 178], ["macropinosome", "SIMPLE_CHEMICAL", 219, 232], ["plasma membrane", "CELLULAR_COMPONENT", 433, 448], ["fluid", "ORGANISM_SUBSTANCE", 489, 494], ["cell", "CELL", 531, 535], ["cytoplasmic vesicles", "CELLULAR_COMPONENT", 541, 561], ["EGFR Tyr845", "PROTEIN", 59, 70], ["Src", "PROTEIN", 76, 79], ["EGF", "PROTEIN", 87, 90], ["Src-kinase", "PROTEIN", 168, 178], ["EGFR", "TEST", 59, 63], ["macropinocytosis", "PROBLEM", 140, 156], ["extensive, nonspecific fluidic uptake at the plasma membrane", "PROBLEM", 388, 448], ["engulf fluid and solid cargo", "PROBLEM", 482, 510], ["extensive", "OBSERVATION_MODIFIER", 388, 397], ["nonspecific", "OBSERVATION_MODIFIER", 399, 410], ["fluidic uptake", "OBSERVATION", 411, 425], ["plasma membrane", "ANATOMY", 433, 448], ["fluid", "OBSERVATION", 489, 494], ["solid cargo", "OBSERVATION", 499, 510], ["cytoplasmic vesicles", "OBSERVATION", 541, 561]]], ["They are heterogeneous in size and are larger than other endocytic vesicles, with diameters of 0.5-5 \u03bcm.", [["endocytic vesicles", "ANATOMY", 57, 75], ["endocytic vesicles", "CELLULAR_COMPONENT", 57, 75], ["diameters", "TEST", 82, 91], ["heterogeneous", "OBSERVATION_MODIFIER", 9, 22], ["size", "OBSERVATION_MODIFIER", 26, 30], ["larger", "OBSERVATION_MODIFIER", 39, 45], ["endocytic vesicles", "OBSERVATION", 57, 75], ["diameters", "OBSERVATION_MODIFIER", 82, 91], ["0.5-5 \u03bcm", "OBSERVATION_MODIFIER", 95, 103]]], ["In RSV-infected cells, extensive macropinocytosis began very early in infection.", [["cells", "ANATOMY", 16, 21], ["RSV-infected", "DISEASE", 3, 15], ["infection", "DISEASE", 70, 79], ["RSV", "ORGANISM", 3, 6], ["cells", "CELL", 16, 21], ["RSV-infected cells", "CELL_TYPE", 3, 21], ["RSV", "SPECIES", 3, 6], ["RSV", "PROBLEM", 3, 6], ["infected cells", "PROBLEM", 7, 21], ["extensive macropinocytosis", "PROBLEM", 23, 49], ["infection", "PROBLEM", 70, 79], ["RSV", "ANATOMY", 3, 6], ["infected cells", "OBSERVATION", 7, 21], ["extensive", "OBSERVATION_MODIFIER", 23, 32], ["macropinocytosis", "OBSERVATION", 33, 49], ["infection", "OBSERVATION", 70, 79]]], ["Macropinosome formation under these conditions was confirmed to be dependent upon ATP1A1, and was significantly reduced if ATP1A1 expression was decreased or if the cells were treated with ouabain or PST2238.", [["Macropinosome", "ANATOMY", 0, 13], ["cells", "ANATOMY", 165, 170], ["ouabain", "CHEMICAL", 189, 196], ["PST2238", "CHEMICAL", 200, 207], ["ouabain", "CHEMICAL", 189, 196], ["PST2238", "CHEMICAL", 200, 207], ["Macropinosome", "SIMPLE_CHEMICAL", 0, 13], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 82, 88], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 123, 129], ["cells", "CELL", 165, 170], ["ouabain", "SIMPLE_CHEMICAL", 189, 196], ["PST2238", "SIMPLE_CHEMICAL", 200, 207], ["ATP1A1", "PROTEIN", 82, 88], ["ATP1A1", "PROTEIN", 123, 129], ["ATP1A1", "TEST", 82, 88], ["ATP1A1 expression", "PROBLEM", 123, 140], ["ouabain", "TREATMENT", 189, 196]]], ["Depletion of cholesterol resulted in a decrease in the formation of macropinosomes, consistent with the involvement of signaling complexes in the caveolae.", [["caveolae", "ANATOMY", 146, 154], ["cholesterol", "CHEMICAL", 13, 24], ["cholesterol", "CHEMICAL", 13, 24], ["cholesterol", "SIMPLE_CHEMICAL", 13, 24], ["macropinosomes", "GENE_OR_GENE_PRODUCT", 68, 82], ["caveolae", "CELLULAR_COMPONENT", 146, 154], ["macropinosomes", "PROTEIN", 68, 82], ["signaling complexes", "PROTEIN", 119, 138], ["Depletion of cholesterol", "PROBLEM", 0, 24], ["a decrease in the formation of macropinosomes", "PROBLEM", 37, 82], ["signaling complexes in the caveolae", "PROBLEM", 119, 154], ["cholesterol", "OBSERVATION_MODIFIER", 13, 24], ["decrease", "OBSERVATION_MODIFIER", 39, 47], ["consistent with", "UNCERTAINTY", 84, 99], ["signaling complexes", "OBSERVATION", 119, 138], ["caveolae", "ANATOMY", 146, 154]]], ["In addition, immunostaining revealed the co-localization of ATP1A1, RSV F protein (marker of viral envelope) and RSV N protein (marker of viral nucleocapsid), and dextran in macropinosomes.", [["dextran", "CHEMICAL", 163, 170], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 60, 66], ["RSV F", "GENE_OR_GENE_PRODUCT", 68, 73], ["RSV N protein", "GENE_OR_GENE_PRODUCT", 113, 126], ["dextran", "SIMPLE_CHEMICAL", 163, 170], ["macropinosomes", "PATHOLOGICAL_FORMATION", 174, 188], ["ATP1A1", "PROTEIN", 60, 66], ["RSV F protein", "PROTEIN", 68, 81], ["RSV N protein", "PROTEIN", 113, 126], ["viral nucleocapsid", "PROTEIN", 138, 156], ["RSV", "SPECIES", 68, 71], ["RSV", "SPECIES", 113, 116], ["immunostaining", "TEST", 13, 27], ["ATP1A1", "TEST", 60, 66], ["RSV F protein", "TEST", 68, 81], ["viral envelope", "PROBLEM", 93, 107], ["RSV N protein", "TREATMENT", 113, 126], ["viral nucleocapsid)", "TREATMENT", 138, 157], ["dextran in macropinosomes", "TREATMENT", 163, 188]]], ["This supports a model in which RSV virions are taken up by the macropinosome, and membrane fusion and release of the nucleocapsid presumably taking place at a later step after the macropinocytic uptake.", [["macropinosome", "ANATOMY", 63, 76], ["membrane", "ANATOMY", 82, 90], ["RSV", "ORGANISM", 31, 34], ["macropinosome", "GENE_OR_GENE_PRODUCT", 63, 76], ["membrane", "CELLULAR_COMPONENT", 82, 90], ["nucleocapsid", "CELLULAR_COMPONENT", 117, 129], ["RSV", "SPECIES", 31, 34], ["a model in which RSV virions", "TREATMENT", 14, 42], ["membrane fusion", "TREATMENT", 82, 97], ["the nucleocapsid", "PROBLEM", 113, 129], ["the macropinocytic uptake", "PROBLEM", 176, 201], ["RSV virions", "OBSERVATION", 31, 42], ["membrane fusion", "OBSERVATION", 82, 97]]], ["Although the data provide evidence on the role of ATP1A1 in macropinocytic uptake, they do not exclude the possibility of clathrin-mediated endocytosis as an additional mode of RSV entry.DiscussionIt was somewhat surprising that both ouabain and PST2238 inhibited RSV infection in short-term treatments, since they have opposite effects on ATP1A1 signaling, namely that ouabain induces and PST2238 inhibits signaling.", [["ouabain", "CHEMICAL", 234, 241], ["PST2238", "CHEMICAL", 246, 253], ["RSV infection", "DISEASE", 264, 277], ["ouabain", "CHEMICAL", 370, 377], ["PST2238", "CHEMICAL", 390, 397], ["ouabain", "CHEMICAL", 234, 241], ["PST2238", "CHEMICAL", 246, 253], ["ouabain", "CHEMICAL", 370, 377], ["PST2238", "CHEMICAL", 390, 397], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 50, 56], ["clathrin", "GENE_OR_GENE_PRODUCT", 122, 130], ["RSV", "ORGANISM", 177, 180], ["ouabain", "SIMPLE_CHEMICAL", 234, 241], ["PST2238", "SIMPLE_CHEMICAL", 246, 253], ["RSV", "ORGANISM", 264, 267], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 340, 346], ["ouabain", "SIMPLE_CHEMICAL", 370, 377], ["PST2238", "SIMPLE_CHEMICAL", 390, 397], ["ATP1A1", "PROTEIN", 50, 56], ["clathrin", "PROTEIN", 122, 130], ["ATP1A1", "PROTEIN", 340, 346], ["RSV", "SPECIES", 177, 180], ["RSV", "SPECIES", 264, 267], ["the data", "TEST", 9, 17], ["clathrin-mediated endocytosis", "PROBLEM", 122, 151], ["RSV infection", "PROBLEM", 264, 277], ["short-term treatments", "TREATMENT", 281, 302], ["endocytosis", "OBSERVATION", 140, 151], ["RSV", "OBSERVATION_MODIFIER", 264, 267], ["infection", "OBSERVATION", 268, 277], ["short-term treatments", "OBSERVATION_MODIFIER", 281, 302]]], ["The mechanism by which PST2238 inhibits RSV infection seems straight-forward: specifically, blockade of RSV-induced ATP1A1 signaling.", [["PST2238", "CHEMICAL", 23, 30], ["RSV infection", "DISEASE", 40, 53], ["PST2238", "CHEMICAL", 23, 30], ["PST2238", "GENE_OR_GENE_PRODUCT", 23, 30], ["RSV", "ORGANISM", 40, 43], ["RSV", "ORGANISM", 104, 107], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 116, 122], ["ATP1A1", "PROTEIN", 116, 122], ["RSV", "SPECIES", 40, 43], ["RSV", "SPECIES", 104, 107], ["RSV infection", "PROBLEM", 40, 53], ["RSV", "PROBLEM", 104, 107], ["ATP1A1 signaling", "PROBLEM", 116, 132], ["RSV", "OBSERVATION", 104, 107]]], ["The mechanism by which ouabain inhibits RSV infection is less clear, since both ouabain and RSV individually induce ATP1A1 signaling.", [["ouabain", "CHEMICAL", 23, 30], ["RSV infection", "DISEASE", 40, 53], ["ouabain", "CHEMICAL", 80, 87], ["ouabain", "CHEMICAL", 23, 30], ["ouabain", "CHEMICAL", 80, 87], ["ouabain", "SIMPLE_CHEMICAL", 23, 30], ["RSV", "ORGANISM", 40, 43], ["ouabain", "SIMPLE_CHEMICAL", 80, 87], ["RSV", "ORGANISM", 92, 95], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 116, 122], ["ATP1A1", "PROTEIN", 116, 122], ["RSV", "SPECIES", 40, 43], ["RSV", "SPECIES", 92, 95], ["RSV infection", "PROBLEM", 40, 53], ["RSV", "PROBLEM", 92, 95], ["ATP1A1 signaling", "PROBLEM", 116, 132], ["RSV", "OBSERVATION_MODIFIER", 40, 43], ["infection", "OBSERVATION", 44, 53]]], ["We hypothesize that, while the signaling cascades induced by ouabain versus RSV employ some of the same signaling intermediates, their outcomes are not exactly the same.", [["ouabain", "CHEMICAL", 61, 68], ["ouabain", "CHEMICAL", 61, 68], ["ouabain", "SIMPLE_CHEMICAL", 61, 68], ["RSV", "ORGANISM", 76, 79], ["RSV", "SPECIES", 76, 79], ["RSV", "PROBLEM", 76, 79]]], ["Ouabain-induced signaling results in clathrin-mediated endocytosis, whereas RSV-induced signaling results in macropinocytosis.", [["Ouabain", "CHEMICAL", 0, 7], ["Ouabain", "CHEMICAL", 0, 7], ["Ouabain", "SIMPLE_CHEMICAL", 0, 7], ["clathrin", "GENE_OR_GENE_PRODUCT", 37, 45], ["RSV", "ORGANISM", 76, 79], ["clathrin", "PROTEIN", 37, 45], ["RSV", "SPECIES", 76, 79], ["Ouabain", "TEST", 0, 7], ["mediated endocytosis", "PROBLEM", 46, 66], ["RSV", "PROBLEM", 76, 79], ["macropinocytosis", "PROBLEM", 109, 125], ["macropinocytosis", "OBSERVATION", 109, 125]]], ["Also, we could readily detect phosphorylation of EGFR Tyr845 following infection with RSV, but not following treatment with ouabain, suggestive of a quantitative or qualitative difference in EGFR phosphorylation.", [["infection", "DISEASE", 71, 80], ["ouabain", "CHEMICAL", 124, 131], ["ouabain", "CHEMICAL", 124, 131], ["EGFR", "GENE_OR_GENE_PRODUCT", 49, 53], ["Tyr845", "GENE_OR_GENE_PRODUCT", 54, 60], ["RSV", "ORGANISM", 86, 89], ["ouabain", "SIMPLE_CHEMICAL", 124, 131], ["EGFR", "GENE_OR_GENE_PRODUCT", 191, 195], ["EGFR Tyr845", "PROTEIN", 49, 60], ["EGFR", "PROTEIN", 191, 195], ["RSV", "SPECIES", 86, 89], ["phosphorylation of EGFR", "PROBLEM", 30, 53], ["infection", "PROBLEM", 71, 80], ["RSV", "PROBLEM", 86, 89], ["ouabain", "TREATMENT", 124, 131], ["a quantitative or qualitative difference in EGFR phosphorylation", "PROBLEM", 147, 211], ["suggestive of", "UNCERTAINTY", 133, 146]]], ["Thus, while signaling through ATP1A1 by ouabain versus RSV may involve a number of steps in a common signal transduction pathway, we suggest that the ouabain-induced signaling cascade from ATP1A1 not only is different from that of RSV, but also competes with and thereby inhibits ATP1A1 signaling induced by RSV.", [["ouabain", "CHEMICAL", 40, 47], ["ouabain", "CHEMICAL", 150, 157], ["ouabain", "CHEMICAL", 40, 47], ["ouabain", "CHEMICAL", 150, 157], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 30, 36], ["ouabain", "SIMPLE_CHEMICAL", 40, 47], ["RSV", "ORGANISM", 55, 58], ["ouabain", "SIMPLE_CHEMICAL", 150, 157], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 189, 195], ["RSV", "ORGANISM", 231, 234], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 280, 286], ["RSV", "ORGANISM", 308, 311], ["ATP1A1", "PROTEIN", 30, 36], ["ATP1A1", "PROTEIN", 189, 195], ["ATP1A1", "PROTEIN", 280, 286], ["RSV", "SPECIES", 55, 58], ["RSV", "SPECIES", 231, 234], ["RSV", "SPECIES", 308, 311], ["RSV", "PROBLEM", 55, 58], ["the ouabain", "TREATMENT", 146, 157], ["signaling cascade", "PROBLEM", 166, 183], ["RSV", "PROBLEM", 231, 234], ["RSV", "PROBLEM", 308, 311], ["RSV", "OBSERVATION", 231, 234]]], ["ATP1A1-mediated signaling cascades have been reported to take place in the cholesterolrich microdomains called caveolae [27, 28] , which are thought to serve as a region to integrate multiple signaling pathways by concentrating signaling proteins and creating temporal and spatial patterns of cell regulation [24] .", [["cholesterolrich microdomains", "ANATOMY", 75, 103], ["caveolae", "ANATOMY", 111, 119], ["cell", "ANATOMY", 293, 297], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 0, 6], ["cholesterolrich microdomains", "CELLULAR_COMPONENT", 75, 103], ["caveolae", "CELLULAR_COMPONENT", 111, 119], ["cell", "CELL", 293, 297], ["ATP1A1", "PROTEIN", 0, 6], ["signaling proteins", "PROTEIN", 228, 246], ["ATP1A1", "TEST", 0, 6], ["signaling cascades", "PROBLEM", 16, 34], ["concentrating signaling proteins", "PROBLEM", 214, 246], ["creating temporal and spatial patterns of cell regulation", "PROBLEM", 251, 308], ["temporal", "OBSERVATION_MODIFIER", 260, 268], ["cell", "OBSERVATION", 293, 297]]], ["Many proteins associated with signaling functions are present in the caveolae, including ATP1A1, EGFR and c-Src [17, 50, 51] .", [["caveolae", "ANATOMY", 69, 77], ["caveolae", "CELLULAR_COMPONENT", 69, 77], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 89, 95], ["EGFR", "GENE_OR_GENE_PRODUCT", 97, 101], ["c-Src", "GENE_OR_GENE_PRODUCT", 106, 111], ["ATP1A1", "PROTEIN", 89, 95], ["EGFR", "PROTEIN", 97, 101], ["c", "PROTEIN", 106, 107], ["Src", "PROTEIN", 108, 111], ["Many proteins", "PROBLEM", 0, 13], ["signaling functions", "PROBLEM", 30, 49], ["ATP1A1", "TEST", 89, 95], ["EGFR", "TEST", 97, 101], ["c", "TEST", 106, 107], ["signaling functions", "OBSERVATION", 30, 49], ["caveolae", "ANATOMY", 69, 77]]], ["It has also been described that cholesterol is needed for the ouabain-induced ATP1A1-Src-EGFR signaling cascade, and that depletion of cholesterol reduced the recruitment of c-Src and therefore reduced ATP1A1 signaling [27] .", [["cholesterol", "CHEMICAL", 32, 43], ["ouabain", "CHEMICAL", 62, 69], ["cholesterol", "CHEMICAL", 135, 146], ["cholesterol", "CHEMICAL", 32, 43], ["ouabain", "CHEMICAL", 62, 69], ["cholesterol", "CHEMICAL", 135, 146], ["cholesterol", "SIMPLE_CHEMICAL", 32, 43], ["ouabain", "SIMPLE_CHEMICAL", 62, 69], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 78, 84], ["Src", "GENE_OR_GENE_PRODUCT", 85, 88], ["EGFR", "GENE_OR_GENE_PRODUCT", 89, 93], ["cholesterol", "SIMPLE_CHEMICAL", 135, 146], ["c-Src", "GENE_OR_GENE_PRODUCT", 174, 179], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 202, 208], ["ATP1A1", "PROTEIN", 78, 84], ["Src", "PROTEIN", 85, 88], ["EGFR", "PROTEIN", 89, 93], ["c", "PROTEIN", 174, 175], ["Src", "PROTEIN", 176, 179], ["ATP1A1", "PROTEIN", 202, 208], ["the ouabain", "TEST", 58, 69], ["ATP1A1", "TEST", 78, 84], ["EGFR signaling cascade", "PROBLEM", 89, 111], ["depletion of cholesterol", "TREATMENT", 122, 146], ["reduced ATP1A1 signaling", "PROBLEM", 194, 218]]], ["Interestingly, it has been reported that the cholesterol-rich lipid rafts are required as a docking platform for RSV entry [9] .", [["lipid rafts", "ANATOMY", 62, 73], ["cholesterol", "CHEMICAL", 45, 56], ["cholesterol", "CHEMICAL", 45, 56], ["cholesterol", "SIMPLE_CHEMICAL", 45, 56], ["lipid rafts", "CELLULAR_COMPONENT", 62, 73], ["RSV", "ORGANISM", 113, 116], ["RSV", "SPECIES", 113, 116], ["the cholesterol-rich lipid rafts", "TREATMENT", 41, 73], ["lipid rafts", "OBSERVATION", 62, 73]]], ["In the present study, depletion of cholesterol with MBCD and Mevinolin indeed reduced the efficiency of RSV infection, consistent with the signaling by ATP1A1, c-Src, and EGFR taking place in caveolae.", [["caveolae", "ANATOMY", 192, 200], ["cholesterol", "CHEMICAL", 35, 46], ["MBCD", "CHEMICAL", 52, 56], ["Mevinolin", "CHEMICAL", 61, 70], ["RSV infection", "DISEASE", 104, 117], ["cholesterol", "CHEMICAL", 35, 46], ["MBCD", "CHEMICAL", 52, 56], ["Mevinolin", "CHEMICAL", 61, 70], ["cholesterol", "SIMPLE_CHEMICAL", 35, 46], ["MBCD", "SIMPLE_CHEMICAL", 52, 56], ["Mevinolin", "SIMPLE_CHEMICAL", 61, 70], ["RSV", "ORGANISM", 104, 107], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 152, 158], ["c-Src", "GENE_OR_GENE_PRODUCT", 160, 165], ["EGFR", "GENE_OR_GENE_PRODUCT", 171, 175], ["caveolae", "CELLULAR_COMPONENT", 192, 200], ["ATP1A1", "PROTEIN", 152, 158], ["Src", "PROTEIN", 162, 165], ["EGFR", "PROTEIN", 171, 175], ["RSV", "SPECIES", 104, 107], ["depletion of cholesterol", "TREATMENT", 22, 46], ["MBCD", "TREATMENT", 52, 56], ["Mevinolin", "TREATMENT", 61, 70], ["RSV infection", "PROBLEM", 104, 117], ["ATP1A1", "TEST", 152, 158], ["RSV infection", "OBSERVATION", 104, 117], ["consistent with", "UNCERTAINTY", 119, 134], ["caveolae", "ANATOMY", 192, 200]]], ["We speculate that the inhibitory effects of depleting cholesterol could be due to disintegration of the caveolar ATP1A1-Src-EGFR signaling complexes.DiscussionA number of key observations made using the A549 cell line were reproduced using primary human small airway epithelial HSAEC cultures, including inhibition of RSV-GFP by siRNA as well as by PST2238 and Ouabain, clustering of ATP1A1 on RSV exposure, and phosphorylation of EGFR.", [["caveolar", "ANATOMY", 104, 112], ["A549 cell line", "ANATOMY", 203, 217], ["small airway epithelial HSAEC cultures", "ANATOMY", 254, 292], ["cholesterol", "CHEMICAL", 54, 65], ["PST2238", "CHEMICAL", 349, 356], ["Ouabain", "CHEMICAL", 361, 368], ["cholesterol", "CHEMICAL", 54, 65], ["PST2238", "CHEMICAL", 349, 356], ["Ouabain", "CHEMICAL", 361, 368], ["cholesterol", "SIMPLE_CHEMICAL", 54, 65], ["caveolar", "CELLULAR_COMPONENT", 104, 112], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 113, 119], ["EGFR", "GENE_OR_GENE_PRODUCT", 124, 128], ["A549 cell line", "CELL", 203, 217], ["human", "ORGANISM", 248, 253], ["airway epithelial HSAEC cultures", "CELL", 260, 292], ["RSV", "ORGANISM", 318, 321], ["GFP", "GENE_OR_GENE_PRODUCT", 322, 325], ["PST2238", "SIMPLE_CHEMICAL", 349, 356], ["Ouabain", "SIMPLE_CHEMICAL", 361, 368], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 384, 390], ["RSV", "ORGANISM", 394, 397], ["EGFR", "GENE_OR_GENE_PRODUCT", 431, 435], ["ATP1A1", "PROTEIN", 113, 119], ["Src-EGFR signaling complexes", "PROTEIN", 120, 148], ["A549 cell line", "CELL_LINE", 203, 217], ["primary human small airway epithelial HSAEC cultures", "CELL_LINE", 240, 292], ["GFP", "PROTEIN", 322, 325], ["ATP1A1", "PROTEIN", 384, 390], ["EGFR", "PROTEIN", 431, 435], ["human", "SPECIES", 248, 253], ["human", "SPECIES", 248, 253], ["RSV", "SPECIES", 318, 321], ["RSV", "SPECIES", 394, 397], ["depleting cholesterol", "TREATMENT", 44, 65], ["the caveolar ATP1A1", "TEST", 100, 119], ["Src-EGFR signaling complexes", "PROBLEM", 120, 148], ["the A549 cell line", "TREATMENT", 199, 217], ["primary human small airway epithelial HSAEC cultures", "TEST", 240, 292], ["RSV", "PROBLEM", 318, 321], ["Ouabain", "TREATMENT", 361, 368], ["ATP1A1", "TREATMENT", 384, 390], ["RSV exposure", "TREATMENT", 394, 406], ["phosphorylation of EGFR", "TREATMENT", 412, 435], ["caveolar", "ANATOMY", 104, 112], ["airway epithelial", "ANATOMY", 260, 277]]], ["We also used differentiated HAE-ALI cultures to confirm clustering of ATP1A1 on RSV infection, and to evaluate the distribution of ATP1A1 in a polarized epithelial cell.", [["epithelial cell", "ANATOMY", 153, 168], ["HAE", "DISEASE", 28, 31], ["RSV infection", "DISEASE", 80, 93], ["HAE-ALI cultures", "CELL", 28, 44], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 70, 76], ["RSV", "ORGANISM", 80, 83], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 131, 137], ["epithelial cell", "CELL", 153, 168], ["HAE-ALI cultures", "CELL_LINE", 28, 44], ["ATP1A1", "PROTEIN", 70, 76], ["ATP1A1", "PROTEIN", 131, 137], ["polarized epithelial cell", "CELL_TYPE", 143, 168], ["RSV", "SPECIES", 80, 83], ["differentiated HAE", "PROBLEM", 13, 31], ["ALI cultures", "TEST", 32, 44], ["ATP1A1", "PROBLEM", 70, 76], ["RSV infection", "PROBLEM", 80, 93], ["ATP1A1", "PROBLEM", 131, 137], ["RSV", "ANATOMY", 80, 83], ["infection", "OBSERVATION", 84, 93], ["polarized epithelial cell", "OBSERVATION", 143, 168]]], ["This showed a strong basolateral presence of ATP1A1 and much reduced speckled expression on the apical surface.", [["basolateral", "ANATOMY", 21, 32], ["apical surface", "ANATOMY", 96, 110], ["basolateral", "CELLULAR_COMPONENT", 21, 32], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 45, 51], ["apical surface", "CELLULAR_COMPONENT", 96, 110], ["ATP1A1", "PROTEIN", 45, 51], ["ATP1A1", "PROBLEM", 45, 51], ["much reduced speckled expression on the apical surface", "PROBLEM", 56, 110], ["strong", "OBSERVATION_MODIFIER", 14, 20], ["basolateral", "OBSERVATION_MODIFIER", 21, 32], ["much", "OBSERVATION_MODIFIER", 56, 60], ["reduced", "OBSERVATION_MODIFIER", 61, 68], ["speckled", "OBSERVATION_MODIFIER", 69, 77], ["expression", "OBSERVATION_MODIFIER", 78, 88], ["apical", "ANATOMY_MODIFIER", 96, 102], ["surface", "ANATOMY_MODIFIER", 103, 110]]], ["However, upon RSV infection, ATP1A1 cluster formation was observed on the apical surface, associated with an increase in the apical amount of ATP1A1 that might be due to increased trafficking to the apical surface.", [["apical surface", "ANATOMY", 74, 88], ["apical surface", "ANATOMY", 199, 213], ["RSV infection", "DISEASE", 14, 27], ["RSV", "ORGANISM", 14, 17], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 29, 35], ["apical surface", "CELLULAR_COMPONENT", 74, 88], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 142, 148], ["apical surface", "CELLULAR_COMPONENT", 199, 213], ["ATP1A1", "PROTEIN", 29, 35], ["ATP1A1", "PROTEIN", 142, 148], ["RSV", "SPECIES", 14, 17], ["RSV infection", "PROBLEM", 14, 27], ["ATP1A1 cluster formation", "PROBLEM", 29, 53], ["an increase in the apical amount of ATP1A1", "PROBLEM", 106, 148], ["increased trafficking to the apical surface", "PROBLEM", 170, 213], ["RSV", "OBSERVATION_MODIFIER", 14, 17], ["infection", "OBSERVATION", 18, 27], ["cluster", "OBSERVATION_MODIFIER", 36, 43], ["apical", "ANATOMY_MODIFIER", 74, 80], ["surface", "ANATOMY_MODIFIER", 81, 88], ["increase", "OBSERVATION_MODIFIER", 109, 117], ["apical", "ANATOMY_MODIFIER", 125, 131], ["amount", "OBSERVATION_MODIFIER", 132, 138], ["might be due to", "UNCERTAINTY", 154, 169], ["increased", "OBSERVATION_MODIFIER", 170, 179], ["trafficking", "OBSERVATION", 180, 191], ["apical", "ANATOMY_MODIFIER", 199, 205], ["surface", "ANATOMY_MODIFIER", 206, 213]]], ["This also showed that the small amounts of apical ATP1A1 present in the uninfected cells is likely sufficient for initiating the signaling cascade.DiscussionATP1A1 also has been implicated as a pro-viral factor in the infection cycles of Ebola virus [52] , coronavirus [53] , hepatitis C virus [54] , and mammarenaviruses [55] , but the nature and mechanism of its involvement for those viruses remains largely unknown.", [["apical", "ANATOMY", 43, 49], ["cells", "ANATOMY", 83, 88], ["ATP1A1", "CHEMICAL", 50, 56], ["DiscussionATP1A1", "CHEMICAL", 147, 163], ["infection", "DISEASE", 218, 227], ["Ebola virus", "DISEASE", 238, 249], ["hepatitis C", "DISEASE", 276, 287], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 50, 56], ["cells", "CELL", 83, 88], ["DiscussionATP1A1", "GENE_OR_GENE_PRODUCT", 147, 163], ["Ebola virus [52]", "ORGANISM", 238, 254], ["coronavirus [53] ,", "ORGANISM", 257, 275], ["hepatitis C virus", "ORGANISM", 276, 293], ["ATP1A1", "PROTEIN", 50, 56], ["uninfected cells", "CELL_TYPE", 72, 88], ["DiscussionATP1A1", "PROTEIN", 147, 163], ["pro-viral factor", "PROTEIN", 194, 210], ["Ebola virus", "SPECIES", 238, 249], ["coronavirus", "SPECIES", 257, 268], ["hepatitis C virus", "SPECIES", 276, 293], ["Ebola virus", "SPECIES", 238, 249], ["hepatitis C virus", "SPECIES", 276, 293], ["the small amounts of apical ATP1A1", "PROBLEM", 22, 56], ["the signaling cascade", "TREATMENT", 125, 146], ["a pro-viral factor", "PROBLEM", 192, 210], ["the infection cycles", "PROBLEM", 214, 234], ["Ebola virus", "PROBLEM", 238, 249], ["coronavirus", "PROBLEM", 257, 268], ["hepatitis C virus", "PROBLEM", 276, 293], ["mammarenaviruses", "TEST", 305, 321], ["those viruses", "PROBLEM", 381, 394], ["small", "OBSERVATION_MODIFIER", 26, 31], ["amounts", "OBSERVATION_MODIFIER", 32, 39], ["apical", "ANATOMY_MODIFIER", 43, 49], ["ATP1A1", "OBSERVATION", 50, 56], ["uninfected cells", "OBSERVATION", 72, 88], ["likely sufficient for", "UNCERTAINTY", 92, 113]]], ["In the present study, we showed that VSV infection was not inhibited by ATP1A1 knockdown, indicating that the effect is specific to particular viruses and does not involve a general inhibitory cellular effect.", [["cellular", "ANATOMY", 193, 201], ["infection", "DISEASE", 41, 50], ["VSV", "ORGANISM", 37, 40], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 72, 78], ["cellular", "CELL", 193, 201], ["ATP1A1", "PROTEIN", 72, 78], ["VSV", "SPECIES", 37, 40], ["the present study", "TEST", 3, 20], ["VSV infection", "PROBLEM", 37, 50], ["particular viruses", "PROBLEM", 132, 150], ["a general inhibitory cellular effect", "PROBLEM", 172, 208], ["VSV", "OBSERVATION_MODIFIER", 37, 40], ["infection", "OBSERVATION", 41, 50]]], ["Ouabain has been described to have anti-viral properties for several viruses, namely herpes simplex virus [56, 57] , chikungunya virus [58] , human immunodeficiency virus [59] , adenovirus [60] and porcine reproductive and respiratory syndrome virus [61] , but the mechanism of inhibition was not conclusively identified.", [["Ouabain", "CHEMICAL", 0, 7], ["herpes simplex virus", "DISEASE", 85, 105], ["chikungunya virus", "DISEASE", 117, 134], ["human immunodeficiency virus", "DISEASE", 142, 170], ["porcine reproductive and respiratory syndrome", "DISEASE", 198, 243], ["Ouabain", "CHEMICAL", 0, 7], ["Ouabain", "SIMPLE_CHEMICAL", 0, 7], ["herpes simplex virus", "ORGANISM", 85, 105], ["chikungunya virus", "ORGANISM", 117, 134], ["human immunodeficiency virus", "ORGANISM", 142, 170], ["adenovirus [60", "ORGANISM", 178, 192], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 198, 249], ["herpes simplex virus", "SPECIES", 85, 105], ["chikungunya virus", "SPECIES", 117, 134], ["human immunodeficiency virus", "SPECIES", 142, 170], ["porcine", "SPECIES", 198, 205], ["herpes simplex virus", "SPECIES", 85, 105], ["chikungunya virus", "SPECIES", 117, 134], ["human immunodeficiency virus", "SPECIES", 142, 170], ["adenovirus", "SPECIES", 178, 188], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 198, 249], ["Ouabain", "TREATMENT", 0, 7], ["anti-viral properties", "TREATMENT", 35, 56], ["several viruses", "PROBLEM", 61, 76], ["namely herpes simplex virus", "PROBLEM", 78, 105], ["chikungunya virus", "PROBLEM", 117, 134], ["human immunodeficiency virus", "PROBLEM", 142, 170], ["adenovirus", "PROBLEM", 178, 188], ["porcine reproductive", "PROBLEM", 198, 218], ["respiratory syndrome virus", "PROBLEM", 223, 249], ["respiratory syndrome", "OBSERVATION", 223, 243]]], ["It may be that ouabain inhibits these other viruses in the same way that we propose for RSV, namely that it competes with the virus for signaling through ATP1A1.", [["ouabain", "CHEMICAL", 15, 22], ["ouabain", "CHEMICAL", 15, 22], ["ouabain", "SIMPLE_CHEMICAL", 15, 22], ["RSV", "ORGANISM", 88, 91], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 154, 160], ["ATP1A1", "PROTEIN", 154, 160], ["RSV", "SPECIES", 88, 91], ["ouabain", "PROBLEM", 15, 22], ["these other viruses", "PROBLEM", 32, 51], ["RSV", "PROBLEM", 88, 91], ["the virus", "PROBLEM", 122, 131], ["signaling through ATP1A1", "PROBLEM", 136, 160], ["viruses", "OBSERVATION", 44, 51]]], ["To our knowledge, PST2238 has not previously been investigated for anti-viral activity against any virus, including RSV.", [["PST2238", "CHEMICAL", 18, 25], ["PST2238", "CHEMICAL", 18, 25], ["PST2238", "SIMPLE_CHEMICAL", 18, 25], ["RSV", "ORGANISM", 116, 119], ["RSV", "SPECIES", 116, 119], ["anti-viral activity", "TREATMENT", 67, 86], ["any virus", "PROBLEM", 95, 104], ["RSV", "PROBLEM", 116, 119]]], ["We speculate that PST2238 might also inhibit the replication of other viruses that are ouabain-sensitive by directly blocking ATP1A1 signaling.", [["PST2238", "CHEMICAL", 18, 25], ["ouabain", "CHEMICAL", 87, 94], ["PST2238", "CHEMICAL", 18, 25], ["ouabain", "CHEMICAL", 87, 94], ["PST2238", "SIMPLE_CHEMICAL", 18, 25], ["ouabain", "SIMPLE_CHEMICAL", 87, 94], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 126, 132], ["ATP1A1", "PROTEIN", 126, 132], ["other viruses", "PROBLEM", 64, 77], ["ouabain", "TEST", 87, 94]]], ["PST2238 is being evaluated as an anti-hypertensive drug in phase II clinical trials for ouabain-and adducin-induced hypertension patients [38] .", [["PST2238", "CHEMICAL", 0, 7], ["ouabain", "CHEMICAL", 88, 95], ["hypertension", "DISEASE", 116, 128], ["PST2238", "CHEMICAL", 0, 7], ["ouabain", "CHEMICAL", 88, 95], ["PST2238", "SIMPLE_CHEMICAL", 0, 7], ["ouabain", "SIMPLE_CHEMICAL", 88, 95], ["adducin", "GENE_OR_GENE_PRODUCT", 100, 107], ["patients", "ORGANISM", 129, 137], ["adducin", "PROTEIN", 100, 107], ["patients", "SPECIES", 129, 137], ["an anti-hypertensive drug", "TREATMENT", 30, 55], ["ouabain", "TEST", 88, 95], ["adducin-induced hypertension", "PROBLEM", 100, 128], ["hypertension", "OBSERVATION", 116, 128]]], ["PST2238 does not have any known adverse effects, does not lower the blood pressure of healthy humans [62] , and therefore might be well-tolerated as an anti-viral drug.DiscussionThe prevailing paradigm of virus spread involves packaging, release, and infection of the neighboring cells.", [["blood", "ANATOMY", 68, 73], ["cells", "ANATOMY", 280, 285], ["PST2238", "CHEMICAL", 0, 7], ["infection", "DISEASE", 251, 260], ["PST2238", "CHEMICAL", 0, 7], ["PST2238", "SIMPLE_CHEMICAL", 0, 7], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["humans", "ORGANISM", 94, 100], ["cells", "CELL", 280, 285], ["neighboring cells", "CELL_TYPE", 268, 285], ["humans", "SPECIES", 94, 100], ["humans", "SPECIES", 94, 100], ["an anti-viral drug", "TREATMENT", 149, 167], ["virus spread", "PROBLEM", 205, 217], ["infection of the neighboring cells", "PROBLEM", 251, 285], ["virus spread", "OBSERVATION", 205, 217], ["infection", "OBSERVATION", 251, 260], ["neighboring cells", "OBSERVATION", 268, 285]]], ["However, an emerging model suggests direct cell-to-cell spread of partially assembled virions, nucleocapsids, and inclusion bodies via intercellular channels [63] .", [["cell", "ANATOMY", 43, 47], ["cell", "ANATOMY", 51, 55], ["virions", "ANATOMY", 86, 93], ["nucleocapsids", "ANATOMY", 95, 108], ["intercellular", "ANATOMY", 135, 148], ["cell", "CELL", 43, 47], ["cell", "CELL", 51, 55], ["virions", "CELLULAR_COMPONENT", 86, 93], ["nucleocapsids", "CELLULAR_COMPONENT", 95, 108], ["inclusion bodies", "CELLULAR_COMPONENT", 114, 130], ["intercellular channels", "PROTEIN", 135, 157], ["direct cell", "PROBLEM", 36, 47], ["partially assembled virions", "PROBLEM", 66, 93], ["direct cell", "OBSERVATION", 36, 47], ["cell spread", "OBSERVATION", 51, 62], ["virions", "OBSERVATION", 86, 93]]], ["Given the very different nature of this exit/entry, likely requiring a different set of proteins and mechanisms, we speculate that ATP1A1 may not have a role in this and would be primarily engaged in mediating uptake of the extracellular packaged virions.", [["extracellular", "ANATOMY", 224, 237], ["virions", "ANATOMY", 247, 254], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 131, 137], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 224, 237], ["ATP1A1", "PROTEIN", 131, 137], ["uptake", "OBSERVATION", 210, 216], ["extracellular", "ANATOMY_MODIFIER", 224, 237], ["packaged virions", "OBSERVATION", 238, 254]]], ["The proposed direct intercellular spread presumably occurs only between adjoining cells, while ATP1A1 would be important for spread/uptake into non-contiguous cells.", [["intercellular", "ANATOMY", 20, 33], ["cells", "ANATOMY", 82, 87], ["cells", "ANATOMY", 159, 164], ["cells", "CELL", 82, 87], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 95, 101], ["cells", "CELL", 159, 164], ["ATP1A1", "PROTEIN", 95, 101], ["non-contiguous cells", "CELL_TYPE", 144, 164], ["The proposed direct intercellular spread", "PROBLEM", 0, 40], ["ATP1A1", "TEST", 95, 101], ["spread/uptake into non-contiguous cells", "PROBLEM", 125, 164], ["intercellular", "OBSERVATION_MODIFIER", 20, 33], ["spread", "OBSERVATION", 34, 40], ["non-contiguous cells", "OBSERVATION", 144, 164]]], ["Note that most studies have described the direct intercellular transmission using cell lines (reviewed in [63] ).", [["intercellular", "ANATOMY", 49, 62], ["cell lines", "ANATOMY", 82, 92], ["cell lines", "CELL", 82, 92], ["cell lines", "CELL_LINE", 82, 92], ["cell lines", "TREATMENT", 82, 92], ["cell lines", "OBSERVATION", 82, 92]]], ["Specifically, among respiratory viruses, intercellular transmission in primary HAE cells has been shown only for measles virus [64] and this manner of spread for other respiratory viruses including RSV remains to be determined in a primary differentiated HAE-ALI system.DiscussionIn summary, we propose a model for RSV entry into human airway epithelial cells that is illustrated in Fig 13.", [["intercellular", "ANATOMY", 41, 54], ["primary HAE cells", "ANATOMY", 71, 88], ["airway epithelial cells", "ANATOMY", 336, 359], ["respiratory viruses", "DISEASE", 20, 39], ["HAE", "DISEASE", 79, 82], ["respiratory viruses", "DISEASE", 168, 187], ["RSV", "DISEASE", 198, 201], ["HAE", "DISEASE", 255, 258], ["ALI", "DISEASE", 259, 262], ["intercellular", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 54], ["HAE cells", "CELL", 79, 88], ["measles virus", "ORGANISM", 113, 126], ["RSV", "ORGANISM", 198, 201], ["RSV", "ORGANISM", 315, 318], ["human", "ORGANISM", 330, 335], ["airway epithelial cells", "CELL", 336, 359], ["primary HAE cells", "CELL_TYPE", 71, 88], ["human airway epithelial cells", "CELL_TYPE", 330, 359], ["measles virus", "SPECIES", 113, 126], ["human", "SPECIES", 330, 335], ["measles virus", "SPECIES", 113, 126], ["RSV", "SPECIES", 198, 201], ["RSV", "SPECIES", 315, 318], ["human", "SPECIES", 330, 335], ["among respiratory viruses", "PROBLEM", 14, 39], ["intercellular transmission in primary HAE cells", "PROBLEM", 41, 88], ["measles virus", "PROBLEM", 113, 126], ["other respiratory viruses", "PROBLEM", 162, 187], ["RSV", "PROBLEM", 198, 201], ["human airway epithelial cells", "PROBLEM", 330, 359], ["respiratory viruses", "OBSERVATION", 20, 39], ["respiratory", "ANATOMY", 168, 179], ["viruses", "OBSERVATION", 180, 187], ["ALI system", "OBSERVATION", 259, 269], ["airway", "ANATOMY", 336, 342], ["epithelial cells", "OBSERVATION", 343, 359]]], ["RSV infection activates ATP1A1 signaling by an unknown mechanism that involves the RSV G protein and does not rely on viral transcription and genome or virus replication.", [["RSV infection", "DISEASE", 0, 13], ["RSV", "ORGANISM", 0, 3], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 24, 30], ["RSV G protein", "GENE_OR_GENE_PRODUCT", 83, 96], ["genome", "CELLULAR_COMPONENT", 142, 148], ["ATP1A1", "PROTEIN", 24, 30], ["RSV G protein", "PROTEIN", 83, 96], ["RSV", "SPECIES", 0, 3], ["RSV", "SPECIES", 83, 86], ["RSV infection", "PROBLEM", 0, 13], ["the RSV G protein", "PROBLEM", 79, 96], ["viral transcription", "TREATMENT", 118, 137], ["virus replication", "TREATMENT", 152, 169], ["infection", "OBSERVATION", 4, 13]]], ["Activation of ATP1A1 leads to transactivation of EGFR that requires c-Src kinase activity.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 14, 20], ["EGFR", "GENE_OR_GENE_PRODUCT", 49, 53], ["c-Src", "GENE_OR_GENE_PRODUCT", 68, 73], ["ATP1A1", "PROTEIN", 14, 20], ["EGFR", "PROTEIN", 49, 53], ["Src kinase", "PROTEIN", 70, 80], ["Activation of ATP1A1", "TREATMENT", 0, 20], ["transactivation of EGFR", "TREATMENT", 30, 53], ["c-Src kinase activity", "TREATMENT", 68, 89]]], ["Signaling events downstream of EGFR cause actin rearrangement and ruffling at the plasma membrane, where membrane extensions engulf fluid and RSV into large vesicles-the macropinosomes.", [["plasma membrane", "ANATOMY", 82, 97], ["membrane", "ANATOMY", 105, 113], ["fluid", "ANATOMY", 132, 137], ["vesicles", "ANATOMY", 157, 165], ["macropinosomes", "ANATOMY", 170, 184], ["EGFR", "GENE_OR_GENE_PRODUCT", 31, 35], ["actin", "GENE_OR_GENE_PRODUCT", 42, 47], ["plasma membrane", "CELLULAR_COMPONENT", 82, 97], ["membrane extensions", "CELLULAR_COMPONENT", 105, 124], ["engulf fluid", "CELLULAR_COMPONENT", 125, 137], ["vesicles", "CELLULAR_COMPONENT", 157, 165], ["macropinosomes", "CELLULAR_COMPONENT", 170, 184], ["EGFR", "PROTEIN", 31, 35], ["actin", "PROTEIN", 42, 47], ["RSV", "SPECIES", 142, 145], ["Signaling events downstream of EGFR", "PROBLEM", 0, 35], ["actin rearrangement", "PROBLEM", 42, 61], ["ruffling at the plasma membrane", "TEST", 66, 97], ["membrane extensions engulf fluid", "TEST", 105, 137], ["actin rearrangement", "OBSERVATION", 42, 61], ["plasma membrane", "ANATOMY", 82, 97], ["engulf fluid", "OBSERVATION", 125, 137], ["large", "OBSERVATION_MODIFIER", 151, 156], ["vesicles", "OBSERVATION_MODIFIER", 157, 165]]], ["RSV is taken up in its enveloped form into the macropinosome, presumably followed by fusion and entry into the host cell.", [["macropinosome", "ANATOMY", 47, 60], ["cell", "ANATOMY", 116, 120], ["RSV", "ORGANISM", 0, 3], ["macropinosome", "GENE_OR_GENE_PRODUCT", 47, 60], ["host cell", "CELL", 111, 120], ["host cell", "CELL_TYPE", 111, 120], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["macropinosome", "ANATOMY", 47, 60], ["fusion", "OBSERVATION", 85, 91], ["host cell", "OBSERVATION", 111, 120]]], ["We also provided evidence suggesting that the ATP1A1-Src-EGFR signaling occurs predominantly in the cholesterol-rich domains of the caveolae which are thus important for efficient infection.", [["caveolae", "ANATOMY", 132, 140], ["cholesterol", "CHEMICAL", 100, 111], ["infection", "DISEASE", 180, 189], ["cholesterol", "CHEMICAL", 100, 111], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 46, 52], ["Src-", "GENE_OR_GENE_PRODUCT", 53, 57], ["EGFR", "GENE_OR_GENE_PRODUCT", 57, 61], ["cholesterol", "SIMPLE_CHEMICAL", 100, 111], ["caveolae", "CELLULAR_COMPONENT", 132, 140], ["ATP1A1", "PROTEIN", 46, 52], ["EGFR", "PROTEIN", 57, 61], ["cholesterol-rich domains", "PROTEIN", 100, 124], ["the ATP1A1", "TEST", 42, 52], ["Src-EGFR signaling", "PROBLEM", 53, 71], ["efficient infection", "PROBLEM", 170, 189], ["evidence suggesting", "UNCERTAINTY", 17, 36], ["cholesterol", "ANATOMY", 100, 111], ["caveolae", "ANATOMY", 132, 140], ["thus important for", "UNCERTAINTY", 151, 169], ["efficient", "OBSERVATION_MODIFIER", 170, 179], ["infection", "OBSERVATION", 180, 189]]], ["This study identified ATP1A1 signaling as a new target for the development of anti-RSV drugs.", [["anti-RSV", "ANATOMY", 78, 86], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 22, 28], ["anti-RSV", "SIMPLE_CHEMICAL", 78, 86], ["ATP1A1", "PROTEIN", 22, 28], ["anti-RSV", "SPECIES", 78, 86], ["This study", "TEST", 0, 10], ["anti-RSV drugs", "TREATMENT", 78, 92]]], ["PST2238 in particular is a drug that already has been shown to be well-tolerated in humans, specifically acts on ATP1A1, decreases the efficiency of infection by reducing the RSV-ATP1A1 signaling needed for entry, and could be further developed as an antiviral drug for RSV.Cells and virusesA549 cells (ATCC CCL-185) were maintained in F12-K media (ATCC, Manassas, VA) supplemented with 10% fetal bovine serum (FBS, Thermo Scientific, Atlanta, GA) and 1x L-Glutamine (Life Technologies, Grand Island, NY), Vero cells (ATCC CCL-81) were maintained in Opti-MEM I medium with GlutaMax-I (Life Technologies) supplemented with 5% FBS.", [["Cells", "ANATOMY", 274, 279], ["A549 cells", "ANATOMY", 291, 301], ["ATCC CCL-185", "ANATOMY", 303, 315], ["fetal bovine serum", "ANATOMY", 391, 409], ["FBS", "ANATOMY", 411, 414], ["Vero cells", "ANATOMY", 506, 516], ["ATCC CCL-81", "ANATOMY", 518, 529], ["FBS", "ANATOMY", 625, 628], ["PST2238", "CHEMICAL", 0, 7], ["infection", "DISEASE", 149, 158], ["RSV", "DISEASE", 270, 273], ["CCL-185", "CHEMICAL", 308, 315], ["F12-K", "CHEMICAL", 336, 341], ["L-Glutamine", "CHEMICAL", 455, 466], ["GlutaMax-I", "CHEMICAL", 573, 583], ["PST2238", "CHEMICAL", 0, 7], ["L-Glutamine", "CHEMICAL", 455, 466], ["PST2238", "SIMPLE_CHEMICAL", 0, 7], ["humans", "ORGANISM", 84, 90], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 113, 119], ["RSV", "ORGANISM", 175, 178], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 179, 185], ["RSV", "ORGANISM", 270, 273], ["Cells", "CELL", 274, 279], ["A549 cells", "CELL", 291, 301], ["ATCC CCL-185", "CELL", 303, 315], ["F12-K", "CELL", 336, 341], ["ATCC", "CELL", 349, 353], ["bovine", "ORGANISM", 397, 403], ["serum", "ORGANISM_SUBSTANCE", 404, 409], ["FBS", "ORGANISM_SUBSTANCE", 411, 414], ["1x L-Glutamine", "SIMPLE_CHEMICAL", 452, 466], ["Vero cells", "CELL", 506, 516], ["ATCC CCL-81", "CELL", 518, 529], ["FBS", "ORGANISM_SUBSTANCE", 625, 628], ["ATP1A1", "PROTEIN", 113, 119], ["ATP1A1", "PROTEIN", 179, 185], ["A549 cells", "CELL_LINE", 291, 301], ["ATCC CCL-185", "CELL_LINE", 303, 315], ["Vero cells", "CELL_LINE", 506, 516], ["ATCC CCL-81", "CELL_LINE", 518, 529], ["humans", "SPECIES", 84, 90], ["bovine", "SPECIES", 397, 403], ["humans", "SPECIES", 84, 90], ["RSV", "SPECIES", 175, 178], ["RSV", "SPECIES", 270, 273], ["ATCC CCL-185", "SPECIES", 303, 315], ["ATCC", "SPECIES", 349, 353], ["Manassas", "SPECIES", 355, 363], ["bovine", "SPECIES", 397, 403], ["ATCC CCL-81", "SPECIES", 518, 529], ["ATP1A1", "TREATMENT", 113, 119], ["infection", "PROBLEM", 149, 158], ["the RSV", "TEST", 171, 178], ["an antiviral drug", "TREATMENT", 248, 265], ["RSV", "PROBLEM", 270, 273], ["Cells", "TEST", 274, 279], ["virusesA549 cells", "TEST", 284, 301], ["ATCC CCL", "TEST", 303, 311], ["F12", "TEST", 336, 339], ["ATCC", "TEST", 349, 353], ["fetal bovine serum", "TEST", 391, 409], ["FBS", "TEST", 411, 414], ["Atlanta, GA", "TREATMENT", 435, 446], ["1x L-Glutamine", "TREATMENT", 452, 466], ["Vero cells", "TEST", 506, 516], ["ATCC CCL", "TEST", 518, 526], ["GlutaMax-I (Life Technologies", "TREATMENT", 573, 602], ["5% FBS", "TREATMENT", 622, 628], ["infection", "OBSERVATION", 149, 158], ["viruses", "OBSERVATION_MODIFIER", 284, 291], ["A549 cells", "OBSERVATION", 291, 301], ["Vero cells", "ANATOMY", 506, 516]]], ["Normal primary human small airway epithelial cells (HSAEC) (ATCC PCS-301-010) were derived from a 16 year old male Hispanic/Latino donor (Lot: 64079184) and were maintained in airway cell basal medium (ATCC PCS-300-030), supplemented with bronchial epithelial cell growth kit (ATCC PCS-300-040), and detached for passage using trypsin and trypsin-neutralizing solution formulated specifically for primary cells (ATCC PCS-999-003 and ATCC PCS-999-004.", [["small airway epithelial cells", "ANATOMY", 21, 50], ["HSAEC", "ANATOMY", 52, 57], ["ATCC PCS-301-010", "ANATOMY", 60, 76], ["airway cell", "ANATOMY", 176, 187], ["bronchial epithelial cell", "ANATOMY", 239, 264], ["primary cells", "ANATOMY", 397, 410], ["ATCC PCS-999-003", "ANATOMY", 412, 428], ["ATCC PCS-999-004", "ANATOMY", 433, 449], ["ATCC PCS-300-030", "CHEMICAL", 202, 218], ["ATCC PCS-300-040", "CHEMICAL", 277, 293], ["human", "ORGANISM", 15, 20], ["small airway epithelial cells", "CELL", 21, 50], ["HSAEC", "CELL", 52, 57], ["ATCC PCS-301-010", "CELL", 60, 76], ["airway cell", "CELL", 176, 187], ["bronchial epithelial cell", "CELL", 239, 264], ["trypsin", "GENE_OR_GENE_PRODUCT", 327, 334], ["trypsin", "SIMPLE_CHEMICAL", 339, 346], ["cells", "CELL", 405, 410], ["ATCC PCS-999-003", "CELL", 412, 428], ["ATCC PCS-999-004", "CELL", 433, 449], ["primary human small airway epithelial cells", "CELL_TYPE", 7, 50], ["HSAEC", "CELL_TYPE", 52, 57], ["trypsin", "PROTEIN", 327, 334], ["trypsin", "PROTEIN", 339, 346], ["primary cells", "CELL_TYPE", 397, 410], ["ATCC PCS-999-003", "CELL_LINE", 412, 428], ["ATCC PCS-999-004", "CELL_LINE", 433, 449], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["ATCC PCS-999-004", "SPECIES", 433, 449], ["ATCC PCS", "TEST", 60, 68], ["ATCC PCS", "TEST", 202, 210], ["bronchial epithelial cell growth kit", "TEST", 239, 275], ["ATCC PCS", "TEST", 277, 285], ["trypsin", "TREATMENT", 327, 334], ["trypsin-neutralizing solution", "TREATMENT", 339, 368], ["primary cells", "PROBLEM", 397, 410], ["small", "OBSERVATION_MODIFIER", 21, 26], ["airway epithelial cells", "OBSERVATION", 27, 50], ["airway", "ANATOMY", 176, 182], ["bronchial epithelial", "ANATOMY", 239, 259], ["cell", "OBSERVATION", 260, 264]]], ["The primary cells were passaged a maximum of two times.", [["primary cells", "ANATOMY", 4, 17], ["cells", "CELL", 12, 17], ["primary cells", "CELL_TYPE", 4, 17], ["The primary cells", "TREATMENT", 0, 17], ["primary cells", "OBSERVATION", 4, 17]]], ["HAE-ALI cultures (EpiAirway, AIR-100) were obtained from MatTek Corporation (Ashland, MA) and were cultured at the air-liquid interface as described in the manufacturer's protocol with the provided maintenance medium, with daily medium changes.Cells and virusesThe recombinant viruses RSV-GFP [65] , VSV-GFP [66] , wt RSV A2 (Genbank accession # KT992094), rgRSV-dSH and rgRSV-dSH/dG [7] have been previously described.", [["Cells", "ANATOMY", 244, 249], ["HAE", "DISEASE", 0, 3], ["ALI", "DISEASE", 4, 7], ["dG", "CHEMICAL", 381, 383], ["Cells", "CELL", 244, 249], ["recombinant viruses", "ORGANISM", 265, 284], ["RSV-GFP [65]", "ORGANISM", 285, 297], ["VSV-GFP [66", "ORGANISM", 300, 311], ["wt", "ORGANISM", 315, 317], ["RSV A2", "ORGANISM", 318, 324], ["rgRSV-dSH", "GENE_OR_GENE_PRODUCT", 357, 366], ["rgRSV", "ORGANISM", 371, 376], ["ALI cultures", "CELL_LINE", 4, 16], ["rgRSV", "PROTEIN", 357, 362], ["dSH", "PROTEIN", 363, 366], ["rgRSV", "PROTEIN", 371, 376], ["RSV", "SPECIES", 318, 321], ["RSV", "SPECIES", 285, 288], ["RSV", "SPECIES", 318, 321], ["HAE", "TEST", 0, 3], ["ALI cultures", "TEST", 4, 16], ["EpiAirway", "TEST", 18, 27], ["AIR", "TEST", 29, 32], ["maintenance medium", "TREATMENT", 198, 216], ["viruses", "PROBLEM", 254, 261], ["The recombinant viruses RSV", "TEST", 261, 288], ["GFP", "TEST", 289, 292], ["VSV", "TEST", 300, 303], ["GFP", "TEST", 304, 307], ["wt RSV A2", "TEST", 315, 324], ["Genbank accession", "TEST", 326, 343], ["KT992094", "TEST", 346, 354], ["rgRSV", "TEST", 357, 362], ["dSH", "TEST", 363, 366], ["rgRSV", "TEST", 371, 376], ["dSH", "PROBLEM", 377, 380], ["ALI", "ANATOMY", 4, 7], ["viruses", "OBSERVATION", 254, 261], ["viruses", "OBSERVATION", 277, 284], ["RSV A2", "ANATOMY", 318, 324]]], ["For all experiments, virus stocks were purified on a discontinuous (60% and 30% w/v) sucrose gradient as described previously [65] .", [["sucrose", "CHEMICAL", 85, 92], ["sucrose", "CHEMICAL", 85, 92], ["virus stocks", "TREATMENT", 21, 33], ["/v) sucrose gradient", "TREATMENT", 81, 101]]], ["Cell cultures were maintained at 37\u00baC and 5% CO 2 , and any cells used in experiments were incubated under these conditions.siRNA screenThe high-throughput screen was performed and the data were analyzed as described previously [67] .", [["Cell cultures", "ANATOMY", 0, 13], ["cells", "ANATOMY", 60, 65], ["CO 2", "CHEMICAL", 45, 49], ["Cell cultures", "CELL", 0, 13], ["cells", "CELL", 60, 65], ["Cell cultures", "TEST", 0, 13], ["any cells", "PROBLEM", 56, 65], ["siRNA screen", "TEST", 124, 136], ["The high-throughput screen", "TEST", 136, 162], ["the data", "TEST", 181, 189]]], ["In brief, the siRNAs were from the Ambion Silencer Select Human Genome siRNA library version 4 (Fischer Scientific), targeting~21,500 human genes with 3 siRNAs per gene, evaluated individually.", [["Human", "ORGANISM", 58, 63], ["human", "ORGANISM", 134, 139], ["21,500 human genes", "DNA", 127, 145], ["Human", "SPECIES", 58, 63], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["the siRNAs", "TREATMENT", 10, 20], ["the Ambion Silencer", "TREATMENT", 31, 50], ["Human Genome siRNA library version", "TREATMENT", 58, 92]]], ["High throughput screening was performed in 384-well plates (total of 186 plates) using a Bravo VPrep liquid handler within a BioCel automation platform (Agilent).", [["High throughput screening", "TEST", 0, 25], ["a Bravo VPrep liquid handler", "TREATMENT", 87, 115], ["a BioCel automation platform (Agilent)", "TREATMENT", 123, 161]]], ["Single siRNAs (0.8 pmol) were added to wells followed by 20 \u03bcl of serum-free medium containing 0.12 \u03bcl Lipofectamine RNAiMax.", [["serum", "ANATOMY", 66, 71], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["Single siRNAs (0.8 pmol)", "TREATMENT", 0, 24], ["serum-free medium", "TREATMENT", 66, 83], ["\u03bcl Lipofectamine RNAiMax", "TREATMENT", 100, 124]]], ["The mixtures were incubated for 45 min at room temperature, followed by the addition of A549 cells that we had engineered to constitutively express DsRed as a viability marker.", [["A549 cells", "ANATOMY", 88, 98], ["A549 cells", "CELL", 88, 98], ["DsRed", "GENE_OR_GENE_PRODUCT", 148, 153], ["A549 cells", "CELL_LINE", 88, 98], ["DsRed", "PROTEIN", 148, 153], ["A549 cells", "TREATMENT", 88, 98]]], ["The final transfection mixtures contained 1000 A549 cells and 20 nM siRNA in F12 medium and 10% FBS.", [["A549 cells", "ANATOMY", 47, 57], ["FBS", "ANATOMY", 96, 99], ["A549 cells", "CELL", 47, 57], ["FBS", "ORGANISM_SUBSTANCE", 96, 99], ["A549 cells", "CELL_LINE", 47, 57], ["The final transfection mixtures", "TEST", 0, 31], ["A549 cells", "TEST", 47, 57], ["nM siRNA in F12 medium", "TREATMENT", 65, 87], ["10% FBS", "TEST", 92, 99], ["A549 cells", "OBSERVATION", 47, 57]]], ["The cells were incubated for 48 h, RSV-GFP was added at a multiplicity of infection (MOI) of 1 PFU/cell, and cells were incubated for an additional 48 h.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 99, 103], ["cells", "ANATOMY", 109, 114], ["infection", "DISEASE", 74, 83], ["cells", "CELL", 4, 9], ["RSV", "ORGANISM", 35, 38], ["GFP", "GENE_OR_GENE_PRODUCT", 39, 42], ["cell", "CELL", 99, 103], ["cells", "CELL", 109, 114], ["RSV", "SPECIES", 35, 38], ["RSV-GFP", "TEST", 35, 42], ["infection", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 74, 83]]], ["The cells were fixed with paraformaldehyde and stained with Hoechst 33342.", [["cells", "ANATOMY", 4, 9], ["Hoechst 33342", "CHEMICAL", 60, 73], ["paraformaldehyde", "CHEMICAL", 26, 42], ["Hoechst 33342", "CHEMICAL", 60, 73], ["cells", "CELL", 4, 9], ["paraformaldehyde", "SIMPLE_CHEMICAL", 26, 42], ["Hoechst 33342", "SIMPLE_CHEMICAL", 60, 73], ["paraformaldehyde", "TREATMENT", 26, 42]]], ["Images were acquired on an ImageXpress Micro XL (Molecular Devices) automated microscope and analyzed with associated MetaXpress software using the \"Multi Wavelength Cell Scoring\" analysis module.", [["Images", "TEST", 0, 6], ["an ImageXpress Micro XL (Molecular Devices", "TREATMENT", 24, 66]]], ["Ambion Silencer Select Negative Control #2 was present in all screening plates (16 wells) and the median negative control value on each plate was used for On exposure to respiratory epithelial cells, RSV triggers the activation and clustering of ATP1A1 in the plasma membrane through an unknown mechanism.", [["respiratory epithelial cells", "ANATOMY", 170, 198], ["plasma membrane", "ANATOMY", 260, 275], ["respiratory epithelial cells", "CELL", 170, 198], ["RSV", "ORGANISM", 200, 203], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 246, 252], ["plasma membrane", "CELLULAR_COMPONENT", 260, 275], ["respiratory epithelial cells", "CELL_TYPE", 170, 198], ["ATP1A1", "PROTEIN", 246, 252], ["RSV", "SPECIES", 200, 203], ["Ambion Silencer", "TREATMENT", 0, 15], ["all screening plates", "TEST", 58, 78], ["respiratory epithelial cells", "PROBLEM", 170, 198], ["RSV", "PROBLEM", 200, 203], ["clustering of ATP1A1 in the plasma membrane", "PROBLEM", 232, 275], ["respiratory epithelial cells", "OBSERVATION", 170, 198]]], ["ATP1A1 then signals via phosphorylated Src-kinase and transactivates EGFR by its phosphorylation at Tyr845.", [["Tyr845", "CHEMICAL", 100, 106], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 0, 6], ["Src-", "GENE_OR_GENE_PRODUCT", 39, 43], ["EGFR", "GENE_OR_GENE_PRODUCT", 69, 73], ["Tyr845", "AMINO_ACID", 100, 106], ["ATP1A1", "PROTEIN", 0, 6], ["Src-kinase", "PROTEIN", 39, 49], ["EGFR", "PROTEIN", 69, 73], ["phosphorylated Src-kinase", "TEST", 24, 49], ["transactivates EGFR", "TEST", 54, 73], ["its phosphorylation", "TEST", 77, 96]]], ["Upon activation, EGFR signaling causes cytoskeletal rearrangement resulting in plasma membrane ruffling and formation of membrane extensions (reported previously [31, 33, 34] ) that engulf fluid and RSV into macropinosomes.", [["cytoskeletal", "ANATOMY", 39, 51], ["plasma membrane", "ANATOMY", 79, 94], ["membrane", "ANATOMY", 121, 129], ["fluid", "ANATOMY", 189, 194], ["EGFR", "GENE_OR_GENE_PRODUCT", 17, 21], ["cytoskeletal", "CELLULAR_COMPONENT", 39, 51], ["plasma membrane", "CELLULAR_COMPONENT", 79, 94], ["membrane", "CELLULAR_COMPONENT", 121, 129], ["fluid", "ORGANISM_SUBSTANCE", 189, 194], ["RSV", "ORGANISM", 199, 202], ["macropinosomes", "GENE_OR_GENE_PRODUCT", 208, 222], ["EGFR", "PROTEIN", 17, 21], ["RSV", "SPECIES", 199, 202], ["EGFR signaling", "TEST", 17, 31], ["cytoskeletal rearrangement", "PROBLEM", 39, 65], ["plasma membrane ruffling", "PROBLEM", 79, 103], ["membrane extensions", "PROBLEM", 121, 140], ["engulf fluid and RSV into macropinosomes", "PROBLEM", 182, 222], ["cytoskeletal rearrangement", "OBSERVATION", 39, 65], ["plasma membrane ruffling", "OBSERVATION", 79, 103], ["membrane extensions", "OBSERVATION", 121, 140], ["fluid", "OBSERVATION", 189, 194], ["RSV", "OBSERVATION", 199, 202]]], ["Note that RSV is taken up into the macropinosome in its enveloped state suggesting that it does not fuse at the cell surface; fusion and release of the nucleocapsid likely occurs within the internalized macropinosome. normalization.", [["macropinosome", "ANATOMY", 35, 48], ["cell surface", "ANATOMY", 112, 124], ["macropinosome", "ANATOMY", 203, 216], ["RSV", "ORGANISM", 10, 13], ["macropinosome", "CANCER", 35, 48], ["cell surface", "CELLULAR_COMPONENT", 112, 124], ["nucleocapsid", "CELLULAR_COMPONENT", 152, 164], ["macropinosome", "CELLULAR_COMPONENT", 203, 216], ["macropinosome", "PROTEIN", 203, 216], ["RSV", "SPECIES", 10, 13], ["RSV", "PROBLEM", 10, 13], ["fusion", "TREATMENT", 126, 132], ["the nucleocapsid", "PROBLEM", 148, 164], ["RSV", "OBSERVATION", 10, 13], ["cell", "OBSERVATION_MODIFIER", 112, 116], ["surface", "OBSERVATION_MODIFIER", 117, 124], ["fusion", "OBSERVATION", 126, 132], ["nucleocapsid", "OBSERVATION", 152, 164]]], ["An siRNA targeting GFP was used as a positive control (16 well per plate) and yielded near-complete elimination of cells scoring positive for GFP.", [["cells", "ANATOMY", 115, 120], ["GFP", "GENE_OR_GENE_PRODUCT", 19, 22], ["cells", "CELL", 115, 120], ["GFP", "GENE_OR_GENE_PRODUCT", 142, 145], ["GFP", "PROTEIN", 19, 22], ["GFP", "PROTEIN", 142, 145], ["An siRNA targeting GFP", "TEST", 0, 22], ["GFP", "TEST", 142, 145]]], ["The median absolute deviation (MAD) based z-score was calculated for each siRNA [68] .", [["The median absolute deviation (MAD) based z-score", "PROBLEM", 0, 49], ["median", "OBSERVATION_MODIFIER", 4, 10], ["absolute deviation", "OBSERVATION", 11, 29]]], ["Scores were adjusted for seedbased off-target effects to help deprioritize likely false positives [69] .", [["Scores", "TEST", 0, 6], ["false positives", "PROBLEM", 82, 97], ["false positives", "OBSERVATION", 82, 97]]], ["The median seed-adjusted Z-scores are provided in the S1 Table. siRNA transfection to knock down the host proteins ATP1A1 and EGFRCell viability assayCell viability was measured by an ATP-based assay CellTiter-Glo (Promega, Madison, WI) performed as described by the manufacturer.", [["ATP", "CHEMICAL", 184, 187], ["ATP", "CHEMICAL", 184, 187], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 115, 121], ["EGFRCell", "GENE_OR_GENE_PRODUCT", 126, 134], ["ATP", "SIMPLE_CHEMICAL", 184, 187], ["Glo", "SIMPLE_CHEMICAL", 210, 213], ["host proteins", "PROTEIN", 101, 114], ["ATP1A1", "PROTEIN", 115, 121], ["EGFRCell", "PROTEIN", 126, 134], ["The median seed-adjusted Z-scores", "TREATMENT", 0, 33], ["siRNA transfection", "TREATMENT", 64, 82], ["the host proteins", "TEST", 97, 114], ["ATP1A1", "TEST", 115, 121], ["EGFRCell viability assayCell viability", "TEST", 126, 164], ["an ATP", "TEST", 181, 187], ["median seed", "OBSERVATION", 4, 15]]], ["Cells in white 96-well plates were lysed and the ATP concentration was determined by luciferase activation.", [["Cells", "ANATOMY", 0, 5], ["ATP", "CHEMICAL", 49, 52], ["ATP", "CHEMICAL", 49, 52], ["Cells", "CELL", 0, 5], ["ATP", "SIMPLE_CHEMICAL", 49, 52], ["luciferase", "GENE_OR_GENE_PRODUCT", 85, 95], ["luciferase", "PROTEIN", 85, 95], ["Cells", "TEST", 0, 5], ["white", "TEST", 9, 14], ["the ATP concentration", "TEST", 45, 66]]], ["Luciferase light emission was analyzed using a Synergy 2 ELISA reader (BioTek, Winooski, VT).", [["Luciferase light emission", "TEST", 0, 25], ["a Synergy", "TREATMENT", 45, 54]]], ["Reduction in ATP relative to control cells was indicative of reduced viability.Western blot analysis for the quantification of ATP1A1A549 or HSAEC cells in 12-well plates were lysed with 75 \u03bcl 1x LDS sample buffer (Life Technologies).", [["cells", "ANATOMY", 37, 42], ["HSAEC cells", "ANATOMY", 141, 152], ["ATP", "CHEMICAL", 13, 16], ["ATP", "CHEMICAL", 13, 16], ["ATP", "SIMPLE_CHEMICAL", 13, 16], ["cells", "CELL", 37, 42], ["ATP1A1A549", "GENE_OR_GENE_PRODUCT", 127, 137], ["HSAEC cells", "CELL", 141, 152], ["control cells", "CELL_TYPE", 29, 42], ["ATP1A1A549", "PROTEIN", 127, 137], ["HSAEC cells", "CELL_LINE", 141, 152], ["Reduction in ATP", "TREATMENT", 0, 16], ["reduced viability", "PROBLEM", 61, 78], ["blot analysis", "TEST", 87, 100], ["the quantification", "TEST", 105, 123], ["ATP1A1A549", "TEST", 127, 137], ["HSAEC cells", "TEST", 141, 152], ["indicative of", "UNCERTAINTY", 47, 60], ["reduced", "OBSERVATION_MODIFIER", 61, 68], ["viability", "OBSERVATION_MODIFIER", 69, 78]]], ["22.5 \u03bcL aliquots of lysate were reduced, denatured, and electrophoresed on 4-12% Bis-Tris SDS gels (Life Technologies).", [["lysate", "ANATOMY", 20, 26], ["Bis-Tris", "CHEMICAL", 81, 89], ["Bis-Tris SDS", "CHEMICAL", 81, 93], ["lysate", "ORGANISM_SUBSTANCE", 20, 26], ["Bis-Tris SDS gels", "SIMPLE_CHEMICAL", 81, 98], ["lysate", "TREATMENT", 20, 26]]], ["Proteins were transferred onto PVDF membranes using the iBlot2 transfer system (Life Technologies) and analyzed by Western blotting.", [["PVDF membranes", "ANATOMY", 31, 45], ["PVDF", "CHEMICAL", 31, 35], ["membranes", "CELLULAR_COMPONENT", 36, 45], ["PVDF membranes", "TREATMENT", 31, 45], ["the iBlot2 transfer system", "TREATMENT", 52, 78]]], ["ATP1A1 was detected with an anti-ATP1A1 rabbit MAb (Abcam, Cambridge, MA; ab76020) and the corresponding infrared dye-conjugated goat anti-rabbit immunoglobulin 680RD (Li-Cor, Lincoln, NE).", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 0, 6], ["Abcam", "GENE_OR_GENE_PRODUCT", 52, 57], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 146, 160], ["ATP1A1", "PROTEIN", 0, 6], ["anti-ATP1A1 rabbit MAb", "PROTEIN", 28, 50], ["Abcam, Cambridge, MA; ab76020", "PROTEIN", 52, 81], ["infrared dye-conjugated goat anti-rabbit immunoglobulin 680RD", "PROTEIN", 105, 166], ["Li-Cor", "PROTEIN", 168, 174], ["Lincoln", "PROTEIN", 176, 183], ["NE", "PROTEIN", 185, 187], ["rabbit", "SPECIES", 40, 46], ["goat", "SPECIES", 129, 133], ["anti-rabbit", "SPECIES", 134, 145], ["rabbit", "SPECIES", 40, 46], ["ATP1A1", "TEST", 0, 6], ["an anti-ATP1A1 rabbit MAb", "TREATMENT", 25, 50], ["anti-rabbit immunoglobulin", "TEST", 134, 160]]], ["Tubulin was used as a loading control and was detected with an anti-tubulin mouse MAb and an infrared dye-conjugated goat anti-mouse immunoglobulin 800CW (Li-Cor).", [["Tubulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["mouse", "ORGANISM", 76, 81], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 133, 147], ["Li-Cor", "GENE_OR_GENE_PRODUCT", 155, 161], ["Tubulin", "PROTEIN", 0, 7], ["anti-tubulin mouse MAb", "PROTEIN", 63, 85], ["infrared dye-conjugated goat anti-mouse immunoglobulin 800CW", "PROTEIN", 93, 153], ["Li-Cor", "PROTEIN", 155, 161], ["mouse", "SPECIES", 76, 81], ["goat", "SPECIES", 117, 121], ["anti-mouse", "SPECIES", 122, 132], ["mouse", "SPECIES", 76, 81], ["goat", "SPECIES", 117, 121], ["Tubulin", "TREATMENT", 0, 7], ["a loading control", "TREATMENT", 20, 37], ["an anti-tubulin mouse MAb", "TREATMENT", 60, 85], ["an infrared dye-conjugated goat anti-mouse immunoglobulin", "TREATMENT", 90, 147]]], ["Western blot images were acquired on the Odyssey infrared scanner (Li-Cor) and analyzed with Image Studio Software (Version 5.2.5, Li-Cor).", [["Western blot images", "TEST", 0, 19]]], ["ATP1A1 band intensity values were normalized to tubulin and reported relative to Neg. siRNA1 transfected cells.Quantitative RT-PCRCells were harvested and total RNA was isolated with RNeasy Mini Kit (Qiagen) as described by the manufacturer's protocol, including on-column DNase digestion.", [["cells", "ANATOMY", 105, 110], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 0, 6], ["tubulin", "GENE_OR_GENE_PRODUCT", 48, 55], ["cells", "CELL", 105, 110], ["DNase", "GENE_OR_GENE_PRODUCT", 273, 278], ["ATP1A1", "PROTEIN", 0, 6], ["tubulin", "PROTEIN", 48, 55], ["Neg. siRNA1 transfected cells", "CELL_LINE", 81, 110], ["DNase", "PROTEIN", 273, 278], ["ATP1A1 band intensity values", "TEST", 0, 28], ["tubulin", "TEST", 48, 55], ["siRNA1 transfected cells", "PROBLEM", 86, 110], ["Quantitative RT-PCRCells", "TREATMENT", 111, 135], ["total RNA", "TEST", 155, 164], ["RNeasy Mini Kit (Qiagen)", "TREATMENT", 183, 207], ["column DNase digestion", "TREATMENT", 266, 288], ["intensity", "OBSERVATION_MODIFIER", 12, 21], ["transfected cells", "OBSERVATION", 93, 110]]], ["1 \u03bcg total RNA was used for reverse transcription with oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers and the SuperScript TM First-Strand Synthesis System for RT-PCR (Life Technologies).", [["[12] [13] [14] [15] [16] [17] [18", "CHEMICAL", 65, 98], ["oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers", "SIMPLE_CHEMICAL", 55, 107], ["1 \u03bcg total RNA", "RNA", 0, 14], ["total RNA", "TREATMENT", 5, 14], ["oligo(dT)", "TEST", 55, 64], ["primers", "TEST", 100, 107], ["the SuperScript TM", "TEST", 112, 130], ["Strand Synthesis System", "TEST", 137, 160], ["RT-PCR", "TEST", 165, 171]]], ["The synthesized cDNA was prediluted 1:10 and used for the TaqMan gene expression analysis of ATP1A1 (Hs00167556_m1) and 18S rRNA (Hs99999901_s1) as a normalization control.", [["ATP1A1", "GENE_OR_GENE_PRODUCT", 93, 99], ["18S rRNA", "GENE_OR_GENE_PRODUCT", 120, 128], ["synthesized cDNA", "DNA", 4, 20], ["ATP1A1", "DNA", 93, 99], ["Hs00167556_m1", "DNA", 101, 114], ["18S rRNA", "DNA", 120, 128], ["Hs99999901_s1", "DNA", 130, 143], ["ATP1A1", "TEST", 93, 99], ["18S rRNA", "TEST", 120, 128], ["Hs", "TEST", 130, 132], ["a normalization control", "TREATMENT", 148, 171]]], ["The TaqMan assay reactions were analyzed on the 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA).", [["The TaqMan assay reactions", "TEST", 0, 26]]], ["The threshold cycle (Ct) for each reaction was determined by the SDS RQ Manager program (Applied Biosystems).", [["The threshold cycle", "TEST", 0, 19], ["Ct", "TEST", 21, 23], ["each reaction", "PROBLEM", 29, 42]]], ["The relative changes in ATP1A1 transcript level were calculated by the 2 -\u0394\u0394Ct method [70] and reported relative to cells transfected with Neg. siRNA 1.Quantification of RSV gene expression by viral expressed GFPRSV gene expression was measured using RSV-GFP, a recombinantly derived virus that expresses enhanced green fluorescent protein (eGFP) from an additional gene inserted between the P and M genes.", [["cells", "ANATOMY", 116, 121], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 24, 30], ["cells", "CELL", 116, 121], ["RSV", "ORGANISM", 170, 173], ["GFPRSV", "GENE_OR_GENE_PRODUCT", 209, 215], ["RSV", "ORGANISM", 251, 254], ["GFP", "GENE_OR_GENE_PRODUCT", 255, 258], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 314, 339], ["eGFP", "GENE_OR_GENE_PRODUCT", 341, 345], ["ATP1A1 transcript", "RNA", 24, 41], ["RSV gene", "DNA", 170, 178], ["GFPRSV gene", "DNA", 209, 220], ["GFP", "PROTEIN", 255, 258], ["enhanced green fluorescent protein", "PROTEIN", 305, 339], ["eGFP", "PROTEIN", 341, 345], ["P and M genes", "DNA", 392, 405], ["RSV", "SPECIES", 170, 173], ["RSV", "SPECIES", 251, 254], ["The relative changes in ATP1A1 transcript level", "PROBLEM", 0, 47], ["RSV gene expression", "PROBLEM", 170, 189], ["viral expressed GFPRSV gene expression", "PROBLEM", 193, 231], ["RSV-GFP", "TEST", 251, 258], ["a recombinantly derived virus", "PROBLEM", 260, 289], ["enhanced green fluorescent protein (eGFP", "PROBLEM", 305, 345], ["an additional gene", "TREATMENT", 352, 370], ["RSV", "OBSERVATION", 170, 173]]], ["SiRNA transfected or pre-treated A549 cells in 12-well plates were inoculated with an MOI of 1 PFU/cell.", [["A549 cells", "ANATOMY", 33, 43], ["cell", "ANATOMY", 99, 103], ["A549 cells", "CELL", 33, 43], ["cell", "CELL", 99, 103], ["pre-treated A549 cells", "CELL_LINE", 21, 43], ["SiRNA transfected", "TREATMENT", 0, 17], ["A549 cells", "TEST", 33, 43], ["an MOI", "TEST", 83, 89], ["A549 cells", "OBSERVATION", 33, 43]]], ["Inoculum was adsorbed for 2 h on a rocking platform at 37\u02daC and then washed off and replaced with fresh media.", [["C", "SIMPLE_CHEMICAL", 58, 59], ["fresh media", "TREATMENT", 98, 109]]], ["The infected cells were incubated for 17 h, and GFP expression was quantified either by ELISA reader or flow cytometry.", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["GFP", "GENE_OR_GENE_PRODUCT", 48, 51], ["infected cells", "CELL_TYPE", 4, 18], ["GFP", "PROTEIN", 48, 51], ["The infected cells", "PROBLEM", 0, 18], ["GFP expression", "TEST", 48, 62], ["flow cytometry", "TEST", 104, 118], ["infected cells", "OBSERVATION", 4, 18], ["flow cytometry", "OBSERVATION", 104, 118]]], ["For the ELISA reader quantification, the GFP intensity of the infected monolayer was quantified by an area scan (average GFP intensity of 29 individual measurements per well) on a Synergy 2 ELISA reader (BioTek).", [["monolayer", "ANATOMY", 71, 80], ["GFP", "GENE_OR_GENE_PRODUCT", 41, 44], ["monolayer", "CELL", 71, 80], ["the ELISA reader quantification", "TEST", 4, 35], ["the GFP intensity", "TEST", 37, 54], ["the infected monolayer", "PROBLEM", 58, 80], ["an area scan", "TEST", 99, 111], ["GFP intensity", "TEST", 121, 134], ["a Synergy", "TREATMENT", 178, 187], ["infected monolayer", "OBSERVATION", 62, 80]]], ["The intensity values were adjusted by subtracting the average intensity of mock-infected cells as background and reported relative to Neg. siRNA 1 transfected or mock-treated cells that had been infected with RSV-GFP.", [["cells", "ANATOMY", 89, 94], ["cells", "ANATOMY", 175, 180], ["cells", "CELL", 89, 94], ["cells", "CELL", 175, 180], ["RSV", "ORGANISM", 209, 212], ["GFP", "GENE_OR_GENE_PRODUCT", 213, 216], ["mock-infected cells", "CELL_LINE", 75, 94], ["mock-treated cells", "CELL_LINE", 162, 180], ["GFP", "PROTEIN", 213, 216], ["RSV", "SPECIES", 209, 212], ["The intensity values", "TEST", 0, 20], ["infected cells", "PROBLEM", 80, 94], ["mock-treated cells", "PROBLEM", 162, 180], ["infected cells", "OBSERVATION", 80, 94]]], ["For the flow cytometry-based GFP quantification, the cells were detached with 1 mM EDTA, stained with LIVE/DEAD fixable dead cell staining kit (Life Technologies), and fixed with 4% paraformaldehyde (PFA, Electron Microscopy Science, PA).", [["cells", "ANATOMY", 53, 58], ["cell", "ANATOMY", 125, 129], ["EDTA", "CHEMICAL", 83, 87], ["paraformaldehyde", "CHEMICAL", 182, 198], ["PFA", "CHEMICAL", 200, 203], ["GFP", "GENE_OR_GENE_PRODUCT", 29, 32], ["cells", "CELL", 53, 58], ["EDTA", "SIMPLE_CHEMICAL", 83, 87], ["cell", "CELL", 125, 129], ["paraformaldehyde", "SIMPLE_CHEMICAL", 182, 198], ["PFA", "SIMPLE_CHEMICAL", 200, 203], ["DEAD", "PROTEIN", 107, 111], ["the flow cytometry", "TEST", 4, 22], ["4% paraformaldehyde (PFA", "TREATMENT", 179, 203], ["dead cell staining", "OBSERVATION", 120, 138]]], ["The GFP intensities of single, live cells were analyzed on a Canto II flow cytometer (BD Biosciences, Franklin Lakes, NJ).", [["cells", "ANATOMY", 36, 41], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["cells", "CELL", 36, 41], ["The GFP intensities", "TEST", 0, 19]]], ["The median fluorescence intensity (MFI) of GFP-positive cells was determined and reported as change relative to Neg. siRNA 1 transfected or mock-treated cells that had been infected with RSV-GFP.Virus titrationInfected cell monolayers were scraped into the media supernatant, vortexed for 30 s, clarified by centrifugation at 478 x g, snap frozen on dry-ice, and stored at -80\u02daC. Samples were 10-fold serially diluted and Vero cells were inoculated with each dilution in duplicate and incubated for 2 h on a rocking platform at 37\u02daC. Cells were overlaid with OptiMEM I (Life Technologies) containing 0.8% methylcellulose (Sigma-Aldrich), 1x L-Glutamine, 2% FBS and 50 \u03bcg/ml Gentamicin and incubated for 6 days at 37\u02daC. For RSV that expressed GFP, the plaques were visualized directly by GFP expression with a Typhoon imaging system (GE Healthcare, Chicago, IL).", [["GFP-positive cells", "ANATOMY", 43, 61], ["cells", "ANATOMY", 153, 158], ["cell monolayers", "ANATOMY", 219, 234], ["supernatant", "ANATOMY", 263, 274], ["Samples", "ANATOMY", 380, 387], ["Vero cells", "ANATOMY", 422, 432], ["Cells", "ANATOMY", 534, 539], ["plaques", "ANATOMY", 751, 758], ["methylcellulose", "CHEMICAL", 605, 620], ["Sigma-Aldrich", "CHEMICAL", 622, 635], ["L-Glutamine", "CHEMICAL", 641, 652], ["FBS", "CHEMICAL", 657, 660], ["Gentamicin", "CHEMICAL", 674, 684], ["methylcellulose", "CHEMICAL", 605, 620], ["L-Glutamine", "CHEMICAL", 641, 652], ["Gentamicin", "CHEMICAL", 674, 684], ["GFP", "GENE_OR_GENE_PRODUCT", 43, 46], ["cells", "CELL", 153, 158], ["RSV", "ORGANISM", 187, 190], ["GFP", "GENE_OR_GENE_PRODUCT", 191, 194], ["Virus", "ORGANISM", 195, 200], ["cell monolayers", "CELL", 219, 234], ["Vero cells", "CELL", 422, 432], ["Cells", "CELL", 534, 539], ["methylcellulose", "SIMPLE_CHEMICAL", 605, 620], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 622, 635], ["1x L-Glutamine", "SIMPLE_CHEMICAL", 638, 652], ["FBS", "ORGANISM_SUBSTANCE", 657, 660], ["Gentamicin", "SIMPLE_CHEMICAL", 674, 684], ["RSV", "ORGANISM", 723, 726], ["GFP", "GENE_OR_GENE_PRODUCT", 742, 745], ["plaques", "PATHOLOGICAL_FORMATION", 751, 758], ["GFP", "GENE_OR_GENE_PRODUCT", 787, 790], ["GFP", "PROTEIN", 43, 46], ["mock-treated cells", "CELL_LINE", 140, 158], ["GFP", "PROTEIN", 191, 194], ["Vero cells", "CELL_LINE", 422, 432], ["GFP", "PROTEIN", 742, 745], ["GFP", "PROTEIN", 787, 790], ["RSV", "SPECIES", 187, 190], ["Vero", "SPECIES", 422, 426], ["RSV", "SPECIES", 723, 726], ["The median fluorescence intensity", "TEST", 0, 33], ["GFP", "TEST", 43, 46], ["positive cells", "PROBLEM", 47, 61], ["siRNA", "TEST", 117, 122], ["mock-treated cells", "PROBLEM", 140, 158], ["Virus titration", "TREATMENT", 195, 210], ["Infected cell monolayers", "TREATMENT", 210, 234], ["Samples", "TEST", 380, 387], ["Vero cells", "TEST", 422, 432], ["each dilution", "TEST", 454, 467], ["a rocking platform", "TREATMENT", 506, 524], ["OptiMEM I (Life Technologies", "TREATMENT", 559, 587], ["0.8% methylcellulose (Sigma-Aldrich)", "TREATMENT", 600, 636], ["1x L-Glutamine", "TREATMENT", 638, 652], ["2% FBS", "TREATMENT", 654, 660], ["Gentamicin", "TREATMENT", 674, 684], ["RSV", "PROBLEM", 723, 726], ["the plaques", "PROBLEM", 747, 758], ["a Typhoon imaging system", "TEST", 807, 831], ["positive cells", "OBSERVATION", 47, 61], ["cell monolayers", "OBSERVATION", 219, 234], ["plaques", "OBSERVATION", 751, 758]]], ["Wt RSV plaques were fixed with ice-cold 80% methanol and immunostained with a mix of three RSV F-specific mouse MAbs [71] followed by a 680RD infrared dye-conjugated goat anti-mouse secondary immunoglobulin (Li-Cor).", [["plaques", "ANATOMY", 7, 14], ["methanol", "CHEMICAL", 44, 52], ["methanol", "CHEMICAL", 44, 52], ["RSV", "ORGANISM", 3, 6], ["methanol", "SIMPLE_CHEMICAL", 44, 52], ["RSV", "ORGANISM", 91, 94], ["mouse", "ORGANISM", 106, 111], ["goat", "ORGANISM", 166, 170], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 192, 206], ["Li-Cor", "GENE_OR_GENE_PRODUCT", 208, 214], ["RSV F-specific mouse MAbs", "PROTEIN", 91, 116], ["680RD infrared dye-conjugated goat anti-mouse secondary immunoglobulin", "PROTEIN", 136, 206], ["Li-Cor", "PROTEIN", 208, 214], ["mouse", "SPECIES", 106, 111], ["goat", "SPECIES", 166, 170], ["anti-mouse", "SPECIES", 171, 181], ["RSV", "SPECIES", 3, 6], ["RSV", "SPECIES", 91, 94], ["mouse", "SPECIES", 106, 111], ["goat", "SPECIES", 166, 170], ["Wt RSV plaques", "PROBLEM", 0, 14], ["ice-cold 80% methanol", "TREATMENT", 31, 52], ["a 680RD infrared dye-conjugated goat anti-mouse", "TREATMENT", 134, 181], ["RSV", "OBSERVATION_MODIFIER", 3, 6], ["plaques", "OBSERVATION", 7, 14]]], ["The plaques were imaged on the Odyssey infrared scanner (Li-Cor) and were counted using the ImageJ software (Version 1.46r; NIH, Bethesda, MD).Immunofluorescence microscopyA549 cells were seeded on glass cover slips in 24-well plates and used when still sub-confluent.", [["plaques", "ANATOMY", 4, 11], ["microscopyA549 cells", "ANATOMY", 162, 182], ["plaques", "MULTI-TISSUE_STRUCTURE", 4, 11], ["microscopyA549 cells", "CELL", 162, 182], ["microscopyA549 cells", "CELL_LINE", 162, 182], ["The plaques", "PROBLEM", 0, 11], ["Immunofluorescence microscopyA549 cells", "PROBLEM", 143, 182], ["glass cover slips", "TREATMENT", 198, 215], ["plaques", "OBSERVATION", 4, 11], ["confluent", "OBSERVATION", 258, 267]]], ["For the immunofluorescence microscopy based assays, cells were fixed with 4% paraformaldehyde for 16 h at 4\u02daC, permeabilized with 0.1% TritonX-100 (Sigma Aldrich) for 15 min and blocked with PBS containing 5% bovine serum albumin (BSA) (Sigma Aldrich) for 1 h at room temperature.", [["cells", "ANATOMY", 52, 57], ["serum", "ANATOMY", 216, 221], ["TritonX-100", "CHEMICAL", 135, 146], ["paraformaldehyde", "CHEMICAL", 77, 93], ["TritonX-100", "CHEMICAL", 135, 146], ["cells", "CELL", 52, 57], ["paraformaldehyde", "SIMPLE_CHEMICAL", 77, 93], ["TritonX-100", "SIMPLE_CHEMICAL", 135, 146], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 148, 161], ["bovine", "ORGANISM", 209, 215], ["serum", "ORGANISM_SUBSTANCE", 216, 221], ["albumin", "SIMPLE_CHEMICAL", 222, 229], ["BSA", "SIMPLE_CHEMICAL", 231, 234], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 237, 250], ["bovine", "SPECIES", 209, 215], ["the immunofluorescence microscopy", "TEST", 4, 37], ["4% paraformaldehyde", "TREATMENT", 74, 93], ["PBS", "TREATMENT", 191, 194], ["5% bovine serum albumin (BSA)", "TREATMENT", 206, 235]]], ["All antibody dilutions were prepared in PBS, containing 5% BSA and 0.1% TritonX-100.", [["BSA", "CHEMICAL", 59, 62], ["TritonX-100", "CHEMICAL", 72, 83], ["BSA", "SIMPLE_CHEMICAL", 59, 62], ["TritonX-100", "SIMPLE_CHEMICAL", 72, 83], ["All antibody dilutions", "TREATMENT", 0, 22]]], ["The primary antibody incubation was performed in a humidified chamber for 2 h with the following antibodies: rabbit anti-ATP1A1 (Abcam; ab76020, 1:100), rat anti-EGFR (Abcam; ab231, 1:100), mouse anti-RSV-N (Abcam; ab94806, 1:1,500) and anti-RSV-F (mouse MAb #1129 [72] , 1:200).", [["rabbit", "ORGANISM", 109, 115], ["anti-ATP1A1", "GENE_OR_GENE_PRODUCT", 116, 127], ["Abcam", "GENE_OR_GENE_PRODUCT", 129, 134], ["rat", "ORGANISM", 153, 156], ["anti-EGFR", "GENE_OR_GENE_PRODUCT", 157, 166], ["Abcam", "GENE_OR_GENE_PRODUCT", 168, 173], ["ab231", "GENE_OR_GENE_PRODUCT", 175, 180], ["mouse", "ORGANISM", 190, 195], ["RSV", "ORGANISM", 201, 204], ["Abcam", "GENE_OR_GENE_PRODUCT", 208, 213], ["anti-RSV-F", "GENE_OR_GENE_PRODUCT", 237, 247], ["mouse", "ORGANISM", 249, 254], ["antibodies", "PROTEIN", 97, 107], ["rabbit anti-ATP1A1", "PROTEIN", 109, 127], ["Abcam", "PROTEIN", 129, 134], ["ab76020", "PROTEIN", 136, 143], ["1:100", "PROTEIN", 145, 150], ["rat anti-EGFR", "PROTEIN", 153, 166], ["Abcam", "PROTEIN", 168, 173], ["ab231", "PROTEIN", 175, 180], ["1:100", "PROTEIN", 182, 187], ["mouse anti-RSV-N", "PROTEIN", 190, 206], ["Abcam", "PROTEIN", 208, 213], ["ab94806", "PROTEIN", 215, 222], ["1:1,500", "PROTEIN", 224, 231], ["anti-RSV", "PROTEIN", 237, 245], ["F", "PROTEIN", 246, 247], ["rabbit", "SPECIES", 109, 115], ["rat", "SPECIES", 153, 156], ["mouse", "SPECIES", 190, 195], ["mouse", "SPECIES", 249, 254], ["rabbit", "SPECIES", 109, 115], ["rat", "SPECIES", 153, 156], ["mouse", "SPECIES", 190, 195], ["RSV", "SPECIES", 201, 204], ["mouse", "SPECIES", 249, 254], ["The primary antibody incubation", "TREATMENT", 0, 31], ["a humidified chamber", "TREATMENT", 49, 69], ["Abcam", "TEST", 129, 134], ["rat anti-EGFR", "TEST", 153, 166], ["Abcam", "TEST", 168, 173], ["mouse anti-RSV", "TEST", 190, 204], ["Abcam", "TEST", 208, 213], ["anti-RSV", "TEST", 237, 245]]], ["After washing with PBS, the secondary antibody staining was performed with the respective Alexa Fluor (AF) conjugated secondary antibodies: donkey anti-rabbit AF488, goat anti-rabbit AF700, donkey anti-mouse AF647, goat anti-rat AF647.", [["Alexa Fluor", "CHEMICAL", 90, 101], ["Alexa Fluor", "SIMPLE_CHEMICAL", 90, 101], ["donkey", "ORGANISM", 140, 146], ["anti-rabbit AF488", "SIMPLE_CHEMICAL", 147, 164], ["goat", "ORGANISM", 166, 170], ["anti-rabbit AF700", "SIMPLE_CHEMICAL", 171, 188], ["donkey", "ORGANISM", 190, 196], ["anti-mouse AF647", "SIMPLE_CHEMICAL", 197, 213], ["goat", "ORGANISM", 215, 219], ["Alexa Fluor (AF) conjugated secondary antibodies", "PROTEIN", 90, 138], ["donkey anti-rabbit AF488", "PROTEIN", 140, 164], ["goat anti-rabbit AF700", "PROTEIN", 166, 188], ["donkey anti-mouse AF647", "PROTEIN", 190, 213], ["goat anti-rat AF647", "PROTEIN", 215, 234], ["donkey", "SPECIES", 140, 146], ["anti-rabbit", "SPECIES", 147, 158], ["goat", "SPECIES", 166, 170], ["anti-rabbit", "SPECIES", 171, 182], ["donkey", "SPECIES", 190, 196], ["anti-mouse", "SPECIES", 197, 207], ["goat", "SPECIES", 215, 219], ["anti-rabbit", "SPECIES", 147, 158], ["goat", "SPECIES", 166, 170], ["donkey", "SPECIES", 190, 196], ["goat", "SPECIES", 215, 219], ["PBS", "TREATMENT", 19, 22], ["the secondary antibody staining", "TEST", 24, 55], ["the respective Alexa Fluor", "TEST", 75, 101], ["donkey anti-rabbit", "TEST", 140, 158], ["donkey anti-mouse", "TREATMENT", 190, 207]]], ["Simultaneous staining of RSV-F and RSV-N was performed with conjugated primary antibodies: specifically, anti-RSV-F mouse MAb #1129 [72] that we conjugated with AF488 [Antibody Labeling Kit (Thermo Fisher Scientific, Waltham, MA)]; and a commercially-available anti-RSV N mouse MAb conjugated with allophycocyanin (APC) (NB100-64752APC, Novus Biologicals, Littleton, CO).", [["AF488", "CHEMICAL", 161, 166], ["NB100-64752APC", "CHEMICAL", 321, 335], ["AF488", "CHEMICAL", 161, 166], ["NB100-64752APC", "CHEMICAL", 321, 335], ["RSV", "ORGANISM", 25, 28], ["-F", "GENE_OR_GENE_PRODUCT", 28, 30], ["RSV", "ORGANISM", 35, 38], ["RSV", "ORGANISM", 110, 113], ["mouse", "ORGANISM", 116, 121], ["AF488", "SIMPLE_CHEMICAL", 161, 166], ["mouse", "ORGANISM", 272, 277], ["allophycocyanin", "GENE_OR_GENE_PRODUCT", 298, 313], ["APC", "GENE_OR_GENE_PRODUCT", 315, 318], ["conjugated primary antibodies", "PROTEIN", 60, 89], ["anti-RSV N mouse MAb", "PROTEIN", 261, 281], ["allophycocyanin", "PROTEIN", 298, 313], ["APC", "PROTEIN", 315, 318], ["CO", "PROTEIN", 367, 369], ["mouse", "SPECIES", 116, 121], ["mouse", "SPECIES", 272, 277], ["RSV", "SPECIES", 25, 28], ["RSV", "SPECIES", 35, 38], ["RSV", "SPECIES", 110, 113], ["mouse", "SPECIES", 116, 121], ["mouse", "SPECIES", 272, 277], ["Simultaneous staining", "TEST", 0, 21], ["RSV", "PROBLEM", 25, 28], ["RSV", "PROBLEM", 35, 38], ["conjugated primary antibodies", "TEST", 60, 89], ["anti-RSV N mouse MAb", "TREATMENT", 261, 281], ["allophycocyanin (APC", "TREATMENT", 298, 318], ["RSV", "OBSERVATION", 25, 28]]], ["Nuclei were counterstained with 300 nM DAPI (Life Technologies) in PBS for 5 min and mounted on glass-slides with ProLong Diamond Antifade mountant (Life Technologies).", [["Nuclei", "ANATOMY", 0, 6], ["DAPI", "CHEMICAL", 39, 43], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["DAPI", "SIMPLE_CHEMICAL", 39, 43], ["Life Technologies", "TREATMENT", 45, 62]]], ["Immunostainings of HAE-ALI cells were performed as described above for A549 cells, except the incubation times of the primary and secondary antibodies were extended to 16 h at 4\u02daC. In addition, the cultures were stained for F-Actin with the SiR-actin kit (CY-SC001; Cytoskeleton; Inc, Denver, CO).", [["HAE-ALI cells", "ANATOMY", 19, 32], ["A549 cells", "ANATOMY", 71, 81], ["primary", "ANATOMY", 118, 125], ["cultures", "ANATOMY", 198, 206], ["HAE", "DISEASE", 19, 22], ["HAE-ALI cells", "CELL", 19, 32], ["A549 cells", "CELL", 71, 81], ["F-Actin", "GENE_OR_GENE_PRODUCT", 224, 231], ["SiR-actin", "GENE_OR_GENE_PRODUCT", 241, 250], ["HAE-ALI cells", "CELL_LINE", 19, 32], ["A549 cells", "CELL_LINE", 71, 81], ["F", "PROTEIN", 224, 225], ["Actin", "PROTEIN", 226, 231], ["SiR", "PROTEIN", 241, 244], ["actin", "PROTEIN", 245, 250], ["Denver", "PROTEIN", 285, 291], ["CO", "PROTEIN", 293, 295], ["Immunostainings of HAE-ALI cells", "TEST", 0, 32], ["A549 cells", "PROBLEM", 71, 81], ["secondary antibodies", "PROBLEM", 130, 150], ["the cultures", "TEST", 194, 206], ["ALI cells", "OBSERVATION", 23, 32]]], ["Images were acquired on a Leica TCS-SP8 confocal microscope (Leica Microsystems, Mannheim, Germany) using a 63x oil immersion objective (NA 1.4), a zoom between 1.0 to 4.0x, laser emission at 488nm for AF488, 561 nm for AF568 and 633 nm for AF647.", [["TCS", "CHEMICAL", 32, 35], ["AF647", "PROTEIN", 241, 246], ["Images", "TEST", 0, 6], ["a Leica TCS", "TEST", 24, 35], ["a 63x oil immersion", "TREATMENT", 106, 125], ["NA", "TEST", 137, 139], ["AF568", "TEST", 220, 225]]], ["DAPI was excited using a 450 nm diode laser.", [["DAPI", "CHEMICAL", 0, 4], ["DAPI", "SIMPLE_CHEMICAL", 0, 4], ["a 450 nm diode laser", "TREATMENT", 23, 43]]], ["Detector slits were configured to minimize any crosstalk between the channels and, if necessary, the channels were collected sequentially and merged afterwards.", [["Detector slits", "PROBLEM", 0, 14]]], ["Images were processed using Leica Application Suite X (LAS-X) software, Imaris (Version 9.0.0, Bitplane AG, Zurich, Switzerland) and ImageJ.", [["Images", "TEST", 0, 6], ["Imaris", "TEST", 72, 78], ["Version", "TEST", 80, 87], ["ImageJ", "TEST", 133, 139]]], ["Images of the HAE-ALI cells were deconvolved with Huygens Essential deconvolution software (Scientific Volume Imaging B.V, Hilversum, The Netherlands).Quantification of EGFR phosphorylationAn EGFR phosphorylation array (Ray Biotech, Norcross, GA) was used to analyze phosphorylation of the EGFR receptor family.", [["HAE-ALI cells", "ANATOMY", 14, 27], ["HAE", "DISEASE", 14, 17], ["ALI", "DISEASE", 18, 21], ["HAE-ALI cells", "CELL", 14, 27], ["EGFR", "GENE_OR_GENE_PRODUCT", 169, 173], ["EGFR", "GENE_OR_GENE_PRODUCT", 192, 196], ["EGFR receptor", "GENE_OR_GENE_PRODUCT", 290, 303], ["HAE-ALI cells", "CELL_LINE", 14, 27], ["EGFR", "PROTEIN", 169, 173], ["EGFR", "PROTEIN", 192, 196], ["EGFR receptor family", "PROTEIN", 290, 310], ["Images", "TEST", 0, 6], ["Scientific Volume Imaging", "TEST", 92, 117], ["EGFR phosphorylationAn EGFR phosphorylation array", "TREATMENT", 169, 218], ["Ray Biotech, Norcross, GA", "TREATMENT", 220, 245], ["ALI cells", "OBSERVATION", 18, 27]]], ["The array consisted of nitrocellulose membrane that was spotted in duplicate with phospho-specific antibodies against 17 different phosphorylation sites of the human EGFR family, plus a positive control antibody that binds EGFR irrespective of phosphorylation.", [["membrane", "ANATOMY", 38, 46], ["nitrocellulose", "CHEMICAL", 23, 37], ["membrane", "CELLULAR_COMPONENT", 38, 46], ["human", "ORGANISM", 160, 165], ["EGFR", "GENE_OR_GENE_PRODUCT", 166, 170], ["EGFR", "GENE_OR_GENE_PRODUCT", 223, 227], ["phospho-specific antibodies", "PROTEIN", 82, 109], ["phosphorylation sites", "PROTEIN", 131, 152], ["human EGFR family", "PROTEIN", 160, 177], ["positive control antibody", "PROTEIN", 186, 211], ["EGFR", "PROTEIN", 223, 227], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["nitrocellulose membrane", "TREATMENT", 23, 46], ["phospho-specific antibodies", "TEST", 82, 109], ["a positive control antibody", "PROBLEM", 184, 211], ["phosphorylation", "PROBLEM", 244, 259], ["nitrocellulose membrane", "OBSERVATION", 23, 46]]], ["Cells were treated as indicated, either transfected with siRNA 48 h prior or pre-treated with the indicated chemical compound for 16 h.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["Coincident with transfection or treatment, the cells were serum-starved for 16 h and then infected with wt RSV (MOI = 5 PFU/cell) for 5 h at 37\u02daC. Cells treated with Ouabain or PST2238 for 16 h were incubated in F12 medium containing EGF (Sigma-Aldrich, 100 ng/ml) for 45 min as controls for PST2238 and Ouabain specificity.", [["cells", "ANATOMY", 47, 52], ["serum", "ANATOMY", 58, 63], ["cell", "ANATOMY", 124, 128], ["Cells", "ANATOMY", 147, 152], ["Ouabain", "CHEMICAL", 166, 173], ["PST2238", "CHEMICAL", 177, 184], ["EGF", "CHEMICAL", 234, 237], ["PST2238", "CHEMICAL", 292, 299], ["Ouabain", "CHEMICAL", 304, 311], ["Ouabain", "CHEMICAL", 166, 173], ["PST2238", "CHEMICAL", 177, 184], ["PST2238", "CHEMICAL", 292, 299], ["Ouabain", "CHEMICAL", 304, 311], ["cells", "CELL", 47, 52], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["RSV", "ORGANISM", 107, 110], ["cell", "CELL", 124, 128], ["Cells", "CELL", 147, 152], ["Ouabain", "SIMPLE_CHEMICAL", 166, 173], ["PST2238", "SIMPLE_CHEMICAL", 177, 184], ["EGF", "GENE_OR_GENE_PRODUCT", 234, 237], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 239, 252], ["PST2238", "SIMPLE_CHEMICAL", 292, 299], ["Ouabain", "SIMPLE_CHEMICAL", 304, 311], ["RSV", "SPECIES", 107, 110], ["transfection", "TREATMENT", 16, 28], ["treatment", "TREATMENT", 32, 41], ["the cells", "PROBLEM", 43, 52], ["serum", "TEST", 58, 63], ["wt RSV", "PROBLEM", 104, 110], ["MOI", "TEST", 112, 115], ["Ouabain", "TREATMENT", 166, 173], ["Aldrich", "TREATMENT", 245, 252], ["Ouabain specificity", "TEST", 304, 323]]], ["Cells were washed twice with cold PBS and lysed in the provided lysis buffer, containing protease and phosphatase inhibitor cocktails.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["protease", "PROTEIN", 89, 97], ["phosphatase", "PROTEIN", 102, 113], ["cold PBS", "TREATMENT", 29, 37], ["the provided lysis buffer", "TREATMENT", 51, 76], ["protease", "TREATMENT", 89, 97], ["phosphatase inhibitor cocktails", "TREATMENT", 102, 133]]], ["The protein concentration of the lysate was quantified by bicinchoninic acid (BCA) assay (Thermo Fisher Scientific) and lysate containing 150 \u03bcg total protein was used for each array.", [["lysate", "ANATOMY", 33, 39], ["bicinchoninic acid", "CHEMICAL", 58, 76], ["BCA", "CHEMICAL", 78, 81], ["bicinchoninic acid", "CHEMICAL", 58, 76], ["BCA", "CHEMICAL", 78, 81], ["bicinchoninic acid", "SIMPLE_CHEMICAL", 58, 76], ["BCA", "SIMPLE_CHEMICAL", 78, 81], ["The protein concentration", "TREATMENT", 0, 25], ["the lysate", "TREATMENT", 29, 39], ["lysate", "TREATMENT", 120, 126]]], ["The array was processed as described by the manufacturer, in brief: the array was incubated with the diluted lysate for 16 h at 4\u02daC on a rocking platform, washed, and incubated with a biotinylated pan EGFR antibody followed by horseradish peroxidase-conjugated streptavidin, and luminescence was detected with X-ray film.", [["lysate", "ANATOMY", 109, 115], ["EGFR", "GENE_OR_GENE_PRODUCT", 201, 205], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 227, 249], ["conjugated streptavidin", "SIMPLE_CHEMICAL", 250, 273], ["EGFR antibody", "PROTEIN", 201, 214], ["horseradish peroxidase", "PROTEIN", 227, 249], ["horseradish", "SPECIES", 227, 238], ["the diluted lysate", "TREATMENT", 97, 115], ["a rocking platform", "TREATMENT", 135, 153], ["a biotinylated pan EGFR antibody", "TREATMENT", 182, 214], ["horseradish peroxidase-conjugated streptavidin", "TREATMENT", 227, 273], ["X-ray film", "TEST", 310, 320]]], ["The films were scanned and spot intensity was quantified by ImageQuant TL (Array Version 8.1., GE Healthcare).", [["The films", "TEST", 0, 9], ["spot intensity", "TEST", 27, 41]]], ["Three independent experiments with two technical replicates each were normalized to the internal array controls and pan EGFR.", [["EGFR", "GENE_OR_GENE_PRODUCT", 120, 124], ["EGFR", "PROTEIN", 120, 124], ["pan EGFR", "TEST", 116, 124]]], ["Values are reported relative to the average signal of Neg. siRNA 1 (for siRNA-transfected) or to mock-treated (for inhibitor-treated), RSV-infected samples.Dextran uptake assay for macropinocytosisFollowing a published procedure [73] , A549 cells on cover slips were transfected with siRNA for 48 h or were treated with indicated chemical compound.", [["samples", "ANATOMY", 148, 155], ["A549 cells", "ANATOMY", 236, 246], ["RSV-infected", "DISEASE", 135, 147], ["Dextran", "CHEMICAL", 156, 163], ["Neg. siRNA 1", "GENE_OR_GENE_PRODUCT", 54, 66], ["RSV", "ORGANISM", 135, 138], ["samples", "CANCER", 148, 155], ["Dextran", "SIMPLE_CHEMICAL", 156, 163], ["A549 cells", "CELL", 236, 246], ["A549 cells", "CELL_LINE", 236, 246], ["RSV", "SPECIES", 135, 138], ["Values", "TEST", 0, 6], ["siRNA", "TEST", 59, 64], ["siRNA", "PROBLEM", 72, 77], ["inhibitor", "TREATMENT", 115, 124], ["RSV", "PROBLEM", 135, 138], ["infected samples", "PROBLEM", 139, 155], ["Dextran uptake assay", "TEST", 156, 176], ["macropinocytosis", "PROBLEM", 181, 197], ["a published procedure", "TREATMENT", 207, 228], ["A549 cells", "PROBLEM", 236, 246], ["cover slips", "TREATMENT", 250, 261], ["siRNA", "TREATMENT", 284, 289], ["infected", "OBSERVATION", 139, 147]]], ["Coincident with transfection or treatment, the cells were serum-starved for 16 h.", [["cells", "ANATOMY", 47, 52], ["serum", "ANATOMY", 58, 63], ["cells", "CELL", 47, 52], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["transfection", "TREATMENT", 16, 28], ["treatment", "TREATMENT", 32, 41], ["serum", "TEST", 58, 63]]], ["The cells were infected with wt RSV (MOI = 5 PFU/cell) in media containing AF568-conjugated dextran (Dextran-AF568; 10,000 MW; Life Technologies), incubated for 5 h at 37\u02daC, and washed and fixed for 16 h with 4% PFA at 4\u02daC. For co-localization experiments, the cells also were stained for ATP1A1, RSV F, and RSV N using specific antibodies as described above.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 49, 53], ["cells", "ANATOMY", 261, 266], ["AF568", "CHEMICAL", 75, 80], ["dextran", "CHEMICAL", 92, 99], ["Dextran-AF568", "CHEMICAL", 101, 114], ["AF568", "CHEMICAL", 75, 80], ["PFA", "CHEMICAL", 212, 215], ["cells", "CELL", 4, 9], ["RSV", "ORGANISM", 32, 35], ["cell", "CELL", 49, 53], ["AF568-conjugated dextran", "SIMPLE_CHEMICAL", 75, 99], ["Dextran-AF568", "SIMPLE_CHEMICAL", 101, 114], ["PFA", "SIMPLE_CHEMICAL", 212, 215], ["4\u02daC", "SIMPLE_CHEMICAL", 219, 222], ["cells", "CELL", 261, 266], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 289, 295], ["RSV F", "GENE_OR_GENE_PRODUCT", 297, 302], ["RSV", "ORGANISM", 308, 311], ["ATP1A1", "PROTEIN", 289, 295], ["RSV F", "PROTEIN", 297, 302], ["RSV N", "PROTEIN", 308, 313], ["specific antibodies", "PROTEIN", 320, 339], ["RSV", "SPECIES", 32, 35], ["RSV", "SPECIES", 297, 300], ["RSV", "SPECIES", 308, 311], ["wt RSV", "TEST", 29, 35], ["MOI", "TEST", 37, 40], ["conjugated dextran (Dextran", "TREATMENT", 81, 108], ["Life Technologies", "TREATMENT", 127, 144], ["4% PFA", "TREATMENT", 209, 215], ["co-localization experiments", "TEST", 228, 255], ["ATP1A1", "TEST", 289, 295], ["RSV F", "TEST", 297, 302], ["infected", "OBSERVATION_MODIFIER", 15, 23]]], ["Nuclei were counterstained with DAPI (300 nM in PBS for 5 min) and mounted on glass slides with ProLong Diamond Antifade mountant.", [["Nuclei", "ANATOMY", 0, 6], ["DAPI", "CHEMICAL", 32, 36], ["DAPI", "CHEMICAL", 32, 36], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["DAPI", "SIMPLE_CHEMICAL", 32, 36], ["DAPI", "TREATMENT", 32, 36]]], ["For each treatment, at least ten random images were acquired, using the mark and find function of the Leica LAS-X image acquisition software, as Z-stacks on a Leica TCS-SP8 confocal microscope (Leica) with a 63x Objective (NA 1.4) and a zoom of 1.0x.", [["TCS", "CHEMICAL", 165, 168], ["each treatment", "TREATMENT", 4, 18], ["software", "TEST", 132, 140], ["Z", "TEST", 145, 146], ["a Leica TCS", "TEST", 157, 168], ["NA", "TEST", 223, 225]]], ["The images were analyzed by batch process with the software Imaris (Version 9.0.0, Bitplane AG).", [["The images", "TEST", 0, 10], ["Version", "TEST", 68, 75]]], ["The DAPI-stained nuclei were detected as spots to count the number of cells per field.", [["nuclei", "ANATOMY", 17, 23], ["cells", "ANATOMY", 70, 75], ["DAPI", "CHEMICAL", 4, 8], ["DAPI", "SIMPLE_CHEMICAL", 4, 8], ["nuclei", "CELLULAR_COMPONENT", 17, 23], ["cells", "CELL", 70, 75], ["The DAPI-stained nuclei", "PROBLEM", 0, 23], ["DAPI", "OBSERVATION", 4, 8], ["stained nuclei", "OBSERVATION", 9, 23]]], ["The uptake of dextran was quantified by using the surface function of Imaris to recognize distinct dextran-positive vesicles.", [["surface", "ANATOMY", 50, 57], ["vesicles", "ANATOMY", 116, 124], ["dextran", "CHEMICAL", 14, 21], ["dextran", "CHEMICAL", 99, 106], ["dextran", "SIMPLE_CHEMICAL", 14, 21], ["Imaris", "SIMPLE_CHEMICAL", 70, 76], ["dextran", "SIMPLE_CHEMICAL", 99, 106], ["vesicles", "CELLULAR_COMPONENT", 116, 124], ["dextran", "TREATMENT", 14, 21], ["uptake", "OBSERVATION_MODIFIER", 4, 10], ["distinct", "OBSERVATION_MODIFIER", 90, 98], ["dextran", "OBSERVATION", 99, 106], ["positive vesicles", "OBSERVATION", 107, 124]]], ["The total intensity of dextran-AF568 within the created surfaces, which had a volume larger than 1.0 \u03bcm 3 , of one field was normalized to the number of nuclei per field.", [["nuclei", "ANATOMY", 153, 159], ["dextran-AF568", "CHEMICAL", 23, 36], ["dextran-AF568", "SIMPLE_CHEMICAL", 23, 36], ["nuclei", "CELLULAR_COMPONENT", 153, 159], ["dextran", "TREATMENT", 23, 30], ["a volume", "TEST", 76, 84], ["total", "OBSERVATION_MODIFIER", 4, 9], ["intensity", "OBSERVATION_MODIFIER", 10, 19], ["surfaces", "OBSERVATION_MODIFIER", 56, 64], ["volume", "OBSERVATION_MODIFIER", 78, 84], ["larger", "OBSERVATION_MODIFIER", 85, 91], ["number", "OBSERVATION_MODIFIER", 143, 149]]], ["The values were reported relative to Neg. siRNA 1-transfected or mock treated cells that had been infected with RSV.", [["cells", "ANATOMY", 78, 83], ["cells", "CELL", 78, 83], ["RSV", "ORGANISM", 112, 115], ["mock treated cells", "CELL_LINE", 65, 83], ["RSV", "SPECIES", 112, 115], ["The values", "TEST", 0, 10], ["siRNA", "TEST", 42, 47], ["mock treated cells", "TREATMENT", 65, 83], ["RSV", "PROBLEM", 112, 115]]], ["For each experiment a total of at least 600 cells per condition were analyzed.Ethics statementAll animal studies were approved by the NIH Institutional Animal Care and Use Committee (IACUC) under the animal study protocol number LID 34E.", [["cells", "ANATOMY", 44, 49], ["LID", "DISEASE", 229, 232], ["cells", "CELL", 44, 49], ["All animal studies", "TEST", 94, 112]]], ["The National Research Council's Guide for the care and use of laboratory animals and the Public Health Service Policy on humane care and use of laboratory animals served as the guidelines for the care and use of mice in this study.Ethics statementThe primary HSAEC and HAE-ALI cells were obtained from the American Type Culture Collection (ATCC) and MatTek Corporation, respectively.", [["primary HSAEC", "ANATOMY", 251, 264], ["HAE-ALI cells", "ANATOMY", 269, 282], ["HAE", "DISEASE", 269, 272], ["ALI", "DISEASE", 273, 276], ["mice", "ORGANISM", 212, 216], ["HSAEC", "CELL", 259, 264], ["HAE-ALI cells", "CELL", 269, 282], ["primary HSAEC", "CELL_TYPE", 251, 264], ["HAE-ALI cells", "CELL_LINE", 269, 282], ["mice", "SPECIES", 212, 216], ["mice", "SPECIES", 212, 216], ["humane care", "TREATMENT", 121, 132], ["this study", "TEST", 220, 230], ["The primary HSAEC", "TEST", 247, 264], ["HAE", "PROBLEM", 269, 272], ["ALI cells", "PROBLEM", 273, 282], ["ALI cells", "OBSERVATION", 273, 282]]], ["The cells were isolated under informed consent and conform to HIPAA standards to protect the privacy of the donor's personal health information.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9]]], ["The research with these human cells is not considered human subjects research because the cells are publicly available and therefore was exempt from 45 CFR Part 46 and no Institutional Review Board (IRB) approval was required.Ethics statementSupporting information S1 Table.", [["cells", "ANATOMY", 30, 35], ["cells", "ANATOMY", 90, 95], ["human", "ORGANISM", 24, 29], ["cells", "CELL", 30, 35], ["human", "ORGANISM", 54, 59], ["cells", "CELL", 90, 95], ["human cells", "CELL_TYPE", 24, 35], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 54, 59], ["these human cells", "TREATMENT", 18, 35]]], ["Summary of the primary siRNA screen.", [["the primary siRNA screen", "TEST", 11, 35]]], ["The expression knock-down siRNA screen was performed by transfecting A549 cells, engineered to express DsRed as a viability marker, with the Ambion Silencer Select Genome-wide siRNA library V4 targeting 21,566 genes, with three independent siRNAs per gene evaluated individually.", [["A549 cells", "ANATOMY", 69, 79], ["A549 cells", "CELL", 69, 79], ["DsRed", "GENE_OR_GENE_PRODUCT", 103, 108], ["A549 cells", "CELL_LINE", 69, 79], ["DsRed", "PROTEIN", 103, 108], ["Ambion Silencer Select Genome-wide siRNA library V4", "DNA", 141, 192], ["21,566 genes", "DNA", 203, 215], ["The expression knock", "TEST", 0, 20], ["siRNA screen", "TEST", 26, 38], ["the Ambion Silencer", "TREATMENT", 137, 156]]], ["Forty-eight h post-transfection the cells were infected with 1 PFU/cell of RSV-GFP.", [["cells", "ANATOMY", 36, 41], ["cell", "ANATOMY", 67, 71], ["cells", "CELL", 36, 41], ["cell", "CELL", 67, 71], ["RSV", "ORGANISM", 75, 78], ["GFP", "GENE_OR_GENE_PRODUCT", 79, 82], ["RSV", "SPECIES", 75, 78], ["transfection the cells", "PROBLEM", 19, 41], ["RSV", "TEST", 75, 78]]], ["The effect of knock-down on GFP expression was measured 48 h post-infection, and the data analyzed as previously described [67] .", [["GFP", "GENE_OR_GENE_PRODUCT", 28, 31], ["GFP", "PROTEIN", 28, 31], ["GFP expression", "TEST", 28, 42], ["infection", "PROBLEM", 66, 75], ["the data", "TEST", 81, 89], ["infection", "OBSERVATION", 66, 75]]], ["The median seed corrected Z-scores for all the tested targets is shown.", [["seed", "ANATOMY", 11, 15]]], ["(D) Cell viability.", [["Cell", "ANATOMY", 4, 8], ["Cell", "CELL", 4, 8], ["Cell viability", "OBSERVATION", 4, 18]]], ["An ATP-based cell viability assay [CellTiter-Glo (Promega)] was performed 72 h p.t. to evaluate the viability of the transfected cells.", [["cell", "ANATOMY", 13, 17], ["cells", "ANATOMY", 129, 134], ["ATP", "CHEMICAL", 3, 6], ["ATP", "CHEMICAL", 3, 6], ["ATP", "SIMPLE_CHEMICAL", 3, 6], ["cell", "CELL", 13, 17], ["CellTiter-Glo", "SIMPLE_CHEMICAL", 35, 48], ["Promega", "ORGANISM", 50, 57], ["cells", "CELL", 129, 134], ["transfected cells", "CELL_LINE", 117, 134], ["An ATP", "TEST", 0, 6], ["based cell viability assay", "TEST", 7, 33], ["CellTiter", "TEST", 35, 44], ["cell viability", "OBSERVATION", 13, 27], ["transfected cells", "OBSERVATION", 117, 134]]], ["Cells were lysed, the ATP concentration was determined by ATP-dependent luciferase activity, which was detected with an ELISA reader, and the viability was reported relative to mock-transfected cells assigned the value of 1.0.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 194, 199], ["ATP", "CHEMICAL", 22, 25], ["ATP", "CHEMICAL", 58, 61], ["ATP", "CHEMICAL", 22, 25], ["ATP", "CHEMICAL", 58, 61], ["Cells", "CELL", 0, 5], ["ATP", "SIMPLE_CHEMICAL", 22, 25], ["ATP", "SIMPLE_CHEMICAL", 58, 61], ["luciferase", "GENE_OR_GENE_PRODUCT", 72, 82], ["cells", "CELL", 194, 199], ["luciferase", "PROTEIN", 72, 82], ["mock-transfected cells", "CELL_LINE", 177, 199], ["Cells", "TEST", 0, 5], ["the ATP concentration", "TEST", 18, 39], ["ATP-dependent luciferase activity", "PROBLEM", 58, 91], ["an ELISA reader", "TEST", 117, 132], ["the viability", "TEST", 138, 151], ["luciferase activity", "OBSERVATION", 72, 91]]], ["(TIF) S2 Fig. ATP1A1 clustering induced by UV-inactivated RSV.", [["UV", "CHEMICAL", 43, 45], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 14, 20], ["RSV", "ORGANISM", 58, 61], ["ATP1A1", "PROTEIN", 14, 20], ["RSV", "SPECIES", 58, 61], ["RSV", "PROBLEM", 58, 61], ["S2 Fig", "OBSERVATION", 6, 12]]], ["A549 cells were inoculated (MOI = 5 PFU/cell) as described for Fig 3 and incubated for 5 h.", [["A549 cells", "ANATOMY", 0, 10], ["cell", "ANATOMY", 40, 44], ["A549 cells", "CELL", 0, 10], ["cell", "CELL", 40, 44], ["A549 cells", "CELL_LINE", 0, 10], ["A549 cells", "PROBLEM", 0, 10], ["MOI", "TEST", 28, 31]]], ["The UV wt RSV inoculum was UV-inactivated by 0.5 J/cm 2 UV radiation using a Stratalinker UV Crosslinker 1800 (Agilent).", [["RSV", "ORGANISM", 10, 13], ["RSV", "SPECIES", 10, 13], ["The UV wt RSV inoculum", "TREATMENT", 0, 22], ["0.5 J/cm 2 UV radiation", "TREATMENT", 45, 68], ["a Stratalinker UV Crosslinker", "TREATMENT", 75, 104], ["RSV inoculum", "OBSERVATION", 10, 22]]], ["Total inactivation of the inoculum was confirmed by plaque titration on Vero cells.", [["plaque", "ANATOMY", 52, 58], ["Vero cells", "ANATOMY", 72, 82], ["Vero cells", "CELL", 72, 82], ["Vero cells", "CELL_LINE", 72, 82], ["Total inactivation of the inoculum", "TREATMENT", 0, 34], ["plaque titration", "TREATMENT", 52, 68], ["Vero cells", "TREATMENT", 72, 82], ["plaque", "OBSERVATION", 52, 58], ["Vero cells", "OBSERVATION", 72, 82]]], ["Cells were subjected to immunofluorescence staining for ATP1A1 (AF488, green), RSV-N (AF568, red), and counterstained the nuclei with DAPI (blue).", [["Cells", "ANATOMY", 0, 5], ["nuclei", "ANATOMY", 122, 128], ["DAPI", "CHEMICAL", 134, 138], ["Cells", "CELL", 0, 5], ["ATP1A1", "GENE_OR_GENE_PRODUCT", 56, 62], ["AF488", "SIMPLE_CHEMICAL", 64, 69], ["RSV", "ORGANISM", 79, 82], ["AF568", "SIMPLE_CHEMICAL", 86, 91], ["nuclei", "CELLULAR_COMPONENT", 122, 128], ["DAPI", "SIMPLE_CHEMICAL", 134, 138], ["ATP1A1", "PROTEIN", 56, 62], ["AF568", "PROTEIN", 86, 91], ["RSV", "SPECIES", 79, 82], ["immunofluorescence staining", "TEST", 24, 51], ["ATP1A1", "TEST", 56, 62], ["AF488", "TEST", 64, 69], ["RSV", "TEST", 79, 82], ["nuclei", "ANATOMY", 122, 128]]], ["The image was acquired as described for", [["The image", "TEST", 0, 9]]]], "PMC280685": [["BackgroundAlthough the existence of tripeptidyl-peptidase I (TPP-I) was first noted over 40 years ago [1], the structural and mechanistic basis of its activity has been largely misunderstood until quite recently.", [["tripeptidyl", "CHEMICAL", 36, 47], ["tripeptidyl-peptidase I", "GENE_OR_GENE_PRODUCT", 36, 59], ["TPP-I", "GENE_OR_GENE_PRODUCT", 61, 66], ["tripeptidyl-peptidase I", "PROTEIN", 36, 59], ["TPP-I", "PROTEIN", 61, 66]]], ["The situation changed after it was shown that TPP-I is identical to an independently characterized enzyme named CLN2.", [["TPP", "CHEMICAL", 46, 49], ["TPP-I", "GENE_OR_GENE_PRODUCT", 46, 51], ["CLN2", "GENE_OR_GENE_PRODUCT", 112, 116], ["TPP-I", "PROTEIN", 46, 51], ["enzyme", "PROTEIN", 99, 105], ["CLN2", "DNA", 112, 116]]], ["It was also demonstrated that mutations leading to abolishment of the enzymatic activity of CLN2 were the direct cause of a fatal inherited neurodegenerative disease, classical late-infantile neuronal ceroid lipofuscinosis [2].", [["neuronal", "ANATOMY", 192, 200], ["neurodegenerative disease", "DISEASE", 140, 165], ["ceroid lipofuscinosis", "DISEASE", 201, 222], ["CLN2", "GENE_OR_GENE_PRODUCT", 92, 96], ["neuronal", "CELL", 192, 200], ["CLN2", "DNA", 92, 96], ["mutations", "PROBLEM", 30, 39], ["the enzymatic activity of CLN2", "PROBLEM", 66, 96], ["a fatal inherited neurodegenerative disease", "PROBLEM", 122, 165], ["infantile neuronal ceroid lipofuscinosis", "PROBLEM", 182, 222], ["fatal", "OBSERVATION_MODIFIER", 124, 129], ["neurodegenerative disease", "OBSERVATION", 140, 165], ["ceroid lipofuscinosis", "OBSERVATION", 201, 222]]], ["This important observation was followed by the identification of CLN2 as a serine peptidase [3,4], without, however, specifying its structural fold and the details of the catalytic site.", [["serine", "CHEMICAL", 75, 81], ["CLN2", "GENE_OR_GENE_PRODUCT", 65, 69], ["CLN2", "DNA", 65, 69], ["serine peptidase", "PROTEIN", 75, 91], ["catalytic site", "PROTEIN", 171, 185], ["a serine peptidase", "TEST", 73, 91]]], ["More accurate placement of CLN2 within the context of a family of related enzymes became possible only after high-resolution crystal structures of two bacterial enzymes with a limited sequence similarity to CLN2, sedolisin and kumamolisin, became available [5-7].", [["sedolisin", "CHEMICAL", 213, 222], ["kumamolisin", "CHEMICAL", 227, 238], ["kumamolisin", "CHEMICAL", 227, 238], ["CLN2", "GENE_OR_GENE_PRODUCT", 27, 31], ["CLN2", "GENE_OR_GENE_PRODUCT", 207, 211], ["sedolisin", "GENE_OR_GENE_PRODUCT", 213, 222], ["kumamolisin", "SIMPLE_CHEMICAL", 227, 238], ["CLN2", "DNA", 27, 31], ["enzymes", "PROTEIN", 74, 81], ["bacterial enzymes", "PROTEIN", 151, 168], ["CLN2", "DNA", 207, 211], ["two bacterial enzymes", "TEST", 147, 168], ["CLN2", "TEST", 207, 211], ["sedolisin", "TREATMENT", 213, 222], ["kumamolisin", "TREATMENT", 227, 238]]], ["These structures defined a novel family of enzymes, now called sedolisins or serine-carboxyl peptidases, that is characterized by the utilization of a fully conserved catalytic triad (Ser, Glu, Asp) and by the presence of an Asp in the oxyanion hole [8].", [["sedolisins", "CHEMICAL", 63, 73], ["serine", "CHEMICAL", 77, 83], ["carboxyl", "CHEMICAL", 84, 92], ["Ser", "CHEMICAL", 184, 187], ["Glu", "CHEMICAL", 189, 192], ["Asp", "CHEMICAL", 194, 197], ["Asp", "CHEMICAL", 225, 228], ["sedolisins", "GENE_OR_GENE_PRODUCT", 63, 73], ["serine-carboxyl peptidases", "SIMPLE_CHEMICAL", 77, 103], ["Ser", "AMINO_ACID", 184, 187], ["Glu", "AMINO_ACID", 189, 192], ["Asp", "AMINO_ACID", 194, 197], ["Asp", "AMINO_ACID", 225, 228], ["enzymes", "PROTEIN", 43, 50], ["sedolisins", "PROTEIN", 63, 73], ["serine-carboxyl peptidases", "PROTEIN", 77, 103], ["catalytic triad", "PROTEIN", 167, 182], ["enzymes", "TEST", 43, 50], ["serine-carboxyl peptidases", "TREATMENT", 77, 103], ["Asp", "TEST", 194, 197], ["an Asp in the oxyanion hole", "TREATMENT", 222, 249], ["Asp", "OBSERVATION", 225, 228]]], ["Sedolisin and its several variants (e.g., kumamolisin, aorsin [9], and physarolisin [10]) have now been found in archaea, bacteria, fungi and amoebae, whereas the higher organisms seem to contain only variants of CLN2 [8].", [["Sedolisin", "CHEMICAL", 0, 9], ["kumamolisin", "CHEMICAL", 42, 53], ["aorsin [9], and physarolisin [10]", "CHEMICAL", 55, 88], ["Sedolisin", "CHEMICAL", 0, 9], ["physarolisin", "CHEMICAL", 71, 83], ["Sedolisin", "GENE_OR_GENE_PRODUCT", 0, 9], ["kumamolisin", "GENE_OR_GENE_PRODUCT", 42, 53], ["aorsin [9]", "GENE_OR_GENE_PRODUCT", 55, 65], ["physarolisin [10]", "SIMPLE_CHEMICAL", 71, 88], ["CLN2 [8]", "GENE_OR_GENE_PRODUCT", 213, 221], ["CLN2", "DNA", 213, 217], ["Sedolisin", "TREATMENT", 0, 9], ["kumamolisin", "TREATMENT", 42, 53], ["physarolisin", "TREATMENT", 71, 83], ["archaea", "PROBLEM", 113, 120], ["bacteria", "PROBLEM", 122, 130], ["fungi", "PROBLEM", 132, 137], ["amoebae", "PROBLEM", 142, 149], ["the higher organisms", "PROBLEM", 159, 179]]], ["The physiological role of sedolisins in the lower organisms has not yet been elucidated.BackgroundDespite the potential medical importance of CLN2 and related enzymes, no systematic studies of their genomic distribution have been published to date.", [["sedolisins", "CHEMICAL", 26, 36], ["sedolisins", "CHEMICAL", 26, 36], ["sedolisins", "GENE_OR_GENE_PRODUCT", 26, 36], ["CLN2", "GENE_OR_GENE_PRODUCT", 142, 146], ["CLN2", "DNA", 142, 146], ["enzymes", "PROTEIN", 159, 166], ["sedolisins in the lower organisms", "PROBLEM", 26, 59], ["CLN2", "PROBLEM", 142, 146], ["related enzymes", "TEST", 151, 166], ["systematic studies", "TEST", 171, 189]]], ["There are also no published reports of the crystallization of this enzyme.", [["enzyme", "PROTEIN", 67, 73], ["this enzyme", "TEST", 62, 73]]], ["In the absence of an experimental structure obtained by crystallography or NMR it is sometimes necessary to resort to molecular modeling in order to provide a structural basis for the explanation of the biological properties of an enzyme, and, in particular, to initiate design of its inhibitors.", [["an enzyme", "TEST", 228, 237], ["its inhibitors", "TREATMENT", 281, 295]]], ["Examples of such very successful and useful modeling efforts are provided by HIV protease [11], or very recently by the peptidase from a coronavirus involved in the severe acute respiratory syndrome [12], among others.", [["coronavirus", "DISEASE", 137, 148], ["acute respiratory syndrome", "DISEASE", 172, 198], ["peptidase", "PROTEIN", 120, 129], ["coronavirus", "SPECIES", 137, 148], ["HIV", "SPECIES", 77, 80], ["a coronavirus", "PROBLEM", 135, 148], ["the severe acute respiratory syndrome", "PROBLEM", 161, 198], ["coronavirus", "OBSERVATION", 137, 148], ["severe", "OBSERVATION_MODIFIER", 165, 171], ["acute", "OBSERVATION_MODIFIER", 172, 177], ["respiratory syndrome", "OBSERVATION", 178, 198]]], ["We have now applied the tools of molecular homology modeling to predicting a structure of CLN2 that could be used as a basis for a search for the biological substrates of this family of enzymes and for the design of specific inhibitors.Sequence comparisons of the CLN2-like enzymes ::: Results and discussionMammalian enzymes homologous to human CLN2 [2,4] form a subfamily of sedolisins with highly conserved sequences (Figure 1).", [["CLN2", "GENE_OR_GENE_PRODUCT", 90, 94], ["CLN2", "GENE_OR_GENE_PRODUCT", 264, 268], ["human", "ORGANISM", 340, 345], ["CLN2", "GENE_OR_GENE_PRODUCT", 346, 350], ["sedolisins", "GENE_OR_GENE_PRODUCT", 377, 387], ["CLN2", "DNA", 90, 94], ["enzymes", "PROTEIN", 186, 193], ["CLN2", "DNA", 264, 268], ["enzymes", "PROTEIN", 274, 281], ["Mammalian enzymes", "PROTEIN", 308, 325], ["CLN2", "DNA", 346, 350], ["sedolisins", "PROTEIN", 377, 387], ["highly conserved sequences", "DNA", 393, 419], ["human", "SPECIES", 340, 345], ["human", "SPECIES", 340, 345], ["molecular homology modeling", "PROBLEM", 33, 60], ["enzymes", "TEST", 186, 193], ["specific inhibitors", "TREATMENT", 216, 235], ["Sequence comparisons", "TEST", 236, 256], ["the CLN2", "TEST", 260, 268], ["Mammalian enzymes homologous", "TEST", 308, 336], ["human CLN2", "TEST", 340, 350]]], ["These enzymes are expressed with a prosegment consisting of 195 residues that is cleaved off during maturation, yielding the active catalytic domain.", [["enzymes", "PROTEIN", 6, 13], ["catalytic domain", "PROTEIN", 132, 148], ["These enzymes", "TEST", 0, 13], ["the active catalytic domain", "PROBLEM", 121, 148], ["active", "OBSERVATION_MODIFIER", 125, 131], ["catalytic domain", "OBSERVATION", 132, 148]]], ["Complete sequences are available for CLN2 from six species in which it has been found so far (human, macaque, dog, mouse, rat, and cow).", [["CLN2", "GENE_OR_GENE_PRODUCT", 37, 41], ["human", "ORGANISM", 94, 99], ["macaque", "ORGANISM", 101, 108], ["dog", "ORGANISM", 110, 113], ["mouse", "ORGANISM", 115, 120], ["rat", "ORGANISM", 122, 125], ["cow", "ORGANISM", 131, 134], ["CLN2", "DNA", 37, 41], ["human", "SPECIES", 94, 99], ["dog", "SPECIES", 110, 113], ["mouse", "SPECIES", 115, 120], ["rat", "SPECIES", 122, 125], ["cow", "SPECIES", 131, 134], ["human", "SPECIES", 94, 99], ["mouse", "SPECIES", 115, 120], ["rat", "SPECIES", 122, 125], ["cow", "SPECIES", 131, 134], ["Complete sequences", "TEST", 0, 18], ["CLN2", "PROBLEM", 37, 41]]], ["The full-length enzymes consist of 563 amino acids arranged in a single polypeptide chain containing both the prosegment and the catalytic domain, with the exception of mouse CLN2 that has a single deletion in the prosegment.", [["amino acids", "CHEMICAL", 39, 50], ["amino acids", "CHEMICAL", 39, 50], ["amino acids", "AMINO_ACID", 39, 50], ["mouse", "ORGANISM", 169, 174], ["CLN2", "GENE_OR_GENE_PRODUCT", 175, 179], ["full-length enzymes", "PROTEIN", 4, 23], ["polypeptide chain", "PROTEIN", 72, 89], ["prosegment", "PROTEIN", 110, 120], ["catalytic domain", "PROTEIN", 129, 145], ["mouse CLN2", "PROTEIN", 169, 179], ["mouse", "SPECIES", 169, 174], ["mouse", "SPECIES", 169, 174], ["The full-length enzymes", "TEST", 0, 23], ["amino acids", "TEST", 39, 50], ["a single polypeptide chain", "TREATMENT", 63, 89], ["mouse CLN2", "PROBLEM", 169, 179], ["a single deletion in the prosegment", "PROBLEM", 189, 224], ["catalytic domain", "OBSERVATION", 129, 145], ["mouse CLN2", "OBSERVATION", 169, 179], ["single", "OBSERVATION_MODIFIER", 191, 197], ["deletion", "OBSERVATION", 198, 206], ["prosegment", "ANATOMY_MODIFIER", 214, 224]]], ["The overall sequence identity for these enzymes is 81%, whereas the similarity is 92%.", [["enzymes", "PROTEIN", 40, 47], ["these enzymes", "TEST", 34, 47]]], ["A pairwise comparison of the human and mouse enzymes yields 88% identity and 94% similarity, considerably higher than the median 78.5% identity reported for all identified mouse-human orthologs [13].", [["human", "ORGANISM", 29, 34], ["mouse", "ORGANISM", 39, 44], ["mouse", "ORGANISM", 172, 177], ["human", "ORGANISM", 178, 183], ["human and mouse enzymes", "PROTEIN", 29, 52], ["mouse-human orthologs", "DNA", 172, 193], ["human", "SPECIES", 29, 34], ["mouse", "SPECIES", 39, 44], ["mouse", "SPECIES", 172, 177], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 29, 34], ["mouse", "SPECIES", 39, 44], ["mouse", "SPECIES", 172, 177], ["human", "SPECIES", 178, 183], ["mouse enzymes", "TEST", 39, 52], ["% identity", "TEST", 62, 72]]], ["Thus, mammalian CLN2 appears to be a highly conserved enzyme.Sequence comparisons of the CLN2-like enzymes ::: Results and discussionIn addition to the mammals, CLN2-like enzymes are also found in fugu (puffer fish \u2013 unannotated record SINFRUP00000077297 in the NCBI fugu sequence database, ) and zebrafish (contig wz4596.2 in the zebrafish EST database, ).", [["CLN2", "GENE_OR_GENE_PRODUCT", 16, 20], ["CLN2", "GENE_OR_GENE_PRODUCT", 89, 93], ["CLN2-like enzymes", "GENE_OR_GENE_PRODUCT", 161, 178], ["fugu", "ORGANISM", 197, 201], ["zebrafish", "ORGANISM", 297, 306], ["zebrafish", "ORGANISM", 331, 340], ["mammalian CLN2", "PROTEIN", 6, 20], ["CLN2", "DNA", 89, 93], ["enzymes", "PROTEIN", 99, 106], ["CLN2", "DNA", 161, 165], ["fugu", "DNA", 197, 201], ["puffer fish \u2013 unannotated record SINFRUP00000077297", "DNA", 203, 254], ["NCBI fugu sequence database", "DNA", 262, 289], ["contig wz4596.2", "DNA", 308, 323], ["zebrafish EST database", "DNA", 331, 353], ["zebrafish", "SPECIES", 297, 306], ["NCBI fugu", "SPECIES", 262, 271], ["Sequence comparisons", "TEST", 61, 81], ["the CLN2", "TEST", 85, 93], ["CLN2", "TEST", 161, 165]]], ["Only a fragment of the sequence of the latter enzyme agreed with the former.", [["enzyme", "PROTEIN", 46, 52], ["fragment", "OBSERVATION", 7, 15]]], ["However, a few comparatively minor modifications can bring the zebrafish sequence into good agreement with that of the fugu CLN2.", [["zebrafish", "ORGANISM", 63, 72], ["fugu", "ORGANISM", 119, 123], ["CLN2", "GENE_OR_GENE_PRODUCT", 124, 128], ["zebrafish sequence", "DNA", 63, 81], ["fugu CLN2", "DNA", 119, 128], ["the fugu CLN2", "TEST", 115, 128], ["few", "OBSERVATION_MODIFIER", 11, 14]]], ["These modifications include a deletion of a single nucleotide from a run of three, as well as three insertions of repeated nucleotide pairs (Figure 2).", [["nucleotide", "CHEMICAL", 123, 133], ["nucleotide", "CHEMICAL", 51, 61], ["nucleotide", "CHEMICAL", 123, 133], ["repeated nucleotide pairs", "DNA", 114, 139], ["a single nucleotide", "TREATMENT", 42, 61], ["repeated nucleotide pairs", "PROBLEM", 114, 139]]], ["It must be stressed that these modifications are speculative and may lead to prediction of several incorrect amino acids; however, they bring the two sequences into good global agreement (69% identities and 83% similarities).Sequence comparisons of the CLN2-like enzymes ::: Results and discussionThe available amino acid sequence of the fugu CLN2 analog, named by us sedolisin-TPP [8], is also in good agreement with the sequences of the mammalian orthologs (Figure 3).", [["amino acids", "CHEMICAL", 109, 120], ["amino acid", "CHEMICAL", 311, 321], ["sedolisin-TPP", "CHEMICAL", 368, 381], ["amino acids", "CHEMICAL", 109, 120], ["amino acid", "CHEMICAL", 311, 321], ["sedolisin-TPP", "CHEMICAL", 368, 381], ["amino acids", "AMINO_ACID", 109, 120], ["CLN2", "GENE_OR_GENE_PRODUCT", 253, 257], ["amino acid", "AMINO_ACID", 311, 321], ["CLN2", "GENE_OR_GENE_PRODUCT", 343, 347], ["CLN2", "DNA", 253, 257], ["enzymes", "PROTEIN", 263, 270], ["amino acid sequence", "PROTEIN", 311, 330], ["fugu CLN2 analog", "PROTEIN", 338, 354], ["mammalian orthologs", "DNA", 439, 458], ["several incorrect amino acids", "PROBLEM", 91, 120], ["Sequence comparisons", "TEST", 225, 245], ["the CLN2", "TEST", 249, 257], ["The available amino acid sequence", "TREATMENT", 297, 330]]], ["The only major difference in the translated amino acid sequence compared to the mammalian and zebrafish enzymes is in the amino terminus of the propeptide region that is shorter by 30 amino acids (not shown).", [["amino acid", "CHEMICAL", 44, 54], ["amino acids", "CHEMICAL", 184, 195], ["amino acid", "CHEMICAL", 44, 54], ["amino", "CHEMICAL", 122, 127], ["amino acids", "CHEMICAL", 184, 195], ["amino acid", "AMINO_ACID", 44, 54], ["zebrafish", "ORGANISM", 94, 103], ["amino", "AMINO_ACID", 122, 127], ["amino acids", "AMINO_ACID", 184, 195], ["amino acid sequence", "PROTEIN", 44, 63], ["mammalian and zebrafish enzymes", "PROTEIN", 80, 111], ["amino terminus", "PROTEIN", 122, 136], ["propeptide region", "PROTEIN", 144, 161], ["the translated amino acid sequence", "TEST", 29, 63], ["zebrafish enzymes", "TEST", 94, 111], ["amino acids", "TEST", 184, 195], ["major", "OBSERVATION_MODIFIER", 9, 14], ["difference", "OBSERVATION_MODIFIER", 15, 25], ["amino terminus", "OBSERVATION", 122, 136]]], ["It is very likely that this represents a fault in the assembled sequence rather than a real variation, since the current coding frame is not initiated with a methionine, and a few extra residues are present in the full genomic sequence available from the fugu sequencing consortium .Sequence comparisons of the CLN2-like enzymes ::: Results and discussionCLN2 is present not only in fish, but also in amphibians, in particular in Xenopus tropicalis (a species of frog).", [["methionine", "CHEMICAL", 158, 168], ["methionine", "CHEMICAL", 158, 168], ["methionine", "SIMPLE_CHEMICAL", 158, 168], ["CLN2", "GENE_OR_GENE_PRODUCT", 311, 315], ["discussionCLN2", "GENE_OR_GENE_PRODUCT", 345, 359], ["fish", "ORGANISM_SUBDIVISION", 383, 387], ["Xenopus tropicalis", "ORGANISM", 430, 448], ["frog", "ORGANISM_SUBDIVISION", 463, 467], ["current coding frame", "DNA", 113, 133], ["CLN2", "DNA", 311, 315], ["enzymes", "PROTEIN", 321, 328], ["discussionCLN2", "PROTEIN", 345, 359], ["Xenopus tropicalis", "SPECIES", 430, 448], ["Xenopus tropicalis", "SPECIES", 430, 448], ["a methionine", "TREATMENT", 156, 168], ["a few extra residues", "PROBLEM", 174, 194], ["Sequence comparisons", "TEST", 283, 303], ["the CLN2", "TEST", 307, 315], ["Xenopus tropicalis", "PROBLEM", 430, 448], ["very likely", "UNCERTAINTY", 6, 17], ["fault", "OBSERVATION", 41, 46], ["few", "OBSERVATION_MODIFIER", 176, 179]]], ["A partial sequence of its sedolisin-TPP (AL594774) found in the EST database spans the middle part of the catalytic domain, without reaching the part of the active site closer to the N terminus that contains the aspartic and glutamic acids that belong to the catalytic triad.", [["sedolisin-TPP", "CHEMICAL", 26, 39], ["AL594774", "CHEMICAL", 41, 49], ["glutamic acids", "CHEMICAL", 225, 239], ["TPP", "CHEMICAL", 36, 39], ["AL594774", "CHEMICAL", 41, 49], ["N", "CHEMICAL", 183, 184], ["aspartic and glutamic acids", "CHEMICAL", 212, 239], ["sedolisin-TPP", "GENE_OR_GENE_PRODUCT", 26, 39], ["glutamic acids", "AMINO_ACID", 225, 239], ["sedolisin-TPP", "DNA", 26, 39], ["AL594774", "DNA", 41, 49], ["EST database", "DNA", 64, 76], ["catalytic domain", "PROTEIN", 106, 122], ["N terminus", "PROTEIN", 183, 193], ["catalytic triad", "PROTEIN", 259, 274], ["its sedolisin-TPP", "TREATMENT", 22, 39], ["the EST database", "TEST", 60, 76], ["the aspartic and glutamic acids", "TREATMENT", 208, 239], ["middle", "ANATOMY_MODIFIER", 87, 93], ["catalytic domain", "OBSERVATION", 106, 122], ["active", "OBSERVATION_MODIFIER", 157, 163], ["site", "OBSERVATION", 164, 168]]], ["However, the sequenced part of the enzyme shows 75% identity with the fugu sedolisin-TPP, and 69% identity with human CLN2 (Figure 3).", [["sedolisin-TPP", "GENE_OR_GENE_PRODUCT", 75, 88], ["human", "ORGANISM", 112, 117], ["CLN2", "GENE_OR_GENE_PRODUCT", 118, 122], ["enzyme", "PROTEIN", 35, 41], ["fugu sedolisin", "PROTEIN", 70, 84], ["TPP", "PROTEIN", 85, 88], ["human CLN2", "PROTEIN", 112, 122], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["the enzyme", "TEST", 31, 41], ["the fugu sedolisin", "TEST", 66, 84], ["TPP", "TEST", 85, 88], ["human CLN2", "TEST", 112, 122]]], ["Sequence similarity to bacterial or fungal sedolisins is much lower, indicating that the enzyme found in frogs might also share the functional properties of the CLN2 subfamily.Sequence comparisons of the CLN2-like enzymes ::: Results and discussionThe discovery of highly conserved CLN2-like enzymes not only in mammals but also in two fish species and one of frogs may indicate that these peptidases are universally present in the vertebrates, and that their important role identified in humans [2] and mice [14] might be a more general feature.Modeling of the structure of human CLN2 ::: Results and discussionThe medical importance of CLN2 and the lack of a crystal structure inspired attempts at protein modeling.", [["frogs", "ORGANISM", 105, 110], ["CLN2", "GENE_OR_GENE_PRODUCT", 161, 165], ["CLN2", "GENE_OR_GENE_PRODUCT", 204, 208], ["CLN2", "GENE_OR_GENE_PRODUCT", 282, 286], ["frogs", "ORGANISM", 360, 365], ["humans", "ORGANISM", 489, 495], ["mice", "ORGANISM", 504, 508], ["human", "ORGANISM", 575, 580], ["CLN2", "GENE_OR_GENE_PRODUCT", 581, 585], ["CLN2", "GENE_OR_GENE_PRODUCT", 638, 642], ["CLN2 subfamily", "PROTEIN", 161, 175], ["CLN2", "DNA", 204, 208], ["enzymes", "PROTEIN", 214, 221], ["CLN2", "DNA", 282, 286], ["peptidases", "PROTEIN", 390, 400], ["human CLN2", "PROTEIN", 575, 585], ["CLN2", "DNA", 638, 642], ["humans", "SPECIES", 489, 495], ["mice", "SPECIES", 504, 508], ["human", "SPECIES", 575, 580], ["humans", "SPECIES", 489, 495], ["human", "SPECIES", 575, 580], ["bacterial or fungal sedolisins", "TEST", 23, 53], ["the enzyme", "TEST", 85, 95], ["Sequence comparisons", "TEST", 176, 196], ["the CLN2", "TEST", 200, 208], ["highly conserved CLN2-like enzymes", "PROBLEM", 265, 299], ["two fish species", "PROBLEM", 332, 348], ["these peptidases", "PROBLEM", 384, 400], ["CLN2", "PROBLEM", 638, 642], ["a crystal structure", "PROBLEM", 659, 678], ["fungal", "OBSERVATION", 36, 42], ["CLN2", "OBSERVATION", 282, 286], ["human CLN2", "OBSERVATION", 575, 585]]], ["The first such model assumed that this enzyme is membrane-bound, with the sequence 271\u2013294 (numbering corresponding to the mature enzyme, Figure 1) forming the putative transmembrane anchor [15].", [["membrane", "ANATOMY", 49, 57], ["transmembrane", "ANATOMY", 169, 182], ["membrane", "CELLULAR_COMPONENT", 49, 57], ["transmembrane", "CELLULAR_COMPONENT", 169, 182], ["mature enzyme", "PROTEIN", 123, 136], ["Figure 1", "PROTEIN", 138, 146], ["this enzyme", "TEST", 34, 45], ["the sequence", "TEST", 70, 82]]], ["However, in view of the subsequently obtained structures of the fully water-soluble sedolisins, this model was clearly incorrect.", [["sedolisins", "CHEMICAL", 84, 94], ["sedolisins", "SIMPLE_CHEMICAL", 84, 94], ["the fully water-soluble sedolisins", "TREATMENT", 60, 94]]], ["Exploiting the sequence similarity between CLN2, sedolisin, and kumamolisin (Figure 4), we have now used the experimentally obtained structures of the latter two enzymes to form a new, homology-derived model of human CLN2.", [["kumamolisin", "CHEMICAL", 64, 75], ["kumamolisin", "CHEMICAL", 64, 75], ["CLN2", "GENE_OR_GENE_PRODUCT", 43, 47], ["sedolisin", "GENE_OR_GENE_PRODUCT", 49, 58], ["kumamolisin", "GENE_OR_GENE_PRODUCT", 64, 75], ["human", "ORGANISM", 211, 216], ["CLN2", "GENE_OR_GENE_PRODUCT", 217, 221], ["CLN2", "DNA", 43, 47], ["sedolisin", "DNA", 49, 58], ["enzymes", "PROTEIN", 162, 169], ["human CLN2", "PROTEIN", 211, 221], ["human", "SPECIES", 211, 216], ["human", "SPECIES", 211, 216], ["CLN2", "TEST", 43, 47], ["sedolisin", "TREATMENT", 49, 58]]], ["The primary basis of the homology model was the structure of a complex of sedolisin with a covalently-bound inhibitor, pseudo-iodotyrostatin.", [["sedolisin", "CHEMICAL", 74, 83], ["pseudo-iodotyrostatin", "CHEMICAL", 119, 140], ["sedolisin", "CHEMICAL", 74, 83], ["pseudo-iodotyrostatin", "CHEMICAL", 119, 140], ["sedolisin", "SIMPLE_CHEMICAL", 74, 83], ["pseudo-iodotyrostatin", "SIMPLE_CHEMICAL", 119, 140], ["sedolisin", "TREATMENT", 74, 83], ["a covalently-bound inhibitor", "TREATMENT", 89, 117], ["pseudo", "PROBLEM", 119, 125], ["iodotyrostatin", "TREATMENT", 126, 140]]], ["Although it has not been directly shown that this compound can inhibit human CLN2, other similar peptides with an aldehyde functionality on their \"C-termini\" are weak, but detectable, inhibitors of this enzyme (Oda, unpublished).", [["aldehyde", "CHEMICAL", 114, 122], ["aldehyde", "CHEMICAL", 114, 122], ["C", "CHEMICAL", 147, 148], ["human", "ORGANISM", 71, 76], ["CLN2", "GENE_OR_GENE_PRODUCT", 77, 81], ["aldehyde", "SIMPLE_CHEMICAL", 114, 122], ["human CLN2", "PROTEIN", 71, 81], ["enzyme", "PROTEIN", 203, 209], ["Oda", "PROTEIN", 211, 214], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["human CLN2", "PROBLEM", 71, 81], ["weak", "PROBLEM", 162, 166], ["this enzyme", "TEST", 198, 209]]], ["It is thus likely that pseudo-iodotyrostatin or a similar inhibitor might work for CLN2 as well, although the actual contacts between the inhibitor and the enzyme that are seen in the model have to be treated with caution.", [["pseudo-iodotyrostatin", "CHEMICAL", 23, 44], ["pseudo-iodotyrostatin", "CHEMICAL", 23, 44], ["pseudo-iodotyrostatin", "SIMPLE_CHEMICAL", 23, 44], ["CLN2", "GENE_OR_GENE_PRODUCT", 83, 87], ["CLN2", "DNA", 83, 87], ["pseudo-iodotyrostatin", "TREATMENT", 23, 44], ["a similar inhibitor", "TREATMENT", 48, 67], ["CLN2", "PROBLEM", 83, 87], ["the inhibitor", "TREATMENT", 134, 147], ["the enzyme", "TEST", 152, 162], ["caution", "TREATMENT", 214, 221], ["thus likely", "UNCERTAINTY", 6, 17]]], ["Another reason for the modeling of a pseudo-iodotyrostatin complex is that CLN2 is a tripeptidase, and that this inhibitor it represents the only experimental structure of a tripeptide analog bound to sedolisin.Modeling of the structure of human CLN2 ::: Results and discussionThe r.m.s. deviation between the corresponding C\u03b1 coordinates of the model of CLN2 (Figure 5) and the experimental structure of sedolisin is about 1.75 \u00c5, not much larger than the experimental difference between sedolisin and kumamolisin.", [["sedolisin", "CHEMICAL", 201, 210], ["sedolisin", "CHEMICAL", 405, 414], ["sedolisin", "CHEMICAL", 489, 498], ["kumamolisin", "CHEMICAL", 503, 514], ["-iodotyrostatin", "CHEMICAL", 43, 58], ["tripeptide", "CHEMICAL", 174, 184], ["sedolisin", "CHEMICAL", 201, 210], ["sedolisin", "CHEMICAL", 405, 414], ["sedolisin", "CHEMICAL", 489, 498], ["kumamolisin", "CHEMICAL", 503, 514], ["-iodotyrostatin", "GENE_OR_GENE_PRODUCT", 43, 58], ["CLN2", "GENE_OR_GENE_PRODUCT", 75, 79], ["sedolisin", "SIMPLE_CHEMICAL", 201, 210], ["human", "ORGANISM", 240, 245], ["CLN2", "GENE_OR_GENE_PRODUCT", 246, 250], ["CLN2", "GENE_OR_GENE_PRODUCT", 355, 359], ["sedolisin", "SIMPLE_CHEMICAL", 405, 414], ["sedolisin", "SIMPLE_CHEMICAL", 489, 498], ["kumamolisin", "SIMPLE_CHEMICAL", 503, 514], ["-iodotyrostatin complex", "PROTEIN", 43, 66], ["CLN2", "PROTEIN", 75, 79], ["human CLN2", "PROTEIN", 240, 250], ["C\u03b1 coordinates", "PROTEIN", 324, 338], ["CLN2", "PROTEIN", 355, 359], ["Figure 5", "PROTEIN", 361, 369], ["human", "SPECIES", 240, 245], ["human", "SPECIES", 240, 245], ["a pseudo-iodotyrostatin complex", "PROBLEM", 35, 66], ["this inhibitor", "TREATMENT", 108, 122], ["a tripeptide analog bound", "PROBLEM", 172, 197], ["sedolisin", "TREATMENT", 201, 210], ["The r.m.s. deviation", "TEST", 277, 297], ["sedolisin", "TREATMENT", 489, 498], ["kumamolisin", "TREATMENT", 503, 514], ["human CLN2", "OBSERVATION", 240, 250], ["larger", "OBSERVATION_MODIFIER", 441, 447]]], ["Interestingly, the Cys327 and Cys342 residues in the model were found to be ideally positioned to form a disulfide bond even though this was not part of the design strategy.", [["Cys327", "CHEMICAL", 19, 25], ["Cys342", "CHEMICAL", 30, 36], ["disulfide", "CHEMICAL", 105, 114], ["Cys327", "GENE_OR_GENE_PRODUCT", 19, 25], ["the Cys327", "TEST", 15, 25], ["a disulfide bond", "TREATMENT", 103, 119]]], ["That this bond likely occurs in the real protein is suggested by the fact that these two cysteines are strictly conserved in all known animal species of CLN2 (Figures 1 and 3), although they are absent in all known sequences of bacterial sedolisins.", [["cysteines", "CHEMICAL", 89, 98], ["CLN2 (Figures 1", "GENE_OR_GENE_PRODUCT", 153, 168], ["3", "GENE_OR_GENE_PRODUCT", 173, 174], ["sedolisins", "GENE_OR_GENE_PRODUCT", 238, 248], ["CLN2", "DNA", 153, 157], ["these two cysteines", "PROBLEM", 79, 98], ["Figures", "TEST", 159, 166], ["bacterial sedolisins", "PROBLEM", 228, 248], ["cysteines", "OBSERVATION", 89, 98], ["absent", "OBSERVATION", 195, 201], ["bacterial sedolisins", "OBSERVATION", 228, 248]]], ["Thus, if this disulfide were experimentally found to exist in CLN2 it would provide support for the correctness of the model.Comparisons of the substrate binding pockets of CLN2 and sedolisin ::: Results and discussionSince the principal known activity of CLN2 is that of a tripeptidase, it is expected that three substrate-binding pockets, S1 through S3 (using the nomenclature of Schechter and Berger [16]), should be discernible.", [["sedolisin", "CHEMICAL", 182, 191], ["disulfide", "CHEMICAL", 14, 23], ["sedolisin", "CHEMICAL", 182, 191], ["CLN2", "GENE_OR_GENE_PRODUCT", 62, 66], ["CLN2", "GENE_OR_GENE_PRODUCT", 173, 177], ["sedolisin", "SIMPLE_CHEMICAL", 182, 191], ["CLN2", "GENE_OR_GENE_PRODUCT", 256, 260], ["tripeptidase", "GENE_OR_GENE_PRODUCT", 274, 286], ["CLN2", "DNA", 62, 66], ["substrate binding pockets", "PROTEIN", 144, 169], ["CLN2", "DNA", 173, 177], ["CLN2", "DNA", 256, 260], ["tripeptidase", "PROTEIN", 274, 286], ["S1", "PROTEIN", 341, 343], ["S3", "PROTEIN", 352, 354], ["three substrate-binding pockets", "PROBLEM", 308, 339], ["binding pockets", "OBSERVATION", 324, 339]]], ["Residues P1-P3 of the inhibitor that should occupy these pockets are shown in Figure 6.", [["the inhibitor", "TREATMENT", 18, 31], ["pockets", "OBSERVATION", 57, 64]]], ["All the available structures of the complexes of either sedolisin or kumamolisin with inhibitors contain either a tyrosine or a phenylalanine occupying the S1 pocket.", [["sedolisin", "CHEMICAL", 56, 65], ["kumamolisin", "CHEMICAL", 69, 80], ["tyrosine", "CHEMICAL", 114, 122], ["phenylalanine", "CHEMICAL", 128, 141], ["sedolisin", "CHEMICAL", 56, 65], ["kumamolisin", "CHEMICAL", 69, 80], ["tyrosine", "CHEMICAL", 114, 122], ["phenylalanine", "CHEMICAL", 128, 141], ["sedolisin", "SIMPLE_CHEMICAL", 56, 65], ["kumamolisin", "SIMPLE_CHEMICAL", 69, 80], ["tyrosine", "AMINO_ACID", 114, 122], ["phenylalanine", "AMINO_ACID", 128, 141], ["S1 pocket", "PROTEIN", 156, 165], ["sedolisin", "TREATMENT", 56, 65], ["kumamolisin", "TREATMENT", 69, 80], ["inhibitors", "TREATMENT", 86, 96], ["a tyrosine", "TREATMENT", 112, 122], ["a phenylalanine occupying the S1 pocket", "PROBLEM", 126, 165], ["S1 pocket", "OBSERVATION", 156, 165]]], ["Parts of this pocket are fully conserved among different sedolisins, whereas other parts of it differ.", [["sedolisins", "GENE_OR_GENE_PRODUCT", 57, 67], ["this pocket", "PROBLEM", 9, 20], ["pocket", "OBSERVATION", 14, 20]]], ["The right-hand side of the pocket (in the view used in Figure 6) is made of the main chain including residues 164\u2013165 (unless otherwise indicated, the numbering refers to the sequence of the mature human CLN2).", [["right-hand", "ANATOMY", 4, 14], ["human", "ORGANISM", 198, 203], ["CLN2", "GENE_OR_GENE_PRODUCT", 204, 208], ["mature human CLN2", "PROTEIN", 191, 208], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 198, 203], ["right", "ANATOMY_MODIFIER", 4, 9], ["hand side", "ANATOMY_MODIFIER", 10, 19], ["pocket", "OBSERVATION", 27, 33], ["main", "ANATOMY_MODIFIER", 80, 84], ["chain", "ANATOMY_MODIFIER", 85, 90]]], ["This part of the main chain is held in place through a hydrogen-bonded interaction with the side chain of Thr279, part of the signature sequence SGTSAS surrounding the catalytic Ser280 and its equivalents in the other enzymes.", [["hydrogen", "CHEMICAL", 55, 63], ["hydrogen", "CHEMICAL", 55, 63], ["Thr279", "CHEMICAL", 106, 112], ["Ser280", "CHEMICAL", 178, 184], ["Thr279", "GENE_OR_GENE_PRODUCT", 106, 112], ["SGTSAS", "SIMPLE_CHEMICAL", 145, 151], ["Ser280", "AMINO_ACID", 178, 184], ["Thr279", "PROTEIN", 106, 112], ["SGTSAS", "PROTEIN", 145, 151], ["catalytic Ser280", "PROTEIN", 168, 184], ["enzymes", "PROTEIN", 218, 225], ["the other enzymes", "TEST", 208, 225], ["main", "OBSERVATION_MODIFIER", 17, 21], ["chain", "OBSERVATION_MODIFIER", 22, 27]]], ["Asp165 itself is also conserved since that residue provides the lining of the oxyanion hole, so it can be safely assumed that this part of the S1 pocket is virtually identical.", [["Asp", "CHEMICAL", 0, 3], ["Asp", "CHEMICAL", 0, 3], ["Asp165", "AMINO_ACID", 0, 6], ["S1 pocket", "PROTEIN", 143, 152], ["Asp", "TEST", 0, 3], ["the lining of the oxyanion hole", "TREATMENT", 60, 91], ["oxyanion hole", "OBSERVATION", 78, 91], ["S1", "ANATOMY", 143, 145], ["pocket", "OBSERVATION", 146, 152]]], ["No side chains point into the pocket from there, though, so its importance is limited to providing a steric barrier and excluding solvent.", [["side chains", "PROBLEM", 3, 14], ["a steric barrier", "TREATMENT", 99, 115], ["side chains", "OBSERVATION_MODIFIER", 3, 14], ["pocket", "OBSERVATION_MODIFIER", 30, 36]]], ["Another wall of the pocket is made up of the main chain of residues 130\u2013132 that flank the conserved Gly131.", [["wall", "ANATOMY", 8, 12], ["Gly131", "CHEMICAL", 101, 107], ["Gly", "CHEMICAL", 101, 104], ["Gly131", "AMINO_ACID", 101, 107], ["Gly131", "PROTEIN", 101, 107], ["Another wall of the pocket", "PROBLEM", 0, 26], ["wall", "ANATOMY_MODIFIER", 8, 12], ["pocket", "OBSERVATION", 20, 26], ["main", "OBSERVATION_MODIFIER", 45, 49], ["chain", "OBSERVATION_MODIFIER", 50, 55], ["flank", "ANATOMY", 81, 86]]], ["Again, this part of the chain does not provide any specific interactions with the P1 residue of the substrate.Comparisons of the substrate binding pockets of CLN2 and sedolisin ::: Results and discussionConsiderable differences are seen, however, at the bottom of the pocket, where the side chains of Asp179 in kumamolisin and the equivalent Ser190 in sedolisin make hydrogen bonds to the P1 tyrosine of the inhibitor (if present).", [["sedolisin", "CHEMICAL", 167, 176], ["Asp179", "CHEMICAL", 301, 307], ["kumamolisin", "CHEMICAL", 311, 322], ["sedolisin", "CHEMICAL", 352, 361], ["tyrosine", "CHEMICAL", 392, 400], ["sedolisin", "CHEMICAL", 167, 176], ["Asp179", "CHEMICAL", 301, 307], ["kumamolisin", "CHEMICAL", 311, 322], ["Ser190", "CHEMICAL", 342, 348], ["sedolisin", "CHEMICAL", 352, 361], ["hydrogen", "CHEMICAL", 367, 375], ["tyrosine", "CHEMICAL", 392, 400], ["CLN2", "GENE_OR_GENE_PRODUCT", 158, 162], ["sedolisin", "SIMPLE_CHEMICAL", 167, 176], ["Asp179", "GENE_OR_GENE_PRODUCT", 301, 307], ["kumamolisin", "GENE_OR_GENE_PRODUCT", 311, 322], ["Ser190", "GENE_OR_GENE_PRODUCT", 342, 348], ["sedolisin", "SIMPLE_CHEMICAL", 352, 361], ["tyrosine", "AMINO_ACID", 392, 400], ["substrate binding pockets", "PROTEIN", 129, 154], ["CLN2", "DNA", 158, 162], ["Asp179", "PROTEIN", 301, 307], ["kumamolisin", "PROTEIN", 311, 322], ["Asp179 in kumamolisin", "TREATMENT", 301, 322], ["hydrogen bonds", "PROBLEM", 367, 381], ["the inhibitor", "TREATMENT", 404, 417], ["pocket", "OBSERVATION", 268, 274]]], ["The equivalent residue in CLN2 is Thr182, but it is very unlikely that it can assume an orientation that would allow it to make a hydrogen bond to a P1 tyrosine.", [["tyrosine", "CHEMICAL", 152, 160], ["Thr", "CHEMICAL", 34, 37], ["hydrogen", "CHEMICAL", 130, 138], ["tyrosine", "CHEMICAL", 152, 160], ["CLN2", "GENE_OR_GENE_PRODUCT", 26, 30], ["Thr182", "AMINO_ACID", 34, 40], ["tyrosine", "AMINO_ACID", 152, 160], ["CLN2", "DNA", 26, 30], ["The equivalent residue in CLN2", "PROBLEM", 0, 30], ["a P1 tyrosine", "TREATMENT", 147, 160], ["equivalent", "OBSERVATION_MODIFIER", 4, 14], ["residue", "OBSERVATION_MODIFIER", 15, 22], ["very unlikely", "UNCERTAINTY", 52, 65]]], ["Other polar residues in the vicinity are Glu175 in sedolisin and the corresponding Asp169 in kumamolisin.", [["Glu175", "CHEMICAL", 41, 47], ["Asp169", "CHEMICAL", 83, 89], ["kumamolisin", "CHEMICAL", 93, 104], ["Glu175", "CHEMICAL", 41, 47], ["sedolisin", "CHEMICAL", 51, 60], ["Asp169", "CHEMICAL", 83, 89], ["kumamolisin", "CHEMICAL", 93, 104], ["Glu175", "SIMPLE_CHEMICAL", 41, 47], ["sedolisin", "SIMPLE_CHEMICAL", 51, 60], ["Asp169", "SIMPLE_CHEMICAL", 83, 89], ["kumamolisin", "SIMPLE_CHEMICAL", 93, 104], ["Asp169", "PROTEIN", 83, 89], ["sedolisin", "TREATMENT", 51, 60], ["polar residues", "OBSERVATION", 6, 20]]], ["However, the residue found here in CLN2 is Cys170, much less polar than its counterparts.", [["Cys170", "CHEMICAL", 43, 49], ["Cys", "CHEMICAL", 43, 46], ["CLN2", "GENE_OR_GENE_PRODUCT", 35, 39], ["Cys170", "AMINO_ACID", 43, 49], ["CLN2", "DNA", 35, 39], ["the residue", "PROBLEM", 9, 20], ["Cys", "TEST", 43, 46]]], ["There is also no equivalent to the polar interaction between Glu175 and Glu171 in sedolisin, since the equivalent of the latter residue in CLN2 is Ser166, much smaller and pointing away.Comparisons of the substrate binding pockets of CLN2 and sedolisin ::: Results and discussionThe side of the S1 pocket that is created by the very flexible side chain of Arg179 in sedolisin contains only a much smaller Ser174 in CLN2, and thus is much more open in the latter protein.", [["Glu171", "CHEMICAL", 72, 78], ["sedolisin", "CHEMICAL", 82, 91], ["sedolisin", "CHEMICAL", 243, 252], ["Arg179", "CHEMICAL", 356, 362], ["Glu175", "CHEMICAL", 61, 67], ["Glu171", "CHEMICAL", 72, 78], ["sedolisin", "CHEMICAL", 82, 91], ["sedolisin", "CHEMICAL", 243, 252], ["Arg179", "CHEMICAL", 356, 362], ["Glu175", "GENE_OR_GENE_PRODUCT", 61, 67], ["Glu171", "GENE_OR_GENE_PRODUCT", 72, 78], ["sedolisin", "GENE_OR_GENE_PRODUCT", 82, 91], ["CLN2", "GENE_OR_GENE_PRODUCT", 139, 143], ["Ser166", "AMINO_ACID", 147, 153], ["CLN2", "GENE_OR_GENE_PRODUCT", 234, 238], ["sedolisin", "SIMPLE_CHEMICAL", 243, 252], ["Arg179", "GENE_OR_GENE_PRODUCT", 356, 362], ["sedolisin", "GENE_OR_GENE_PRODUCT", 366, 375], ["Ser174", "GENE_OR_GENE_PRODUCT", 405, 411], ["CLN2", "GENE_OR_GENE_PRODUCT", 415, 419], ["CLN2", "DNA", 139, 143], ["Ser166", "PROTEIN", 147, 153], ["substrate binding pockets", "PROTEIN", 205, 230], ["CLN2", "DNA", 234, 238], ["S1 pocket", "PROTEIN", 295, 304], ["Arg179", "PROTEIN", 356, 362], ["sedolisin", "PROTEIN", 366, 375], ["Ser174", "PROTEIN", 405, 411], ["CLN2", "PROTEIN", 415, 419], ["Glu175", "TEST", 61, 67], ["sedolisin", "TREATMENT", 82, 91], ["the latter residue in CLN2", "PROBLEM", 117, 143], ["the S1 pocket", "PROBLEM", 291, 304], ["a much smaller Ser174 in CLN2", "PROBLEM", 390, 419], ["no", "UNCERTAINTY", 14, 16], ["equivalent", "OBSERVATION_MODIFIER", 17, 27], ["smaller", "OBSERVATION_MODIFIER", 160, 167], ["S1", "ANATOMY", 295, 297], ["pocket", "OBSERVATION", 298, 304], ["very", "OBSERVATION_MODIFIER", 328, 332], ["flexible", "OBSERVATION_MODIFIER", 333, 341], ["smaller", "OBSERVATION_MODIFIER", 397, 404]]], ["This part of the pocket, with the main chain of the protein quite distant from the substrate, is indeed not well conserved in these proteins, with kumamolisin missing it entirely due to a deletion in the corresponding sequence position.", [["kumamolisin", "CHEMICAL", 147, 158], ["kumamolisin", "GENE_OR_GENE_PRODUCT", 147, 158], ["kumamolisin", "PROTEIN", 147, 158], ["the pocket", "PROBLEM", 13, 23], ["kumamolisin", "TREATMENT", 147, 158], ["a deletion in the corresponding sequence position", "PROBLEM", 186, 235], ["pocket", "OBSERVATION_MODIFIER", 17, 23], ["main", "OBSERVATION_MODIFIER", 34, 38], ["chain", "OBSERVATION_MODIFIER", 39, 44], ["deletion", "OBSERVATION", 188, 196]]], ["In summary, the S1 pocket in CLN2 has less polar character than the equivalent pocket in the related proteins, and is lacking direct polar anchors for any side chains that might be present in the substrate.Comparisons of the substrate binding pockets of CLN2 and sedolisin ::: Results and discussionThe S2 pocket in CLN2 is also quite open and accessible to solvent.", [["sedolisin", "CHEMICAL", 263, 272], ["sedolisin", "CHEMICAL", 263, 272], ["CLN2", "GENE_OR_GENE_PRODUCT", 29, 33], ["CLN2", "GENE_OR_GENE_PRODUCT", 254, 258], ["sedolisin", "SIMPLE_CHEMICAL", 263, 272], ["CLN2", "GENE_OR_GENE_PRODUCT", 316, 320], ["S1 pocket", "PROTEIN", 16, 25], ["CLN2", "DNA", 29, 33], ["substrate binding pockets", "PROTEIN", 225, 250], ["CLN2", "DNA", 254, 258], ["CLN2", "DNA", 316, 320], ["the S1 pocket in CLN2", "PROBLEM", 12, 33], ["any side chains", "PROBLEM", 151, 166], ["The S2 pocket in CLN2", "PROBLEM", 299, 320], ["S1", "ANATOMY", 16, 18], ["pocket", "OBSERVATION", 19, 25], ["less", "OBSERVATION_MODIFIER", 38, 42], ["polar character", "OBSERVATION_MODIFIER", 43, 58], ["equivalent", "OBSERVATION_MODIFIER", 68, 78], ["pocket", "OBSERVATION_MODIFIER", 79, 85]]], ["It is most likely larger than the equivalent pockets in either sedolisin or kumamolisin, since these are limited by Trp81 in the former and Trp129 in the latter (these residues originate from different parts of the backbone in the two enzymes and are not topologically related).", [["sedolisin", "CHEMICAL", 63, 72], ["kumamolisin", "CHEMICAL", 76, 87], ["kumamolisin", "CHEMICAL", 76, 87], ["sedolisin", "GENE_OR_GENE_PRODUCT", 63, 72], ["kumamolisin", "SIMPLE_CHEMICAL", 76, 87], ["Trp81", "GENE_OR_GENE_PRODUCT", 116, 121], ["Trp129", "GENE_OR_GENE_PRODUCT", 140, 146], ["Trp81", "PROTEIN", 116, 121], ["Trp129", "PROTEIN", 140, 146], ["enzymes", "PROTEIN", 235, 242], ["kumamolisin", "TREATMENT", 76, 87], ["these residues", "PROBLEM", 162, 176], ["the two enzymes", "TEST", 227, 242], ["most likely", "UNCERTAINTY", 6, 17], ["larger", "OBSERVATION_MODIFIER", 18, 24], ["equivalent", "OBSERVATION_MODIFIER", 34, 44], ["pockets", "OBSERVATION", 45, 52]]], ["Tyr130, an equivalent of the latter residue in CLN2, is unlikely to come into direct contact with the P2 residue of the substrate due to its greater distance (almost 4 \u00c5 for the closest atoms).Comparisons of the substrate binding pockets of CLN2 and sedolisin ::: Results and discussionAn important remaining puzzle is that the predicted structure of CLN2 does not show any clear limitations of the S3 pocket that could explain the tripeptidase activity of this enzyme.", [["sedolisin", "CHEMICAL", 250, 259], ["sedolisin", "CHEMICAL", 250, 259], ["Tyr130", "GENE_OR_GENE_PRODUCT", 0, 6], ["CLN2", "GENE_OR_GENE_PRODUCT", 47, 51], ["CLN2", "GENE_OR_GENE_PRODUCT", 241, 245], ["sedolisin", "SIMPLE_CHEMICAL", 250, 259], ["CLN2", "GENE_OR_GENE_PRODUCT", 351, 355], ["Tyr130", "PROTEIN", 0, 6], ["CLN2", "PROTEIN", 47, 51], ["substrate binding pockets", "PROTEIN", 212, 237], ["CLN2", "DNA", 241, 245], ["CLN2", "DNA", 351, 355], ["enzyme", "PROTEIN", 462, 468], ["the latter residue in CLN2", "PROBLEM", 25, 51], ["the S3 pocket", "PROBLEM", 395, 408], ["this enzyme", "TEST", 457, 468], ["S3 pocket", "OBSERVATION", 399, 408]]], ["The location of the P3 side chain of the substrate is ambiguous, since it could point in either one of two directions by exchange with the N-terminal amine.", [["amine", "CHEMICAL", 150, 155], ["N-terminal amine", "CHEMICAL", 139, 155], ["N-terminal amine", "SIMPLE_CHEMICAL", 139, 155], ["P3 side chain", "PROTEIN", 20, 33], ["N-terminal amine", "PROTEIN", 139, 155], ["the N-terminal amine", "TREATMENT", 135, 155], ["ambiguous", "OBSERVATION", 54, 63]]], ["The only negatively charged residue of CLN2 that is found in this vicinity is Asp132.", [["Asp132", "CHEMICAL", 78, 84], ["Asp", "CHEMICAL", 78, 81], ["CLN2", "GENE_OR_GENE_PRODUCT", 39, 43], ["Asp132", "AMINO_ACID", 78, 84], ["CLN2", "DNA", 39, 43], ["negatively charged residue of CLN2", "PROBLEM", 9, 43], ["Asp", "TEST", 78, 81], ["negatively", "OBSERVATION_MODIFIER", 9, 19], ["charged residue", "OBSERVATION", 20, 35]]], ["Although in the current model the distance between its carboxylate and the nitrogen of the N-terminus of the modeled substrate is about 6 \u00c5, these two groups could be brought into hydrogen-bonding range by some allowed changes in the torsion angles of the protein.", [["carboxylate", "CHEMICAL", 55, 66], ["nitrogen", "CHEMICAL", 75, 83], ["carboxylate", "CHEMICAL", 55, 66], ["nitrogen", "CHEMICAL", 75, 83], ["N", "CHEMICAL", 91, 92], ["hydrogen", "CHEMICAL", 180, 188], ["carboxylate", "SIMPLE_CHEMICAL", 55, 66], ["N-terminus", "PROTEIN", 91, 101], ["its carboxylate", "TREATMENT", 51, 66]]], ["Such a conformational change would involve breaking of the hydrogen bond between Asp132 and Ser139.", [["Asp132", "CHEMICAL", 81, 87], ["hydrogen", "CHEMICAL", 59, 67], ["Asp", "CHEMICAL", 81, 84], ["Ser139", "CHEMICAL", 92, 98], ["Asp132", "AMINO_ACID", 81, 87], ["Ser139", "AMINO_ACID", 92, 98], ["a conformational change", "PROBLEM", 5, 28], ["Asp", "TEST", 81, 84]]], ["However, this latter interaction is not likely to be structurally crucial since the serine is not absolutely conserved in all CLN2-like enzymes.Location of mutations implicated in disease ::: Results and discussionLocation of mutations found through a genetic survey of families of classic late-infantile neuronal ceroid lipofuscinosis patients has been described previously [17].", [["neuronal", "ANATOMY", 305, 313], ["ceroid lipofuscinosis", "DISEASE", 314, 335], ["serine", "CHEMICAL", 84, 90], ["serine", "AMINO_ACID", 84, 90], ["CLN2-like enzymes", "GENE_OR_GENE_PRODUCT", 126, 143], ["neuronal", "CELL", 305, 313], ["patients", "ORGANISM", 336, 344], ["CLN2-like enzymes", "PROTEIN", 126, 143], ["patients", "SPECIES", 336, 344], ["mutations", "PROBLEM", 226, 235], ["classic late-infantile neuronal ceroid lipofuscinosis", "PROBLEM", 282, 335], ["not likely to be", "UNCERTAINTY", 36, 52], ["mutations", "OBSERVATION", 156, 165], ["ceroid lipofuscinosis", "OBSERVATION", 314, 335]]], ["Most such mutations result in expression of either truncated enzyme or in incorrect intron-exon splices.", [["truncated enzyme", "PROTEIN", 51, 67], ["intron-exon splices", "DNA", 84, 103], ["Most such mutations", "PROBLEM", 0, 19], ["either truncated enzyme", "PROBLEM", 44, 67], ["incorrect intron-exon splices", "PROBLEM", 74, 103]]], ["However, some of the mutations lead to single amino acid substitutions in the mature enzyme.", [["amino acid", "CHEMICAL", 46, 56], ["amino acid", "CHEMICAL", 46, 56], ["amino acid", "AMINO_ACID", 46, 56], ["mature enzyme", "PROTEIN", 78, 91], ["the mutations", "PROBLEM", 17, 30], ["single amino acid substitutions", "PROBLEM", 39, 70], ["acid substitutions", "OBSERVATION", 52, 70]]], ["Such mutations include I92N, E148K, C170R and C170Y, V190D, G194E, Q227H, R252H, A259E, and S280L (Figure 5).", [["I92N", "GENE_OR_GENE_PRODUCT", 23, 27]]], ["Only the role of the latter mutation is completely clear, since it replaces the catalytic serine of CLN2 with a side chain that cannot support its enzymatic activity.", [["serine", "CHEMICAL", 90, 96], ["serine", "AMINO_ACID", 90, 96], ["CLN2", "GENE_OR_GENE_PRODUCT", 100, 104], ["CLN2", "PROTEIN", 100, 104], ["the latter mutation", "PROBLEM", 17, 36], ["clear", "OBSERVATION", 51, 56], ["enzymatic activity", "OBSERVATION", 147, 165]]], ["No other residues appear to be located in the immediate vicinity of the substrate.", [["other residues", "PROBLEM", 3, 17], ["residues", "OBSERVATION", 9, 17]]], ["Residues Val190, Gly194, and Arg252 are very highly conserved not only in CLN2 but also in other sedolisins and must play an important structural role.", [["Val190", "CHEMICAL", 9, 15], ["Gly194", "CHEMICAL", 17, 23], ["Arg252", "CHEMICAL", 29, 35], ["Val190", "GENE_OR_GENE_PRODUCT", 9, 15], ["Gly194", "GENE_OR_GENE_PRODUCT", 17, 23], ["Arg252", "GENE_OR_GENE_PRODUCT", 29, 35], ["CLN2", "GENE_OR_GENE_PRODUCT", 74, 78], ["sedolisins", "GENE_OR_GENE_PRODUCT", 97, 107], ["CLN2", "DNA", 74, 78]]], ["The reasons why the remaining mutations would lead to the loss of enzymatic activity are much less clear, but the wide distribution of these mutations in the structure supports the conclusion that any modifications to CLN2 that would abolish or impair its function could lead to the development of the disease.Substrates and inhibitors of CLN2 ::: Results and discussionLittle is known at this time about biologically-relevant substrates of CLN2.", [["CLN2", "GENE_OR_GENE_PRODUCT", 218, 222], ["CLN2", "GENE_OR_GENE_PRODUCT", 339, 343], ["CLN2", "GENE_OR_GENE_PRODUCT", 441, 445], ["CLN2", "DNA", 218, 222], ["CLN2", "DNA", 339, 343], ["CLN2", "DNA", 441, 445], ["the remaining mutations", "PROBLEM", 16, 39], ["the loss of enzymatic activity", "PROBLEM", 54, 84], ["these mutations", "PROBLEM", 135, 150], ["any modifications to CLN2", "PROBLEM", 197, 222], ["the disease", "PROBLEM", 298, 309], ["enzymatic activity", "OBSERVATION", 66, 84], ["wide", "OBSERVATION_MODIFIER", 114, 118], ["distribution", "OBSERVATION_MODIFIER", 119, 131], ["mutations", "OBSERVATION", 141, 150], ["disease", "OBSERVATION", 302, 309]]], ["Various defects that include truncations and single-site mutations in CLN2 have been found in the genes of patients that display symptoms of late-infantile neuronal ceroid lipofuscinosis [17].", [["neuronal", "ANATOMY", 156, 164], ["neuronal ceroid lipofuscinosis", "DISEASE", 156, 186], ["CLN2", "GENE_OR_GENE_PRODUCT", 70, 74], ["patients", "ORGANISM", 107, 115], ["neuronal", "CELL", 156, 164], ["CLN2", "DNA", 70, 74], ["patients", "SPECIES", 107, 115], ["Various defects", "PROBLEM", 0, 15], ["truncations", "PROBLEM", 29, 40], ["single-site mutations in CLN2", "PROBLEM", 45, 74], ["symptoms", "PROBLEM", 129, 137], ["late-infantile neuronal ceroid lipofuscinosis", "PROBLEM", 141, 186], ["defects", "OBSERVATION", 8, 15], ["ceroid lipofuscinosis", "OBSERVATION", 165, 186]]], ["One of the symptoms of the disease is the accumulation of an autofluorescent material, ceroid-lipofuscin, in lysosomal storage bodies in various cell types, primarily in the nervous system.", [["lysosomal storage bodies", "ANATOMY", 109, 133], ["cell", "ANATOMY", 145, 149], ["nervous system", "ANATOMY", 174, 188], ["ceroid", "DISEASE", 87, 93], ["lipofuscin", "SIMPLE_CHEMICAL", 94, 104], ["lysosomal storage bodies", "CELLULAR_COMPONENT", 109, 133], ["cell", "CELL", 145, 149], ["nervous system", "ANATOMICAL_SYSTEM", 174, 188], ["the symptoms", "PROBLEM", 7, 19], ["the disease", "PROBLEM", 23, 34], ["an autofluorescent material", "PROBLEM", 58, 85], ["lysosomal storage bodies", "PROBLEM", 109, 133], ["disease", "OBSERVATION", 27, 34], ["accumulation", "OBSERVATION_MODIFIER", 42, 54], ["autofluorescent material", "OBSERVATION", 61, 85], ["lysosomal storage bodies", "OBSERVATION", 109, 133], ["various cell types", "OBSERVATION", 137, 155], ["nervous system", "ANATOMY", 174, 188]]], ["Since a major component of such bodies appears to be intact subunit c of mitochondrial ATP synthase, this protein has been implicated as a potential biological target of the protease.", [["mitochondrial", "ANATOMY", 73, 86], ["ATP", "CHEMICAL", 87, 90], ["ATP", "CHEMICAL", 87, 90], ["mitochondrial", "CELLULAR_COMPONENT", 73, 86], ["ATP synthase", "GENE_OR_GENE_PRODUCT", 87, 99], ["subunit c", "PROTEIN", 60, 69], ["mitochondrial ATP synthase", "PROTEIN", 73, 99], ["protease", "PROTEIN", 174, 182], ["such bodies", "PROBLEM", 27, 38], ["mitochondrial ATP synthase", "TREATMENT", 73, 99], ["the protease", "TREATMENT", 170, 182], ["such bodies", "OBSERVATION", 27, 38], ["appears to be", "UNCERTAINTY", 39, 52], ["intact", "OBSERVATION", 53, 59], ["mitochondrial ATP synthase", "OBSERVATION", 73, 99]]], ["It has been shown recently that CLN2 can indeed degrade this subunit on its N terminus [18], but the unambiguous proof that this is indeed the most important target is still lacking.", [["N", "CHEMICAL", 76, 77], ["CLN2", "GENE_OR_GENE_PRODUCT", 32, 36], ["CLN2", "PROTEIN", 32, 36], ["N terminus", "PROTEIN", 76, 86]]], ["CLN2 is capable of processing a number of different angiotensin-derived peptides [19], with the efficiency of cleavage dependent on the length of such peptides.", [["angiotensin", "CHEMICAL", 52, 63], ["CLN2", "GENE_OR_GENE_PRODUCT", 0, 4], ["CLN2", "DNA", 0, 4], ["different angiotensin", "TREATMENT", 42, 63], ["cleavage dependent", "PROBLEM", 110, 128], ["such peptides", "TREATMENT", 146, 159], ["cleavage", "OBSERVATION", 110, 118], ["dependent", "OBSERVATION_MODIFIER", 119, 128]]], ["The most efficiently processed peptide consisted of 14 amino acids, with the tripeptide Asp-Arg-Val removed from its N terminus.", [["amino acids", "CHEMICAL", 55, 66], ["Asp-Arg-Val", "CHEMICAL", 88, 99], ["amino acids", "CHEMICAL", 55, 66], ["Asp-Arg-Val", "CHEMICAL", 88, 99], ["N", "CHEMICAL", 117, 118], ["amino acids", "AMINO_ACID", 55, 66], ["Arg-Val", "AMINO_ACID", 92, 99], ["N terminus", "PROTEIN", 117, 127], ["14 amino acids", "TREATMENT", 52, 66], ["the tripeptide Asp", "TREATMENT", 73, 91], ["Arg-Val", "TREATMENT", 92, 99], ["terminus", "OBSERVATION_MODIFIER", 119, 127]]], ["The model of CLN2 presented here can easily accommodate this peptide on the P side of the substrate-binding site, although the exact mode of binding of the long P' portion of the substrate remains obscure.", [["CLN2", "GENE_OR_GENE_PRODUCT", 13, 17], ["CLN2", "DNA", 13, 17], ["substrate-binding site", "DNA", 90, 112], ["long P' portion", "DNA", 156, 171], ["binding site", "OBSERVATION", 100, 112]]], ["The observation that an analogous peptide acetylated on its N terminus cannot be processed supports the postulate that the interactions of the N-terminal amino group with the side chain of Asp132 may be the most important feature defining the tripeptidase specificity of CLN2.", [["N-terminal amino", "CHEMICAL", 143, 159], ["Asp132", "CHEMICAL", 189, 195], ["N", "CHEMICAL", 60, 61], ["N", "CHEMICAL", 143, 144], ["amino", "CHEMICAL", 154, 159], ["Asp", "CHEMICAL", 189, 192], ["Asp132", "AMINO_ACID", 189, 195], ["tripeptidase", "SIMPLE_CHEMICAL", 243, 255], ["CLN2", "GENE_OR_GENE_PRODUCT", 271, 275], ["N terminus", "PROTEIN", 60, 70], ["N-terminal amino group", "PROTEIN", 143, 165], ["CLN2", "DNA", 271, 275], ["an analogous peptide acetylated", "TREATMENT", 21, 52], ["its N terminus", "TREATMENT", 56, 70], ["the N-terminal amino group", "TREATMENT", 139, 165], ["Asp", "TEST", 189, 192]]], ["A number of different tripeptides can be serially processed from glucagon, with their sequences varying widely [20].", [["glucagon", "CHEMICAL", 65, 73], ["glucagon", "GENE_OR_GENE_PRODUCT", 65, 73], ["different tripeptides", "TREATMENT", 12, 33], ["glucagon", "TREATMENT", 65, 73]]], ["Again, however, all of these tripeptides can be easily accommodated in the substrate-binding site of the CLN2 model.", [["CLN2", "GENE_OR_GENE_PRODUCT", 105, 109], ["substrate-binding site", "PROTEIN", 75, 97], ["CLN2", "DNA", 105, 109], ["these tripeptides", "TREATMENT", 23, 40]]], ["Other potentially biologically relevant substrates include cholecystokinin and possibly other neuropeptides [21].Substrates and inhibitors of CLN2 ::: Results and discussionAn intriguing property of CLN2 is its reported ability to cleave collagen-related peptides [22].", [["cholecystokinin", "CHEMICAL", 59, 74], ["cholecystokinin", "GENE_OR_GENE_PRODUCT", 59, 74], ["CLN2", "GENE_OR_GENE_PRODUCT", 142, 146], ["CLN2", "GENE_OR_GENE_PRODUCT", 199, 203], ["collagen", "GENE_OR_GENE_PRODUCT", 238, 246], ["CLN2", "DNA", 142, 146], ["CLN2", "DNA", 199, 203], ["collagen", "PROTEIN", 238, 246], ["cholecystokinin", "TREATMENT", 59, 74], ["other neuropeptides", "PROBLEM", 88, 107]]], ["The tripeptides resulting from such processing include Gly-Pro-Met, Gly-Pro-Arg, and Gly-Pro-Ala.", [["Gly-Pro-Met", "CHEMICAL", 55, 66], ["Gly-Pro-Arg", "CHEMICAL", 68, 79], ["Gly-Pro-Ala", "CHEMICAL", 85, 96], ["Gly-Pro-Met", "CHEMICAL", 55, 66], ["Gly-Pro-Arg", "CHEMICAL", 68, 79], ["Gly-Pro-Ala", "CHEMICAL", 85, 96], ["Gly-Pro-Met", "SIMPLE_CHEMICAL", 55, 66], ["Gly-Pro-Arg", "SIMPLE_CHEMICAL", 68, 79], ["Gly-Pro-Ala", "SIMPLE_CHEMICAL", 85, 96], ["The tripeptides", "TREATMENT", 0, 15], ["Gly", "TEST", 55, 58], ["Gly", "TEST", 68, 71], ["Pro-Ala", "ANATOMY", 89, 96]]], ["It has been recently reported that kumamolisin, and particularly a closely related protein from Alicyclobacillus sendaiensis (kumamolisin-As) can efficiently cleave not only collagen-related peptides, but also native type I collagen [23].", [["kumamolisin", "CHEMICAL", 35, 46], ["kumamolisin", "CHEMICAL", 126, 137], ["kumamolisin", "CHEMICAL", 35, 46], ["kumamolisin", "SIMPLE_CHEMICAL", 35, 46], ["Alicyclobacillus sendaiensis", "ORGANISM", 96, 124], ["kumamolisin-As", "GENE_OR_GENE_PRODUCT", 126, 140], ["collagen", "GENE_OR_GENE_PRODUCT", 174, 182], ["type I collagen", "GENE_OR_GENE_PRODUCT", 217, 232], ["collagen", "PROTEIN", 174, 182], ["native type I collagen", "PROTEIN", 210, 232], ["Alicyclobacillus sendaiensis", "SPECIES", 96, 124], ["Alicyclobacillus sendaiensis", "SPECIES", 96, 124], ["kumamolisin", "TREATMENT", 35, 46], ["a closely related protein", "PROBLEM", 65, 90], ["Alicyclobacillus sendaiensis", "PROBLEM", 96, 124], ["collagen-related peptides", "PROBLEM", 174, 199]]], ["With the substrate-binding site of CLN2 resembling that of kumamolisin more than sedolisin (the latter enzyme has low, if any, collagenase activity), the potential collagen-processing role of CLN2 might warrant further investigation.ConclusionsSince the catalytic machinery of CLN2 matches closely that of sedolisin, kumamolisin, and other members of the family of serine-carboxyl peptidases, the enzymatic mechanism of all these enzymes is most likely the same.", [["kumamolisin", "CHEMICAL", 59, 70], ["kumamolisin", "CHEMICAL", 317, 328], ["kumamolisin", "CHEMICAL", 59, 70], ["sedolisin", "CHEMICAL", 81, 90], ["serine", "CHEMICAL", 365, 371], ["carboxyl", "CHEMICAL", 372, 380], ["CLN2", "GENE_OR_GENE_PRODUCT", 35, 39], ["kumamolisin", "GENE_OR_GENE_PRODUCT", 59, 70], ["sedolisin", "SIMPLE_CHEMICAL", 81, 90], ["collagenase", "GENE_OR_GENE_PRODUCT", 127, 138], ["collagen", "GENE_OR_GENE_PRODUCT", 164, 172], ["CLN2", "GENE_OR_GENE_PRODUCT", 192, 196], ["CLN2", "GENE_OR_GENE_PRODUCT", 277, 281], ["sedolisin", "GENE_OR_GENE_PRODUCT", 306, 315], ["kumamolisin", "GENE_OR_GENE_PRODUCT", 317, 328], ["serine", "AMINO_ACID", 365, 371], ["substrate-binding site", "DNA", 9, 31], ["CLN2", "DNA", 35, 39], ["kumamolisin", "PROTEIN", 59, 70], ["collagenase", "PROTEIN", 127, 138], ["collagen", "PROTEIN", 164, 172], ["CLN2", "DNA", 192, 196], ["CLN2", "DNA", 277, 281], ["sedolisin", "PROTEIN", 306, 315], ["serine-carboxyl peptidases", "PROTEIN", 365, 391], ["enzymes", "PROTEIN", 430, 437], ["kumamolisin", "TREATMENT", 59, 70], ["sedolisin", "TREATMENT", 81, 90], ["the latter enzyme", "TEST", 92, 109], ["further investigation", "TEST", 211, 232], ["sedolisin", "TREATMENT", 306, 315], ["kumamolisin", "TREATMENT", 317, 328], ["serine-carboxyl peptidases", "TREATMENT", 365, 391], ["all these enzymes", "TEST", 420, 437], ["most likely", "UNCERTAINTY", 441, 452]]], ["Design of inhibitors specific for CLN2 should incorporate the features that have been proven to be important for the related enzymes, such as the placement of an aldehyde functionality capable of making covalent interactions with the catalytic serine, or the utilization of chloromethyl ketone for the same purpose.", [["aldehyde", "CHEMICAL", 162, 170], ["chloromethyl ketone", "CHEMICAL", 274, 293], ["aldehyde", "CHEMICAL", 162, 170], ["serine", "CHEMICAL", 244, 250], ["chloromethyl ketone", "CHEMICAL", 274, 293], ["CLN2", "GENE_OR_GENE_PRODUCT", 34, 38], ["aldehyde", "SIMPLE_CHEMICAL", 162, 170], ["serine", "AMINO_ACID", 244, 250], ["chloromethyl ketone", "SIMPLE_CHEMICAL", 274, 293], ["CLN2", "DNA", 34, 38], ["enzymes", "PROTEIN", 125, 132], ["Design of inhibitors", "TREATMENT", 0, 20], ["CLN2", "PROBLEM", 34, 38], ["the related enzymes", "PROBLEM", 113, 132], ["an aldehyde functionality", "TREATMENT", 159, 184], ["the catalytic serine", "TREATMENT", 230, 250], ["chloromethyl ketone", "TREATMENT", 274, 293], ["aldehyde functionality", "OBSERVATION", 162, 184]]], ["Since the few inhibitors that have been successfully used in the studies of sedolisins are either longer than tripeptides or contain blocking groups on their N termini, new tripeptide-based inhibitors with free N termini are now being synthesized (Oda, unpublished).", [["sedolisins", "CHEMICAL", 76, 86], ["N", "CHEMICAL", 158, 159], ["N", "CHEMICAL", 211, 212], ["sedolisins", "SIMPLE_CHEMICAL", 76, 86], ["N termini", "PROTEIN", 158, 167], ["N termini", "PROTEIN", 211, 220], ["the few inhibitors", "TREATMENT", 6, 24], ["sedolisins", "TREATMENT", 76, 86], ["tripeptides", "TREATMENT", 110, 121], ["blocking groups", "PROBLEM", 133, 148], ["their N termini", "TREATMENT", 152, 167], ["new tripeptide-based inhibitors", "TREATMENT", 169, 200], ["free N termini", "TREATMENT", 206, 220]]], ["Analysis of the model of CLN2 suggests that the size of the S1 subsite is much larger than in either sedolisin or kumamolisin, and thus the use of a large P1 group might be indicated.", [["kumamolisin", "CHEMICAL", 114, 125], ["sedolisin", "CHEMICAL", 101, 110], ["kumamolisin", "CHEMICAL", 114, 125], ["CLN2", "GENE_OR_GENE_PRODUCT", 25, 29], ["sedolisin", "SIMPLE_CHEMICAL", 101, 110], ["kumamolisin", "SIMPLE_CHEMICAL", 114, 125], ["CLN2", "DNA", 25, 29], ["S1 subsite", "PROTEIN", 60, 70], ["the model of CLN2", "TEST", 12, 29], ["a large P1 group", "TREATMENT", 147, 163], ["size", "OBSERVATION_MODIFIER", 48, 52], ["S1", "ANATOMY", 60, 62], ["much", "OBSERVATION_MODIFIER", 74, 78], ["larger", "OBSERVATION_MODIFIER", 79, 85]]], ["Of course, the availability of an experimental crystal structure will make the design of inhibitors easier and we are continuing our efforts to crystallize CLN2 from different sources.Homology modeling ::: MethodsThree-dimensional, atomic-scale models of CLN2 were developed by exploiting the sequence similarity to the sedolisin and kumamolisin proteins (r.m.s. deviation of 1.0 \u00c5 for 273 pairs of C\u03b1 atoms in the core of the enzymes).", [["C\u03b1", "CHEMICAL", 399, 401], ["CLN2", "GENE_OR_GENE_PRODUCT", 156, 160], ["CLN2", "GENE_OR_GENE_PRODUCT", 255, 259], ["sedolisin", "GENE_OR_GENE_PRODUCT", 320, 329], ["kumamolisin", "GENE_OR_GENE_PRODUCT", 334, 345], ["CLN2", "DNA", 156, 160], ["CLN2", "DNA", 255, 259], ["sedolisin and kumamolisin proteins", "PROTEIN", 320, 354], ["C\u03b1 atoms", "PROTEIN", 399, 407], ["enzymes", "PROTEIN", 427, 434], ["an experimental crystal structure", "PROBLEM", 31, 64], ["inhibitors", "TREATMENT", 89, 99], ["CLN2", "TEST", 255, 259], ["the sedolisin", "TREATMENT", 316, 329], ["r.m.s. deviation", "TEST", 356, 372], ["the enzymes", "TEST", 423, 434]]], ["Presently, these two enzymes are the only members of the newly-defined sedolisin/serine-carboxyl peptidase family [8] for which the crystal structures have been published [5-7].", [["sedolisin", "CHEMICAL", 71, 80], ["serine", "CHEMICAL", 81, 87], ["carboxyl", "CHEMICAL", 88, 96], ["sedolisin", "GENE_OR_GENE_PRODUCT", 71, 80], ["serine", "AMINO_ACID", 81, 87], ["sedolisin/serine-carboxyl peptidase family", "PROTEIN", 71, 113], ["these two enzymes", "TEST", 11, 28], ["serine-carboxyl peptidase family", "TREATMENT", 81, 113]]], ["The actual Protein Data Bank [24]: ) entries used in the modeling were 1GA4.pdb and 1GT9.pdb for sedolisin and kumamolisin, respectively.Homology modeling ::: MethodsThe first step was to form a global, multiple sequence alignment between all known members of the sedolisin family.", [["sedolisin", "CHEMICAL", 97, 106], ["kumamolisin", "CHEMICAL", 111, 122], ["sedolisin", "CHEMICAL", 97, 106], ["kumamolisin", "CHEMICAL", 111, 122], ["pdb", "GENE_OR_GENE_PRODUCT", 76, 79], ["1GT9", "GENE_OR_GENE_PRODUCT", 84, 88], ["sedolisin", "GENE_OR_GENE_PRODUCT", 97, 106], ["kumamolisin", "SIMPLE_CHEMICAL", 111, 122], ["sedolisin", "GENE_OR_GENE_PRODUCT", 264, 273], ["1GT9", "PROTEIN", 84, 88], ["sedolisin family", "PROTEIN", 264, 280], ["1GT9", "TREATMENT", 84, 88], ["sedolisin", "TREATMENT", 97, 106], ["kumamolisin", "TREATMENT", 111, 122], ["Methods", "TREATMENT", 159, 166], ["a global, multiple sequence alignment", "PROBLEM", 193, 230]]], ["Studies have shown that incorporating the specific patterns of amino acid residue-type variation and conservation among a family of homologous proteins provides superior results over simple, pair-wise sequence alignment [25].", [["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 63, 73], ["amino acid", "AMINO_ACID", 63, 73], ["homologous proteins", "PROTEIN", 132, 151], ["Studies", "TEST", 0, 7], ["amino acid residue", "PROBLEM", 63, 81], ["type variation", "PROBLEM", 82, 96]]], ["Sequence files representing the different subfamilies were extracted from the non-redundant GenBank database [26] using sedolisin, kumamolisin, and the human CLN2 sequences as queries to the web-based version of the BLAST program [27]: .", [["sedolisin", "GENE_OR_GENE_PRODUCT", 120, 129], ["kumamolisin", "GENE_OR_GENE_PRODUCT", 131, 142], ["human", "ORGANISM", 152, 157], ["CLN2", "GENE_OR_GENE_PRODUCT", 158, 162], ["sedolisin, kumamolisin, and the human CLN2 sequences", "DNA", 120, 172], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["Sequence files", "TEST", 0, 14], ["sedolisin", "TREATMENT", 120, 129], ["kumamolisin", "TREATMENT", 131, 142], ["the human CLN2 sequences", "TEST", 148, 172]]], ["Initial multiple sequence alignments were formed with the ClustalX computer program [28].", [["Initial multiple sequence alignments", "TEST", 0, 36]]], ["As is expected for a family of proteins, highly-conserved segments were found aligned to the crystal structure-identified core regions of the sedolisin and kumamolisin sequences.", [["sedolisin", "GENE_OR_GENE_PRODUCT", 142, 151], ["kumamolisin", "GENE_OR_GENE_PRODUCT", 156, 167], ["sedolisin and kumamolisin sequences", "DNA", 142, 177], ["the sedolisin and kumamolisin sequences", "TREATMENT", 138, 177]]], ["Subsequently, the sequences were divided into two groups: those closer to sedolisin than kumamolisin and vise-a-versa.", [["kumamolisin", "CHEMICAL", 89, 100], ["sedolisin", "CHEMICAL", 74, 83], ["kumamolisin", "CHEMICAL", 89, 100], ["sedolisin", "SIMPLE_CHEMICAL", 74, 83], ["kumamolisin", "SIMPLE_CHEMICAL", 89, 100], ["vise-a-versa", "SIMPLE_CHEMICAL", 105, 117], ["the sequences", "TEST", 14, 27], ["sedolisin", "TREATMENT", 74, 83], ["kumamolisin", "TREATMENT", 89, 100]]], ["The alignment of these two groups was then manually set by the observed structural alignment of the sedolisin and kumamolisin proteins.", [["sedolisin", "GENE_OR_GENE_PRODUCT", 100, 109], ["kumamolisin", "GENE_OR_GENE_PRODUCT", 114, 125], ["sedolisin", "PROTEIN", 100, 109], ["kumamolisin proteins", "PROTEIN", 114, 134], ["the sedolisin", "TREATMENT", 96, 109], ["kumamolisin proteins", "TREATMENT", 114, 134], ["alignment", "OBSERVATION_MODIFIER", 4, 13]]], ["Finally, some additional adjustment was required to correct the few places where highly conserved residues of the core regions were slightly out of alignment among different subfamilies of sequences.Homology modeling ::: MethodsThe model of human CLN2 was built using the structure of sedolisin complexed with the inhibitor pseudo-tyrostatin [5,6] as a template.", [["sedolisin", "CHEMICAL", 285, 294], ["pseudo-tyrostatin", "CHEMICAL", 324, 341], ["sedolisin", "CHEMICAL", 285, 294], ["pseudo-tyrostatin", "CHEMICAL", 324, 341], ["human", "ORGANISM", 241, 246], ["CLN2", "GENE_OR_GENE_PRODUCT", 247, 251], ["sedolisin", "GENE_OR_GENE_PRODUCT", 285, 294], ["pseudo-tyrostatin [5,6]", "SIMPLE_CHEMICAL", 324, 347], ["human CLN2", "PROTEIN", 241, 251], ["sedolisin", "PROTEIN", 285, 294], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 241, 246], ["Methods", "TREATMENT", 221, 228], ["human CLN2", "PROBLEM", 241, 251], ["sedolisin complexed", "TREATMENT", 285, 304], ["the inhibitor pseudo-tyrostatin", "TREATMENT", 310, 341], ["a template", "TREATMENT", 351, 361], ["residues", "OBSERVATION_MODIFIER", 98, 106], ["core", "ANATOMY_MODIFIER", 114, 118], ["regions", "ANATOMY_MODIFIER", 119, 126], ["slightly", "OBSERVATION_MODIFIER", 132, 140]]], ["The reason for this choice is that while different protein models were generally comparable, the chosen inhibitor was most compatible with the tripeptidase character of CLN2.", [["CLN2", "GENE_OR_GENE_PRODUCT", 169, 173], ["CLN2", "DNA", 169, 173], ["different protein models", "PROBLEM", 41, 65], ["the chosen inhibitor", "TREATMENT", 93, 113]]], ["For the core and active site of the protein, coordinates for identical residues were simply transferred unchanged; whereas, special care was required to position the side chains of residues differing from the template.", [["identical residues", "PROBLEM", 61, 79], ["active", "OBSERVATION", 17, 23], ["unchanged", "OBSERVATION_MODIFIER", 104, 113]]], ["A similar two-step approach was used to manifest the insertions and deletions in the variable, loop regions of the protein, where it was necessary to create new backbone as well as side chain coordinates for the models.", [["A similar two-step approach", "TREATMENT", 0, 27], ["the insertions and deletions", "TREATMENT", 49, 77], ["new", "OBSERVATION_MODIFIER", 157, 160], ["backbone", "OBSERVATION_MODIFIER", 161, 169]]], ["It should be noted that, for obvious reasons, the conformation of poorly conserved loop regions is generally the least accurate aspect of a homology model.", [["loop regions", "PROTEIN", 83, 95], ["poorly conserved loop regions", "PROBLEM", 66, 95], ["loop", "OBSERVATION", 83, 87]]], ["Fortunately, these problematic loops will not significantly affect the active site of the model, since only two of them impinge on the boundary of this highly conserved, functional region.Refinement and analysis of the model ::: MethodsThe model was finished by performing energy minimization in vacuo with the computer program CHARMM [31].", [["these problematic loops", "PROBLEM", 13, 36], ["Methods", "TREATMENT", 229, 236], ["loops", "OBSERVATION", 31, 36], ["active", "OBSERVATION_MODIFIER", 71, 77]]], ["Such optimizations included adjusting bond lengths, 3-point angles and 4-point dihedral angles, as well as eliminating atomic overlap and forming salt-bridges and hydrogen bonds.", [["hydrogen", "CHEMICAL", 163, 171], ["salt-bridges", "SIMPLE_CHEMICAL", 146, 158], ["hydrogen bonds", "SIMPLE_CHEMICAL", 163, 177], ["adjusting bond lengths", "TEST", 28, 50], ["hydrogen bonds", "OBSERVATION", 163, 177]]], ["The structure was deposited at the PDB under accession code 1R60.Authors' contributionsAW initiated this project and analyzed the genomic distribution of this family of enzymes.", [["enzymes", "PROTEIN", 169, 176], ["enzymes", "TEST", 169, 176], ["PDB", "ANATOMY", 35, 38]]], ["SRD contributed the modeling of the three-dimensional structure of CLN2.", [["SRD", "DISEASE", 0, 3], ["CLN2", "GENE_OR_GENE_PRODUCT", 67, 71], ["CLN2", "DNA", 67, 71], ["SRD", "PROBLEM", 0, 3], ["CLN2", "OBSERVATION", 67, 71]]], ["ML analyzed the model and compared it to the crystal structures of sedolisins.", [["sedolisins", "CHEMICAL", 67, 77], ["sedolisins", "CHEMICAL", 67, 77], ["sedolisins", "SIMPLE_CHEMICAL", 67, 77]]], ["HO, KO and BMD contributed their experience gained from studies of serine-carboxyl peptidases and the design of their inhibitors, aimed at analysis of substrate-enzyme interactions and enzyme specificity.", [["serine", "CHEMICAL", 67, 73], ["carboxyl", "CHEMICAL", 74, 82], ["HO", "GENE_OR_GENE_PRODUCT", 0, 2], ["serine-carboxyl peptidases", "SIMPLE_CHEMICAL", 67, 93], ["HO", "PROTEIN", 0, 2], ["serine-carboxyl peptidases", "TREATMENT", 67, 93], ["their inhibitors", "TREATMENT", 112, 128], ["enzyme specificity", "TEST", 185, 203]]]], "PMC7426916": [["IntroductionThe ongoing coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in Wuhan, China in late 20191,2.", [["coronavirus disease", "DISEASE", 24, 43], ["COVID-19", "CHEMICAL", 50, 58], ["acute respiratory syndrome coronavirus", "DISEASE", 89, 127], ["coronavirus", "ORGANISM", 24, 35], ["COVID-19", "ORGANISM", 50, 58], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 82, 129], ["SARS-CoV-2", "ORGANISM", 131, 141], ["severe acute respiratory syndrome coronavirus", "SPECIES", 82, 127], ["SARS-CoV-2", "SPECIES", 131, 141], ["The ongoing coronavirus disease", "PROBLEM", 12, 43], ["COVID", "TEST", 50, 55], ["pandemic", "PROBLEM", 60, 68], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 82, 127], ["SARS-CoV", "TEST", 131, 139], ["coronavirus disease", "OBSERVATION", 24, 43], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["respiratory syndrome", "OBSERVATION", 95, 115]]], ["As of June 28, 2020, COVID-19 has caused 10.3 million confirmed infections and over 505,741 deaths worldwide (https://www.worldometers.info/coronavirus/).", [["COVID-19", "CHEMICAL", 21, 29], ["infections", "DISEASE", 64, 74], ["deaths", "DISEASE", 92, 98], ["COVID", "TEST", 21, 26], ["infections", "PROBLEM", 64, 74], ["infections", "OBSERVATION", 64, 74]]], ["Many areas of the world have been in lockdown mode to curb the viral transmission, but the reality is that COVID-19 is here to stay until a safe and efficacious vaccine becomes available.", [["a safe and efficacious vaccine", "TREATMENT", 138, 168]]], ["The pandemic\u2019s catastrophic economic impact is pushing governments to reopen their economies, and this creates a public health quandary.", [["catastrophic", "OBSERVATION_MODIFIER", 15, 27], ["economic", "OBSERVATION_MODIFIER", 28, 36]]], ["At this time, our only option is to minimize viral transmission through social distancing and contact tracing, which relies on the diagnosis of viral RNA through reverse transcription polymerase chain reaction (RT-PCR) (https://www.fda.gov/media/134922/download).", [["viral RNA", "RNA", 144, 153], ["contact tracing", "TEST", 94, 109], ["viral RNA", "PROBLEM", 144, 153], ["reverse transcription polymerase chain reaction", "PROBLEM", 162, 209], ["RT-PCR", "TEST", 211, 217], ["viral RNA", "OBSERVATION", 144, 153]]], ["Proper public health policy would be greatly enhanced if we had a reliable and facile assay to measure the immune protection among COVID-19 recovered patients.IntroductionCoronavirus infections typically induce neutralizing antibody responses3.", [["Coronavirus infections", "DISEASE", 171, 193], ["patients", "ORGANISM", 150, 158], ["Coronavirus", "ORGANISM", 171, 182], ["patients", "SPECIES", 150, 158], ["facile assay", "TEST", 79, 91], ["COVID", "TEST", 131, 136], ["IntroductionCoronavirus infections", "PROBLEM", 159, 193], ["neutralizing antibody responses3", "PROBLEM", 211, 243], ["neutralizing antibody", "OBSERVATION", 211, 232]]], ["The seroconversion rates in COVID-19 patients are 50% and 100% on day 7 and 14 post symptom onset, respectively4.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["COVID-19", "SPECIES", 28, 36], ["The seroconversion rates", "TEST", 0, 24], ["COVID", "TEST", 28, 33], ["symptom onset", "PROBLEM", 84, 97]]], ["Given the unknown scale of asymptomatic infections, there is a pressing need for serological diagnosis to determine the real number of infections.", [["infections", "DISEASE", 40, 50], ["infections", "DISEASE", 135, 145], ["asymptomatic infections", "PROBLEM", 27, 50], ["serological diagnosis", "TEST", 81, 102], ["infections", "PROBLEM", 135, 145], ["asymptomatic", "OBSERVATION_MODIFIER", 27, 39], ["infections", "OBSERVATION", 40, 50], ["infections", "OBSERVATION", 135, 145]]], ["The serological assays are also required to identify donors with high-neutralizing titers for convalescent plasma for therapy, and to define correlates of protection from SARS-CoV-2.", [["plasma", "ANATOMY", 107, 113], ["SARS", "DISEASE", 171, 175], ["donors", "ORGANISM", 53, 59], ["convalescent", "ORGANISM", 94, 106], ["plasma", "ORGANISM_SUBSTANCE", 107, 113], ["SARS-CoV-2", "ORGANISM", 171, 181], ["SARS-CoV", "SPECIES", 171, 179], ["The serological assays", "TEST", 0, 22], ["donors", "TEST", 53, 59], ["therapy", "TREATMENT", 118, 125], ["SARS", "PROBLEM", 171, 175], ["CoV", "TEST", 176, 179]]], ["While viral RNA-based testing for acute infection is the current standard, surveying antibody protection is a necessary part of any return to social normality.IntroductionFor serodiagnosis, several COVID-19 assay platforms have achieved FDA emergency use authorizations (EUA), including ELISA5 (https://www.fda.gov/media/137029/download), lateral flow immunoassay (https://www.fda.gov/media/136625/download), and Microsphere Immunoassay (https://www.fda.gov/media/137541/download).", [["acute infection", "DISEASE", 34, 49], ["viral RNA", "TEST", 6, 15], ["based testing", "TEST", 16, 29], ["acute infection", "PROBLEM", 34, 49], ["surveying antibody protection", "TREATMENT", 75, 104], ["serodiagnosis", "TEST", 175, 188], ["several COVID", "TEST", 190, 203], ["lateral flow immunoassay", "TEST", 339, 363], ["Microsphere Immunoassay", "TEST", 413, 436], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["infection", "OBSERVATION", 40, 49]]], ["These assays measure antibody binding to SARS-CoV-2 spike protein.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 41, 51], ["SARS-CoV-2 spike protein", "PROTEIN", 41, 65], ["SARS-CoV", "SPECIES", 41, 49], ["These assays", "TEST", 0, 12], ["antibody binding", "PROBLEM", 21, 37], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49]]], ["Since not all spike-binding antibodies can block viral infection, these platforms do not functionally measure antibody inhibition of SARS-CoV-2 infection.", [["viral infection", "DISEASE", 49, 64], ["SARS", "DISEASE", 133, 137], ["infection", "DISEASE", 144, 153], ["SARS-CoV-2", "ORGANISM", 133, 143], ["spike-binding antibodies", "PROTEIN", 14, 38], ["SARS-CoV-2", "SPECIES", 133, 143], ["all spike-binding antibodies", "PROBLEM", 10, 38], ["block viral infection", "PROBLEM", 43, 64], ["these platforms", "TEST", 66, 81], ["SARS", "PROBLEM", 133, 137], ["CoV", "PROBLEM", 138, 141], ["2 infection", "PROBLEM", 142, 153], ["infection", "OBSERVATION", 144, 153]]], ["An ideal serological assay should measure neutralizing antibody levels, which should predict protection from reinfection.", [["An ideal serological assay", "TEST", 0, 26], ["neutralizing antibody levels", "TEST", 42, 70], ["reinfection", "PROBLEM", 109, 120], ["reinfection", "OBSERVATION", 109, 120]]], ["Conventionally, neutralizing antibodies are measured by plaque reduction neutralization test (PRNT).", [["plaque", "ANATOMY", 56, 62], ["neutralizing antibodies", "PROTEIN", 16, 39], ["neutralizing antibodies", "TEST", 16, 39], ["plaque reduction neutralization test", "TEST", 56, 92], ["neutralizing antibodies", "OBSERVATION", 16, 39], ["plaque", "OBSERVATION", 56, 62]]], ["Although PRNT and ELISA results generally corelate with each other, particularly when the receptor-binding domain of SARS-CoV-2 spike protein is used as an ELISA antigen (https://www.genscript.com/cpass-sars-cov-2-neutralization-antibody-detection-Kit.html)6,7, PRNT remains the gold standard for serological testing and determining immune protection8,9.", [["PRNT", "GENE_OR_GENE_PRODUCT", 9, 13], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 117, 127], ["PRNT", "PROTEIN", 9, 13], ["receptor-binding domain", "PROTEIN", 90, 113], ["SARS-CoV-2 spike protein", "PROTEIN", 117, 141], ["ELISA antigen", "PROTEIN", 156, 169], ["PRNT", "PROTEIN", 262, 266], ["SARS-CoV", "SPECIES", 117, 125], ["PRNT and ELISA", "TEST", 9, 23], ["SARS", "TEST", 117, 121], ["CoV", "TEST", 122, 125], ["2 spike protein", "PROBLEM", 126, 141], ["an ELISA antigen", "TEST", 153, 169], ["serological testing", "TEST", 297, 316], ["immune protection", "TREATMENT", 333, 350]]], ["However, due to its low throughput, PRNT is not practical for large scale serodiagnosis and vaccine evaluation.", [["PRNT", "PROTEIN", 36, 40], ["large scale serodiagnosis", "TEST", 62, 87], ["vaccine evaluation", "TEST", 92, 110]]], ["This is a major gap for COVID-19 surveillance and vaccine development.IntroductionHere, we report a fluorescence-based high-throughput neutralization assay that detects SARS-CoV-2 neutralizing antibodies in patient specimens and yields equivalent results to the gold standard plaque reduction neutralizing assay.A high-throughput fluorescence-based neutralization assay ::: ResultsTo fill in the gap for COVID-19 serodiagnosis and vaccine evaluation, we developed a fluorescence-based assay that rapidly and reliably measures neutralization of a reporter SARS-CoV-2 by antibodies from patient specimens.", [["specimens", "ANATOMY", 215, 224], ["plaque", "ANATOMY", 276, 282], ["specimens", "ANATOMY", 593, 602], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 169, 179], ["patient", "ORGANISM", 207, 214], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 555, 565], ["patient", "ORGANISM", 585, 592], ["SARS-CoV-2 neutralizing antibodies", "PROTEIN", 169, 203], ["antibodies", "PROTEIN", 569, 579], ["patient", "SPECIES", 207, 214], ["patient", "SPECIES", 585, 592], ["SARS-CoV", "SPECIES", 169, 177], ["SARS-CoV", "SPECIES", 555, 563], ["COVID", "TEST", 24, 29], ["vaccine", "TREATMENT", 50, 57], ["a fluorescence", "TEST", 98, 112], ["neutralization assay", "TEST", 135, 155], ["SARS", "TEST", 169, 173], ["CoV", "TEST", 174, 177], ["neutralizing antibodies", "TEST", 180, 203], ["the gold standard plaque reduction neutralizing assay", "TREATMENT", 258, 311], ["COVID", "TEST", 404, 409], ["vaccine evaluation", "TEST", 431, 449], ["a fluorescence", "TEST", 464, 478], ["a reporter SARS", "TEST", 544, 559], ["CoV", "TEST", 560, 563], ["patient specimens", "TEST", 585, 602], ["plaque", "OBSERVATION", 276, 282], ["neutralizing assay", "OBSERVATION", 293, 311]]], ["The assay was built on a stable mNeonGreen (mNG) SARS-CoV-2 where the mNG gene was engineered at the ORF7 of the viral genome (Fig. 1a)10.", [["NG", "CHEMICAL", 45, 47], ["mNG", "GENE_OR_GENE_PRODUCT", 70, 73], ["ORF7", "GENE_OR_GENE_PRODUCT", 101, 105], ["mNG gene", "DNA", 70, 78], ["ORF7", "DNA", 101, 105], ["viral genome", "DNA", 113, 125], ["The assay", "TEST", 0, 9], ["a stable mNeonGreen (mNG", "TREATMENT", 23, 47], ["the viral genome", "TREATMENT", 109, 125], ["viral genome", "OBSERVATION", 113, 125]]], ["The complete sequence of mNG SARS-CoV-2 is described in Supplementary Fig. 1.", [["SARS", "DISEASE", 29, 33], ["mNG SARS-CoV-2", "DNA", 25, 39], ["mNG SARS", "PROBLEM", 25, 33]]], ["Figure 1b depicts the flowchart of the reporter neutralization assay in a 96-well format.", [["the reporter neutralization assay", "TEST", 35, 68]]], ["The assay protocol is detailed in Supplementary Methods.", [["The assay protocol", "TREATMENT", 0, 18]]], ["Briefly, patient sera were serially diluted and incubated with the reporter virus.", [["sera", "ANATOMY", 17, 21], ["patient", "ORGANISM", 9, 16], ["sera", "ORGANISM_SUBSTANCE", 17, 21], ["patient", "SPECIES", 9, 16], ["the reporter virus", "PROBLEM", 63, 81]]], ["After incubation at 37\u00b0C for 1 h, Vero CC-81 cells (pre-seeded in a 96-well plate) were infected with the virus/serum mixtures at a multiplicity of infection (MOI) of 0.5.", [["Vero CC-81 cells", "ANATOMY", 34, 50], ["serum", "ANATOMY", 112, 117], ["CC-81", "CHEMICAL", 39, 44], ["infection", "DISEASE", 148, 157], ["Vero CC-81 cells", "CELL", 34, 50], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["Vero CC-81 cells", "CELL_LINE", 34, 50], ["Vero CC-81", "SPECIES", 34, 44], ["Vero CC", "TEST", 34, 41], ["the virus/serum mixtures", "TEST", 102, 126], ["infection", "PROBLEM", 148, 157], ["infection", "OBSERVATION", 148, 157]]], ["At 16 h post-infection, the mNG-positive cells were quantitated using a high-content imaging reader (Fig. 1b).", [["mNG-positive cells", "ANATOMY", 28, 46], ["mNG", "GENE_OR_GENE_PRODUCT", 28, 31], ["cells", "CELL", 41, 46], ["mNG-positive cells", "CELL_LINE", 28, 46], ["infection", "PROBLEM", 13, 22], ["the mNG", "TEST", 24, 31], ["positive cells", "PROBLEM", 32, 46], ["infection", "OBSERVATION", 13, 22], ["positive cells", "OBSERVATION", 32, 46]]], ["It should be noted that Vero CC-81 cells, not Vero E6 cells, were chosen for the mNG assay to enable accurate quantification of fluorescent cells.", [["Vero CC-81 cells", "ANATOMY", 24, 40], ["Vero E6 cells", "ANATOMY", 46, 59], ["cells", "ANATOMY", 140, 145], ["CC", "CHEMICAL", 29, 31], ["Vero CC-81 cells", "CELL", 24, 40], ["Vero E6 cells", "CELL", 46, 59], ["cells", "CELL", 140, 145], ["Vero CC-81 cells", "CELL_LINE", 24, 40], ["Vero E6 cells", "CELL_LINE", 46, 59], ["fluorescent cells", "CELL_TYPE", 128, 145], ["Vero CC-81", "SPECIES", 24, 34], ["Vero E6", "SPECIES", 46, 53], ["Vero CC", "TEST", 24, 31], ["Vero E6 cells", "PROBLEM", 46, 59], ["the mNG assay", "TEST", 77, 90], ["fluorescent cells", "PROBLEM", 128, 145], ["E6 cells", "OBSERVATION", 51, 59], ["fluorescent cells", "OBSERVATION", 128, 145]]], ["Sixty COVID-19 serum specimens from RT-PCR-confirmed patients and 60 non-COVID-19 serum samples (archived before COVID-19 emergence) were analyzed using the reporter virus.", [["serum specimens", "ANATOMY", 15, 30], ["serum samples", "ANATOMY", 82, 95], ["serum specimens", "ORGANISM_SUBSTANCE", 15, 30], ["patients", "ORGANISM", 53, 61], ["serum samples", "ORGANISM_SUBSTANCE", 82, 95], ["patients", "SPECIES", 53, 61], ["Sixty COVID", "TEST", 0, 11], ["serum specimens", "TEST", 15, 30], ["RT", "TEST", 36, 38], ["PCR", "TEST", 39, 42], ["non-COVID", "TEST", 69, 78], ["serum samples", "TEST", 82, 95], ["COVID", "TEST", 113, 118], ["the reporter virus", "PROBLEM", 153, 171]]], ["For some COVID-19-positive specimens, the sample collection days post viral RT-PCR positive were available and are indicated in Table 1.", [["specimens", "ANATOMY", 27, 36], ["sample", "ANATOMY", 42, 48], ["COVID-19", "GENE_OR_GENE_PRODUCT", 9, 17], ["some COVID", "TEST", 4, 14], ["the sample collection", "TEST", 38, 59], ["viral RT-PCR", "TEST", 70, 82]]], ["After reporter viral infection, the cells turned green in the absence of serum (Fig. 1c, bottom panel); in contrast, incubation of the reporter virus with COVID-19 patient serum decreased the number of fluorescent cells (top panel).", [["cells", "ANATOMY", 36, 41], ["serum", "ANATOMY", 73, 78], ["serum", "ANATOMY", 172, 177], ["cells", "ANATOMY", 214, 219], ["viral infection", "DISEASE", 15, 30], ["cells", "CELL", 36, 41], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["COVID-19", "ORGANISM", 155, 163], ["patient", "ORGANISM", 164, 171], ["serum", "ORGANISM_SUBSTANCE", 172, 177], ["cells", "CELL", 214, 219], ["COVID", "PROTEIN", 155, 160], ["fluorescent cells", "CELL_TYPE", 202, 219], ["patient", "SPECIES", 164, 171], ["reporter viral infection", "PROBLEM", 6, 30], ["the cells", "PROBLEM", 32, 41], ["serum (Fig. 1c", "TEST", 73, 87], ["bottom panel", "TEST", 89, 101], ["the reporter virus", "TEST", 131, 149], ["COVID", "TEST", 155, 160], ["patient serum", "TEST", 164, 177], ["top panel", "TEST", 221, 230], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30], ["fluorescent cells", "OBSERVATION", 202, 219]]], ["A dose\u2013response curve was obtained between the number of fluorescent cells and the fold of serum dilution (Fig. 1d and Supplementary Fig. 2), which allowed for determination of the dilution fold that neutralized 50% of fluorescent cells (NT50).", [["cells", "ANATOMY", 69, 74], ["serum", "ANATOMY", 91, 96], ["cells", "ANATOMY", 231, 236], ["cells", "CELL", 69, 74], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["cells", "CELL", 231, 236], ["NT50", "CELL", 238, 242], ["fluorescent cells", "CELL_TYPE", 57, 74], ["fluorescent cells", "CELL_TYPE", 219, 236], ["A dose\u2013response curve", "TEST", 0, 21], ["serum dilution", "TEST", 91, 105], ["the dilution fold", "TREATMENT", 177, 194], ["fluorescent cells", "TEST", 219, 236]]], ["The reporter assay rapidly diagnosed 120 specimens within 24 h: all 60 COVID-19 sera (specimens 1\u201360) showed positive NT50 of 35 to 5711, and all 60 non-COVID-19 sera (specimens 61\u2013120) showed negative NT50 of <20 (Table 1).Assay validation by plaque reduction test ::: ResultsTo validate the reporter virus neutralization results, we performed the conventional PRNT on the same set of patient specimens.", [["specimens", "ANATOMY", 41, 50], ["sera", "ANATOMY", 80, 84], ["specimens", "ANATOMY", 86, 95], ["sera", "ANATOMY", 162, 166], ["specimens", "ANATOMY", 168, 177], ["plaque", "ANATOMY", 244, 250], ["specimens", "ANATOMY", 394, 403], ["plaque reduction", "DISEASE", 244, 260], ["sera", "ORGANISM_SUBSTANCE", 80, 84], ["sera", "ORGANISM_SUBSTANCE", 162, 166], ["patient", "ORGANISM", 386, 393], ["PRNT", "DNA", 362, 366], ["patient", "SPECIES", 386, 393], ["The reporter assay", "TEST", 0, 18], ["COVID", "TEST", 71, 76], ["sera (specimens", "TEST", 80, 95], ["COVID", "TEST", 153, 158], ["sera", "TEST", 162, 166], ["specimens", "TEST", 168, 177], ["Assay validation", "TEST", 224, 240], ["the reporter virus neutralization", "TEST", 289, 322], ["the conventional PRNT", "TEST", 345, 366], ["patient specimens", "TEST", 386, 403]]], ["All 60 negative sera (specimens 61\u2013120) exhibited PRNT50 of <20 (Table 1).", [["sera", "ANATOMY", 16, 20], ["specimens", "ANATOMY", 22, 31], ["sera", "ORGANISM_SUBSTANCE", 16, 20], ["sera", "TEST", 16, 20], ["specimens", "TEST", 22, 31], ["PRNT50", "TEST", 50, 56]]], ["Among the 60 positive specimens, 57 sera (specimens 4\u201360) showed PRNT50 of 40 to 3200, whereas 3 sera (specimens 1\u20133) exhibited PRNT50 of <20 (Table 1).", [["specimens", "ANATOMY", 22, 31], ["sera", "ANATOMY", 36, 40], ["specimens", "ANATOMY", 42, 51], ["sera", "ANATOMY", 97, 101], ["specimens", "ANATOMY", 103, 112], ["sera", "ORGANISM_SUBSTANCE", 36, 40], ["sera", "ORGANISM_SUBSTANCE", 97, 101], ["sera (specimens", "TEST", 36, 51], ["PRNT50", "TEST", 65, 71], ["sera", "TEST", 97, 101], ["specimens", "TEST", 103, 112], ["PRNT50", "TEST", 128, 134]]], ["The discrepancy between the PRNT50 and NT50 values for specimens 1\u20133 is likely due to the early infection time (within 5 days post RT-PCR positive) when neutralizing antibodies just began to develop; this discrepancy suggests that the mNG SARS-CoV-2 assay has a higher sensitivity than the conventional PRNT assay.", [["specimens", "ANATOMY", 55, 64], ["infection", "DISEASE", 96, 105], ["PRNT50", "GENE_OR_GENE_PRODUCT", 28, 34], ["NT50", "GENE_OR_GENE_PRODUCT", 39, 43], ["PRNT50", "DNA", 28, 34], ["NT50", "DNA", 39, 43], ["neutralizing antibodies", "PROTEIN", 153, 176], ["PRNT", "PROTEIN", 303, 307], ["the PRNT50 and NT50 values", "TEST", 24, 50], ["specimens", "TEST", 55, 64], ["the early infection time", "PROBLEM", 86, 110], ["RT-PCR", "TEST", 131, 137], ["neutralizing antibodies", "PROBLEM", 153, 176], ["the mNG SARS", "TEST", 231, 243], ["CoV", "TEST", 244, 247], ["a higher sensitivity", "PROBLEM", 260, 280], ["the conventional PRNT assay", "TEST", 286, 313], ["likely due to", "UNCERTAINTY", 72, 85], ["early", "OBSERVATION_MODIFIER", 90, 95], ["infection", "OBSERVATION", 96, 105]]], ["Nevertheless, a strong correlation was observed between the reporter virus and PRNT results, with a correlation efficiency R2 of 0.85 (Fig. 1e).", [["the reporter virus", "TEST", 56, 74], ["a correlation efficiency R2", "TEST", 98, 125]]], ["The results demonstrate that when diagnosing patient specimens, the reporter virus assay delivers neutralization results comparable to the PRNT assay, the gold standard of serological testing.Assay specificity ::: ResultsWe evaluated the specificity of reporter neutralization assay using potentially cross-reactive sera and interfering substances (Table 2).", [["specimens", "ANATOMY", 53, 62], ["sera", "ANATOMY", 316, 320], ["patient", "ORGANISM", 45, 52], ["sera", "ORGANISM_SUBSTANCE", 316, 320], ["patient", "SPECIES", 45, 52], ["diagnosing patient specimens", "TEST", 34, 62], ["the reporter virus assay", "TEST", 64, 88], ["the PRNT assay", "TEST", 135, 149], ["serological testing", "TEST", 172, 191], ["reporter neutralization assay", "TEST", 253, 282], ["cross-reactive sera and interfering substances", "TREATMENT", 301, 347]]], ["Two groups of specimens were tested for cross reactivity.", [["specimens", "ANATOMY", 14, 23], ["specimens", "CANCER", 14, 23], ["specimens", "TEST", 14, 23]]], ["Group I included 150 clinical sera from patients with antigens or antibodies against different viruses, bacteria, and parasites.", [["sera", "ANATOMY", 30, 34], ["sera", "ORGANISM_SUBSTANCE", 30, 34], ["patients", "ORGANISM", 40, 48], ["antigens", "PROTEIN", 54, 62], ["antibodies", "PROTEIN", 66, 76], ["patients", "SPECIES", 40, 48], ["clinical sera", "TEST", 21, 34], ["antibodies", "PROBLEM", 66, 76], ["different viruses", "PROBLEM", 85, 102], ["bacteria", "PROBLEM", 104, 112], ["parasites", "PROBLEM", 118, 127]]], ["These human specimens were obtained according to two types of diagnostic results: some samples were tested positive for antibodies against specific pathogens (e.g., anti-Chikungunya virus; this group of samples are indicated by prefix \u201canti\u201d in Table 2); other specimens were collected within 1 to 6 months after the patients were tested positive on pathogen antigens or nucleic acids (e.g., adenovirus antigen; this group of samples are not indicated by prefix in Table 2).", [["specimens", "ANATOMY", 12, 21], ["samples", "ANATOMY", 87, 94], ["samples", "ANATOMY", 203, 210], ["specimens", "ANATOMY", 261, 270], ["samples", "ANATOMY", 426, 433], ["nucleic acids", "CHEMICAL", 371, 384], ["human", "ORGANISM", 6, 11], ["specimens", "CANCER", 12, 21], ["samples", "CANCER", 87, 94], ["anti-Chikungunya virus", "ORGANISM", 165, 187], ["samples", "CANCER", 203, 210], ["specimens", "CANCER", 261, 270], ["patients", "ORGANISM", 317, 325], ["nucleic acids", "SIMPLE_CHEMICAL", 371, 384], ["adenovirus", "ORGANISM", 392, 402], ["samples", "CANCER", 426, 433], ["antibodies", "PROTEIN", 120, 130], ["pathogen antigens", "PROTEIN", 350, 367], ["adenovirus antigen", "PROTEIN", 392, 410], ["human", "SPECIES", 6, 11], ["patients", "SPECIES", 317, 325], ["human", "SPECIES", 6, 11], ["These human specimens", "TEST", 0, 21], ["some samples", "TEST", 82, 94], ["antibodies", "PROBLEM", 120, 130], ["specific pathogens", "PROBLEM", 139, 157], ["anti-Chikungunya virus", "PROBLEM", 165, 187], ["other specimens", "TEST", 255, 270], ["pathogen antigens", "TEST", 350, 367], ["nucleic acids", "TEST", 371, 384], ["adenovirus antigen", "PROBLEM", 392, 410]]], ["Group II consisted of 19 samples with albumin, elevated bilirubin, cholesterol, rheumatoid factor, and autoimmune nuclear antibodies.", [["samples", "ANATOMY", 25, 32], ["nuclear", "ANATOMY", 114, 121], ["bilirubin", "CHEMICAL", 56, 65], ["cholesterol", "CHEMICAL", 67, 78], ["bilirubin", "CHEMICAL", 56, 65], ["cholesterol", "CHEMICAL", 67, 78], ["albumin", "GENE_OR_GENE_PRODUCT", 38, 45], ["bilirubin", "SIMPLE_CHEMICAL", 56, 65], ["cholesterol", "SIMPLE_CHEMICAL", 67, 78], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 80, 97], ["albumin", "PROTEIN", 38, 45], ["bilirubin", "PROTEIN", 56, 65], ["rheumatoid factor", "PROTEIN", 80, 97], ["autoimmune nuclear antibodies", "PROTEIN", 103, 132], ["albumin", "TEST", 38, 45], ["elevated bilirubin", "PROBLEM", 47, 65], ["cholesterol", "TEST", 67, 78], ["rheumatoid factor", "PROBLEM", 80, 97], ["autoimmune nuclear antibodies", "PROBLEM", 103, 132], ["elevated bilirubin", "OBSERVATION", 47, 65], ["rheumatoid factor", "OBSERVATION", 80, 97]]], ["None of these specimens cross-neutralized mNG SARS-CoV-2 (Table 2), including the four common cold coronaviruses (NL63, 229E, OC43, and HUK1).", [["specimens", "ANATOMY", 14, 23], ["SARS", "DISEASE", 46, 50], ["OC43", "GENE_OR_GENE_PRODUCT", 126, 130], ["HUK1", "GENE_OR_GENE_PRODUCT", 136, 140], ["these specimens cross", "TEST", 8, 29], ["CoV", "TEST", 51, 54], ["OC43", "TEST", 126, 130]]], ["Despite the low number of common cold coronavirus serum specimens, our result is consistent with the recent reports that sera from common cold coronavirus patients did not cross react with SARS-CoV-25,11.", [["serum specimens", "ANATOMY", 50, 65], ["sera", "ANATOMY", 121, 125], ["cold coronavirus", "DISEASE", 138, 154], ["SARS", "DISEASE", 189, 193], ["coronavirus", "ORGANISM", 38, 49], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["sera", "ORGANISM_SUBSTANCE", 121, 125], ["cold coronavirus", "ORGANISM", 138, 154], ["patients", "ORGANISM", 155, 163], ["SARS-CoV-25,11", "ORGANISM", 189, 203], ["cold coronavirus", "SPECIES", 138, 154], ["patients", "SPECIES", 155, 163], ["cold coronavirus", "SPECIES", 33, 49], ["cold coronavirus", "SPECIES", 138, 154], ["SARS-CoV-25,11", "SPECIES", 189, 203], ["common cold coronavirus serum specimens", "PROBLEM", 26, 65], ["sera from common cold coronavirus", "PROBLEM", 121, 154], ["SARS", "TEST", 189, 193], ["CoV", "TEST", 194, 197], ["low number", "OBSERVATION_MODIFIER", 12, 22], ["consistent with", "UNCERTAINTY", 81, 96]]], ["More specimens are required to further validate the cross reactivity, particularly between SARS-CoV-2 and other human coronaviruses, including SARS-CoV-1 and MERS-CoV.DiscussionIn this study, we developed a rapid fluorescence-based high-throughput assay for COVID-19 serodiagnosis.", [["specimens", "ANATOMY", 5, 14], ["specimens", "CANCER", 5, 14], ["SARS-CoV-2", "ORGANISM", 91, 101], ["human", "ORGANISM", 112, 117], ["SARS-CoV-1", "ORGANISM", 143, 153], ["MERS-CoV", "ORGANISM", 158, 166], ["human", "SPECIES", 112, 117], ["SARS-CoV", "SPECIES", 91, 99], ["human coronaviruses", "SPECIES", 112, 131], ["SARS-CoV-1", "SPECIES", 143, 153], ["MERS-CoV", "SPECIES", 158, 166], ["COVID-19", "SPECIES", 258, 266], ["the cross reactivity", "TEST", 48, 68], ["SARS", "TEST", 91, 95], ["CoV", "TEST", 96, 99], ["other human coronaviruses", "PROBLEM", 106, 131], ["SARS", "TEST", 143, 147], ["CoV", "TEST", 148, 151], ["this study", "TEST", 180, 190], ["a rapid fluorescence", "TEST", 205, 225], ["COVID", "TEST", 258, 263], ["human coronaviruses", "ANATOMY", 112, 131]]], ["The reporter virus assay is superior to many antigen/antibody binding assays because it measures functional SARS-CoV-2 neutralizing activity in the specimens.", [["specimens", "ANATOMY", 148, 157], ["CoV-2", "GENE_OR_GENE_PRODUCT", 113, 118], ["The reporter virus assay", "TEST", 0, 24], ["many antigen/antibody binding assays", "TEST", 40, 76], ["functional SARS", "PROBLEM", 97, 112], ["CoV", "TEST", 113, 116]]], ["When diagnosing patient sera, the reporter virus assay generated NT50 values comparable to the conventional PRNT assay.", [["sera", "ANATOMY", 24, 28], ["patient", "ORGANISM", 16, 23], ["sera", "ORGANISM_SUBSTANCE", 24, 28], ["PRNT", "PROTEIN", 108, 112], ["patient", "SPECIES", 16, 23], ["diagnosing patient sera", "TEST", 5, 28], ["the reporter virus assay", "TEST", 30, 54], ["the conventional PRNT assay", "TEST", 91, 118]]], ["Compared with the PRNT assay, our reporter neutralization test has shortened the assay turnaround time by several days and increased the testing capacity to high throughput.", [["the PRNT assay", "TEST", 14, 28], ["our reporter neutralization test", "TEST", 30, 62], ["the testing capacity", "TEST", 133, 153]]], ["Toward the same direction, VSV and lentivirus pseudotyped with SARS-CoV-2 spike protein have been reported for COVID-19 neutralization assays at biosafety level 2 (BSL-2) lab12.DiscussionSince mNG SARS-CoV-2 is stable and replicates like wild-type virus, our reporter neutralization assay provides an ideal model for high-throughput serological testing.", [["VSV", "ORGANISM", 27, 30], ["lentivirus", "ORGANISM", 35, 45], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 63, 73], ["wild-type virus", "ORGANISM", 238, 253], ["SARS-CoV-2 spike protein", "PROTEIN", 63, 87], ["VSV", "SPECIES", 27, 30], ["lentivirus", "SPECIES", 35, 45], ["SARS-CoV", "SPECIES", 63, 71], ["VSV", "TEST", 27, 30], ["lentivirus pseudotyped", "PROBLEM", 35, 57], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["2 spike protein", "PROBLEM", 72, 87], ["COVID", "TEST", 111, 116], ["neutralization assays", "TEST", 120, 141], ["biosafety level", "TEST", 145, 160], ["BSL", "TEST", 164, 167], ["CoV", "TEST", 202, 205], ["type virus", "PROBLEM", 243, 253], ["our reporter neutralization assay", "TEST", 255, 288], ["serological testing", "TEST", 333, 352], ["lentivirus pseudotyped", "OBSERVATION", 35, 57], ["stable", "OBSERVATION_MODIFIER", 211, 217]]], ["As the mNG SARS-CoV-2 grows to >107 PFU/ml in cell culture10, the reporter virus can be easily scaled up for testing large sample volumes.", [["cell culture10", "ANATOMY", 46, 60], ["sample", "ANATOMY", 123, 129], ["SARS", "DISEASE", 11, 15], ["cell culture10", "CELL", 46, 60], ["the mNG SARS", "TEST", 3, 15], ["CoV", "TEST", 16, 19], ["cell culture10", "TEST", 46, 60], ["the reporter virus", "PROBLEM", 62, 80]]], ["Besides mNG, we have begun to develop other reporter SARS-CoV-2 (e.g., luciferase or mCherry) that can also be used for such serological testing13.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 53, 63], ["luciferase", "GENE_OR_GENE_PRODUCT", 71, 81], ["mCherry", "GENE_OR_GENE_PRODUCT", 85, 92], ["mNG", "PROTEIN", 8, 11], ["luciferase", "PROTEIN", 71, 81], ["mCherry", "PROTEIN", 85, 92], ["such serological testing", "TEST", 120, 144], ["mNG", "OBSERVATION", 8, 11]]], ["Although the current study performed the assay in a 96-well format, the assay can be readily adapted to 384- and 1536-well formats.", [["the current study", "TEST", 9, 26], ["the assay", "TEST", 37, 46], ["the assay", "TEST", 68, 77]]], ["Despite the strengths of high throughput and reliability, the current reporter neutralization assay must be performed in BSL-3 containment.", [["BSL-3", "GENE_OR_GENE_PRODUCT", 121, 126], ["the current reporter neutralization assay", "TEST", 58, 99]]], ["Efforts are ongoing to engineer an attenuated version of SARS-CoV-2 so that the assay could be performed at a BSL-2 facility.", [["SARS", "DISEASE", 57, 61], ["SARS-CoV", "SPECIES", 57, 65], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["the assay", "TEST", 76, 85]]], ["Despite the BSL-3 limitation, the mNG reporter assay offers a rapid, high-throughput platform to test COVID-19 patient sera not previously available.", [["sera", "ANATOMY", 119, 123], ["BSL-3", "GENE_OR_GENE_PRODUCT", 12, 17], ["mNG", "GENE_OR_GENE_PRODUCT", 34, 37], ["patient", "ORGANISM", 111, 118], ["sera", "ORGANISM_SUBSTANCE", 119, 123], ["mNG reporter", "DNA", 34, 46], ["COVID", "PROTEIN", 102, 107], ["patient", "SPECIES", 111, 118], ["the mNG reporter assay", "TEST", 30, 52], ["test COVID", "TEST", 97, 107]]], ["Indeed, the mNG SARS-CoV-2 assay is currently being used to support clinical trials for COVID-19 vaccine candidates14.DiscussionAs neutralizing titer is a key parameter to predict immunity, the reporter neutralization assay should be useful for high-throughput evaluation of COVID-19 vaccines and for identification of high-neutralizing convalescent plasma for therapy.", [["plasma", "ANATOMY", 350, 356], ["convalescent", "ORGANISM", 337, 349], ["plasma", "ORGANISM_SUBSTANCE", 350, 356], ["the mNG SARS", "TEST", 8, 20], ["CoV", "TEST", 21, 24], ["COVID-19 vaccine candidates", "TREATMENT", 88, 115], ["the reporter neutralization assay", "TEST", 190, 223], ["evaluation", "TEST", 261, 271], ["COVID-19 vaccines", "TREATMENT", 275, 292], ["identification", "TEST", 301, 315], ["therapy", "TREATMENT", 361, 368]]], ["Treatment of severe COVID-19 patients with convalescent plasma shows clinical benefits15.", [["plasma", "ANATOMY", 56, 62], ["COVID", "DISEASE", 20, 25], ["patients", "ORGANISM", 29, 37], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["patients", "SPECIES", 29, 37], ["severe COVID", "PROBLEM", 13, 25], ["convalescent plasma", "TEST", 43, 62], ["severe", "OBSERVATION_MODIFIER", 13, 19]]], ["For vaccine development, a standardized neutralizing assay will facilitate down selection of various candidates for clinical development.", [["vaccine development", "TREATMENT", 4, 23], ["a standardized neutralizing assay", "TREATMENT", 25, 58]]], ["Furthermore, the reporter assay could be used over time to monitor the waning of protective neutralizing titers in COVID-19 patients and vaccinated individuals, to study the correlates of protection from SARS-CoV-2, and to monitor high-risk populations (such as healthcare workers) for infection prevention.", [["SARS", "DISEASE", 204, 208], ["infection", "DISEASE", 286, 295], ["patients", "ORGANISM", 124, 132], ["SARS-CoV-2", "ORGANISM", 204, 214], ["patients", "SPECIES", 124, 132], ["SARS-CoV", "SPECIES", 204, 212], ["the reporter assay", "TEST", 13, 31], ["protective neutralizing titers", "TREATMENT", 81, 111], ["infection prevention", "TREATMENT", 286, 306]]], ["Thus, the ability to rapidly measure neutralizing antibody levels in populations is essential for guiding policymakers to reopen the economy and society, deploy healthcare workers, and prepare for SARS-CoV-2 reemergence.Cells ::: MethodsVero (ATCC\u00aeCCL-81) and Vero E6 (ATCC\u00ae CRL-1586) were purchased from the American Type Culture Collection (ATCC, Bethesda, MD), and maintained in a high-glucose Dulbecco\u2019s modified Eagle\u2019s medium (DMEM) supplemented with 10% fetal bovine serum (FBS; HyClone Laboratories, South Logan, UT) and 1% penicillin/streptomycin at 37\u00b0C with 5% CO2.", [["Cells", "ANATOMY", 220, 225], ["fetal bovine serum", "ANATOMY", 461, 479], ["FBS", "ANATOMY", 481, 484], ["SARS", "DISEASE", 197, 201], ["CRL-1586", "CHEMICAL", 275, 283], ["glucose", "CHEMICAL", 389, 396], ["penicillin", "CHEMICAL", 532, 542], ["streptomycin", "CHEMICAL", 543, 555], ["CO2", "CHEMICAL", 572, 575], ["glucose", "CHEMICAL", 389, 396], ["penicillin", "CHEMICAL", 532, 542], ["streptomycin", "CHEMICAL", 543, 555], ["CO2", "CHEMICAL", 572, 575], ["CoV-2", "ORGANISM", 202, 207], ["Cells", "CELL", 220, 225], ["ATCC\u00aeCCL-81", "CELL", 243, 254], ["Vero E6", "CELL", 260, 267], ["ATCC\u00ae", "CELL", 269, 274], ["bovine", "ORGANISM", 467, 473], ["serum", "ORGANISM_SUBSTANCE", 474, 479], ["FBS", "ORGANISM_SUBSTANCE", 481, 484], ["penicillin", "SIMPLE_CHEMICAL", 532, 542], ["streptomycin", "SIMPLE_CHEMICAL", 543, 555], ["CO2", "SIMPLE_CHEMICAL", 572, 575], ["Vero E6", "CELL_LINE", 260, 267], ["bovine", "SPECIES", 467, 473], ["SARS-CoV", "SPECIES", 197, 205], ["ATCC\u00aeCCL-81", "SPECIES", 243, 254], ["Vero E6", "SPECIES", 260, 267], ["ATCC\u00ae", "SPECIES", 269, 274], ["ATCC", "SPECIES", 343, 347], ["bovine", "SPECIES", 467, 473], ["neutralizing antibody levels", "TEST", 37, 65], ["Cells", "TEST", 220, 225], ["Methods", "TEST", 230, 237], ["Vero", "TEST", 237, 241], ["ATCC", "TEST", 243, 247], ["CCL", "TEST", 248, 251], ["Vero", "TEST", 260, 264], ["CRL", "TEST", 275, 278], ["a high-glucose Dulbecco\u2019s modified Eagle\u2019s medium (DMEM)", "TREATMENT", 382, 438], ["fetal bovine serum", "TEST", 461, 479], ["FBS", "TEST", 481, 484], ["1% penicillin", "TREATMENT", 529, 542], ["streptomycin", "TREATMENT", 543, 555]]], ["All culture medium and antibiotics were purchased from ThermoFisher Scientific (Waltham, MA).", [["All culture medium", "TEST", 0, 18], ["antibiotics", "TREATMENT", 23, 34]]], ["All cell lines were tested negative for mycoplasma.mNG SARS-CoV-2 ::: MethodsThe virus stock of mNG SARS-CoV-2 was produced using an infectious complementary DNA (cDNA) clone of SARS-CoV-2 in which the ORF7 of the viral genome was replaced with reporter mNG gene10.", [["cell lines", "ANATOMY", 4, 14], ["cell lines", "CELL", 4, 14], ["mNG SARS-CoV-2", "ORGANISM", 96, 110], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["SARS-CoV-2", "ORGANISM", 178, 188], ["ORF7", "GENE_OR_GENE_PRODUCT", 202, 206], ["mNG", "GENE_OR_GENE_PRODUCT", 254, 257], ["cell lines", "CELL_LINE", 4, 14], ["infectious complementary DNA (cDNA) clone", "DNA", 133, 174], ["SARS-CoV-2", "DNA", 178, 188], ["ORF7", "DNA", 202, 206], ["viral genome", "DNA", 214, 226], ["reporter mNG gene10", "DNA", 245, 264], ["SARS-CoV", "SPECIES", 100, 108], ["SARS-CoV", "SPECIES", 178, 186], ["All cell lines", "TEST", 0, 14], ["mycoplasma.mNG SARS", "TEST", 40, 59], ["mNG SARS", "PROBLEM", 96, 104], ["an infectious complementary DNA", "PROBLEM", 130, 161], ["SARS", "TEST", 178, 182], ["CoV", "TEST", 183, 186], ["the viral genome", "TREATMENT", 210, 226], ["reporter mNG gene10", "TREATMENT", 245, 264], ["cell lines", "OBSERVATION", 4, 14], ["virus stock", "OBSERVATION", 81, 92], ["infectious", "OBSERVATION", 133, 143], ["viral genome", "OBSERVATION", 214, 226]]], ["After rescued from the genome-length viral RNA-electroporated cells, the viral stock was prepared by amplifying the mNG SARS-CoV-2 on Vero E6 cells for one or two rounds.", [["cells", "ANATOMY", 62, 67], ["Vero E6 cells", "ANATOMY", 134, 147], ["cells", "CELL", 62, 67], ["Vero E6 cells", "CELL", 134, 147], ["electroporated cells", "CELL_LINE", 47, 67], ["mNG SARS-CoV-2", "DNA", 116, 130], ["Vero E6 cells", "CELL_LINE", 134, 147], ["Vero E6", "SPECIES", 134, 141], ["the genome-length viral RNA-electroporated cells", "TREATMENT", 19, 67], ["the viral stock", "TREATMENT", 69, 84], ["CoV", "TEST", 125, 128], ["Vero E6 cells", "TREATMENT", 134, 147], ["electroporated cells", "OBSERVATION", 47, 67], ["viral stock", "OBSERVATION", 73, 84]]], ["The titer of the virus stock was determined by a standard plaque assay.Human sera and interfering substances ::: MethodsThe research protocol regarding the use of human serum specimens was reviewed and approved by the University of Texas Medical Branch (UTMB) Institutional Review Board.", [["plaque", "ANATOMY", 58, 64], ["sera", "ANATOMY", 77, 81], ["serum specimens", "ANATOMY", 169, 184], ["Human", "ORGANISM", 71, 76], ["sera", "ORGANISM_SUBSTANCE", 77, 81], ["human", "ORGANISM", 163, 168], ["serum specimens", "ORGANISM_SUBSTANCE", 169, 184], ["Human", "SPECIES", 71, 76], ["human", "SPECIES", 163, 168], ["Human", "SPECIES", 71, 76], ["human", "SPECIES", 163, 168], ["the virus stock", "TREATMENT", 13, 28], ["a standard plaque assay", "TEST", 47, 70], ["Methods", "TREATMENT", 113, 120], ["human serum specimens", "TEST", 163, 184], ["virus stock", "OBSERVATION", 17, 28], ["plaque", "OBSERVATION", 58, 64]]], ["All human serum specimens were obtained at the UTMB.", [["serum specimens", "ANATOMY", 10, 25], ["human", "ORGANISM", 4, 9], ["serum specimens", "ORGANISM_SUBSTANCE", 10, 25], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["All human serum specimens", "TEST", 0, 25]]], ["All specimens were de-identified from patient information.", [["specimens", "ANATOMY", 4, 13], ["specimens", "CANCER", 4, 13], ["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["All specimens", "TEST", 0, 13]]], ["A total of 60 de-identified convalescent sera from COVID-19 patients (confirmed with viral RT-PCR positive) were tested in this study.", [["sera", "ANATOMY", 41, 45], ["convalescent", "ORGANISM", 28, 40], ["sera", "ORGANISM_SUBSTANCE", 41, 45], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["convalescent sera", "TEST", 28, 45], ["COVID", "TEST", 51, 56], ["viral RT-PCR", "TEST", 85, 97], ["this study", "TEST", 123, 133]]], ["Sixty non-COVID-19 sera, collected before COVID-19 emergence16,17, were also tested in the reporter virus and PRNT assays.", [["sera", "ANATOMY", 19, 23], ["sera", "ORGANISM_SUBSTANCE", 19, 23], ["Sixty non-COVID", "TEST", 0, 15], ["COVID", "TEST", 42, 47], ["PRNT assays", "TEST", 110, 121]]], ["For testing cross reactivity, a total of 150 de-identified specimens from patients with antigens or antibodies against different viruses, bacteria, and parasites were tested in the mNG SARS-COV-2 neutralization assay (Table 2).", [["specimens", "ANATOMY", 59, 68], ["specimens", "CANCER", 59, 68], ["patients", "ORGANISM", 74, 82], ["antigens", "PROTEIN", 88, 96], ["antibodies", "PROTEIN", 100, 110], ["patients", "SPECIES", 74, 82], ["testing cross reactivity", "TEST", 4, 28], ["antigens", "TEST", 88, 96], ["antibodies", "PROBLEM", 100, 110], ["different viruses", "PROBLEM", 119, 136], ["bacteria", "PROBLEM", 138, 146], ["parasites", "PROBLEM", 152, 161], ["the mNG SARS", "TEST", 177, 189], ["COV", "TEST", 190, 193]]], ["For testing interfering substances, 19 de-identified serum specimens with albumin, elevated bilirubin, cholesterol, rheumatoid factor, and autoimmune nuclear antibodies were tested in the reporter neutralization assay.", [["serum specimens", "ANATOMY", 53, 68], ["nuclear", "ANATOMY", 150, 157], ["bilirubin", "CHEMICAL", 92, 101], ["cholesterol", "CHEMICAL", 103, 114], ["bilirubin", "CHEMICAL", 92, 101], ["cholesterol", "CHEMICAL", 103, 114], ["serum specimens", "ORGANISM_SUBSTANCE", 53, 68], ["albumin", "GENE_OR_GENE_PRODUCT", 74, 81], ["bilirubin", "SIMPLE_CHEMICAL", 92, 101], ["cholesterol", "SIMPLE_CHEMICAL", 103, 114], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 116, 133], ["albumin", "PROTEIN", 74, 81], ["bilirubin", "PROTEIN", 92, 101], ["rheumatoid factor", "PROTEIN", 116, 133], ["autoimmune nuclear antibodies", "PROTEIN", 139, 168], ["testing interfering substances", "TEST", 4, 34], ["de-identified serum specimens", "TEST", 39, 68], ["albumin", "TEST", 74, 81], ["elevated bilirubin", "PROBLEM", 83, 101], ["cholesterol", "TEST", 103, 114], ["rheumatoid factor", "PROBLEM", 116, 133], ["autoimmune nuclear antibodies", "PROBLEM", 139, 168], ["elevated bilirubin", "OBSERVATION", 83, 101], ["rheumatoid", "ANATOMY", 116, 126]]], ["All human sera were heat-inactivated at 56\u00b0C for 30 min before testing.mNG SARS-CoV-2 reporter neutralization assay ::: MethodsVero CCL-81 cells (1.2 \u00d7 104) in 50 \u00b5l of DMEM (Gibco) containing 2% FBS (Hyclone) and 100 U/ml Penicillium\u2013Streptomycin (P/S; Gibco) were seeded in each well of black \u00b5CLEAR flat-bottom 96-well plate (Greiner Bio-one\u2122).", [["sera", "ANATOMY", 10, 14], ["CCL-81 cells", "ANATOMY", 132, 144], ["NG", "CHEMICAL", 72, 74], ["CCL-81", "CHEMICAL", 132, 138], ["Streptomycin", "CHEMICAL", 235, 247], ["human", "ORGANISM", 4, 9], ["sera", "ORGANISM_SUBSTANCE", 10, 14], ["Vero CCL-81 cells", "CELL", 127, 144], ["FBS", "ORGANISM_SUBSTANCE", 196, 199], ["Hyclone", "ORGANISM_SUBSTANCE", 201, 208], ["Penicillium\u2013Streptomycin", "SIMPLE_CHEMICAL", 223, 247], ["Vero CCL-81 cells", "CELL_LINE", 127, 144], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["Vero CCL-81", "SPECIES", 127, 138], ["All human sera", "TREATMENT", 0, 14], ["testing", "TEST", 63, 70], ["MethodsVero CCL", "TEST", 120, 135], ["DMEM (Gibco)", "TREATMENT", 169, 181], ["2% FBS (Hyclone)", "TREATMENT", 193, 209], ["Penicillium", "TREATMENT", 223, 234], ["Streptomycin (P/S; Gibco)", "TREATMENT", 235, 260], ["CLEAR", "OBSERVATION", 296, 301]]], ["Vero CCL-81 cells, not Vero E6 cells, were selected for the mNG SARS-COV-2 assay to facilitate accurate quantification of fluorescent cells by high-content imaging.", [["CCL-81 cells", "ANATOMY", 5, 17], ["Vero E6 cells", "ANATOMY", 23, 36], ["cells", "ANATOMY", 134, 139], ["Vero CCL-81 cells", "CELL", 0, 17], ["Vero E6 cells", "CELL", 23, 36], ["cells", "CELL", 134, 139], ["Vero CCL-81 cells", "CELL_LINE", 0, 17], ["Vero E6 cells", "CELL_LINE", 23, 36], ["fluorescent cells", "CELL_TYPE", 122, 139], ["Vero CCL-81", "SPECIES", 0, 11], ["Vero E6", "SPECIES", 23, 30], ["Vero CCL", "TEST", 0, 8], ["Vero E6 cells", "PROBLEM", 23, 36], ["the mNG SARS", "TEST", 56, 68], ["COV", "TEST", 69, 72], ["fluorescent cells", "TEST", 122, 139], ["high-content imaging", "TEST", 143, 163], ["E6 cells", "OBSERVATION", 28, 36]]], ["The cells were incubated overnight at 37\u00b0C with 5% CO2.", [["cells", "ANATOMY", 4, 9], ["CO2", "CHEMICAL", 51, 54], ["CO2", "CHEMICAL", 51, 54], ["cells", "CELL", 4, 9], ["CO2", "SIMPLE_CHEMICAL", 51, 54], ["5% CO2", "TREATMENT", 48, 54]]], ["On the following day, each serum was twofold serially diluted in 2% FBS and 100 U/ml P/S DMEM, and incubated with mNG SARS-CoV-2 at 37\u00b0C for 1 h.", [["serum", "ANATOMY", 27, 32], ["FBS", "ANATOMY", 68, 71], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["FBS", "ORGANISM_SUBSTANCE", 68, 71], ["37\u00b0C", "SIMPLE_CHEMICAL", 132, 136], ["each serum", "TEST", 22, 32], ["2% FBS", "TREATMENT", 65, 71]]], ["The virus-serum mixture was transferred to the Vero CCL-81 cell plate with the final multiplicity of infection (MOI) of 0.5.", [["serum", "ANATOMY", 10, 15], ["CCL-81 cell plate", "ANATOMY", 52, 69], ["infection", "DISEASE", 101, 110], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["Vero CCL-81 cell", "CELL", 47, 63], ["Vero CCL-81", "SPECIES", 47, 58], ["The virus-serum mixture", "TEST", 0, 23], ["infection", "PROBLEM", 101, 110], ["virus", "OBSERVATION", 4, 9], ["cell plate", "OBSERVATION", 59, 69], ["infection", "OBSERVATION", 101, 110]]], ["For each serum, the starting dilution was 1/20 with nine two-fold dilutions to the final dilution of 1/5120.", [["serum", "ANATOMY", 9, 14], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["each serum", "TEST", 4, 14]]], ["After incubating the infected cells at 37\u00b0C for 16 h, 25 \u03bcl of Hoechst 33342 Solution (400-fold diluted in Hank\u2019s Balanced Salt Solution; Gibco) were added to each well to stain cell nucleus.", [["cells", "ANATOMY", 30, 35], ["cell nucleus", "ANATOMY", 178, 190], ["Hoechst 33342", "CHEMICAL", 63, 76], ["Hoechst 33342", "CHEMICAL", 63, 76], ["cells", "CELL", 30, 35], ["Hoechst 33342", "SIMPLE_CHEMICAL", 63, 76], ["cell nucleus", "CELL", 178, 190], ["infected cells", "CELL_TYPE", 21, 35], ["the infected cells", "TREATMENT", 17, 35], ["Hoechst 33342 Solution", "TREATMENT", 63, 85], ["Balanced Salt Solution", "TREATMENT", 114, 136], ["Gibco)", "TREATMENT", 138, 144], ["infected cells", "OBSERVATION", 21, 35], ["cell nucleus", "OBSERVATION", 178, 190]]], ["The plate was sealed with Breath-Easy sealing membrane (Diversified Biotech), incubated at 37\u00b0C for 20 min, and quantified for mNG fluorescence on CytationTM 7 (BioTek).", [["membrane", "ANATOMY", 46, 54], ["mNG", "SIMPLE_CHEMICAL", 127, 130], ["The plate", "TREATMENT", 0, 9], ["Easy sealing membrane", "TREATMENT", 33, 54], ["mNG fluorescence", "PROBLEM", 127, 143], ["CytationTM", "TREATMENT", 147, 157], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["The raw images (2 \u00d7 2 montage) were acquired using 4\u00d7 objective, processed, and stitched using the default setting.", [["The raw images", "TEST", 0, 14]]], ["The total cells (indicated by nucleus staining) and mNG-positive cells were quantified for each well.", [["cells", "ANATOMY", 10, 15], ["nucleus", "ANATOMY", 30, 37], ["mNG-positive cells", "ANATOMY", 52, 70], ["cells", "CELL", 10, 15], ["nucleus", "CELLULAR_COMPONENT", 30, 37], ["mNG", "GENE_OR_GENE_PRODUCT", 52, 55], ["mNG-positive cells", "CELL_LINE", 52, 70], ["The total cells", "TEST", 0, 15], ["nucleus staining", "TEST", 30, 46], ["mNG", "TEST", 52, 55], ["total cells", "OBSERVATION", 4, 15], ["positive cells", "OBSERVATION", 56, 70]]], ["Infection rates were determined by dividing the mNG-positive cell number to total cell number.", [["cell", "ANATOMY", 61, 65], ["cell", "ANATOMY", 82, 86], ["mNG", "GENE_OR_GENE_PRODUCT", 48, 51], ["cell", "CELL", 61, 65], ["cell", "CELL", 82, 86], ["mNG", "PROTEIN", 48, 51], ["Infection rates", "PROBLEM", 0, 15], ["positive cell", "OBSERVATION_MODIFIER", 52, 65], ["total cell", "OBSERVATION_MODIFIER", 76, 86]]], ["Relative infection rates were obtained by normalizing the infection rates of serum-treated groups to those of non-serum-treated controls.", [["serum", "ANATOMY", 77, 82], ["infection", "DISEASE", 9, 18], ["infection", "DISEASE", 58, 67], ["non-serum", "CHEMICAL", 110, 119], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["non-serum", "SIMPLE_CHEMICAL", 110, 119], ["Relative infection rates", "PROBLEM", 0, 24], ["the infection rates of serum", "PROBLEM", 54, 82], ["non-serum-treated controls", "TREATMENT", 110, 136], ["infection", "OBSERVATION", 9, 18], ["infection", "OBSERVATION", 58, 67]]], ["The curves of the relative infection rates versus the serum dilutions (log10 values) were plotted using Prism 8 (GraphPad).", [["serum", "ANATOMY", 54, 59], ["infection", "DISEASE", 27, 36], ["serum", "ORGANISM_SUBSTANCE", 54, 59], ["the relative infection rates", "PROBLEM", 14, 42], ["the serum dilutions", "TEST", 50, 69], ["Prism", "TEST", 104, 109], ["relative", "OBSERVATION_MODIFIER", 18, 26], ["infection", "OBSERVATION", 27, 36]]], ["A nonlinear regression method was used to determine the dilution fold that neutralized 50% of mNG fluorescence (NT50).", [["mNG", "SIMPLE_CHEMICAL", 94, 97], ["A nonlinear regression method", "TREATMENT", 0, 29], ["the dilution fold", "PROBLEM", 52, 69], ["mNG fluorescence", "TEST", 94, 110]]], ["Each serum was tested in duplicates.", [["serum", "ANATOMY", 5, 10], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["Each serum", "TEST", 0, 10]]], ["All mNG SARS-CoV-2 reporter neutralization assay was performed at the BSL-3 facility at UTMB.Plaque reduction neutralization test (PRNT) ::: MethodsVero E6 cells (1.2 \u00d7 106 per well) were seeded to six-well plates.", [["Plaque", "ANATOMY", 93, 99], ["Vero E6 cells", "ANATOMY", 148, 161], ["Vero E6 cells", "CELL", 148, 161], ["Vero E6 cells", "CELL_LINE", 148, 161], ["All mNG SARS", "TEST", 0, 12], ["CoV", "TEST", 13, 16], ["reporter neutralization assay", "TEST", 19, 48], ["Plaque reduction neutralization test", "TEST", 93, 129], ["MethodsVero E6 cells", "TREATMENT", 141, 161]]], ["On the following day, 100 PFU of infectious clone-derived wild-type SARS-CoV-2 was incubated with serially diluted serum (total volume of 200 \u00b5l) at 37\u00b0C for 1 h.", [["serum", "ANATOMY", 115, 120], ["clone", "CELL", 44, 49], ["SARS-CoV-2", "ORGANISM", 68, 78], ["serum", "ORGANISM_SUBSTANCE", 115, 120], ["infectious clone", "TEST", 33, 49], ["type SARS", "PROBLEM", 63, 72], ["serially diluted serum (total volume", "TREATMENT", 98, 134]]], ["The virus-serum mixture was added to the pre-seeded Vero E6 cells.", [["serum", "ANATOMY", 10, 15], ["Vero E6 cells", "ANATOMY", 52, 65], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["Vero E6 cells", "CELL", 52, 65], ["pre-seeded Vero E6 cells", "CELL_LINE", 41, 65], ["Vero E6", "SPECIES", 52, 59], ["The virus-serum mixture", "TEST", 0, 23], ["the pre-seeded Vero E6 cells", "TREATMENT", 37, 65], ["virus", "OBSERVATION", 4, 9], ["E6 cells", "OBSERVATION", 57, 65]]], ["After 1 h 37\u00b0C incubation, 2 ml of 2% high gel temperature agar (SeaKem) in DMEM containing 5% FBS and 1% P/S was added to the infected cells.", [["FBS", "ANATOMY", 95, 98], ["cells", "ANATOMY", 136, 141], ["FBS", "ORGANISM_SUBSTANCE", 95, 98], ["cells", "CELL", 136, 141], ["infected cells", "CELL_TYPE", 127, 141], ["2% high gel temperature agar (SeaKem) in DMEM", "TREATMENT", 35, 80], ["5% FBS", "TREATMENT", 92, 98], ["1% P/S", "TREATMENT", 103, 109], ["the infected cells", "PROBLEM", 123, 141], ["infected cells", "OBSERVATION", 127, 141]]], ["After 2 days of incubation, 2 ml neutral red (1 g/l in PBS; Sigma) was added to the agar-covered cells.", [["cells", "ANATOMY", 97, 102], ["cells", "CELL", 97, 102], ["agar-covered cells", "CELL_LINE", 84, 102], ["incubation", "TREATMENT", 16, 26], ["2 ml neutral red (1 g/l in PBS", "TREATMENT", 28, 58]]], ["After another 5-h incubation, neutral red was removed.", [["neutral red", "TREATMENT", 30, 41]]], ["Plaques were counted for NT50 calculation.", [["Plaques", "ANATOMY", 0, 7], ["Plaques", "PROBLEM", 0, 7], ["NT50 calculation", "TEST", 25, 41]]], ["Each serum was tested in duplicates.", [["serum", "ANATOMY", 5, 10], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["Each serum", "TEST", 0, 10]]], ["The PRNT assay was performed at the BSL-3 facility at UTMB.Statistical analysis ::: MethodsThe correlation of the NT50 values from mNG reporter SARS-CoV-2 assay and the PRNT50 values from plaque neutralization assay was analyzed using a linear regression model in the software Prism 8 (GraphPad).", [["plaque", "ANATOMY", 188, 194], ["NT50", "GENE_OR_GENE_PRODUCT", 114, 118], ["PRNT50", "GENE_OR_GENE_PRODUCT", 169, 175], ["plaque", "PATHOLOGICAL_FORMATION", 188, 194], ["PRNT", "PROTEIN", 4, 8], ["NT50", "PROTEIN", 114, 118], ["PRNT50", "PROTEIN", 169, 175], ["The PRNT assay", "TEST", 0, 14], ["Methods", "TREATMENT", 84, 91], ["the NT50 values", "TEST", 110, 125], ["mNG reporter SARS", "TEST", 131, 148], ["CoV", "TEST", 149, 152], ["the PRNT50 values", "TEST", 165, 182], ["plaque neutralization assay", "TEST", 188, 215], ["a linear regression model", "TREATMENT", 235, 260]]]], "PMC7087286": [["IntroductionPorcine deltacoronavirus (PDCoV), a member of the family Coronaviridae, order Nidovirales, is an enveloped, single-stranded positive-sense RNA virus [1].", [["deltacoronavirus", "GENE_OR_GENE_PRODUCT", 20, 36], ["PDCoV", "GENE_OR_GENE_PRODUCT", 38, 43], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 69, 82], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 90, 101], ["IntroductionPorcine deltacoronavirus", "TREATMENT", 0, 36], ["Nidovirales", "TREATMENT", 90, 101]]], ["The genome of PDCoV is 25.4 kb in length, making it the smallest genome among the known coronaviruses (CoVs) [2].", [["PDCoV", "GENE_OR_GENE_PRODUCT", 14, 19], ["coronaviruses", "ORGANISM", 88, 101], ["PDCoV", "DNA", 14, 19], ["25.4 kb", "OBSERVATION_MODIFIER", 23, 30], ["smallest genome", "OBSERVATION", 56, 71], ["coronaviruses", "OBSERVATION", 88, 101]]], ["The coding region of PDCoV is flanked by short 5\u2032 and 3\u2032 untranslated regions (UTRs), and the gene order is 5\u2032-UTR-ORF1a-ORF1b-S-E-M-NS6-N-NS7-3\u2032-UTR.", [["PDCoV", "GENE_OR_GENE_PRODUCT", 21, 26], ["PDCoV", "DNA", 21, 26], ["short 5\u2032 and 3\u2032 untranslated regions", "DNA", 41, 77], ["UTRs", "DNA", 79, 83], ["UTR", "DNA", 111, 114], ["ORF1a", "DNA", 115, 120], ["ORF1b", "DNA", 121, 126], ["S", "DNA", 127, 128], ["E", "DNA", 129, 130], ["NS6", "DNA", 133, 136], ["N", "DNA", 137, 138], ["NS7", "DNA", 139, 142], ["3\u2032", "DNA", 143, 145], ["UTR", "DNA", 146, 149], ["short 5\u2032 and 3\u2032 untranslated regions", "PROBLEM", 41, 77], ["UTR", "TEST", 111, 114], ["ORF1a", "TEST", 115, 120], ["ORF1b", "TEST", 121, 126], ["NS6", "TEST", 133, 136], ["NS7", "TEST", 139, 142], ["PDCoV", "OBSERVATION", 21, 26], ["short", "OBSERVATION_MODIFIER", 41, 46]]], ["PDCoV encodes at least four structural proteins, including the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, as well as two accessory proteins, NS6 and NS7 [3\u20136].", [["membrane", "ANATOMY", 88, 96], ["PDCoV", "GENE_OR_GENE_PRODUCT", 0, 5], ["E", "GENE_OR_GENE_PRODUCT", 84, 85], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["nucleocapsid (N) proteins", "GENE_OR_GENE_PRODUCT", 106, 131], ["NS6", "GENE_OR_GENE_PRODUCT", 168, 171], ["NS7", "GENE_OR_GENE_PRODUCT", 176, 179], ["PDCoV", "PROTEIN", 0, 5], ["structural proteins", "PROTEIN", 28, 47], ["spike (S), envelope (E), membrane (M)", "PROTEIN", 63, 100], ["nucleocapsid (N) proteins", "PROTEIN", 106, 131], ["accessory proteins", "PROTEIN", 148, 166], ["NS6", "PROTEIN", 168, 171], ["NS7", "PROTEIN", 176, 179], ["3\u20136", "PROTEIN", 181, 184], ["the spike (S", "TEST", 59, 71], ["envelope (E), membrane (M), and nucleocapsid (N) proteins", "TEST", 74, 131], ["two accessory proteins", "TEST", 144, 166], ["NS7", "TEST", 176, 179]]], ["The S protein is responsible for receptor binding and membrane fusion and acts as the major antigen inducing neutralizing antibodies [7].", [["membrane", "ANATOMY", 54, 62], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["S protein", "PROTEIN", 4, 13], ["neutralizing antibodies", "PROTEIN", 109, 132], ["The S protein", "TEST", 0, 13], ["receptor binding", "PROBLEM", 33, 49], ["membrane fusion", "TREATMENT", 54, 69], ["neutralizing antibodies", "PROBLEM", 109, 132], ["membrane fusion", "OBSERVATION", 54, 69]]], ["The N protein is highly conserved and plays a critical role in viral RNA encapsidation [8].", [["N protein", "PROTEIN", 4, 13], ["The N protein", "TEST", 0, 13], ["viral RNA encapsidation", "TREATMENT", 63, 86]]], ["The M and E proteins are important for virion assembly and budding [9].IntroductionDuring a molecular surveillance study performed by Yuen and coworkers in 2012, PDCoV was first identified in swine specimens in Hong Kong [10].", [["virion", "ANATOMY", 39, 45], ["specimens", "ANATOMY", 198, 207], ["virion", "CELLULAR_COMPONENT", 39, 45], ["PDCoV", "CANCER", 162, 167], ["swine", "ORGANISM", 192, 197], ["M and E proteins", "PROTEIN", 4, 20], ["swine", "SPECIES", 192, 197], ["swine", "SPECIES", 192, 197], ["The M and E proteins", "TREATMENT", 0, 20], ["a molecular surveillance study", "TEST", 90, 120]]], ["Following the first detection of PDCoV in pigs with diarrhea in Ohio, USA, in February 2014, dozens of PDCoV strains were identified in the United States, Canada, South Korea, China, and Thailand [4, 5, 11\u201316].", [["PDCoV", "CHEMICAL", 33, 38], ["diarrhea", "DISEASE", 52, 60], ["PDCoV", "CANCER", 33, 38], ["pigs", "ORGANISM", 42, 46], ["pigs", "SPECIES", 42, 46], ["PDCoV", "SPECIES", 33, 38], ["pigs", "SPECIES", 42, 46], ["PDCoV", "SPECIES", 103, 108], ["PDCoV", "TREATMENT", 33, 38], ["diarrhea", "PROBLEM", 52, 60], ["PDCoV strains", "TREATMENT", 103, 116], ["diarrhea", "OBSERVATION", 52, 60]]], ["Piglets infected with PDCoV are characterized by watery diarrhea, variable vomiting, and dehydration [3].", [["PDCoV", "CHEMICAL", 22, 27], ["watery diarrhea", "DISEASE", 49, 64], ["vomiting", "DISEASE", 75, 83], ["dehydration", "DISEASE", 89, 100], ["Piglets", "ORGANISM", 0, 7], ["Piglets", "SPECIES", 0, 7], ["PDCoV", "SPECIES", 22, 27], ["PDCoV", "TREATMENT", 22, 27], ["watery diarrhea", "PROBLEM", 49, 64], ["variable vomiting", "PROBLEM", 66, 83], ["dehydration", "PROBLEM", 89, 100], ["infected", "OBSERVATION", 8, 16], ["watery", "OBSERVATION_MODIFIER", 49, 55], ["diarrhea", "OBSERVATION", 56, 64], ["variable", "OBSERVATION_MODIFIER", 66, 74], ["vomiting", "OBSERVATION", 75, 83]]], ["Notably, PDCoV-positive piglets are frequently co-infected with other enteric viruses, such as porcine epidemic diarrhea virus (PEDV), rotavirus, transmissible gastroenteritis coronavirus (TGEV), and porcine respiratory coronavirus (PRCV), which considerably increases the morbidity and mortality of piglets [17].", [["piglets", "ANATOMY", 24, 31], ["enteric viruses", "DISEASE", 70, 85], ["porcine epidemic diarrhea virus", "DISEASE", 95, 126], ["rotavirus", "DISEASE", 135, 144], ["transmissible gastroenteritis coronavirus", "DISEASE", 146, 187], ["TGEV", "DISEASE", 189, 193], ["porcine respiratory coronavirus", "DISEASE", 200, 231], ["PRCV", "DISEASE", 233, 237], ["PDCoV", "GENE_OR_GENE_PRODUCT", 9, 14], ["piglets", "ORGANISM", 24, 31], ["porcine epidemic diarrhea virus", "ORGANISM", 95, 126], ["rotavirus", "ORGANISM", 135, 144], ["transmissible gastroenteritis coronavirus", "ORGANISM", 146, 187], ["TGEV", "ORGANISM", 189, 193], ["porcine respiratory coronavirus", "ORGANISM", 200, 231], ["piglets", "ORGANISM", 300, 307], ["PDCoV", "PROTEIN", 9, 14], ["piglets", "SPECIES", 24, 31], ["porcine epidemic diarrhea virus", "SPECIES", 95, 126], ["transmissible gastroenteritis coronavirus", "SPECIES", 146, 187], ["TGEV", "SPECIES", 189, 193], ["porcine respiratory coronavirus", "SPECIES", 200, 231], ["piglets", "SPECIES", 300, 307], ["porcine epidemic diarrhea virus", "SPECIES", 95, 126], ["PEDV", "SPECIES", 128, 132], ["rotavirus", "SPECIES", 135, 144], ["transmissible gastroenteritis coronavirus", "SPECIES", 146, 187], ["TGEV", "SPECIES", 189, 193], ["porcine respiratory coronavirus", "SPECIES", 200, 231], ["PRCV", "SPECIES", 233, 237], ["PDCoV", "TEST", 9, 14], ["positive piglets", "PROBLEM", 15, 31], ["other enteric viruses", "PROBLEM", 64, 85], ["porcine epidemic diarrhea virus", "PROBLEM", 95, 126], ["PEDV", "PROBLEM", 128, 132], ["rotavirus", "PROBLEM", 135, 144], ["transmissible gastroenteritis coronavirus (TGEV)", "PROBLEM", 146, 194], ["porcine respiratory coronavirus", "PROBLEM", 200, 231], ["positive piglets", "OBSERVATION", 15, 31], ["enteric", "ANATOMY", 70, 77], ["viruses", "OBSERVATION", 78, 85], ["gastroenteritis coronavirus", "OBSERVATION", 160, 187], ["respiratory coronavirus", "OBSERVATION", 208, 231]]], ["PDCoV outbreaks have been reported in many countries worldwide and have caused significant economic losses in the pork industry.", [["pork", "ORGANISM_SUBDIVISION", 114, 118], ["PDCoV", "SPECIES", 0, 5], ["pork", "SPECIES", 114, 118], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["economic", "OBSERVATION_MODIFIER", 91, 99], ["losses", "OBSERVATION", 100, 106]]], ["Moreover, due to the unique genome replication strategy of coronavirus, PDCoV undergoes RNA mutation and recombination events at high frequency, giving rise to new variants, which makes it extremely difficult to control and eliminate [18].IntroductionIn 2015, Saif and coworkers reported that a PDCoV strain named OH-FD22 caused severe atrophic enteritis accompanied by severe diarrhea and vomiting in gnotobiotic piglets [19].", [["OH-FD22", "CHEMICAL", 314, 321], ["enteritis", "DISEASE", 345, 354], ["diarrhea", "DISEASE", 377, 385], ["vomiting", "DISEASE", 390, 398], ["OH-FD22", "CHEMICAL", 314, 321], ["coronavirus", "ORGANISM", 59, 70], ["PDCoV", "GENE_OR_GENE_PRODUCT", 72, 77], ["OH-FD22", "SIMPLE_CHEMICAL", 314, 321], ["PDCoV", "DNA", 72, 77], ["piglets", "SPECIES", 414, 421], ["coronavirus", "PROBLEM", 59, 70], ["PDCoV", "TREATMENT", 72, 77], ["RNA mutation", "PROBLEM", 88, 100], ["recombination events", "PROBLEM", 105, 125], ["new variants", "PROBLEM", 160, 172], ["a PDCoV strain", "TREATMENT", 293, 307], ["severe atrophic enteritis", "PROBLEM", 329, 354], ["severe diarrhea", "PROBLEM", 370, 385], ["vomiting", "PROBLEM", 390, 398], ["gnotobiotic piglets", "TREATMENT", 402, 421], ["severe", "OBSERVATION_MODIFIER", 329, 335], ["atrophic", "OBSERVATION_MODIFIER", 336, 344], ["enteritis", "OBSERVATION", 345, 354], ["severe", "OBSERVATION_MODIFIER", 370, 376], ["diarrhea", "OBSERVATION", 377, 385]]], ["Macroscopic examination revealed that the jejunum and ileum are the major targets for PDCoV infection, and the pathological lesions were similar to, but milder than, those caused by PEDV [19].", [["jejunum", "ANATOMY", 42, 49], ["ileum", "ANATOMY", 54, 59], ["lesions", "ANATOMY", 124, 131], ["infection", "DISEASE", 92, 101], ["jejunum", "MULTI-TISSUE_STRUCTURE", 42, 49], ["ileum", "ORGAN", 54, 59], ["PDCoV", "CANCER", 86, 91], ["lesions", "PATHOLOGICAL_FORMATION", 124, 131], ["PDCoV", "SPECIES", 86, 91], ["PEDV", "SPECIES", 182, 186], ["Macroscopic examination", "TEST", 0, 23], ["PDCoV infection", "PROBLEM", 86, 101], ["the pathological lesions", "PROBLEM", 107, 131], ["PEDV", "PROBLEM", 182, 186], ["jejunum", "ANATOMY", 42, 49], ["ileum", "ANATOMY", 54, 59], ["infection", "OBSERVATION", 92, 101], ["pathological", "OBSERVATION_MODIFIER", 111, 123], ["lesions", "OBSERVATION", 124, 131]]], ["Subsequently, the pathogenicity of several American strains, including USA/IL/2014, Michigan/8977, and Ohio CVM I, was investigated in piglets [20].", [["IL", "GENE_OR_GENE_PRODUCT", 75, 77], ["piglets", "ORGANISM", 135, 142], ["piglets", "SPECIES", 135, 142], ["USA/IL/2014, Michigan/8977", "SPECIES", 71, 97], ["Ohio CVM I", "SPECIES", 103, 113]]], ["These American strains exhibited pathogenic characteristics similar to those of OH-FD22.", [["OH-FD22", "CHEMICAL", 80, 87], ["OH-FD22", "SIMPLE_CHEMICAL", 80, 87], ["pathogenic characteristics", "PROBLEM", 33, 59]]], ["In addition, it has been reported that newborn piglets inoculated with two recent Chinese PDCoV isolates, named CHN-HN-2014 and CHN-GD-2016, developed clear clinical signs, including severe diarrhea, vomiting, and dehydration [21, 22].IntroductionIn this study, we successfully isolated a high-growth PDCoV strain, hereafter referred to as CHN-HG-2017, from feces of a pig on a farm located in Huanggang, Hubei province.", [["feces", "ANATOMY", 358, 363], ["CHN", "CHEMICAL", 112, 115], ["diarrhea", "DISEASE", 190, 198], ["vomiting", "DISEASE", 200, 208], ["dehydration", "DISEASE", 214, 225], ["CHN-HG-2017", "CHEMICAL", 340, 351], ["piglets", "ORGANISM", 47, 54], ["PDCoV", "ORGANISM", 90, 95], ["CHN-HN-2014", "CELL", 112, 123], ["CHN-GD-2016", "CELL", 128, 139], ["CHN-HG-2017", "CELL", 340, 351], ["feces", "ORGANISM_SUBDIVISION", 358, 363], ["pig", "ORGANISM", 369, 372], ["piglets", "SPECIES", 47, 54], ["pig", "SPECIES", 369, 372], ["Chinese PDCoV", "SPECIES", 82, 95], ["pig", "SPECIES", 369, 372], ["clear clinical signs", "PROBLEM", 151, 171], ["severe diarrhea", "PROBLEM", 183, 198], ["vomiting", "PROBLEM", 200, 208], ["dehydration", "PROBLEM", 214, 225], ["this study", "TEST", 250, 260], ["a high-growth PDCoV strain", "PROBLEM", 287, 313], ["severe", "OBSERVATION_MODIFIER", 183, 189], ["diarrhea", "OBSERVATION", 190, 198]]], ["Analysis of the genomic sequence suggested that CHN-HG-2017 is a potential recombinant virus derived from Chinese and Vietnam PDCoV strains.", [["CHN-HG-2017", "CHEMICAL", 48, 59], ["the genomic sequence", "TEST", 12, 32], ["HG", "TEST", 52, 54], ["a potential recombinant virus", "PROBLEM", 63, 92], ["Vietnam PDCoV strains", "TREATMENT", 118, 139]]], ["Furthermore, the pathogenicity of CHN-HG-2017 in 5-day-old piglets was investigated by clinical assessment, the quantification of viral shedding and distribution, histology, and immunohistochemistry.Collection of clinical samples and treatment ::: Materials and methodsFeces (n = 17) from pigs experiencing diarrhea were obtained from farms in Huanggang, Hubei province.", [["samples", "ANATOMY", 222, 229], ["CHN-HG-2017", "CHEMICAL", 34, 45], ["diarrhea", "DISEASE", 307, 315], ["CHN-HG-2017", "CELL", 34, 45], ["piglets", "ORGANISM", 59, 66], ["pigs", "ORGANISM", 289, 293], ["piglets", "SPECIES", 59, 66], ["pigs", "SPECIES", 289, 293], ["pigs", "SPECIES", 289, 293], ["HG", "TEST", 38, 40], ["clinical assessment", "TEST", 87, 106], ["viral shedding", "PROBLEM", 130, 144], ["histology", "TEST", 163, 172], ["immunohistochemistry", "TEST", 178, 198], ["methodsFeces", "TEST", 262, 274], ["diarrhea", "PROBLEM", 307, 315], ["viral shedding", "OBSERVATION", 130, 144]]], ["They tested PDCoV-positive by N-gene-based RT-PCR as reported previously [12].", [["PDCoV", "GENE_OR_GENE_PRODUCT", 12, 17], ["PDCoV", "DNA", 12, 17], ["N-gene", "DNA", 30, 36], ["PDCoV", "TEST", 12, 17], ["PCR", "TEST", 46, 49]]], ["These clinical samples were subsequently subjected to virus isolation.", [["samples", "ANATOMY", 15, 22], ["samples", "CANCER", 15, 22], ["These clinical samples", "TEST", 0, 22], ["virus isolation", "TREATMENT", 54, 69]]], ["Briefly, 1 g of PDCoV-positive feces was suspended in 5 ml of Dulbecco\u2032s modified Eagle\u2032s medium (Gibco, Grand Island, NY, USA), vortexed for 5 minutes, and centrifuged at 4000\u00d7g for 15 minutes at 4 \u00b0C. The supernatants were filtered through a 0.22-\u03bcm filter (Millipore, Billerica, MA) and stored at -80 \u00b0C for PDCoV isolation.Virus isolation, propagation, and titration ::: Materials and methodsLLC-PK1 cells (ATCC CL-101) were obtained from the American Type Culture Collection (Rockville, MD, USA) and were used for PDCoV isolation.", [["feces", "ANATOMY", 31, 36], ["supernatants", "ANATOMY", 207, 219], ["methodsLLC-PK1 cells", "ANATOMY", 389, 409], ["ATCC CL-101", "ANATOMY", 411, 422], ["PDCoV", "CHEMICAL", 16, 21], ["PDCoV", "GENE_OR_GENE_PRODUCT", 16, 21], ["feces", "ORGANISM", 31, 36], ["Virus", "ORGANISM", 327, 332], ["methodsLLC-PK1 cells", "CELL", 389, 409], ["ATCC CL-101", "CELL", 411, 422], ["PDCoV", "PROTEIN", 16, 21], ["methodsLLC-PK1 cells", "CELL_LINE", 389, 409], ["ATCC CL-101", "CELL_LINE", 411, 422], ["ATCC CL-101", "SPECIES", 411, 422], ["PDCoV", "SPECIES", 519, 524], ["PDCoV", "TEST", 16, 21], ["positive feces", "PROBLEM", 22, 36], ["a 0.22-\u03bcm filter (Millipore, Billerica, MA", "TREATMENT", 242, 284], ["PDCoV isolation", "TREATMENT", 311, 326], ["Virus isolation", "TREATMENT", 327, 342], ["Materials", "TEST", 375, 384], ["methodsLLC", "TEST", 389, 399], ["PK1 cells", "TEST", 400, 409], ["ATCC CL", "TEST", 411, 418], ["PDCoV isolation", "TREATMENT", 519, 534], ["feces", "OBSERVATION", 31, 36]]], ["LLC-PK1 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS, Gibco).", [["LLC-PK1 cells", "ANATOMY", 0, 13], ["fetal bovine serum", "ANATOMY", 58, 76], ["FBS", "ANATOMY", 78, 81], ["LLC-PK1 cells", "CELL", 0, 13], ["bovine", "ORGANISM", 64, 70], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["FBS", "ORGANISM_SUBSTANCE", 78, 81], ["Gibco", "ORGANISM_SUBSTANCE", 83, 88], ["LLC-PK1 cells", "CELL_LINE", 0, 13], ["bovine", "SPECIES", 64, 70], ["bovine", "SPECIES", 64, 70], ["LLC", "TEST", 0, 3], ["PK1 cells", "PROBLEM", 4, 13], ["DMEM", "TEST", 31, 35], ["fetal bovine serum", "TEST", 58, 76], ["FBS", "TEST", 78, 81], ["PK1 cells", "OBSERVATION", 4, 13]]], ["The maintenance medium for PDCoV propagation was DMEM with 10% tryptose phosphate broth (TPB) and 10 \u03bcg of trypsin (Sigma) per ml.", [["tryptose phosphate", "CHEMICAL", 63, 81], ["tryptose phosphate", "CHEMICAL", 63, 81], ["PDCoV", "SIMPLE_CHEMICAL", 27, 32], ["tryptose phosphate broth", "SIMPLE_CHEMICAL", 63, 87], ["trypsin", "GENE_OR_GENE_PRODUCT", 107, 114], ["trypsin", "PROTEIN", 107, 114], ["PDCoV propagation", "TREATMENT", 27, 44], ["10% tryptose phosphate broth (TPB", "TREATMENT", 59, 92], ["trypsin", "TREATMENT", 107, 114]]], ["Cells were cultured in a 6-well plate until they reached 70-80% confluence and were then washed three times with PBS.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["PBS", "TREATMENT", 113, 116]]], ["Filtered inoculum (500 \u03bcl) in 1.5 ml of maintenance medium was added to the cell monolayers, and the cells were kept at 37 \u00b0C in 5% CO2 for 2 h.", [["cell monolayers", "ANATOMY", 76, 91], ["cells", "ANATOMY", 101, 106], ["CO2", "CHEMICAL", 132, 135], ["CO2", "CHEMICAL", 132, 135], ["cell monolayers", "CELL", 76, 91], ["cells", "CELL", 101, 106], ["CO2", "SIMPLE_CHEMICAL", 132, 135], ["Filtered inoculum", "TREATMENT", 0, 17], ["maintenance medium", "TREATMENT", 40, 58], ["the cell monolayers", "TREATMENT", 72, 91], ["the cells", "TREATMENT", 97, 106], ["inoculum", "OBSERVATION_MODIFIER", 9, 17], ["cell monolayers", "OBSERVATION", 76, 91]]], ["The cells were then washed three times with PBS, and 2 ml of maintenance medium was added to each well.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["PBS", "TREATMENT", 44, 47], ["maintenance medium", "TREATMENT", 61, 79]]], ["The inoculated cells were cultured continuously at 37 \u00b0C in 5% CO2.", [["cells", "ANATOMY", 15, 20], ["CO2", "CHEMICAL", 63, 66], ["CO2", "CHEMICAL", 63, 66], ["cells", "CELL", 15, 20], ["CO2", "SIMPLE_CHEMICAL", 63, 66], ["inoculated cells", "CELL_LINE", 4, 20], ["The inoculated cells", "TEST", 0, 20], ["inoculated cells", "OBSERVATION", 4, 20]]], ["When a cytopathic effect (CPE) was obvious in the infected cells, the plates were frozen and thawed twice.", [["cells", "ANATOMY", 59, 64], ["cells", "CELL", 59, 64], ["infected cells", "CELL_TYPE", 50, 64], ["a cytopathic effect (CPE", "PROBLEM", 5, 29], ["the infected cells", "PROBLEM", 46, 64], ["cytopathic", "OBSERVATION_MODIFIER", 7, 17], ["infected cells", "OBSERVATION", 50, 64]]], ["Subsequently, the supernatants were stored at -80 \u00b0C as seed stocks for plaque purification and for the next passage.", [["supernatants", "ANATOMY", 18, 30], ["plaque", "ANATOMY", 72, 78], ["the supernatants", "TEST", 14, 30], ["plaque purification", "TREATMENT", 72, 91]]], ["The isolates were plaque-purified as described previously [20].", [["plaque", "ANATOMY", 18, 24], ["plaque", "PROBLEM", 18, 24], ["plaque", "OBSERVATION", 18, 24]]], ["The virus titer was determined based on the 50% tissue culture infectious dose (TCID50) on LLC-PK1 cells in 96-well plates as described previously [20].Immunofluorescence assay (IFA) ::: Materials and methodsThe N gene of CHN-HG-2017 was amplified by RT-PCR, and the PCR product was cloned into the pET28a vector.", [["tissue", "ANATOMY", 48, 54], ["LLC-PK1 cells", "ANATOMY", 91, 104], ["tissue", "TISSUE", 48, 54], ["LLC-PK1 cells", "CELL", 91, 104], ["CHN-HG-2017", "CELL", 222, 233], ["pET28a", "GENE_OR_GENE_PRODUCT", 299, 305], ["LLC-PK1 cells", "CELL_LINE", 91, 104], ["N gene", "DNA", 212, 218], ["CHN-HG-2017", "DNA", 222, 233], ["PCR product", "DNA", 267, 278], ["pET28a vector", "DNA", 299, 312], ["The virus titer", "TEST", 0, 15], ["LLC", "TEST", 91, 94], ["PK1 cells", "TEST", 95, 104], ["Immunofluorescence assay", "TEST", 152, 176], ["HG", "TEST", 226, 228], ["PCR", "TEST", 254, 257], ["the PCR product", "TREATMENT", 263, 278], ["virus", "OBSERVATION", 4, 9]]], ["The recombinant plasmid was expressed in Escherichia coli Rosetta (DE3) under IPTG induction.", [["plasmid", "ANATOMY", 16, 23], ["IPTG", "CHEMICAL", 78, 82], ["IPTG", "CHEMICAL", 78, 82], ["Escherichia coli", "ORGANISM", 41, 57], ["Rosetta", "ORGANISM", 58, 65], ["DE3", "GENE_OR_GENE_PRODUCT", 67, 70], ["recombinant plasmid", "DNA", 4, 23], ["Escherichia coli Rosetta", "SPECIES", 41, 65], ["Escherichia coli", "SPECIES", 41, 57], ["The recombinant plasmid", "TREATMENT", 0, 23], ["Escherichia coli Rosetta (DE3", "TREATMENT", 41, 70], ["IPTG induction", "TREATMENT", 78, 92], ["Escherichia coli Rosetta", "OBSERVATION", 41, 65]]], ["Subsequently, female BALB/c mice were immunized with the purified recombinant N protein.", [["female", "ORGANISM", 14, 20], ["BALB/c mice", "ORGANISM", 21, 32], ["purified recombinant N protein", "PROTEIN", 57, 87], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["female BALB/c mice", "TREATMENT", 14, 32]]], ["After hybridoma cell fusion and selection, one strain of hybridoma cells that secreted an anti-N protein monoclonal antibody (mAb), named A3, was selected.Immunofluorescence assay (IFA) ::: Materials and methodsLLC-PK1 cells were seeded on sterilized coverslips placed in 24-well plates and then mock-infected or infected with plaque-purified PDCoV at a multiplicity of infection (MOI) of 0.01.", [["hybridoma cell", "ANATOMY", 6, 20], ["hybridoma cells", "ANATOMY", 57, 72], ["methodsLLC-PK1 cells", "ANATOMY", 204, 224], ["plaque", "ANATOMY", 327, 333], ["PDCoV", "CHEMICAL", 343, 348], ["infection", "DISEASE", 370, 379], ["hybridoma cell", "CELL", 6, 20], ["hybridoma cells", "CELL", 57, 72], ["methodsLLC-PK1 cells", "CELL", 204, 224], ["hybridoma cells", "CELL_LINE", 57, 72], ["anti-N protein monoclonal antibody", "PROTEIN", 90, 124], ["mAb", "PROTEIN", 126, 129], ["A3", "PROTEIN", 138, 140], ["methodsLLC-PK1 cells", "CELL_LINE", 204, 224], ["hybridoma cell fusion", "TREATMENT", 6, 27], ["selection", "TREATMENT", 32, 41], ["hybridoma cells", "PROBLEM", 57, 72], ["an anti-N protein monoclonal antibody", "TEST", 87, 124], ["Immunofluorescence assay", "TEST", 155, 179], ["Materials", "TEST", 190, 199], ["methodsLLC", "TEST", 204, 214], ["PK1 cells", "PROBLEM", 215, 224], ["sterilized coverslips", "TREATMENT", 240, 261], ["plaque", "PROBLEM", 327, 333], ["infection", "PROBLEM", 370, 379], ["hybridoma cell fusion", "OBSERVATION", 6, 27], ["hybridoma cells", "OBSERVATION", 57, 72], ["plaque", "OBSERVATION", 327, 333], ["infection", "OBSERVATION", 370, 379]]], ["At 24 h postinfection (HPI), cells were fixed with 4% paraformaldehyde for 15 min at room temperature (RT) and then permeabilized with 0.1% Triton X-100 for 10 min.", [["cells", "ANATOMY", 29, 34], ["paraformaldehyde", "CHEMICAL", 54, 70], ["Triton X-100", "CHEMICAL", 140, 152], ["paraformaldehyde", "CHEMICAL", 54, 70], ["cells", "CELL", 29, 34], ["paraformaldehyde", "SIMPLE_CHEMICAL", 54, 70], ["Triton X-100", "SIMPLE_CHEMICAL", 140, 152], ["4% paraformaldehyde", "TREATMENT", 51, 70], ["0.1% Triton", "TREATMENT", 135, 146]]], ["Subsequently, cells were blocked with 5% skimmed milk in PBS for 1 h at room temperature and incubated with mAb A3 for 1 h.", [["cells", "ANATOMY", 14, 19], ["milk", "ANATOMY", 49, 53], ["cells", "CELL", 14, 19], ["milk", "ORGANISM_SUBSTANCE", 49, 53], ["mAb A3", "PROTEIN", 108, 114], ["5% skimmed milk in PBS", "TREATMENT", 38, 60]]], ["The cells were treated with fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG secondary antibodies (Invitrogen) and then stained with 4\u2032,6-diamidino-2-phenylindole (Invitrogen) for 15 min at room temperature.", [["cells", "ANATOMY", 4, 9], ["fluorescein isothiocyanate", "CHEMICAL", 28, 54], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 146, 175], ["fluorescein isothiocyanate", "CHEMICAL", 28, 54], ["FITC", "CHEMICAL", 56, 60], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 146, 175], ["cells", "CELL", 4, 9], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 28, 54], ["FITC", "SIMPLE_CHEMICAL", 56, 60], ["goat", "ORGANISM", 70, 74], ["4\u2032,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 146, 175], ["Invitrogen", "SIMPLE_CHEMICAL", 177, 187], ["fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG secondary antibodies", "PROTEIN", 28, 110], ["goat", "SPECIES", 70, 74], ["anti-mouse", "SPECIES", 75, 85], ["goat", "SPECIES", 70, 74], ["fluorescein isothiocyanate (FITC)", "TREATMENT", 28, 61], ["labeled goat anti-mouse IgG secondary antibodies", "TREATMENT", 62, 110], ["diamidino", "TREATMENT", 151, 160], ["phenylindole (Invitrogen", "TREATMENT", 163, 187]]], ["Fluorescence was examined using a fluorescence microscope (Olympus IX73, Japan).Western blot analysis ::: Materials and methodsLLC-PK1 cells were infected with PDCoV and harvested with lysis buffer (65 mM Tris-HCl [pH 6.8], 4% sodium dodecyl sulfate, 3% DL-dithiothreitol and 40% glycerol) supplemented with PMSF.", [["methodsLLC-PK1 cells", "ANATOMY", 120, 140], ["Tris-HCl", "CHEMICAL", 205, 213], ["sodium dodecyl sulfate", "CHEMICAL", 227, 249], ["DL-dithiothreitol", "CHEMICAL", 254, 271], ["glycerol", "CHEMICAL", 280, 288], ["Tris-HCl", "CHEMICAL", 205, 213], ["sodium dodecyl sulfate", "CHEMICAL", 227, 249], ["dithiothreitol", "CHEMICAL", 257, 271], ["glycerol", "CHEMICAL", 280, 288], ["PMSF", "CHEMICAL", 308, 312], ["methodsLLC-PK1 cells", "CELL", 120, 140], ["Tris-HCl", "SIMPLE_CHEMICAL", 205, 213], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 227, 249], ["DL-dithiothreitol", "SIMPLE_CHEMICAL", 254, 271], ["glycerol", "SIMPLE_CHEMICAL", 280, 288], ["PMSF", "SIMPLE_CHEMICAL", 308, 312], ["methodsLLC-PK1 cells", "CELL_LINE", 120, 140], ["PDCoV", "SPECIES", 160, 165], ["a fluorescence microscope", "TEST", 32, 57], ["Materials", "TEST", 106, 115], ["methodsLLC", "TEST", 120, 130], ["PK1 cells", "PROBLEM", 131, 140], ["PDCoV", "TREATMENT", 160, 165], ["lysis buffer", "TREATMENT", 185, 197], ["Tris", "TEST", 205, 209], ["pH", "TEST", 215, 217], ["4% sodium dodecyl sulfate", "TREATMENT", 224, 249], ["dithiothreitol", "TREATMENT", 257, 271], ["40% glycerol)", "TREATMENT", 276, 289], ["PMSF", "TREATMENT", 308, 312]]], ["Proteins isolated from the lysate were separated by 12% SDS-PAGE and then transferred to a polyvinylidene difluoride membrane.", [["lysate", "ANATOMY", 27, 33], ["polyvinylidene", "CHEMICAL", 91, 105], ["difluoride", "CHEMICAL", 106, 116], ["lysate", "ORGANISM_SUBSTANCE", 27, 33], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["Proteins", "TEST", 0, 8], ["the lysate", "TREATMENT", 23, 33], ["a polyvinylidene difluoride membrane", "TREATMENT", 89, 125]]], ["The membrane was blocked with 10% dry milk and then incubated with the PDCoV-N-specific mAb A3.", [["membrane", "ANATOMY", 4, 12], ["milk", "ANATOMY", 38, 42], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 38, 42], ["mAb A3", "GENE_OR_GENE_PRODUCT", 88, 94], ["PDCoV", "PROTEIN", 71, 76], ["N-specific mAb A3", "PROTEIN", 77, 94], ["10% dry milk", "TREATMENT", 30, 42], ["the PDCoV", "TREATMENT", 67, 76]]], ["After washing three times with PBST, the membrane was incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (ABclonal) for 45 min at room temperature.", [["membrane", "ANATOMY", 41, 49], ["membrane", "CELLULAR_COMPONENT", 41, 49], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 69, 91], ["HRP", "SIMPLE_CHEMICAL", 93, 96], ["goat", "ORGANISM", 109, 113], ["ABclonal", "SIMPLE_CHEMICAL", 130, 138], ["horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG", "PROTEIN", 69, 128], ["ABclonal", "PROTEIN", 130, 138], ["horseradish", "SPECIES", 69, 80], ["goat", "SPECIES", 109, 113], ["anti-mouse", "SPECIES", 114, 124], ["goat", "SPECIES", 109, 113], ["PBST", "TREATMENT", 31, 35], ["horseradish peroxidase", "TREATMENT", 69, 91], ["conjugated goat anti-mouse IgG", "TREATMENT", 98, 128]]], ["Signals were detected using a SuperSignal West Pico Luminal Kit (Pierce).Electron microscopy ::: Materials and methodsAfter inoculation with CHN-HG-2017, LLC-PK1 cells were harvested when more than 80% CPE was observed.", [["LLC-PK1 cells", "ANATOMY", 154, 167], ["CHN", "CHEMICAL", 141, 144], ["CHN-HG-2017", "CELL", 141, 152], ["LLC-PK1 cells", "CELL", 154, 167], ["LLC-PK1 cells", "CELL_LINE", 154, 167], ["a SuperSignal West Pico Luminal Kit (Pierce)", "TREATMENT", 28, 72], ["Electron microscopy", "TEST", 73, 92], ["CHN", "TEST", 141, 144], ["HG", "TEST", 145, 147], ["LLC", "TEST", 154, 157], ["PK1 cells", "PROBLEM", 158, 167], ["LLC", "ANATOMY", 154, 157]]], ["Cells were frozen and thawed three times and then centrifuged at 10,000\u00d7g at 4 \u00b0C for 20 min.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5]]], ["The supernatants were filtered and ultracentrifuged at 30,000\u00d7g for 2 h at 4 \u00b0C. The pellets were resuspended in PBS and centrifuged in a non-linear 30%\u201360% sucrose gradient at 30,000\u00d7g for 3 h at 4 \u00b0C. The virions that sedimented in the interphase between the 30% and 45% sucrose layers were diluted with sterile PBS.", [["supernatants", "ANATOMY", 4, 16], ["virions", "ANATOMY", 207, 214], ["interphase", "ANATOMY", 238, 248], ["sucrose", "CHEMICAL", 157, 164], ["sucrose", "CHEMICAL", 273, 280], ["sucrose", "CHEMICAL", 157, 164], ["sucrose", "CHEMICAL", 273, 280], ["sucrose", "SIMPLE_CHEMICAL", 157, 164], ["interphase", "CELLULAR_COMPONENT", 238, 248], ["ultracentrifuged", "TREATMENT", 35, 51], ["The pellets", "TREATMENT", 81, 92], ["sucrose gradient", "TREATMENT", 157, 173], ["The virions", "PROBLEM", 203, 214], ["45% sucrose layers", "TREATMENT", 269, 287], ["sterile PBS", "TREATMENT", 306, 317], ["virions", "OBSERVATION", 207, 214], ["sedimented", "OBSERVATION_MODIFIER", 220, 230]]], ["The sucrose was then removed by centrifugation for 1 h at 30,000\u00d7g.", [["sucrose", "CHEMICAL", 4, 11], ["sucrose", "CHEMICAL", 4, 11], ["sucrose", "SIMPLE_CHEMICAL", 4, 11], ["The sucrose", "TREATMENT", 0, 11]]], ["The virions were resuspended in PBS, stained with 2% phosphotungstic acid, and examined using a transmission electron microscope (Hitachi H-7000FA, Japan).Phylogenetic and recombination analysis ::: Materials and methodsViral RNA was extracted from CHN-HG-2017-infected LLC-PK1 cells using TRIzol Reagent (Invitrogen, USA) according to manufacturer\u2032s instructions. cDNA was synthesized from the extracted RNA using random primers and a Takara RNA PCR Kit (Takara, Japan).", [["virions", "ANATOMY", 4, 11], ["LLC-PK1 cells", "ANATOMY", 270, 283], ["phosphotungstic acid", "CHEMICAL", 53, 73], ["phosphotungstic acid", "CHEMICAL", 53, 73], ["phosphotungstic acid", "SIMPLE_CHEMICAL", 53, 73], ["Viral", "ORGANISM", 220, 225], ["CHN-HG-2017", "CELL", 249, 260], ["LLC-PK1 cells", "CELL", 270, 283], ["Viral RNA", "RNA", 220, 229], ["CHN-HG-2017-infected LLC-PK1 cells", "CELL_LINE", 249, 283], ["cDNA", "DNA", 365, 369], ["The virions", "TREATMENT", 0, 11], ["2% phosphotungstic acid", "TREATMENT", 50, 73], ["a transmission electron microscope", "TEST", 94, 128], ["Hitachi H", "TEST", 130, 139], ["methodsViral RNA", "TEST", 213, 229], ["HG", "TEST", 253, 255], ["infected LLC", "PROBLEM", 261, 273], ["PK1 cells", "TREATMENT", 274, 283], ["TRIzol Reagent", "TREATMENT", 290, 304], ["random primers", "TREATMENT", 415, 429], ["a Takara RNA PCR Kit", "TREATMENT", 434, 454], ["LLC", "ANATOMY", 270, 273]]], ["The whole genome of CHN-HG-2017 was sequenced using 26 pairs of primers reported by Lorsirigool et al. [23].", [["CHN-HG-2017", "CELL", 20, 31], ["CHN", "DNA", 20, 23], ["2017", "DNA", 27, 31], ["CHN-HG-2017", "SPECIES", 20, 31], ["HG", "TEST", 24, 26], ["primers", "TREATMENT", 64, 71]]], ["Based on the sequence that was obtained, a pair of primers (PDCoV-5\u2032GSP, 5\u2032- GATTACGCCAAGCTTTAGATCGCAAGGTGGGTTGGGCTCC-3\u2032; PDCoV-3\u2032GSP, 5\u2032-GATTACGCCAAGCTTCGTCGTAAGACCCAACATCAAGCT-3\u2032) was designed to verify the 5\u2032- and 3\u2032- terminal sequences of CHN-HG-2017 using a SMARTer RACE 5\u2032/3\u2032 Kit (Takara) according to manufacturer\u2032s instructions.", [["PDCoV", "DNA", 60, 65], ["PDCoV", "DNA", 122, 127], ["5\u2032- and 3\u2032- terminal sequences", "DNA", 209, 239], ["SMARTer RACE 5", "DNA", 263, 277], ["a pair of primers", "TEST", 41, 58], ["PDCoV", "TEST", 60, 65], ["GSP", "TEST", 68, 71], ["\u2032", "TEST", 74, 75], ["GATTACGCCAAGCTTTAGATCGCAAGGTGGGTTGGGCTCC", "TEST", 77, 117], ["PDCoV", "TEST", 122, 127], ["GATTACGCCAAGCTTCGTCGTAAGACCCAACATCAAGCT", "TEST", 138, 177], ["a SMARTer RACE", "TREATMENT", 261, 275], ["Kit (Takara)", "TREATMENT", 282, 294]]], ["The sequences were combined using DNASTAR Lasergene 7.0, and the assembled genome sequence was submitted to the GenBank database under the accession number MF095123.", [["MF095123", "CHEMICAL", 156, 164], ["assembled genome sequence", "DNA", 65, 90], ["The sequences", "TEST", 0, 13], ["DNASTAR Lasergene", "TEST", 34, 51]]], ["Multiple sequence alignments and phylogenetic analysis were performed using the neighbor-joining method with MEGA 7 software (http://www.mehasoftware.net/).", [["MEGA 7 software", "DNA", 109, 124], ["Multiple sequence alignments", "TEST", 0, 28], ["phylogenetic analysis", "TEST", 33, 54]]], ["The aligned sequences were scanned for recombination events, using the Recombination Detection Program (RDP).Inoculation of pigs with PDCoV strain CHN-HG-2017 ::: Materials and methodsAnimal experiments were carried out strictly according to the Guide for the Care and Use of Animals in Research of the People\u2032s Republic of China.", [["pigs", "ORGANISM", 124, 128], ["pigs", "SPECIES", 124, 128], ["pigs", "SPECIES", 124, 128]]], ["All experimental procedures were approved by the Scientific Ethics Committee of Huazhong Agricultural University (HZAUSW-2018-005).", [["HZAUSW-2018-005", "CHEMICAL", 114, 129], ["All experimental procedures", "TREATMENT", 0, 27]]], ["Twelve 5-day-old piglets were purchased from a commercial pig farm and were randomly divided into two groups, which were housed in separated containments.", [["piglets", "ORGANISM", 17, 24], ["pig", "ORGANISM", 58, 61], ["piglets", "SPECIES", 17, 24], ["pig", "SPECIES", 58, 61], ["pig", "SPECIES", 58, 61], ["a commercial pig farm", "TREATMENT", 45, 66]]], ["Prior to PDCoV inoculation, piglets were confirmed to be negative for PDCoV, PEDV, TGEV, and rotavirus by testing rectal swabs by RT-PCR.", [["rectal swabs", "ANATOMY", 114, 126], ["PDCoV", "CHEMICAL", 9, 14], ["piglets", "ORGANISM", 28, 35], ["PDCoV", "GENE_OR_GENE_PRODUCT", 70, 75], ["PEDV", "GENE_OR_GENE_PRODUCT", 77, 81], ["TGEV", "ORGANISM", 83, 87], ["rotavirus", "ORGANISM", 93, 102], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 114, 126], ["piglets", "SPECIES", 28, 35], ["PDCoV", "SPECIES", 9, 14], ["piglets", "SPECIES", 28, 35], ["PDCoV", "SPECIES", 70, 75], ["PEDV", "SPECIES", 77, 81], ["TGEV", "SPECIES", 83, 87], ["rotavirus", "SPECIES", 93, 102], ["PDCoV inoculation", "TREATMENT", 9, 26], ["piglets", "TREATMENT", 28, 35], ["PDCoV", "PROBLEM", 70, 75], ["PEDV", "PROBLEM", 77, 81], ["TGEV", "PROBLEM", 83, 87], ["rotavirus", "PROBLEM", 93, 102], ["rectal swabs", "TEST", 114, 126], ["RT", "TEST", 130, 132], ["PCR", "TEST", 133, 136]]], ["Neutralizing antibodies against PDCoV were not detected in sera of the piglets or sows.", [["sera", "ANATOMY", 59, 63], ["PDCoV", "GENE_OR_GENE_PRODUCT", 32, 37], ["sera", "ORGANISM_SUBSTANCE", 59, 63], ["piglets", "ORGANISM", 71, 78], ["sows", "ORGANISM", 82, 86], ["Neutralizing antibodies", "PROTEIN", 0, 23], ["PDCoV", "PROTEIN", 32, 37], ["piglets", "SPECIES", 71, 78], ["PDCoV", "SPECIES", 32, 37], ["piglets", "SPECIES", 71, 78], ["Neutralizing antibodies", "TEST", 0, 23], ["PDCoV", "PROBLEM", 32, 37]]], ["After acclimation for 24 h, the challenged group was inoculated orally with a CHN-HG-2017 preparation with a titer of 1 \u00d7 106 TCID50/ml (10 ml per pig), while the mock-infected group was inoculated with 10 ml of maintenance medium.", [["CHN-HG-2017", "CHEMICAL", 78, 89], ["CHN", "SIMPLE_CHEMICAL", 78, 81], ["pig", "ORGANISM", 147, 150], ["pig", "SPECIES", 147, 150], ["pig", "SPECIES", 147, 150], ["a titer", "TREATMENT", 107, 114], ["maintenance medium", "TREATMENT", 212, 230]]], ["Clinical symptoms, including vomiting, diarrhea, lethargy, and appetite loss, were observed and recorded daily.", [["vomiting", "DISEASE", 29, 37], ["diarrhea", "DISEASE", 39, 47], ["lethargy", "DISEASE", 49, 57], ["appetite loss", "DISEASE", 63, 76], ["Clinical symptoms", "PROBLEM", 0, 17], ["vomiting", "PROBLEM", 29, 37], ["diarrhea", "PROBLEM", 39, 47], ["lethargy", "PROBLEM", 49, 57], ["appetite loss", "PROBLEM", 63, 76]]], ["Rectal swabs were collected daily from each piglet from the first day post-inoculation (DPI) to the end of the experiment.", [["Rectal swabs", "ANATOMY", 0, 12], ["Rectal swabs", "ORGANISM_SUBSTANCE", 0, 12], ["piglet", "ORGANISM_SUBDIVISION", 44, 50], ["Rectal swabs", "TEST", 0, 12]]], ["Swabs were submerged into 1 ml of PBS immediately after collection.", [["Swabs", "ANATOMY", 0, 5], ["Swabs", "TREATMENT", 0, 5], ["PBS", "TREATMENT", 34, 37], ["collection", "PROBLEM", 56, 66]]], ["Randomly selected piglets from each group (n = 3) were subjected to necropsy at 4 DPI, and prolonged PDCoV shedding was monitored in the remaining pigs until 21 DPI.", [["DPI", "CHEMICAL", 161, 164], ["piglets", "ORGANISM", 18, 25], ["pigs", "ORGANISM", 147, 151], ["piglets", "SPECIES", 18, 25], ["pigs", "SPECIES", 147, 151], ["PDCoV", "SPECIES", 101, 106], ["prolonged PDCoV shedding", "TREATMENT", 91, 115]]], ["At necropsy, tissues of duodenum, jejunum, ileum, cecum, colon, rectum, liver, spleen, lung, kidney, and blood were collected for analysis by real-time RT-PCR.", [["tissues", "ANATOMY", 13, 20], ["duodenum", "ANATOMY", 24, 32], ["jejunum", "ANATOMY", 34, 41], ["ileum", "ANATOMY", 43, 48], ["cecum", "ANATOMY", 50, 55], ["colon", "ANATOMY", 57, 62], ["rectum", "ANATOMY", 64, 70], ["liver", "ANATOMY", 72, 77], ["spleen", "ANATOMY", 79, 85], ["lung", "ANATOMY", 87, 91], ["kidney", "ANATOMY", 93, 99], ["blood", "ANATOMY", 105, 110], ["tissues", "TISSUE", 13, 20], ["duodenum", "MULTI-TISSUE_STRUCTURE", 24, 32], ["jejunum", "MULTI-TISSUE_STRUCTURE", 34, 41], ["ileum", "MULTI-TISSUE_STRUCTURE", 43, 48], ["cecum", "MULTI-TISSUE_STRUCTURE", 50, 55], ["colon", "MULTI-TISSUE_STRUCTURE", 57, 62], ["rectum", "MULTI-TISSUE_STRUCTURE", 64, 70], ["liver", "ORGAN", 72, 77], ["spleen", "ORGAN", 79, 85], ["lung", "ORGAN", 87, 91], ["kidney", "ORGAN", 93, 99], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["tissues of duodenum, jejunum, ileum, cecum, colon, rectum, liver, spleen, lung, kidney, and blood", "PROBLEM", 13, 110], ["analysis", "TEST", 130, 138], ["duodenum", "ANATOMY", 24, 32], ["jejunum", "ANATOMY", 34, 41], ["ileum", "ANATOMY", 43, 48], ["cecum", "ANATOMY", 50, 55], ["colon", "ANATOMY", 57, 62], ["rectum", "ANATOMY", 64, 70], ["liver", "ANATOMY", 72, 77], ["spleen", "ANATOMY", 79, 85], ["lung", "ANATOMY", 87, 91], ["kidney", "ANATOMY", 93, 99]]], ["Tissues of duodenum, jejunum, ileum, cecum, and colon were also fixed with 10% formalin for histopathology and immunohistochemistry analysis.", [["Tissues", "ANATOMY", 0, 7], ["duodenum", "ANATOMY", 11, 19], ["jejunum", "ANATOMY", 21, 28], ["ileum", "ANATOMY", 30, 35], ["cecum", "ANATOMY", 37, 42], ["colon", "ANATOMY", 48, 53], ["formalin", "CHEMICAL", 79, 87], ["formalin", "CHEMICAL", 79, 87], ["Tissues", "TISSUE", 0, 7], ["duodenum", "MULTI-TISSUE_STRUCTURE", 11, 19], ["jejunum", "MULTI-TISSUE_STRUCTURE", 21, 28], ["ileum", "MULTI-TISSUE_STRUCTURE", 30, 35], ["cecum", "MULTI-TISSUE_STRUCTURE", 37, 42], ["colon", "ORGAN", 48, 53], ["formalin", "SIMPLE_CHEMICAL", 79, 87], ["10% formalin", "TREATMENT", 75, 87], ["histopathology", "TEST", 92, 106], ["immunohistochemistry analysis", "TEST", 111, 140], ["duodenum", "ANATOMY", 11, 19], ["jejunum", "ANATOMY", 21, 28], ["ileum", "ANATOMY", 30, 35], ["cecum", "ANATOMY", 37, 42], ["colon", "ANATOMY", 48, 53]]], ["Sera collected at 0, 4, 7, 21 DPI from piglets were tested for neutralizing antibodies against PDCoV.Real-time RT-PCR analysis ::: Materials and methodsThe number of viral RNA copies in fecal swabs, sera, and tissue samples was determined by real-time RT-PCR.", [["Sera", "ANATOMY", 0, 4], ["fecal swabs", "ANATOMY", 186, 197], ["sera", "ANATOMY", 199, 203], ["tissue samples", "ANATOMY", 209, 223], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["piglets", "ORGANISM", 39, 46], ["fecal swabs", "ORGANISM_SUBSTANCE", 186, 197], ["sera", "ORGANISM_SUBSTANCE", 199, 203], ["tissue samples", "TISSUE", 209, 223], ["neutralizing antibodies", "PROTEIN", 63, 86], ["PDCoV", "PROTEIN", 95, 100], ["viral RNA copies", "RNA", 166, 182], ["piglets", "SPECIES", 39, 46], ["PDCoV", "SPECIES", 95, 100], ["Sera", "TEST", 0, 4], ["neutralizing antibodies", "TREATMENT", 63, 86], ["PDCoV", "TREATMENT", 95, 100], ["viral RNA copies", "TEST", 166, 182], ["fecal swabs", "TEST", 186, 197], ["sera", "TEST", 199, 203], ["tissue samples", "TEST", 209, 223], ["viral RNA", "OBSERVATION", 166, 175], ["fecal swabs", "ANATOMY", 186, 197]]], ["Briefly, fecal swab samples diluted in DMEM were homogenized and centrifuged at 6000\u00d7g for 5 min.", [["fecal swab samples", "ANATOMY", 9, 27], ["fecal swab samples", "ORGANISM_SUBSTANCE", 9, 27], ["fecal swab samples", "TEST", 9, 27], ["fecal", "ANATOMY", 9, 14]]], ["An aliquot (200 \u03bcl) of supernatant was extracted for viral RNA isolation.", [["supernatant", "ANATOMY", 23, 34], ["viral RNA", "RNA", 53, 62], ["An aliquot", "TREATMENT", 0, 10], ["supernatant", "TREATMENT", 23, 34], ["viral RNA isolation", "TREATMENT", 53, 72], ["viral RNA isolation", "OBSERVATION", 53, 72]]], ["One gram of various tissue samples was mechanically homogenized in 1 ml of DMEM, and 200 \u03bcl of the supernatant was used for RNA extraction.", [["tissue samples", "ANATOMY", 20, 34], ["supernatant", "ANATOMY", 99, 110], ["tissue samples", "TISSUE", 20, 34], ["various tissue samples", "TEST", 12, 34], ["DMEM", "TREATMENT", 75, 79], ["the supernatant", "TREATMENT", 95, 110], ["RNA extraction", "TREATMENT", 124, 138], ["various tissue", "OBSERVATION_MODIFIER", 12, 26]]], ["Two hundred \u03bcl of serum was also used for RNA extraction.", [["serum", "ANATOMY", 18, 23], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["RNA extraction", "TREATMENT", 42, 56]]], ["Viral RNA was extracted using TRIzol Reagent (Invitrogen, USA) according to the manufacturer\u2032s protocols and was treated with DNase I. One \u03bcg of total RNA was used for cDNA synthesis by reverse transcription using an iScript cDNA Synthesis Kit (Bio-Rad). cDNA amplification was performed using the iTaq Universal Probes Supermix (Bio-Rad) with primers and probes targeting the N gene of PDCoV, as described by Ma et al. [3].", [["Viral", "ORGANISM", 0, 5], ["Bio-Rad", "GENE_OR_GENE_PRODUCT", 245, 252], ["PDCoV", "GENE_OR_GENE_PRODUCT", 387, 392], ["Viral RNA", "RNA", 0, 9], ["cDNA", "DNA", 255, 259], ["iTaq Universal Probes Supermix (Bio-Rad", "DNA", 298, 337], ["N gene", "DNA", 377, 383], ["PDCoV", "DNA", 387, 392], ["Viral RNA", "PROBLEM", 0, 9], ["TRIzol Reagent", "TREATMENT", 30, 44], ["the manufacturer\u2032s protocols", "TREATMENT", 76, 104], ["DNase I.", "TREATMENT", 126, 134], ["total RNA", "TREATMENT", 145, 154], ["cDNA synthesis", "TREATMENT", 168, 182], ["an iScript cDNA Synthesis Kit", "TREATMENT", 214, 243], ["cDNA amplification", "TEST", 255, 273], ["the iTaq Universal Probes Supermix (Bio-Rad) with primers", "TREATMENT", 294, 351], ["the N gene of PDCoV", "TREATMENT", 373, 392]]], ["The recombinant plasmid pET28a-N containing the N gene of PDCoV was serially diluted tenfold to generate a standard curve for each plate.", [["plasmid", "ANATOMY", 16, 23], ["pET28a-N", "GENE_OR_GENE_PRODUCT", 24, 32], ["PDCoV", "CANCER", 58, 63], ["pET28a", "DNA", 24, 30], ["N", "DNA", 31, 32], ["N gene", "DNA", 48, 54], ["PDCoV", "DNA", 58, 63], ["The recombinant plasmid pET28a", "TREATMENT", 0, 30], ["the N gene of PDCoV", "TREATMENT", 44, 63], ["a standard curve for each plate", "TREATMENT", 105, 136]]], ["Real-time RT-PCR was carried out using an Applied Biosystems 7500 Fast Real-Time PCR System (Life Technologies, USA).", [["RT-PCR", "TEST", 10, 16], ["an Applied Biosystems", "TEST", 39, 60]]], ["The thermal cycling parameters were as follows: 2 min at 50 \u00b0C, 10 min at 95 \u00b0C, and 40 cycles of 15 s at 95 \u00b0C and 1 min at 60 \u00b0C. The number of copies of PDCoV viral RNA in the tested samples was calculated based on the standard curve.Neutralization assay (NA) ::: Materials and methodsThe presence of PDCoV-specific neutralizing antibodies in serum samples was determined using a virus neutralizing (VN) test.", [["samples", "ANATOMY", 186, 193], ["serum samples", "ANATOMY", 346, 359], ["PDCoV", "GENE_OR_GENE_PRODUCT", 156, 161], ["PDCoV", "GENE_OR_GENE_PRODUCT", 304, 309], ["serum samples", "ORGANISM_SUBSTANCE", 346, 359], ["PDCoV viral RNA", "RNA", 156, 171], ["PDCoV", "PROTEIN", 304, 309], ["neutralizing antibodies", "PROTEIN", 319, 342], ["PDCoV", "SPECIES", 156, 161], ["The thermal cycling parameters", "TEST", 0, 30], ["PDCoV viral RNA", "TREATMENT", 156, 171], ["the tested samples", "TEST", 175, 193], ["the standard curve", "TEST", 218, 236], ["Neutralization assay", "TEST", 237, 257], ["PDCoV", "TEST", 304, 309], ["specific neutralizing antibodies", "PROBLEM", 310, 342], ["serum samples", "TEST", 346, 359], ["a virus neutralizing (VN) test", "TEST", 381, 411], ["viral RNA", "OBSERVATION", 162, 171], ["neutralizing", "OBSERVATION_MODIFIER", 319, 331]]], ["Briefly, LLC-PK1 cells were grown in 96-well plates until they reached 90% confluence.", [["LLC-PK1 cells", "ANATOMY", 9, 22], ["LLC-PK1 cells", "CELL", 9, 22], ["LLC-PK1 cells", "CELL_LINE", 9, 22], ["LLC-PK1 cells", "TEST", 9, 22], ["LLC", "ANATOMY", 9, 12], ["PK1 cells", "OBSERVATION", 13, 22], ["confluence", "OBSERVATION_MODIFIER", 75, 85]]], ["The CHN-HG-2017 stock was diluted in DMEM to make 200 TCID50 viral stocks.", [["CHN-HG-2017", "CHEMICAL", 4, 15], ["CHN", "SIMPLE_CHEMICAL", 4, 7]]], ["Fifty \u03bcl of the diluted virus was then mixed with an equal volume of twofold serial dilutions of individual inactivated sera in 96-well plates and incubated at 37 \u00b0C for 1 h.", [["sera", "ANATOMY", 120, 124], ["sera", "ORGANISM_SUBSTANCE", 120, 124], ["the diluted virus", "TREATMENT", 12, 29], ["twofold serial dilutions", "TREATMENT", 69, 93], ["individual inactivated sera", "TEST", 97, 124]]], ["After washing twice with maintenance medium, LLC-PK1 cells were incubated with the mixture at 37 \u00b0C for 1 h.", [["LLC-PK1 cells", "ANATOMY", 45, 58], ["LLC-PK1 cells", "CELL", 45, 58], ["LLC-PK1 cells", "CELL_LINE", 45, 58], ["maintenance medium", "TREATMENT", 25, 43], ["PK1 cells", "PROBLEM", 49, 58], ["LLC", "ANATOMY", 45, 48]]], ["The mixture was then removed, and the cell monolayers were washed three times with PBS and cultured in maintenance medium at 37 \u00b0C in a 5% CO2 incubator for 2 days.", [["cell monolayers", "ANATOMY", 38, 53], ["CO2", "CHEMICAL", 139, 142], ["CO2", "CHEMICAL", 139, 142], ["cell monolayers", "CELL", 38, 53], ["the cell monolayers", "TREATMENT", 34, 53], ["PBS", "TREATMENT", 83, 86], ["a 5% CO2 incubator", "TREATMENT", 134, 152], ["cell monolayers", "OBSERVATION", 38, 53]]], ["The neutralization antibody titers were calculated as the reciprocal of the highest dilution of serum at which PDCoV infection was blocked.Histology and immunohistochemistry ::: Materials and methodsAt necropsy, tissues of duodenum, jejunum, ileum, cecum, colon, and rectum collected from the inoculated and control groups were separated and fixed in 10% formalin for 24 h at room temperature and then dehydrated, embedded, sectioned, and mounted on glass slides.", [["serum", "ANATOMY", 96, 101], ["tissues", "ANATOMY", 212, 219], ["duodenum", "ANATOMY", 223, 231], ["jejunum", "ANATOMY", 233, 240], ["ileum", "ANATOMY", 242, 247], ["cecum", "ANATOMY", 249, 254], ["colon", "ANATOMY", 256, 261], ["rectum", "ANATOMY", 267, 273], ["infection", "DISEASE", 117, 126], ["formalin", "CHEMICAL", 355, 363], ["formalin", "CHEMICAL", 355, 363], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["PDCoV", "GENE_OR_GENE_PRODUCT", 111, 116], ["tissues", "TISSUE", 212, 219], ["duodenum", "MULTI-TISSUE_STRUCTURE", 223, 231], ["jejunum", "MULTI-TISSUE_STRUCTURE", 233, 240], ["ileum", "MULTI-TISSUE_STRUCTURE", 242, 247], ["cecum", "MULTI-TISSUE_STRUCTURE", 249, 254], ["colon", "ORGAN", 256, 261], ["rectum", "ORGAN", 267, 273], ["formalin", "SIMPLE_CHEMICAL", 355, 363], ["PDCoV", "SPECIES", 111, 116], ["The neutralization antibody titers", "TEST", 0, 34], ["PDCoV infection", "PROBLEM", 111, 126], ["dehydrated", "PROBLEM", 402, 412], ["neutralization", "OBSERVATION", 4, 18], ["antibody titers", "OBSERVATION", 19, 34], ["infection", "OBSERVATION", 117, 126], ["duodenum", "ANATOMY", 223, 231], ["jejunum", "ANATOMY", 233, 240], ["ileum", "ANATOMY", 242, 247], ["cecum", "ANATOMY", 249, 254], ["colon", "ANATOMY", 256, 261], ["rectum", "ANATOMY", 267, 273], ["inoculated", "OBSERVATION_MODIFIER", 293, 303]]], ["The samples were stained with hematoxylin and eosin (H&E), and the slides were examined and analyzed by conventional microscopy.", [["samples", "ANATOMY", 4, 11], ["hematoxylin", "CHEMICAL", 30, 41], ["eosin", "CHEMICAL", 46, 51], ["hematoxylin", "SIMPLE_CHEMICAL", 30, 41], ["eosin", "SIMPLE_CHEMICAL", 46, 51], ["The samples", "TEST", 0, 11], ["hematoxylin", "TREATMENT", 30, 41], ["eosin", "TEST", 46, 51], ["the slides", "TEST", 63, 73], ["conventional microscopy", "TEST", 104, 127]]], ["Three representative villi and crypts with integrated longitudinal sections were randomly selected from each H&E-stained jejunum and ileum.", [["villi", "ANATOMY", 21, 26], ["crypts", "ANATOMY", 31, 37], ["sections", "ANATOMY", 67, 75], ["jejunum", "ANATOMY", 121, 128], ["ileum", "ANATOMY", 133, 138], ["villi", "MULTI-TISSUE_STRUCTURE", 21, 26], ["crypts", "MULTI-TISSUE_STRUCTURE", 31, 37], ["longitudinal sections", "MULTI-TISSUE_STRUCTURE", 54, 75], ["jejunum", "MULTI-TISSUE_STRUCTURE", 121, 128], ["ileum", "MULTI-TISSUE_STRUCTURE", 133, 138], ["integrated longitudinal sections", "TREATMENT", 43, 75], ["villi", "ANATOMY", 21, 26], ["jejunum", "ANATOMY", 121, 128], ["ileum", "ANATOMY", 133, 138]]], ["Villus-height-to-crypt-depth (VH/CD) ratios were calculated using a computerized image system (NIS-Elements 3.2).", [["Villus", "ANATOMY", 0, 6], ["crypt", "ANATOMY", 17, 22], ["crypt", "MULTI-TISSUE_STRUCTURE", 17, 22], ["Villus", "TEST", 0, 6], ["height", "TEST", 7, 13], ["VH/CD) ratios", "TEST", 30, 43], ["a computerized image system", "TEST", 66, 93], ["NIS", "TEST", 95, 98], ["height", "OBSERVATION_MODIFIER", 7, 13], ["crypt", "ANATOMY_MODIFIER", 17, 22]]], ["Five-micron-thick sections obtained from formalin-fixed paraffin-embedded tissues were placed onto positively charged glass slides, and the slides were air dried for 30 min.", [["sections", "ANATOMY", 18, 26], ["tissues", "ANATOMY", 74, 81], ["formalin", "CHEMICAL", 41, 49], ["formalin", "CHEMICAL", 41, 49], ["paraffin", "CHEMICAL", 56, 64], ["sections", "MULTI-TISSUE_STRUCTURE", 18, 26], ["tissues", "TISSUE", 74, 81], ["micron-thick sections", "TEST", 5, 26], ["formalin-fixed paraffin-embedded tissues", "TREATMENT", 41, 81], ["air dried", "OBSERVATION", 152, 161]]], ["The tissue sections were deparaffinized, and the slides were rinsed and then incubated with target retrieval solution (Sigma-Aldrich, USA).", [["tissue sections", "ANATOMY", 4, 19], ["tissue sections", "CANCER", 4, 19], ["The tissue sections", "TEST", 0, 19], ["the slides", "TEST", 45, 55], ["target retrieval solution", "TREATMENT", 92, 117]]], ["The sections were blocked with 1% BSA, incubated with PDCoV-N-specific monoclonal antibodies for 30 min, and then with HRP-conjugated goat anti-mouse IgG secondary antibodies (Zhongshan Biotechnology Co., Beijing, China).", [["sections", "ANATOMY", 4, 12], ["sections", "MULTI-TISSUE_STRUCTURE", 4, 12], ["BSA", "SIMPLE_CHEMICAL", 34, 37], ["PDCoV-N-", "SIMPLE_CHEMICAL", 54, 62], ["HRP", "SIMPLE_CHEMICAL", 119, 122], ["PDCoV", "PROTEIN", 54, 59], ["N-specific monoclonal antibodies", "PROTEIN", 60, 92], ["HRP", "PROTEIN", 119, 122], ["conjugated goat anti-mouse IgG secondary antibodies", "PROTEIN", 123, 174], ["goat", "SPECIES", 134, 138], ["anti-mouse", "SPECIES", 139, 149], ["goat", "SPECIES", 134, 138], ["The sections", "TEST", 0, 12], ["1% BSA", "TEST", 31, 37], ["PDCoV", "TEST", 54, 59], ["N-specific monoclonal antibodies", "TEST", 60, 92], ["HRP", "TEST", 119, 122]]], ["The samples were visualized using a substrate-chromogen reagent (3-amino-9-ethylcarbazole/H2O2, Solarbio, China).", [["samples", "ANATOMY", 4, 11], ["3-amino-9-ethylcarbazole", "CHEMICAL", 65, 89], ["H2O2", "CHEMICAL", 90, 94], ["chromogen", "CHEMICAL", 46, 55], ["3-amino-9-ethylcarbazole", "CHEMICAL", 65, 89], ["H2O2", "CHEMICAL", 90, 94], ["3-amino-9-ethylcarbazole", "SIMPLE_CHEMICAL", 65, 89], ["H2O2", "SIMPLE_CHEMICAL", 90, 94], ["The samples", "TEST", 0, 11], ["a substrate-chromogen reagent", "TREATMENT", 34, 63], ["amino", "TEST", 67, 72], ["ethylcarbazole", "TREATMENT", 75, 89], ["H2O2", "TREATMENT", 90, 94]]], ["Tissues from piglets in the negative control group were used as controls.Virus isolation ::: ResultsOf the 17 PDCoV-positive feces inoculated onto LLC-PK1 monolayers, only one caused obvious CPE in the form of enlarged, rounded and clustered cells at 24 HPI and rapidly detached from the monolayers at 36 HPI (Fig. 1A).", [["Tissues", "ANATOMY", 0, 7], ["feces", "ANATOMY", 125, 130], ["LLC-PK1 monolayers", "ANATOMY", 147, 165], ["cells", "ANATOMY", 242, 247], ["monolayers", "ANATOMY", 288, 298], ["Tissues", "CANCER", 0, 7], ["piglets", "ORGANISM", 13, 20], ["Virus", "ORGANISM", 73, 78], ["PDCoV", "GENE_OR_GENE_PRODUCT", 110, 115], ["feces", "ORGANISM", 125, 130], ["LLC-PK1 monolayers", "CELL", 147, 165], ["cells", "CELL", 242, 247], ["monolayers", "CELL", 288, 298], ["LLC-PK1 monolayers", "CELL_LINE", 147, 165], ["enlarged, rounded and clustered cells", "CELL_TYPE", 210, 247], ["piglets", "SPECIES", 13, 20], ["PDCoV", "TEST", 110, 115], ["LLC", "TEST", 147, 150], ["PK1 monolayers", "TEST", 151, 165], ["obvious CPE", "PROBLEM", 183, 194], ["enlarged, rounded and clustered cells", "PROBLEM", 210, 247], ["piglets", "OBSERVATION_MODIFIER", 13, 20], ["negative", "OBSERVATION_MODIFIER", 28, 36], ["obvious", "OBSERVATION_MODIFIER", 183, 190], ["CPE", "OBSERVATION", 191, 194], ["enlarged", "OBSERVATION", 210, 218], ["rounded", "OBSERVATION_MODIFIER", 220, 227], ["clustered cells", "OBSERVATION", 232, 247]]], ["This PDCoV isolate, designated as CHN-HG-2017, tested positive for PDCoV and negative for other enteric viruses by RT-PCR (data not shown).", [["PDCoV", "CANCER", 5, 10], ["CHN-HG-2017", "CELL", 34, 45], ["PDCoV", "GENE_OR_GENE_PRODUCT", 67, 72], ["PDCoV", "SPECIES", 67, 72], ["HG", "TEST", 38, 40], ["PDCoV", "PROBLEM", 67, 72], ["other enteric viruses", "PROBLEM", 90, 111], ["RT-PCR", "TEST", 115, 121], ["viruses", "OBSERVATION", 104, 111]]], ["CHN-HG-2017 was further passaged in LLC-PK1 cells for a total of 10 passages, indicating that the PDCoV CHN-HG-2017 strain could be stably propagated in LLC-PK1 cells.Virus isolation ::: ResultsTo confirm that virus propagation had occurred, the infectivity of the plaque-purified CHN-HG-2017 strain in LLC-PK1 cells was tested by IFA and western blot with an mAb against the PDCoV N protein.", [["LLC-PK1 cells", "ANATOMY", 36, 49], ["LLC-PK1 cells", "ANATOMY", 153, 166], ["plaque", "ANATOMY", 265, 271], ["LLC-PK1 cells", "ANATOMY", 303, 316], ["CHN-HG-2017", "CHEMICAL", 0, 11], ["CHN-HG-2017", "CHEMICAL", 104, 115], ["CHN-HG-2017", "CHEMICAL", 281, 292], ["CHN", "SIMPLE_CHEMICAL", 0, 3], ["LLC-PK1 cells", "CELL", 36, 49], ["PDCoV", "GENE_OR_GENE_PRODUCT", 98, 103], ["HG-2017 strain", "CELL", 108, 122], ["LLC-PK1 cells", "CELL", 153, 166], ["Virus", "ORGANISM", 167, 172], ["plaque", "PATHOLOGICAL_FORMATION", 265, 271], ["CHN-HG-2017 strain", "CELL", 281, 299], ["LLC-PK1 cells", "CELL", 303, 316], ["PDCoV N", "GENE_OR_GENE_PRODUCT", 376, 383], ["LLC-PK1 cells", "CELL_LINE", 36, 49], ["LLC-PK1 cells", "CELL_LINE", 153, 166], ["LLC-PK1 cells", "CELL_LINE", 303, 316], ["mAb", "PROTEIN", 360, 363], ["PDCoV N protein", "PROTEIN", 376, 391], ["HG", "TEST", 4, 6], ["PK1 cells", "TEST", 40, 49], ["the PDCoV CHN", "TEST", 94, 107], ["HG", "TEST", 108, 110], ["strain", "PROBLEM", 116, 122], ["virus propagation", "PROBLEM", 210, 227], ["the plaque", "PROBLEM", 261, 271], ["purified CHN", "TEST", 272, 284], ["HG", "TEST", 285, 287], ["PK1 cells", "PROBLEM", 307, 316], ["IFA", "TEST", 331, 334], ["western blot", "TEST", 339, 351], ["an mAb", "TEST", 357, 363], ["LLC", "ANATOMY", 36, 39], ["LLC", "ANATOMY", 153, 156], ["PK1 cells", "OBSERVATION", 157, 166], ["virus", "OBSERVATION", 210, 215], ["plaque", "OBSERVATION", 265, 271], ["LLC", "ANATOMY", 303, 306]]], ["As shown in Fig. 1A, PDCoV-specific immunofluorescence was detected in most cells at 24 HPI, and the N protein was mainly localized in the cytoplasm.", [["cells", "ANATOMY", 76, 81], ["cytoplasm", "ANATOMY", 139, 148], ["1A", "GENE_OR_GENE_PRODUCT", 17, 19], ["PDCoV", "GENE_OR_GENE_PRODUCT", 21, 26], ["cells", "CELL", 76, 81], ["cytoplasm", "ORGANISM_SUBSTANCE", 139, 148], ["PDCoV", "PROTEIN", 21, 26], ["N protein", "PROTEIN", 101, 110], ["PDCoV", "TEST", 21, 26], ["specific immunofluorescence", "TEST", 27, 54], ["the N protein", "TEST", 97, 110], ["Fig", "OBSERVATION", 12, 15], ["most cells", "OBSERVATION_MODIFIER", 71, 81]]], ["N protein was also detected in PDCoV-infected LLC-PK1 cells by western blot (Fig. 1B).", [["LLC-PK1 cells", "ANATOMY", 46, 59], ["PDCoV", "SIMPLE_CHEMICAL", 31, 36], ["LLC-PK1 cells", "CELL", 46, 59], ["N protein", "PROTEIN", 0, 9], ["PDCoV-infected LLC-PK1 cells", "CELL_LINE", 31, 59], ["N protein", "TEST", 0, 9], ["PDCoV", "TEST", 31, 36], ["PK1 cells", "PROBLEM", 50, 59], ["western blot", "TEST", 63, 75], ["infected", "OBSERVATION_MODIFIER", 37, 45], ["LLC", "ANATOMY", 46, 49]]], ["The morphology of the PDCoV particles purified from the supernatants of CHN-HG-2017-infected LLC-PK1 cells was examined by electron microscopy (EM) using negatively stained preparations.", [["supernatants", "ANATOMY", 56, 68], ["LLC-PK1 cells", "ANATOMY", 93, 106], ["CHN-HG-2017", "CHEMICAL", 72, 83], ["PDCoV", "GENE_OR_GENE_PRODUCT", 22, 27], ["CHN-HG-2017", "CELL", 72, 83], ["LLC-PK1 cells", "CELL", 93, 106], ["CHN-HG-2017-infected LLC-PK1 cells", "CELL_LINE", 72, 106], ["the PDCoV particles", "PROBLEM", 18, 37], ["HG", "TEST", 76, 78], ["PK1 cells", "PROBLEM", 97, 106], ["electron microscopy", "TEST", 123, 142], ["LLC", "ANATOMY", 93, 96]]], ["As shown in Fig. 2, typical crown-shaped coronavirus particles with spiky surface projections and an average diameter of 80-160 nm were observed.", [["surface", "ANATOMY", 74, 81], ["coronavirus", "ORGANISM", 41, 52], ["typical crown-shaped coronavirus particles", "PROBLEM", 20, 62], ["Fig", "OBSERVATION", 12, 15], ["typical", "OBSERVATION_MODIFIER", 20, 27], ["crown", "OBSERVATION_MODIFIER", 28, 33], ["shaped", "OBSERVATION_MODIFIER", 34, 40], ["coronavirus particles", "OBSERVATION", 41, 62], ["spiky", "OBSERVATION_MODIFIER", 68, 73], ["surface", "OBSERVATION_MODIFIER", 74, 81], ["average", "OBSERVATION_MODIFIER", 101, 108], ["diameter", "OBSERVATION_MODIFIER", 109, 117], ["160 nm", "OBSERVATION_MODIFIER", 124, 130]]], ["These results clearly showed that a strain of PDCoV had been successfully isolated and identified.Phylogenetic and recombination analysis of the genome sequence of CHN-HG-2017 ::: ResultsThe complete nucleotide sequence of the genome of CHN-HG-2017 was determined and deposited in the GenBank database under the accession number MF095123.", [["PDCoV", "CHEMICAL", 46, 51], ["CHN-HG-2017", "CHEMICAL", 237, 248], ["MF095123", "CHEMICAL", 329, 337], ["PDCoV", "GENE_OR_GENE_PRODUCT", 46, 51], ["CHN-HG-2017", "CELL", 237, 248], ["CHN", "DNA", 237, 240], ["PDCoV", "SPECIES", 46, 51], ["CHN-HG-2017", "SPECIES", 237, 248], ["a strain of PDCoV", "PROBLEM", 34, 51], ["HG", "TEST", 241, 243]]], ["Similar to other PDCoV strains, the complete genome sequence of CHN-HG-2017 is 25,399 nt in length, consisting of 5\u2032 UTR-1ab-S-E-M-NS6-N-NS7-3\u2032 UTR, and predicted transcription regulatory sequences (TRSs) were located at the 5\u2032 end of each gene with a highly conserved core sequence of 5\u2032 -ACCAC-3\u2032 (Table 1).", [["PDCoV", "GENE_OR_GENE_PRODUCT", 17, 22], ["CHN-HG-2017", "CELL", 64, 75], ["UTR", "DNA", 117, 120], ["1ab", "DNA", 121, 124], ["S", "DNA", 125, 126], ["E", "DNA", 127, 128], ["M", "DNA", 129, 130], ["NS6", "DNA", 131, 134], ["N", "DNA", 135, 136], ["NS7-3\u2032 UTR", "DNA", 137, 147], ["transcription regulatory sequences", "DNA", 163, 197], ["TRSs", "DNA", 199, 203], ["5\u2032 end", "DNA", 225, 231], ["other PDCoV strains", "PROBLEM", 11, 30], ["HG", "TEST", 68, 70], ["UTR", "TEST", 117, 120], ["NS6", "TEST", 131, 134], ["NS7", "TEST", 137, 140], ["UTR", "TEST", 144, 147], ["TRSs", "TEST", 199, 203], ["ACCAC", "TEST", 290, 295]]], ["Moreover, CHN-HG-2017 shared 97.6%-99.1% nucleotide sequence identity with the other 74 PDCoV strains in the database.", [["CHN-HG-2017", "CHEMICAL", 10, 21], ["nucleotide", "CHEMICAL", 41, 51], ["nucleotide", "CHEMICAL", 41, 51], ["HG", "TEST", 14, 16], ["nucleotide sequence identity", "TEST", 41, 69]]], ["Phylogenetic analysis indicated that the PDCoV strains from the United States and South Korea clustered into a large clade, whereas CHN-HG-2017 clustered with other PDCoV strains detected in China since 2014.", [["CHN-HG-2017", "CELL", 132, 143], ["Phylogenetic analysis", "TEST", 0, 21], ["the PDCoV strains", "PROBLEM", 37, 54], ["HG", "TEST", 136, 138], ["other PDCoV strains", "PROBLEM", 159, 178], ["large", "OBSERVATION_MODIFIER", 111, 116], ["clade", "OBSERVATION", 117, 122]]], ["These data imply that the Chinese strains might share a more recent common ancestor with the US and South Korean strains than the ancestor of the strains from Thailand, Laos, and Vietnam (Fig. 3A).", [["the Chinese strains", "PROBLEM", 22, 41]]], ["Notably, phylogenetic trees based on the S gene displayed a similar clustering pattern (Fig. 3B).Phylogenetic and recombination analysis of the genome sequence of CHN-HG-2017 ::: ResultsThe RNA genome of coronaviruses can undergo high-frequency recombination due to its large size [24].", [["coronaviruses", "ORGANISM", 204, 217], ["S gene", "DNA", 41, 47], ["RNA genome", "DNA", 190, 200], ["phylogenetic trees", "PROBLEM", 9, 27], ["coronaviruses", "PROBLEM", 204, 217], ["high-frequency recombination", "TREATMENT", 230, 258], ["phylogenetic trees", "OBSERVATION", 9, 27], ["large", "OBSERVATION_MODIFIER", 270, 275], ["size", "OBSERVATION_MODIFIER", 276, 280]]], ["We therefore analyzed the genome sequence of CHN-HG-2017 using RDP.", [["CHN-HG-2017", "CELL", 45, 56], ["HG", "TEST", 49, 51]]], ["As depicted in Fig. 4A, two PDCoV strains, Vietnam/HaNoi6/2015 (GenBank accession number: KX834351) and CH/SXD1/2015 (GenBank accession number: KT021234), might represent the parent lineages of CHN-HG-2017.", [["CHN", "CHEMICAL", 194, 197], ["4A", "GENE_OR_GENE_PRODUCT", 20, 22], ["CHN-HG-2017", "CELL", 194, 205], ["Vietnam/HaNoi6/2015 (GenBank accession number: KX834351) and CH/SXD1/2015 (GenBank accession number: KT021234", "SPECIES", 43, 152], ["Fig", "OBSERVATION", 15, 18]]], ["Similarity plot and bootscanning analyses predicted the potential breakpoints in CHN-HG-2017 to be at nt 3153 and 4249.", [["CHN", "CHEMICAL", 81, 84], ["Similarity plot", "TEST", 0, 15], ["bootscanning analyses", "TEST", 20, 41], ["HG", "TEST", 85, 87]]], ["We therefore divided the aligned sequences into three separate segments: one from nt 1 up to the breakpoint at position 3153, another from the breakpoint at position 3153 to the breakpoint at position 4249, and the last one from the breakpoint at position 4249 to the end.", [["nt 1", "DNA", 82, 86], ["position 3153", "DNA", 111, 124], ["position 3153", "DNA", 157, 170], ["position 4249", "DNA", 192, 205], ["position 4249", "DNA", 247, 260]]], ["A phylogenetic analysis of these segments using the maximum-likelihood algorithm suggested the CH/SXD1/2015 strain from China to be its major parent and the Vietnam/HaNoi6/2015 strain from Vietnam to be its minor parent (Fig. 4B), providing strong evidence that recombination events had occurred.Clinical observations in pigs challenged with CHN-HG-2017 ::: ResultsTo investigate the pathogenicity of CHN-HG-2017, 5-day-old piglets were challenged with CHN-HG-2017 via oral feeding (Table 2).", [["oral", "ANATOMY", 469, 473], ["CHN", "CHEMICAL", 342, 345], ["CHN", "CHEMICAL", 401, 404], ["CHN-HG-2017", "CHEMICAL", 453, 464], ["pigs", "ORGANISM", 321, 325], ["CHN-HG-2017", "CELL", 401, 412], ["piglets", "ORGANISM", 424, 431], ["oral", "ORGANISM_SUBDIVISION", 469, 473], ["pigs", "SPECIES", 321, 325], ["piglets", "SPECIES", 424, 431], ["Vietnam/HaNoi6/2015 strain", "SPECIES", 157, 183], ["pigs", "SPECIES", 321, 325], ["A phylogenetic analysis", "TEST", 0, 23], ["likelihood algorithm", "TEST", 60, 80], ["recombination events", "PROBLEM", 262, 282], ["HG", "TEST", 405, 407]]], ["All piglets from the negative control groups were in good health throughout the course of study with no observed clinical signs (Fig. 5A and B).", [["piglets", "ORGANISM", 4, 11], ["piglets", "SPECIES", 4, 11]]], ["As expected, three of the six piglets in the challenged group showed diarrhea at 1 DPI, and more piglets developed varying degrees of diarrhea, vomiting, lethargy and anorexia at 2-6 DPI (Fig. 5C and D).", [["diarrhea", "DISEASE", 69, 77], ["DPI", "CHEMICAL", 83, 86], ["diarrhea", "DISEASE", 134, 142], ["vomiting", "DISEASE", 144, 152], ["lethargy", "DISEASE", 154, 162], ["anorexia", "DISEASE", 167, 175], ["piglets", "ORGANISM", 30, 37], ["piglets", "ORGANISM", 97, 104], ["piglets", "SPECIES", 30, 37], ["piglets", "SPECIES", 97, 104], ["diarrhea", "PROBLEM", 69, 77], ["diarrhea", "PROBLEM", 134, 142], ["vomiting", "PROBLEM", 144, 152], ["lethargy", "PROBLEM", 154, 162], ["anorexia", "PROBLEM", 167, 175], ["diarrhea", "OBSERVATION", 69, 77], ["varying degrees", "OBSERVATION_MODIFIER", 115, 130], ["diarrhea", "OBSERVATION", 134, 142]]], ["Lethargy, anorexia and the progression to watery diarrhea were most severe at 3-6 DPI, and the piglets gradually recovered thereafter (Table 3).", [["Lethargy", "DISEASE", 0, 8], ["anorexia", "DISEASE", 10, 18], ["diarrhea", "DISEASE", 49, 57], ["piglets", "ORGANISM", 95, 102], ["piglets", "SPECIES", 95, 102], ["Lethargy", "PROBLEM", 0, 8], ["anorexia", "PROBLEM", 10, 18], ["watery diarrhea", "PROBLEM", 42, 57], ["anorexia", "OBSERVATION", 10, 18], ["progression", "OBSERVATION_MODIFIER", 27, 38], ["most severe", "OBSERVATION_MODIFIER", 63, 74]]], ["Notably, no PDCoV-associated deaths were observed in this study.", [["PDCoV", "CHEMICAL", 12, 17], ["deaths", "DISEASE", 29, 35], ["PDCoV-associated deaths", "PROBLEM", 12, 35], ["this study", "TEST", 53, 63], ["no", "UNCERTAINTY", 9, 11], ["deaths", "OBSERVATION", 29, 35]]], ["These results demonstrated that CHN-HG-2017 is pathogenic to newborn piglets.Fecal shedding, virus distribution, and neutralizing antibody against CHN-HG-2017 ::: ResultsTo determine the duration of fecal shedding and to monitor the changing load of CHN-HG-2017, we attempted to detect viral RNA in rectal swab samples from 1 to 21 DPI by quantitative real-time RT-PCR.", [["Fecal", "ANATOMY", 77, 82], ["fecal", "ANATOMY", 199, 204], ["rectal swab samples", "ANATOMY", 299, 318], ["CHN-HG-2017", "CHEMICAL", 32, 43], ["CHN", "CHEMICAL", 250, 253], ["CHN", "SIMPLE_CHEMICAL", 32, 35], ["piglets", "ORGANISM", 69, 76], ["Fecal", "ORGANISM_SUBSTANCE", 77, 82], ["fecal", "ORGANISM_SUBSTANCE", 199, 204], ["CHN-HG-2017", "CELL", 250, 261], ["rectal swab samples", "ORGANISM_SUBSTANCE", 299, 318], ["neutralizing antibody", "PROTEIN", 117, 138], ["viral RNA", "RNA", 286, 295], ["piglets", "SPECIES", 69, 76], ["Fecal shedding, virus distribution", "PROBLEM", 77, 111], ["neutralizing antibody", "TEST", 117, 138], ["fecal shedding", "PROBLEM", 199, 213], ["HG", "TEST", 254, 256], ["viral RNA", "PROBLEM", 286, 295], ["rectal swab samples", "TEST", 299, 318], ["PCR", "TEST", 365, 368], ["shedding", "OBSERVATION", 83, 91], ["virus distribution", "OBSERVATION", 93, 111], ["viral RNA", "OBSERVATION", 286, 295], ["rectal", "ANATOMY", 299, 305]]], ["The viral RNA was detected in six out of six rectal swab samples collected from the challenged group from 1 DPI to 14 DPI.", [["rectal swab samples", "ANATOMY", 45, 64], ["DPI", "CHEMICAL", 118, 121], ["viral RNA", "RNA", 4, 13], ["The viral RNA", "PROBLEM", 0, 13], ["six rectal swab samples", "TEST", 41, 64], ["viral RNA", "OBSERVATION", 4, 13]]], ["The PDCoV RNA copy number in homogenized rectal swab supernatants reached a peak of over 108 copies/ml at 2-4 DPI (Fig. 6A).", [["rectal swab supernatants", "ANATOMY", 41, 65], ["PDCoV", "GENE_OR_GENE_PRODUCT", 4, 9], ["rectal swab", "ORGANISM_SUBSTANCE", 41, 52], ["PDCoV RNA", "RNA", 4, 13], ["rectal swab supernatants", "TEST", 41, 65]]], ["Notably, no PDCoV RNA was detected in samples from piglets in the negative control throughout the study.Fecal shedding, virus distribution, and neutralizing antibody against CHN-HG-2017 ::: ResultsThe distribution of CHN-HG-2017 in various tissues was also examined by quantitative real-time RT-PCR in three pigs from each group sacrificed at 4 DPI.", [["samples", "ANATOMY", 38, 45], ["Fecal", "ANATOMY", 104, 109], ["tissues", "ANATOMY", 240, 247], ["CHN-HG-2017", "CHEMICAL", 217, 228], ["PDCoV", "GENE_OR_GENE_PRODUCT", 12, 17], ["piglets", "ORGANISM", 51, 58], ["Fecal", "ORGANISM_SUBSTANCE", 104, 109], ["CHN-HG-2017", "CELL", 217, 228], ["tissues", "TISSUE", 240, 247], ["pigs", "ORGANISM", 308, 312], ["PDCoV RNA", "RNA", 12, 21], ["neutralizing antibody", "PROTEIN", 144, 165], ["piglets", "SPECIES", 51, 58], ["pigs", "SPECIES", 308, 312], ["PDCoV", "SPECIES", 12, 17], ["pigs", "SPECIES", 308, 312], ["PDCoV RNA", "PROBLEM", 12, 21], ["the study", "TEST", 94, 103], ["Fecal shedding, virus distribution", "PROBLEM", 104, 138], ["neutralizing antibody", "TEST", 144, 165], ["HG", "TEST", 221, 223], ["no", "UNCERTAINTY", 9, 11], ["PDCoV RNA", "OBSERVATION", 12, 21], ["negative", "OBSERVATION", 66, 74], ["shedding", "OBSERVATION", 110, 118], ["virus distribution", "OBSERVATION", 120, 138], ["distribution", "OBSERVATION_MODIFIER", 201, 213]]], ["Viral RNA was detected in two of three duodenums (average 106.86 copies/g), three of three jejunums (average 108.26 copies/g), three of three ileums (average 108.4 copies/g), three of three ceca (average 108.42 copies/g), three of three colons (average 107.96 copies/g), and three of three rectums (average 106.95 copies/g).", [["duodenums", "ANATOMY", 39, 48], ["jejunums", "ANATOMY", 91, 99], ["ileums", "ANATOMY", 142, 148], ["ceca", "ANATOMY", 190, 194], ["colons", "ANATOMY", 237, 243], ["rectums", "ANATOMY", 290, 297], ["Viral", "ORGANISM", 0, 5], ["duodenums", "CANCER", 39, 48], ["jejunums", "CANCER", 91, 99], ["ileums", "CANCER", 142, 148], ["ceca", "ORGAN", 190, 194], ["colons", "MULTI-TISSUE_STRUCTURE", 237, 243], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["RNA", "OBSERVATION", 6, 9], ["ceca", "ANATOMY", 190, 194], ["colons", "ANATOMY", 237, 243]]], ["It was also detected in one of three livers (105.96 copies/g), one of three spleens (106.91 copies/g), one of three kidneys (106.9 copies/g) and one of three lungs (106.02 copies/g), but no viral RNA was detected in the blood (Fig. 6B).Fecal shedding, virus distribution, and neutralizing antibody against CHN-HG-2017 ::: ResultsTo investigate when PDCoV neutralizing antibodies were detectable in the infected piglets, serum samples collected at 0, 4, 7, 21 DPI were tested for PDCoV-neutralizing antibodies.", [["livers", "ANATOMY", 37, 43], ["spleens", "ANATOMY", 76, 83], ["kidneys", "ANATOMY", 116, 123], ["lungs", "ANATOMY", 158, 163], ["blood", "ANATOMY", 220, 225], ["Fecal", "ANATOMY", 236, 241], ["piglets", "ANATOMY", 411, 418], ["serum samples", "ANATOMY", 420, 433], ["livers", "ORGAN", 37, 43], ["spleens", "ORGAN", 76, 83], ["kidneys", "ORGAN", 116, 123], ["lungs", "ORGAN", 158, 163], ["blood", "ORGANISM_SUBSTANCE", 220, 225], ["Fecal", "ORGANISM_SUBSTANCE", 236, 241], ["PDCoV", "GENE_OR_GENE_PRODUCT", 349, 354], ["piglets", "ORGANISM", 411, 418], ["serum samples", "ORGANISM_SUBSTANCE", 420, 433], ["PDCoV", "GENE_OR_GENE_PRODUCT", 479, 484], ["viral RNA", "RNA", 190, 199], ["neutralizing antibody", "PROTEIN", 276, 297], ["PDCoV neutralizing antibodies", "PROTEIN", 349, 378], ["PDCoV", "PROTEIN", 479, 484], ["neutralizing antibodies", "PROTEIN", 485, 508], ["piglets", "SPECIES", 411, 418], ["PDCoV", "SPECIES", 349, 354], ["PDCoV", "SPECIES", 479, 484], ["copies/g", "TEST", 92, 100], ["copies/g", "TEST", 131, 139], ["copies/g", "TEST", 172, 180], ["viral RNA", "PROBLEM", 190, 199], ["the blood", "TEST", 216, 225], ["Fecal shedding, virus distribution", "PROBLEM", 236, 270], ["neutralizing antibody", "TEST", 276, 297], ["PDCoV neutralizing antibodies", "TEST", 349, 378], ["serum samples", "TEST", 420, 433], ["DPI", "TEST", 459, 462], ["PDCoV", "TEST", 479, 484], ["neutralizing antibodies", "PROBLEM", 485, 508], ["livers", "ANATOMY", 37, 43], ["spleens", "ANATOMY", 76, 83], ["kidneys", "ANATOMY", 116, 123], ["lungs", "ANATOMY", 158, 163], ["no", "UNCERTAINTY", 187, 189], ["viral RNA", "OBSERVATION", 190, 199], ["shedding", "OBSERVATION", 242, 250], ["virus distribution", "OBSERVATION", 252, 270]]], ["Virus-neutralizing (VN) antibodies in sera were detected as early as 4 DPI in sera of PDCoV-inoculated piglets, and the titers increased gradually and peaked at 21 DPI (Table 4).", [["sera", "ANATOMY", 38, 42], ["sera", "ANATOMY", 78, 82], ["piglets", "ANATOMY", 103, 110], ["DPI", "CHEMICAL", 71, 74], ["PDCoV", "CHEMICAL", 86, 91], ["Virus-neutralizing (VN) antibodies", "GENE_OR_GENE_PRODUCT", 0, 34], ["sera", "ORGANISM_SUBSTANCE", 38, 42], ["DPI", "SIMPLE_CHEMICAL", 71, 74], ["sera", "ORGANISM_SUBSTANCE", 78, 82], ["PDCoV", "SIMPLE_CHEMICAL", 86, 91], ["piglets", "ORGANISM", 103, 110], ["Virus-neutralizing (VN) antibodies", "PROTEIN", 0, 34], ["piglets", "SPECIES", 103, 110], ["PDCoV", "SPECIES", 86, 91], ["Virus", "TEST", 0, 5], ["neutralizing (VN) antibodies in sera", "TEST", 6, 42], ["sera", "TEST", 78, 82], ["PDCoV", "TEST", 86, 91], ["the titers", "TEST", 116, 126], ["neutralizing", "OBSERVATION", 6, 18]]], ["PDCoV-specific neutralizing antibodies were not observed in sera from the control piglets.Gross pathology, histopathology, and immunohistochemistry ::: ResultsTo determine the gross pathological and histological changes in piglets infected with CHN-HG-2017, three of the six pigs in each group were selected randomly for necropsy at 4 DPI.", [["sera", "ANATOMY", 60, 64], ["PDCoV", "CHEMICAL", 0, 5], ["CHN", "CHEMICAL", 245, 248], ["PDCoV", "SIMPLE_CHEMICAL", 0, 5], ["sera", "ORGANISM_SUBSTANCE", 60, 64], ["piglets", "ORGANISM", 82, 89], ["piglets", "ORGANISM", 223, 230], ["pigs", "ORGANISM", 275, 279], ["PDCoV", "PROTEIN", 0, 5], ["neutralizing antibodies", "PROTEIN", 15, 38], ["piglets", "SPECIES", 82, 89], ["piglets", "SPECIES", 223, 230], ["pigs", "SPECIES", 275, 279], ["PDCoV", "TREATMENT", 0, 5], ["specific neutralizing antibodies", "TEST", 6, 38], ["Gross pathology", "TEST", 90, 105], ["the gross pathological and histological changes", "PROBLEM", 172, 219], ["HG", "TEST", 249, 251], ["necropsy", "TREATMENT", 321, 329], ["neutralizing antibodies", "OBSERVATION", 15, 38], ["pathology", "OBSERVATION", 96, 105], ["gross", "OBSERVATION_MODIFIER", 176, 181], ["pathological", "OBSERVATION", 182, 194], ["histological", "OBSERVATION", 199, 211], ["piglets", "OBSERVATION_MODIFIER", 223, 230], ["infected", "OBSERVATION_MODIFIER", 231, 239]]], ["The small intestines, where yellow watery contents had accumulated, were clearly transparent, thin-walled, and gas-distended in the PDCoV-challenged pigs (Fig. 7A).", [["intestines", "ANATOMY", 10, 20], ["PDCoV", "CHEMICAL", 132, 137], ["intestines", "ORGAN", 10, 20], ["watery", "ORGANISM_SUBDIVISION", 35, 41], ["PDCoV", "SIMPLE_CHEMICAL", 132, 137], ["pigs", "ORGANISM", 149, 153], ["pigs", "SPECIES", 149, 153], ["yellow watery contents", "PROBLEM", 28, 50], ["distended", "PROBLEM", 115, 124], ["small", "OBSERVATION_MODIFIER", 4, 9], ["intestines", "ANATOMY", 10, 20], ["transparent", "OBSERVATION_MODIFIER", 81, 92], ["walled", "OBSERVATION_MODIFIER", 99, 105], ["gas", "OBSERVATION_MODIFIER", 111, 114], ["distended", "OBSERVATION", 115, 124]]], ["No other lesions were observed in any other organs of the challenged groups or in any of the organs of the negative control pigs (Fig. 7B).", [["lesions", "ANATOMY", 9, 16], ["organs", "ANATOMY", 44, 50], ["organs", "ANATOMY", 93, 99], ["lesions", "PATHOLOGICAL_FORMATION", 9, 16], ["organs", "ORGAN", 44, 50], ["organs", "ORGAN", 93, 99], ["pigs", "ORGANISM", 124, 128], ["pigs", "SPECIES", 124, 128], ["other lesions", "PROBLEM", 3, 16], ["lesions", "OBSERVATION", 9, 16], ["negative", "OBSERVATION", 107, 115]]], ["These results showed that the small intestine is the major target of CHN-HG-2017 infection.", [["small intestine", "ANATOMY", 30, 45], ["CHN-HG-2017", "CHEMICAL", 69, 80], ["infection", "DISEASE", 81, 90], ["small intestine", "ORGAN", 30, 45], ["CHN-HG-2017", "CELL", 69, 80], ["the small intestine", "PROBLEM", 26, 45], ["infection", "PROBLEM", 81, 90], ["small", "OBSERVATION_MODIFIER", 30, 35], ["intestine", "ANATOMY", 36, 45], ["HG", "OBSERVATION_MODIFIER", 73, 75], ["infection", "OBSERVATION", 81, 90]]], ["Microscopic lesions in the small intestine were also observed by microscopy.", [["lesions", "ANATOMY", 12, 19], ["small intestine", "ANATOMY", 27, 42], ["Microscopic lesions", "PATHOLOGICAL_FORMATION", 0, 19], ["small intestine", "ORGAN", 27, 42], ["Microscopic lesions in the small intestine", "PROBLEM", 0, 42], ["microscopy", "TEST", 65, 75], ["lesions", "OBSERVATION", 12, 19], ["small intestine", "ANATOMY", 27, 42]]], ["Compared to those of the negative control piglets, the intestinal villi of the PDCoV-infected piglets were blunted and fragmented and exhibited atrophy and vacuolation, especially in the jejunum and ileum (Fig. 7C and D and Table 5).", [["intestinal villi", "ANATOMY", 55, 71], ["piglets", "ANATOMY", 94, 101], ["jejunum", "ANATOMY", 187, 194], ["ileum", "ANATOMY", 199, 204], ["atrophy", "DISEASE", 144, 151], ["piglets", "ORGANISM", 42, 49], ["intestinal villi", "MULTI-TISSUE_STRUCTURE", 55, 71], ["PDCoV", "GENE_OR_GENE_PRODUCT", 79, 84], ["piglets", "ORGANISM", 94, 101], ["jejunum", "MULTI-TISSUE_STRUCTURE", 187, 194], ["ileum", "MULTI-TISSUE_STRUCTURE", 199, 204], ["piglets", "SPECIES", 42, 49], ["piglets", "SPECIES", 94, 101], ["blunted", "PROBLEM", 107, 114], ["atrophy", "PROBLEM", 144, 151], ["vacuolation", "PROBLEM", 156, 167], ["intestinal villi", "ANATOMY", 55, 71], ["infected piglets", "OBSERVATION", 85, 101], ["blunted", "OBSERVATION_MODIFIER", 107, 114], ["fragmented", "OBSERVATION_MODIFIER", 119, 129], ["atrophy", "OBSERVATION", 144, 151], ["vacuolation", "OBSERVATION_MODIFIER", 156, 167], ["jejunum", "ANATOMY", 187, 194], ["ileum", "ANATOMY", 199, 204]]], ["Moreover, aggregation of lymphocytes and hyperemia in the intestinal lamina propria were also observed (Fig. 7C and D), but the intestines of the negative control were normal (Fig. 7E and F).", [["lymphocytes", "ANATOMY", 25, 36], ["intestinal lamina propria", "ANATOMY", 58, 83], ["intestines", "ANATOMY", 128, 138], ["hyperemia", "DISEASE", 41, 50], ["lymphocytes", "CELL", 25, 36], ["intestinal lamina propria", "TISSUE", 58, 83], ["intestines", "ORGAN", 128, 138], ["lymphocytes", "CELL_TYPE", 25, 36], ["aggregation of lymphocytes", "PROBLEM", 10, 36], ["hyperemia in the intestinal lamina propria", "PROBLEM", 41, 83], ["aggregation", "OBSERVATION_MODIFIER", 10, 21], ["lymphocytes", "OBSERVATION", 25, 36], ["hyperemia", "OBSERVATION_MODIFIER", 41, 50], ["intestinal lamina", "ANATOMY", 58, 75], ["propria", "ANATOMY_MODIFIER", 76, 83], ["intestines", "ANATOMY", 128, 138], ["negative", "OBSERVATION", 146, 154]]], ["Consistent with the histopathological results, PDCoV antigen was detected by immunohistochemical staining in the cytoplasm of the infected villous enterocytes (Fig. 7G and H).", [["cytoplasm", "ANATOMY", 113, 122], ["villous enterocytes", "ANATOMY", 139, 158], ["PDCoV antigen", "GENE_OR_GENE_PRODUCT", 47, 60], ["cytoplasm", "ORGANISM_SUBSTANCE", 113, 122], ["villous enterocytes", "CELL", 139, 158], ["PDCoV antigen", "PROTEIN", 47, 60], ["infected villous enterocytes", "CELL_TYPE", 130, 158], ["PDCoV antigen", "TEST", 47, 60], ["immunohistochemical staining", "TEST", 77, 105], ["infected villous enterocytes", "OBSERVATION", 130, 158]]], ["No PDCoV antigen was detected in the negative controls (Fig. 7I and J).", [["PDCoV antigen", "GENE_OR_GENE_PRODUCT", 3, 16], ["PDCoV antigen", "PROTEIN", 3, 16], ["PDCoV antigen", "PROBLEM", 3, 16]]], ["These results show that CHN-HG-2017 infection can cause intestinal lesions in newborn piglets, especially in the jejunum and ileum.DiscussionPDCoV is a newly emerged enteropathogenic coronavirus that causes diarrhea, dehydration and death in neonatal piglets.", [["intestinal lesions", "ANATOMY", 56, 74], ["jejunum", "ANATOMY", 113, 120], ["ileum", "ANATOMY", 125, 130], ["CHN-HG-2017", "CHEMICAL", 24, 35], ["infection", "DISEASE", 36, 45], ["intestinal lesions", "DISEASE", 56, 74], ["DiscussionPDCoV", "CHEMICAL", 131, 146], ["enteropathogenic coronavirus", "DISEASE", 166, 194], ["diarrhea", "DISEASE", 207, 215], ["dehydration", "DISEASE", 217, 228], ["death", "DISEASE", 233, 238], ["CHN", "SIMPLE_CHEMICAL", 24, 27], ["intestinal lesions", "PATHOLOGICAL_FORMATION", 56, 74], ["piglets", "ORGANISM", 86, 93], ["jejunum", "MULTI-TISSUE_STRUCTURE", 113, 120], ["ileum", "ORGAN", 125, 130], ["coronavirus", "ORGANISM", 183, 194], ["piglets", "ORGANISM", 251, 258], ["piglets", "SPECIES", 86, 93], ["piglets", "SPECIES", 251, 258], ["HG", "TEST", 28, 30], ["infection", "PROBLEM", 36, 45], ["intestinal lesions in newborn piglets", "PROBLEM", 56, 93], ["a newly emerged enteropathogenic coronavirus", "PROBLEM", 150, 194], ["diarrhea", "PROBLEM", 207, 215], ["dehydration", "PROBLEM", 217, 228], ["death in neonatal piglets", "PROBLEM", 233, 258], ["intestinal", "ANATOMY", 56, 66], ["lesions", "OBSERVATION", 67, 74], ["newborn piglets", "OBSERVATION", 78, 93], ["jejunum", "ANATOMY", 113, 120], ["ileum", "ANATOMY", 125, 130], ["enteropathogenic coronavirus", "OBSERVATION", 166, 194], ["diarrhea", "OBSERVATION", 207, 215]]], ["Since PDCoV was first reported in Hong Kong, it has spread to many countries around the world, leading to significant economic losses in the pork industry.", [["PDCoV", "CHEMICAL", 6, 11], ["PDCoV", "GENE_OR_GENE_PRODUCT", 6, 11], ["pork", "ORGANISM_SUBDIVISION", 141, 145], ["pork", "SPECIES", 141, 145], ["significant", "OBSERVATION_MODIFIER", 106, 117], ["economic", "OBSERVATION_MODIFIER", 118, 126], ["losses", "OBSERVATION", 127, 133]]], ["In mainland China, the prevalence of PDCoV in pigs was reported to be 33.71% in Jiangxi province [17], 23.4% in Guangdong province [15], and 10.2% in Hebei province [25].", [["PDCoV", "DISEASE", 37, 42], ["PDCoV", "CANCER", 37, 42], ["pigs", "ORGANISM", 46, 50], ["pigs", "SPECIES", 46, 50], ["PDCoV", "SPECIES", 37, 42], ["pigs", "SPECIES", 46, 50]]], ["Although the prevalence of PDCoV in China has been widely reported, only a few PDCoV strains could be successfully isolated in cultured cells until now.DiscussionIn the present study, feces from PDCoV-infected pigs on farms located in central China were used to isolate PDCoV in LLC-PK1 cells.", [["cells", "ANATOMY", 136, 141], ["feces", "ANATOMY", 184, 189], ["LLC-PK1 cells", "ANATOMY", 279, 292], ["PDCoV", "DISEASE", 27, 32], ["PDCoV", "CHEMICAL", 195, 200], ["PDCoV", "CANCER", 27, 32], ["cells", "CELL", 136, 141], ["feces", "ORGANISM_SUBDIVISION", 184, 189], ["pigs", "ORGANISM", 210, 214], ["PDCoV", "CELL", 270, 275], ["LLC-PK1 cells", "CELL", 279, 292], ["cultured cells", "CELL_LINE", 127, 141], ["LLC-PK1 cells", "CELL_LINE", 279, 292], ["pigs", "SPECIES", 210, 214], ["PDCoV", "SPECIES", 27, 32], ["pigs", "SPECIES", 210, 214], ["PDCoV", "SPECIES", 270, 275], ["a few PDCoV strains", "PROBLEM", 73, 92], ["the present study", "TEST", 165, 182], ["PDCoV", "TREATMENT", 195, 200], ["infected pigs on farms", "TREATMENT", 201, 223], ["infected", "OBSERVATION", 201, 209], ["central China", "ANATOMY", 235, 248], ["LLC", "ANATOMY", 279, 282], ["PK1 cells", "OBSERVATION", 283, 292]]], ["Typical CPE was observed in infected LLC-PK1 cells at 24 h after inoculation.", [["LLC-PK1 cells", "ANATOMY", 37, 50], ["LLC-PK1 cells", "CELL", 37, 50], ["LLC-PK1 cells", "CELL_LINE", 37, 50], ["Typical CPE", "PROBLEM", 0, 11], ["PK1 cells", "PROBLEM", 41, 50], ["inoculation", "PROBLEM", 65, 76], ["CPE", "OBSERVATION", 8, 11], ["infected", "OBSERVATION_MODIFIER", 28, 36], ["LLC", "ANATOMY", 37, 40]]], ["Following plaque purification, the PDCoV strain was confirmed by IFA and electron microscopy.", [["plaque", "ANATOMY", 10, 16], ["plaque purification", "TREATMENT", 10, 29], ["the PDCoV strain", "PROBLEM", 31, 47], ["electron microscopy", "TEST", 73, 92], ["plaque", "OBSERVATION", 10, 16]]], ["Notably, only one PDCoV strain was isolated from a total of 17 PDCoV-positive feces samples, indicating that the success rate for virus isolation was still relatively low.", [["samples", "ANATOMY", 84, 91], ["PDCoV", "GENE_OR_GENE_PRODUCT", 18, 23], ["PDCoV", "GENE_OR_GENE_PRODUCT", 63, 68], ["feces", "ORGANISM", 78, 83], ["one PDCoV strain", "PROBLEM", 14, 30], ["positive feces samples", "PROBLEM", 69, 91], ["the success rate", "TEST", 109, 125], ["virus isolation", "PROBLEM", 130, 145]]], ["This low rate of PDCoV isolation might be attributed to a small amount of infectious virus in the fecal samples collected for virus isolation.", [["fecal samples", "ANATOMY", 98, 111], ["PDCoV", "CANCER", 17, 22], ["fecal samples", "ORGANISM_SUBSTANCE", 98, 111], ["PDCoV isolation", "TREATMENT", 17, 32], ["a small amount of infectious virus", "PROBLEM", 56, 90], ["the fecal samples", "TEST", 94, 111], ["virus isolation", "TREATMENT", 126, 141], ["small", "OBSERVATION_MODIFIER", 58, 63], ["amount", "OBSERVATION_MODIFIER", 64, 70], ["infectious virus", "OBSERVATION", 74, 90], ["fecal", "ANATOMY", 98, 103]]], ["In addition, the time at which the sample is collected might also contribute to the success of PDCoV isolation.DiscussionTo characterize the virus isolate, the complete genome of CHN-HG-2017 was sequenced and analyzed.", [["PDCoV", "CANCER", 95, 100], ["CHN-HG-2017", "CELL", 179, 190], ["CHN", "DNA", 179, 182], ["2017", "DNA", 186, 190], ["PDCoV", "SPECIES", 95, 100], ["CHN-HG-2017", "SPECIES", 179, 190], ["PDCoV isolation", "TREATMENT", 95, 110], ["the virus isolate", "PROBLEM", 137, 154], ["HG", "TEST", 183, 185]]], ["While the genome organization is similar to those of other reported PDCoVs, the genome size of 25,399 nt is somewhat different from the others.", [["PDCoVs", "GENE_OR_GENE_PRODUCT", 68, 74], ["PDCoVs", "DNA", 68, 74], ["25,399 nt", "DNA", 95, 104], ["the genome size", "TEST", 76, 91], ["genome", "OBSERVATION_MODIFIER", 80, 86], ["size", "OBSERVATION_MODIFIER", 87, 91], ["somewhat", "OBSERVATION_MODIFIER", 108, 116], ["different", "OBSERVATION_MODIFIER", 117, 126]]], ["Moreover, we identified predicted TRSs at the 5\u2032 end of each gene of CHN-HG-2017, each with a highly conserved core sequence of 5\u2032-ACCAC-3\u2032, which appears to be unique to members of the genus Deltacoronavirus.", [["TRSs", "GENE_OR_GENE_PRODUCT", 34, 38], ["5\u2032-ACCAC-3", "GENE_OR_GENE_PRODUCT", 128, 138], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 192, 208], ["TRSs", "DNA", 34, 38], ["5\u2032 end", "DNA", 46, 52], ["CHN", "DNA", 69, 72], ["5\u2032-ACCAC-3\u2032", "DNA", 128, 139], ["TRSs", "TEST", 34, 38], ["HG", "TEST", 73, 75], ["genus Deltacoronavirus", "OBSERVATION", 186, 208]]], ["Multiple sequence alignment and phylogenetic analysis showed that all of the known PDCoV strains share a high level of nucleotide sequence identities.", [["nucleotide", "CHEMICAL", 119, 129], ["nucleotide", "CHEMICAL", 119, 129], ["PDCoV", "GENE_OR_GENE_PRODUCT", 83, 88], ["Multiple sequence alignment", "TEST", 0, 27], ["phylogenetic analysis", "TEST", 32, 53], ["the known PDCoV strains", "PROBLEM", 73, 96]]], ["However, CHN-HG-2017 was most closely related to other Chinese PDCoV strains.", [["CHN-HG-2017", "CHEMICAL", 9, 20], ["PDCoV", "GENE_OR_GENE_PRODUCT", 63, 68], ["Chinese PDCoV", "SPECIES", 55, 68], ["HG", "TEST", 13, 15], ["Chinese PDCoV strains", "TREATMENT", 55, 76]]], ["Our phylogenetic analysis suggests that PDCoV strains from China, the United States and South Korea are clustered in the same clade, whereas the PDCoV strains from Thailand, Laos, and Vietnam are clustered in another clade.DiscussionLike other coronaviruses, PDCoV has the potential to undergo recombination at a very high frequency.", [["PDCoV", "CHEMICAL", 259, 264], ["PDCoV strains", "ORGANISM", 40, 53], ["PDCoV strains", "ORGANISM", 145, 158], ["coronaviruses", "ORGANISM", 244, 257], ["PDCoV", "GENE_OR_GENE_PRODUCT", 259, 264], ["Our phylogenetic analysis", "TEST", 0, 25], ["PDCoV strains", "PROBLEM", 40, 53], ["the PDCoV strains", "PROBLEM", 141, 158], ["PDCoV", "TREATMENT", 259, 264]]], ["In this study, we employed the Recombination Detection Program (RDP) to analyze the genome of CHN-HG-2017 in search of any recombined fragments.", [["fragments", "ANATOMY", 134, 143], ["CHN-HG-2017", "CELL", 94, 105], ["CHN", "DNA", 94, 97], ["recombined fragments", "DNA", 123, 143], ["this study", "TEST", 3, 13], ["HG", "TEST", 98, 100], ["any recombined fragments", "PROBLEM", 119, 143], ["fragments", "OBSERVATION", 134, 143]]], ["Intriguingly, CHN-HG-2017 was found to be a possible recombinant virus derived from parental strains from China and Vietnam.", [["CHN-HG-2017", "CHEMICAL", 14, 25], ["CHN-HG", "TEST", 14, 20], ["recombinant virus", "PROBLEM", 53, 70], ["parental strains", "PROBLEM", 84, 100], ["virus", "OBSERVATION", 65, 70]]], ["The potential breakpoints in CHN-HG-2017 were located at nt 3153 and 4249 in the nsp3 region.", [["nt 3153 and 4249", "DNA", 57, 73], ["nsp3 region", "DNA", 81, 92], ["HG", "TEST", 33, 35]]], ["Deletion mutations in the nsp3 region in PDCoV have been reported recently [6, 26], suggesting that nsp3 which encodes a papain-like protease, may be a hotspot for genetic modification.", [["nsp3", "GENE_OR_GENE_PRODUCT", 26, 30], ["PDCoV", "GENE_OR_GENE_PRODUCT", 41, 46], ["nsp3", "GENE_OR_GENE_PRODUCT", 100, 104], ["papain", "GENE_OR_GENE_PRODUCT", 121, 127], ["nsp3 region", "DNA", 26, 37], ["PDCoV", "DNA", 41, 46], ["nsp3", "PROTEIN", 100, 104], ["papain-like protease", "PROTEIN", 121, 141], ["Deletion mutations in the nsp3 region", "PROBLEM", 0, 37], ["nsp3", "PROBLEM", 100, 104], ["a papain-like protease", "PROBLEM", 119, 141], ["genetic modification", "TREATMENT", 164, 184]]], ["To our knowledge, this is the first time that a recombination event has been identified in the Nsp3 region of PDCoV.", [["Nsp3", "GENE_OR_GENE_PRODUCT", 95, 99], ["PDCoV", "GENE_OR_GENE_PRODUCT", 110, 115], ["Nsp3 region", "DNA", 95, 106], ["PDCoV", "DNA", 110, 115], ["a recombination event", "PROBLEM", 46, 67]]], ["The emergence of recombinant strains from China and Vietnam will probably bring new challenges to the prevention and control of PDCoV.DiscussionTo investigate the pathogenicity of this putative recombinant strain, 5-day-old piglets were inoculated orally with CHN-HG-2017.", [["PDCoV", "DISEASE", 128, 133], ["CHN-HG", "CHEMICAL", 260, 266], ["PDCoV", "CANCER", 128, 133], ["piglets", "ORGANISM", 224, 231], ["piglets", "SPECIES", 224, 231], ["PDCoV", "SPECIES", 128, 133], ["Vietnam", "TREATMENT", 52, 59], ["PDCoV", "TREATMENT", 128, 133], ["this putative recombinant strain", "PROBLEM", 180, 212]]], ["As expected, severe diarrhea with vomiting and lethargy in piglets was observed from 1 to 6 DPI, suggesting that CHN-HG-2017 is pathogenic to newborn piglets.", [["diarrhea", "DISEASE", 20, 28], ["vomiting", "DISEASE", 34, 42], ["lethargy", "DISEASE", 47, 55], ["DPI", "CHEMICAL", 92, 95], ["CHN-HG-2017", "CHEMICAL", 113, 124], ["piglets", "ORGANISM", 59, 66], ["CHN", "SIMPLE_CHEMICAL", 113, 116], ["piglets", "ORGANISM", 150, 157], ["piglets", "SPECIES", 59, 66], ["piglets", "SPECIES", 150, 157], ["severe diarrhea", "PROBLEM", 13, 28], ["vomiting", "PROBLEM", 34, 42], ["lethargy", "PROBLEM", 47, 55], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["diarrhea", "OBSERVATION", 20, 28]]], ["The viral RNA distribution in various tissues was also examined.", [["tissues", "ANATOMY", 38, 45], ["tissues", "TISSUE", 38, 45], ["The viral RNA distribution in various tissues", "PROBLEM", 0, 45], ["viral RNA", "OBSERVATION", 4, 13], ["distribution", "OBSERVATION_MODIFIER", 14, 26], ["various tissues", "ANATOMY", 30, 45]]], ["Viral RNA levels were higher in intestines than in other tissues.", [["intestines", "ANATOMY", 32, 42], ["tissues", "ANATOMY", 57, 64], ["Viral", "ORGANISM", 0, 5], ["intestines", "ORGAN", 32, 42], ["tissues", "TISSUE", 57, 64], ["Viral RNA levels", "TEST", 0, 16], ["RNA levels", "OBSERVATION", 6, 16], ["higher", "OBSERVATION_MODIFIER", 22, 28], ["intestines", "ANATOMY", 32, 42]]], ["Previously, it was reported that coronavirus HKU15 may be able to spread through the respiratory route, in addition to fecal-oral transmission [27].", [["respiratory", "ANATOMY", 85, 96], ["oral", "ANATOMY", 125, 129], ["HKU15", "CHEMICAL", 45, 50], ["fecal-oral transmission", "DISEASE", 119, 142], ["coronavirus HKU15", "ORGANISM", 33, 50], ["oral", "ORGANISM_SUBDIVISION", 125, 129], ["coronavirus", "SPECIES", 33, 44], ["coronavirus HKU15", "PROBLEM", 33, 50], ["fecal", "ANATOMY", 119, 124]]], ["In line with other reports, viral RNA of CHN-HG-2017 was also detected in the lungs of some animals, albeit with no gross lesions observed, suggesting that PDCoV may also cause respiratory infection.DiscussionIt is noteworthy that we only observed microscopic lesions in the jejunum and ileum in piglets challenged with CHN-HG-2017.", [["lungs", "ANATOMY", 78, 83], ["gross lesions", "ANATOMY", 116, 129], ["respiratory", "ANATOMY", 177, 188], ["lesions", "ANATOMY", 260, 267], ["jejunum", "ANATOMY", 275, 282], ["ileum", "ANATOMY", 287, 292], ["CHN-HG-2017", "CHEMICAL", 41, 52], ["PDCoV", "CHEMICAL", 156, 161], ["respiratory infection", "DISEASE", 177, 198], ["CHN-HG", "CHEMICAL", 320, 326], ["CHN-HG-2017", "CELL", 41, 52], ["lungs", "ORGAN", 78, 83], ["gross lesions", "PATHOLOGICAL_FORMATION", 116, 129], ["PDCoV", "GENE_OR_GENE_PRODUCT", 156, 161], ["lesions", "PATHOLOGICAL_FORMATION", 260, 267], ["jejunum", "MULTI-TISSUE_STRUCTURE", 275, 282], ["ileum", "ORGAN", 287, 292], ["piglets", "ORGANISM", 296, 303], ["viral RNA", "RNA", 28, 37], ["piglets", "SPECIES", 296, 303], ["HG", "TEST", 45, 47], ["gross lesions", "PROBLEM", 116, 129], ["PDCoV", "TREATMENT", 156, 161], ["respiratory infection", "PROBLEM", 177, 198], ["microscopic lesions in the jejunum", "PROBLEM", 248, 282], ["viral RNA", "OBSERVATION", 28, 37], ["lungs", "ANATOMY", 78, 83], ["no", "UNCERTAINTY", 113, 115], ["gross", "OBSERVATION_MODIFIER", 116, 121], ["lesions", "OBSERVATION", 122, 129], ["may also cause", "UNCERTAINTY", 162, 176], ["respiratory", "ANATOMY", 177, 188], ["infection", "OBSERVATION", 189, 198], ["microscopic", "OBSERVATION_MODIFIER", 248, 259], ["lesions", "OBSERVATION", 260, 267], ["jejunum", "ANATOMY", 275, 282], ["ileum", "ANATOMY", 287, 292]]], ["In striking contrast, microscopic lesions were observed in all sections of small intestine infected with PEDV [28].", [["lesions", "ANATOMY", 34, 41], ["sections", "ANATOMY", 63, 71], ["small intestine", "ANATOMY", 75, 90], ["PEDV", "CHEMICAL", 105, 109], ["lesions", "PATHOLOGICAL_FORMATION", 34, 41], ["small intestine", "ORGAN", 75, 90], ["PEDV", "SPECIES", 105, 109], ["microscopic lesions", "PROBLEM", 22, 41], ["small intestine", "PROBLEM", 75, 90], ["PEDV", "PROBLEM", 105, 109], ["microscopic", "OBSERVATION_MODIFIER", 22, 33], ["lesions", "OBSERVATION", 34, 41], ["small", "OBSERVATION_MODIFIER", 75, 80], ["intestine", "ANATOMY", 81, 90], ["infected", "OBSERVATION", 91, 99]]], ["Moreover, unlike PEDV, PDCoV infection usually does not result in the death of newborn piglets despite the fact that these animals exhibit lethargy and anorexia and have watery diarrhea.", [["PEDV", "CHEMICAL", 17, 21], ["infection", "DISEASE", 29, 38], ["death", "DISEASE", 70, 75], ["lethargy", "DISEASE", 139, 147], ["anorexia", "DISEASE", 152, 160], ["watery diarrhea", "DISEASE", 170, 185], ["PDCoV", "GENE_OR_GENE_PRODUCT", 23, 28], ["piglets", "ORGANISM", 87, 94], ["piglets", "SPECIES", 87, 94], ["PEDV", "SPECIES", 17, 21], ["PDCoV", "SPECIES", 23, 28], ["PEDV", "PROBLEM", 17, 21], ["PDCoV infection", "PROBLEM", 23, 38], ["the death of newborn piglets", "PROBLEM", 66, 94], ["lethargy", "PROBLEM", 139, 147], ["anorexia", "PROBLEM", 152, 160], ["watery diarrhea", "PROBLEM", 170, 185], ["PEDV", "OBSERVATION", 17, 21], ["infection", "OBSERVATION", 29, 38], ["lethargy", "OBSERVATION", 139, 147]]], ["These results indicated that the virulence of PDCoV is milder than that of PEDV.DiscussionRecently, it was shown that VN antibodies could be detected in 14-day-old piglets inoculated with PDCoV OH-FD22 at about 7 DPI and that VN antibody titers increased gradually and remained high at the end of the experiment [29].", [["PDCoV", "CHEMICAL", 46, 51], ["PEDV", "CHEMICAL", 75, 79], ["PDCoV OH-FD22", "CHEMICAL", 188, 201], ["DPI", "CHEMICAL", 213, 216], ["OH-FD22", "CHEMICAL", 194, 201], ["PDCoV", "SIMPLE_CHEMICAL", 46, 51], ["VN antibodies", "GENE_OR_GENE_PRODUCT", 118, 131], ["piglets", "ORGANISM", 164, 171], ["PDCoV OH-FD22", "SIMPLE_CHEMICAL", 188, 201], ["VN antibody", "GENE_OR_GENE_PRODUCT", 226, 237], ["VN antibodies", "PROTEIN", 118, 131], ["VN antibody", "PROTEIN", 226, 237], ["piglets", "SPECIES", 164, 171], ["PEDV", "SPECIES", 75, 79], ["PDCoV", "SPECIES", 188, 193], ["the virulence of PDCoV", "PROBLEM", 29, 51], ["PEDV", "PROBLEM", 75, 79], ["VN antibodies", "TEST", 118, 131], ["PDCoV OH", "TREATMENT", 188, 196], ["FD22", "TREATMENT", 197, 201], ["VN antibody titers", "TEST", 226, 244], ["high", "OBSERVATION_MODIFIER", 278, 282]]], ["However, to our knowledge, there are currently no reports on the development of PDCoV-specific antibodies in sera of pigs infected with Chinese PDCoV.", [["sera", "ANATOMY", 109, 113], ["PDCoV", "CHEMICAL", 80, 85], ["PDCoV", "SIMPLE_CHEMICAL", 80, 85], ["sera", "ORGANISM_SUBSTANCE", 109, 113], ["pigs", "ORGANISM", 117, 121], ["PDCoV", "PROTEIN", 80, 85], ["specific antibodies", "PROTEIN", 86, 105], ["pigs", "SPECIES", 117, 121], ["pigs", "SPECIES", 117, 121], ["Chinese PDCoV", "SPECIES", 136, 149], ["PDCoV", "TEST", 80, 85], ["Chinese PDCoV", "TREATMENT", 136, 149]]], ["Our study showed that serum PDCoV VN antibodies could be detected as early as 4 DPI in PDCoV-infected piglets.", [["serum", "ANATOMY", 22, 27], ["DPI", "CHEMICAL", 80, 83], ["PDCoV", "CHEMICAL", 87, 92], ["serum", "ORGANISM_SUBSTANCE", 22, 27], ["PDCoV VN antibodies", "GENE_OR_GENE_PRODUCT", 28, 47], ["PDCoV", "SIMPLE_CHEMICAL", 87, 92], ["piglets", "ORGANISM", 102, 109], ["serum PDCoV VN antibodies", "PROTEIN", 22, 47], ["piglets", "SPECIES", 102, 109], ["PDCoV", "SPECIES", 28, 33], ["PDCoV", "SPECIES", 87, 92], ["Our study", "TEST", 0, 9], ["serum PDCoV VN antibodies", "TEST", 22, 47], ["infected piglets", "OBSERVATION", 93, 109]]], ["VN antibody titers increased and remained high until 21 DPI, when all pigs in the challenged groups had completely recuperated.DiscussionIn conclusion, we successfully isolated, characterized and obtained a high titer of CHN-HG-2017 in cultured cells.", [["cells", "ANATOMY", 245, 250], ["CHN-HG-2017", "CHEMICAL", 221, 232], ["VN antibody", "GENE_OR_GENE_PRODUCT", 0, 11], ["pigs", "ORGANISM", 70, 74], ["CHN-HG-2017", "CELL", 221, 232], ["cells", "CELL", 245, 250], ["VN antibody", "PROTEIN", 0, 11], ["cultured cells", "CELL_LINE", 236, 250], ["pigs", "SPECIES", 70, 74], ["pigs", "SPECIES", 70, 74], ["VN antibody titers", "TEST", 0, 18], ["HG", "TEST", 225, 227]]], ["We showed that CHN-HG-2017 is probably a recombinant virus derived from CH/SXD1/2015 and Vietnam/HaNoi6/2015.", [["CHN-HG-2017", "CHEMICAL", 15, 26], ["CHN", "SIMPLE_CHEMICAL", 15, 18], ["HG", "TEST", 19, 21], ["a recombinant virus", "PROBLEM", 39, 58]]], ["Pathogenicity testing of CHN-HG-2017 revealed that this virus is still pathogenic in piglets despite multiple passages in cultured cells.", [["cells", "ANATOMY", 131, 136], ["CHN-HG-2017", "CHEMICAL", 25, 36], ["CHN-HG-2017", "CELL", 25, 36], ["piglets", "ORGANISM", 85, 92], ["cells", "CELL", 131, 136], ["cultured cells", "CELL_LINE", 122, 136], ["piglets", "SPECIES", 85, 92], ["Pathogenicity testing of CHN", "TEST", 0, 28], ["HG", "TEST", 29, 31], ["this virus", "PROBLEM", 51, 61], ["pathogenic in piglets", "PROBLEM", 71, 92], ["multiple passages in cultured cells", "PROBLEM", 101, 136], ["pathogenic", "OBSERVATION", 71, 81], ["multiple", "OBSERVATION_MODIFIER", 101, 109], ["passages", "OBSERVATION", 110, 118]]], ["High levels of serum VN antibodies were also detected in sera of infected animals.", [["serum", "ANATOMY", 15, 20], ["sera", "ANATOMY", 57, 61], ["serum", "ORGANISM_SUBSTANCE", 15, 20], ["VN antibodies", "GENE_OR_GENE_PRODUCT", 21, 34], ["sera", "ORGANISM_SUBSTANCE", 57, 61], ["serum VN antibodies", "PROTEIN", 15, 34], ["serum VN antibodies", "TEST", 15, 34]]], ["Not only will our findings be useful for understanding the molecular epidemiology and pathogenesis of PDCoV, but they also provide insights for the development of effective vaccines against this important pathogen.", [["PDCoV", "DISEASE", 102, 107], ["PDCoV", "CANCER", 102, 107], ["PDCoV", "TREATMENT", 102, 107], ["effective vaccines", "TREATMENT", 163, 181], ["this important pathogen", "PROBLEM", 190, 213]]]], "PMC7095783": [["MainRecently, ACE2 was identified as a functional SARS coronavirus receptor in cell lines14.", [["cell lines", "ANATOMY", 79, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["cell lines14", "CELL", 79, 91], ["ACE2", "PROTEIN", 14, 18], ["SARS coronavirus receptor", "PROTEIN", 50, 75], ["cell lines14", "CELL_LINE", 79, 91], ["SARS coronavirus", "SPECIES", 50, 66], ["ACE2", "TEST", 14, 18], ["a functional SARS coronavirus receptor in cell lines", "TREATMENT", 37, 89], ["cell lines", "OBSERVATION", 79, 89]]], ["But a possible second receptor, CD209L (L-SIGN) has also been identified from in vitro studies15.", [["CD209L", "GENE_OR_GENE_PRODUCT", 32, 38], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 40, 46], ["CD209L", "PROTEIN", 32, 38], ["L", "PROTEIN", 40, 41], ["SIGN", "PROTEIN", 42, 46], ["vitro studies", "TEST", 81, 94], ["possible", "UNCERTAINTY", 6, 14]]], ["Thus, it was not known whether ACE2 is indeed crucial for SARS-CoV infections in vivo.", [["SARS-CoV infections", "DISEASE", 58, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["SARS-CoV", "ORGANISM", 58, 66], ["ACE2", "PROTEIN", 31, 35], ["SARS-CoV", "SPECIES", 58, 66], ["SARS", "PROBLEM", 58, 62], ["CoV infections in vivo", "PROBLEM", 63, 85], ["infections", "OBSERVATION", 67, 77]]], ["To address this question genetically, we infected Ace2 knockout16 and control wild-type mice with SARS-CoV.", [["Ace2 knockout16", "ANATOMY", 50, 65], ["Ace2 knockout16", "CELL", 50, 65], ["mice", "ORGANISM", 88, 92], ["SARS-CoV", "ORGANISM", 98, 106], ["Ace2 knockout16", "PROTEIN", 50, 65], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["SARS-CoV", "SPECIES", 98, 106], ["infected Ace2 knockout16", "TREATMENT", 41, 65]]], ["As reported previously17, SARS-CoV infections of wild-type mice result in viral replication in the lungs and the recovery of large amounts (>107 the tissue culture\u2013infectious dose, which will infect 50% of the cell monolayers (TCID50T) per gram lung tissue) of infectious virus (Fig. 1a).", [["lungs", "ANATOMY", 99, 104], ["tissue", "ANATOMY", 149, 155], ["cell monolayers", "ANATOMY", 210, 225], ["lung tissue", "ANATOMY", 245, 256], ["SARS-CoV infections", "DISEASE", 26, 45], ["SARS-CoV", "ORGANISM", 26, 34], ["wild-type", "ORGANISM", 49, 58], ["mice", "ORGANISM", 59, 63], ["lungs", "ORGAN", 99, 104], ["tissue", "TISSUE", 149, 155], ["cell monolayers", "CELL", 210, 225], ["TCID50T", "CELL", 227, 234], ["lung tissue", "TISSUE", 245, 256], ["infectious virus", "ORGANISM", 261, 277], ["mice", "SPECIES", 59, 63], ["SARS-CoV", "SPECIES", 26, 34], ["mice", "SPECIES", 59, 63], ["SARS-CoV infections", "PROBLEM", 26, 45], ["viral replication in the lungs", "PROBLEM", 74, 104], ["large amounts", "PROBLEM", 125, 138], ["the cell monolayers", "TREATMENT", 206, 225], ["infectious virus", "PROBLEM", 261, 277], ["viral replication", "OBSERVATION", 74, 91], ["lungs", "ANATOMY", 99, 104], ["large", "OBSERVATION_MODIFIER", 125, 130], ["amounts", "OBSERVATION_MODIFIER", 131, 138], ["lung tissue", "ANATOMY", 245, 256], ["infectious virus", "OBSERVATION", 261, 277]]], ["In Ace2 knockout mice, only a very low quantity of infectious SARS-CoV virus could be recovered (<102 TCID50 per gram lung tissue; Fig. 1a), and the copy numbers of SARS-CoV Spike RNA were greatly reduced (Fig. 1b).", [["lung tissue", "ANATOMY", 118, 129], ["SARS", "DISEASE", 62, 66], ["SARS", "DISEASE", 165, 169], ["Ace2", "GENE_OR_GENE_PRODUCT", 3, 7], ["mice", "ORGANISM", 17, 21], ["SARS-CoV virus", "ORGANISM", 62, 76], ["lung tissue", "TISSUE", 118, 129], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 165, 173], ["Ace2", "PROTEIN", 3, 7], ["SARS-CoV Spike RNA", "RNA", 165, 183], ["mice", "SPECIES", 17, 21], ["SARS-CoV virus", "SPECIES", 62, 76], ["mice", "SPECIES", 17, 21], ["SARS-CoV virus", "SPECIES", 62, 76], ["SARS-CoV", "SPECIES", 165, 173], ["infectious SARS", "PROBLEM", 51, 66], ["CoV virus", "PROBLEM", 67, 76], ["SARS", "PROBLEM", 165, 169], ["CoV Spike RNA", "PROBLEM", 170, 183], ["very", "OBSERVATION_MODIFIER", 30, 34], ["low quantity", "OBSERVATION_MODIFIER", 35, 47], ["infectious", "OBSERVATION", 51, 61], ["lung", "ANATOMY", 118, 122]]], ["SARS-CoV infection of mice is associated with the development of mild pathological changes in the lungs (Fig. 1c,d).", [["lungs", "ANATOMY", 98, 103], ["SARS-CoV infection", "DISEASE", 0, 18], ["SARS-CoV", "ORGANISM", 0, 8], ["mice", "ORGANISM", 22, 26], ["lungs", "ORGAN", 98, 103], ["mice", "SPECIES", 22, 26], ["SARS-CoV", "SPECIES", 0, 8], ["mice", "SPECIES", 22, 26], ["SARS", "PROBLEM", 0, 4], ["CoV infection of mice", "PROBLEM", 5, 26], ["mild pathological changes in the lungs", "PROBLEM", 65, 103], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["infection", "OBSERVATION", 9, 18], ["mild", "OBSERVATION_MODIFIER", 65, 69], ["pathological", "OBSERVATION", 70, 82], ["lungs", "ANATOMY", 98, 103]]], ["Moreover, pathologic alterations in lungs were reduced in Ace2 mutant mice compared to wild-type mice (Fig. 1c,d).", [["lungs", "ANATOMY", 36, 41], ["lungs", "ORGAN", 36, 41], ["Ace2 mutant mice", "ORGANISM", 58, 74], ["mice", "ORGANISM", 97, 101], ["Ace2", "PROTEIN", 58, 62], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 70, 74], ["pathologic alterations in lungs", "PROBLEM", 10, 41], ["pathologic", "OBSERVATION", 10, 20], ["lungs", "ANATOMY", 36, 41], ["reduced", "OBSERVATION_MODIFIER", 47, 54]]], ["These data provide the first genetic proof that ACE2 is indeed a crucial in vivo SARS receptor required for effective replication of infectious SARS-CoV.MainWe have recently shown that the renin-angiotensin system has a crucial role in severe acute lung injury and that the SARS-CoV receptor ACE2 has a protective role in acute lung failure18 (Fig. 2a).", [["lung", "ANATOMY", 249, 253], ["lung", "ANATOMY", 328, 332], ["SARS", "DISEASE", 144, 148], ["angiotensin", "CHEMICAL", 195, 206], ["acute lung injury", "DISEASE", 243, 260], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["SARS receptor", "GENE_OR_GENE_PRODUCT", 81, 94], ["SARS-CoV", "ORGANISM", 144, 152], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 189, 206], ["lung", "ORGAN", 249, 253], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 274, 282], ["ACE2", "GENE_OR_GENE_PRODUCT", 292, 296], ["lung", "ORGAN", 328, 332], ["ACE2", "PROTEIN", 48, 52], ["SARS receptor", "PROTEIN", 81, 94], ["renin", "PROTEIN", 189, 194], ["SARS-CoV receptor", "PROTEIN", 274, 291], ["ACE2", "PROTEIN", 292, 296], ["SARS-CoV", "SPECIES", 144, 152], ["SARS-CoV", "SPECIES", 274, 282], ["a crucial in vivo SARS receptor", "TREATMENT", 63, 94], ["infectious SARS", "PROBLEM", 133, 148], ["the renin-angiotensin system", "TREATMENT", 185, 213], ["severe acute lung injury", "PROBLEM", 236, 260], ["the SARS", "PROBLEM", 270, 278], ["CoV receptor ACE2", "TREATMENT", 279, 296], ["acute lung failure18", "PROBLEM", 322, 342], ["infectious", "OBSERVATION", 133, 143], ["severe", "OBSERVATION_MODIFIER", 236, 242], ["acute", "OBSERVATION_MODIFIER", 243, 248], ["lung", "ANATOMY", 249, 253], ["injury", "OBSERVATION", 254, 260], ["acute", "OBSERVATION_MODIFIER", 322, 327], ["lung", "ANATOMY", 328, 332], ["failure18", "OBSERVATION", 333, 342]]], ["Notably, experimental SARS-CoV infections of wild-type mice in vivo resulted in considerably reduced ACE2 expression in the lungs (Fig. 2b) suggesting that reduced ACE2 expression might have a role in SARS-CoV\u2013mediated severe acute lung pathologies.", [["lungs", "ANATOMY", 124, 129], ["lung", "ANATOMY", 232, 236], ["SARS-CoV infections", "DISEASE", 22, 41], ["acute lung pathologies", "DISEASE", 226, 248], ["SARS-CoV", "ORGANISM", 22, 30], ["mice", "ORGANISM", 55, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 101, 105], ["lungs", "ORGAN", 124, 129], ["ACE2", "GENE_OR_GENE_PRODUCT", 164, 168], ["lung", "ORGAN", 232, 236], ["ACE2", "PROTEIN", 101, 105], ["ACE2", "PROTEIN", 164, 168], ["mice", "SPECIES", 55, 59], ["SARS-CoV", "SPECIES", 22, 30], ["mice", "SPECIES", 55, 59], ["experimental SARS", "PROBLEM", 9, 26], ["CoV infections", "PROBLEM", 27, 41], ["reduced ACE2 expression in the lungs", "PROBLEM", 93, 129], ["reduced ACE2 expression", "PROBLEM", 156, 179], ["SARS", "PROBLEM", 201, 205], ["CoV\u2013mediated severe acute lung pathologies", "PROBLEM", 206, 248], ["SARS", "OBSERVATION", 22, 26], ["CoV", "OBSERVATION_MODIFIER", 27, 30], ["infections", "OBSERVATION", 31, 41], ["reduced", "OBSERVATION_MODIFIER", 93, 100], ["ACE2 expression", "OBSERVATION", 101, 116], ["lungs", "ANATOMY", 124, 129], ["severe", "OBSERVATION_MODIFIER", 219, 225], ["acute", "OBSERVATION_MODIFIER", 226, 231], ["lung", "ANATOMY", 232, 236], ["pathologies", "OBSERVATION", 237, 248]]], ["By contrast, ACE lung expression levels were not overtly changed in SARS-CoV\u2013infected mice (Fig. 2b).", [["lung", "ANATOMY", 17, 21], ["SARS", "DISEASE", 68, 72], ["ACE", "GENE_OR_GENE_PRODUCT", 13, 16], ["lung", "ORGAN", 17, 21], ["mice", "ORGANISM", 86, 90], ["ACE", "PROTEIN", 13, 16], ["mice", "SPECIES", 86, 90], ["SARS-CoV\u2013infected mice", "SPECIES", 68, 90], ["ACE lung expression levels", "TEST", 13, 39], ["SARS", "PROBLEM", 68, 72], ["lung", "ANATOMY", 17, 21]]], ["We therefore speculated that SARS-CoV might affect lung pathologies through ACE2.", [["lung", "ANATOMY", 51, 55], ["SARS", "DISEASE", 29, 33], ["lung pathologies", "DISEASE", 51, 67], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 29, 37], ["lung", "ORGAN", 51, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["ACE2", "PROTEIN", 76, 80], ["SARS-CoV", "SPECIES", 29, 37], ["SARS", "PROBLEM", 29, 33], ["lung pathologies", "PROBLEM", 51, 67], ["SARS", "OBSERVATION", 29, 33], ["lung", "ANATOMY", 51, 55], ["pathologies", "OBSERVATION", 56, 67]]], ["To test this idea, we established a defined model system using recombinant SARS-CoV surface-Spike protein, which is the essential ligand for ACE2 binding14.", [["SARS-CoV surface-Spike protein", "GENE_OR_GENE_PRODUCT", 75, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 141, 145], ["recombinant SARS-CoV surface-Spike protein", "PROTEIN", 63, 105], ["ACE2 binding14", "PROTEIN", 141, 155], ["SARS-CoV", "SPECIES", 75, 83], ["recombinant SARS", "TEST", 63, 79], ["CoV surface", "TEST", 80, 91], ["Spike protein", "PROBLEM", 92, 105], ["ACE2 binding", "TEST", 141, 153]]], ["This model system allowed us to avoid possible secondary effects resulting from viral replication or infections in vivo and to directly test whether SARS-CoV Spike protein might adversely affect acute lung injury through modulation of ACE2.MainWe first tested whether recombinant SARS-CoV Spike protein (Supplementary Fig. 1 online) binds to human as well as mouse ACE2 protein using in vitro pull-down assays.", [["lung", "ANATOMY", 201, 205], ["infections", "DISEASE", 101, 111], ["acute lung injury", "DISEASE", 195, 212], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 149, 157], ["lung", "ORGAN", 201, 205], ["ACE2", "GENE_OR_GENE_PRODUCT", 235, 239], ["SARS-CoV Spike", "GENE_OR_GENE_PRODUCT", 280, 294], ["human", "ORGANISM", 342, 347], ["mouse", "ORGANISM", 359, 364], ["ACE2", "GENE_OR_GENE_PRODUCT", 365, 369], ["SARS-CoV Spike protein", "PROTEIN", 149, 171], ["ACE2", "PROTEIN", 235, 239], ["recombinant SARS-CoV Spike protein", "PROTEIN", 268, 302], ["mouse ACE2 protein", "PROTEIN", 359, 377], ["human", "SPECIES", 342, 347], ["mouse", "SPECIES", 359, 364], ["SARS-CoV", "SPECIES", 149, 157], ["SARS-CoV", "SPECIES", 280, 288], ["human", "SPECIES", 342, 347], ["mouse", "SPECIES", 359, 364], ["secondary effects", "PROBLEM", 47, 64], ["viral replication", "PROBLEM", 80, 97], ["infections", "PROBLEM", 101, 111], ["SARS", "PROBLEM", 149, 153], ["CoV Spike protein", "PROBLEM", 154, 171], ["acute lung injury", "PROBLEM", 195, 212], ["recombinant SARS", "PROBLEM", 268, 284], ["CoV Spike protein (Supplementary Fig.", "TREATMENT", 285, 322], ["mouse ACE2 protein", "TREATMENT", 359, 377], ["vitro pull", "TEST", 387, 397], ["viral replication", "OBSERVATION", 80, 97], ["infections", "OBSERVATION", 101, 111], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["lung", "ANATOMY", 201, 205], ["injury", "OBSERVATION", 206, 212]]], ["Our recombinant Spike-Fc protein indeed pulled down both human and mouse ACE2 (Fig. 2c).", [["Spike-Fc", "GENE_OR_GENE_PRODUCT", 16, 24], ["human", "ORGANISM", 57, 62], ["mouse", "ORGANISM", 67, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 73, 77], ["Spike", "PROTEIN", 16, 21], ["Fc protein", "PROTEIN", 22, 32], ["human and mouse ACE2", "PROTEIN", 57, 77], ["Fig. 2c", "PROTEIN", 79, 86], ["human", "SPECIES", 57, 62], ["mouse", "SPECIES", 67, 72], ["human", "SPECIES", 57, 62], ["mouse", "SPECIES", 67, 72], ["Our recombinant Spike", "TEST", 0, 21], ["Fc protein", "PROBLEM", 22, 32], ["Spike", "OBSERVATION_MODIFIER", 16, 21]]], ["SARS-CoV Spike-Fc binding to human and mouse ACE2 was confirmed by FACS binding assays of Spike-Fc to 293 cells overexpressing human or mouse ACE2 (Fig. 2d).", [["293 cells", "ANATOMY", 102, 111], ["SARS", "DISEASE", 0, 4], ["SARS-CoV Spike-Fc", "GENE_OR_GENE_PRODUCT", 0, 17], ["human", "ORGANISM", 29, 34], ["mouse", "ORGANISM", 39, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 90, 98], ["293 cells", "CELL", 102, 111], ["human", "ORGANISM", 127, 132], ["mouse", "ORGANISM", 136, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 142, 146], ["SARS-CoV Spike-Fc", "PROTEIN", 0, 17], ["human and mouse ACE2", "PROTEIN", 29, 49], ["Spike", "PROTEIN", 90, 95], ["Fc", "PROTEIN", 96, 98], ["293 cells", "CELL_LINE", 102, 111], ["human or mouse ACE2", "PROTEIN", 127, 146], ["Fig. 2d", "PROTEIN", 148, 155], ["human", "SPECIES", 29, 34], ["mouse", "SPECIES", 39, 44], ["human", "SPECIES", 127, 132], ["mouse", "SPECIES", 136, 141], ["human", "SPECIES", 29, 34], ["mouse", "SPECIES", 39, 44], ["human", "SPECIES", 127, 132], ["mouse", "SPECIES", 136, 141], ["SARS", "PROBLEM", 0, 4], ["CoV Spike", "PROBLEM", 5, 14], ["Spike", "PROBLEM", 90, 95]]], ["Moreover, Spike-Fc bound to endogenous ACE2 in Vero E6 cells (Fig. 2e).", [["Vero E6 cells", "ANATOMY", 47, 60], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 10, 18], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["Vero E6 cells", "CELL", 47, 60], ["Spike", "PROTEIN", 10, 15], ["Fc", "PROTEIN", 16, 18], ["ACE2", "PROTEIN", 39, 43], ["Vero E6 cells", "CELL_LINE", 47, 60], ["Vero E6", "SPECIES", 47, 54], ["Spike", "PROBLEM", 10, 15], ["Fc bound", "PROBLEM", 16, 24], ["endogenous ACE2 in Vero E6 cells", "PROBLEM", 28, 60]]], ["Notably, binding of Spike-Fc to endogenous ACE2 in Vero E6 cells resulted in downregulation of ACE2 surface expression (Fig. 2e and Supplementary Fig. 1 online).", [["Vero E6 cells", "ANATOMY", 51, 64], ["surface", "ANATOMY", 100, 107], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 20, 28], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["Vero E6 cells", "CELL", 51, 64], ["ACE2", "GENE_OR_GENE_PRODUCT", 95, 99], ["Spike", "PROTEIN", 20, 25], ["Fc", "PROTEIN", 26, 28], ["ACE2", "PROTEIN", 43, 47], ["Vero E6 cells", "CELL_LINE", 51, 64], ["ACE2", "PROTEIN", 95, 99], ["Vero E6", "SPECIES", 51, 58], ["Spike", "PROBLEM", 20, 25], ["endogenous ACE2", "PROBLEM", 32, 47], ["Vero E6 cells", "TREATMENT", 51, 64], ["downregulation of ACE2 surface expression", "TREATMENT", 77, 118]]], ["Spike-Fc also decreased surface levels of human and mouse ACE2 overexpressed in 293 cells (not shown) and triggered syncytia formation of mouse ACE2-transfected but not control CD4-transfected 293 cells (data not shown).", [["surface", "ANATOMY", 24, 31], ["293 cells", "ANATOMY", 80, 89], ["syncytia", "ANATOMY", 116, 124], ["293 cells", "ANATOMY", 193, 202], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 42, 47], ["mouse", "ORGANISM", 52, 57], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["293 cells", "CELL", 80, 89], ["syncytia", "CELL", 116, 124], ["mouse", "ORGANISM", 138, 143], ["ACE2", "GENE_OR_GENE_PRODUCT", 144, 148], ["CD4", "GENE_OR_GENE_PRODUCT", 177, 180], ["293 cells", "CELL", 193, 202], ["Spike-Fc", "PROTEIN", 0, 8], ["human and mouse ACE2", "PROTEIN", 42, 62], ["293 cells", "CELL_LINE", 80, 89], ["ACE2", "PROTEIN", 144, 148], ["CD4", "PROTEIN", 177, 180], ["293 cells", "CELL_LINE", 193, 202], ["human", "SPECIES", 42, 47], ["mouse", "SPECIES", 52, 57], ["mouse", "SPECIES", 138, 143], ["human", "SPECIES", 42, 47], ["mouse", "SPECIES", 52, 57], ["mouse", "SPECIES", 138, 143], ["Spike", "PROBLEM", 0, 5], ["Fc", "PROBLEM", 6, 8], ["surface levels", "TEST", 24, 38], ["human and mouse ACE2", "TEST", 42, 62], ["mouse ACE2", "TEST", 138, 148], ["CD4", "TEST", 177, 180], ["syncytia", "OBSERVATION", 116, 124]]], ["Thus, analogous to other virus-receptor interactions19, SARS-CoV Spike protein binding to ACE2 in cell lines or SARS-CoV infections in vivo results in reduced ACE2 protein expression.MainBecause ACE2 is a crucial SARS-CoV receptor (Fig. 1), SARS-CoV Spike protein binding to ACE2 downmodulates ACE2 expression (Fig. 2), and loss of ACE2 expression results in severe acute respiratory failure18, we tested whether SARS-CoV Spike protein, which is the crucial ACE2 binding protein20,21, could affect the severity of acute lung injury in vivo.", [["cell lines", "ANATOMY", 98, 108], ["respiratory", "ANATOMY", 372, 383], ["lung", "ANATOMY", 520, 524], ["SARS-CoV infections", "DISEASE", 112, 131], ["acute lung injury", "DISEASE", 514, 531], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 56, 64], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["cell lines", "CELL", 98, 108], ["SARS-CoV", "ORGANISM", 112, 120], ["ACE2", "GENE_OR_GENE_PRODUCT", 159, 163], ["ACE2", "GENE_OR_GENE_PRODUCT", 195, 199], ["SARS-CoV receptor", "GENE_OR_GENE_PRODUCT", 213, 230], ["Fig. 1", "GENE_OR_GENE_PRODUCT", 232, 238], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 241, 249], ["ACE2", "GENE_OR_GENE_PRODUCT", 275, 279], ["ACE2", "GENE_OR_GENE_PRODUCT", 294, 298], ["Fig. 2", "GENE_OR_GENE_PRODUCT", 311, 317], ["ACE2", "GENE_OR_GENE_PRODUCT", 332, 336], ["SARS-CoV Spike", "GENE_OR_GENE_PRODUCT", 413, 427], ["ACE2 binding protein20,21", "GENE_OR_GENE_PRODUCT", 458, 483], ["lung", "ORGAN", 520, 524], ["ACE2", "PROTEIN", 90, 94], ["cell lines", "CELL_LINE", 98, 108], ["ACE2", "PROTEIN", 159, 163], ["ACE2", "PROTEIN", 195, 199], ["SARS-CoV receptor", "PROTEIN", 213, 230], ["Fig. 1", "PROTEIN", 232, 238], ["SARS-CoV Spike protein", "PROTEIN", 241, 263], ["ACE2", "PROTEIN", 275, 279], ["ACE2", "PROTEIN", 294, 298], ["ACE2", "PROTEIN", 332, 336], ["SARS-CoV Spike protein", "PROTEIN", 413, 435], ["ACE2 binding protein20,21", "PROTEIN", 458, 483], ["SARS-CoV", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 112, 120], ["SARS-CoV", "SPECIES", 241, 249], ["SARS-CoV", "SPECIES", 413, 421], ["SARS", "PROBLEM", 56, 60], ["CoV Spike protein binding", "PROBLEM", 61, 86], ["ACE2 in cell lines", "TREATMENT", 90, 108], ["SARS", "PROBLEM", 112, 116], ["CoV infections", "PROBLEM", 117, 131], ["reduced ACE2 protein expression", "PROBLEM", 151, 182], ["ACE2", "TEST", 195, 199], ["a crucial SARS", "PROBLEM", 203, 217], ["CoV receptor", "TEST", 218, 230], ["SARS", "PROBLEM", 241, 245], ["Spike protein binding", "PROBLEM", 250, 271], ["ACE2", "TEST", 275, 279], ["ACE2 expression", "TEST", 294, 309], ["ACE2 expression", "TEST", 332, 347], ["severe acute respiratory failure18", "PROBLEM", 359, 393], ["SARS", "PROBLEM", 413, 417], ["CoV Spike protein", "PROBLEM", 418, 435], ["acute lung injury", "PROBLEM", 514, 531], ["cell lines", "OBSERVATION", 98, 108], ["CoV", "OBSERVATION_MODIFIER", 117, 120], ["infections", "OBSERVATION", 121, 131], ["protein expression", "OBSERVATION", 164, 182], ["severe", "OBSERVATION_MODIFIER", 359, 365], ["acute", "OBSERVATION_MODIFIER", 366, 371], ["respiratory failure18", "OBSERVATION", 372, 393], ["acute", "OBSERVATION_MODIFIER", 514, 519], ["lung", "ANATOMY", 520, 524], ["injury", "OBSERVATION", 525, 531]]], ["Notably, treatment with Spike-Fc protein worsened the lung function in wild-type mice, whereas control-Fc protein showed no apparent effects (Fig. 3a).", [["lung", "ANATOMY", 54, 58], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 24, 32], ["lung", "ORGAN", 54, 58], ["mice", "ORGANISM", 81, 85], ["Spike", "PROTEIN", 24, 29], ["Fc protein", "PROTEIN", 30, 40], ["Fc protein", "PROTEIN", 103, 113], ["mice", "SPECIES", 81, 85], ["Spike", "TEST", 24, 29], ["Fc protein", "PROBLEM", 30, 40], ["the lung function", "TEST", 50, 67], ["Fc protein", "TEST", 103, 113], ["apparent effects", "PROBLEM", 124, 140], ["lung", "ANATOMY", 54, 58], ["no apparent", "UNCERTAINTY", 121, 132]]], ["Moreover, Spike-Fc treatment of acid-challenged wild-type mice augmented the pathological changes in the lung parenchyma (Fig. 3b,c and Supplementary Table 1 online) and increased lung edemas as defined by a wet/dry lung weight ratios (Fig. 3d).", [["lung parenchyma", "ANATOMY", 105, 120], ["lung", "ANATOMY", 180, 184], ["lung", "ANATOMY", 216, 220], ["acid-", "CHEMICAL", 32, 37], ["lung edemas", "DISEASE", 180, 191], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 10, 18], ["acid-", "SIMPLE_CHEMICAL", 32, 37], ["mice", "ORGANISM", 58, 62], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 105, 120], ["lung", "ORGAN", 180, 184], ["lung", "ORGAN", 216, 220], ["Spike", "PROTEIN", 10, 15], ["Fc", "PROTEIN", 16, 18], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["Spike", "PROBLEM", 10, 15], ["Fc treatment", "TREATMENT", 16, 28], ["acid-challenged", "TREATMENT", 32, 47], ["the pathological changes in the lung parenchyma", "PROBLEM", 73, 120], ["increased lung edemas", "PROBLEM", 170, 191], ["a wet/dry lung weight ratios", "PROBLEM", 206, 234], ["pathological", "OBSERVATION", 77, 89], ["lung", "ANATOMY", 105, 109], ["parenchyma", "ANATOMY_MODIFIER", 110, 120], ["increased", "OBSERVATION_MODIFIER", 170, 179], ["lung", "ANATOMY", 180, 184], ["edemas", "OBSERVATION", 185, 191], ["lung", "ANATOMY", 216, 220]]], ["We next made a Spike-deletion mutant that only contained the previously mapped ACE2-binding domain (amino acids 318\u2013510)21 fused to human Fc (Fig. 3e and Supplementary Fig. 1 online).", [["amino acids 318\u2013510)21", "CHEMICAL", 100, 122], ["amino acids", "CHEMICAL", 100, 111], ["Spike", "GENE_OR_GENE_PRODUCT", 15, 20], ["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["amino acids 318\u2013510)21", "AMINO_ACID", 100, 122], ["human", "ORGANISM", 132, 137], ["Spike", "PROTEIN", 15, 20], ["ACE2-binding domain", "PROTEIN", 79, 98], ["amino acids 318\u2013510)21", "PROTEIN", 100, 122], ["human Fc", "PROTEIN", 132, 140], ["Fig. 3e", "PROTEIN", 142, 149], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["a Spike-deletion mutant", "PROBLEM", 13, 36], ["amino acids", "TEST", 100, 111], ["human Fc", "TEST", 132, 140]]], ["This short Spike(S318-510)-Fc protein containing the minimal ACE2 binding site also binds to ACE2 in cell lines using FACS assays and downmodulates the cell-surface expression of ACE2 (Supplementary Fig. 1 online).", [["cell lines", "ANATOMY", 101, 111], ["cell", "ANATOMY", 152, 156], ["surface", "ANATOMY", 157, 164], ["S318-510)-Fc", "GENE_OR_GENE_PRODUCT", 17, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 93, 97], ["cell lines", "CELL", 101, 111], ["FACS", "CELL", 118, 122], ["cell", "CELL", 152, 156], ["ACE2", "GENE_OR_GENE_PRODUCT", 179, 183], ["short Spike(S318-510)-Fc protein", "PROTEIN", 5, 37], ["minimal ACE2 binding site", "DNA", 53, 78], ["ACE2", "PROTEIN", 93, 97], ["cell lines", "CELL_LINE", 101, 111], ["ACE2", "PROTEIN", 179, 183], ["This short Spike", "PROBLEM", 0, 16], ["Fc protein", "PROBLEM", 27, 37], ["the minimal ACE2 binding site", "PROBLEM", 49, 78], ["FACS assays", "TEST", 118, 129], ["minimal", "OBSERVATION_MODIFIER", 53, 60], ["ACE2 binding", "OBSERVATION", 61, 73], ["cell lines", "OBSERVATION", 101, 111]]], ["Treatment with Spike(S318-510)-Fc again worsened acid-induced acute lung injury in wild-type mice (Fig. 3e).", [["lung", "ANATOMY", 68, 72], ["acid-", "CHEMICAL", 49, 54], ["lung injury", "DISEASE", 68, 79], ["Spike(S318-510)-Fc", "GENE_OR_GENE_PRODUCT", 15, 33], ["acid-", "SIMPLE_CHEMICAL", 49, 54], ["lung", "ORGAN", 68, 72], ["mice", "ORGANISM", 93, 97], ["Spike(S318-510)-Fc", "PROTEIN", 15, 33], ["mice", "SPECIES", 93, 97], ["Spike", "TEST", 15, 20], ["worsened acid-", "PROBLEM", 40, 54], ["acute lung injury", "PROBLEM", 62, 79], ["worsened", "OBSERVATION_MODIFIER", 40, 48], ["acid-induced", "OBSERVATION_MODIFIER", 49, 61], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["lung", "ANATOMY", 68, 72], ["injury", "OBSERVATION", 73, 79]]], ["Notably, in vivo Spike-Fc protein administration did not affect the severity of lung failure in Ace2 knockout mice (Fig. 3f), indicating that the effect of Spike protein on acute lung injury is ACE2 specific.MainTo further clarify whether the intraperitoneally injected Spike-Fc protein directly affected lung pathology in mice, we examined the localization of the injected Spike-Fc protein in lung.", [["lung", "ANATOMY", 80, 84], ["lung", "ANATOMY", 179, 183], ["intraperitoneally", "ANATOMY", 243, 260], ["lung", "ANATOMY", 305, 309], ["lung", "ANATOMY", 394, 398], ["lung failure", "DISEASE", 80, 92], ["lung injury", "DISEASE", 179, 190], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 17, 25], ["lung", "ORGAN", 80, 84], ["Ace2", "GENE_OR_GENE_PRODUCT", 96, 100], ["mice", "ORGANISM", 110, 114], ["Spike", "GENE_OR_GENE_PRODUCT", 156, 161], ["lung", "ORGAN", 179, 183], ["ACE2", "GENE_OR_GENE_PRODUCT", 194, 198], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 270, 278], ["lung", "ORGAN", 305, 309], ["mice", "ORGANISM", 323, 327], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 374, 382], ["lung", "ORGAN", 394, 398], ["Spike", "PROTEIN", 17, 22], ["Fc protein", "PROTEIN", 23, 33], ["Ace2", "PROTEIN", 96, 100], ["Spike protein", "PROTEIN", 156, 169], ["ACE2", "PROTEIN", 194, 198], ["Spike", "PROTEIN", 270, 275], ["Fc protein", "PROTEIN", 276, 286], ["Spike", "PROTEIN", 374, 379], ["Fc protein", "PROTEIN", 380, 390], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 323, 327], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 323, 327], ["Fc protein administration", "TREATMENT", 23, 48], ["lung failure", "PROBLEM", 80, 92], ["Spike protein", "PROBLEM", 156, 169], ["acute lung injury", "PROBLEM", 173, 190], ["the intraperitoneally injected Spike", "PROBLEM", 239, 275], ["Fc protein directly affected lung pathology", "PROBLEM", 276, 319], ["Fc protein in lung", "PROBLEM", 380, 398], ["lung", "ANATOMY", 80, 84], ["failure", "OBSERVATION", 85, 92], ["acute", "OBSERVATION_MODIFIER", 173, 178], ["lung", "ANATOMY", 179, 183], ["injury", "OBSERVATION", 184, 190], ["lung", "ANATOMY", 305, 309], ["pathology", "OBSERVATION", 310, 319], ["lung", "ANATOMY", 394, 398]]], ["Spike-Fc was detected in lung homogenates by western blot using human Fc\u2013specific antibody (Fig. 4a), whereas injected control-Fc was not detected.", [["lung homogenates", "ANATOMY", 25, 41], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 0, 8], ["lung homogenates", "ORGANISM_SUBSTANCE", 25, 41], ["human", "ORGANISM", 64, 69], ["Fc", "GENE_OR_GENE_PRODUCT", 127, 129], ["Spike-Fc", "PROTEIN", 0, 8], ["human Fc\u2013specific antibody", "PROTEIN", 64, 90], ["Fc", "PROTEIN", 127, 129], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["Spike", "PROBLEM", 0, 5], ["Fc", "PROBLEM", 6, 8], ["human Fc\u2013specific antibody", "TEST", 64, 90], ["lung", "ANATOMY", 25, 29]]], ["In addition, using immunohistochemistry, we found that Spike-Fc protein localized to bronchial epithelial cells, inflammatory exudates and alveolar pneumocytes (Fig. 4b).", [["bronchial epithelial cells", "ANATOMY", 85, 111], ["inflammatory exudates", "ANATOMY", 113, 134], ["alveolar pneumocytes", "ANATOMY", 139, 159], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 55, 63], ["bronchial epithelial cells", "CELL", 85, 111], ["inflammatory exudates", "TISSUE", 113, 134], ["alveolar pneumocytes", "CELL", 139, 159], ["Spike", "PROTEIN", 55, 60], ["Fc protein", "PROTEIN", 61, 71], ["bronchial epithelial cells", "CELL_TYPE", 85, 111], ["alveolar pneumocytes", "CELL_TYPE", 139, 159], ["immunohistochemistry", "TEST", 19, 39], ["Spike", "TEST", 55, 60], ["Fc protein", "TEST", 61, 71], ["bronchial epithelial cells", "PROBLEM", 85, 111], ["inflammatory exudates", "PROBLEM", 113, 134], ["alveolar pneumocytes", "PROBLEM", 139, 159], ["bronchial", "ANATOMY", 85, 94], ["epithelial cells", "OBSERVATION", 95, 111], ["inflammatory", "OBSERVATION_MODIFIER", 113, 125], ["alveolar pneumocytes", "OBSERVATION", 139, 159]]], ["Notably, Spike-Fc primarily localized to severe lesions (Fig. 4b).", [["lesions", "ANATOMY", 48, 55], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 9, 17], ["lesions", "PATHOLOGICAL_FORMATION", 48, 55], ["Spike", "PROTEIN", 9, 14], ["Fc", "PROTEIN", 15, 17], ["Spike", "PROBLEM", 9, 14], ["severe lesions", "PROBLEM", 41, 55], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["lesions", "OBSERVATION", 48, 55]]], ["This localization of Spike-Fc protein is similar to Spike antigen staining in SARS-CoV\u2013infected mice22.", [["Spike-Fc", "GENE_OR_GENE_PRODUCT", 21, 29], ["Spike antigen", "GENE_OR_GENE_PRODUCT", 52, 65], ["Spike", "PROTEIN", 21, 26], ["Fc protein", "PROTEIN", 27, 37], ["Spike antigen", "PROTEIN", 52, 65], ["Spike", "PROBLEM", 21, 26], ["Fc protein", "PROBLEM", 27, 37], ["Spike antigen staining", "PROBLEM", 52, 74], ["SARS", "PROBLEM", 78, 82], ["Spike", "OBSERVATION_MODIFIER", 21, 26]]], ["Spike-Fc treatment resulted in downregulation of ACE2 protein expression in lungs of acid-treated wild-type mice in vivo (Fig. 4c), consistent with ACE2 protein downregulation in SARS-CoV\u2013infected mice (Fig. 2a) and Spike-Fc protein\u2013treated cells in vitro (Fig. 2e).", [["lungs", "ANATOMY", 76, 81], ["cells", "ANATOMY", 241, 246], ["acid-", "CHEMICAL", 85, 90], ["acid-", "CHEMICAL", 85, 90], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 0, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["lungs", "ORGAN", 76, 81], ["acid-", "SIMPLE_CHEMICAL", 85, 90], ["mice", "ORGANISM", 108, 112], ["ACE2", "GENE_OR_GENE_PRODUCT", 148, 152], ["SARS-CoV\u2013infected mice", "ORGANISM", 179, 201], ["Fig. 2a", "ORGANISM", 203, 210], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 216, 224], ["cells", "CELL", 241, 246], ["Spike-Fc", "PROTEIN", 0, 8], ["ACE2", "PROTEIN", 49, 53], ["ACE2", "PROTEIN", 148, 152], ["Spike-Fc protein\u2013treated cells", "CELL_LINE", 216, 246], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 197, 201], ["SARS-CoV\u2013infected mice", "SPECIES", 179, 201], ["Spike", "PROBLEM", 0, 5], ["Fc treatment", "TREATMENT", 6, 18], ["downregulation of ACE2 protein expression", "TREATMENT", 31, 72], ["acid-", "TEST", 85, 90], ["ACE2 protein downregulation", "PROBLEM", 148, 175], ["SARS", "PROBLEM", 179, 183], ["Spike", "PROBLEM", 216, 221], ["Fc protein\u2013treated cells", "TREATMENT", 222, 246], ["lungs", "ANATOMY", 76, 81], ["consistent with", "UNCERTAINTY", 132, 147], ["protein downregulation", "OBSERVATION", 153, 175]]], ["These results show that the SARS-CoV Spike protein can directly affect the development of severe acute lung failure through ACE2.MainACE2 functions as a carboxypeptidase, cleaving a single residue from angiotensin I (AngI), generating Ang1\u20139 (refs.", [["lung", "ANATOMY", 103, 107], ["acute lung failure", "DISEASE", 97, 115], ["angiotensin", "CHEMICAL", 202, 213], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 28, 36], ["lung", "ORGAN", 103, 107], ["ACE2", "GENE_OR_GENE_PRODUCT", 124, 128], ["MainACE2", "SIMPLE_CHEMICAL", 129, 137], ["carboxypeptidase", "GENE_OR_GENE_PRODUCT", 153, 169], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 202, 215], ["AngI", "GENE_OR_GENE_PRODUCT", 217, 221], ["Ang1\u20139", "GENE_OR_GENE_PRODUCT", 235, 241], ["SARS-CoV Spike protein", "PROTEIN", 28, 50], ["ACE2", "PROTEIN", 124, 128], ["MainACE2", "PROTEIN", 129, 137], ["carboxypeptidase", "PROTEIN", 153, 169], ["angiotensin I", "PROTEIN", 202, 215], ["AngI", "PROTEIN", 217, 221], ["Ang1\u20139", "PROTEIN", 235, 241], ["SARS-CoV", "SPECIES", 28, 36], ["the SARS-CoV Spike protein", "PROBLEM", 24, 50], ["severe acute lung failure", "PROBLEM", 90, 115], ["a carboxypeptidase", "TREATMENT", 151, 169], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["lung", "ANATOMY", 103, 107], ["failure", "OBSERVATION", 108, 115]]], ["23,24), and a single residue from angiotensin II (AngII) to generate Ang1\u20137 (ref.", [["angiotensin II", "CHEMICAL", 34, 48], ["AngII", "CHEMICAL", 50, 55], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 34, 48], ["AngII", "GENE_OR_GENE_PRODUCT", 50, 55], ["Ang1\u20137", "GENE_OR_GENE_PRODUCT", 69, 75], ["angiotensin II", "PROTEIN", 34, 48], ["AngII", "PROTEIN", 50, 55], ["Ang1\u20137", "PROTEIN", 69, 75], ["a single residue", "PROBLEM", 12, 28], ["angiotensin II (AngII)", "TREATMENT", 34, 56]]], ["The ACE2 homologue ACE, by contrast, cleaves the decapeptide AngI into the octapeptide AngII25.", [["ACE2", "GENE_OR_GENE_PRODUCT", 4, 8], ["ACE", "GENE_OR_GENE_PRODUCT", 19, 22], ["AngI", "GENE_OR_GENE_PRODUCT", 61, 65], ["AngII25", "GENE_OR_GENE_PRODUCT", 87, 94], ["ACE2", "PROTEIN", 4, 8], ["ACE", "PROTEIN", 19, 22], ["decapeptide AngI", "PROTEIN", 49, 65], ["octapeptide AngII25", "PROTEIN", 75, 94], ["The ACE2 homologue ACE", "TREATMENT", 0, 22], ["the octapeptide AngII25", "TREATMENT", 71, 94]]], ["Thus, ACE2 counterbalances the function of ACE and negatively regulates AngII production (Fig. 2a).", [["AngII", "CHEMICAL", 72, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["ACE", "GENE_OR_GENE_PRODUCT", 43, 46], ["AngII", "SIMPLE_CHEMICAL", 72, 77], ["ACE2", "PROTEIN", 6, 10], ["ACE", "PROTEIN", 43, 46], ["ACE", "TREATMENT", 43, 46]]], ["To test whether Spike-Fc injections indeed affect the function of the renin-angiotensin system, we analyzed AngII levels in the lungs of acid- and Spike-Fc\u2013treated mice.", [["lungs", "ANATOMY", 128, 133], ["angiotensin", "CHEMICAL", 76, 87], ["AngII", "CHEMICAL", 108, 113], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 16, 24], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 70, 87], ["AngII", "GENE_OR_GENE_PRODUCT", 108, 113], ["lungs", "ORGAN", 128, 133], ["Spike", "GENE_OR_GENE_PRODUCT", 147, 152], ["mice", "ORGANISM", 164, 168], ["Spike", "PROTEIN", 16, 21], ["renin", "PROTEIN", 70, 75], ["mice", "SPECIES", 164, 168], ["Spike", "PROBLEM", 16, 21], ["Fc injections", "TREATMENT", 22, 35], ["the renin-angiotensin system", "TEST", 66, 94], ["AngII levels", "TEST", 108, 120], ["acid", "TEST", 137, 141], ["Spike", "PROBLEM", 147, 152], ["lungs", "ANATOMY", 128, 133]]], ["Acid aspiration increased AngII levels in the lungs of wild-type mice.", [["lungs", "ANATOMY", 46, 51], ["AngII", "CHEMICAL", 26, 31], ["Acid", "SIMPLE_CHEMICAL", 0, 4], ["AngII", "SIMPLE_CHEMICAL", 26, 31], ["lungs", "ORGAN", 46, 51], ["mice", "ORGANISM", 65, 69], ["AngII", "PROTEIN", 26, 31], ["mice", "SPECIES", 65, 69], ["Acid aspiration", "PROBLEM", 0, 15], ["AngII levels", "TEST", 26, 38], ["aspiration", "OBSERVATION", 5, 15], ["AngII levels", "OBSERVATION", 26, 38], ["lungs", "ANATOMY", 46, 51]]], ["Notably, we observed a further, significant increase in AngII levels in the lung tissue of mice treated with Spike-Fc (Fig. 4d).", [["lung tissue", "ANATOMY", 76, 87], ["AngII", "CHEMICAL", 56, 61], ["AngII", "GENE_OR_GENE_PRODUCT", 56, 61], ["lung tissue", "TISSUE", 76, 87], ["mice", "ORGANISM", 91, 95], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 109, 117], ["AngII", "PROTEIN", 56, 61], ["Spike", "PROTEIN", 109, 114], ["Fc", "PROTEIN", 115, 117], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["significant increase in AngII levels", "PROBLEM", 32, 68], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["increase", "OBSERVATION_MODIFIER", 44, 52], ["AngII levels", "OBSERVATION", 56, 68], ["lung", "ANATOMY", 76, 80], ["tissue", "ANATOMY_MODIFIER", 81, 87]]], ["To confirm whether Spike-Fc promotes lung disease pathogenesis through increased AngII production and functional alterations of the renin-angiotensin system, we blocked the AngII receptor type 1 (AT1R)26 with a specific inhibitor.", [["lung", "ANATOMY", 37, 41], ["lung disease", "DISEASE", 37, 49], ["AngII", "CHEMICAL", 81, 86], ["angiotensin", "CHEMICAL", 138, 149], ["AngII", "CHEMICAL", 173, 178], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 19, 27], ["lung", "ORGAN", 37, 41], ["AngII", "SIMPLE_CHEMICAL", 81, 86], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 132, 149], ["AngII receptor type 1", "GENE_OR_GENE_PRODUCT", 173, 194], ["AT1R)26", "GENE_OR_GENE_PRODUCT", 196, 203], ["Spike", "PROTEIN", 19, 24], ["Fc", "PROTEIN", 25, 27], ["renin", "PROTEIN", 132, 137], ["AngII receptor type 1 (AT1R)26", "PROTEIN", 173, 203], ["Spike", "PROBLEM", 19, 24], ["lung disease pathogenesis", "PROBLEM", 37, 62], ["increased AngII production", "PROBLEM", 71, 97], ["functional alterations", "PROBLEM", 102, 124], ["the renin-angiotensin system", "TREATMENT", 128, 156], ["the AngII receptor type 1 (AT1R)", "TREATMENT", 169, 201], ["a specific inhibitor", "TREATMENT", 209, 229], ["lung", "ANATOMY", 37, 41], ["disease", "OBSERVATION", 42, 49], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["AngII production", "OBSERVATION", 81, 97]]], ["The AT1R is the crucial receptor that mediates AngII-induced vascular permeability and severe acute lung injury18.", [["vascular", "ANATOMY", 61, 69], ["lung", "ANATOMY", 100, 104], ["AngII", "CHEMICAL", 47, 52], ["acute lung injury", "DISEASE", 94, 111], ["AT1R", "GENE_OR_GENE_PRODUCT", 4, 8], ["AngII", "SIMPLE_CHEMICAL", 47, 52], ["vascular", "MULTI-TISSUE_STRUCTURE", 61, 69], ["lung", "ORGAN", 100, 104], ["AT1R", "PROTEIN", 4, 8], ["vascular permeability", "PROBLEM", 61, 82], ["severe acute lung injury", "PROBLEM", 87, 111], ["AngII", "OBSERVATION", 47, 52], ["vascular", "ANATOMY", 61, 69], ["permeability", "OBSERVATION_MODIFIER", 70, 82], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["lung", "ANATOMY", 100, 104], ["injury", "OBSERVATION", 105, 111]]], ["Inhibition of the AT1R indeed attenuated acute severe lung injury in Spike-Fc\u2013treated mice (Fig. 4e).", [["lung", "ANATOMY", 54, 58], ["lung injury", "DISEASE", 54, 65], ["AT1R", "GENE_OR_GENE_PRODUCT", 18, 22], ["lung", "ORGAN", 54, 58], ["mice", "ORGANISM", 86, 90], ["AT1R", "PROTEIN", 18, 22], ["mice", "SPECIES", 86, 90], ["acute severe lung injury", "PROBLEM", 41, 65], ["attenuated", "OBSERVATION_MODIFIER", 30, 40], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["lung", "ANATOMY", 54, 58], ["injury", "OBSERVATION", 59, 65], ["Spike", "OBSERVATION_MODIFIER", 69, 74]]], ["Inhibition of the AT1R also attenuated pulmonary edema (Fig. 4f).", [["pulmonary", "ANATOMY", 39, 48], ["pulmonary edema", "DISEASE", 39, 54], ["AT1R", "GENE_OR_GENE_PRODUCT", 18, 22], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 39, 54], ["AT1R", "PROTEIN", 18, 22], ["the AT1R also attenuated pulmonary edema", "PROBLEM", 14, 54], ["attenuated", "OBSERVATION_MODIFIER", 28, 38], ["pulmonary", "ANATOMY", 39, 48], ["edema", "OBSERVATION", 49, 54]]], ["Taken together, our data show that SARS-CoV Spike can exaggerate acute lung failure through deregulation of the renin-angiotensin system.", [["lung", "ANATOMY", 71, 75], ["SARS", "DISEASE", 35, 39], ["acute lung failure", "DISEASE", 65, 83], ["angiotensin", "CHEMICAL", 118, 129], ["SARS-CoV", "ORGANISM", 35, 43], ["lung", "ORGAN", 71, 75], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 112, 129], ["renin", "PROTEIN", 112, 117], ["SARS-CoV", "SPECIES", 35, 43], ["our data", "TEST", 16, 24], ["SARS", "PROBLEM", 35, 39], ["CoV Spike", "PROBLEM", 40, 49], ["acute lung failure", "PROBLEM", 65, 83], ["the renin-angiotensin system", "TREATMENT", 108, 136], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["lung", "ANATOMY", 71, 75], ["failure", "OBSERVATION", 76, 83], ["angiotensin system", "OBSERVATION", 118, 136]]], ["Moreover, SARS-CoV Spike\u2013mediated lung failure can be rescued by inhibition of AT1R.MainIt has been estimated that the Spanish flu virus that killed more than 20 million people at the beginning of the twentieth century was lethal to around 0.5% of infected people9,10, whereas the lethality of SARS-CoV infections reached 10% even with modern intensive care treatment1,2,3.", [["lung", "ANATOMY", 34, 38], ["SARS", "DISEASE", 10, 14], ["lung failure", "DISEASE", 34, 46], ["SARS-CoV infections", "DISEASE", 294, 313], ["SARS-CoV", "ORGANISM", 10, 18], ["lung", "ORGAN", 34, 38], ["AT1R", "GENE_OR_GENE_PRODUCT", 79, 83], ["Spanish flu virus", "ORGANISM", 119, 136], ["people", "ORGANISM", 170, 176], ["SARS-CoV", "ORGANISM", 294, 302], ["AT1R", "PROTEIN", 79, 83], ["people", "SPECIES", 170, 176], ["SARS-CoV", "SPECIES", 10, 18], ["Spanish flu virus", "SPECIES", 119, 136], ["SARS-CoV", "SPECIES", 294, 302], ["SARS", "PROBLEM", 10, 14], ["CoV Spike\u2013mediated lung failure", "PROBLEM", 15, 46], ["the Spanish flu virus", "PROBLEM", 115, 136], ["SARS", "PROBLEM", 294, 298], ["CoV infections", "PROBLEM", 299, 313], ["modern intensive care treatment1", "TREATMENT", 336, 368], ["lung", "ANATOMY", 34, 38], ["failure", "OBSERVATION", 39, 46], ["CoV", "OBSERVATION_MODIFIER", 299, 302], ["infections", "OBSERVATION", 303, 313]]], ["Given this very high lethality of SARS and the enormous economic and social impact of the worldwide SARS outbreak, elucidation of the disease pathogenesis is crucial for future treatment in case of renewed outbreaks.", [["SARS", "DISEASE", 34, 38], ["SARS", "DISEASE", 100, 104], ["this very high lethality", "PROBLEM", 6, 30], ["SARS", "PROBLEM", 34, 38], ["the worldwide SARS outbreak", "PROBLEM", 86, 113], ["the disease pathogenesis", "PROBLEM", 130, 154], ["future treatment", "TREATMENT", 170, 186], ["SARS", "OBSERVATION", 34, 38], ["enormous", "OBSERVATION_MODIFIER", 47, 55], ["economic", "OBSERVATION_MODIFIER", 56, 64]]], ["Moreover, a recent outbreak of avian influenza A (H5N1) in humans resulted in up to 70% of lethality from acute respiratory failure12.", [["respiratory", "ANATOMY", 112, 123], ["avian influenza A", "DISEASE", 31, 48], ["H5N1", "DISEASE", 50, 54], ["avian influenza A (H5N1)", "ORGANISM", 31, 55], ["humans", "ORGANISM", 59, 65], ["avian influenza A (H5N1", "SPECIES", 31, 54], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65], ["avian influenza A", "PROBLEM", 31, 48], ["lethality", "PROBLEM", 91, 100], ["acute respiratory failure12", "PROBLEM", 106, 133], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["respiratory failure12", "OBSERVATION", 112, 133]]], ["Before the discovery of SARS-CoV, two coronaviruses (HCoV-229E and HCoV-OC43) were known to infect humans, but they caused only self-limiting upper respiratory tract infections (30% of the common colds) and had never been reported to cause severe illness27.", [["upper respiratory tract", "ANATOMY", 142, 165], ["SARS", "DISEASE", 24, 28], ["respiratory tract infections", "DISEASE", 148, 176], ["colds", "DISEASE", 196, 201], ["illness", "DISEASE", 247, 254], ["SARS-CoV", "ORGANISM", 24, 32], ["coronaviruses", "ORGANISM", 38, 51], ["HCoV-229E", "ORGANISM", 53, 62], ["HCoV-OC43", "ORGANISM", 67, 76], ["humans", "ORGANISM", 99, 105], ["upper", "ORGANISM_SUBDIVISION", 142, 147], ["respiratory tract", "ORGANISM_SUBDIVISION", 148, 165], ["humans", "SPECIES", 99, 105], ["SARS-CoV", "SPECIES", 24, 32], ["HCoV-229E", "SPECIES", 53, 62], ["humans", "SPECIES", 99, 105], ["SARS", "PROBLEM", 24, 28], ["CoV", "TEST", 29, 32], ["two coronaviruses", "TEST", 34, 51], ["HCoV", "TEST", 53, 57], ["HCoV", "TEST", 67, 71], ["self-limiting upper respiratory tract infections", "PROBLEM", 128, 176], ["severe illness", "PROBLEM", 240, 254], ["upper", "ANATOMY_MODIFIER", 142, 147], ["respiratory tract", "ANATOMY", 148, 165], ["infections", "OBSERVATION", 166, 176], ["severe", "OBSERVATION_MODIFIER", 240, 246], ["illness", "OBSERVATION", 247, 254]]], ["The molecular determinants that may account for the dramatic differences in pathogenesis between these human coronaviruses and SARS-CoV were unknown.MainOur data provide a molecular explanation for the severe lung failure and lethality associated with SARS: we hypothesize that infections with SARS-CoV result in ACE2 downregulation through binding of SARS-CoV Spike protein to ACE2.", [["lung", "ANATOMY", 209, 213], ["SARS", "DISEASE", 127, 131], ["lung failure", "DISEASE", 209, 221], ["SARS", "DISEASE", 252, 256], ["infections", "DISEASE", 278, 288], ["SARS", "DISEASE", 294, 298], ["human", "ORGANISM", 103, 108], ["SARS-CoV", "ORGANISM", 127, 135], ["lung", "ORGAN", 209, 213], ["SARS-CoV", "ORGANISM", 294, 302], ["ACE2", "GENE_OR_GENE_PRODUCT", 313, 317], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 352, 360], ["ACE2", "GENE_OR_GENE_PRODUCT", 378, 382], ["ACE2", "PROTEIN", 313, 317], ["SARS-CoV Spike protein", "PROTEIN", 352, 374], ["ACE2", "PROTEIN", 378, 382], ["human", "SPECIES", 103, 108], ["human coronaviruses", "SPECIES", 103, 122], ["SARS-CoV", "SPECIES", 127, 135], ["SARS-CoV", "SPECIES", 294, 302], ["SARS-CoV", "SPECIES", 352, 360], ["the dramatic differences in pathogenesis", "PROBLEM", 48, 88], ["these human coronaviruses", "PROBLEM", 97, 122], ["SARS", "PROBLEM", 127, 131], ["the severe lung failure", "PROBLEM", 198, 221], ["lethality", "PROBLEM", 226, 235], ["SARS", "PROBLEM", 252, 256], ["SARS", "PROBLEM", 294, 298], ["ACE2 downregulation", "PROBLEM", 313, 332], ["SARS", "PROBLEM", 352, 356], ["ACE2", "TEST", 378, 382], ["may account for", "UNCERTAINTY", 32, 47], ["dramatic", "OBSERVATION_MODIFIER", 52, 60], ["severe", "OBSERVATION_MODIFIER", 202, 208], ["lung", "ANATOMY", 209, 213], ["failure", "OBSERVATION", 214, 221], ["infections", "OBSERVATION", 278, 288]]], ["Given that ACE2 is a key negative regulatory factor for severity of lung edema and acute lung failure, SARS-CoV Spike protein\u2013mediated ACE2 downregulation then contributes to the severity of lung pathologies.", [["lung edema", "ANATOMY", 68, 78], ["lung", "ANATOMY", 89, 93], ["lung", "ANATOMY", 191, 195], ["lung edema", "DISEASE", 68, 78], ["acute lung failure", "DISEASE", 83, 101], ["lung pathologies", "DISEASE", 191, 207], ["ACE2", "GENE_OR_GENE_PRODUCT", 11, 15], ["lung edema", "PATHOLOGICAL_FORMATION", 68, 78], ["lung", "ORGAN", 89, 93], ["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["lung", "ORGAN", 191, 195], ["ACE2", "PROTEIN", 11, 15], ["negative regulatory factor", "PROTEIN", 25, 51], ["ACE2", "PROTEIN", 135, 139], ["lung edema", "PROBLEM", 68, 78], ["acute lung failure", "PROBLEM", 83, 101], ["SARS-CoV Spike protein\u2013mediated ACE2 downregulation", "PROBLEM", 103, 154], ["lung pathologies", "PROBLEM", 191, 207], ["lung", "ANATOMY", 68, 72], ["edema", "OBSERVATION", 73, 78], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["lung", "ANATOMY", 89, 93], ["failure", "OBSERVATION", 94, 101], ["lung", "ANATOMY", 191, 195], ["pathologies", "OBSERVATION", 196, 207]]], ["This scenario would explain how this family member of the 'relatively harmless' coronaviruses has turned into a lethal virus.", [["coronaviruses", "ORGANISM", 80, 93], ["a lethal virus", "PROBLEM", 110, 124]]], ["Notably, recent data in a small cohort of individuals with SARS suggested that an insertion deletion ACE polymorphism that affects ACE function correlates with disease severity28, implying that our findings are indeed relevant for humans.MainOur data provide a molecular link between SARS pathogenesis and the role of the renin-angiotensin system in lung failure.", [["lung", "ANATOMY", 350, 354], ["SARS", "DISEASE", 59, 63], ["SARS", "DISEASE", 284, 288], ["angiotensin", "CHEMICAL", 328, 339], ["lung failure", "DISEASE", 350, 362], ["ACE", "GENE_OR_GENE_PRODUCT", 101, 104], ["ACE", "GENE_OR_GENE_PRODUCT", 131, 134], ["humans", "ORGANISM", 231, 237], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 322, 339], ["lung", "ORGAN", 350, 354], ["insertion deletion ACE polymorphism", "DNA", 82, 117], ["ACE", "PROTEIN", 131, 134], ["renin", "PROTEIN", 322, 327], ["humans", "SPECIES", 231, 237], ["humans", "SPECIES", 231, 237], ["SARS", "PROBLEM", 59, 63], ["an insertion deletion ACE polymorphism", "TREATMENT", 79, 117], ["disease severity28", "PROBLEM", 160, 178], ["SARS pathogenesis", "PROBLEM", 284, 301], ["the renin-angiotensin system", "TREATMENT", 318, 346], ["lung failure", "PROBLEM", 350, 362], ["lung", "ANATOMY", 350, 354], ["failure", "OBSERVATION", 355, 362]]], ["Recombinant ACE2 protein therefore could not only be a treatment to block spreading of SARS-CoV, but modulation of the renin-angiotensin system could also be used to protect individuals with SARS, and possibly individuals infected with other viruses such as strains of avian influenza A strains, from developing acute severe lung failure and acute respiratory distress syndrome.In vivo SARS infections. ::: MethodsThe SARS-CoV (Beijing strain, PUMC01 isolate) used in this study was provided by Z. Wang and Y. Liu (Chinese Academy of Medical Sciences, Chinese National Human Genome Center).", [["lung", "ANATOMY", 325, 329], ["respiratory", "ANATOMY", 348, 359], ["SARS", "DISEASE", 87, 91], ["angiotensin", "CHEMICAL", 125, 136], ["SARS", "DISEASE", 191, 195], ["influenza A", "DISEASE", 275, 286], ["lung failure", "DISEASE", 325, 337], ["acute respiratory distress syndrome", "DISEASE", 342, 377], ["SARS infections", "DISEASE", 386, 401], ["SARS", "DISEASE", 418, 422], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["SARS-CoV", "ORGANISM", 87, 95], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 119, 136], ["avian influenza A strains", "ORGANISM", 269, 294], ["lung", "ORGAN", 325, 329], ["SARS-CoV", "ORGANISM", 418, 426], ["PUMC01", "ORGANISM", 444, 450], ["Human", "ORGANISM", 569, 574], ["ACE2", "PROTEIN", 12, 16], ["renin", "PROTEIN", 119, 124], ["avian influenza", "SPECIES", 269, 284], ["Human", "SPECIES", 569, 574], ["SARS-CoV", "SPECIES", 87, 95], ["SARS-CoV", "SPECIES", 418, 426], ["Recombinant ACE2 protein", "TREATMENT", 0, 24], ["a treatment", "TREATMENT", 53, 64], ["SARS", "PROBLEM", 87, 91], ["CoV", "PROBLEM", 92, 95], ["the renin-angiotensin system", "TREATMENT", 115, 143], ["SARS", "PROBLEM", 191, 195], ["other viruses", "PROBLEM", 236, 249], ["avian influenza A strains", "PROBLEM", 269, 294], ["acute severe lung failure", "PROBLEM", 312, 337], ["acute respiratory distress syndrome", "PROBLEM", 342, 377], ["vivo SARS infections", "PROBLEM", 381, 401], ["Methods", "TEST", 407, 414], ["CoV (Beijing strain, PUMC01 isolate", "TREATMENT", 423, 458], ["this study", "TEST", 468, 478], ["acute", "OBSERVATION_MODIFIER", 312, 317], ["severe", "OBSERVATION_MODIFIER", 318, 324], ["lung", "ANATOMY", 325, 329], ["failure", "OBSERVATION", 330, 337], ["acute", "OBSERVATION_MODIFIER", 342, 347], ["respiratory distress syndrome", "OBSERVATION", 348, 377], ["SARS infections", "OBSERVATION", 386, 401]]], ["All mouse studies were approved by the Ministry of Health Science and Technology division of the People's Republic of China.", [["mouse", "ORGANISM", 4, 9], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 4, 9], ["All mouse studies", "TEST", 0, 17]]], ["We intranasally inoculated mice with 100 \u03bcl virus (105.23 TCID50).", [["mice", "ORGANISM", 27, 31], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31]]], ["At day 2, mice were killed, and the lungs were removed for further analyses.", [["lungs", "ANATOMY", 36, 41], ["mice", "ORGANISM", 10, 14], ["lungs", "ORGAN", 36, 41], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["further analyses", "TEST", 59, 75], ["lungs", "ANATOMY", 36, 41]]], ["We assessed lung injury scores as described previously30.SARS-CoV Spike protein binding experiments. ::: MethodsWe cloned the coding sequence of SARS-CoV Spike protein (amino acids 1\u20131,190 from Urbani strain) or a Spike sequence that only contains the previously mapped21 ACE2-binding domain (amino acids 318\u2013510) to generate a fusion protein with the Fc portion of human IgG1.", [["lung", "ANATOMY", 12, 16], ["lung injury", "DISEASE", 12, 23], ["amino acids", "CHEMICAL", 169, 180], ["amino acids 318\u2013510", "CHEMICAL", 293, 312], ["amino acids", "CHEMICAL", 169, 180], ["amino acids", "CHEMICAL", 293, 304], ["lung", "ORGAN", 12, 16], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 57, 65], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 145, 153], ["amino acids", "AMINO_ACID", 169, 180], ["ACE2", "GENE_OR_GENE_PRODUCT", 272, 276], ["amino acids 318\u2013510", "AMINO_ACID", 293, 312], ["human", "ORGANISM", 366, 371], ["IgG1", "GENE_OR_GENE_PRODUCT", 372, 376], ["SARS-CoV Spike protein", "PROTEIN", 145, 167], ["amino acids 1\u20131,190", "PROTEIN", 169, 188], ["Spike sequence", "DNA", 214, 228], ["mapped21 ACE2-binding domain", "PROTEIN", 263, 291], ["amino acids 318\u2013510", "PROTEIN", 293, 312], ["fusion protein", "PROTEIN", 328, 342], ["Fc portion", "PROTEIN", 352, 362], ["human IgG1", "PROTEIN", 366, 376], ["human", "SPECIES", 366, 371], ["SARS-CoV", "SPECIES", 57, 65], ["SARS-CoV", "SPECIES", 145, 153], ["human", "SPECIES", 366, 371], ["lung injury scores", "PROBLEM", 12, 30], ["SARS", "PROBLEM", 57, 61], ["SARS", "PROBLEM", 145, 149], ["CoV Spike protein", "TEST", 150, 167], ["amino acids", "TEST", 169, 180], ["Urbani strain", "PROBLEM", 194, 207], ["a Spike sequence", "TEST", 212, 228], ["amino acids", "TEST", 293, 304], ["a fusion protein", "TREATMENT", 326, 342], ["lung", "ANATOMY", 12, 16], ["injury", "OBSERVATION", 17, 23]]], ["We purified Spike-Fc protein from transfected CHO cells using affinity chromatography.", [["CHO cells", "ANATOMY", 46, 55], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 12, 20], ["CHO cells", "CELL", 46, 55], ["Spike", "PROTEIN", 12, 17], ["Fc protein", "PROTEIN", 18, 28], ["transfected CHO cells", "CELL_LINE", 34, 55], ["Spike", "TEST", 12, 17], ["affinity chromatography", "TEST", 62, 85]]], ["For in vitro binding assays, we used cell lysates from A549 human alveolar epithelial cells or IMCD mouse kidney epithelial cells, and we pulled down Spike-Fc or control human IgG-Fc protein using Protein G Sepharose followed by western blot.", [["cell lysates", "ANATOMY", 37, 49], ["A549", "ANATOMY", 55, 59], ["alveolar epithelial cells", "ANATOMY", 66, 91], ["IMCD", "ANATOMY", 95, 99], ["kidney epithelial cells", "ANATOMY", 106, 129], ["cell lysates", "CELL", 37, 49], ["A549", "CELL", 55, 59], ["human", "ORGANISM", 60, 65], ["alveolar epithelial cells", "CELL", 66, 91], ["IMCD mouse kidney epithelial cells", "CELL", 95, 129], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 150, 158], ["human", "ORGANISM", 170, 175], ["IgG-Fc", "GENE_OR_GENE_PRODUCT", 176, 182], ["Protein G Sepharose", "GENE_OR_GENE_PRODUCT", 197, 216], ["A549 human alveolar epithelial cells", "CELL_LINE", 55, 91], ["IMCD mouse kidney epithelial cells", "CELL_LINE", 95, 129], ["Spike", "PROTEIN", 150, 155], ["Fc", "PROTEIN", 156, 158], ["human IgG", "PROTEIN", 170, 179], ["Fc protein", "PROTEIN", 180, 190], ["Protein G Sepharose", "PROTEIN", 197, 216], ["human", "SPECIES", 60, 65], ["mouse", "SPECIES", 100, 105], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 60, 65], ["mouse", "SPECIES", 100, 105], ["human", "SPECIES", 170, 175], ["vitro binding assays", "TEST", 7, 27], ["cell lysates", "TREATMENT", 37, 49], ["A549 human alveolar epithelial cells", "TEST", 55, 91], ["IMCD mouse kidney epithelial cells", "PROBLEM", 95, 129], ["human IgG", "TREATMENT", 170, 179], ["Fc protein", "TREATMENT", 180, 190], ["Protein G Sepharose", "TREATMENT", 197, 216], ["alveolar epithelial cells", "OBSERVATION", 66, 91], ["kidney", "ANATOMY", 106, 112], ["epithelial cells", "OBSERVATION", 113, 129]]], ["For flow cytometry, we detached Vero E6 cells using a 2 mM mixture of EDTA and PBS and incubated them with Spike-Fc or control human IgG-Fc protein at 4 \u00b0C or 37 \u00b0C for 3 h.", [["Vero E6 cells", "ANATOMY", 32, 45], ["EDTA", "CHEMICAL", 70, 74], ["EDTA", "CHEMICAL", 70, 74], ["Vero E6 cells", "CELL", 32, 45], ["EDTA", "SIMPLE_CHEMICAL", 70, 74], ["PBS", "SIMPLE_CHEMICAL", 79, 82], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 107, 115], ["human", "ORGANISM", 127, 132], ["IgG-Fc", "GENE_OR_GENE_PRODUCT", 133, 139], ["Vero E6 cells", "CELL_LINE", 32, 45], ["Spike", "PROTEIN", 107, 112], ["Fc", "PROTEIN", 113, 115], ["human IgG", "PROTEIN", 127, 136], ["Fc protein", "PROTEIN", 137, 147], ["human", "SPECIES", 127, 132], ["Vero E6", "SPECIES", 32, 39], ["human", "SPECIES", 127, 132], ["flow cytometry", "TEST", 4, 18], ["Vero E6 cells", "TREATMENT", 32, 45], ["a 2 mM mixture of EDTA", "TREATMENT", 52, 74], ["PBS", "TREATMENT", 79, 82], ["Spike", "TEST", 107, 112], ["human IgG", "TEST", 127, 136], ["Fc protein", "TEST", 137, 147]]], ["We then incubated cells with ACE2-specific antibodies or a FITC-conjugated human IgG\u2013specific antibody.Recombinant Spike-Fc in vivo challenge in mice. ::: MethodsWe used the mouse model of acid aspiration\u2013induced acute lung injury18 for all Spike-Fc in vivo experiments.", [["cells", "ANATOMY", 18, 23], ["lung", "ANATOMY", 219, 223], ["FITC", "CHEMICAL", 59, 63], ["cells", "CELL", 18, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["FITC", "SIMPLE_CHEMICAL", 59, 63], ["human", "ORGANISM", 75, 80], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 115, 123], ["mice", "ORGANISM", 145, 149], ["mouse", "ORGANISM", 174, 179], ["lung", "ORGAN", 219, 223], ["Spike-Fc", "GENE_OR_GENE_PRODUCT", 241, 249], ["ACE2", "PROTEIN", 29, 33], ["specific antibodies", "PROTEIN", 34, 53], ["FITC-conjugated human IgG\u2013specific antibody", "PROTEIN", 59, 102], ["Spike", "PROTEIN", 115, 120], ["Fc", "PROTEIN", 121, 123], ["Spike", "PROTEIN", 241, 246], ["Fc", "PROTEIN", 247, 249], ["human", "SPECIES", 75, 80], ["mice", "SPECIES", 145, 149], ["mouse", "SPECIES", 174, 179], ["human", "SPECIES", 75, 80], ["mice", "SPECIES", 145, 149], ["mouse", "SPECIES", 174, 179], ["ACE2", "TEST", 29, 33], ["specific antibodies", "TEST", 34, 53], ["a FITC", "TEST", 57, 63], ["MethodsWe", "TREATMENT", 155, 164], ["acid aspiration\u2013induced acute lung injury18", "PROBLEM", 189, 232], ["Spike", "OBSERVATION_MODIFIER", 115, 120], ["acute", "OBSERVATION_MODIFIER", 213, 218], ["lung", "ANATOMY", 219, 223]]], ["Mice received Spike(S1190)-Fc, Spike(S318-510)-Fc or control-Fc (5.5 nmol/kg each) intraperitoneally three times (at 30 min before and at 1 and 2 h after) during acid treatment.", [["Mice", "ORGANISM", 0, 4], ["S318-510)-Fc", "SIMPLE_CHEMICAL", 37, 49], ["control-Fc", "SIMPLE_CHEMICAL", 53, 63], ["Fc", "PROTEIN", 27, 29], ["Fc", "PROTEIN", 47, 49], ["Fc", "PROTEIN", 61, 63], ["Mice", "SPECIES", 0, 4], ["Spike", "TEST", 14, 19], ["Spike", "PROBLEM", 31, 36], ["Fc", "TREATMENT", 61, 63], ["acid treatment", "TREATMENT", 162, 176]]], ["For AT1 inhibition of Spike-Fc\u2013mediated acute lung injury, we treated the Spike(S1190)-Fc\u2013challenged mice with the AT1 inhibitor losartan (15 mg/kg).", [["lung", "ANATOMY", 46, 50], ["lung injury", "DISEASE", 46, 57], ["losartan", "CHEMICAL", 129, 137], ["losartan", "CHEMICAL", 129, 137], ["AT1", "GENE_OR_GENE_PRODUCT", 4, 7], ["Spike", "GENE_OR_GENE_PRODUCT", 22, 27], ["lung", "ORGAN", 46, 50], ["mice", "ORGANISM", 101, 105], ["AT1", "GENE_OR_GENE_PRODUCT", 115, 118], ["losartan", "SIMPLE_CHEMICAL", 129, 137], ["Spike", "PROTEIN", 22, 27], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["Spike", "PROBLEM", 22, 27], ["Fc\u2013mediated acute lung injury", "PROBLEM", 28, 57], ["the AT1 inhibitor losartan", "TREATMENT", 111, 137], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["lung", "ANATOMY", 46, 50], ["injury", "OBSERVATION", 51, 57]]], ["Lung injury scores were assessed as described previously30.Statistical analyses. ::: MethodsAll data are shown as mean \u00b1 s.e.m.", [["Lung", "ANATOMY", 0, 4], ["Lung injury", "DISEASE", 0, 11], ["Lung", "ORGAN", 0, 4], ["Lung injury scores", "PROBLEM", 0, 18], ["Statistical analyses", "TEST", 59, 79], ["Methods", "TREATMENT", 85, 92], ["All data", "TEST", 92, 100], ["injury", "OBSERVATION", 5, 11]]], ["Measurements at single time points were analyzed by unpaired t-test (virus titers, SARS-CoV Spike-RNA levels), ANOVA with two tailed t-test (percent changes in elastance, wet/dry ratio AngII levels) or Kruskal-Wallis test (histological scores).", [["SARS-CoV", "SPECIES", 83, 91], ["Measurements", "TEST", 0, 12], ["unpaired t-test", "TEST", 52, 67], ["virus titers", "TEST", 69, 81], ["SARS", "TEST", 83, 87], ["CoV Spike", "TEST", 88, 97], ["RNA levels", "TEST", 98, 108], ["two tailed t-test", "TEST", 122, 139], ["elastance", "TEST", 160, 169], ["wet/dry ratio AngII levels", "TEST", 171, 197], ["Kruskal-Wallis test", "TEST", 202, 221], ["histological scores", "TEST", 223, 242]]], ["Time courses were analyzed by repeated measurements (mixed model) ANOVA with Bonferroni post-t tests.", [["Bonferroni post-t tests", "TEST", 77, 100]]], ["All statistical tests were calculated using the GraphPad Prism 4.00 (GraphPad Software) and a JMP (SAS Institute) programs.", [["All statistical tests", "TEST", 0, 21], ["the GraphPad Prism", "TEST", 44, 62], ["a JMP (SAS Institute) programs", "TREATMENT", 92, 122]]], ["P < 0.05 was considered to indicate statistical significance.Accession number. ::: MethodsThe Genbank accession number for the SARS coronavirus (Beijing strain, PUMC01 isolate) is AY350750.Accession number. ::: MethodsNote: Supplementary information is available on the Nature Medicine website.", [["SARS coronavirus", "DISEASE", 127, 143], ["AY350750", "CHEMICAL", 180, 188], ["AY350750", "CHEMICAL", 180, 188], ["SARS coronavirus", "ORGANISM", 127, 143], ["Beijing strain", "ORGANISM", 145, 159], ["AY350750", "SIMPLE_CHEMICAL", 180, 188], ["coronavirus", "SPECIES", 132, 143], ["SARS coronavirus", "SPECIES", 127, 143], ["Methods", "TREATMENT", 83, 90], ["the SARS coronavirus", "PROBLEM", 123, 143]]]], "e9207c6c168af783b4c8b8c3fe8cdfcd29348242": [], "PMC7229920": [["Funding SourcesNoneConflict of interest statementCarlo Catassi has received consultancy honoraria from Dr. Schaer and Takeda.", [["Carlo Catassi", "CHEMICAL", 49, 62], ["honoraria", "ORGANISM", 88, 97]]], ["Other authors have no conflicts of interest or relevant financial activities to disclose.Conflict of interest statementWritten informed consent was obtained by the patient's parents to produce this manuscript and publish it with accompanying clinical images of the patient.Uncited references", [["patient", "ORGANISM", 164, 171], ["patient", "ORGANISM", 265, 272], ["patient", "SPECIES", 164, 171], ["patient", "SPECIES", 265, 272], ["clinical images", "TEST", 242, 257]]]]}